data_2krs_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2krs _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.487 ' CD ' ' N ' ' A' ' 2' ' ' GLN . 1.4 pm0 . . . . . 0 N--CA 1.462 0.16 0 CA-C-O 120.954 0.406 . . . . 0.0 110.538 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -88.42 149.8 21.47 Favored Glycine 0 CA--C 1.525 0.68 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 179.66 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 53.9 t -122.05 129.39 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 87.4 t -93.56 126.47 45.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.188 179.752 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 33.1 tptt -118.52 110.8 17.82 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.153 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 12.5 p -144.42 144.74 22.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.075 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -63.41 -41.23 98.71 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.7 -179.615 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 38.6 m -119.06 -75.12 0.58 Allowed 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.985 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -157.87 145.67 18.61 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.386 -179.633 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 60.7 tp -108.98 131.12 55.37 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.138 -179.177 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 10.9 m120 -80.89 145.63 31.22 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.666 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 42.5 ttp -106.81 149.84 26.96 Favored 'General case' 0 N--CA 1.471 0.597 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 179.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . 0.649 HH11 ' HA ' ' A' ' 19' ' ' SER . 58.1 mtt-85 -133.5 140.77 47.43 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-O 121.031 0.443 . . . . 0.0 111.768 -176.925 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 35.8 t -59.16 -41.93 89.55 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.358 -178.364 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -109.6 161.92 12.88 Favored Glycine 0 CA--C 1.53 0.987 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -77.99 73.3 5.78 Favored 'Trans proline' 0 N--CA 1.496 1.663 0 C-N-CA 122.922 2.414 . . . . 0.0 112.044 179.348 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 176.26 160.44 23.59 Favored Glycine 0 CA--C 1.516 0.146 0 N-CA-C 110.013 -1.235 . . . . 0.0 110.013 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' SER . . . . . 0.649 ' HA ' HH11 ' A' ' 14' ' ' ARG . 5.4 m -78.88 -16.9 56.44 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 120.457 -0.497 . . . . 0.0 110.54 -179.638 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -64.88 -36.05 83.1 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.971 -179.034 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -59.25 -42.52 91.32 Favored 'General case' 0 C--N 1.329 -0.284 0 C-N-CA 120.851 -0.339 . . . . 0.0 111.423 -178.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 101.86 162.21 26.8 Favored Glycine 0 N--CA 1.468 0.77 0 N-CA-C 111.29 -0.724 . . . . 0.0 111.29 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 7.2 p -77.16 132.79 32.11 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.123 0 CA-C-O 121.018 0.437 . . . . 0.0 111.594 -179.627 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 44.1 pt -113.45 -8.5 12.15 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.302 179.318 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -170.97 175.59 44.62 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.529 -1.029 . . . . 0.0 110.529 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 86.9 m -123.2 132.1 53.92 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-O 120.715 0.293 . . . . 0.0 110.451 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 73.0 mt -109.19 141.96 40.68 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.267 179.767 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . 0.664 HH11 ' HG2' ' A' ' 28' ' ' ARG . 46.0 mtt-85 -95.32 168.06 10.96 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.274 179.383 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 50.7 p-10 -75.27 159.0 32.02 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 178.863 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 77.4 m-20 56.23 31.91 19.31 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.322 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 47.3 t0 -96.37 112.81 24.42 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 116.559 -0.291 . . . . 0.0 110.639 179.336 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 56.3 mtpt -74.06 134.34 42.96 Favored 'General case' 0 C--N 1.329 -0.288 0 C-N-CA 120.601 -0.44 . . . . 0.0 110.075 179.606 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 28.5 m -136.94 162.37 34.51 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.606 -179.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -101.82 121.1 41.45 Favored 'General case' 0 C--O 1.233 0.232 0 CA-C-N 116.083 -0.508 . . . . 0.0 109.869 179.618 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.418 HG21 HD12 ' A' ' 35' ' ' ILE . 96.3 mt -88.58 127.81 41.23 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.139 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.396 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 95.8 mt -91.77 -42.76 13.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.576 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 62.0 pttt -174.82 165.04 3.6 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.567 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -113.01 121.87 45.92 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.181 179.594 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 70.1 t -126.73 131.51 71.07 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.65 -179.64 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . 0.418 ' OD1' ' O ' ' A' ' 40' ' ' ASP . 56.6 t0 53.96 31.17 12.94 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.414 179.082 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 85.43 -16.49 39.48 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 111.043 -0.823 . . . . 0.0 111.043 179.694 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 79.9 m95 -83.35 146.14 28.65 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.401 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 58.7 m-85 -101.17 130.19 47.21 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.904 0.383 . . . . 0.0 110.402 179.669 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . 0.526 ' OE1' ' CE1' ' A' ' 53' ' ' TYR . 3.5 tp10 -88.12 118.52 27.75 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 179.207 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.422 HD12 HG21 ' A' ' 45' ' ' ILE . 44.7 pt -126.03 161.37 31.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-O 121.334 0.588 . . . . 0.0 110.678 -179.468 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . 0.405 HH11 ' HD3' ' A' ' 46' ' ' ARG . 0.6 OUTLIER -126.88 127.23 44.61 Favored 'General case' 0 CA--C 1.537 0.467 0 CA-C-N 115.397 -0.82 . . . . 0.0 110.041 -178.262 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 32.9 t80 -145.79 133.47 21.03 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.461 -178.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 57.67 33.34 23.12 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.245 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 74.01 8.13 77.72 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 111.514 -0.634 . . . . 0.0 111.514 179.098 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 58.6 mttp -106.98 150.19 26.74 Favored 'General case' 0 N--CA 1.466 0.356 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 53.4 t -116.55 132.56 65.83 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.054 -179.808 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . 0.416 ' O ' ' OE1' ' A' ' 44' ' ' GLU . . . -159.78 -169.46 23.12 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 110.97 -0.852 . . . . 0.0 110.97 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . 0.526 ' CE1' ' OE1' ' A' ' 44' ' ' GLU . 97.8 m-85 -125.39 154.78 41.38 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.799 0.333 . . . . 0.0 110.482 -179.759 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -136.12 151.8 50.17 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.281 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 21.2 m -63.24 145.2 56.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.533 -179.71 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 58.8 pttt -77.53 -24.79 49.89 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.919 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 21.4 m -62.25 -41.27 98.29 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.394 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 90.2 m-85 -92.65 -2.07 56.38 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 116.552 -0.295 . . . . 0.0 111.635 -178.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.3 mp -113.7 130.03 68.5 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 92.6 m -118.51 127.92 54.09 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.25 179.677 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 25.2 mm -77.36 133.83 29.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.439 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 78.7 t . . . . . 0 N--CA 1.463 0.224 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.608 -179.6 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 99.2 mm-40 . . . . . 0 N--CA 1.463 0.188 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -91.89 145.0 17.47 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 111.487 -0.645 . . . . 0.0 111.487 -179.471 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 58.8 t -123.62 131.83 72.4 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.451 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 70.6 t -93.28 127.39 45.39 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.249 0 CA-C-O 120.817 0.341 . . . . 0.0 110.607 -179.715 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 53.8 mtmt -126.43 107.1 9.96 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.37 179.703 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 9.8 p -137.96 159.46 33.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.002 -179.853 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 93.9 m-20 -61.26 -41.65 97.27 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.522 -0.308 . . . . 0.0 110.813 -179.291 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 5.2 t -143.68 -51.62 0.33 Allowed 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 120.803 0.335 . . . . 0.0 110.961 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -157.69 144.14 17.78 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.469 -179.659 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 52.3 tp -117.85 132.99 56.37 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 120.864 0.364 . . . . 0.0 110.118 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 99.7 m-20 -76.3 139.23 40.97 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.021 179.672 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 35.6 ttp -100.21 139.11 36.35 Favored 'General case' 0 N--CA 1.465 0.276 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . 0.436 ' HE ' ' HA ' ' A' ' 19' ' ' SER . 84.3 mtt85 -113.27 158.03 21.03 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.858 0.361 . . . . 0.0 110.818 -178.504 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 8.8 m -80.04 -11.53 59.77 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.94 -179.303 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -164.23 -173.01 32.41 Favored Glycine 0 CA--C 1.52 0.406 0 N-CA-C 110.815 -0.914 . . . . 0.0 110.815 179.47 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -82.74 75.82 4.37 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 122.612 2.208 . . . . 0.0 111.667 179.753 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.76 130.9 1.35 Allowed Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 179.722 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' SER . . . . . 0.436 ' HA ' ' HE ' ' A' ' 14' ' ' ARG . 80.6 p -70.1 -9.02 54.14 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.666 0.27 . . . . 0.0 110.963 -179.884 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 12.9 m120 -83.55 -0.78 51.82 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.798 -179.876 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 43.0 m-85 -90.98 -2.71 57.66 Favored 'General case' 0 N--CA 1.462 0.167 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 71.87 -179.34 34.84 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 14.2 p -108.61 127.04 65.39 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 CA-C-O 120.889 0.376 . . . . 0.0 110.176 179.594 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 26.1 pt -104.49 -3.3 9.67 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 CA-C-O 120.953 0.406 . . . . 0.0 110.717 -179.65 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.88 -178.52 48.53 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.865 -0.894 . . . . 0.0 110.865 -179.876 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 44.7 p -133.41 155.97 48.53 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.913 0.387 . . . . 0.0 110.549 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 78.6 mt -122.84 146.99 47.06 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.294 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 66.0 mtm180 -106.42 153.46 22.22 Favored 'General case' 0 CA--C 1.515 -0.368 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.517 179.877 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 50.8 p-10 -60.0 157.02 13.53 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.359 179.667 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 11.2 t-20 64.39 4.27 2.14 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.266 179.718 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 67.2 t0 -79.95 120.75 24.57 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.466 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 31.1 mtmm -101.15 138.18 38.51 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 120.864 0.364 . . . . 0.0 110.445 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 33.5 m -138.32 163.57 28.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.621 -179.723 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -85.34 134.95 34.08 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.479 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.402 HD11 HG21 ' A' ' 35' ' ' ILE . 86.6 mt -103.5 128.23 56.82 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.485 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.846 -179.92 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.553 ' CD1' ' N ' ' A' ' 36' ' ' ILE . 2.0 mp -91.36 -44.49 14.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.834 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 62.6 pttt -172.52 160.09 4.67 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.648 -179.651 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . 0.473 ' CD ' ' CE1' ' A' ' 43' ' ' TYR . 82.6 tt0 -111.39 127.77 55.77 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.439 -179.866 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 57.5 t -127.91 129.94 69.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.707 179.794 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 53.19 30.83 10.47 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.361 -0.382 . . . . 0.0 111.592 179.137 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.9 -28.37 7.26 Favored Glycine 0 CA--C 1.521 0.427 0 N-CA-C 110.919 -0.873 . . . . 0.0 110.919 179.655 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 58.6 m95 -71.7 142.36 49.83 Favored 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 120.865 -0.334 . . . . 0.0 110.11 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . 0.473 ' CE1' ' CD ' ' A' ' 38' ' ' GLU . 59.9 m-85 -102.94 133.01 48.76 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.379 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 75.1 tt0 -91.79 121.36 33.34 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.308 179.414 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 46.2 pt -125.53 160.08 32.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.526 -0.306 . . . . 0.0 110.977 -179.124 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 22.0 ttt180 -120.54 126.95 51.63 Favored 'General case' 0 CA--C 1.54 0.566 0 CA-C-N 115.896 -0.593 . . . . 0.0 109.698 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.43 ' O ' ' CG ' ' A' ' 48' ' ' ASN . 32.7 t80 -145.09 145.39 31.4 Favored 'General case' 0 N--CA 1.473 0.676 0 O-C-N 123.04 0.212 . . . . 0.0 110.471 -178.353 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.43 ' CG ' ' O ' ' A' ' 47' ' ' PHE . 10.1 p30 51.52 25.74 2.88 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.109 -179.851 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 77.94 17.5 78.39 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 111.447 -0.661 . . . . 0.0 111.447 179.441 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -124.24 145.65 49.23 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-O 120.82 0.343 . . . . 0.0 110.283 179.675 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 53.2 t -112.14 131.65 62.99 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.317 -179.691 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -150.21 -164.17 11.67 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.478 -1.049 . . . . 0.0 110.478 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 55.3 m-85 -132.3 152.16 51.51 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 120.841 0.353 . . . . 0.0 110.695 -179.692 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -141.49 157.37 45.22 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.509 -179.581 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' SER . . . . . 0.541 ' HG ' ' H ' ' A' ' 57' ' ' SER . 38.1 t -61.19 139.8 58.05 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.226 -179.475 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -83.96 -12.94 54.58 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.691 179.807 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' SER . . . . . 0.541 ' H ' ' HG ' ' A' ' 55' ' ' SER . 37.3 m -70.6 -21.06 62.7 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.22 -179.28 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -115.74 4.43 14.01 Favored 'General case' 0 N--CA 1.47 0.562 0 CA-C-O 120.624 0.249 . . . . 0.0 111.131 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . 0.428 HG21 HD11 ' A' ' 59' ' ' ILE . 97.1 mt -125.42 129.62 72.92 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 CA-C-O 120.879 0.371 . . . . 0.0 110.763 179.693 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 85.0 m -127.96 132.36 49.23 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.836 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.1 mt -80.79 128.32 38.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.359 179.583 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 22.1 m . . . . . 0 N--CA 1.465 0.319 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.693 -179.876 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 24.5 mp0 . . . . . 0 N--CA 1.465 0.29 0 CA-C-O 120.762 0.315 . . . . 0.0 110.567 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -90.68 171.0 35.7 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 179.49 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 53.3 t -124.71 130.12 73.48 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.541 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 59.7 t -91.0 127.24 43.54 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.259 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 59.9 mttp -121.79 110.57 16.07 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 120.841 0.353 . . . . 0.0 110.089 179.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 72.4 t -126.69 138.29 55.23 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.185 -179.317 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.422 ' OD1' ' O ' ' A' ' 8' ' ' ASN . 56.5 t-20 -62.73 -41.6 99.25 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.345 -179.192 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 21.6 m -130.87 -76.73 0.53 Allowed 'General case' 0 N--CA 1.468 0.433 0 CA-C-O 120.776 0.322 . . . . 0.0 110.806 -179.552 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -151.93 140.61 20.83 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.818 -179.696 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 53.8 tp -123.17 133.22 54.26 Favored 'General case' 0 N--CA 1.469 0.488 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.203 179.8 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 99.5 m-20 -81.7 140.08 34.54 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.977 179.755 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 7.3 tmm? -91.31 136.29 33.21 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-O 121.257 0.551 . . . . 0.0 110.37 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 4.0 mmt-85 -105.63 140.61 38.43 Favored 'General case' 0 CA--C 1.542 0.648 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.708 -178.127 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 68.5 m -78.6 -7.44 57.6 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.893 -177.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -153.77 -166.04 14.33 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -85.48 -0.68 8.92 Favored 'Trans proline' 0 C--N 1.302 -1.887 0 C-N-CA 122.479 2.119 . . . . 0.0 111.794 -179.768 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -99.12 128.2 9.49 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 110.808 -0.917 . . . . 0.0 110.808 179.503 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 78.5 p -69.64 -14.97 63.09 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.83 0.348 . . . . 0.0 110.622 179.672 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 96.7 m-20 -91.72 14.07 16.34 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.482 -179.368 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 7.9 m-85 -87.26 0.7 54.97 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.879 0.371 . . . . 0.0 110.041 179.853 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 79.47 171.33 41.32 Favored Glycine 0 CA--C 1.524 0.619 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 179.781 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 11.3 p -106.99 126.72 63.01 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 CA-C-O 120.728 0.299 . . . . 0.0 110.471 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 24.9 pt -106.07 -2.43 9.91 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.475 0 CA-C-O 121.005 0.431 . . . . 0.0 110.552 179.734 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -176.46 -177.15 45.22 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 110.47 -1.052 . . . . 0.0 110.47 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 61.3 p -131.92 153.6 50.1 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-O 121.03 0.443 . . . . 0.0 110.469 179.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 83.0 mt -123.6 147.62 47.16 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.402 179.238 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 1.7 mtm180 -124.32 153.84 41.17 Favored 'General case' 0 C--O 1.224 -0.287 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.666 -178.277 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 53.1 p-10 -56.19 165.52 1.01 Allowed 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.35 0.595 . . . . 0.0 112.059 -179.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 71.0 m-80 59.29 13.18 2.95 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 114.995 -1.002 . . . . 0.0 111.316 179.579 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 91.3 m-20 -87.86 113.78 23.85 Favored 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 120.844 -0.342 . . . . 0.0 110.451 179.493 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.448 ' HZ3' ' CB ' ' A' ' 32' ' ' LYS . 0.4 OUTLIER -92.23 129.57 38.15 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.016 0.436 . . . . 0.0 110.441 179.915 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.4 m -137.11 161.16 35.77 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.145 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.081 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -89.91 131.09 36.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.298 -179.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.2 mt -97.69 107.71 20.55 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.216 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.435 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 97.5 mt -66.64 -44.21 89.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.925 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 63.2 pttt -173.05 178.9 2.38 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.769 -179.533 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -119.94 123.92 44.71 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.12 179.554 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 62.3 t -126.07 131.68 71.42 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-O 120.974 0.416 . . . . 0.0 110.626 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 54.5 31.39 14.74 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.278 179.361 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.537 ' O ' ' NZ ' ' A' ' 56' ' ' LYS . . . 82.97 -15.91 30.13 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 179.755 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 11.4 m95 -86.08 148.29 25.78 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.708 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 51.5 m-85 -100.91 132.94 46.07 Favored 'General case' 0 C--O 1.233 0.187 0 CA-C-O 121.111 0.482 . . . . 0.0 110.523 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -94.46 127.04 40.11 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.376 -0.829 . . . . 0.0 109.271 179.163 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.42 HD12 HG21 ' A' ' 45' ' ' ILE . 43.7 pt -129.22 157.14 42.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 CA-C-O 121.135 0.493 . . . . 0.0 111.784 -178.862 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 31.1 ttp180 -115.6 124.37 50.79 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.719 178.748 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 34.4 t80 -145.14 132.95 21.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.709 -179.466 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 62.2 t30 56.62 32.92 21.86 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.608 179.77 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 71.83 11.87 74.13 Favored Glycine 0 CA--C 1.528 0.875 0 N-CA-C 111.369 -0.693 . . . . 0.0 111.369 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 65.6 mttp -111.62 147.31 35.75 Favored 'General case' 0 N--CA 1.467 0.409 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.755 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 52.9 t -117.44 132.06 68.35 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.067 -179.778 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . 0.418 ' C ' ' CD1' ' A' ' 53' ' ' TYR . . . -156.27 -167.02 16.99 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.491 -1.044 . . . . 0.0 110.491 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . 0.535 ' N ' ' CD1' ' A' ' 53' ' ' TYR . 10.1 m-85 -137.15 154.6 50.21 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-O 120.811 0.338 . . . . 0.0 110.451 -179.486 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -147.05 152.85 39.23 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.322 179.802 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 9.7 p -63.95 142.92 58.23 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.881 0.372 . . . . 0.0 110.753 -179.708 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.537 ' NZ ' ' O ' ' A' ' 41' ' ' GLY . 0.0 OUTLIER -66.24 -12.74 58.08 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.711 -179.358 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 6.1 m -65.06 -15.74 62.69 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.544 -0.298 . . . . 0.0 111.215 -179.515 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 95.2 m-85 -117.8 5.67 12.26 Favored 'General case' 0 N--CA 1.472 0.651 0 N-CA-C 111.69 0.256 . . . . 0.0 111.69 -179.737 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 4.2 mp -121.49 130.15 74.9 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 CA-C-O 121.246 0.546 . . . . 0.0 110.154 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 85.5 m -123.91 132.63 53.77 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.197 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.41 HG23 HD11 ' A' ' 61' ' ' ILE . 96.0 mt -72.79 129.22 35.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.169 179.769 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 89.2 t . . . . . 0 C--N 1.327 -0.406 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.671 -179.882 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 98.4 mm-40 . . . . . 0 N--CA 1.466 0.327 0 CA-C-O 121.094 0.473 . . . . 0.0 110.148 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -100.03 154.27 19.52 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.748 -0.941 . . . . 0.0 110.748 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 64.1 t -124.4 130.85 73.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.586 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 88.1 t -88.47 128.41 40.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.62 -179.786 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -127.46 105.51 8.56 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.242 179.606 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 30.9 m -138.89 159.96 30.03 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.254 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.715 179.799 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 11.7 m120 -91.41 -4.05 56.06 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.38 179.698 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 17.4 m -154.39 -166.95 2.48 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.34 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -67.18 143.82 56.35 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.466 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 51.3 tp -117.51 130.62 56.55 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 116.182 -0.463 . . . . 0.0 109.88 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 10.7 m120 -89.22 134.2 34.13 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.439 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 52.1 ttp -105.38 145.96 30.08 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 116.174 -0.466 . . . . 0.0 109.834 179.765 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 93.8 mtt-85 -119.13 159.82 23.25 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-O 120.936 0.398 . . . . 0.0 111.162 -179.554 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 86.2 p -81.67 -5.94 58.56 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.617 -0.72 . . . . 0.0 110.133 179.638 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.467 ' C ' ' H ' ' A' ' 18' ' ' GLY . . . -159.55 167.31 35.13 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 110.625 -0.99 . . . . 0.0 110.625 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo -69.94 12.27 0.36 Allowed 'Trans proline' 0 C--N 1.308 -1.6 0 C-N-CA 121.883 1.722 . . . . 0.0 111.904 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . 0.467 ' H ' ' C ' ' A' ' 16' ' ' GLY . . . -99.4 124.12 8.13 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.861 -0.895 . . . . 0.0 110.861 179.225 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 79.5 p -66.94 -10.21 46.6 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.757 0.313 . . . . 0.0 110.535 179.779 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 55.0 p30 -90.95 6.18 45.7 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.64 -179.284 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 32.4 m-85 -88.5 -10.41 49.06 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.39 179.852 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 75.9 176.75 41.11 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 111.361 -0.696 . . . . 0.0 111.361 179.102 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 12.1 p -92.48 127.17 44.82 Favored 'Isoleucine or valine' 0 C--O 1.232 0.151 0 CA-C-O 120.711 0.291 . . . . 0.0 110.528 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 24.5 pt -106.11 -5.02 9.97 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-O 120.872 0.368 . . . . 0.0 110.623 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.6 175.3 47.24 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.808 -0.917 . . . . 0.0 110.808 -179.824 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 73.9 m -125.88 130.36 51.18 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 120.878 0.371 . . . . 0.0 110.463 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 72.8 mt -112.44 142.43 44.99 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.711 179.633 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . 0.72 HH11 ' HG3' ' A' ' 28' ' ' ARG . 71.4 mtm-85 -108.42 164.12 12.61 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-O 121.345 0.593 . . . . 0.0 111.117 -179.551 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.458 ' C ' ' H ' ' A' ' 31' ' ' ASP . 57.1 p30 -67.26 166.84 13.44 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.024 179.803 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 10.0 m120 59.41 3.16 0.37 Allowed 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.098 -179.765 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.495 ' OD2' ' N ' ' A' ' 28' ' ' ARG . 98.3 m-20 -72.66 140.02 47.67 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.987 0.422 . . . . 0.0 110.59 179.37 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 53.4 mttp -107.19 125.78 51.55 Favored 'General case' 0 N--CA 1.476 0.859 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.38 179.017 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.3 m -136.65 162.4 35.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 178.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -100.56 123.89 45.37 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-O 120.835 0.35 . . . . 0.0 110.555 -179.738 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.428 HG23 HD12 ' A' ' 35' ' ' ILE . 96.7 mt -84.68 130.12 36.55 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.128 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.469 179.588 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.5 mt -98.88 -54.86 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.196 -179.603 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 8.7 ttmm -150.64 153.01 34.88 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-O 120.799 0.333 . . . . 0.0 110.974 -179.405 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . 0.448 ' CD ' ' CE1' ' A' ' 43' ' ' TYR . 83.5 tt0 -112.86 122.65 48.28 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.146 179.351 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 62.7 t -130.73 132.88 63.97 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.154 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 53.2 25.46 4.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.011 179.431 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.63 -24.62 25.03 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 179.625 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 33.2 m95 -74.38 144.74 44.24 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.762 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . 0.448 ' CE1' ' CD ' ' A' ' 38' ' ' GLU . 78.3 m-85 -105.98 131.67 53.0 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 120.852 0.358 . . . . 0.0 110.847 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 76.9 tt0 -88.21 123.23 32.63 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.328 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.417 HD13 HG23 ' A' ' 45' ' ' ILE . 46.2 pt -126.95 160.66 35.22 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.673 0 CA-C-O 121.594 0.711 . . . . 0.0 110.944 -179.017 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 12.5 ttm180 -122.6 129.46 51.92 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.123 -0.944 . . . . 0.0 110.853 -179.285 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 59.2 t80 -148.69 131.55 16.11 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.257 -179.82 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.411 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 17.1 t-20 57.48 36.74 27.32 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.907 179.518 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 69.64 15.36 70.89 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 179.774 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 35.9 ttmt -117.18 137.22 52.48 Favored 'General case' 0 N--CA 1.466 0.329 0 N-CA-C 110.321 -0.252 . . . . 0.0 110.321 -179.714 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 53.4 t -111.11 131.04 63.43 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.86 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -145.17 -161.94 9.33 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.759 -0.936 . . . . 0.0 110.759 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 81.3 m-85 -138.58 154.21 48.7 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 120.721 0.296 . . . . 0.0 110.396 -179.689 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -145.18 150.54 36.92 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.198 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' SER . . . . . 0.46 ' OG ' ' CD2' ' A' ' 58' ' ' TYR . 8.7 p -75.49 153.0 37.79 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.097 0.475 . . . . 0.0 111.434 -179.177 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -65.95 -30.17 70.7 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.63 -0.713 . . . . 0.0 111.609 179.278 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 95.8 p -55.67 -28.95 58.3 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.532 -178.719 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' TYR . . . . . 0.46 ' CD2' ' OG ' ' A' ' 55' ' ' SER . 19.9 m-85 -108.52 -6.22 16.19 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 111.446 0.165 . . . . 0.0 111.446 -179.709 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.4 mp -112.68 130.05 67.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 N-CA-C 109.595 -0.521 . . . . 0.0 109.595 -179.764 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 92.8 m -123.63 132.03 53.76 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-N 115.716 -0.674 . . . . 0.0 109.979 179.591 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.3 mt -76.82 131.4 34.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.625 -179.63 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 95.3 t . . . . . 0 C--N 1.33 -0.24 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.26 179.641 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 23.0 mp0 . . . . . 0 N--CA 1.463 0.189 0 CA-C-O 120.813 0.339 . . . . 0.0 110.253 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -85.34 163.73 37.66 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.881 -0.888 . . . . 0.0 110.881 179.803 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 77.3 t -127.1 134.13 66.74 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-O 120.85 0.357 . . . . 0.0 110.131 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 19.8 t -83.15 128.39 38.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.55 179.76 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 68.0 mmtt -123.02 105.5 10.02 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.151 179.652 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.6 m -148.79 157.92 7.07 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.557 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 50.9 p30 -83.96 -9.78 58.43 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.81 179.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' SER . . . . . 0.473 ' OG ' ' N ' ' A' ' 10' ' ' ALA . 48.4 t -155.24 -165.26 1.97 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.856 0.36 . . . . 0.0 110.722 -179.759 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.473 ' N ' ' OG ' ' A' ' 9' ' ' SER . . . -64.38 143.55 57.82 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.659 -179.858 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 47.3 tp -121.55 133.08 55.01 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-O 120.953 0.406 . . . . 0.0 110.307 179.675 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 99.5 m-20 -82.74 142.47 31.59 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.991 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 49.6 ttp -113.48 148.57 35.72 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.939 179.544 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . 0.81 ' NH2' ' CH2' ' A' ' 42' ' ' TRP . 43.4 mtm180 -121.41 153.87 37.27 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-O 121.117 0.484 . . . . 0.0 111.599 -179.001 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 11.3 t -62.76 -41.83 99.4 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.439 179.748 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -140.99 -164.97 10.13 Favored Glycine 0 N--CA 1.466 0.676 0 N-CA-C 111.382 -0.687 . . . . 0.0 111.382 -179.401 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -85.03 71.41 5.08 Favored 'Trans proline' 0 C--N 1.31 -1.471 0 C-N-CA 122.893 2.395 . . . . 0.0 112.103 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . 0.707 ' N ' HH12 ' A' ' 14' ' ' ARG . . . -167.74 120.22 0.89 Allowed Glycine 0 CA--C 1.523 0.545 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 179.654 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 8.9 t -60.95 -9.01 3.6 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.944 0.402 . . . . 0.0 110.326 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 11.8 m120 -89.79 5.55 45.57 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.993 -179.456 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 22.0 m-85 -88.22 -7.94 56.05 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 120.681 0.277 . . . . 0.0 110.377 179.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 67.68 179.07 14.02 Favored Glycine 0 CA--C 1.521 0.447 0 N-CA-C 110.84 -0.904 . . . . 0.0 110.84 179.641 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 9.3 p -92.18 124.21 44.57 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.183 0 CA-C-O 120.787 0.327 . . . . 0.0 110.704 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 24.4 pt -104.35 -5.52 9.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.802 -179.856 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.65 177.05 47.52 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 111.038 -0.825 . . . . 0.0 111.038 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 91.0 m -126.56 130.47 50.61 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-O 120.853 0.359 . . . . 0.0 110.301 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 72.7 mt -112.38 146.31 38.55 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.22 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 87.0 mtm-85 -115.42 161.51 18.46 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.028 179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.518 ' C ' ' H ' ' A' ' 31' ' ' ASP . 50.8 p30 -69.13 166.77 17.52 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.929 -179.501 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 56.5 t30 71.03 -27.85 0.18 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.509 179.735 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.518 ' H ' ' C ' ' A' ' 29' ' ' ASN . 33.9 m-20 -67.48 137.6 55.95 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.583 -0.447 . . . . 0.0 109.926 179.954 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 18.1 ptpt -104.06 145.81 29.63 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.654 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.0 m -133.91 161.72 40.5 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.266 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.234 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -92.28 132.93 36.3 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.231 -0.44 . . . . 0.0 109.875 179.552 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 5.5 mm -98.89 125.77 52.26 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 CA-C-O 120.947 0.404 . . . . 0.0 110.721 -179.461 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.6 mt -93.14 -46.88 13.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.565 179.828 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 31.6 ttpt -173.03 162.57 4.62 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 120.941 0.4 . . . . 0.0 111.153 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . 0.501 ' OE1' ' CE1' ' A' ' 43' ' ' TYR . 82.2 tt0 -110.54 124.05 51.1 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.034 179.497 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 96.9 t -128.04 131.63 69.31 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.099 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 54.41 29.99 11.97 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.569 178.886 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.69 -11.25 64.68 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 111.254 -0.739 . . . . 0.0 111.254 179.388 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.81 ' CH2' ' NH2' ' A' ' 14' ' ' ARG . 82.8 m95 -89.45 143.25 26.97 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.604 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . 0.501 ' CE1' ' OE1' ' A' ' 38' ' ' GLU . 53.4 m-85 -100.94 130.52 46.95 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.732 0.301 . . . . 0.0 110.654 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -82.54 132.57 35.19 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 179.157 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 43.2 pt -132.67 153.02 37.28 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.241 0 CA-C-O 121.098 0.475 . . . . 0.0 111.236 -179.474 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 60.3 ttp180 -127.6 125.36 40.1 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.515 -0.766 . . . . 0.0 109.923 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.443 ' O ' ' OD1' ' A' ' 48' ' ' ASN . 19.0 t80 -151.4 146.13 25.74 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.886 -179.276 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.443 ' OD1' ' O ' ' A' ' 47' ' ' PHE . 8.2 p-10 47.19 38.2 6.54 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.526 179.723 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 67.62 23.1 73.76 Favored Glycine 0 CA--C 1.522 0.5 0 N-CA-C 111.33 -0.708 . . . . 0.0 111.33 179.085 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 69.4 mmtt -128.33 144.13 51.09 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.825 0.345 . . . . 0.0 110.143 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 75.4 t -113.82 133.29 60.27 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.205 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.158 -179.678 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -153.32 -166.26 14.38 Favored Glycine 0 CA--C 1.521 0.431 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 179.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 45.9 m-85 -136.24 155.88 49.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.837 0.351 . . . . 0.0 110.062 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -137.22 154.97 50.05 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.548 -179.647 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 41.3 t -61.78 142.39 57.32 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.505 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 61.9 pttt -68.24 -31.67 71.31 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.353 -179.601 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 19.8 m -60.92 -41.32 95.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.822 -179.245 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 70.7 m-85 -96.23 11.9 32.85 Favored 'General case' 0 N--CA 1.467 0.411 0 N-CA-C 111.837 0.31 . . . . 0.0 111.837 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 5.4 mm -121.33 129.32 75.72 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 CA-C-O 121.01 0.433 . . . . 0.0 110.503 179.748 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 99.4 m -122.71 127.52 49.36 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.348 179.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.7 mt -83.2 131.16 34.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.568 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 94.3 t . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.312 -0.403 . . . . 0.0 110.471 -179.852 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 22.4 mm100 . . . . . 0 N--CA 1.464 0.267 0 CA-C-O 120.911 0.386 . . . . 0.0 110.373 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -87.58 156.94 28.36 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 110.813 -0.915 . . . . 0.0 110.813 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 59.1 t -125.88 132.71 70.39 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.632 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 21.9 t -81.68 128.66 38.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.675 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 71.2 mmtt -115.48 105.84 13.28 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.188 -0.46 . . . . 0.0 109.764 179.512 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 12.5 p -145.79 155.88 12.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.535 -179.711 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 9.6 m120 -62.56 -41.45 98.92 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.909 -179.426 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 21.5 m -136.59 -57.58 0.74 Allowed 'General case' 0 N--CA 1.466 0.326 0 CA-C-O 120.656 0.265 . . . . 0.0 110.92 -179.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -157.65 144.62 18.15 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.8 0.333 . . . . 0.0 110.558 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 44.9 tp -111.83 130.62 55.75 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.463 -179.627 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . 0.4 ' OD1' ' O ' ' A' ' 12' ' ' ASN . 47.3 p-10 -71.95 137.99 47.73 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.701 179.762 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 37.7 ttp -100.45 136.69 39.94 Favored 'General case' 0 N--CA 1.464 0.275 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 179.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . 0.64 HH21 ' HG ' ' A' ' 19' ' ' SER . 84.0 mtt85 -107.67 157.52 18.02 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.669 -179.143 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 85.6 p -84.18 -10.34 57.82 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.681 179.795 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -161.99 -171.89 28.68 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 111.161 -0.776 . . . . 0.0 111.161 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_endo -84.02 68.84 6.61 Favored 'Trans proline' 0 C--N 1.309 -1.549 0 C-N-CA 122.815 2.344 . . . . 0.0 111.653 -179.833 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -179.97 134.77 2.3 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' SER . . . . . 0.64 ' HG ' HH21 ' A' ' 14' ' ' ARG . 15.9 m -76.89 -8.94 58.27 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.724 0.297 . . . . 0.0 111.003 -179.526 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 67.1 t30 -83.59 -1.48 53.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.878 -179.798 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 50.1 m-85 -86.71 -5.93 58.98 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 120.768 0.318 . . . . 0.0 110.294 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 77.18 166.35 25.74 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.92 -0.872 . . . . 0.0 110.92 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 14.4 p -95.26 127.25 47.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.731 0.3 . . . . 0.0 110.481 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 25.4 pt -101.89 -5.06 9.23 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.288 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.804 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.76 -177.43 47.37 Favored Glycine 0 CA--C 1.529 0.948 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 62.8 p -134.74 157.99 45.28 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-O 120.885 0.374 . . . . 0.0 111.025 -179.705 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 67.6 mt -124.88 145.06 49.99 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.168 -0.469 . . . . 0.0 109.846 179.804 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 13.8 mtm180 -93.63 173.48 7.67 Favored 'General case' 0 C--O 1.233 0.235 0 CA-C-O 121.262 0.553 . . . . 0.0 110.847 179.863 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.433 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 51.7 p-10 -73.6 144.48 45.96 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.43 -0.804 . . . . 0.0 109.554 178.359 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 12.3 t-20 58.49 34.7 24.15 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.564 -0.289 . . . . 0.0 111.192 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -88.79 112.7 23.52 Favored 'General case' 0 N--CA 1.468 0.44 0 N-CA-C 110.018 -0.364 . . . . 0.0 110.018 179.447 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -75.88 130.37 38.43 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 120.665 -0.414 . . . . 0.0 110.091 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 33.2 m -137.87 163.24 30.46 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-O 120.902 0.382 . . . . 0.0 110.689 -179.696 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -102.28 123.64 46.44 Favored 'General case' 0 N--CA 1.463 0.203 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.265 179.805 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.412 HG22 HD12 ' A' ' 35' ' ' ILE . 96.2 mt -89.06 126.03 42.09 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.169 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.408 179.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.7 mt -92.91 -47.11 13.91 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.183 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.678 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 32.2 ttpt -168.94 158.0 8.42 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.876 -179.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -108.4 120.98 43.98 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.962 179.819 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 77.8 t -126.22 132.31 70.61 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.849 -179.442 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 47.5 t0 58.14 25.92 13.07 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.394 179.056 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.93 -10.69 67.18 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 179.774 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 65.9 m95 -89.56 144.63 25.87 Favored 'General case' 0 C--N 1.331 -0.198 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 179.407 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 79.9 m-85 -97.43 127.91 43.78 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.87 0.367 . . . . 0.0 110.45 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 79.4 tt0 -88.3 126.62 35.27 Favored 'General case' 0 CA--C 1.522 -0.119 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 179.499 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 42.0 pt -132.47 161.48 41.39 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.283 0 CA-C-O 121.011 0.434 . . . . 0.0 111.784 -178.752 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 78.7 ttt-85 -114.64 124.38 51.69 Favored 'General case' 0 N--CA 1.464 0.268 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 178.806 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 45.5 t80 -156.68 146.06 20.55 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.924 0.392 . . . . 0.0 111.191 -179.106 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 54.9 t30 58.76 31.63 21.39 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.356 179.59 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 69.74 18.56 74.2 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 111.704 -0.558 . . . . 0.0 111.704 178.783 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.4 ' CB ' ' HZ3' ' A' ' 50' ' ' LYS . 1.0 OUTLIER -144.37 152.4 40.65 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 120.825 0.345 . . . . 0.0 110.775 -179.965 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.8 t -85.59 157.99 3.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.176 179.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -167.84 -178.2 39.68 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 111.422 -0.671 . . . . 0.0 111.422 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 85.1 m-85 -133.33 153.02 51.94 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 120.734 0.302 . . . . 0.0 110.4 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -139.65 152.32 46.65 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.008 -179.824 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 27.2 t -64.91 142.36 58.46 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.033 -179.796 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 61.3 pttt -66.79 -33.65 76.09 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.461 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 38.9 t -61.69 -42.99 99.67 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.602 -178.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 90.2 m-85 -90.43 4.02 52.19 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.66 -0.245 . . . . 0.0 111.48 -179.115 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 5.8 mm -119.7 127.99 75.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 CA-C-O 120.909 0.385 . . . . 0.0 110.246 179.797 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 94.4 m -123.69 129.75 51.58 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.422 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.409 HG21 HD11 ' A' ' 61' ' ' ILE . 96.0 mt -80.12 131.75 33.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.649 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 93.9 t . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.14 179.62 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 . . . . . 0 N--CA 1.466 0.338 0 CA-C-O 120.82 0.343 . . . . 0.0 110.606 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -89.44 166.53 33.24 Favored Glycine 0 CA--C 1.522 0.491 0 N-CA-C 110.542 -1.023 . . . . 0.0 110.542 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 56.1 t -124.11 129.33 74.19 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.756 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 13.7 t -97.01 110.28 24.69 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.145 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.092 179.795 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 32.0 ttmt -119.11 120.01 35.89 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.162 179.764 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 9.3 p -140.59 159.72 24.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.32 -179.884 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 28.9 t-20 -60.85 -41.58 96.14 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.352 -178.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 5.1 t -130.14 -68.47 0.7 Allowed 'General case' 0 N--CA 1.467 0.419 0 CA-C-O 120.901 0.381 . . . . 0.0 110.563 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -158.11 144.14 17.21 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.997 -0.547 . . . . 0.0 109.948 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 40.0 tp -111.45 129.06 56.15 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-O 120.895 0.378 . . . . 0.0 110.585 -179.525 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 77.2 m-20 -75.69 141.43 42.72 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.413 179.694 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 30.9 ttp -102.73 147.52 26.74 Favored 'General case' 0 N--CA 1.47 0.575 0 CA-C-N 116.701 -0.227 . . . . 0.0 111.14 -179.287 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 76.2 mtt85 -119.54 142.11 48.63 Favored 'General case' 0 CA--C 1.506 -0.74 0 CA-C-O 121.285 0.564 . . . . 0.0 111.934 -178.819 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 78.9 p -66.98 -39.51 87.19 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.079 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -115.4 170.34 13.24 Favored Glycine 0 CA--C 1.527 0.793 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 179.509 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.3 Cg_endo -79.51 58.25 6.87 Favored 'Trans proline' 0 N--CA 1.492 1.425 0 C-N-CA 122.644 2.229 . . . . 0.0 112.175 179.557 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -176.99 149.68 9.73 Favored Glycine 0 CA--C 1.532 1.11 0 C-N-CA 120.938 -0.648 . . . . 0.0 111.756 179.879 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 32.7 t -64.37 -16.14 61.74 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 120.869 0.366 . . . . 0.0 110.888 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -72.67 -7.39 50.17 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.984 -179.536 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 55.9 m-85 -92.52 -6.21 50.15 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-O 120.635 0.255 . . . . 0.0 110.801 -179.877 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 67.03 -175.78 23.28 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 110.978 -0.849 . . . . 0.0 110.978 179.681 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 10.9 p -105.29 128.86 58.89 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 CA-C-O 120.81 0.338 . . . . 0.0 110.77 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 41.6 pt -105.94 -6.76 10.07 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.551 179.462 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.39 -177.25 44.31 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 -179.849 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 57.8 p -131.17 155.95 46.14 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-O 120.924 0.392 . . . . 0.0 110.358 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 71.4 mt -123.76 149.48 45.57 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.77 -179.583 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 34.5 ttp85 -113.7 143.17 45.05 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 -179.561 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.432 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 57.2 p30 -46.65 153.38 0.39 Allowed 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.316 0.579 . . . . 0.0 112.263 -179.022 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 63.3 m-20 58.93 31.25 21.14 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.106 -0.952 . . . . 0.0 111.856 179.299 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 29.3 t0 -93.55 118.16 31.0 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-O 120.68 0.276 . . . . 0.0 110.258 179.11 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 29.5 mmtp -72.97 132.37 43.34 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 109.986 -0.375 . . . . 0.0 109.986 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 26.8 m -138.41 160.97 31.54 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.518 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -108.39 120.25 41.87 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.031 179.566 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.402 HG21 HD12 ' A' ' 35' ' ' ILE . 95.8 mt -85.46 128.81 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.155 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.527 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 26.1 mt -93.63 -61.31 2.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.188 -179.742 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 22.0 mtmm -149.31 158.51 44.24 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.747 179.608 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . 0.408 ' CD ' ' CE1' ' A' ' 43' ' ' TYR . 83.9 tt0 -111.35 122.47 47.94 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.049 179.616 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 74.8 t -125.35 130.02 72.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.598 -179.794 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 44.8 t0 52.57 27.29 4.97 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.101 179.333 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.02 -21.92 37.21 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 179.56 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 43.8 m95 -77.32 140.18 39.95 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . 0.408 ' CE1' ' CD ' ' A' ' 38' ' ' GLU . 71.0 m-85 -99.06 129.97 45.36 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.831 0.348 . . . . 0.0 110.341 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -88.13 120.46 29.51 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 179.413 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 45.6 pt -127.17 158.6 38.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.455 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.075 -179.195 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 16.4 ttm180 -119.95 126.46 50.92 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 116.203 -0.453 . . . . 0.0 109.979 179.61 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 71.7 t80 -145.26 140.93 28.17 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.129 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 12.0 t-20 58.69 33.25 22.94 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.601 -179.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 71.34 3.98 55.09 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 179.614 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -107.65 150.32 27.04 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-O 120.685 0.278 . . . . 0.0 110.589 -179.818 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 55.1 t -116.4 131.94 67.46 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.226 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.36 -160.1 9.62 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.854 -0.898 . . . . 0.0 110.854 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 78.2 m-85 -132.85 157.5 44.89 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.835 0.35 . . . . 0.0 110.367 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -141.15 151.19 43.67 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.254 179.803 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 19.8 m -64.55 148.13 51.39 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.61 -179.678 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 26.6 pttm -79.36 -20.93 46.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.067 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 78.4 p -66.07 -37.88 86.91 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.465 -179.794 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -97.03 -1.53 45.23 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 116.68 -0.237 . . . . 0.0 111.567 -179.119 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.3 mp -113.51 130.86 66.77 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 96.2 m -121.02 127.84 52.12 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.002 179.508 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.3 mt -80.56 129.25 37.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.405 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 94.8 t . . . . . 0 C--N 1.327 -0.403 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.964 -179.67 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 . . . . . 0 N--CA 1.465 0.321 0 CA-C-O 120.959 0.409 . . . . 0.0 110.757 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -88.63 162.21 31.52 Favored Glycine 0 CA--C 1.521 0.466 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 179.319 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 95.4 t -125.62 129.2 72.74 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.575 0 CA-C-O 120.985 0.422 . . . . 0.0 110.086 179.759 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 16.3 t -87.05 127.96 40.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.418 -179.748 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 63.6 mttp -124.13 107.56 11.38 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.129 -0.487 . . . . 0.0 109.982 179.634 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 11.9 p -140.27 151.41 21.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.434 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.63 -179.748 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.532 ' OD1' ' N ' ' A' ' 9' ' ' SER . 30.4 p30 -61.67 -42.64 99.19 Favored 'General case' 0 C--N 1.333 -0.127 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.196 -179.526 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' SER . . . . . 0.532 ' N ' ' OD1' ' A' ' 8' ' ' ASN . 8.0 t -125.07 -67.19 0.92 Allowed 'General case' 0 N--CA 1.47 0.541 0 CA-C-O 120.617 0.246 . . . . 0.0 110.94 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -158.24 144.77 17.48 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.777 0.322 . . . . 0.0 110.649 -179.603 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 44.9 tp -106.77 125.98 51.7 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.076 179.681 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -79.53 143.57 34.72 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.438 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 48.4 ttp -109.4 151.46 26.64 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 116.057 -0.519 . . . . 0.0 109.731 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 94.4 mtt-85 -127.63 151.53 48.82 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-O 120.924 0.392 . . . . 0.0 110.313 -179.274 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 35.0 t -62.36 -41.79 98.89 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.818 -179.34 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -124.97 163.16 19.07 Favored Glycine 0 N--CA 1.471 0.985 0 N-CA-C 111.482 -0.647 . . . . 0.0 111.482 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -68.32 86.32 0.42 Allowed 'Trans proline' 0 N--CA 1.496 1.628 0 C-N-CA 122.485 2.123 . . . . 0.0 111.692 179.543 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 164.4 143.31 3.67 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 111.218 -0.753 . . . . 0.0 111.218 179.581 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 75.4 p -66.44 -16.18 63.91 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.851 0.358 . . . . 0.0 110.825 179.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 50.5 p30 -80.64 -2.38 46.3 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.565 -179.542 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 47.0 m-85 -89.7 -7.77 53.85 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-O 120.756 0.312 . . . . 0.0 110.554 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 71.55 168.38 9.37 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 179.553 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 7.5 p -94.77 128.16 46.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 CA-C-O 120.79 0.329 . . . . 0.0 110.537 179.795 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 43.6 pt -108.2 -6.62 10.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.702 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -173.02 169.33 42.49 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 111.325 -0.71 . . . . 0.0 111.325 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 92.1 m -123.3 135.01 54.01 Favored 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 67.9 mt -107.72 155.16 20.5 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-O 120.871 0.367 . . . . 0.0 110.499 -179.559 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 90.2 mtm-85 -105.25 165.75 10.89 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.595 -179.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.402 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 52.6 p-10 -69.53 149.0 48.7 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.181 -179.613 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 21.7 t-20 56.12 32.98 21.13 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 115.91 -0.586 . . . . 0.0 111.014 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -89.92 116.27 27.85 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-O 120.825 0.345 . . . . 0.0 110.645 179.587 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 2.4 mmmp? -71.84 129.39 38.51 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.465 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.9 m -140.18 162.03 25.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.647 -179.496 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -104.89 121.06 42.91 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.353 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 89.3 mt -91.52 108.31 19.8 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.302 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 97.5 mt -67.41 -43.86 87.34 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.046 -0.524 . . . . 0.0 111.006 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 63.7 pttt -173.19 160.82 4.15 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.823 0.344 . . . . 0.0 111.001 -179.369 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -106.93 124.23 49.32 Favored 'General case' 0 N--CA 1.465 0.3 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 179.314 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 73.3 t -127.16 132.15 70.0 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 CA-C-O 120.952 0.406 . . . . 0.0 110.671 -179.436 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . 0.415 ' OD1' ' O ' ' A' ' 40' ' ' ASP . 36.1 t0 56.26 23.86 7.59 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.013 179.246 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.52 -10.02 74.95 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 111.016 -0.834 . . . . 0.0 111.016 179.705 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 34.3 m95 -91.21 149.26 21.85 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-O 120.751 0.31 . . . . 0.0 110.188 179.748 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 52.4 m-85 -99.94 130.84 46.16 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.136 -179.731 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . 0.412 ' CD ' ' HH ' ' A' ' 53' ' ' TYR . 76.1 tt0 -98.29 120.24 38.36 Favored 'General case' 0 CA--C 1.518 -0.269 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 179.223 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.41 HG23 HD12 ' A' ' 45' ' ' ILE . 39.2 pt -126.05 160.21 33.44 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.321 0 CA-C-O 120.969 0.414 . . . . 0.0 110.983 -179.207 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 43.6 ttm180 -117.89 127.85 54.26 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-N 115.694 -0.685 . . . . 0.0 109.503 179.486 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 34.1 t80 -144.77 131.17 19.72 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-O 121.16 0.505 . . . . 0.0 111.11 -179.736 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 6.1 m120 56.93 35.17 26.01 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 115.36 -0.837 . . . . 0.0 112.145 179.3 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 77.23 15.56 81.43 Favored Glycine 0 N--CA 1.465 0.592 0 C-N-CA 121.264 -0.493 . . . . 0.0 111.893 178.531 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -126.0 145.54 50.26 Favored 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 61.5 t -115.55 132.32 65.3 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.302 -179.732 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -149.67 -163.12 10.86 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . 0.412 ' HH ' ' CD ' ' A' ' 44' ' ' GLU . 62.1 m-85 -132.86 160.27 37.46 Favored 'General case' 0 N--CA 1.466 0.347 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -149.72 159.17 44.57 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.04 0.448 . . . . 0.0 111.061 -179.617 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 18.4 p -69.54 148.89 48.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.696 -0.683 . . . . 0.0 110.304 179.885 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.415 ' O ' ' O ' ' A' ' 59' ' ' ILE . 59.0 pttt -82.59 -19.12 39.04 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.77 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 39.1 t -62.07 -42.39 99.15 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.954 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 90.5 m-85 -92.19 3.81 54.55 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.336 -179.171 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . 0.423 HG23 HD11 ' A' ' 59' ' ' ILE . 98.1 mt -128.51 132.25 68.12 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 CA-C-O 120.699 0.285 . . . . 0.0 110.351 179.601 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 99.3 m -123.15 132.12 53.95 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.465 179.732 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 27.0 mm -80.45 129.46 37.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.063 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 35.7 m . . . . . 0 N--CA 1.469 0.476 0 CA-C-O 120.954 0.407 . . . . 0.0 110.427 -179.687 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 58.0 tt0 . . . . . 0 N--CA 1.467 0.388 0 CA-C-O 120.858 0.361 . . . . 0.0 110.231 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -93.16 155.2 22.22 Favored Glycine 0 CA--C 1.524 0.626 0 N-CA-C 111.054 -0.819 . . . . 0.0 111.054 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.414 ' CG1' ' HZ3' ' A' ' 6' ' ' LYS . 59.9 t -128.01 132.14 68.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.698 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 18.0 t -88.74 127.74 41.38 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.087 179.694 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.414 ' HZ3' ' CG1' ' A' ' 4' ' ' VAL . 64.7 mttp -124.57 105.81 9.65 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-O 120.912 0.386 . . . . 0.0 110.537 179.902 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 7.1 p -157.15 148.83 10.53 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-N 115.943 -0.572 . . . . 0.0 110.604 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.42 ' O ' ' ND2' ' A' ' 29' ' ' ASN . 7.7 m120 -68.54 -50.84 48.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.937 0.399 . . . . 0.0 110.554 179.452 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 9.2 p -95.88 165.53 12.23 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.564 179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -65.88 144.39 56.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.354 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 45.1 tp -111.22 132.78 54.07 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-O 120.972 0.415 . . . . 0.0 110.67 -179.794 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 6.2 m120 -78.02 146.26 35.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.892 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 40.0 ttp -98.11 148.66 23.32 Favored 'General case' 0 C--O 1.233 0.201 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.616 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 84.9 mtt85 -123.32 157.75 32.55 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 120.715 0.293 . . . . 0.0 110.493 -179.23 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' SER . . . . . 0.455 ' N ' ' CD1' ' A' ' 24' ' ' ILE . 88.5 p -84.11 -13.11 53.84 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.972 -179.321 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -162.31 -172.58 29.92 Favored Glycine 0 CA--C 1.529 0.952 0 C-N-CA 120.846 -0.692 . . . . 0.0 111.388 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -80.0 78.95 3.49 Favored 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.771 2.314 . . . . 0.0 112.143 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 167.4 134.12 1.65 Allowed Glycine 0 CA--C 1.524 0.603 0 C-N-CA 120.68 -0.771 . . . . 0.0 111.448 179.713 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 95.7 p -71.2 -12.3 61.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.95 0.405 . . . . 0.0 110.215 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 52.1 p-10 -78.91 -4.63 50.72 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.692 -179.822 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -85.85 -1.62 57.44 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.291 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 71.6 178.5 29.75 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 110.724 -0.95 . . . . 0.0 110.724 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 9.2 p -107.4 134.52 48.89 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.37 0 CA-C-O 120.861 0.362 . . . . 0.0 110.474 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.455 ' CD1' ' N ' ' A' ' 15' ' ' SER . 3.5 mp -106.0 -12.01 9.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.52 -179.758 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -173.55 -170.66 37.3 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 110.8 -0.92 . . . . 0.0 110.8 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 82.0 p -131.84 152.21 51.16 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 120.737 0.303 . . . . 0.0 110.302 179.846 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 78.5 mt -122.7 146.29 47.63 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.07 -0.514 . . . . 0.0 109.841 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -106.84 164.52 12.04 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.877 -179.364 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.42 ' ND2' ' O ' ' A' ' 8' ' ' ASN . 2.9 m-20 -64.07 148.93 48.66 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.671 -179.836 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 58.96 32.71 22.51 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.324 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 16.5 m-20 -82.0 137.38 35.12 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.113 179.02 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 63.3 mttp -104.99 122.73 46.46 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.858 0.361 . . . . 0.0 110.317 179.55 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.6 m -138.69 161.61 29.95 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.185 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.12 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -99.03 132.74 44.11 Favored 'General case' 0 C--O 1.234 0.287 0 N-CA-C 109.727 -0.472 . . . . 0.0 109.727 179.689 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.409 HD11 HG22 ' A' ' 35' ' ' ILE . 96.2 mt -100.71 107.5 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.309 179.917 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.8 mt -66.55 -43.87 90.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.89 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 63.6 pttt -173.05 169.98 4.52 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.829 -179.41 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . 0.429 ' CD ' ' CE1' ' A' ' 43' ' ' TYR . 83.1 tt0 -111.91 126.29 54.96 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.646 179.591 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 76.3 t -126.79 131.91 70.61 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 CA-C-O 121.07 0.462 . . . . 0.0 111.133 -179.438 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 52.65 30.42 8.68 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.661 -0.7 . . . . 0.0 111.759 178.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.14 -18.02 47.66 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 111.651 -0.58 . . . . 0.0 111.651 179.204 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 40.3 m95 -85.95 145.23 27.23 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.845 0.355 . . . . 0.0 110.244 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . 0.429 ' CE1' ' CD ' ' A' ' 38' ' ' GLU . 72.7 m-85 -100.75 126.99 47.34 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.481 -179.642 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 79.2 tt0 -78.54 152.42 31.95 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 179.715 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.4 pt -144.04 153.36 15.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.679 0.276 . . . . 0.0 110.854 -179.702 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 76.3 ttt180 -121.16 123.32 42.0 Favored 'General case' 0 N--CA 1.468 0.454 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.265 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 74.5 t80 -142.08 125.8 16.96 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-O 120.884 0.373 . . . . 0.0 110.885 -179.444 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 17.0 t-20 54.8 35.97 25.37 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.999 179.766 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 73.01 15.19 78.52 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 111.145 -0.782 . . . . 0.0 111.145 179.521 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.9 ttmp? -112.43 147.93 35.42 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 110.228 -0.286 . . . . 0.0 110.228 179.771 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.0 t -110.2 132.85 57.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.933 0.397 . . . . 0.0 110.32 -179.785 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . 0.467 ' C ' ' CD1' ' A' ' 53' ' ' TYR . . . -148.63 -165.02 11.84 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 179.823 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . 0.467 ' CD1' ' C ' ' A' ' 52' ' ' GLY . 72.9 m-85 -146.46 157.81 43.81 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.729 0.299 . . . . 0.0 110.456 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -141.63 155.72 45.7 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.398 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' SER . . . . . 0.403 ' O ' ' CG1' ' A' ' 59' ' ' ILE . 18.1 m -69.41 147.87 50.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.031 -179.623 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 62.0 pttt -66.34 -34.69 78.53 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.233 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 37.1 m -61.56 -41.11 96.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.706 -179.205 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 89.1 m-85 -94.22 7.64 44.57 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 116.518 -0.31 . . . . 0.0 111.002 -179.285 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . 0.403 ' CG1' ' O ' ' A' ' 55' ' ' SER . 5.3 mm -122.4 128.77 75.54 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-O 121.119 0.485 . . . . 0.0 110.293 179.637 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 86.8 m -122.56 126.89 48.67 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.512 -179.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.6 mt -91.22 127.9 43.32 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.497 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 33.2 m . . . . . 0 C--N 1.33 -0.256 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.437 179.873 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 27.0 mt-30 . . . . . 0 N--CA 1.464 0.265 0 CA-C-O 120.799 0.333 . . . . 0.0 110.131 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -84.69 164.88 39.81 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 -179.605 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 57.2 t -123.91 133.62 68.76 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.394 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 72.4 t -100.88 127.85 53.62 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-O 120.876 0.37 . . . . 0.0 110.314 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.656 ' HZ2' ' ND2' ' A' ' 30' ' ' ASN . 68.8 mmtt -119.58 106.41 12.17 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.559 179.423 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.495 ' O ' ' ND2' ' A' ' 29' ' ' ASN . 28.0 m -131.41 160.05 42.62 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.302 -179.456 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 52.8 t-20 -63.59 -41.67 98.34 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.097 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 4.3 t -150.7 -53.33 0.14 Allowed 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.464 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -157.64 142.88 16.96 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.422 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 65.1 tp -125.46 135.68 52.59 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 116.1 -0.5 . . . . 0.0 109.92 -179.802 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 13.7 m120 -77.93 138.83 39.09 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.197 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 50.5 ttp -98.11 138.59 35.18 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.074 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . 0.5 ' HE ' ' HA ' ' A' ' 19' ' ' SER . 22.0 mmt180 -103.9 156.96 17.42 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.517 -178.675 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 4.6 m -83.07 -7.68 59.62 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.76 -179.636 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -159.23 -169.63 22.8 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -83.24 72.21 5.82 Favored 'Trans proline' 0 C--N 1.304 -1.777 0 C-N-CA 122.659 2.239 . . . . 0.0 111.857 -179.755 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.78 147.81 6.34 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 111.104 -0.799 . . . . 0.0 111.104 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' SER . . . . . 0.5 ' HA ' ' HE ' ' A' ' 14' ' ' ARG . 15.7 m -81.47 -11.64 59.15 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.948 0.404 . . . . 0.0 110.728 -179.82 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 28.6 t-20 -84.14 7.06 20.09 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.979 -179.693 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 49.9 m-85 -92.71 -0.23 57.32 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 120.772 0.32 . . . . 0.0 110.414 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 75.62 179.22 44.61 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 7.2 p -108.84 125.31 65.85 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-O 120.826 0.345 . . . . 0.0 110.621 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 41.2 pt -108.66 -4.51 10.58 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.809 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -172.96 170.76 43.9 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 111.116 -0.793 . . . . 0.0 111.116 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 86.4 m -128.64 138.02 51.96 Favored 'General case' 0 N--CA 1.472 0.635 0 CA-C-O 120.494 0.187 . . . . 0.0 110.541 -179.673 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 77.4 mt -110.18 143.7 39.92 Favored 'General case' 0 N--CA 1.476 0.844 0 N-CA-C 112.12 0.415 . . . . 0.0 112.12 -178.793 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 49.2 mtt-85 -105.24 167.76 9.52 Favored 'General case' 0 N--CA 1.477 0.88 0 CA-C-O 121.773 0.797 . . . . 0.0 111.812 -179.079 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.495 ' ND2' ' O ' ' A' ' 7' ' ' VAL . 1.3 m-20 -64.32 146.17 54.83 Favored 'General case' 0 N--CA 1.437 -1.107 0 CA-C-N 114.993 -1.003 . . . . 0.0 108.976 -179.055 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . 0.656 ' ND2' ' HZ2' ' A' ' 6' ' ' LYS . 15.5 m120 57.07 34.41 24.86 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.287 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 67.1 t0 -88.27 110.39 20.7 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 110.016 -0.364 . . . . 0.0 110.016 179.329 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -78.61 132.67 37.19 Favored 'General case' 0 C--N 1.331 -0.212 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 -179.811 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 28.9 m -139.88 162.05 25.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.657 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -99.89 131.55 45.79 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.19 -0.459 . . . . 0.0 109.811 179.393 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 86.7 mt -96.65 126.77 49.26 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-N 116.33 -0.396 . . . . 0.0 111.022 -179.245 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.438 HD12 HG23 ' A' ' 36' ' ' ILE . 18.5 mm -94.71 -62.97 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.427 179.825 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 22.2 mtmm -148.33 159.78 43.65 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 120.918 0.39 . . . . 0.0 111.018 179.756 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -111.81 123.34 50.03 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.339 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 72.0 t -127.47 132.47 69.29 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.604 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 55.23 30.7 15.1 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.143 179.25 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.5 -16.6 34.3 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 111.02 -0.832 . . . . 0.0 111.02 179.711 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.616 ' CZ2' ' OG ' ' A' ' 55' ' ' SER . 11.7 m95 -83.58 147.37 27.78 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 179.423 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 46.2 m-85 -100.83 130.34 46.84 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 121.047 0.451 . . . . 0.0 110.941 -179.609 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -87.1 122.74 31.33 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 178.805 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 39.1 pt -130.59 161.62 40.12 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.407 0 CA-C-O 121.176 0.512 . . . . 0.0 111.537 -178.601 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 13.6 ttt180 -118.7 123.66 45.44 Favored 'General case' 0 N--CA 1.464 0.275 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.332 179.432 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 87.4 t80 -144.39 135.97 25.74 Favored 'General case' 0 N--CA 1.473 0.713 0 CA-C-O 120.824 0.345 . . . . 0.0 111.322 -178.401 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.438 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 17.6 t-20 57.51 34.84 25.14 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.7 179.347 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 69.45 18.46 73.56 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 179.77 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -124.67 146.14 49.29 Favored 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 66.5 t -113.99 131.56 65.56 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.389 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . 0.405 ' C ' ' CD1' ' A' ' 53' ' ' TYR . . . -150.47 -164.6 12.02 Favored Glycine 0 CA--C 1.52 0.39 0 N-CA-C 110.664 -0.974 . . . . 0.0 110.664 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . 0.427 ' N ' ' CD1' ' A' ' 53' ' ' TYR . 28.4 m-85 -134.96 156.71 48.54 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.796 0.332 . . . . 0.0 110.54 -179.737 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -146.67 150.6 35.73 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.028 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' SER . . . . . 0.616 ' OG ' ' CZ2' ' A' ' 42' ' ' TRP . 37.8 m -70.39 142.0 52.13 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 177.81 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 64.4 pttt -68.2 -13.07 61.96 Favored 'General case' 0 CA--C 1.51 -0.578 0 CA-C-O 121.8 0.809 . . . . 0.0 108.847 178.84 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 87.8 p -56.29 -14.0 2.55 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 114.015 -1.448 . . . . 0.0 109.321 178.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 91.7 m-85 -127.16 -28.26 2.88 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.202 179.816 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . 0.535 ' N ' ' CD1' ' A' ' 59' ' ' ILE . 1.3 mp -90.1 129.29 41.21 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 179.162 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 87.5 m -123.81 129.34 50.89 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.388 -179.881 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.548 ' N ' ' CD1' ' A' ' 61' ' ' ILE . 1.7 mp -83.0 128.14 39.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.286 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 15.7 m . . . . . 0 C--N 1.328 -0.336 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.319 179.807 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 78.2 mt-30 . . . . . 0 N--CA 1.463 0.209 0 CA-C-O 120.841 0.353 . . . . 0.0 110.204 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -87.18 158.1 29.91 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 97.7 t -127.65 133.3 67.93 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 179.703 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 71.9 t -93.33 128.2 44.92 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-N 116.46 -0.337 . . . . 0.0 110.392 -179.884 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 65.5 mttp -132.02 107.01 8.38 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.453 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.402 HG23 ' H ' ' A' ' 9' ' ' SER . 4.0 p -138.79 154.03 26.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.162 -179.897 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 92.1 m-20 -62.06 -42.85 99.62 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-O 120.83 0.348 . . . . 0.0 111.235 -178.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' SER . . . . . 0.402 ' H ' HG23 ' A' ' 7' ' ' VAL . 85.2 p -136.76 -153.84 0.52 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.035 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -66.98 143.15 56.97 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.017 0.437 . . . . 0.0 110.545 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 47.2 tp -122.0 130.46 53.32 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.062 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . 0.425 ' OD1' ' O ' ' A' ' 12' ' ' ASN . 45.1 p30 -82.12 140.53 33.76 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.693 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 58.1 ttp -108.33 138.65 44.25 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.215 -0.448 . . . . 0.0 109.869 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 4.3 mpt_? -106.45 157.37 17.69 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 120.983 0.42 . . . . 0.0 111.233 -178.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 84.2 p -82.27 -6.22 59.08 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.243 179.732 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -162.36 -174.86 32.76 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.765 -0.934 . . . . 0.0 110.765 179.762 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -80.94 79.09 3.41 Favored 'Trans proline' 0 C--N 1.306 -1.692 0 C-N-CA 122.86 2.373 . . . . 0.0 111.926 179.766 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 171.03 137.17 2.24 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 94.9 p -74.64 -7.7 54.04 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.764 0.316 . . . . 0.0 110.857 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 12.0 m120 -89.01 5.6 43.54 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.069 -179.414 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 42.7 m-85 -91.31 -0.56 57.68 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.869 0.366 . . . . 0.0 110.208 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 73.28 174.43 27.89 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 11.7 p -105.64 125.34 60.99 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-O 120.894 0.378 . . . . 0.0 110.412 179.743 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 40.8 pt -101.81 -4.75 9.26 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.758 -179.855 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -174.3 174.08 46.29 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 89.7 m -125.17 132.21 53.09 Favored 'General case' 0 N--CA 1.464 0.226 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.627 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 72.1 mt -108.09 143.93 36.16 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 116.194 -0.457 . . . . 0.0 109.968 -179.759 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 37.8 ttt85 -119.51 142.62 48.15 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.171 0.51 . . . . 0.0 110.26 179.42 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 44.0 p-10 -48.26 165.09 0.04 OUTLIER 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.65 -0.704 . . . . 0.0 111.0 -179.766 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 65.8 t30 62.8 6.48 2.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.554 -0.748 . . . . 0.0 111.366 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 31.5 t0 -87.13 118.68 26.68 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.548 -0.297 . . . . 0.0 110.663 179.517 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -76.3 137.39 39.86 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.2 179.471 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.2 m -137.39 162.05 33.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.62 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 48.4 tp10 -105.84 123.65 48.3 Favored 'General case' 0 C--O 1.234 0.274 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 179.581 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.5 mt -91.38 127.8 43.52 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.123 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.94 -179.355 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 81.9 mt -91.4 -51.27 11.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.176 179.597 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 62.6 pttt -174.9 179.0 1.71 Allowed 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.558 179.705 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -112.84 125.06 53.95 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.219 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 79.5 t -124.93 129.74 73.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.28 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . 0.44 ' OD1' ' O ' ' A' ' 40' ' ' ASP . 55.2 t0 54.74 24.28 5.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.071 179.362 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.86 -5.62 84.66 Favored Glycine 0 CA--C 1.526 0.753 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 179.739 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 56.4 m95 -90.52 149.38 22.2 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 179.364 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -96.88 130.35 44.18 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-O 121.098 0.475 . . . . 0.0 110.137 -179.669 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -94.47 126.51 39.79 Favored 'General case' 0 CA--C 1.506 -0.714 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.018 179.369 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 44.3 pt -125.93 160.76 32.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 121.356 0.598 . . . . 0.0 110.249 179.626 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 3.2 ttp180 -126.89 113.89 17.14 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 114.777 -1.101 . . . . 0.0 109.624 -176.763 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 61.8 t80 -141.51 139.1 33.2 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 120.947 0.403 . . . . 0.0 111.605 -178.111 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 15.0 t-20 57.13 34.62 25.15 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.904 179.298 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 69.74 20.71 76.08 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 111.431 -0.668 . . . . 0.0 111.431 179.52 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 53.9 mtmt -131.23 143.58 50.68 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-O 120.688 0.28 . . . . 0.0 110.823 -179.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 19.8 t -102.26 111.8 33.29 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 CA-C-O 121.115 0.483 . . . . 0.0 110.656 179.535 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -107.55 -172.69 22.17 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 111.053 -0.819 . . . . 0.0 111.053 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 48.1 m-85 -132.3 142.36 49.33 Favored 'General case' 0 C--N 1.331 -0.233 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 179.624 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -154.29 153.0 30.93 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.404 -179.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' SER . . . . . 0.489 ' HG ' ' H ' ' A' ' 57' ' ' SER . 48.5 t -70.1 148.15 49.1 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.787 -179.887 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 63.9 pttt -64.2 -17.65 63.75 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.73 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' SER . . . . . 0.489 ' H ' ' HG ' ' A' ' 55' ' ' SER . 38.6 t -65.7 -18.22 65.17 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.395 -179.669 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 71.7 m-85 -105.73 -19.16 13.84 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 121.271 -0.172 . . . . 0.0 111.323 -179.554 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . 0.455 ' N ' ' CD1' ' A' ' 59' ' ' ILE . 1.9 mp -109.87 130.99 62.04 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 CA-C-O 121.159 0.504 . . . . 0.0 110.631 -179.68 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 88.6 m -116.12 127.06 54.53 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-N 115.49 -0.777 . . . . 0.0 109.824 179.644 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.4 mt -78.91 133.21 30.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.774 -179.593 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 75.1 t . . . . . 0 C--N 1.332 -0.173 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.087 -179.907 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 . . . . . 0 N--CA 1.465 0.319 0 CA-C-O 120.884 0.373 . . . . 0.0 110.517 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -94.83 150.5 19.74 Favored Glycine 0 CA--C 1.521 0.452 0 N-CA-C 110.474 -1.05 . . . . 0.0 110.474 179.466 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 55.4 t -119.15 131.12 72.79 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 89.1 t -83.51 129.44 37.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.322 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 19.7 mmmt -115.35 106.27 13.82 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.128 179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.2 p -141.7 144.5 25.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.062 -179.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 19.3 m120 -63.04 -41.26 99.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.091 -179.607 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 44.4 m -133.03 -96.15 0.31 Allowed 'General case' 0 N--CA 1.466 0.363 0 CA-C-O 120.891 0.377 . . . . 0.0 110.402 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -112.97 143.65 43.89 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.409 179.886 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 42.8 tp -116.97 128.69 55.44 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 120.985 0.421 . . . . 0.0 110.086 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -82.94 138.64 33.74 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.478 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 37.5 ttp -103.63 152.11 22.14 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.294 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . 0.414 ' NH1' ' HG3' ' A' ' 14' ' ' ARG . 1.9 mtt85 -129.82 155.33 46.15 Favored 'General case' 0 CA--C 1.543 0.697 0 N-CA-C 109.198 -0.667 . . . . 0.0 109.198 -178.871 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 86.2 p -84.39 -4.92 59.18 Favored 'General case' 0 N--CA 1.478 0.936 0 N-CA-C 113.291 0.849 . . . . 0.0 113.291 -179.536 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -162.64 158.05 30.15 Favored Glycine 0 CA--C 1.524 0.63 0 C-N-CA 120.367 -0.921 . . . . 0.0 110.842 -179.073 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -64.5 87.61 0.16 Allowed 'Trans proline' 0 C--N 1.307 -1.622 0 C-N-CA 122.273 1.982 . . . . 0.0 111.64 -179.803 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 157.75 136.96 2.18 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 111.012 -0.835 . . . . 0.0 111.012 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 32.6 t -65.41 -13.13 58.0 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.777 0.322 . . . . 0.0 110.702 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -75.71 -3.7 36.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.254 -179.284 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 40.6 m-85 -90.0 -5.66 56.43 Favored 'General case' 0 C--N 1.332 -0.169 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.479 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 66.88 178.92 10.36 Favored Glycine 0 CA--C 1.522 0.477 0 N-CA-C 110.634 -0.986 . . . . 0.0 110.634 179.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 8.3 p -103.07 126.3 57.39 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.163 0 CA-C-O 120.783 0.325 . . . . 0.0 110.279 179.595 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 25.5 pt -101.97 -4.61 9.29 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.783 -179.677 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 175.35 -176.14 47.27 Favored Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 -179.866 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 59.6 p -134.87 158.67 43.64 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-O 120.848 0.356 . . . . 0.0 110.758 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 71.5 mt -122.63 150.39 42.72 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.015 -179.899 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . 0.676 HH11 ' HG3' ' A' ' 28' ' ' ARG . 1.0 OUTLIER -94.56 160.96 14.4 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 -179.24 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.427 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 51.7 p30 -64.97 150.48 47.94 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.614 -178.791 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 56.2 t-20 59.61 32.08 21.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.69 -0.687 . . . . 0.0 111.514 179.555 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.518 ' OD2' ' N ' ' A' ' 28' ' ' ARG . 77.5 m-20 -82.78 136.85 34.55 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 179.22 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 53.0 mtmt -107.88 122.25 46.41 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.13 179.299 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.7 m -135.95 162.35 36.63 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.416 -179.876 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -85.82 129.82 34.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.269 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.6 mt -100.19 121.38 50.85 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.265 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.328 179.889 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.415 HG23 HD12 ' A' ' 36' ' ' ILE . 77.8 mt -83.99 -46.95 18.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.103 -179.832 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 62.1 pttt -174.79 163.28 3.37 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.749 -179.602 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -107.21 124.44 49.74 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.305 179.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 77.4 t -124.42 130.2 73.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.616 -179.578 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.5 m-20 53.97 27.06 6.92 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.022 179.508 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.33 -11.38 67.98 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 111.201 -0.76 . . . . 0.0 111.201 179.595 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 72.9 m95 -87.65 148.68 24.7 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 110.118 -0.327 . . . . 0.0 110.118 179.747 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 7.0 m-85 -103.56 132.25 49.98 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-O 121.099 0.476 . . . . 0.0 110.581 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -93.73 121.89 35.62 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 178.307 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 41.6 pt -127.53 157.9 39.14 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-O 120.922 0.391 . . . . 0.0 111.284 -178.803 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 38.6 ttm180 -112.05 119.65 39.18 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.699 179.51 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 39.9 t80 -138.92 132.28 30.11 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.52 -179.433 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 64.3 t30 58.38 34.58 24.13 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.821 179.813 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 72.85 5.93 66.05 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.985 -0.846 . . . . 0.0 110.985 179.614 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 62.2 tttp -114.18 146.31 40.53 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.721 0.296 . . . . 0.0 110.576 -179.498 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 53.9 t -113.12 130.9 66.2 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.015 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -145.19 -161.7 9.21 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 110.978 -0.849 . . . . 0.0 110.978 -179.664 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 65.2 m-85 -122.15 157.08 32.31 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-O 120.662 0.268 . . . . 0.0 110.346 -179.852 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -144.59 154.68 43.1 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.63 -179.694 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 47.6 t -68.27 133.9 49.53 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.231 -179.46 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -65.5 -44.7 86.23 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.537 179.79 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 35.8 t -57.11 -19.11 17.86 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.255 -178.584 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 43.1 m-85 -103.57 6.31 37.2 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 116.504 -0.316 . . . . 0.0 111.218 -179.699 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 96.7 mt -131.82 132.23 61.81 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 CA-C-O 121.098 0.475 . . . . 0.0 111.455 179.756 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 92.5 m -123.41 130.55 52.87 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.085 179.33 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 22.1 mm -82.17 130.28 36.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.614 -179.781 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 99.5 t . . . . . 0 C--N 1.327 -0.371 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.449 -179.949 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 99.4 mt-30 . . . . . 0 N--CA 1.464 0.261 0 CA-C-O 120.764 0.316 . . . . 0.0 110.385 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -93.41 139.32 14.53 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.449 -1.06 . . . . 0.0 110.449 179.608 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 54.2 t -122.38 131.99 72.04 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.254 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 179.899 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 84.6 t -90.01 128.6 41.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.592 -179.431 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 55.4 mtpt -125.05 105.95 9.57 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.032 -0.531 . . . . 0.0 109.848 179.402 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 11.3 p -139.14 155.28 26.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.037 -179.61 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 23.4 t-20 -61.2 -41.24 96.49 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.144 -179.241 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 4.8 t -140.02 -62.78 0.51 Allowed 'General case' 0 N--CA 1.466 0.364 0 CA-C-O 120.747 0.308 . . . . 0.0 111.07 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -150.49 144.22 25.23 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.617 -179.63 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 50.8 tp -120.64 134.6 55.27 Favored 'General case' 0 N--CA 1.469 0.48 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.097 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . 0.426 ' OD1' ' O ' ' A' ' 12' ' ' ASN . 50.5 p-10 -81.47 140.11 34.79 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.669 -179.879 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 42.4 ttp -101.13 153.79 19.28 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.065 -179.706 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . 0.776 ' HG3' HH11 ' A' ' 14' ' ' ARG . 22.2 mtm-85 -125.83 156.83 38.95 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-O 121.381 0.61 . . . . 0.0 112.233 -178.196 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 94.0 p -80.52 -6.26 57.93 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.062 -0.972 . . . . 0.0 110.052 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -159.48 -171.0 24.75 Favored Glycine 0 CA--C 1.525 0.716 0 N-CA-C 110.942 -0.863 . . . . 0.0 110.942 179.678 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -87.05 6.99 5.04 Favored 'Trans proline' 0 C--N 1.305 -1.747 0 C-N-CA 122.744 2.296 . . . . 0.0 111.997 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -99.75 128.71 9.66 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 111.134 -0.787 . . . . 0.0 111.134 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 97.6 p -67.24 -10.33 49.55 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.786 0.327 . . . . 0.0 110.297 179.642 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 54.9 p30 -91.55 8.12 38.13 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.33 -179.574 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 19.6 m-85 -87.13 -5.59 58.96 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.904 0.383 . . . . 0.0 110.322 -179.896 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 72.53 177.14 30.45 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 111.587 -0.605 . . . . 0.0 111.587 179.039 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 7.2 p -97.54 126.96 50.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-O 120.844 0.354 . . . . 0.0 110.539 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 42.7 pt -106.88 -6.44 10.35 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.542 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.26 175.39 47.15 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 88.5 m -125.45 134.74 51.98 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-O 120.891 0.377 . . . . 0.0 110.337 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 82.1 mt -105.63 148.31 27.49 Favored 'General case' 0 CA--C 1.516 -0.334 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.891 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 31.8 mmm-85 -103.06 161.64 13.6 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.366 -0.834 . . . . 0.0 110.888 -179.098 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.428 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 25.5 p30 -65.71 143.02 57.8 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-O 121.186 0.517 . . . . 0.0 111.271 -179.362 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 66.3 t30 57.26 34.55 24.94 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.761 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 67.3 t0 -84.73 115.01 22.46 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.775 179.379 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 29.9 mmtp -72.7 128.37 35.34 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.89 0.376 . . . . 0.0 110.387 -179.329 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.3 m -137.81 161.24 33.29 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.222 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.15 179.832 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.531 ' N ' ' OE1' ' A' ' 34' ' ' GLU . 55.9 mp0 -106.54 123.69 48.47 Favored 'General case' 0 C--O 1.234 0.248 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.091 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.411 HG21 HD12 ' A' ' 35' ' ' ILE . 95.2 mt -88.52 128.07 41.01 Favored 'Isoleucine or valine' 0 C--O 1.232 0.153 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.45 -179.719 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.404 HD11 HG23 ' A' ' 36' ' ' ILE . 95.9 mt -98.19 -56.62 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.22 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.026 -179.763 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 47.1 mtpt -143.13 153.16 42.61 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 121.2 0.524 . . . . 0.0 111.262 -179.497 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . 0.438 ' CD ' ' CE1' ' A' ' 43' ' ' TYR . 84.3 tt0 -115.47 120.72 40.45 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.747 179.159 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 60.1 t -128.89 131.95 67.86 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.51 0 CA-C-O 120.899 0.381 . . . . 0.0 111.558 -179.48 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 54.11 26.47 6.59 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.35 179.285 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.86 -14.05 64.33 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 179.589 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 46.1 m95 -83.59 144.01 29.75 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 179.499 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . 0.438 ' CE1' ' CD ' ' A' ' 38' ' ' GLU . 65.0 m-85 -103.31 130.35 50.56 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.931 0.396 . . . . 0.0 110.676 -179.809 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 79.4 tt0 -90.08 122.5 33.11 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 179.312 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 24.1 pt -128.72 159.04 40.95 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-O 120.732 0.301 . . . . 0.0 111.309 -178.819 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . 0.43 ' HE ' ' HB2' ' A' ' 46' ' ' ARG . 9.4 ttm180 -118.01 128.65 54.98 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.271 -0.422 . . . . 0.0 109.957 179.553 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 42.1 t80 -146.54 135.28 22.25 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.557 -179.358 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 8.5 m120 56.53 33.82 23.27 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.838 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 73.82 6.33 72.24 Favored Glycine 0 CA--C 1.525 0.716 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 179.576 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 56.4 mtpt -110.41 147.52 33.84 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 120.644 0.259 . . . . 0.0 110.419 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 55.7 t -117.9 131.43 70.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 CA-C-N 116.274 -0.421 . . . . 0.0 109.956 179.674 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -149.4 -160.98 9.48 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.382 -1.087 . . . . 0.0 110.382 -179.914 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 67.6 m-85 -135.22 158.18 45.02 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.933 0.397 . . . . 0.0 110.766 -179.586 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -146.84 155.83 42.64 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.309 -179.848 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 20.2 m -69.77 151.46 45.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.792 -179.559 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 22.6 pttp -75.13 -18.83 60.15 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.718 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 74.7 m -61.85 -42.94 99.66 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.699 -179.589 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 82.8 m-85 -96.73 -2.38 44.55 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.524 0.202 . . . . 0.0 111.395 -179.187 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.6 mp -113.86 128.66 70.68 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 179.46 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 91.7 m -124.88 130.35 52.21 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.055 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.435 HG22 HD12 ' A' ' 61' ' ' ILE . 22.1 mm -78.46 129.61 37.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.353 -179.593 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 94.1 t . . . . . 0 C--N 1.332 -0.182 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.616 -179.908 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 85.8 mt-30 . . . . . 0 N--CA 1.464 0.238 0 N-CA-C 109.897 -0.409 . . . . 0.0 109.897 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -88.59 149.74 21.31 Favored Glycine 0 CA--C 1.523 0.576 0 N-CA-C 111.279 -0.728 . . . . 0.0 111.279 -179.529 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 53.8 t -126.65 132.55 70.06 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 179.818 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 83.0 t -91.11 128.76 42.71 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.196 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.359 179.757 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -125.63 106.46 9.76 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.318 179.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.0 p -138.02 145.4 28.79 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 116.263 -0.426 . . . . 0.0 109.862 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.526 ' OD1' ' N ' ' A' ' 9' ' ' SER . 38.7 p-10 -62.39 -41.18 98.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.776 -179.57 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' SER . . . . . 0.526 ' N ' ' OD1' ' A' ' 8' ' ' ASN . 6.9 t -123.28 -141.33 0.31 Allowed 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.424 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -92.73 144.15 25.59 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.491 179.788 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.408 ' CD1' ' CG ' ' A' ' 58' ' ' TYR . 6.4 tt -121.57 134.42 55.02 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.594 -179.828 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 11.1 m120 -75.88 134.62 40.25 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.226 -179.412 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 27.4 ttt -89.05 152.68 21.53 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-N 115.847 -0.615 . . . . 0.0 109.485 179.104 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 84.2 mtt85 -124.71 144.35 50.27 Favored 'General case' 0 N--CA 1.478 0.971 0 CA-C-O 120.449 0.166 . . . . 0.0 111.026 -179.752 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 23.2 t -89.11 -2.18 58.42 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.909 0.385 . . . . 0.0 110.452 179.3 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -163.41 160.29 32.95 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.35 -1.1 . . . . 0.0 110.35 179.779 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_endo -62.69 99.02 0.2 Allowed 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.368 2.045 . . . . 0.0 111.891 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 135.35 141.82 4.44 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 110.573 -1.011 . . . . 0.0 110.573 179.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 35.3 t -67.53 -16.0 63.96 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.78 0.324 . . . . 0.0 110.725 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 52.6 t30 -84.87 8.38 17.63 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.687 -179.05 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 39.5 m-85 -96.85 8.24 44.82 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-O 120.766 0.317 . . . . 0.0 110.31 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 85.07 176.52 50.79 Favored Glycine 0 CA--C 1.522 0.502 0 N-CA-C 111.355 -0.698 . . . . 0.0 111.355 179.663 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 14.8 p -121.27 133.84 66.57 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 CA-C-O 120.669 0.271 . . . . 0.0 110.397 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 94.8 mt -92.93 -15.25 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-O 120.869 0.366 . . . . 0.0 110.589 -179.696 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 157.35 -145.59 12.22 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 110.668 -0.973 . . . . 0.0 110.668 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 71.2 p -133.71 155.13 50.29 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-O 120.977 0.418 . . . . 0.0 110.309 179.75 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 85.0 mt -124.67 146.57 49.06 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.227 -179.79 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . 0.459 ' N ' ' OD2' ' A' ' 31' ' ' ASP . 31.8 mtp85 -107.47 170.06 8.2 Favored 'General case' 0 CA--C 1.506 -0.714 0 CA-C-O 121.575 0.702 . . . . 0.0 111.206 -179.771 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 56.9 p30 -69.37 157.17 37.57 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 114.466 -1.243 . . . . 0.0 110.761 179.083 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 8.9 m120 59.29 31.49 21.2 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 114.921 -1.036 . . . . 0.0 111.085 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.459 ' OD2' ' N ' ' A' ' 28' ' ' ARG . 98.5 m-20 -93.56 111.13 22.74 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-O 120.696 0.284 . . . . 0.0 110.419 179.343 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 56.2 mtpt -73.64 133.91 43.54 Favored 'General case' 0 C--N 1.328 -0.363 0 C-N-CA 120.639 -0.424 . . . . 0.0 109.986 179.599 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.7 m -136.59 160.9 37.33 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 120.84 0.353 . . . . 0.0 110.674 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -107.86 119.11 38.54 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 116.121 -0.491 . . . . 0.0 109.808 179.395 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.409 HG23 HD13 ' A' ' 35' ' ' ILE . 97.0 mt -84.07 126.88 40.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.604 -179.533 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.558 ' CD1' ' N ' ' A' ' 36' ' ' ILE . 1.6 mp -94.33 -65.43 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.195 0 CA-C-N 116.197 -0.456 . . . . 0.0 109.983 179.9 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 50.4 mtmt -148.28 156.99 43.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.456 179.494 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . 0.45 ' CD ' ' CE1' ' A' ' 43' ' ' TYR . 83.6 tt0 -113.42 123.45 50.1 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.565 179.773 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 67.8 t -130.6 132.33 64.47 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.189 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 55.28 33.59 21.0 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.781 178.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 83.69 -11.39 56.59 Favored Glycine 0 CA--C 1.525 0.688 0 C-N-CA 120.965 -0.636 . . . . 0.0 111.715 179.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 84.2 m95 -89.72 140.69 29.32 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 179.725 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . 0.45 ' CE1' ' CD ' ' A' ' 38' ' ' GLU . 62.9 m-85 -101.56 126.43 48.37 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.822 0.344 . . . . 0.0 110.418 179.709 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -82.29 128.8 34.56 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.321 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 43.4 pt -129.48 156.99 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-O 121.28 0.562 . . . . 0.0 111.641 -179.015 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 28.8 ttt180 -124.83 131.42 53.44 Favored 'General case' 0 CA--C 1.51 -0.578 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.106 178.238 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 38.9 t80 -152.57 135.9 15.86 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.791 -0.641 . . . . 0.0 110.532 179.773 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 10.9 m120 56.56 34.3 24.15 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.307 179.736 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 73.81 5.75 70.4 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.429 -0.668 . . . . 0.0 111.429 179.4 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -107.04 144.87 33.08 Favored 'General case' 0 N--CA 1.467 0.394 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.684 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 53.0 t -118.88 133.57 65.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 CA-C-O 120.939 0.399 . . . . 0.0 110.545 -179.372 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -159.91 -168.63 22.15 Favored Glycine 0 CA--C 1.524 0.638 0 N-CA-C 110.576 -1.01 . . . . 0.0 110.576 179.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . 0.444 ' N ' ' CD1' ' A' ' 53' ' ' TYR . 38.9 m-85 -127.5 156.33 42.33 Favored 'General case' 0 N--CA 1.464 0.271 0 N-CA-C 110.119 -0.326 . . . . 0.0 110.119 -179.702 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -140.0 157.17 46.09 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-O 120.861 0.363 . . . . 0.0 110.62 -179.752 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 28.5 t -63.01 140.49 58.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.211 -179.63 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 25.4 pttm -69.21 -28.75 66.64 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.308 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 52.9 m -59.93 -38.84 83.57 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.463 -179.187 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' TYR . . . . . 0.408 ' CG ' ' CD1' ' A' ' 11' ' ' LEU . 84.2 m-85 -94.81 15.17 19.15 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 111.758 0.281 . . . . 0.0 111.758 -179.012 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 5.5 mm -119.21 128.14 75.83 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 CA-C-O 120.939 0.399 . . . . 0.0 110.163 179.534 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 92.7 m -125.18 127.52 46.92 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.063 179.79 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.412 HG22 HD12 ' A' ' 61' ' ' ILE . 96.6 mt -87.76 125.8 41.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.419 179.782 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 2.3 m . . . . . 0 N--CA 1.465 0.293 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.374 179.876 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 . . . . . 0 N--CA 1.465 0.3 0 CA-C-O 120.962 0.41 . . . . 0.0 110.524 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -86.74 148.08 21.57 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 179.756 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 74.3 t -124.96 130.27 73.28 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 CA-C-O 120.971 0.415 . . . . 0.0 110.271 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 19.1 t -92.57 128.56 44.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.499 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 21.9 mmtp -121.86 105.3 10.23 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.342 -0.39 . . . . 0.0 109.997 179.525 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 19.0 m -139.34 159.65 28.58 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.482 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 18.3 t-20 -81.2 -13.81 58.2 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.639 179.881 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 12.3 t -159.1 -166.19 1.78 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.5 -179.673 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -65.43 143.29 57.8 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.201 179.603 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 44.9 tp -124.13 132.2 53.62 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-O 120.792 0.33 . . . . 0.0 110.293 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 14.3 m120 -75.24 142.77 43.32 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.297 179.688 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 12.0 tmm? -106.95 150.31 26.59 Favored 'General case' 0 N--CA 1.463 0.205 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 179.731 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . 0.699 ' NH2' ' H ' ' A' ' 22' ' ' GLY . 24.6 mtp85 -122.34 156.84 33.08 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-O 121.027 0.441 . . . . 0.0 110.572 -178.955 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 82.2 p -80.84 -6.42 58.56 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.584 -0.735 . . . . 0.0 111.046 -179.42 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.55 -168.95 20.72 Favored Glycine 0 CA--C 1.525 0.692 0 C-N-CA 120.831 -0.699 . . . . 0.0 111.422 -179.848 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -83.69 9.38 4.13 Favored 'Trans proline' 0 C--N 1.309 -1.511 0 C-N-CA 122.832 2.354 . . . . 0.0 112.631 -179.695 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -97.56 127.32 9.18 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' SER . . . . . 0.535 ' O ' ' NH2' ' A' ' 14' ' ' ARG . 96.1 p -70.97 -10.71 60.2 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.347 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 25.1 p30 -106.03 19.8 19.95 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.029 -179.712 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 0.412 ' N ' HH21 ' A' ' 14' ' ' ARG . 3.0 m-85 -86.3 -3.08 58.92 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.552 -0.294 . . . . 0.0 110.326 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.699 ' H ' ' NH2' ' A' ' 14' ' ' ARG . . . 81.1 168.61 40.24 Favored Glycine 0 CA--C 1.521 0.421 0 N-CA-C 111.01 -0.836 . . . . 0.0 111.01 179.913 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 9.7 p -102.25 124.7 56.34 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 CA-C-O 120.827 0.346 . . . . 0.0 110.421 179.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 23.1 pt -106.78 -0.22 9.98 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.804 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.83 167.8 39.77 Favored Glycine 0 CA--C 1.52 0.348 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 89.2 m -124.04 131.16 53.52 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 120.782 0.325 . . . . 0.0 110.626 -179.7 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 69.4 mt -101.67 161.48 13.62 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.744 -179.706 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 81.5 mtt180 -127.66 157.77 39.38 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 120.873 0.368 . . . . 0.0 110.247 179.54 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.436 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 52.7 p30 -57.25 150.64 17.41 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.285 -179.177 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 12.5 t-20 58.47 35.34 24.63 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.364 179.499 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 32.5 t0 -89.15 114.41 25.7 Favored 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 179.234 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -84.03 124.5 31.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.807 0.337 . . . . 0.0 110.357 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 28.2 m -138.22 162.39 30.59 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.94 -179.711 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . 0.634 ' OE1' ' NH1' ' A' ' 46' ' ' ARG . 78.1 tt0 -95.9 140.14 31.1 Favored 'General case' 0 C--O 1.233 0.222 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 179.054 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.42 HG22 HD13 ' A' ' 35' ' ' ILE . 91.3 mt -104.23 125.52 59.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.822 179.862 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 95.9 mt -93.03 -49.56 12.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.386 179.718 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 35.6 ttpt -172.79 157.66 3.76 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.659 -179.331 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . 0.502 ' H ' ' CD ' ' A' ' 38' ' ' GLU . 2.1 pm0 -110.0 143.56 39.82 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.35 -0.387 . . . . 0.0 110.371 179.833 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 34.4 t -129.95 126.35 62.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 CA-C-O 120.757 0.313 . . . . 0.0 110.644 -179.718 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 50.79 30.26 4.93 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.545 178.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 85.84 25.32 38.52 Favored Glycine 0 CA--C 1.525 0.687 0 C-N-CA 121.011 -0.614 . . . . 0.0 112.015 179.361 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 62.2 m95 -124.36 106.24 10.07 Favored 'General case' 0 N--CA 1.471 0.581 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.127 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 91.3 m-85 -70.97 135.3 47.8 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.968 0.413 . . . . 0.0 111.437 -179.243 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . 0.422 ' OE2' ' OH ' ' A' ' 53' ' ' TYR . 96.9 mt-10 -88.4 141.89 28.17 Favored 'General case' 0 CA--C 1.518 -0.262 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 178.325 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 39.9 pt -135.38 154.45 35.42 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.684 0 CA-C-O 121.627 0.727 . . . . 0.0 111.034 -179.582 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . 0.634 ' NH1' ' OE1' ' A' ' 34' ' ' GLU . 11.2 ttp180 -111.4 123.54 50.41 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 114.668 -1.151 . . . . 0.0 110.378 -179.917 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 66.9 t80 -151.72 134.91 15.91 Favored 'General case' 0 N--CA 1.463 0.224 0 C-N-CA 120.87 -0.332 . . . . 0.0 111.158 -179.497 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 55.3 t-20 57.96 35.11 25.01 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.423 179.603 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 66.87 22.5 72.12 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 111.091 -0.804 . . . . 0.0 111.091 179.738 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 54.9 mtpt -128.91 146.74 50.87 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 121.012 0.434 . . . . 0.0 111.019 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 53.8 t -113.51 131.77 64.33 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.922 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -143.97 -163.35 9.86 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -179.806 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . 0.422 ' OH ' ' OE2' ' A' ' 44' ' ' GLU . 44.8 m-85 -127.64 153.1 46.84 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 110.242 -0.281 . . . . 0.0 110.242 -179.675 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -146.69 151.33 37.03 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-N 116.383 -0.372 . . . . 0.0 110.642 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 41.0 t -65.14 143.72 57.69 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.744 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 26.0 pttm -67.58 -17.6 64.69 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.849 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 16.0 m -64.28 -36.06 82.86 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.44 -179.52 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 41.6 m-85 -103.85 12.04 34.94 Favored 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 111.978 0.362 . . . . 0.0 111.978 -178.175 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 46.2 mm -121.43 129.67 75.36 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.573 0 CA-C-O 120.931 0.396 . . . . 0.0 110.623 179.846 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 62.2 p -116.98 131.9 56.84 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.422 -179.601 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.411 HG23 HD13 ' A' ' 61' ' ' ILE . 96.6 mt -84.4 129.65 37.3 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.174 179.597 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 87.9 t . . . . . 0 C--N 1.327 -0.397 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.354 -179.915 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.423 ' CD ' ' N ' ' A' ' 2' ' ' GLN . 21.3 mp0 . . . . . 0 N--CA 1.465 0.321 0 CA-C-O 120.778 0.323 . . . . 0.0 110.416 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -99.62 147.56 18.33 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.625 -0.99 . . . . 0.0 110.625 179.772 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 54.3 t -124.73 130.78 73.31 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-O 120.927 0.394 . . . . 0.0 110.127 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 13.6 t -87.55 127.17 41.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.306 179.865 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -123.09 105.59 10.06 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.858 0.361 . . . . 0.0 110.068 179.491 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 14.8 p -156.51 139.09 6.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.559 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 66.2 t30 -67.84 -48.98 64.65 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.824 0.345 . . . . 0.0 110.756 179.606 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 5.5 m -93.96 152.48 18.81 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.575 179.799 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -61.47 142.7 56.83 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.532 -0.467 . . . . 0.0 110.194 179.568 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 41.1 tp -117.58 128.23 54.74 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.894 179.851 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . 0.533 ' ND2' HH12 ' A' ' 14' ' ' ARG . 21.2 p-10 -72.08 145.47 48.2 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.687 179.549 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 62.6 ttp -96.69 140.05 31.85 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-O 121.207 0.527 . . . . 0.0 110.663 -179.627 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . 0.817 ' HE ' ' HA ' ' A' ' 19' ' ' SER . 1.0 OUTLIER -93.8 153.82 18.08 Favored 'General case' 0 CA--C 1.541 0.608 0 CA-C-N 115.345 -0.843 . . . . 0.0 111.472 -178.443 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 78.5 p -88.34 -9.66 52.01 Favored 'General case' 0 N--CA 1.462 0.127 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.845 179.13 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -162.82 -173.05 31.05 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.154 -1.178 . . . . 0.0 110.154 179.729 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -80.67 78.29 3.72 Favored 'Trans proline' 0 C--N 1.298 -2.115 0 C-N-CA 122.584 2.189 . . . . 0.0 112.391 179.547 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 167.13 134.5 1.71 Allowed Glycine 0 CA--C 1.525 0.676 0 N-CA-C 111.371 -0.691 . . . . 0.0 111.371 179.769 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' SER . . . . . 0.817 ' HA ' ' HE ' ' A' ' 14' ' ' ARG . 23.2 t -68.32 -13.46 62.29 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 112.102 0.408 . . . . 0.0 112.102 -179.113 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 14.1 m120 -88.07 11.44 16.1 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.766 -179.762 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 17.8 m-85 -90.7 1.3 56.97 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.313 179.849 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 76.59 -173.47 54.4 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 179.848 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 4.8 p -118.87 127.69 75.74 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-O 120.841 0.353 . . . . 0.0 110.293 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 25.2 pt -110.21 -3.64 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.448 179.651 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.56 -176.55 43.89 Favored Glycine 0 CA--C 1.529 0.908 0 N-CA-C 111.246 -0.742 . . . . 0.0 111.246 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 69.4 p -131.55 155.29 47.73 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 120.647 0.26 . . . . 0.0 110.691 -179.82 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 84.1 mt -125.37 149.56 48.02 Favored 'General case' 0 N--CA 1.472 0.625 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.519 -179.35 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 92.1 mtt-85 -120.21 161.67 20.68 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 121.669 0.747 . . . . 0.0 111.103 -179.164 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 64.2 t30 -57.97 144.23 40.2 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.581 -178.608 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 59.2 34.23 23.06 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.47 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 65.7 t0 -85.25 114.89 22.68 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-O 120.778 0.323 . . . . 0.0 110.186 178.881 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -80.37 128.87 34.06 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.551 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.1 m -141.59 161.3 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.201 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.439 179.741 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 80.7 mm-40 -102.73 133.35 47.93 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.942 179.637 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.408 HD13 HG22 ' A' ' 35' ' ' ILE . 92.5 mt -102.75 109.43 26.63 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.625 -179.848 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 97.2 mt -66.46 -43.63 90.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.547 179.853 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 25.7 pttm -172.51 179.25 2.52 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.774 -179.401 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 2.5 tm-20 -112.89 124.62 53.03 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.179 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 54.1 t -125.66 133.01 70.16 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.784 -179.663 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 55.81 28.86 12.99 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.133 179.393 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.36 -8.6 57.96 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.854 -0.898 . . . . 0.0 110.854 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 11.1 m95 -94.05 148.38 22.23 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 110.035 -0.357 . . . . 0.0 110.035 179.633 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 64.2 m-85 -96.95 131.39 43.8 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.974 0.416 . . . . 0.0 110.689 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -83.18 152.99 25.0 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 108.496 -0.928 . . . . 0.0 108.496 178.499 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 34.5 pt -145.29 150.55 15.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 C-N-CA 120.707 -0.397 . . . . 0.0 111.143 -179.413 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . 0.454 ' HE ' ' HA2' ' A' ' 49' ' ' GLY . 16.6 ttt180 -115.05 126.18 54.41 Favored 'General case' 0 CA--C 1.511 -0.534 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 177.398 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 79.5 t80 -138.1 129.05 27.09 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-N 115.16 -0.927 . . . . 0.0 110.304 179.574 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 67.0 t30 53.09 36.5 22.44 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.628 -0.714 . . . . 0.0 112.124 179.677 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.454 ' HA2' ' HE ' ' A' ' 46' ' ' ARG . . . 71.05 16.41 74.9 Favored Glycine 0 CA--C 1.525 0.665 0 C-N-CA 120.491 -0.861 . . . . 0.0 111.024 178.924 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 6.0 tmtt? -119.04 125.78 50.15 Favored 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 109.9 -0.408 . . . . 0.0 109.9 -179.366 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 82.5 t -80.25 136.65 22.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.591 179.741 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -157.59 167.66 34.14 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.884 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 76.0 m-85 -122.01 156.87 32.56 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-O 120.645 0.259 . . . . 0.0 110.444 -179.544 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -148.77 151.71 35.3 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-O 120.842 0.354 . . . . 0.0 110.472 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 30.0 t -63.23 141.26 58.83 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.478 -179.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 26.0 pttm -67.21 -15.1 63.5 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.193 -179.671 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 78.0 p -65.64 -33.19 75.33 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.68 -179.661 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -102.31 11.0 38.78 Favored 'General case' 0 N--CA 1.468 0.454 0 N-CA-C 111.867 0.321 . . . . 0.0 111.867 -179.04 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 47.8 mm -115.55 130.12 70.7 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.567 0 CA-C-O 120.997 0.427 . . . . 0.0 110.554 179.795 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 90.1 m -116.75 124.91 50.79 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.189 179.695 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 21.0 mm -81.79 134.64 26.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.44 -179.856 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 75.3 t . . . . . 0 C--N 1.328 -0.343 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.294 -179.901 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 88.6 mt-30 . . . . . 0 N--CA 1.466 0.373 0 CA-C-O 120.822 0.344 . . . . 0.0 110.684 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -93.97 156.78 22.51 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.689 -0.964 . . . . 0.0 110.689 179.713 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 65.1 t -124.59 130.99 73.32 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 179.663 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 13.1 t -86.05 128.97 38.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.778 -179.584 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -130.81 106.23 8.31 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.939 0.4 . . . . 0.0 110.207 179.382 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.2 p -140.82 142.77 29.71 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.205 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.223 -179.563 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.526 ' OD1' ' N ' ' A' ' 9' ' ' SER . 13.9 p30 -63.28 -40.8 98.38 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.717 -179.732 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' SER . . . . . 0.526 ' N ' ' OD1' ' A' ' 8' ' ' ASN . 17.4 m -117.69 -139.76 0.36 Allowed 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.92 179.578 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -91.97 144.35 25.55 Favored 'General case' 0 C--O 1.233 0.21 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 179.498 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 60.6 tp -110.86 130.18 55.65 Favored 'General case' 0 N--CA 1.468 0.451 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 -179.835 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -85.23 133.63 34.17 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.403 179.827 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 38.4 ttp -100.71 142.16 32.57 Favored 'General case' 0 CA--C 1.51 -0.582 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 179.712 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . 0.511 HH12 ' CB ' ' A' ' 19' ' ' SER . 8.6 mtt180 -117.74 155.42 30.04 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.83 -178.83 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 87.5 p -77.73 -11.81 59.91 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 112.057 0.392 . . . . 0.0 112.057 -178.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -162.9 -173.04 31.14 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 179.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -83.29 77.02 3.67 Favored 'Trans proline' 0 C--N 1.307 -1.623 0 C-N-CA 122.704 2.269 . . . . 0.0 112.173 179.605 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 168.54 133.81 1.62 Allowed Glycine 0 CA--C 1.527 0.83 0 C-N-CA 120.753 -0.737 . . . . 0.0 111.699 179.717 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' SER . . . . . 0.511 ' CB ' HH12 ' A' ' 14' ' ' ARG . 6.0 t -65.86 -17.41 64.63 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-O 120.886 0.374 . . . . 0.0 110.985 179.807 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . 0.531 ' OD1' ' N ' ' A' ' 21' ' ' TYR . 41.1 p-10 -60.89 -36.09 78.32 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.508 -179.117 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 0.531 ' N ' ' OD1' ' A' ' 20' ' ' ASN . 76.6 m-85 -62.05 -37.02 83.39 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.04 179.342 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 89.48 173.71 45.91 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.451 ' CG2' ' O ' ' A' ' 25' ' ' GLY . 14.0 p -87.19 128.12 40.06 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.867 0.365 . . . . 0.0 110.487 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.402 HG21 HD13 ' A' ' 24' ' ' ILE . 25.4 pt -104.4 -4.32 9.61 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.502 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.451 ' O ' ' CG2' ' A' ' 23' ' ' VAL . . . -176.32 -177.12 45.06 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.414 -1.075 . . . . 0.0 110.414 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 69.7 p -132.2 150.22 52.2 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-O 120.947 0.403 . . . . 0.0 110.374 179.861 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 84.4 mt -129.06 148.54 51.02 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.757 -179.529 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 71.0 mtp180 -107.0 162.44 13.84 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.23 179.509 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 52.8 p30 -69.29 171.97 7.72 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.172 179.723 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 85.9 m-20 58.33 9.2 0.97 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.122 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 43.4 t0 -85.11 116.54 23.54 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.782 0.325 . . . . 0.0 110.676 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 65.5 mttp -77.0 135.13 38.66 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.056 179.674 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.0 m -137.75 159.85 34.03 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-O 120.89 0.376 . . . . 0.0 110.648 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -104.44 117.95 35.41 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.048 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 95.7 mt -90.72 125.76 43.51 Favored 'Isoleucine or valine' 0 C--O 1.232 0.172 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.518 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.556 ' CD1' ' N ' ' A' ' 36' ' ' ILE . 1.9 mp -92.96 -41.16 12.58 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.67 -179.819 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . 0.565 ' HZ3' ' HH ' ' A' ' 53' ' ' TYR . 22.6 pttp -171.83 158.86 5.01 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.604 -179.805 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . 0.476 ' OE1' ' CE1' ' A' ' 43' ' ' TYR . 81.4 tt0 -112.61 125.04 53.84 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.089 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 65.0 t -128.05 132.63 68.39 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 CA-C-O 120.906 0.384 . . . . 0.0 111.146 -179.694 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . 0.435 ' OD1' ' O ' ' A' ' 40' ' ' ASP . 55.1 t0 56.85 25.37 10.33 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.924 179.394 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.01 -9.71 73.53 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 179.696 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 66.2 m95 -89.44 141.51 28.5 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 110.077 -0.342 . . . . 0.0 110.077 179.783 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . 0.476 ' CE1' ' OE1' ' A' ' 38' ' ' GLU . 38.3 m-85 -95.38 131.8 41.12 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-O 121.01 0.433 . . . . 0.0 110.403 179.915 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -92.03 119.64 31.93 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 178.9 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 41.1 pt -125.88 157.84 35.43 Favored 'Isoleucine or valine' 0 C--O 1.233 0.222 0 CA-C-O 121.123 0.487 . . . . 0.0 111.092 -179.311 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 79.0 ttt180 -115.83 124.93 51.93 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.593 179.035 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 28.2 t80 -141.83 132.77 25.94 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.454 -179.814 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 62.7 t30 61.08 27.67 17.47 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.398 -179.835 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 74.08 9.01 79.88 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 61.5 tttm -102.76 156.69 17.47 Favored 'General case' 0 C--O 1.231 0.129 0 N-CA-C 110.043 -0.355 . . . . 0.0 110.043 -179.825 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 56.6 t -115.9 131.17 69.16 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.009 -179.873 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -160.98 -170.43 25.59 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . 0.565 ' HH ' ' HZ3' ' A' ' 37' ' ' LYS . 66.6 m-85 -130.31 162.62 28.62 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-O 120.779 0.323 . . . . 0.0 110.509 -179.632 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -146.68 154.3 41.28 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.369 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 20.2 m -66.25 143.19 57.37 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.619 -179.863 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 60.7 pttt -79.9 -19.44 48.17 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.167 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 11.7 t -61.59 -42.14 98.43 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.354 -179.558 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 99.3 m-85 -92.24 4.3 53.55 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.439 -0.346 . . . . 0.0 111.786 -178.833 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 97.6 mt -122.29 132.09 71.82 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.54 0 CA-C-O 121.001 0.429 . . . . 0.0 110.881 179.678 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 93.1 m -120.2 134.06 55.35 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.406 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.412 HG21 HD13 ' A' ' 61' ' ' ILE . 23.1 mm -77.15 132.73 32.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.649 -179.893 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 94.7 t . . . . . 0 C--N 1.33 -0.262 0 CA-C-O 120.936 0.398 . . . . 0.0 110.764 -179.938 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.443 ' OE1' ' N ' ' A' ' 2' ' ' GLN . 1.1 mp0 . . . . . 0 N--CA 1.463 0.202 0 CA-C-O 121.116 0.484 . . . . 0.0 111.371 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -92.96 158.18 23.84 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 110.685 -0.966 . . . . 0.0 110.685 179.351 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 73.3 t -126.1 134.47 66.43 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 O-C-N 122.615 -0.344 . . . . 0.0 110.309 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 18.2 t -85.1 126.29 40.34 Favored 'Isoleucine or valine' 0 C--O 1.234 0.248 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.751 -179.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 41.5 mmtm -112.24 106.63 15.25 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-O 120.763 0.316 . . . . 0.0 110.382 179.796 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 9.7 p -140.15 159.11 26.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 N-CA-C 110.307 -0.257 . . . . 0.0 110.307 179.671 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.478 ' OD1' ' N ' ' A' ' 9' ' ' SER . 21.5 p30 -64.37 -39.47 93.94 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.813 -0.355 . . . . 0.0 110.623 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' SER . . . . . 0.498 ' HG ' ' H ' ' A' ' 10' ' ' ALA . 59.5 p -141.09 -60.75 0.49 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.155 -179.656 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.498 ' H ' ' HG ' ' A' ' 9' ' ' SER . . . -149.63 145.84 26.97 Favored 'General case' 0 CA--C 1.519 -0.248 0 CA-C-O 121.196 0.522 . . . . 0.0 110.758 -179.699 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 39.9 tp -116.68 131.66 56.89 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.464 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 99.7 m-20 -74.94 138.38 42.28 Favored 'General case' 0 CA--C 1.518 -0.264 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.573 179.654 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 37.6 ttp -94.72 151.41 19.3 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.621 179.74 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . 0.631 ' NH1' ' H ' ' A' ' 16' ' ' GLY . 0.4 OUTLIER -129.89 154.18 47.56 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.94 0.4 . . . . 0.0 111.668 -179.151 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' SER . . . . . 0.59 ' H ' ' CZ ' ' A' ' 14' ' ' ARG . 85.9 p -87.5 -17.34 32.34 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 115.606 -0.725 . . . . 0.0 111.237 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.631 ' H ' ' NH1' ' A' ' 14' ' ' ARG . . . -149.2 -177.48 23.37 Favored Glycine 0 CA--C 1.528 0.875 0 C-N-CA 120.859 -0.686 . . . . 0.0 111.52 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -81.99 82.39 2.32 Favored 'Trans proline' 0 C--N 1.319 -0.983 0 C-N-CA 123.256 2.637 . . . . 0.0 112.107 -179.691 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 163.99 119.63 0.49 Allowed Glycine 0 CA--C 1.528 0.881 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 179.727 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 80.4 p -70.46 -12.39 61.54 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-O 120.605 0.241 . . . . 0.0 110.732 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -78.25 -14.98 59.21 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.322 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 13.6 m-85 -64.91 -41.89 95.21 Favored 'General case' 0 CA--C 1.519 -0.231 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.844 179.526 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.54 ' O ' ' NE ' ' A' ' 14' ' ' ARG . . . 117.07 133.76 5.12 Favored Glycine 0 C--N 1.333 0.394 0 N-CA-C 110.954 -0.859 . . . . 0.0 110.954 179.324 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 5.4 p -65.93 139.46 21.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 121.065 0.459 . . . . 0.0 110.399 179.756 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 34.8 pt -106.91 -10.08 10.58 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.215 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.975 -179.878 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.23 -172.93 43.16 Favored Glycine 0 CA--C 1.521 0.467 0 N-CA-C 110.626 -0.99 . . . . 0.0 110.626 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 97.5 m -125.94 147.57 49.47 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-O 120.923 0.392 . . . . 0.0 111.222 -179.301 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 60.5 mt -112.88 153.59 27.67 Favored 'General case' 0 C--O 1.233 0.207 0 CA-C-O 121.055 0.455 . . . . 0.0 110.006 179.458 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 24.1 mmt180 -100.83 159.87 14.83 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.436 -179.543 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.437 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 53.5 p-10 -65.32 143.98 57.41 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.828 -179.528 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 56.66 34.0 23.78 Favored 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.598 179.229 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 44.0 t0 -85.08 117.1 23.83 Favored 'General case' 0 N--CA 1.466 0.341 0 C-N-CA 120.884 -0.326 . . . . 0.0 110.891 179.749 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -72.38 130.48 40.82 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.998 0.428 . . . . 0.0 110.49 179.826 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 28.8 m -137.29 162.93 32.7 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.489 179.827 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -100.13 122.56 43.17 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.813 -0.631 . . . . 0.0 109.934 179.56 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.4 mt -97.4 128.66 48.47 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.169 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.211 -179.739 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.403 HG22 HD13 ' A' ' 36' ' ' ILE . 22.7 mm -94.04 -64.32 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.473 -179.693 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . 0.496 ' NZ ' ' OE1' ' A' ' 44' ' ' GLU . 25.3 pttm -154.47 163.52 40.06 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.789 -179.758 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 44.2 tt0 -103.85 126.72 51.18 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.583 179.757 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 61.4 t -127.86 131.64 69.54 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.2 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.335 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 51.1 t0 55.68 24.25 6.98 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.04 179.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.72 -16.01 57.62 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 111.54 -0.624 . . . . 0.0 111.54 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 17.0 m95 -88.2 141.97 28.13 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.806 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 -94.53 131.6 40.08 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-O 120.737 0.303 . . . . 0.0 111.083 -179.52 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . 0.496 ' OE1' ' NZ ' ' A' ' 37' ' ' LYS . 81.0 tt0 -80.65 134.51 35.89 Favored 'General case' 0 N--CA 1.464 0.275 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 179.2 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 40.0 pt -134.54 155.39 38.73 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-O 121.006 0.431 . . . . 0.0 111.77 -179.441 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 56.4 ttp180 -118.58 124.44 47.48 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.501 179.568 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 36.1 t80 -148.19 134.83 19.84 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.683 179.734 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 65.5 t30 58.74 31.35 21.09 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.674 -179.798 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 70.18 19.54 75.82 Favored Glycine 0 CA--C 1.521 0.407 0 N-CA-C 110.668 -0.973 . . . . 0.0 110.668 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -122.0 145.57 48.0 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-O 120.709 0.29 . . . . 0.0 110.256 -179.587 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 16.8 t -96.78 113.3 30.79 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 CA-C-O 120.846 0.355 . . . . 0.0 110.36 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . 0.42 ' C ' ' CD1' ' A' ' 53' ' ' TYR . . . -119.84 -166.97 13.44 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 110.772 -0.931 . . . . 0.0 110.772 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . 0.42 ' CD1' ' C ' ' A' ' 52' ' ' GLY . 85.3 m-85 -147.37 159.59 43.52 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 179.963 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -145.62 154.88 42.62 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.971 0.415 . . . . 0.0 110.809 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 15.1 m -69.51 146.08 52.16 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.666 -179.809 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 20.6 ptmt -68.23 -36.82 80.09 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.465 -179.836 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 78.3 p -66.92 -23.22 65.95 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.865 -179.007 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 80.9 m-85 -104.82 7.33 34.47 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.471 -179.888 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 4.9 mm -127.71 129.74 70.15 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.15 179.811 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 98.5 m -121.22 127.07 51.09 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.593 179.481 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 21.8 mm -86.23 128.94 38.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.107 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 21.2 t . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.822 -179.569 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 26.8 mt-30 . . . . . 0 N--CA 1.465 0.277 0 CA-C-O 120.821 0.343 . . . . 0.0 110.222 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -85.19 163.81 37.99 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.514 -1.034 . . . . 0.0 110.514 179.648 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 54.7 t -125.17 130.15 73.1 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-O 120.785 0.326 . . . . 0.0 110.143 179.858 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 15.7 t -95.4 125.92 48.01 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.08 179.681 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 33.1 ttpt -129.81 117.1 19.68 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.497 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.8 t -140.92 155.9 22.16 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 CA-C-O 120.872 0.368 . . . . 0.0 110.726 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 49.8 p30 -79.9 -11.49 59.8 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.504 179.548 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 73.6 m -162.07 -164.79 1.11 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.385 -179.76 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -65.25 142.95 58.11 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.735 -179.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 53.6 tp -126.16 132.12 51.88 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-N 116.169 -0.468 . . . . 0.0 109.879 179.701 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . 0.445 ' OD1' ' O ' ' A' ' 12' ' ' ASN . 47.8 p30 -77.62 142.44 38.9 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.001 0.429 . . . . 0.0 110.956 -179.873 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 43.3 ttp -111.43 138.44 47.93 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 179.691 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . 0.71 ' NH2' ' CE3' ' A' ' 42' ' ' TRP . 0.5 OUTLIER -109.18 141.2 41.75 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 120.867 0.365 . . . . 0.0 111.03 -178.81 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 38.4 t -63.44 -42.61 98.67 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.037 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -107.73 179.8 22.0 Favored Glycine 0 N--CA 1.466 0.665 0 N-CA-C 110.65 -0.98 . . . . 0.0 110.65 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -82.98 73.09 5.59 Favored 'Trans proline' 0 C--N 1.307 -1.652 0 C-N-CA 122.438 2.092 . . . . 0.0 111.959 179.665 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . 0.649 ' N ' HH21 ' A' ' 14' ' ' ARG . . . 174.52 158.07 17.64 Favored Glycine 0 CA--C 1.528 0.89 0 N-CA-C 111.344 -0.702 . . . . 0.0 111.344 179.918 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 69.5 m -82.4 -10.37 59.08 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.849 0.357 . . . . 0.0 110.643 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 14.4 m120 -89.64 5.03 47.56 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.188 -179.128 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 47.8 m-85 -92.11 -0.59 57.44 Favored 'General case' 0 N--CA 1.465 0.304 0 N-CA-C 109.993 -0.373 . . . . 0.0 109.993 179.775 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 78.53 -178.32 53.13 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 111.127 -0.789 . . . . 0.0 111.127 179.647 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 5.4 p -116.08 126.71 73.69 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 CA-C-O 120.932 0.396 . . . . 0.0 110.33 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 43.6 pt -103.66 -8.94 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.968 -179.866 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -177.87 -171.72 41.58 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 63.2 p -133.51 158.46 43.07 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-O 120.928 0.394 . . . . 0.0 110.642 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 75.9 mt -122.33 153.88 38.37 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 115.899 -0.592 . . . . 0.0 109.945 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . 0.406 ' O ' ' CG ' ' A' ' 31' ' ' ASP . 70.3 mtm180 -124.54 147.14 48.6 Favored 'General case' 0 N--CA 1.465 0.309 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.914 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 53.0 p-10 -51.91 159.38 0.86 Allowed 'General case' 0 C--N 1.324 -0.536 0 C-N-CA 120.76 -0.376 . . . . 0.0 111.14 -179.168 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 58.0 t30 67.16 9.05 6.64 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.489 179.85 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . 0.406 ' CG ' ' O ' ' A' ' 28' ' ' ARG . 35.1 m-20 -84.88 113.7 21.57 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.746 0.308 . . . . 0.0 110.414 179.288 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 25.8 mtpp -78.57 136.77 37.61 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.084 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.4 m -137.24 163.05 32.65 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.252 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.784 -179.542 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 47.8 tp10 -103.01 123.8 47.3 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.401 179.497 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 90.4 mt -97.49 120.13 46.43 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.041 -179.424 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.401 HG22 HD12 ' A' ' 36' ' ' ILE . 82.2 mt -83.88 -44.96 18.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.733 179.533 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 62.1 pttt -173.93 174.89 2.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.452 -179.837 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -118.51 124.98 48.88 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.209 179.873 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 69.0 t -125.33 131.83 71.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.679 -179.577 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 54.83 27.53 9.1 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.12 179.574 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.11 -12.29 62.69 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 179.569 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . 0.71 ' CE3' ' NH2' ' A' ' 14' ' ' ARG . 82.9 m95 -88.73 145.02 25.88 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.731 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 65.6 m-85 -101.25 130.59 47.4 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-O 120.974 0.416 . . . . 0.0 110.521 -179.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -87.9 128.65 35.36 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.526 179.48 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.401 HD12 HG21 ' A' ' 45' ' ' ILE . 42.8 pt -128.94 150.51 34.64 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.253 0 CA-C-O 121.061 0.458 . . . . 0.0 111.312 -179.234 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 4.7 ttp180 -120.22 129.42 54.07 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.019 178.769 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 73.8 t80 -146.43 132.42 19.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.678 179.564 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 16.8 t-20 57.19 31.25 19.73 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.023 179.479 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 76.78 4.77 82.74 Favored Glycine 0 CA--C 1.528 0.863 0 N-CA-C 111.347 -0.701 . . . . 0.0 111.347 179.548 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 51.4 mtmt -102.21 150.27 23.46 Favored 'General case' 0 N--CA 1.466 0.358 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.567 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 58.0 t -116.65 132.79 65.3 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-O 120.881 0.372 . . . . 0.0 110.31 -179.641 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -153.93 -166.39 14.79 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . 0.514 ' C ' ' NH1' ' A' ' 14' ' ' ARG . 52.8 m-85 -139.18 159.03 43.12 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-O 120.815 0.341 . . . . 0.0 110.694 -179.512 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . 0.497 ' N ' HH12 ' A' ' 14' ' ' ARG . . . -144.19 149.59 36.66 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.987 179.223 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 21.1 m -66.26 147.29 53.53 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.849 0.357 . . . . 0.0 110.574 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 62.3 pttt -64.63 -21.65 66.77 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.756 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 68.4 m -63.23 -40.29 97.02 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.55 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 72.7 m-85 -95.69 8.33 43.76 Favored 'General case' 0 N--CA 1.469 0.494 0 N-CA-C 111.93 0.345 . . . . 0.0 111.93 -178.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 46.0 mm -120.59 127.07 75.89 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 CA-C-O 120.905 0.383 . . . . 0.0 110.55 179.814 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 89.8 m -125.42 127.9 47.26 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 115.943 -0.572 . . . . 0.0 109.915 179.252 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.401 HD11 HG21 ' A' ' 61' ' ' ILE . 19.1 mm -85.21 127.93 39.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.543 -179.698 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 27.4 m . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.623 -179.785 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 28.5 mp0 . . . . . 0 N--CA 1.465 0.319 0 CA-C-O 120.733 0.301 . . . . 0.0 110.27 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -97.29 168.02 24.04 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.73 -0.948 . . . . 0.0 110.73 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 55.4 t -125.55 132.07 71.36 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 N-CA-C 109.986 -0.375 . . . . 0.0 109.986 179.652 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 89.4 t -92.27 113.44 27.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.03 179.757 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 75.5 tttt -112.71 117.08 31.25 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.16 -179.765 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 9.1 p -144.11 154.0 15.48 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.995 -179.829 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 40.2 t30 -63.16 -41.03 99.18 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.891 -179.761 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' SER . . . . . 0.659 ' HG ' ' H ' ' A' ' 10' ' ' ALA . 20.3 p -133.3 -72.26 0.51 Allowed 'General case' 0 N--CA 1.468 0.439 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.733 -179.914 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.659 ' H ' ' HG ' ' A' ' 9' ' ' SER . . . -152.78 144.17 23.29 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.242 -179.884 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 42.5 tp -115.06 128.73 56.42 Favored 'General case' 0 N--CA 1.47 0.567 0 CA-C-O 120.979 0.418 . . . . 0.0 110.531 -179.664 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -74.77 144.56 43.53 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.481 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 33.3 ttp -107.26 150.31 26.8 Favored 'General case' 0 CA--C 1.519 -0.244 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 179.601 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . 0.508 ' HE ' ' HA ' ' A' ' 19' ' ' SER . 85.7 mtt85 -128.29 150.16 50.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.762 -178.303 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 23.0 t -69.15 -15.88 63.52 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 115.961 -0.563 . . . . 0.0 112.218 -179.417 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -161.01 -172.68 28.65 Favored Glycine 0 CA--C 1.524 0.646 0 C-N-CA 120.394 -0.908 . . . . 0.0 111.428 -179.673 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -82.76 78.43 3.34 Favored 'Trans proline' 0 C--N 1.304 -1.816 0 C-N-CA 122.729 2.286 . . . . 0.0 111.734 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 169.9 134.91 1.82 Allowed Glycine 0 CA--C 1.525 0.658 0 N-CA-C 111.29 -0.724 . . . . 0.0 111.29 179.878 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' SER . . . . . 0.508 ' HA ' ' HE ' ' A' ' 14' ' ' ARG . 34.5 t -66.69 -14.83 62.98 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.944 0.402 . . . . 0.0 110.642 179.705 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 91.6 m-20 -79.45 -1.13 35.92 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.941 -179.495 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 39.0 m-85 -89.21 -1.77 58.22 Favored 'General case' 0 C--O 1.232 0.163 0 N-CA-C 109.573 -0.529 . . . . 0.0 109.573 179.384 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 66.4 176.31 7.13 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 179.804 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 8.1 p -101.54 124.48 55.33 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 N-CA-C 110.105 -0.331 . . . . 0.0 110.105 179.603 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 42.9 pt -100.72 -3.27 9.45 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.714 -179.775 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 172.37 -177.84 44.8 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 53.0 p -132.73 158.51 42.19 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.76 0.314 . . . . 0.0 110.367 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 69.1 mt -112.65 135.47 53.34 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.286 -179.658 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -82.52 160.8 22.53 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 120.933 0.397 . . . . 0.0 110.407 -179.17 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 24.3 m120 -62.53 136.96 58.15 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.021 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . 0.406 ' OD1' ' O ' ' A' ' 30' ' ' ASN . 15.9 t-20 55.64 36.7 27.72 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.0 179.587 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -84.33 116.57 23.08 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.532 179.753 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -72.72 130.71 41.15 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 120.714 -0.394 . . . . 0.0 110.192 179.613 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.7 m -138.82 162.16 28.97 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.541 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -104.17 123.01 46.53 Favored 'General case' 0 N--CA 1.463 0.218 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 179.551 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.414 HG21 HD12 ' A' ' 35' ' ' ILE . 96.2 mt -90.35 106.25 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.214 -179.642 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.8 mt -66.24 -45.03 90.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.738 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 21.1 ptmt -175.82 170.8 2.77 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.366 -179.501 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -115.34 124.08 50.35 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.401 179.702 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 79.7 t -127.97 133.08 67.99 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.373 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.2 -179.833 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' ASP . . . . . 0.428 ' OD1' ' O ' ' A' ' 40' ' ' ASP . 56.3 t0 56.52 23.02 7.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.901 0.382 . . . . 0.0 110.761 179.666 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 85.22 -6.69 78.69 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 111.249 -0.741 . . . . 0.0 111.249 179.68 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 49.0 m95 -85.85 145.78 27.04 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 109.697 -0.482 . . . . 0.0 109.697 179.31 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -95.75 115.25 27.16 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.977 0.418 . . . . 0.0 110.156 -179.672 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -83.65 122.55 28.76 Favored 'General case' 0 CA--C 1.517 -0.315 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 178.89 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 36.3 pt -128.74 162.42 35.79 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.494 0 CA-C-O 121.388 0.613 . . . . 0.0 111.65 -178.434 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 20.4 ttp180 -124.67 130.05 51.69 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.219 -0.9 . . . . 0.0 109.845 179.789 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 84.1 t80 -149.49 132.71 16.4 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.238 -179.507 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 66.0 t30 55.98 36.15 26.83 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.679 179.534 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 69.84 16.53 72.46 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.949 -0.86 . . . . 0.0 110.949 179.889 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 39.3 tptt -116.16 134.77 54.56 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-O 120.691 0.281 . . . . 0.0 110.285 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 58.5 t -108.89 131.22 60.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.155 -179.619 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -152.06 -156.82 7.65 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.736 -0.946 . . . . 0.0 110.736 -179.893 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 76.0 m-85 -137.75 155.85 48.62 Favored 'General case' 0 N--CA 1.464 0.225 0 CA-C-O 120.885 0.374 . . . . 0.0 110.78 -179.75 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -154.13 160.42 41.91 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.157 -179.709 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.7 p -64.47 151.63 43.82 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.044 -179.526 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 22.9 pttp -84.61 -27.21 27.36 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.665 179.828 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 38.9 t -62.27 -40.67 97.01 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.327 -179.614 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 58.8 m-85 -84.94 2.51 42.53 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.805 -179.027 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 97.6 mt -124.43 129.66 73.81 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.183 179.197 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 91.0 m -115.54 128.45 55.99 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.554 -179.707 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 95.3 mt -83.33 124.4 39.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.925 -0.58 . . . . 0.0 109.884 179.788 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 34.9 m . . . . . 0 N--CA 1.463 0.202 0 CA-C-O 120.938 0.399 . . . . 0.0 110.947 -179.511 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 22.6 tpp . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.165 -0.679 . . . . 0.0 109.165 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.487 ' N ' ' CD ' ' A' ' 2' ' ' GLN . 1.4 pm0 -147.04 117.22 7.32 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-O 120.954 0.406 . . . . 0.0 110.538 -179.855 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -88.42 149.8 21.47 Favored Glycine 0 CA--C 1.525 0.68 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 179.66 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 53.9 t -122.05 129.39 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 87.4 t -93.56 126.47 45.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.188 179.752 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 33.1 tptt -118.52 110.8 17.82 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.153 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 12.5 p -144.42 144.74 22.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.075 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -63.41 -41.23 98.71 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.7 -179.615 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 38.6 m -119.06 -75.12 0.58 Allowed 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.985 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -157.87 145.67 18.61 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.386 -179.633 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 60.7 tp -108.98 131.12 55.37 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.138 -179.177 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 10.9 m120 -80.89 145.63 31.22 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.666 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 42.5 ttp -106.81 149.84 26.96 Favored 'General case' 0 N--CA 1.471 0.597 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 179.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . 0.649 HH11 ' HA ' ' A' ' 19' ' ' SER . 58.1 mtt-85 -133.5 140.77 47.43 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-O 121.031 0.443 . . . . 0.0 111.768 -176.925 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 35.8 t -59.16 -41.93 89.55 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.358 -178.364 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -109.6 161.92 12.88 Favored Glycine 0 CA--C 1.53 0.987 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -77.99 73.3 5.78 Favored 'Trans proline' 0 N--CA 1.496 1.663 0 C-N-CA 122.922 2.414 . . . . 0.0 112.044 179.348 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 176.26 160.44 23.59 Favored Glycine 0 CA--C 1.516 0.146 0 N-CA-C 110.013 -1.235 . . . . 0.0 110.013 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.649 ' HA ' HH11 ' A' ' 14' ' ' ARG . 5.4 m -78.88 -16.9 56.44 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 120.457 -0.497 . . . . 0.0 110.54 -179.638 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -64.88 -36.05 83.1 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.971 -179.034 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -59.25 -42.52 91.32 Favored 'General case' 0 C--N 1.329 -0.284 0 C-N-CA 120.851 -0.339 . . . . 0.0 111.423 -178.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 101.86 162.21 26.8 Favored Glycine 0 N--CA 1.468 0.77 0 N-CA-C 111.29 -0.724 . . . . 0.0 111.29 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 7.2 p -77.16 132.79 32.11 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.123 0 CA-C-O 121.018 0.437 . . . . 0.0 111.594 -179.627 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 44.1 pt -113.45 -8.5 12.15 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.302 179.318 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -170.97 175.59 44.62 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.529 -1.029 . . . . 0.0 110.529 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 86.9 m -123.2 132.1 53.92 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-O 120.715 0.293 . . . . 0.0 110.451 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 73.0 mt -109.19 141.96 40.68 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.267 179.767 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.664 ' HG2' HH11 ' A' ' 28' ' ' ARG . 46.0 mtt-85 -95.32 168.06 10.96 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.274 179.383 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 50.7 p-10 -75.27 159.0 32.02 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 178.863 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 77.4 m-20 56.23 31.91 19.31 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.322 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 47.3 t0 -96.37 112.81 24.42 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 116.559 -0.291 . . . . 0.0 110.639 179.336 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 56.3 mtpt -74.06 134.34 42.96 Favored 'General case' 0 C--N 1.329 -0.288 0 C-N-CA 120.601 -0.44 . . . . 0.0 110.075 179.606 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 28.5 m -136.94 162.37 34.51 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.606 -179.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -101.82 121.1 41.45 Favored 'General case' 0 C--O 1.233 0.232 0 CA-C-N 116.083 -0.508 . . . . 0.0 109.869 179.618 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.418 HG21 HD12 ' A' ' 35' ' ' ILE . 96.3 mt -88.58 127.81 41.23 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.139 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.396 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 95.8 mt -91.77 -42.76 13.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.576 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 62.0 pttt -174.82 165.04 3.6 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.567 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -113.01 121.87 45.92 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.181 179.594 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 70.1 t -126.73 131.51 71.07 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.65 -179.64 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.418 ' O ' ' OD1' ' A' ' 40' ' ' ASP . 56.6 t0 53.96 31.17 12.94 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.414 179.082 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 85.43 -16.49 39.48 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 111.043 -0.823 . . . . 0.0 111.043 179.694 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 79.9 m95 -83.35 146.14 28.65 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.401 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 58.7 m-85 -101.17 130.19 47.21 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.904 0.383 . . . . 0.0 110.402 179.669 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.526 ' OE1' ' CE1' ' A' ' 53' ' ' TYR . 3.5 tp10 -88.12 118.52 27.75 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 179.207 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.422 HG21 HD12 ' A' ' 45' ' ' ILE . 44.7 pt -126.03 161.37 31.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-O 121.334 0.588 . . . . 0.0 110.678 -179.468 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.405 HH11 ' HD3' ' A' ' 46' ' ' ARG . 0.6 OUTLIER -126.88 127.23 44.61 Favored 'General case' 0 CA--C 1.537 0.467 0 CA-C-N 115.397 -0.82 . . . . 0.0 110.041 -178.262 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 32.9 t80 -145.79 133.47 21.03 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.461 -178.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 57.67 33.34 23.12 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.245 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 74.01 8.13 77.72 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 111.514 -0.634 . . . . 0.0 111.514 179.098 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 58.6 mttp -106.98 150.19 26.74 Favored 'General case' 0 N--CA 1.466 0.356 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 53.4 t -116.55 132.56 65.83 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.054 -179.808 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . 0.416 ' O ' ' OE1' ' A' ' 44' ' ' GLU . . . -159.78 -169.46 23.12 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 110.97 -0.852 . . . . 0.0 110.97 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.526 ' CE1' ' OE1' ' A' ' 44' ' ' GLU . 97.8 m-85 -125.39 154.78 41.38 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.799 0.333 . . . . 0.0 110.482 -179.759 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -136.12 151.8 50.17 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.281 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 21.2 m -63.24 145.2 56.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.533 -179.71 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 58.8 pttt -77.53 -24.79 49.89 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.919 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 21.4 m -62.25 -41.27 98.29 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.394 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 90.2 m-85 -92.65 -2.07 56.38 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 116.552 -0.295 . . . . 0.0 111.635 -178.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.3 mp -113.7 130.03 68.5 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 92.6 m -118.51 127.92 54.09 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.25 179.677 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 25.2 mm -77.36 133.83 29.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.439 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 78.7 t -96.41 131.54 42.95 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.224 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.608 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 51.8 t-20 59.0 51.86 6.84 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.157 179.695 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . 0.562 ' H ' ' CD ' ' A' ' 64' ' ' GLU . 2.0 pm0 -68.52 58.65 0.08 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.759 179.902 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 76.44 18.85 78.82 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.73 -0.948 . . . . 0.0 110.73 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 81.4 p -67.6 156.22 37.31 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.928 0.394 . . . . 0.0 110.573 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.408 ' O ' ' CE1' ' A' ' 69' ' ' HIS . 2.5 pp -148.98 -6.38 0.38 Allowed 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.23 -179.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.411 ' OE1' ' N ' ' A' ' 68' ' ' GLU . 57.7 mp0 -67.06 135.04 53.04 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.447 179.906 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.475 ' C ' ' CG ' ' A' ' 70' ' ' HIS . 80.0 m80 -119.83 151.85 38.21 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.432 -179.895 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' HIS . . . . . 0.475 ' CG ' ' C ' ' A' ' 69' ' ' HIS . 12.5 p80 38.63 40.41 0.4 Allowed 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.997 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.469 ' CD2' ' H ' ' A' ' 71' ' ' HIS . 9.5 p80 -72.13 144.63 48.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.416 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 79.5 t60 -133.37 131.61 40.26 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.48 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 99.4 m-70 -85.07 135.43 34.0 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.429 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' HIS . . . . . 0.488 ' ND1' ' O ' ' A' ' 74' ' ' HIS . 60.7 t-80 . . . . . 0 C--O 1.22 -0.466 0 CA-C-O 117.972 -1.013 . . . . 0.0 110.552 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 93.6 mtp . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 120.838 0.351 . . . . 0.0 110.355 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 99.2 mm-40 -116.85 120.69 39.29 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.111 -0.495 . . . . 0.0 109.733 179.169 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -91.89 145.0 17.47 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 111.487 -0.645 . . . . 0.0 111.487 -179.471 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 58.8 t -123.62 131.83 72.4 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.451 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 70.6 t -93.28 127.39 45.39 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.249 0 CA-C-O 120.817 0.341 . . . . 0.0 110.607 -179.715 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 53.8 mtmt -126.43 107.1 9.96 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.37 179.703 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 9.8 p -137.96 159.46 33.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.002 -179.853 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 93.9 m-20 -61.26 -41.65 97.27 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.522 -0.308 . . . . 0.0 110.813 -179.291 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 5.2 t -143.68 -51.62 0.33 Allowed 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 120.803 0.335 . . . . 0.0 110.961 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -157.69 144.14 17.78 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.469 -179.659 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 52.3 tp -117.85 132.99 56.37 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 120.864 0.364 . . . . 0.0 110.118 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 99.7 m-20 -76.3 139.23 40.97 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.021 179.672 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 35.6 ttp -100.21 139.11 36.35 Favored 'General case' 0 N--CA 1.465 0.276 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . 0.436 ' HE ' ' HA ' ' A' ' 19' ' ' SER . 84.3 mtt85 -113.27 158.03 21.03 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.858 0.361 . . . . 0.0 110.818 -178.504 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 8.8 m -80.04 -11.53 59.77 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.94 -179.303 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -164.23 -173.01 32.41 Favored Glycine 0 CA--C 1.52 0.406 0 N-CA-C 110.815 -0.914 . . . . 0.0 110.815 179.47 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -82.74 75.82 4.37 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 122.612 2.208 . . . . 0.0 111.667 179.753 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.76 130.9 1.35 Allowed Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 179.722 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.436 ' HA ' ' HE ' ' A' ' 14' ' ' ARG . 80.6 p -70.1 -9.02 54.14 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.666 0.27 . . . . 0.0 110.963 -179.884 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 12.9 m120 -83.55 -0.78 51.82 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.798 -179.876 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 43.0 m-85 -90.98 -2.71 57.66 Favored 'General case' 0 N--CA 1.462 0.167 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 71.87 -179.34 34.84 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 14.2 p -108.61 127.04 65.39 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 CA-C-O 120.889 0.376 . . . . 0.0 110.176 179.594 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 26.1 pt -104.49 -3.3 9.67 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 CA-C-O 120.953 0.406 . . . . 0.0 110.717 -179.65 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.88 -178.52 48.53 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.865 -0.894 . . . . 0.0 110.865 -179.876 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 44.7 p -133.41 155.97 48.53 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.913 0.387 . . . . 0.0 110.549 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 78.6 mt -122.84 146.99 47.06 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.294 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 66.0 mtm180 -106.42 153.46 22.22 Favored 'General case' 0 CA--C 1.515 -0.368 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.517 179.877 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 50.8 p-10 -60.0 157.02 13.53 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.359 179.667 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 11.2 t-20 64.39 4.27 2.14 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.266 179.718 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 67.2 t0 -79.95 120.75 24.57 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.466 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 31.1 mtmm -101.15 138.18 38.51 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 120.864 0.364 . . . . 0.0 110.445 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 33.5 m -138.32 163.57 28.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.621 -179.723 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -85.34 134.95 34.08 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.479 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.402 HD11 HG21 ' A' ' 35' ' ' ILE . 86.6 mt -103.5 128.23 56.82 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.485 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.846 -179.92 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.553 ' CD1' ' N ' ' A' ' 36' ' ' ILE . 2.0 mp -91.36 -44.49 14.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.834 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 62.6 pttt -172.52 160.09 4.67 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.648 -179.651 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . 0.473 ' CD ' ' CE1' ' A' ' 43' ' ' TYR . 82.6 tt0 -111.39 127.77 55.77 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.439 -179.866 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 57.5 t -127.91 129.94 69.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.707 179.794 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 53.19 30.83 10.47 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.361 -0.382 . . . . 0.0 111.592 179.137 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.9 -28.37 7.26 Favored Glycine 0 CA--C 1.521 0.427 0 N-CA-C 110.919 -0.873 . . . . 0.0 110.919 179.655 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 58.6 m95 -71.7 142.36 49.83 Favored 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 120.865 -0.334 . . . . 0.0 110.11 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . 0.473 ' CE1' ' CD ' ' A' ' 38' ' ' GLU . 59.9 m-85 -102.94 133.01 48.76 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.379 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 75.1 tt0 -91.79 121.36 33.34 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.308 179.414 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 46.2 pt -125.53 160.08 32.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.526 -0.306 . . . . 0.0 110.977 -179.124 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 22.0 ttt180 -120.54 126.95 51.63 Favored 'General case' 0 CA--C 1.54 0.566 0 CA-C-N 115.896 -0.593 . . . . 0.0 109.698 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.43 ' O ' ' CG ' ' A' ' 48' ' ' ASN . 32.7 t80 -145.09 145.39 31.4 Favored 'General case' 0 N--CA 1.473 0.676 0 O-C-N 123.04 0.212 . . . . 0.0 110.471 -178.353 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.43 ' CG ' ' O ' ' A' ' 47' ' ' PHE . 10.1 p30 51.52 25.74 2.88 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.109 -179.851 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 77.94 17.5 78.39 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 111.447 -0.661 . . . . 0.0 111.447 179.441 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -124.24 145.65 49.23 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-O 120.82 0.343 . . . . 0.0 110.283 179.675 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 53.2 t -112.14 131.65 62.99 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.317 -179.691 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -150.21 -164.17 11.67 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.478 -1.049 . . . . 0.0 110.478 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 55.3 m-85 -132.3 152.16 51.51 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 120.841 0.353 . . . . 0.0 110.695 -179.692 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -141.49 157.37 45.22 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.509 -179.581 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' SER . . . . . 0.541 ' HG ' ' H ' ' A' ' 57' ' ' SER . 38.1 t -61.19 139.8 58.05 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.226 -179.475 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -83.96 -12.94 54.58 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.691 179.807 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' SER . . . . . 0.541 ' H ' ' HG ' ' A' ' 55' ' ' SER . 37.3 m -70.6 -21.06 62.7 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.22 -179.28 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -115.74 4.43 14.01 Favored 'General case' 0 N--CA 1.47 0.562 0 CA-C-O 120.624 0.249 . . . . 0.0 111.131 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . 0.428 HG21 HD11 ' A' ' 59' ' ' ILE . 97.1 mt -125.42 129.62 72.92 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 CA-C-O 120.879 0.371 . . . . 0.0 110.763 179.693 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 85.0 m -127.96 132.36 49.23 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.836 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.1 mt -80.79 128.32 38.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.359 179.583 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.425 ' O ' ' CB ' ' A' ' 63' ' ' ASN . 22.1 m -102.92 146.22 11.12 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.693 -179.876 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . 0.425 ' CB ' ' O ' ' A' ' 62' ' ' VAL . 3.1 t-20 79.83 -145.11 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.303 179.823 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 13.7 pt-20 -46.14 141.39 3.35 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.942 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 151.01 13.62 0.08 OUTLIER Glycine 0 CA--C 1.526 0.731 0 N-CA-C 111.224 -0.75 . . . . 0.0 111.224 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 73.7 m -157.79 169.55 24.37 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 110.027 -0.36 . . . . 0.0 110.027 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -89.05 114.08 25.26 Favored 'General case' 0 C--N 1.331 -0.2 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 -179.302 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 45.7 tt0 -74.87 151.32 38.98 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.433 -179.541 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 7.8 p80 -123.34 147.83 46.64 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.087 179.751 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' HIS . . . . . . . . . . . . . 51.7 p-80 -150.7 166.48 30.27 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-O 120.773 0.32 . . . . 0.0 110.628 -179.752 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 79.1 m80 -69.6 145.43 52.52 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.754 -179.479 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 52.7 p-80 -81.33 2.98 25.84 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.848 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 60.4 t-80 -65.25 -42.2 93.53 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.729 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 69.6 m80 . . . . . 0 C--O 1.22 -0.456 0 CA-C-O 117.98 -1.009 . . . . 0.0 110.5 -179.705 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.574 ' H2 ' HE22 ' A' ' 2' ' ' GLN . 26.8 ttt . . . . . 0 N--CA 1.49 1.53 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.574 HE22 ' H2 ' ' A' ' 1' ' ' MET . 24.5 mp0 -136.37 117.27 14.19 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.567 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -90.68 171.0 35.7 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 179.49 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 53.3 t -124.71 130.12 73.48 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.541 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 59.7 t -91.0 127.24 43.54 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.259 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 59.9 mttp -121.79 110.57 16.07 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 120.841 0.353 . . . . 0.0 110.089 179.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 72.4 t -126.69 138.29 55.23 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.185 -179.317 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.422 ' OD1' ' O ' ' A' ' 8' ' ' ASN . 56.5 t-20 -62.73 -41.6 99.25 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.345 -179.192 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 21.6 m -130.87 -76.73 0.53 Allowed 'General case' 0 N--CA 1.468 0.433 0 CA-C-O 120.776 0.322 . . . . 0.0 110.806 -179.552 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -151.93 140.61 20.83 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.818 -179.696 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 53.8 tp -123.17 133.22 54.26 Favored 'General case' 0 N--CA 1.469 0.488 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.203 179.8 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 99.5 m-20 -81.7 140.08 34.54 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.977 179.755 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 7.3 tmm? -91.31 136.29 33.21 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-O 121.257 0.551 . . . . 0.0 110.37 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 4.0 mmt-85 -105.63 140.61 38.43 Favored 'General case' 0 CA--C 1.542 0.648 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.708 -178.127 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 68.5 m -78.6 -7.44 57.6 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.893 -177.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -153.77 -166.04 14.33 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -85.48 -0.68 8.92 Favored 'Trans proline' 0 C--N 1.302 -1.887 0 C-N-CA 122.479 2.119 . . . . 0.0 111.794 -179.768 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -99.12 128.2 9.49 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 110.808 -0.917 . . . . 0.0 110.808 179.503 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 78.5 p -69.64 -14.97 63.09 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.83 0.348 . . . . 0.0 110.622 179.672 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 96.7 m-20 -91.72 14.07 16.34 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.482 -179.368 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 7.9 m-85 -87.26 0.7 54.97 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.879 0.371 . . . . 0.0 110.041 179.853 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 79.47 171.33 41.32 Favored Glycine 0 CA--C 1.524 0.619 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 179.781 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 11.3 p -106.99 126.72 63.01 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 CA-C-O 120.728 0.299 . . . . 0.0 110.471 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 24.9 pt -106.07 -2.43 9.91 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.475 0 CA-C-O 121.005 0.431 . . . . 0.0 110.552 179.734 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -176.46 -177.15 45.22 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 110.47 -1.052 . . . . 0.0 110.47 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 61.3 p -131.92 153.6 50.1 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-O 121.03 0.443 . . . . 0.0 110.469 179.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 83.0 mt -123.6 147.62 47.16 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.402 179.238 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 1.7 mtm180 -124.32 153.84 41.17 Favored 'General case' 0 C--O 1.224 -0.287 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.666 -178.277 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 53.1 p-10 -56.19 165.52 1.01 Allowed 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.35 0.595 . . . . 0.0 112.059 -179.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 71.0 m-80 59.29 13.18 2.95 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 114.995 -1.002 . . . . 0.0 111.316 179.579 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 91.3 m-20 -87.86 113.78 23.85 Favored 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 120.844 -0.342 . . . . 0.0 110.451 179.493 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.448 ' HZ3' ' CB ' ' A' ' 32' ' ' LYS . 0.4 OUTLIER -92.23 129.57 38.15 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.016 0.436 . . . . 0.0 110.441 179.915 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.4 m -137.11 161.16 35.77 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.145 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.081 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -89.91 131.09 36.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.298 -179.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.2 mt -97.69 107.71 20.55 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.216 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.435 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 97.5 mt -66.64 -44.21 89.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.925 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 63.2 pttt -173.05 178.9 2.38 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.769 -179.533 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -119.94 123.92 44.71 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.12 179.554 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 62.3 t -126.07 131.68 71.42 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-O 120.974 0.416 . . . . 0.0 110.626 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 54.5 31.39 14.74 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.278 179.361 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.537 ' O ' ' NZ ' ' A' ' 56' ' ' LYS . . . 82.97 -15.91 30.13 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 179.755 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 11.4 m95 -86.08 148.29 25.78 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.708 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 51.5 m-85 -100.91 132.94 46.07 Favored 'General case' 0 C--O 1.233 0.187 0 CA-C-O 121.111 0.482 . . . . 0.0 110.523 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -94.46 127.04 40.11 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.376 -0.829 . . . . 0.0 109.271 179.163 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.42 HD12 HG21 ' A' ' 45' ' ' ILE . 43.7 pt -129.22 157.14 42.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 CA-C-O 121.135 0.493 . . . . 0.0 111.784 -178.862 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 31.1 ttp180 -115.6 124.37 50.79 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.719 178.748 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 34.4 t80 -145.14 132.95 21.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.709 -179.466 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 62.2 t30 56.62 32.92 21.86 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.608 179.77 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 71.83 11.87 74.13 Favored Glycine 0 CA--C 1.528 0.875 0 N-CA-C 111.369 -0.693 . . . . 0.0 111.369 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 65.6 mttp -111.62 147.31 35.75 Favored 'General case' 0 N--CA 1.467 0.409 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.755 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 52.9 t -117.44 132.06 68.35 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.067 -179.778 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . 0.418 ' C ' ' CD1' ' A' ' 53' ' ' TYR . . . -156.27 -167.02 16.99 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.491 -1.044 . . . . 0.0 110.491 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.535 ' N ' ' CD1' ' A' ' 53' ' ' TYR . 10.1 m-85 -137.15 154.6 50.21 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-O 120.811 0.338 . . . . 0.0 110.451 -179.486 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -147.05 152.85 39.23 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.322 179.802 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 9.7 p -63.95 142.92 58.23 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.881 0.372 . . . . 0.0 110.753 -179.708 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.537 ' NZ ' ' O ' ' A' ' 41' ' ' GLY . 0.0 OUTLIER -66.24 -12.74 58.08 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.711 -179.358 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 6.1 m -65.06 -15.74 62.69 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.544 -0.298 . . . . 0.0 111.215 -179.515 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 95.2 m-85 -117.8 5.67 12.26 Favored 'General case' 0 N--CA 1.472 0.651 0 N-CA-C 111.69 0.256 . . . . 0.0 111.69 -179.737 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 4.2 mp -121.49 130.15 74.9 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 CA-C-O 121.246 0.546 . . . . 0.0 110.154 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 85.5 m -123.91 132.63 53.77 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.197 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.41 HG23 HD11 ' A' ' 61' ' ' ILE . 96.0 mt -72.79 129.22 35.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.169 179.769 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 89.2 t -74.5 134.05 30.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.671 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 57.49 42.11 24.97 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.744 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 11.5 tm-20 -56.67 -37.32 70.66 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.535 -179.75 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -77.11 -121.0 0.19 Allowed Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.635 -0.986 . . . . 0.0 110.635 179.695 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.9 m 56.65 96.65 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.989 0.424 . . . . 0.0 110.744 179.682 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.464 ' CD2' ' N ' ' A' ' 67' ' ' LEU . 3.9 mm? -62.72 -41.33 99.11 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.956 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.535 ' OE2' ' NE2' ' A' ' 70' ' ' HIS . 43.8 tp10 -159.38 -105.62 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.3 179.843 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 69.7 t60 40.42 85.88 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.264 0 CA-C-O 120.906 0.384 . . . . 0.0 111.088 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' HIS . . . . . 0.535 ' NE2' ' OE2' ' A' ' 68' ' ' GLU . 96.3 m-70 -64.76 -37.57 88.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.996 -179.775 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.427 ' O ' ' O ' ' A' ' 70' ' ' HIS . 53.2 t-80 57.11 120.56 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.138 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 31.0 p80 -153.43 159.64 42.4 Favored 'General case' 0 C--N 1.333 -0.142 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.64 179.712 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.519 ' CG ' ' O ' ' A' ' 73' ' ' HIS . 52.9 p-80 -168.76 94.23 0.33 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.635 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 8.5 p80 . . . . . 0 C--O 1.222 -0.378 0 CA-C-O 117.979 -1.01 . . . . 0.0 110.562 -179.75 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 24.3 ptp . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 98.4 mm-40 -124.07 108.59 12.51 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-O 121.094 0.473 . . . . 0.0 110.148 179.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -100.03 154.27 19.52 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.748 -0.941 . . . . 0.0 110.748 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 64.1 t -124.4 130.85 73.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.586 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 88.1 t -88.47 128.41 40.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.62 -179.786 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -127.46 105.51 8.56 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.242 179.606 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 30.9 m -138.89 159.96 30.03 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.254 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.715 179.799 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 11.7 m120 -91.41 -4.05 56.06 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.38 179.698 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 17.4 m -154.39 -166.95 2.48 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.34 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -67.18 143.82 56.35 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.466 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 51.3 tp -117.51 130.62 56.55 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 116.182 -0.463 . . . . 0.0 109.88 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 10.7 m120 -89.22 134.2 34.13 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.439 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 52.1 ttp -105.38 145.96 30.08 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 116.174 -0.466 . . . . 0.0 109.834 179.765 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 93.8 mtt-85 -119.13 159.82 23.25 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-O 120.936 0.398 . . . . 0.0 111.162 -179.554 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 86.2 p -81.67 -5.94 58.56 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.617 -0.72 . . . . 0.0 110.133 179.638 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.467 ' C ' ' H ' ' A' ' 18' ' ' GLY . . . -159.55 167.31 35.13 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 110.625 -0.99 . . . . 0.0 110.625 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo -69.94 12.27 0.36 Allowed 'Trans proline' 0 C--N 1.308 -1.6 0 C-N-CA 121.883 1.722 . . . . 0.0 111.904 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . 0.467 ' H ' ' C ' ' A' ' 16' ' ' GLY . . . -99.4 124.12 8.13 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.861 -0.895 . . . . 0.0 110.861 179.225 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 79.5 p -66.94 -10.21 46.6 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.757 0.313 . . . . 0.0 110.535 179.779 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 55.0 p30 -90.95 6.18 45.7 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.64 -179.284 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 32.4 m-85 -88.5 -10.41 49.06 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.39 179.852 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 75.9 176.75 41.11 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 111.361 -0.696 . . . . 0.0 111.361 179.102 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 12.1 p -92.48 127.17 44.82 Favored 'Isoleucine or valine' 0 C--O 1.232 0.151 0 CA-C-O 120.711 0.291 . . . . 0.0 110.528 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 24.5 pt -106.11 -5.02 9.97 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-O 120.872 0.368 . . . . 0.0 110.623 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.6 175.3 47.24 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.808 -0.917 . . . . 0.0 110.808 -179.824 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 73.9 m -125.88 130.36 51.18 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 120.878 0.371 . . . . 0.0 110.463 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 72.8 mt -112.44 142.43 44.99 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.711 179.633 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.72 HH11 ' HG3' ' A' ' 28' ' ' ARG . 71.4 mtm-85 -108.42 164.12 12.61 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-O 121.345 0.593 . . . . 0.0 111.117 -179.551 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.458 ' C ' ' H ' ' A' ' 31' ' ' ASP . 57.1 p30 -67.26 166.84 13.44 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.024 179.803 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 10.0 m120 59.41 3.16 0.37 Allowed 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.098 -179.765 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.495 ' OD2' ' N ' ' A' ' 28' ' ' ARG . 98.3 m-20 -72.66 140.02 47.67 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.987 0.422 . . . . 0.0 110.59 179.37 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 53.4 mttp -107.19 125.78 51.55 Favored 'General case' 0 N--CA 1.476 0.859 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.38 179.017 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.3 m -136.65 162.4 35.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 178.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -100.56 123.89 45.37 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-O 120.835 0.35 . . . . 0.0 110.555 -179.738 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.428 HG23 HD12 ' A' ' 35' ' ' ILE . 96.7 mt -84.68 130.12 36.55 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.128 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.469 179.588 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.5 mt -98.88 -54.86 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.196 -179.603 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 8.7 ttmm -150.64 153.01 34.88 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-O 120.799 0.333 . . . . 0.0 110.974 -179.405 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . 0.448 ' CD ' ' CE1' ' A' ' 43' ' ' TYR . 83.5 tt0 -112.86 122.65 48.28 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.146 179.351 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 62.7 t -130.73 132.88 63.97 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.154 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 53.2 25.46 4.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.011 179.431 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.63 -24.62 25.03 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 179.625 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 33.2 m95 -74.38 144.74 44.24 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.762 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . 0.448 ' CE1' ' CD ' ' A' ' 38' ' ' GLU . 78.3 m-85 -105.98 131.67 53.0 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 120.852 0.358 . . . . 0.0 110.847 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 76.9 tt0 -88.21 123.23 32.63 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.328 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.417 HD13 HG23 ' A' ' 45' ' ' ILE . 46.2 pt -126.95 160.66 35.22 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.673 0 CA-C-O 121.594 0.711 . . . . 0.0 110.944 -179.017 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 12.5 ttm180 -122.6 129.46 51.92 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.123 -0.944 . . . . 0.0 110.853 -179.285 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 59.2 t80 -148.69 131.55 16.11 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.257 -179.82 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.411 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 17.1 t-20 57.48 36.74 27.32 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.907 179.518 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 69.64 15.36 70.89 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 179.774 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 35.9 ttmt -117.18 137.22 52.48 Favored 'General case' 0 N--CA 1.466 0.329 0 N-CA-C 110.321 -0.252 . . . . 0.0 110.321 -179.714 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 53.4 t -111.11 131.04 63.43 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.86 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -145.17 -161.94 9.33 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.759 -0.936 . . . . 0.0 110.759 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 81.3 m-85 -138.58 154.21 48.7 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 120.721 0.296 . . . . 0.0 110.396 -179.689 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -145.18 150.54 36.92 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.198 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' SER . . . . . 0.46 ' OG ' ' CD2' ' A' ' 58' ' ' TYR . 8.7 p -75.49 153.0 37.79 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.097 0.475 . . . . 0.0 111.434 -179.177 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -65.95 -30.17 70.7 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.63 -0.713 . . . . 0.0 111.609 179.278 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 95.8 p -55.67 -28.95 58.3 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.532 -178.719 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' TYR . . . . . 0.46 ' CD2' ' OG ' ' A' ' 55' ' ' SER . 19.9 m-85 -108.52 -6.22 16.19 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 111.446 0.165 . . . . 0.0 111.446 -179.709 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.4 mp -112.68 130.05 67.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 N-CA-C 109.595 -0.521 . . . . 0.0 109.595 -179.764 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 92.8 m -123.63 132.03 53.76 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-N 115.716 -0.674 . . . . 0.0 109.979 179.591 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.3 mt -76.82 131.4 34.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.625 -179.63 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 95.3 t -82.28 132.14 32.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.26 179.641 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . 0.438 ' O ' ' O ' ' A' ' 64' ' ' GLU . 98.3 m-20 57.34 67.91 0.92 Allowed 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.729 -179.646 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . 0.438 ' O ' ' O ' ' A' ' 63' ' ' ASN . 58.3 mp0 -52.57 -170.04 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.538 -179.789 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -67.42 102.03 0.76 Allowed Glycine 0 CA--C 1.526 0.743 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 36.2 t -71.39 146.82 48.49 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.081 0.467 . . . . 0.0 111.003 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 72.6 mt 58.39 177.32 0.06 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.863 179.663 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 52.95 21.17 1.91 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.728 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 55.9 p-80 -82.46 -14.96 54.19 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.888 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' HIS . . . . . 0.557 ' ND1' ' N ' ' A' ' 71' ' ' HIS . 56.3 t-80 48.67 -107.64 0.23 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.46 -0.337 . . . . 0.0 110.833 179.772 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.557 ' N ' ' ND1' ' A' ' 70' ' ' HIS . 56.4 t-80 -148.12 -47.39 0.16 Allowed 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.589 -179.827 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.492 ' H ' ' HD1' ' A' ' 70' ' ' HIS . 12.8 t60 -154.0 163.72 39.62 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.592 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.466 ' CD2' ' CD2' ' A' ' 72' ' ' HIS . 97.1 m-70 56.91 -178.31 0.05 Allowed 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.009 -179.913 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 76.2 m80 . . . . . 0 C--O 1.22 -0.488 0 CA-C-O 117.938 -1.029 . . . . 0.0 110.675 -179.866 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.638 ' H3 ' ' NE2' ' A' ' 2' ' ' GLN . 39.7 tpp . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.638 ' NE2' ' H3 ' ' A' ' 1' ' ' MET . 23.0 mp0 -139.21 109.44 6.46 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.253 179.8 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -85.34 163.73 37.66 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.881 -0.888 . . . . 0.0 110.881 179.803 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 77.3 t -127.1 134.13 66.74 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-O 120.85 0.357 . . . . 0.0 110.131 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 19.8 t -83.15 128.39 38.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.55 179.76 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 68.0 mmtt -123.02 105.5 10.02 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.151 179.652 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.6 m -148.79 157.92 7.07 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.557 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 50.9 p30 -83.96 -9.78 58.43 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.81 179.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' SER . . . . . 0.473 ' OG ' ' N ' ' A' ' 10' ' ' ALA . 48.4 t -155.24 -165.26 1.97 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.856 0.36 . . . . 0.0 110.722 -179.759 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.473 ' N ' ' OG ' ' A' ' 9' ' ' SER . . . -64.38 143.55 57.82 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.659 -179.858 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 47.3 tp -121.55 133.08 55.01 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-O 120.953 0.406 . . . . 0.0 110.307 179.675 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 99.5 m-20 -82.74 142.47 31.59 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.991 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 49.6 ttp -113.48 148.57 35.72 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.939 179.544 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . 0.81 ' NH2' ' CH2' ' A' ' 42' ' ' TRP . 43.4 mtm180 -121.41 153.87 37.27 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-O 121.117 0.484 . . . . 0.0 111.599 -179.001 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 11.3 t -62.76 -41.83 99.4 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.439 179.748 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -140.99 -164.97 10.13 Favored Glycine 0 N--CA 1.466 0.676 0 N-CA-C 111.382 -0.687 . . . . 0.0 111.382 -179.401 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -85.03 71.41 5.08 Favored 'Trans proline' 0 C--N 1.31 -1.471 0 C-N-CA 122.893 2.395 . . . . 0.0 112.103 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . 0.707 ' N ' HH12 ' A' ' 14' ' ' ARG . . . -167.74 120.22 0.89 Allowed Glycine 0 CA--C 1.523 0.545 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 179.654 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 8.9 t -60.95 -9.01 3.6 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.944 0.402 . . . . 0.0 110.326 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 11.8 m120 -89.79 5.55 45.57 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.993 -179.456 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 22.0 m-85 -88.22 -7.94 56.05 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 120.681 0.277 . . . . 0.0 110.377 179.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 67.68 179.07 14.02 Favored Glycine 0 CA--C 1.521 0.447 0 N-CA-C 110.84 -0.904 . . . . 0.0 110.84 179.641 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 9.3 p -92.18 124.21 44.57 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.183 0 CA-C-O 120.787 0.327 . . . . 0.0 110.704 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 24.4 pt -104.35 -5.52 9.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.802 -179.856 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.65 177.05 47.52 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 111.038 -0.825 . . . . 0.0 111.038 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 91.0 m -126.56 130.47 50.61 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-O 120.853 0.359 . . . . 0.0 110.301 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 72.7 mt -112.38 146.31 38.55 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.22 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 87.0 mtm-85 -115.42 161.51 18.46 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.028 179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.518 ' C ' ' H ' ' A' ' 31' ' ' ASP . 50.8 p30 -69.13 166.77 17.52 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.929 -179.501 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 56.5 t30 71.03 -27.85 0.18 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.509 179.735 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.518 ' H ' ' C ' ' A' ' 29' ' ' ASN . 33.9 m-20 -67.48 137.6 55.95 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.583 -0.447 . . . . 0.0 109.926 179.954 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 18.1 ptpt -104.06 145.81 29.63 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.654 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.0 m -133.91 161.72 40.5 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.266 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.234 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -92.28 132.93 36.3 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.231 -0.44 . . . . 0.0 109.875 179.552 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 5.5 mm -98.89 125.77 52.26 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 CA-C-O 120.947 0.404 . . . . 0.0 110.721 -179.461 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.6 mt -93.14 -46.88 13.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.565 179.828 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 31.6 ttpt -173.03 162.57 4.62 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 120.941 0.4 . . . . 0.0 111.153 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . 0.501 ' OE1' ' CE1' ' A' ' 43' ' ' TYR . 82.2 tt0 -110.54 124.05 51.1 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.034 179.497 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 96.9 t -128.04 131.63 69.31 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.099 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 54.41 29.99 11.97 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.569 178.886 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.69 -11.25 64.68 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 111.254 -0.739 . . . . 0.0 111.254 179.388 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.81 ' CH2' ' NH2' ' A' ' 14' ' ' ARG . 82.8 m95 -89.45 143.25 26.97 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.604 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . 0.501 ' CE1' ' OE1' ' A' ' 38' ' ' GLU . 53.4 m-85 -100.94 130.52 46.95 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.732 0.301 . . . . 0.0 110.654 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -82.54 132.57 35.19 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 179.157 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 43.2 pt -132.67 153.02 37.28 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.241 0 CA-C-O 121.098 0.475 . . . . 0.0 111.236 -179.474 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 60.3 ttp180 -127.6 125.36 40.1 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.515 -0.766 . . . . 0.0 109.923 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.443 ' O ' ' OD1' ' A' ' 48' ' ' ASN . 19.0 t80 -151.4 146.13 25.74 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.886 -179.276 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.443 ' OD1' ' O ' ' A' ' 47' ' ' PHE . 8.2 p-10 47.19 38.2 6.54 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.526 179.723 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 67.62 23.1 73.76 Favored Glycine 0 CA--C 1.522 0.5 0 N-CA-C 111.33 -0.708 . . . . 0.0 111.33 179.085 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 69.4 mmtt -128.33 144.13 51.09 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.825 0.345 . . . . 0.0 110.143 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 75.4 t -113.82 133.29 60.27 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.205 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.158 -179.678 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -153.32 -166.26 14.38 Favored Glycine 0 CA--C 1.521 0.431 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 179.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 45.9 m-85 -136.24 155.88 49.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.837 0.351 . . . . 0.0 110.062 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -137.22 154.97 50.05 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.548 -179.647 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 41.3 t -61.78 142.39 57.32 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.505 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 61.9 pttt -68.24 -31.67 71.31 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.353 -179.601 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 19.8 m -60.92 -41.32 95.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.822 -179.245 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 70.7 m-85 -96.23 11.9 32.85 Favored 'General case' 0 N--CA 1.467 0.411 0 N-CA-C 111.837 0.31 . . . . 0.0 111.837 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 5.4 mm -121.33 129.32 75.72 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 CA-C-O 121.01 0.433 . . . . 0.0 110.503 179.748 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 99.4 m -122.71 127.52 49.36 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.348 179.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.7 mt -83.2 131.16 34.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.568 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 94.3 t -71.43 132.77 32.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.312 -0.403 . . . . 0.0 110.471 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . 0.537 ' CG ' ' H ' ' A' ' 64' ' ' GLU . 6.3 t-20 66.8 -164.75 0.22 Allowed 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.536 -179.803 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . 0.537 ' H ' ' CG ' ' A' ' 63' ' ' ASN . 80.6 mm-40 54.74 102.73 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.466 -179.764 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.469 ' O ' ' N ' ' A' ' 67' ' ' LEU . . . 65.8 -132.18 34.36 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 111.199 -0.76 . . . . 0.0 111.199 179.9 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 3.2 m 64.82 -62.71 0.19 Allowed 'General case' 0 N--CA 1.462 0.166 0 CA-C-O 120.559 0.218 . . . . 0.0 110.878 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.469 ' N ' ' O ' ' A' ' 65' ' ' GLY . 73.6 mt 56.2 -168.6 0.1 Allowed 'General case' 0 C--N 1.33 -0.249 0 N-CA-C 110.199 -0.297 . . . . 0.0 110.199 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 46.0 tp10 54.87 92.04 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.99 0.424 . . . . 0.0 110.31 -179.753 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.649 ' N ' ' HD1' ' A' ' 69' ' ' HIS . 0.4 OUTLIER -150.56 169.85 20.55 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.105 -179.919 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' HIS . . . . . . . . . . . . . 85.3 m-70 56.92 22.39 7.11 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.503 -179.648 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.437 ' C ' ' H ' ' A' ' 73' ' ' HIS . 53.6 p-80 -66.16 -38.55 88.35 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.726 -179.921 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.415 ' N ' ' CG ' ' A' ' 71' ' ' HIS . 42.7 t-80 -60.98 -4.66 1.09 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.667 -179.847 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.465 ' O ' ' CG ' ' A' ' 74' ' ' HIS . 96.7 m-70 55.16 -95.39 0.05 OUTLIER 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.642 -179.849 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' HIS . . . . . 0.465 ' CG ' ' O ' ' A' ' 73' ' ' HIS . 80.9 m80 . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 118.095 -0.955 . . . . 0.0 110.715 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 36.0 ttm . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 22.4 mm100 -129.31 116.42 19.07 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.373 179.682 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -87.58 156.94 28.36 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 110.813 -0.915 . . . . 0.0 110.813 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 59.1 t -125.88 132.71 70.39 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.632 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 21.9 t -81.68 128.66 38.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.675 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 71.2 mmtt -115.48 105.84 13.28 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.188 -0.46 . . . . 0.0 109.764 179.512 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 12.5 p -145.79 155.88 12.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.535 -179.711 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 9.6 m120 -62.56 -41.45 98.92 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.909 -179.426 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 21.5 m -136.59 -57.58 0.74 Allowed 'General case' 0 N--CA 1.466 0.326 0 CA-C-O 120.656 0.265 . . . . 0.0 110.92 -179.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -157.65 144.62 18.15 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.8 0.333 . . . . 0.0 110.558 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 44.9 tp -111.83 130.62 55.75 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.463 -179.627 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . 0.4 ' OD1' ' O ' ' A' ' 12' ' ' ASN . 47.3 p-10 -71.95 137.99 47.73 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.701 179.762 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 37.7 ttp -100.45 136.69 39.94 Favored 'General case' 0 N--CA 1.464 0.275 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 179.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . 0.64 HH21 ' HG ' ' A' ' 19' ' ' SER . 84.0 mtt85 -107.67 157.52 18.02 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.669 -179.143 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 85.6 p -84.18 -10.34 57.82 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.681 179.795 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -161.99 -171.89 28.68 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 111.161 -0.776 . . . . 0.0 111.161 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_endo -84.02 68.84 6.61 Favored 'Trans proline' 0 C--N 1.309 -1.549 0 C-N-CA 122.815 2.344 . . . . 0.0 111.653 -179.833 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -179.97 134.77 2.3 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.64 ' HG ' HH21 ' A' ' 14' ' ' ARG . 15.9 m -76.89 -8.94 58.27 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.724 0.297 . . . . 0.0 111.003 -179.526 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 67.1 t30 -83.59 -1.48 53.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.878 -179.798 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 50.1 m-85 -86.71 -5.93 58.98 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 120.768 0.318 . . . . 0.0 110.294 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 77.18 166.35 25.74 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.92 -0.872 . . . . 0.0 110.92 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 14.4 p -95.26 127.25 47.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.731 0.3 . . . . 0.0 110.481 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 25.4 pt -101.89 -5.06 9.23 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.288 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.804 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.76 -177.43 47.37 Favored Glycine 0 CA--C 1.529 0.948 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 62.8 p -134.74 157.99 45.28 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-O 120.885 0.374 . . . . 0.0 111.025 -179.705 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 67.6 mt -124.88 145.06 49.99 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.168 -0.469 . . . . 0.0 109.846 179.804 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 13.8 mtm180 -93.63 173.48 7.67 Favored 'General case' 0 C--O 1.233 0.235 0 CA-C-O 121.262 0.553 . . . . 0.0 110.847 179.863 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.433 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 51.7 p-10 -73.6 144.48 45.96 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.43 -0.804 . . . . 0.0 109.554 178.359 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 12.3 t-20 58.49 34.7 24.15 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.564 -0.289 . . . . 0.0 111.192 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -88.79 112.7 23.52 Favored 'General case' 0 N--CA 1.468 0.44 0 N-CA-C 110.018 -0.364 . . . . 0.0 110.018 179.447 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -75.88 130.37 38.43 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 120.665 -0.414 . . . . 0.0 110.091 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 33.2 m -137.87 163.24 30.46 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-O 120.902 0.382 . . . . 0.0 110.689 -179.696 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -102.28 123.64 46.44 Favored 'General case' 0 N--CA 1.463 0.203 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.265 179.805 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.412 HG22 HD12 ' A' ' 35' ' ' ILE . 96.2 mt -89.06 126.03 42.09 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.169 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.408 179.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.7 mt -92.91 -47.11 13.91 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.183 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.678 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 32.2 ttpt -168.94 158.0 8.42 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.876 -179.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -108.4 120.98 43.98 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.962 179.819 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 77.8 t -126.22 132.31 70.61 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.849 -179.442 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 47.5 t0 58.14 25.92 13.07 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.394 179.056 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.93 -10.69 67.18 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 179.774 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 65.9 m95 -89.56 144.63 25.87 Favored 'General case' 0 C--N 1.331 -0.198 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 179.407 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 79.9 m-85 -97.43 127.91 43.78 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.87 0.367 . . . . 0.0 110.45 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 79.4 tt0 -88.3 126.62 35.27 Favored 'General case' 0 CA--C 1.522 -0.119 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 179.499 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 42.0 pt -132.47 161.48 41.39 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.283 0 CA-C-O 121.011 0.434 . . . . 0.0 111.784 -178.752 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 78.7 ttt-85 -114.64 124.38 51.69 Favored 'General case' 0 N--CA 1.464 0.268 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 178.806 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 45.5 t80 -156.68 146.06 20.55 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.924 0.392 . . . . 0.0 111.191 -179.106 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 54.9 t30 58.76 31.63 21.39 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.356 179.59 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 69.74 18.56 74.2 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 111.704 -0.558 . . . . 0.0 111.704 178.783 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.4 ' CB ' ' HZ3' ' A' ' 50' ' ' LYS . 1.0 OUTLIER -144.37 152.4 40.65 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 120.825 0.345 . . . . 0.0 110.775 -179.965 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.8 t -85.59 157.99 3.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.176 179.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -167.84 -178.2 39.68 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 111.422 -0.671 . . . . 0.0 111.422 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 85.1 m-85 -133.33 153.02 51.94 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 120.734 0.302 . . . . 0.0 110.4 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -139.65 152.32 46.65 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.008 -179.824 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 27.2 t -64.91 142.36 58.46 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.033 -179.796 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 61.3 pttt -66.79 -33.65 76.09 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.461 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 38.9 t -61.69 -42.99 99.67 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.602 -178.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 90.2 m-85 -90.43 4.02 52.19 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.66 -0.245 . . . . 0.0 111.48 -179.115 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 5.8 mm -119.7 127.99 75.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 CA-C-O 120.909 0.385 . . . . 0.0 110.246 179.797 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 94.4 m -123.69 129.75 51.58 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.422 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.409 HG21 HD11 ' A' ' 61' ' ' ILE . 96.0 mt -80.12 131.75 33.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.649 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 93.9 t -69.23 134.43 30.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.14 179.62 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . 0.438 ' OD1' ' O ' ' A' ' 63' ' ' ASN . 9.3 p30 -40.78 97.74 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.257 -0.428 . . . . 0.0 111.19 -179.533 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -68.59 -95.72 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.319 179.781 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -92.63 105.57 3.31 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.733 -0.947 . . . . 0.0 110.733 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 93.9 p -87.56 -7.18 57.86 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.775 0.321 . . . . 0.0 110.523 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -98.21 -4.95 34.32 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.108 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -69.08 148.74 49.58 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.667 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.671 ' CD2' ' H ' ' A' ' 70' ' ' HIS . 69.2 t60 -152.47 -130.77 0.04 OUTLIER 'General case' 0 N--CA 1.463 0.176 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.662 -179.878 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' HIS . . . . . 0.671 ' H ' ' CD2' ' A' ' 69' ' ' HIS . 85.6 t60 47.9 -115.52 0.69 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.674 -179.81 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.632 ' H ' ' CD2' ' A' ' 70' ' ' HIS . 90.4 m-70 39.04 83.83 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.07 -179.735 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 2.5 t-160 -93.21 123.16 36.29 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.365 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 84.5 t60 -117.41 119.83 36.28 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.43 179.895 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 52.1 p-80 . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 118.005 -0.998 . . . . 0.0 110.526 179.995 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 63.7 ttp . . . . . 0 N--CA 1.491 1.586 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 -129.66 128.05 41.79 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.606 -179.866 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -89.44 166.53 33.24 Favored Glycine 0 CA--C 1.522 0.491 0 N-CA-C 110.542 -1.023 . . . . 0.0 110.542 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 56.1 t -124.11 129.33 74.19 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.756 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 13.7 t -97.01 110.28 24.69 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.145 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.092 179.795 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 32.0 ttmt -119.11 120.01 35.89 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.162 179.764 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 9.3 p -140.59 159.72 24.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.32 -179.884 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 28.9 t-20 -60.85 -41.58 96.14 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.352 -178.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 5.1 t -130.14 -68.47 0.7 Allowed 'General case' 0 N--CA 1.467 0.419 0 CA-C-O 120.901 0.381 . . . . 0.0 110.563 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -158.11 144.14 17.21 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.997 -0.547 . . . . 0.0 109.948 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 40.0 tp -111.45 129.06 56.15 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-O 120.895 0.378 . . . . 0.0 110.585 -179.525 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 77.2 m-20 -75.69 141.43 42.72 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.413 179.694 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 30.9 ttp -102.73 147.52 26.74 Favored 'General case' 0 N--CA 1.47 0.575 0 CA-C-N 116.701 -0.227 . . . . 0.0 111.14 -179.287 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 76.2 mtt85 -119.54 142.11 48.63 Favored 'General case' 0 CA--C 1.506 -0.74 0 CA-C-O 121.285 0.564 . . . . 0.0 111.934 -178.819 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 78.9 p -66.98 -39.51 87.19 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.079 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -115.4 170.34 13.24 Favored Glycine 0 CA--C 1.527 0.793 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 179.509 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.3 Cg_endo -79.51 58.25 6.87 Favored 'Trans proline' 0 N--CA 1.492 1.425 0 C-N-CA 122.644 2.229 . . . . 0.0 112.175 179.557 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -176.99 149.68 9.73 Favored Glycine 0 CA--C 1.532 1.11 0 C-N-CA 120.938 -0.648 . . . . 0.0 111.756 179.879 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 32.7 t -64.37 -16.14 61.74 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 120.869 0.366 . . . . 0.0 110.888 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -72.67 -7.39 50.17 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.984 -179.536 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 55.9 m-85 -92.52 -6.21 50.15 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-O 120.635 0.255 . . . . 0.0 110.801 -179.877 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 67.03 -175.78 23.28 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 110.978 -0.849 . . . . 0.0 110.978 179.681 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 10.9 p -105.29 128.86 58.89 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 CA-C-O 120.81 0.338 . . . . 0.0 110.77 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 41.6 pt -105.94 -6.76 10.07 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.551 179.462 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.39 -177.25 44.31 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 -179.849 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 57.8 p -131.17 155.95 46.14 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-O 120.924 0.392 . . . . 0.0 110.358 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 71.4 mt -123.76 149.48 45.57 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.77 -179.583 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 34.5 ttp85 -113.7 143.17 45.05 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 -179.561 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.432 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 57.2 p30 -46.65 153.38 0.39 Allowed 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.316 0.579 . . . . 0.0 112.263 -179.022 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 63.3 m-20 58.93 31.25 21.14 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.106 -0.952 . . . . 0.0 111.856 179.299 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 29.3 t0 -93.55 118.16 31.0 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-O 120.68 0.276 . . . . 0.0 110.258 179.11 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 29.5 mmtp -72.97 132.37 43.34 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 109.986 -0.375 . . . . 0.0 109.986 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 26.8 m -138.41 160.97 31.54 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.518 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -108.39 120.25 41.87 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.031 179.566 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.402 HG21 HD12 ' A' ' 35' ' ' ILE . 95.8 mt -85.46 128.81 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.155 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.527 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 26.1 mt -93.63 -61.31 2.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.188 -179.742 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 22.0 mtmm -149.31 158.51 44.24 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.747 179.608 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . 0.408 ' CD ' ' CE1' ' A' ' 43' ' ' TYR . 83.9 tt0 -111.35 122.47 47.94 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.049 179.616 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 74.8 t -125.35 130.02 72.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.598 -179.794 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 44.8 t0 52.57 27.29 4.97 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.101 179.333 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.02 -21.92 37.21 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 179.56 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 43.8 m95 -77.32 140.18 39.95 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . 0.408 ' CE1' ' CD ' ' A' ' 38' ' ' GLU . 71.0 m-85 -99.06 129.97 45.36 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.831 0.348 . . . . 0.0 110.341 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -88.13 120.46 29.51 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 179.413 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 45.6 pt -127.17 158.6 38.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.455 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.075 -179.195 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 16.4 ttm180 -119.95 126.46 50.92 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 116.203 -0.453 . . . . 0.0 109.979 179.61 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 71.7 t80 -145.26 140.93 28.17 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.129 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 12.0 t-20 58.69 33.25 22.94 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.601 -179.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 71.34 3.98 55.09 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 179.614 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -107.65 150.32 27.04 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-O 120.685 0.278 . . . . 0.0 110.589 -179.818 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 55.1 t -116.4 131.94 67.46 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.226 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.36 -160.1 9.62 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.854 -0.898 . . . . 0.0 110.854 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 78.2 m-85 -132.85 157.5 44.89 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.835 0.35 . . . . 0.0 110.367 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -141.15 151.19 43.67 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.254 179.803 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 19.8 m -64.55 148.13 51.39 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.61 -179.678 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 26.6 pttm -79.36 -20.93 46.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.067 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 78.4 p -66.07 -37.88 86.91 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.465 -179.794 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -97.03 -1.53 45.23 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 116.68 -0.237 . . . . 0.0 111.567 -179.119 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.3 mp -113.51 130.86 66.77 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 96.2 m -121.02 127.84 52.12 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.002 179.508 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.3 mt -80.56 129.25 37.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.405 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 94.8 t -63.64 147.8 11.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.964 -179.67 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 8.1 t-20 65.73 37.1 5.9 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.231 -179.877 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 89.3 mt-10 -146.95 -26.03 0.4 Allowed 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.372 179.176 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -71.45 145.1 38.41 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 111.274 -0.73 . . . . 0.0 111.274 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 13.3 m -141.25 18.18 2.25 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 120.841 0.353 . . . . 0.0 110.414 179.759 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.521 ' CD2' ' N ' ' A' ' 67' ' ' LEU . 3.5 mm? -87.26 -4.11 59.07 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.325 -179.895 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.52 ' N ' ' OE1' ' A' ' 68' ' ' GLU . 56.0 mp0 -82.04 126.74 32.35 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.417 -179.846 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.435 ' O ' ' O ' ' A' ' 70' ' ' HIS . 99.6 m-70 -135.47 119.15 17.11 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.411 -0.358 . . . . 0.0 110.318 179.68 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' HIS . . . . . 0.435 ' O ' ' O ' ' A' ' 69' ' ' HIS . 75.6 m80 46.52 98.65 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.631 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 70.0 m80 -77.53 106.97 9.65 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 120.779 -0.368 . . . . 0.0 110.253 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 60.2 t-80 -66.5 -42.63 87.07 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.458 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 81.1 t60 -74.49 129.98 38.75 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.524 -179.732 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 86.1 t60 . . . . . 0 C--O 1.22 -0.461 0 CA-C-O 117.954 -1.022 . . . . 0.0 110.556 179.794 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 39.2 ttm . . . . . 0 N--CA 1.492 1.652 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 -140.67 115.19 9.44 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 120.959 0.409 . . . . 0.0 110.757 -179.782 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -88.63 162.21 31.52 Favored Glycine 0 CA--C 1.521 0.466 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 179.319 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 95.4 t -125.62 129.2 72.74 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.575 0 CA-C-O 120.985 0.422 . . . . 0.0 110.086 179.759 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 16.3 t -87.05 127.96 40.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.418 -179.748 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 63.6 mttp -124.13 107.56 11.38 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.129 -0.487 . . . . 0.0 109.982 179.634 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 11.9 p -140.27 151.41 21.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.434 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.63 -179.748 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.532 ' OD1' ' N ' ' A' ' 9' ' ' SER . 30.4 p30 -61.67 -42.64 99.19 Favored 'General case' 0 C--N 1.333 -0.127 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.196 -179.526 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' SER . . . . . 0.532 ' N ' ' OD1' ' A' ' 8' ' ' ASN . 8.0 t -125.07 -67.19 0.92 Allowed 'General case' 0 N--CA 1.47 0.541 0 CA-C-O 120.617 0.246 . . . . 0.0 110.94 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -158.24 144.77 17.48 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.777 0.322 . . . . 0.0 110.649 -179.603 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 44.9 tp -106.77 125.98 51.7 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.076 179.681 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -79.53 143.57 34.72 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.438 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 48.4 ttp -109.4 151.46 26.64 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 116.057 -0.519 . . . . 0.0 109.731 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 94.4 mtt-85 -127.63 151.53 48.82 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-O 120.924 0.392 . . . . 0.0 110.313 -179.274 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 35.0 t -62.36 -41.79 98.89 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.818 -179.34 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -124.97 163.16 19.07 Favored Glycine 0 N--CA 1.471 0.985 0 N-CA-C 111.482 -0.647 . . . . 0.0 111.482 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -68.32 86.32 0.42 Allowed 'Trans proline' 0 N--CA 1.496 1.628 0 C-N-CA 122.485 2.123 . . . . 0.0 111.692 179.543 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 164.4 143.31 3.67 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 111.218 -0.753 . . . . 0.0 111.218 179.581 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 75.4 p -66.44 -16.18 63.91 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.851 0.358 . . . . 0.0 110.825 179.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 50.5 p30 -80.64 -2.38 46.3 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.565 -179.542 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 47.0 m-85 -89.7 -7.77 53.85 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-O 120.756 0.312 . . . . 0.0 110.554 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 71.55 168.38 9.37 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 179.553 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 7.5 p -94.77 128.16 46.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 CA-C-O 120.79 0.329 . . . . 0.0 110.537 179.795 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 43.6 pt -108.2 -6.62 10.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.702 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -173.02 169.33 42.49 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 111.325 -0.71 . . . . 0.0 111.325 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 92.1 m -123.3 135.01 54.01 Favored 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 67.9 mt -107.72 155.16 20.5 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-O 120.871 0.367 . . . . 0.0 110.499 -179.559 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 90.2 mtm-85 -105.25 165.75 10.89 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.595 -179.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.402 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 52.6 p-10 -69.53 149.0 48.7 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.181 -179.613 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 21.7 t-20 56.12 32.98 21.13 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 115.91 -0.586 . . . . 0.0 111.014 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -89.92 116.27 27.85 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-O 120.825 0.345 . . . . 0.0 110.645 179.587 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 2.4 mmmp? -71.84 129.39 38.51 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.465 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.9 m -140.18 162.03 25.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.647 -179.496 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -104.89 121.06 42.91 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.353 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 89.3 mt -91.52 108.31 19.8 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.302 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 97.5 mt -67.41 -43.86 87.34 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.046 -0.524 . . . . 0.0 111.006 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 63.7 pttt -173.19 160.82 4.15 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.823 0.344 . . . . 0.0 111.001 -179.369 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -106.93 124.23 49.32 Favored 'General case' 0 N--CA 1.465 0.3 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 179.314 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 73.3 t -127.16 132.15 70.0 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 CA-C-O 120.952 0.406 . . . . 0.0 110.671 -179.436 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.415 ' OD1' ' O ' ' A' ' 40' ' ' ASP . 36.1 t0 56.26 23.86 7.59 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.013 179.246 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.52 -10.02 74.95 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 111.016 -0.834 . . . . 0.0 111.016 179.705 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 34.3 m95 -91.21 149.26 21.85 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-O 120.751 0.31 . . . . 0.0 110.188 179.748 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 52.4 m-85 -99.94 130.84 46.16 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.136 -179.731 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.412 ' CD ' ' HH ' ' A' ' 53' ' ' TYR . 76.1 tt0 -98.29 120.24 38.36 Favored 'General case' 0 CA--C 1.518 -0.269 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 179.223 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.41 HG23 HD12 ' A' ' 45' ' ' ILE . 39.2 pt -126.05 160.21 33.44 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.321 0 CA-C-O 120.969 0.414 . . . . 0.0 110.983 -179.207 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 43.6 ttm180 -117.89 127.85 54.26 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-N 115.694 -0.685 . . . . 0.0 109.503 179.486 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 34.1 t80 -144.77 131.17 19.72 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-O 121.16 0.505 . . . . 0.0 111.11 -179.736 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 6.1 m120 56.93 35.17 26.01 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 115.36 -0.837 . . . . 0.0 112.145 179.3 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 77.23 15.56 81.43 Favored Glycine 0 N--CA 1.465 0.592 0 C-N-CA 121.264 -0.493 . . . . 0.0 111.893 178.531 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -126.0 145.54 50.26 Favored 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 61.5 t -115.55 132.32 65.3 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.302 -179.732 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -149.67 -163.12 10.86 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.412 ' HH ' ' CD ' ' A' ' 44' ' ' GLU . 62.1 m-85 -132.86 160.27 37.46 Favored 'General case' 0 N--CA 1.466 0.347 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -149.72 159.17 44.57 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.04 0.448 . . . . 0.0 111.061 -179.617 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 18.4 p -69.54 148.89 48.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.696 -0.683 . . . . 0.0 110.304 179.885 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.415 ' O ' ' O ' ' A' ' 59' ' ' ILE . 59.0 pttt -82.59 -19.12 39.04 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.77 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 39.1 t -62.07 -42.39 99.15 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.954 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 90.5 m-85 -92.19 3.81 54.55 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.336 -179.171 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . 0.423 HG23 HD11 ' A' ' 59' ' ' ILE . 98.1 mt -128.51 132.25 68.12 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 CA-C-O 120.699 0.285 . . . . 0.0 110.351 179.601 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 99.3 m -123.15 132.12 53.95 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.465 179.732 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 27.0 mm -80.45 129.46 37.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.063 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 35.7 m -112.59 131.6 63.67 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 CA-C-O 120.954 0.407 . . . . 0.0 110.427 -179.687 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 53.5 t-20 61.69 91.42 0.06 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.592 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -56.64 142.15 40.88 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.127 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -73.29 119.72 6.79 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 111.352 -0.699 . . . . 0.0 111.352 -179.429 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 43.6 t -75.55 150.37 38.13 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.787 0.327 . . . . 0.0 110.312 179.602 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.418 ' N ' ' CD1' ' A' ' 67' ' ' LEU . 10.3 mp -83.79 -5.88 59.3 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.702 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 54.31 92.19 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.561 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.409 ' C ' ' H ' ' A' ' 71' ' ' HIS . 79.5 m80 -93.76 17.83 11.29 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.42 -179.847 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' HIS . . . . . . . . . . . . . 82.2 t60 -52.96 -13.12 0.39 Allowed 'General case' 0 C--N 1.332 -0.196 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.472 -179.669 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.409 ' H ' ' C ' ' A' ' 69' ' ' HIS . 58.9 t-80 -74.18 136.49 42.84 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.966 0.412 . . . . 0.0 111.233 -179.823 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 41.1 p-80 -141.85 124.98 16.32 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.336 179.632 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 49.8 p-80 -85.68 -17.08 37.02 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.288 179.794 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 86.4 t60 . . . . . 0 C--O 1.222 -0.384 0 CA-C-O 117.952 -1.023 . . . . 0.0 110.807 -179.759 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 36.5 ttm . . . . . 0 N--CA 1.49 1.535 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 58.0 tt0 -134.64 121.93 21.55 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-O 120.858 0.361 . . . . 0.0 110.231 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -93.16 155.2 22.22 Favored Glycine 0 CA--C 1.524 0.626 0 N-CA-C 111.054 -0.819 . . . . 0.0 111.054 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.414 ' CG1' ' HZ3' ' A' ' 6' ' ' LYS . 59.9 t -128.01 132.14 68.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.698 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 18.0 t -88.74 127.74 41.38 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.087 179.694 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.414 ' HZ3' ' CG1' ' A' ' 4' ' ' VAL . 64.7 mttp -124.57 105.81 9.65 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-O 120.912 0.386 . . . . 0.0 110.537 179.902 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 7.1 p -157.15 148.83 10.53 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-N 115.943 -0.572 . . . . 0.0 110.604 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.42 ' O ' ' ND2' ' A' ' 29' ' ' ASN . 7.7 m120 -68.54 -50.84 48.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.937 0.399 . . . . 0.0 110.554 179.452 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 9.2 p -95.88 165.53 12.23 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.564 179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -65.88 144.39 56.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.354 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 45.1 tp -111.22 132.78 54.07 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-O 120.972 0.415 . . . . 0.0 110.67 -179.794 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 6.2 m120 -78.02 146.26 35.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.892 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 40.0 ttp -98.11 148.66 23.32 Favored 'General case' 0 C--O 1.233 0.201 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.616 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 84.9 mtt85 -123.32 157.75 32.55 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 120.715 0.293 . . . . 0.0 110.493 -179.23 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' SER . . . . . 0.455 ' N ' ' CD1' ' A' ' 24' ' ' ILE . 88.5 p -84.11 -13.11 53.84 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.972 -179.321 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -162.31 -172.58 29.92 Favored Glycine 0 CA--C 1.529 0.952 0 C-N-CA 120.846 -0.692 . . . . 0.0 111.388 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -80.0 78.95 3.49 Favored 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.771 2.314 . . . . 0.0 112.143 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 167.4 134.12 1.65 Allowed Glycine 0 CA--C 1.524 0.603 0 C-N-CA 120.68 -0.771 . . . . 0.0 111.448 179.713 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 95.7 p -71.2 -12.3 61.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.95 0.405 . . . . 0.0 110.215 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 52.1 p-10 -78.91 -4.63 50.72 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.692 -179.822 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -85.85 -1.62 57.44 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.291 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 71.6 178.5 29.75 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 110.724 -0.95 . . . . 0.0 110.724 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 9.2 p -107.4 134.52 48.89 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.37 0 CA-C-O 120.861 0.362 . . . . 0.0 110.474 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.455 ' CD1' ' N ' ' A' ' 15' ' ' SER . 3.5 mp -106.0 -12.01 9.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.52 -179.758 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -173.55 -170.66 37.3 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 110.8 -0.92 . . . . 0.0 110.8 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 82.0 p -131.84 152.21 51.16 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 120.737 0.303 . . . . 0.0 110.302 179.846 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 78.5 mt -122.7 146.29 47.63 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.07 -0.514 . . . . 0.0 109.841 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -106.84 164.52 12.04 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.877 -179.364 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.42 ' ND2' ' O ' ' A' ' 8' ' ' ASN . 2.9 m-20 -64.07 148.93 48.66 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.671 -179.836 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 58.96 32.71 22.51 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.324 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 16.5 m-20 -82.0 137.38 35.12 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.113 179.02 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 63.3 mttp -104.99 122.73 46.46 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.858 0.361 . . . . 0.0 110.317 179.55 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.6 m -138.69 161.61 29.95 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.185 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.12 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -99.03 132.74 44.11 Favored 'General case' 0 C--O 1.234 0.287 0 N-CA-C 109.727 -0.472 . . . . 0.0 109.727 179.689 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.409 HD11 HG22 ' A' ' 35' ' ' ILE . 96.2 mt -100.71 107.5 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.309 179.917 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.8 mt -66.55 -43.87 90.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.89 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 63.6 pttt -173.05 169.98 4.52 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.829 -179.41 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . 0.429 ' CD ' ' CE1' ' A' ' 43' ' ' TYR . 83.1 tt0 -111.91 126.29 54.96 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.646 179.591 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 76.3 t -126.79 131.91 70.61 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 CA-C-O 121.07 0.462 . . . . 0.0 111.133 -179.438 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 52.65 30.42 8.68 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.661 -0.7 . . . . 0.0 111.759 178.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.14 -18.02 47.66 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 111.651 -0.58 . . . . 0.0 111.651 179.204 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 40.3 m95 -85.95 145.23 27.23 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.845 0.355 . . . . 0.0 110.244 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . 0.429 ' CE1' ' CD ' ' A' ' 38' ' ' GLU . 72.7 m-85 -100.75 126.99 47.34 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.481 -179.642 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 79.2 tt0 -78.54 152.42 31.95 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 179.715 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.4 pt -144.04 153.36 15.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.679 0.276 . . . . 0.0 110.854 -179.702 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 76.3 ttt180 -121.16 123.32 42.0 Favored 'General case' 0 N--CA 1.468 0.454 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.265 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 74.5 t80 -142.08 125.8 16.96 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-O 120.884 0.373 . . . . 0.0 110.885 -179.444 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 17.0 t-20 54.8 35.97 25.37 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.999 179.766 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 73.01 15.19 78.52 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 111.145 -0.782 . . . . 0.0 111.145 179.521 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.9 ttmp? -112.43 147.93 35.42 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 110.228 -0.286 . . . . 0.0 110.228 179.771 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.0 t -110.2 132.85 57.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.933 0.397 . . . . 0.0 110.32 -179.785 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . 0.467 ' C ' ' CD1' ' A' ' 53' ' ' TYR . . . -148.63 -165.02 11.84 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 179.823 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.467 ' CD1' ' C ' ' A' ' 52' ' ' GLY . 72.9 m-85 -146.46 157.81 43.81 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.729 0.299 . . . . 0.0 110.456 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -141.63 155.72 45.7 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.398 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' SER . . . . . 0.403 ' O ' ' CG1' ' A' ' 59' ' ' ILE . 18.1 m -69.41 147.87 50.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.031 -179.623 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 62.0 pttt -66.34 -34.69 78.53 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.233 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 37.1 m -61.56 -41.11 96.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.706 -179.205 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 89.1 m-85 -94.22 7.64 44.57 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 116.518 -0.31 . . . . 0.0 111.002 -179.285 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . 0.403 ' CG1' ' O ' ' A' ' 55' ' ' SER . 5.3 mm -122.4 128.77 75.54 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-O 121.119 0.485 . . . . 0.0 110.293 179.637 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 86.8 m -122.56 126.89 48.67 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.512 -179.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.6 mt -91.22 127.9 43.32 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.497 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 33.2 m -80.36 148.29 5.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.437 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 13.6 m120 60.45 35.9 20.3 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.67 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 39.8 tp10 -85.33 -17.76 35.86 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-O 120.968 0.413 . . . . 0.0 110.459 -179.716 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 165.77 23.26 0.02 OUTLIER Glycine 0 CA--C 1.526 0.739 0 N-CA-C 111.12 -0.792 . . . . 0.0 111.12 179.641 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.3 t 51.43 83.36 0.05 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.797 0.332 . . . . 0.0 110.578 179.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 77.0 mt -73.49 148.41 43.16 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.354 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 51.0 tp10 -52.14 142.32 16.66 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.926 -179.437 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.446 ' O ' ' O ' ' A' ' 70' ' ' HIS . 95.3 m-70 -76.95 136.05 38.76 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.609 179.704 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' HIS . . . . . 0.446 ' O ' ' O ' ' A' ' 69' ' ' HIS . 80.0 m80 45.02 -173.66 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.677 -179.648 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 98.7 m-70 -141.86 140.75 32.99 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.53 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -141.62 145.26 34.8 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.023 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 79.4 m80 -110.49 139.46 45.7 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.689 -179.796 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 77.9 m80 . . . . . 0 C--O 1.221 -0.443 0 CA-C-O 118.002 -0.999 . . . . 0.0 110.433 179.998 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 7.9 ttt . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 27.0 mt-30 -136.11 116.55 13.71 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.131 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -84.69 164.88 39.81 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 -179.605 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 57.2 t -123.91 133.62 68.76 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.394 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 72.4 t -100.88 127.85 53.62 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-O 120.876 0.37 . . . . 0.0 110.314 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.656 ' HZ2' ' ND2' ' A' ' 30' ' ' ASN . 68.8 mmtt -119.58 106.41 12.17 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.559 179.423 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.495 ' O ' ' ND2' ' A' ' 29' ' ' ASN . 28.0 m -131.41 160.05 42.62 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.302 -179.456 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 52.8 t-20 -63.59 -41.67 98.34 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.097 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 4.3 t -150.7 -53.33 0.14 Allowed 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.464 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -157.64 142.88 16.96 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.422 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 65.1 tp -125.46 135.68 52.59 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 116.1 -0.5 . . . . 0.0 109.92 -179.802 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 13.7 m120 -77.93 138.83 39.09 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.197 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 50.5 ttp -98.11 138.59 35.18 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.074 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . 0.5 ' HE ' ' HA ' ' A' ' 19' ' ' SER . 22.0 mmt180 -103.9 156.96 17.42 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.517 -178.675 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 4.6 m -83.07 -7.68 59.62 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.76 -179.636 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -159.23 -169.63 22.8 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -83.24 72.21 5.82 Favored 'Trans proline' 0 C--N 1.304 -1.777 0 C-N-CA 122.659 2.239 . . . . 0.0 111.857 -179.755 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.78 147.81 6.34 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 111.104 -0.799 . . . . 0.0 111.104 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.5 ' HA ' ' HE ' ' A' ' 14' ' ' ARG . 15.7 m -81.47 -11.64 59.15 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.948 0.404 . . . . 0.0 110.728 -179.82 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 28.6 t-20 -84.14 7.06 20.09 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.979 -179.693 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 49.9 m-85 -92.71 -0.23 57.32 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 120.772 0.32 . . . . 0.0 110.414 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 75.62 179.22 44.61 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 7.2 p -108.84 125.31 65.85 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-O 120.826 0.345 . . . . 0.0 110.621 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 41.2 pt -108.66 -4.51 10.58 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.809 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -172.96 170.76 43.9 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 111.116 -0.793 . . . . 0.0 111.116 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 86.4 m -128.64 138.02 51.96 Favored 'General case' 0 N--CA 1.472 0.635 0 CA-C-O 120.494 0.187 . . . . 0.0 110.541 -179.673 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 77.4 mt -110.18 143.7 39.92 Favored 'General case' 0 N--CA 1.476 0.844 0 N-CA-C 112.12 0.415 . . . . 0.0 112.12 -178.793 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 49.2 mtt-85 -105.24 167.76 9.52 Favored 'General case' 0 N--CA 1.477 0.88 0 CA-C-O 121.773 0.797 . . . . 0.0 111.812 -179.079 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.495 ' ND2' ' O ' ' A' ' 7' ' ' VAL . 1.3 m-20 -64.32 146.17 54.83 Favored 'General case' 0 N--CA 1.437 -1.107 0 CA-C-N 114.993 -1.003 . . . . 0.0 108.976 -179.055 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.656 ' ND2' ' HZ2' ' A' ' 6' ' ' LYS . 15.5 m120 57.07 34.41 24.86 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.287 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 67.1 t0 -88.27 110.39 20.7 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 110.016 -0.364 . . . . 0.0 110.016 179.329 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -78.61 132.67 37.19 Favored 'General case' 0 C--N 1.331 -0.212 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 -179.811 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 28.9 m -139.88 162.05 25.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.657 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -99.89 131.55 45.79 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.19 -0.459 . . . . 0.0 109.811 179.393 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 86.7 mt -96.65 126.77 49.26 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-N 116.33 -0.396 . . . . 0.0 111.022 -179.245 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.438 HD12 HG23 ' A' ' 36' ' ' ILE . 18.5 mm -94.71 -62.97 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.427 179.825 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 22.2 mtmm -148.33 159.78 43.65 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 120.918 0.39 . . . . 0.0 111.018 179.756 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -111.81 123.34 50.03 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.339 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 72.0 t -127.47 132.47 69.29 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.604 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 55.23 30.7 15.1 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.143 179.25 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.5 -16.6 34.3 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 111.02 -0.832 . . . . 0.0 111.02 179.711 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.616 ' CZ2' ' OG ' ' A' ' 55' ' ' SER . 11.7 m95 -83.58 147.37 27.78 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 179.423 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 46.2 m-85 -100.83 130.34 46.84 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 121.047 0.451 . . . . 0.0 110.941 -179.609 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -87.1 122.74 31.33 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 178.805 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 39.1 pt -130.59 161.62 40.12 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.407 0 CA-C-O 121.176 0.512 . . . . 0.0 111.537 -178.601 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 13.6 ttt180 -118.7 123.66 45.44 Favored 'General case' 0 N--CA 1.464 0.275 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.332 179.432 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 87.4 t80 -144.39 135.97 25.74 Favored 'General case' 0 N--CA 1.473 0.713 0 CA-C-O 120.824 0.345 . . . . 0.0 111.322 -178.401 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.438 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 17.6 t-20 57.51 34.84 25.14 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.7 179.347 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 69.45 18.46 73.56 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 179.77 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -124.67 146.14 49.29 Favored 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 66.5 t -113.99 131.56 65.56 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.389 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . 0.405 ' C ' ' CD1' ' A' ' 53' ' ' TYR . . . -150.47 -164.6 12.02 Favored Glycine 0 CA--C 1.52 0.39 0 N-CA-C 110.664 -0.974 . . . . 0.0 110.664 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.427 ' N ' ' CD1' ' A' ' 53' ' ' TYR . 28.4 m-85 -134.96 156.71 48.54 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.796 0.332 . . . . 0.0 110.54 -179.737 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -146.67 150.6 35.73 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.028 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' SER . . . . . 0.616 ' OG ' ' CZ2' ' A' ' 42' ' ' TRP . 37.8 m -70.39 142.0 52.13 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 177.81 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 64.4 pttt -68.2 -13.07 61.96 Favored 'General case' 0 CA--C 1.51 -0.578 0 CA-C-O 121.8 0.809 . . . . 0.0 108.847 178.84 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 87.8 p -56.29 -14.0 2.55 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 114.015 -1.448 . . . . 0.0 109.321 178.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 91.7 m-85 -127.16 -28.26 2.88 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.202 179.816 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . 0.535 ' N ' ' CD1' ' A' ' 59' ' ' ILE . 1.3 mp -90.1 129.29 41.21 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 179.162 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 87.5 m -123.81 129.34 50.89 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.388 -179.881 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.548 ' N ' ' CD1' ' A' ' 61' ' ' ILE . 1.7 mp -83.0 128.14 39.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.286 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.421 ' O ' ' O ' ' A' ' 63' ' ' ASN . 15.7 m -83.45 138.36 19.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.319 179.807 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . 0.518 ' CG ' ' H ' ' A' ' 64' ' ' GLU . 6.9 t-20 45.33 -172.17 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.743 -179.769 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . 0.518 ' H ' ' CG ' ' A' ' 63' ' ' ASN . 4.3 tm-20 66.25 69.32 0.43 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.424 -179.77 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -90.18 -72.8 1.26 Allowed Glycine 0 CA--C 1.525 0.69 0 N-CA-C 110.67 -0.972 . . . . 0.0 110.67 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 82.3 p -75.52 161.8 28.86 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 179.815 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 41.1 tp -77.41 126.75 31.4 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.975 0.417 . . . . 0.0 110.798 -179.713 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -83.91 150.72 25.51 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.171 179.584 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 98.7 m-70 -105.44 128.31 53.46 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.328 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' HIS . . . . . . . . . . . . . 59.0 t-80 -85.94 122.62 30.25 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.728 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 98.7 m-70 -91.32 144.32 25.72 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.486 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 56.6 p-80 -67.82 139.7 56.59 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.661 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 85.2 t60 -83.56 126.2 32.58 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.512 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 79.7 m80 . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 118.008 -0.996 . . . . 0.0 110.786 -179.996 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 39.0 tpp . . . . . 0 N--CA 1.49 1.575 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 78.2 mt-30 -142.81 108.34 5.07 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.204 179.747 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -87.18 158.1 29.91 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 97.7 t -127.65 133.3 67.93 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 179.703 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 71.9 t -93.33 128.2 44.92 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-N 116.46 -0.337 . . . . 0.0 110.392 -179.884 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 65.5 mttp -132.02 107.01 8.38 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.453 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.402 HG23 ' H ' ' A' ' 9' ' ' SER . 4.0 p -138.79 154.03 26.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.162 -179.897 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 92.1 m-20 -62.06 -42.85 99.62 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-O 120.83 0.348 . . . . 0.0 111.235 -178.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' SER . . . . . 0.402 ' H ' HG23 ' A' ' 7' ' ' VAL . 85.2 p -136.76 -153.84 0.52 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.035 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -66.98 143.15 56.97 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.017 0.437 . . . . 0.0 110.545 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 47.2 tp -122.0 130.46 53.32 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.062 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . 0.425 ' OD1' ' O ' ' A' ' 12' ' ' ASN . 45.1 p30 -82.12 140.53 33.76 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.693 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 58.1 ttp -108.33 138.65 44.25 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.215 -0.448 . . . . 0.0 109.869 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 4.3 mpt_? -106.45 157.37 17.69 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 120.983 0.42 . . . . 0.0 111.233 -178.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 84.2 p -82.27 -6.22 59.08 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.243 179.732 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -162.36 -174.86 32.76 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.765 -0.934 . . . . 0.0 110.765 179.762 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -80.94 79.09 3.41 Favored 'Trans proline' 0 C--N 1.306 -1.692 0 C-N-CA 122.86 2.373 . . . . 0.0 111.926 179.766 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 171.03 137.17 2.24 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 94.9 p -74.64 -7.7 54.04 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.764 0.316 . . . . 0.0 110.857 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 12.0 m120 -89.01 5.6 43.54 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.069 -179.414 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 42.7 m-85 -91.31 -0.56 57.68 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.869 0.366 . . . . 0.0 110.208 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 73.28 174.43 27.89 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 11.7 p -105.64 125.34 60.99 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-O 120.894 0.378 . . . . 0.0 110.412 179.743 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 40.8 pt -101.81 -4.75 9.26 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.758 -179.855 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -174.3 174.08 46.29 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 89.7 m -125.17 132.21 53.09 Favored 'General case' 0 N--CA 1.464 0.226 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.627 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 72.1 mt -108.09 143.93 36.16 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 116.194 -0.457 . . . . 0.0 109.968 -179.759 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 37.8 ttt85 -119.51 142.62 48.15 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.171 0.51 . . . . 0.0 110.26 179.42 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 44.0 p-10 -48.26 165.09 0.04 OUTLIER 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.65 -0.704 . . . . 0.0 111.0 -179.766 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 65.8 t30 62.8 6.48 2.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.554 -0.748 . . . . 0.0 111.366 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 31.5 t0 -87.13 118.68 26.68 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.548 -0.297 . . . . 0.0 110.663 179.517 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -76.3 137.39 39.86 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.2 179.471 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.2 m -137.39 162.05 33.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.62 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 48.4 tp10 -105.84 123.65 48.3 Favored 'General case' 0 C--O 1.234 0.274 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 179.581 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.5 mt -91.38 127.8 43.52 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.123 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.94 -179.355 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 81.9 mt -91.4 -51.27 11.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.176 179.597 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 62.6 pttt -174.9 179.0 1.71 Allowed 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.558 179.705 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -112.84 125.06 53.95 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.219 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 79.5 t -124.93 129.74 73.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.28 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.44 ' OD1' ' O ' ' A' ' 40' ' ' ASP . 55.2 t0 54.74 24.28 5.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.071 179.362 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.86 -5.62 84.66 Favored Glycine 0 CA--C 1.526 0.753 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 179.739 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 56.4 m95 -90.52 149.38 22.2 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 179.364 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -96.88 130.35 44.18 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-O 121.098 0.475 . . . . 0.0 110.137 -179.669 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -94.47 126.51 39.79 Favored 'General case' 0 CA--C 1.506 -0.714 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.018 179.369 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 44.3 pt -125.93 160.76 32.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 121.356 0.598 . . . . 0.0 110.249 179.626 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 3.2 ttp180 -126.89 113.89 17.14 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 114.777 -1.101 . . . . 0.0 109.624 -176.763 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 61.8 t80 -141.51 139.1 33.2 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 120.947 0.403 . . . . 0.0 111.605 -178.111 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 15.0 t-20 57.13 34.62 25.15 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.904 179.298 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 69.74 20.71 76.08 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 111.431 -0.668 . . . . 0.0 111.431 179.52 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 53.9 mtmt -131.23 143.58 50.68 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-O 120.688 0.28 . . . . 0.0 110.823 -179.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 19.8 t -102.26 111.8 33.29 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 CA-C-O 121.115 0.483 . . . . 0.0 110.656 179.535 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -107.55 -172.69 22.17 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 111.053 -0.819 . . . . 0.0 111.053 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 48.1 m-85 -132.3 142.36 49.33 Favored 'General case' 0 C--N 1.331 -0.233 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 179.624 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -154.29 153.0 30.93 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.404 -179.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' SER . . . . . 0.489 ' HG ' ' H ' ' A' ' 57' ' ' SER . 48.5 t -70.1 148.15 49.1 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.787 -179.887 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 63.9 pttt -64.2 -17.65 63.75 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.73 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' SER . . . . . 0.489 ' H ' ' HG ' ' A' ' 55' ' ' SER . 38.6 t -65.7 -18.22 65.17 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.395 -179.669 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 71.7 m-85 -105.73 -19.16 13.84 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 121.271 -0.172 . . . . 0.0 111.323 -179.554 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . 0.455 ' N ' ' CD1' ' A' ' 59' ' ' ILE . 1.9 mp -109.87 130.99 62.04 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 CA-C-O 121.159 0.504 . . . . 0.0 110.631 -179.68 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 88.6 m -116.12 127.06 54.53 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-N 115.49 -0.777 . . . . 0.0 109.824 179.644 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.4 mt -78.91 133.21 30.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.774 -179.593 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.423 ' O ' ' O ' ' A' ' 63' ' ' ASN . 75.1 t -93.67 131.82 39.56 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.087 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . 0.423 ' O ' ' O ' ' A' ' 62' ' ' VAL . 11.7 m120 59.05 122.62 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.458 -179.641 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -75.33 -4.75 41.07 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.625 -179.746 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.525 ' O ' ' N ' ' A' ' 67' ' ' LEU . . . 144.29 -18.15 2.09 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 111.051 -0.82 . . . . 0.0 111.051 179.884 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 32.0 t 56.19 -80.2 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.598 0.237 . . . . 0.0 110.526 -179.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.525 ' N ' ' O ' ' A' ' 65' ' ' GLY . 3.6 mm? -73.61 146.29 44.76 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 179.58 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -48.8 135.88 14.57 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.68 -179.744 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 50.4 m170 -66.68 -40.05 88.39 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.789 -179.759 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -94.92 123.5 38.43 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.573 -179.763 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -144.28 103.34 3.97 Favored 'General case' 0 N--CA 1.462 0.169 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.46 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 98.4 m-70 -82.3 150.62 27.15 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.56 179.891 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 13.0 p80 -140.41 124.04 17.12 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.487 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 99.5 m-70 . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 118.012 -0.994 . . . . 0.0 110.472 179.953 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 36.9 ttm . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 -132.4 114.21 14.07 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.517 179.683 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -94.83 150.5 19.74 Favored Glycine 0 CA--C 1.521 0.452 0 N-CA-C 110.474 -1.05 . . . . 0.0 110.474 179.466 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 55.4 t -119.15 131.12 72.79 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 89.1 t -83.51 129.44 37.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.322 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 19.7 mmmt -115.35 106.27 13.82 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.128 179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.2 p -141.7 144.5 25.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.062 -179.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 19.3 m120 -63.04 -41.26 99.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.091 -179.607 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 44.4 m -133.03 -96.15 0.31 Allowed 'General case' 0 N--CA 1.466 0.363 0 CA-C-O 120.891 0.377 . . . . 0.0 110.402 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -112.97 143.65 43.89 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.409 179.886 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 42.8 tp -116.97 128.69 55.44 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 120.985 0.421 . . . . 0.0 110.086 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -82.94 138.64 33.74 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.478 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 37.5 ttp -103.63 152.11 22.14 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.294 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . 0.414 ' NH1' ' HG3' ' A' ' 14' ' ' ARG . 1.9 mtt85 -129.82 155.33 46.15 Favored 'General case' 0 CA--C 1.543 0.697 0 N-CA-C 109.198 -0.667 . . . . 0.0 109.198 -178.871 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 86.2 p -84.39 -4.92 59.18 Favored 'General case' 0 N--CA 1.478 0.936 0 N-CA-C 113.291 0.849 . . . . 0.0 113.291 -179.536 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -162.64 158.05 30.15 Favored Glycine 0 CA--C 1.524 0.63 0 C-N-CA 120.367 -0.921 . . . . 0.0 110.842 -179.073 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -64.5 87.61 0.16 Allowed 'Trans proline' 0 C--N 1.307 -1.622 0 C-N-CA 122.273 1.982 . . . . 0.0 111.64 -179.803 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 157.75 136.96 2.18 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 111.012 -0.835 . . . . 0.0 111.012 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 32.6 t -65.41 -13.13 58.0 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.777 0.322 . . . . 0.0 110.702 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -75.71 -3.7 36.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.254 -179.284 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 40.6 m-85 -90.0 -5.66 56.43 Favored 'General case' 0 C--N 1.332 -0.169 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.479 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 66.88 178.92 10.36 Favored Glycine 0 CA--C 1.522 0.477 0 N-CA-C 110.634 -0.986 . . . . 0.0 110.634 179.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 8.3 p -103.07 126.3 57.39 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.163 0 CA-C-O 120.783 0.325 . . . . 0.0 110.279 179.595 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 25.5 pt -101.97 -4.61 9.29 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.783 -179.677 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 175.35 -176.14 47.27 Favored Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 -179.866 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 59.6 p -134.87 158.67 43.64 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-O 120.848 0.356 . . . . 0.0 110.758 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 71.5 mt -122.63 150.39 42.72 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.015 -179.899 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.676 HH11 ' HG3' ' A' ' 28' ' ' ARG . 1.0 OUTLIER -94.56 160.96 14.4 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 -179.24 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.427 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 51.7 p30 -64.97 150.48 47.94 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.614 -178.791 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 56.2 t-20 59.61 32.08 21.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.69 -0.687 . . . . 0.0 111.514 179.555 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.518 ' OD2' ' N ' ' A' ' 28' ' ' ARG . 77.5 m-20 -82.78 136.85 34.55 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 179.22 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 53.0 mtmt -107.88 122.25 46.41 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.13 179.299 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.7 m -135.95 162.35 36.63 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.416 -179.876 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -85.82 129.82 34.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.269 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.6 mt -100.19 121.38 50.85 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.265 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.328 179.889 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.415 HG23 HD12 ' A' ' 36' ' ' ILE . 77.8 mt -83.99 -46.95 18.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.103 -179.832 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 62.1 pttt -174.79 163.28 3.37 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.749 -179.602 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -107.21 124.44 49.74 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.305 179.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 77.4 t -124.42 130.2 73.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.616 -179.578 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.5 m-20 53.97 27.06 6.92 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.022 179.508 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.33 -11.38 67.98 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 111.201 -0.76 . . . . 0.0 111.201 179.595 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 72.9 m95 -87.65 148.68 24.7 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 110.118 -0.327 . . . . 0.0 110.118 179.747 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 7.0 m-85 -103.56 132.25 49.98 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-O 121.099 0.476 . . . . 0.0 110.581 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -93.73 121.89 35.62 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 178.307 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 41.6 pt -127.53 157.9 39.14 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-O 120.922 0.391 . . . . 0.0 111.284 -178.803 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 38.6 ttm180 -112.05 119.65 39.18 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.699 179.51 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 39.9 t80 -138.92 132.28 30.11 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.52 -179.433 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 64.3 t30 58.38 34.58 24.13 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.821 179.813 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 72.85 5.93 66.05 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.985 -0.846 . . . . 0.0 110.985 179.614 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 62.2 tttp -114.18 146.31 40.53 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.721 0.296 . . . . 0.0 110.576 -179.498 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 53.9 t -113.12 130.9 66.2 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.015 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -145.19 -161.7 9.21 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 110.978 -0.849 . . . . 0.0 110.978 -179.664 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 65.2 m-85 -122.15 157.08 32.31 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-O 120.662 0.268 . . . . 0.0 110.346 -179.852 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -144.59 154.68 43.1 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.63 -179.694 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 47.6 t -68.27 133.9 49.53 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.231 -179.46 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -65.5 -44.7 86.23 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.537 179.79 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 35.8 t -57.11 -19.11 17.86 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.255 -178.584 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 43.1 m-85 -103.57 6.31 37.2 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 116.504 -0.316 . . . . 0.0 111.218 -179.699 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 96.7 mt -131.82 132.23 61.81 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 CA-C-O 121.098 0.475 . . . . 0.0 111.455 179.756 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 92.5 m -123.41 130.55 52.87 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.085 179.33 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 22.1 mm -82.17 130.28 36.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.614 -179.781 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 99.5 t -70.66 134.42 30.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.449 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -59.3 122.14 13.15 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.443 -179.821 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -83.49 121.58 27.39 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.7 -179.886 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.466 ' O ' ' N ' ' A' ' 67' ' ' LEU . . . 72.99 -171.7 50.46 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 179.678 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 3.5 m 42.16 22.46 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.925 0.393 . . . . 0.0 110.873 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.466 ' N ' ' O ' ' A' ' 65' ' ' GLY . 47.9 tp -73.5 -82.99 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.605 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.493 ' N ' ' OE1' ' A' ' 68' ' ' GLU . 58.2 mp0 43.76 -169.26 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.385 -179.759 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.52 ' O ' ' N ' ' A' ' 71' ' ' HIS . 98.5 m-70 -87.15 131.21 34.24 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.784 179.743 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' HIS . . . . . . . . . . . . . 75.7 m80 40.7 -90.05 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.949 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.52 ' N ' ' O ' ' A' ' 69' ' ' HIS . 74.1 t60 41.16 82.23 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.997 179.849 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.51 ' O ' ' N ' ' A' ' 74' ' ' HIS . 85.9 t60 -144.02 103.2 3.99 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.144 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 41.32 -91.02 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.805 -179.636 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' HIS . . . . . 0.51 ' N ' ' O ' ' A' ' 72' ' ' HIS . 80.2 m80 . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 117.983 -1.008 . . . . 0.0 110.505 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 86.8 mmm . . . . . 0 N--CA 1.491 1.622 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 99.4 mt-30 -133.53 120.7 21.13 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.385 179.735 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -93.41 139.32 14.53 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.449 -1.06 . . . . 0.0 110.449 179.608 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 54.2 t -122.38 131.99 72.04 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.254 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 179.899 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 84.6 t -90.01 128.6 41.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.592 -179.431 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 55.4 mtpt -125.05 105.95 9.57 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.032 -0.531 . . . . 0.0 109.848 179.402 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 11.3 p -139.14 155.28 26.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.037 -179.61 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 23.4 t-20 -61.2 -41.24 96.49 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.144 -179.241 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 4.8 t -140.02 -62.78 0.51 Allowed 'General case' 0 N--CA 1.466 0.364 0 CA-C-O 120.747 0.308 . . . . 0.0 111.07 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -150.49 144.22 25.23 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.617 -179.63 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 50.8 tp -120.64 134.6 55.27 Favored 'General case' 0 N--CA 1.469 0.48 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.097 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . 0.426 ' OD1' ' O ' ' A' ' 12' ' ' ASN . 50.5 p-10 -81.47 140.11 34.79 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.669 -179.879 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 42.4 ttp -101.13 153.79 19.28 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.065 -179.706 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . 0.776 ' HG3' HH11 ' A' ' 14' ' ' ARG . 22.2 mtm-85 -125.83 156.83 38.95 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-O 121.381 0.61 . . . . 0.0 112.233 -178.196 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 94.0 p -80.52 -6.26 57.93 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.062 -0.972 . . . . 0.0 110.052 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -159.48 -171.0 24.75 Favored Glycine 0 CA--C 1.525 0.716 0 N-CA-C 110.942 -0.863 . . . . 0.0 110.942 179.678 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -87.05 6.99 5.04 Favored 'Trans proline' 0 C--N 1.305 -1.747 0 C-N-CA 122.744 2.296 . . . . 0.0 111.997 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -99.75 128.71 9.66 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 111.134 -0.787 . . . . 0.0 111.134 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 97.6 p -67.24 -10.33 49.55 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.786 0.327 . . . . 0.0 110.297 179.642 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 54.9 p30 -91.55 8.12 38.13 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.33 -179.574 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 19.6 m-85 -87.13 -5.59 58.96 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.904 0.383 . . . . 0.0 110.322 -179.896 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 72.53 177.14 30.45 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 111.587 -0.605 . . . . 0.0 111.587 179.039 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 7.2 p -97.54 126.96 50.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-O 120.844 0.354 . . . . 0.0 110.539 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 42.7 pt -106.88 -6.44 10.35 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.542 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.26 175.39 47.15 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 88.5 m -125.45 134.74 51.98 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-O 120.891 0.377 . . . . 0.0 110.337 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 82.1 mt -105.63 148.31 27.49 Favored 'General case' 0 CA--C 1.516 -0.334 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.891 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 31.8 mmm-85 -103.06 161.64 13.6 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.366 -0.834 . . . . 0.0 110.888 -179.098 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.428 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 25.5 p30 -65.71 143.02 57.8 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-O 121.186 0.517 . . . . 0.0 111.271 -179.362 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 66.3 t30 57.26 34.55 24.94 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.761 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 67.3 t0 -84.73 115.01 22.46 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.775 179.379 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 29.9 mmtp -72.7 128.37 35.34 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.89 0.376 . . . . 0.0 110.387 -179.329 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.3 m -137.81 161.24 33.29 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.222 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.15 179.832 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.531 ' N ' ' OE1' ' A' ' 34' ' ' GLU . 55.9 mp0 -106.54 123.69 48.47 Favored 'General case' 0 C--O 1.234 0.248 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.091 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.411 HG21 HD12 ' A' ' 35' ' ' ILE . 95.2 mt -88.52 128.07 41.01 Favored 'Isoleucine or valine' 0 C--O 1.232 0.153 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.45 -179.719 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.404 HD11 HG23 ' A' ' 36' ' ' ILE . 95.9 mt -98.19 -56.62 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.22 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.026 -179.763 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 47.1 mtpt -143.13 153.16 42.61 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 121.2 0.524 . . . . 0.0 111.262 -179.497 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . 0.438 ' CD ' ' CE1' ' A' ' 43' ' ' TYR . 84.3 tt0 -115.47 120.72 40.45 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.747 179.159 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 60.1 t -128.89 131.95 67.86 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.51 0 CA-C-O 120.899 0.381 . . . . 0.0 111.558 -179.48 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 54.11 26.47 6.59 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.35 179.285 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.86 -14.05 64.33 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 179.589 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 46.1 m95 -83.59 144.01 29.75 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 179.499 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . 0.438 ' CE1' ' CD ' ' A' ' 38' ' ' GLU . 65.0 m-85 -103.31 130.35 50.56 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.931 0.396 . . . . 0.0 110.676 -179.809 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 79.4 tt0 -90.08 122.5 33.11 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 179.312 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 24.1 pt -128.72 159.04 40.95 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-O 120.732 0.301 . . . . 0.0 111.309 -178.819 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.43 ' HE ' ' HB2' ' A' ' 46' ' ' ARG . 9.4 ttm180 -118.01 128.65 54.98 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.271 -0.422 . . . . 0.0 109.957 179.553 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 42.1 t80 -146.54 135.28 22.25 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.557 -179.358 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 8.5 m120 56.53 33.82 23.27 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.838 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 73.82 6.33 72.24 Favored Glycine 0 CA--C 1.525 0.716 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 179.576 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 56.4 mtpt -110.41 147.52 33.84 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 120.644 0.259 . . . . 0.0 110.419 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 55.7 t -117.9 131.43 70.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 CA-C-N 116.274 -0.421 . . . . 0.0 109.956 179.674 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -149.4 -160.98 9.48 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.382 -1.087 . . . . 0.0 110.382 -179.914 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 67.6 m-85 -135.22 158.18 45.02 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.933 0.397 . . . . 0.0 110.766 -179.586 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -146.84 155.83 42.64 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.309 -179.848 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 20.2 m -69.77 151.46 45.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.792 -179.559 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 22.6 pttp -75.13 -18.83 60.15 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.718 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 74.7 m -61.85 -42.94 99.66 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.699 -179.589 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 82.8 m-85 -96.73 -2.38 44.55 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.524 0.202 . . . . 0.0 111.395 -179.187 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 1.6 mp -113.86 128.66 70.68 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 179.46 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 91.7 m -124.88 130.35 52.21 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.055 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.435 HG22 HD12 ' A' ' 61' ' ' ILE . 22.1 mm -78.46 129.61 37.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.353 -179.593 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 94.1 t -95.66 129.24 46.03 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.182 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.616 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 56.5 t-20 57.51 85.08 0.09 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.621 179.759 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 75.9 mt-10 -78.41 -4.11 46.64 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.587 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 91.09 152.83 28.67 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 111.156 -0.778 . . . . 0.0 111.156 179.916 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 21.6 m -74.26 142.59 45.29 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.763 0.316 . . . . 0.0 110.41 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.447 ' N ' ' CD1' ' A' ' 67' ' ' LEU . 10.0 mp -91.43 -3.84 56.24 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.294 179.875 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 43.8 tp10 -67.35 132.52 47.86 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.267 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 99.5 m-70 -82.79 153.05 25.43 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.77 -179.92 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' HIS . . . . . 0.439 ' O ' ' O ' ' A' ' 71' ' ' HIS . 81.0 m80 -74.15 123.69 24.93 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.646 179.87 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.621 ' CG ' ' H ' ' A' ' 72' ' ' HIS . 82.3 t60 49.91 174.33 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.898 179.55 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.621 ' H ' ' CG ' ' A' ' 71' ' ' HIS . 84.3 t60 -83.29 -3.86 57.87 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.698 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.506 ' H ' ' CD2' ' A' ' 71' ' ' HIS . 86.4 t60 47.83 92.5 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.564 -179.672 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 95.6 m-70 . . . . . 0 C--O 1.22 -0.477 0 CA-C-O 118.005 -0.998 . . . . 0.0 110.828 -179.876 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 22.5 tpp . . . . . 0 N--CA 1.491 1.621 0 N-CA-C 109.47 -0.566 . . . . 0.0 109.47 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 85.8 mt-30 -141.61 114.09 8.28 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 116.085 -0.507 . . . . 0.0 109.897 179.727 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -88.59 149.74 21.31 Favored Glycine 0 CA--C 1.523 0.576 0 N-CA-C 111.279 -0.728 . . . . 0.0 111.279 -179.529 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 53.8 t -126.65 132.55 70.06 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 179.818 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 83.0 t -91.11 128.76 42.71 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.196 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.359 179.757 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -125.63 106.46 9.76 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.318 179.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.0 p -138.02 145.4 28.79 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 116.263 -0.426 . . . . 0.0 109.862 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.526 ' OD1' ' N ' ' A' ' 9' ' ' SER . 38.7 p-10 -62.39 -41.18 98.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.776 -179.57 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' SER . . . . . 0.526 ' N ' ' OD1' ' A' ' 8' ' ' ASN . 6.9 t -123.28 -141.33 0.31 Allowed 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.424 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -92.73 144.15 25.59 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.491 179.788 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.408 ' CD1' ' CG ' ' A' ' 58' ' ' TYR . 6.4 tt -121.57 134.42 55.02 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.594 -179.828 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 11.1 m120 -75.88 134.62 40.25 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.226 -179.412 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 27.4 ttt -89.05 152.68 21.53 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-N 115.847 -0.615 . . . . 0.0 109.485 179.104 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 84.2 mtt85 -124.71 144.35 50.27 Favored 'General case' 0 N--CA 1.478 0.971 0 CA-C-O 120.449 0.166 . . . . 0.0 111.026 -179.752 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 23.2 t -89.11 -2.18 58.42 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.909 0.385 . . . . 0.0 110.452 179.3 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -163.41 160.29 32.95 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.35 -1.1 . . . . 0.0 110.35 179.779 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_endo -62.69 99.02 0.2 Allowed 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.368 2.045 . . . . 0.0 111.891 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 135.35 141.82 4.44 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 110.573 -1.011 . . . . 0.0 110.573 179.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 35.3 t -67.53 -16.0 63.96 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.78 0.324 . . . . 0.0 110.725 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 52.6 t30 -84.87 8.38 17.63 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.687 -179.05 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 39.5 m-85 -96.85 8.24 44.82 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-O 120.766 0.317 . . . . 0.0 110.31 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 85.07 176.52 50.79 Favored Glycine 0 CA--C 1.522 0.502 0 N-CA-C 111.355 -0.698 . . . . 0.0 111.355 179.663 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 14.8 p -121.27 133.84 66.57 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 CA-C-O 120.669 0.271 . . . . 0.0 110.397 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 94.8 mt -92.93 -15.25 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-O 120.869 0.366 . . . . 0.0 110.589 -179.696 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 157.35 -145.59 12.22 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 110.668 -0.973 . . . . 0.0 110.668 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 71.2 p -133.71 155.13 50.29 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-O 120.977 0.418 . . . . 0.0 110.309 179.75 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 85.0 mt -124.67 146.57 49.06 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.227 -179.79 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.459 ' N ' ' OD2' ' A' ' 31' ' ' ASP . 31.8 mtp85 -107.47 170.06 8.2 Favored 'General case' 0 CA--C 1.506 -0.714 0 CA-C-O 121.575 0.702 . . . . 0.0 111.206 -179.771 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 56.9 p30 -69.37 157.17 37.57 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 114.466 -1.243 . . . . 0.0 110.761 179.083 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 8.9 m120 59.29 31.49 21.2 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 114.921 -1.036 . . . . 0.0 111.085 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.459 ' OD2' ' N ' ' A' ' 28' ' ' ARG . 98.5 m-20 -93.56 111.13 22.74 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-O 120.696 0.284 . . . . 0.0 110.419 179.343 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 56.2 mtpt -73.64 133.91 43.54 Favored 'General case' 0 C--N 1.328 -0.363 0 C-N-CA 120.639 -0.424 . . . . 0.0 109.986 179.599 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.7 m -136.59 160.9 37.33 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 120.84 0.353 . . . . 0.0 110.674 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -107.86 119.11 38.54 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 116.121 -0.491 . . . . 0.0 109.808 179.395 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.409 HG23 HD13 ' A' ' 35' ' ' ILE . 97.0 mt -84.07 126.88 40.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.604 -179.533 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.558 ' CD1' ' N ' ' A' ' 36' ' ' ILE . 1.6 mp -94.33 -65.43 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.195 0 CA-C-N 116.197 -0.456 . . . . 0.0 109.983 179.9 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 50.4 mtmt -148.28 156.99 43.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.456 179.494 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . 0.45 ' CD ' ' CE1' ' A' ' 43' ' ' TYR . 83.6 tt0 -113.42 123.45 50.1 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.565 179.773 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 67.8 t -130.6 132.33 64.47 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.189 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 55.28 33.59 21.0 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.781 178.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 83.69 -11.39 56.59 Favored Glycine 0 CA--C 1.525 0.688 0 C-N-CA 120.965 -0.636 . . . . 0.0 111.715 179.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 84.2 m95 -89.72 140.69 29.32 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 179.725 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . 0.45 ' CE1' ' CD ' ' A' ' 38' ' ' GLU . 62.9 m-85 -101.56 126.43 48.37 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.822 0.344 . . . . 0.0 110.418 179.709 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -82.29 128.8 34.56 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.321 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 43.4 pt -129.48 156.99 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-O 121.28 0.562 . . . . 0.0 111.641 -179.015 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 28.8 ttt180 -124.83 131.42 53.44 Favored 'General case' 0 CA--C 1.51 -0.578 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.106 178.238 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 38.9 t80 -152.57 135.9 15.86 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.791 -0.641 . . . . 0.0 110.532 179.773 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 10.9 m120 56.56 34.3 24.15 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.307 179.736 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 73.81 5.75 70.4 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.429 -0.668 . . . . 0.0 111.429 179.4 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -107.04 144.87 33.08 Favored 'General case' 0 N--CA 1.467 0.394 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.684 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 53.0 t -118.88 133.57 65.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 CA-C-O 120.939 0.399 . . . . 0.0 110.545 -179.372 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -159.91 -168.63 22.15 Favored Glycine 0 CA--C 1.524 0.638 0 N-CA-C 110.576 -1.01 . . . . 0.0 110.576 179.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.444 ' N ' ' CD1' ' A' ' 53' ' ' TYR . 38.9 m-85 -127.5 156.33 42.33 Favored 'General case' 0 N--CA 1.464 0.271 0 N-CA-C 110.119 -0.326 . . . . 0.0 110.119 -179.702 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -140.0 157.17 46.09 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-O 120.861 0.363 . . . . 0.0 110.62 -179.752 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 28.5 t -63.01 140.49 58.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.211 -179.63 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 25.4 pttm -69.21 -28.75 66.64 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.308 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 52.9 m -59.93 -38.84 83.57 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.463 -179.187 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' TYR . . . . . 0.408 ' CG ' ' CD1' ' A' ' 11' ' ' LEU . 84.2 m-85 -94.81 15.17 19.15 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 111.758 0.281 . . . . 0.0 111.758 -179.012 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 5.5 mm -119.21 128.14 75.83 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 CA-C-O 120.939 0.399 . . . . 0.0 110.163 179.534 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 92.7 m -125.18 127.52 46.92 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.063 179.79 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.412 HG22 HD12 ' A' ' 61' ' ' ILE . 96.6 mt -87.76 125.8 41.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.419 179.782 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 2.3 m -107.08 106.82 21.36 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.374 179.876 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 63.5 t30 -173.45 22.71 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.655 179.831 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 79.8 mm-40 -66.17 140.74 58.21 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.732 -179.555 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.4 ' O ' ' O ' ' A' ' 66' ' ' SER . . . -177.92 73.89 0.07 OUTLIER Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.681 -0.968 . . . . 0.0 110.681 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.4 ' O ' ' O ' ' A' ' 65' ' ' GLY . 2.5 m 59.79 119.65 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.863 0.363 . . . . 0.0 110.475 -179.878 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 83.4 mt -74.53 145.63 43.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.675 -179.716 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -83.02 -84.9 0.12 Allowed 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.577 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 80.5 m80 -85.24 140.07 31.14 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.49 179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' HIS . . . . . . . . . . . . . 86.0 t60 -153.34 143.63 22.37 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.724 -179.839 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -81.92 147.71 29.13 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.946 -179.885 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 85.1 t60 53.14 85.51 0.05 OUTLIER 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.655 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 59.6 t-80 -144.16 137.16 27.24 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.54 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 75.9 m80 . . . . . 0 C--O 1.221 -0.436 0 CA-C-O 118.256 -0.878 . . . . 0.0 110.512 179.762 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 25.8 ttt . . . . . 0 N--CA 1.489 1.518 0 N-CA-C 109.379 -0.601 . . . . 0.0 109.379 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -125.57 123.47 39.13 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 120.962 0.41 . . . . 0.0 110.524 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -86.74 148.08 21.57 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 179.756 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 74.3 t -124.96 130.27 73.28 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 CA-C-O 120.971 0.415 . . . . 0.0 110.271 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 19.1 t -92.57 128.56 44.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.499 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 21.9 mmtp -121.86 105.3 10.23 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.342 -0.39 . . . . 0.0 109.997 179.525 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 19.0 m -139.34 159.65 28.58 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.482 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 18.3 t-20 -81.2 -13.81 58.2 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.639 179.881 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 12.3 t -159.1 -166.19 1.78 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.5 -179.673 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -65.43 143.29 57.8 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.201 179.603 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 44.9 tp -124.13 132.2 53.62 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-O 120.792 0.33 . . . . 0.0 110.293 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 14.3 m120 -75.24 142.77 43.32 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.297 179.688 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 12.0 tmm? -106.95 150.31 26.59 Favored 'General case' 0 N--CA 1.463 0.205 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 179.731 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . 0.699 ' NH2' ' H ' ' A' ' 22' ' ' GLY . 24.6 mtp85 -122.34 156.84 33.08 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-O 121.027 0.441 . . . . 0.0 110.572 -178.955 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 82.2 p -80.84 -6.42 58.56 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.584 -0.735 . . . . 0.0 111.046 -179.42 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.55 -168.95 20.72 Favored Glycine 0 CA--C 1.525 0.692 0 C-N-CA 120.831 -0.699 . . . . 0.0 111.422 -179.848 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -83.69 9.38 4.13 Favored 'Trans proline' 0 C--N 1.309 -1.511 0 C-N-CA 122.832 2.354 . . . . 0.0 112.631 -179.695 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -97.56 127.32 9.18 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.535 ' O ' ' NH2' ' A' ' 14' ' ' ARG . 96.1 p -70.97 -10.71 60.2 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.347 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 25.1 p30 -106.03 19.8 19.95 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.029 -179.712 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 0.412 ' N ' HH21 ' A' ' 14' ' ' ARG . 3.0 m-85 -86.3 -3.08 58.92 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.552 -0.294 . . . . 0.0 110.326 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.699 ' H ' ' NH2' ' A' ' 14' ' ' ARG . . . 81.1 168.61 40.24 Favored Glycine 0 CA--C 1.521 0.421 0 N-CA-C 111.01 -0.836 . . . . 0.0 111.01 179.913 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 9.7 p -102.25 124.7 56.34 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 CA-C-O 120.827 0.346 . . . . 0.0 110.421 179.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 23.1 pt -106.78 -0.22 9.98 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.804 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.83 167.8 39.77 Favored Glycine 0 CA--C 1.52 0.348 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 89.2 m -124.04 131.16 53.52 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 120.782 0.325 . . . . 0.0 110.626 -179.7 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 69.4 mt -101.67 161.48 13.62 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.744 -179.706 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 81.5 mtt180 -127.66 157.77 39.38 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 120.873 0.368 . . . . 0.0 110.247 179.54 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.436 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 52.7 p30 -57.25 150.64 17.41 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.285 -179.177 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 12.5 t-20 58.47 35.34 24.63 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.364 179.499 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 32.5 t0 -89.15 114.41 25.7 Favored 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 179.234 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -84.03 124.5 31.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.807 0.337 . . . . 0.0 110.357 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 28.2 m -138.22 162.39 30.59 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.94 -179.711 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . 0.634 ' OE1' ' NH1' ' A' ' 46' ' ' ARG . 78.1 tt0 -95.9 140.14 31.1 Favored 'General case' 0 C--O 1.233 0.222 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 179.054 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.42 HG22 HD13 ' A' ' 35' ' ' ILE . 91.3 mt -104.23 125.52 59.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.822 179.862 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 95.9 mt -93.03 -49.56 12.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.386 179.718 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 35.6 ttpt -172.79 157.66 3.76 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.659 -179.331 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . 0.502 ' H ' ' CD ' ' A' ' 38' ' ' GLU . 2.1 pm0 -110.0 143.56 39.82 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.35 -0.387 . . . . 0.0 110.371 179.833 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 34.4 t -129.95 126.35 62.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 CA-C-O 120.757 0.313 . . . . 0.0 110.644 -179.718 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 50.79 30.26 4.93 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.545 178.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 85.84 25.32 38.52 Favored Glycine 0 CA--C 1.525 0.687 0 C-N-CA 121.011 -0.614 . . . . 0.0 112.015 179.361 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 62.2 m95 -124.36 106.24 10.07 Favored 'General case' 0 N--CA 1.471 0.581 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.127 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 91.3 m-85 -70.97 135.3 47.8 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.968 0.413 . . . . 0.0 111.437 -179.243 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.422 ' OE2' ' OH ' ' A' ' 53' ' ' TYR . 96.9 mt-10 -88.4 141.89 28.17 Favored 'General case' 0 CA--C 1.518 -0.262 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 178.325 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 39.9 pt -135.38 154.45 35.42 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.684 0 CA-C-O 121.627 0.727 . . . . 0.0 111.034 -179.582 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.634 ' NH1' ' OE1' ' A' ' 34' ' ' GLU . 11.2 ttp180 -111.4 123.54 50.41 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 114.668 -1.151 . . . . 0.0 110.378 -179.917 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 66.9 t80 -151.72 134.91 15.91 Favored 'General case' 0 N--CA 1.463 0.224 0 C-N-CA 120.87 -0.332 . . . . 0.0 111.158 -179.497 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 55.3 t-20 57.96 35.11 25.01 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.423 179.603 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 66.87 22.5 72.12 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 111.091 -0.804 . . . . 0.0 111.091 179.738 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 54.9 mtpt -128.91 146.74 50.87 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 121.012 0.434 . . . . 0.0 111.019 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 53.8 t -113.51 131.77 64.33 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.922 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -143.97 -163.35 9.86 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -179.806 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.422 ' OH ' ' OE2' ' A' ' 44' ' ' GLU . 44.8 m-85 -127.64 153.1 46.84 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 110.242 -0.281 . . . . 0.0 110.242 -179.675 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -146.69 151.33 37.03 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-N 116.383 -0.372 . . . . 0.0 110.642 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 41.0 t -65.14 143.72 57.69 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.744 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 26.0 pttm -67.58 -17.6 64.69 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.849 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 16.0 m -64.28 -36.06 82.86 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.44 -179.52 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 41.6 m-85 -103.85 12.04 34.94 Favored 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 111.978 0.362 . . . . 0.0 111.978 -178.175 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 46.2 mm -121.43 129.67 75.36 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.573 0 CA-C-O 120.931 0.396 . . . . 0.0 110.623 179.846 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 62.2 p -116.98 131.9 56.84 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.422 -179.601 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.411 HG23 HD13 ' A' ' 61' ' ' ILE . 96.6 mt -84.4 129.65 37.3 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.174 179.597 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 87.9 t -84.09 132.52 31.33 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.354 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 95.5 m-20 55.3 -170.67 0.07 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.622 -179.788 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 55.62 25.69 8.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.418 -179.805 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 165.13 48.51 0.02 OUTLIER Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.832 -0.907 . . . . 0.0 110.832 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 22.6 t -84.39 -5.8 59.31 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.732 0.301 . . . . 0.0 111.158 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.455 ' N ' ' CD1' ' A' ' 67' ' ' LEU . 9.4 mp -78.46 132.94 37.48 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.069 0.461 . . . . 0.0 110.45 179.906 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -140.1 48.13 1.79 Allowed 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.48 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.498 ' CG ' ' O ' ' A' ' 69' ' ' HIS . 38.2 t-80 42.55 33.92 0.5 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.038 0.446 . . . . 0.0 110.745 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' HIS . . . . . . . . . . . . . 59.6 t-80 -59.59 -42.48 92.63 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.317 179.864 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.428 ' O ' ' CG ' ' A' ' 71' ' ' HIS . 52.6 p-80 -72.48 124.0 24.29 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.205 179.851 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.602 ' CE1' ' CE1' ' A' ' 74' ' ' HIS . 74.6 t60 -148.51 136.68 21.08 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.58 -179.815 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.518 ' O ' ' CG ' ' A' ' 74' ' ' HIS . 98.7 m-70 -149.46 124.23 9.87 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.376 179.706 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' HIS . . . . . 0.602 ' CE1' ' CE1' ' A' ' 72' ' ' HIS . 74.9 m80 . . . . . 0 C--O 1.221 -0.444 0 CA-C-O 118.136 -0.935 . . . . 0.0 110.483 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.501 ' N ' ' NE2' ' A' ' 2' ' ' GLN . 6.8 ttt . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.501 ' NE2' ' N ' ' A' ' 1' ' ' MET . 21.3 mp0 -136.69 120.53 17.44 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.416 179.93 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -99.62 147.56 18.33 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.625 -0.99 . . . . 0.0 110.625 179.772 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 54.3 t -124.73 130.78 73.31 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-O 120.927 0.394 . . . . 0.0 110.127 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 13.6 t -87.55 127.17 41.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.306 179.865 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -123.09 105.59 10.06 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.858 0.361 . . . . 0.0 110.068 179.491 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 14.8 p -156.51 139.09 6.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.559 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 66.2 t30 -67.84 -48.98 64.65 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.824 0.345 . . . . 0.0 110.756 179.606 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 5.5 m -93.96 152.48 18.81 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.575 179.799 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -61.47 142.7 56.83 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.532 -0.467 . . . . 0.0 110.194 179.568 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 41.1 tp -117.58 128.23 54.74 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.894 179.851 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . 0.533 ' ND2' HH12 ' A' ' 14' ' ' ARG . 21.2 p-10 -72.08 145.47 48.2 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.687 179.549 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 62.6 ttp -96.69 140.05 31.85 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-O 121.207 0.527 . . . . 0.0 110.663 -179.627 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . 0.817 ' HE ' ' HA ' ' A' ' 19' ' ' SER . 1.0 OUTLIER -93.8 153.82 18.08 Favored 'General case' 0 CA--C 1.541 0.608 0 CA-C-N 115.345 -0.843 . . . . 0.0 111.472 -178.443 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 78.5 p -88.34 -9.66 52.01 Favored 'General case' 0 N--CA 1.462 0.127 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.845 179.13 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -162.82 -173.05 31.05 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.154 -1.178 . . . . 0.0 110.154 179.729 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -80.67 78.29 3.72 Favored 'Trans proline' 0 C--N 1.298 -2.115 0 C-N-CA 122.584 2.189 . . . . 0.0 112.391 179.547 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 167.13 134.5 1.71 Allowed Glycine 0 CA--C 1.525 0.676 0 N-CA-C 111.371 -0.691 . . . . 0.0 111.371 179.769 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.817 ' HA ' ' HE ' ' A' ' 14' ' ' ARG . 23.2 t -68.32 -13.46 62.29 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 112.102 0.408 . . . . 0.0 112.102 -179.113 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 14.1 m120 -88.07 11.44 16.1 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.766 -179.762 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 17.8 m-85 -90.7 1.3 56.97 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.313 179.849 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 76.59 -173.47 54.4 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 179.848 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 4.8 p -118.87 127.69 75.74 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-O 120.841 0.353 . . . . 0.0 110.293 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 25.2 pt -110.21 -3.64 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.448 179.651 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.56 -176.55 43.89 Favored Glycine 0 CA--C 1.529 0.908 0 N-CA-C 111.246 -0.742 . . . . 0.0 111.246 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 69.4 p -131.55 155.29 47.73 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 120.647 0.26 . . . . 0.0 110.691 -179.82 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 84.1 mt -125.37 149.56 48.02 Favored 'General case' 0 N--CA 1.472 0.625 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.519 -179.35 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 92.1 mtt-85 -120.21 161.67 20.68 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 121.669 0.747 . . . . 0.0 111.103 -179.164 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 64.2 t30 -57.97 144.23 40.2 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.581 -178.608 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 59.2 34.23 23.06 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.47 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 65.7 t0 -85.25 114.89 22.68 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-O 120.778 0.323 . . . . 0.0 110.186 178.881 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -80.37 128.87 34.06 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.551 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.1 m -141.59 161.3 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.201 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.439 179.741 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 80.7 mm-40 -102.73 133.35 47.93 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.942 179.637 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.408 HD13 HG22 ' A' ' 35' ' ' ILE . 92.5 mt -102.75 109.43 26.63 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.625 -179.848 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 97.2 mt -66.46 -43.63 90.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.547 179.853 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 25.7 pttm -172.51 179.25 2.52 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.774 -179.401 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 2.5 tm-20 -112.89 124.62 53.03 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.179 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 54.1 t -125.66 133.01 70.16 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.784 -179.663 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 55.81 28.86 12.99 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.133 179.393 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.36 -8.6 57.96 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.854 -0.898 . . . . 0.0 110.854 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 11.1 m95 -94.05 148.38 22.23 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 110.035 -0.357 . . . . 0.0 110.035 179.633 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 64.2 m-85 -96.95 131.39 43.8 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.974 0.416 . . . . 0.0 110.689 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -83.18 152.99 25.0 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 108.496 -0.928 . . . . 0.0 108.496 178.499 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 34.5 pt -145.29 150.55 15.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 C-N-CA 120.707 -0.397 . . . . 0.0 111.143 -179.413 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.454 ' HE ' ' HA2' ' A' ' 49' ' ' GLY . 16.6 ttt180 -115.05 126.18 54.41 Favored 'General case' 0 CA--C 1.511 -0.534 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 177.398 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 79.5 t80 -138.1 129.05 27.09 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-N 115.16 -0.927 . . . . 0.0 110.304 179.574 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 67.0 t30 53.09 36.5 22.44 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.628 -0.714 . . . . 0.0 112.124 179.677 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.454 ' HA2' ' HE ' ' A' ' 46' ' ' ARG . . . 71.05 16.41 74.9 Favored Glycine 0 CA--C 1.525 0.665 0 C-N-CA 120.491 -0.861 . . . . 0.0 111.024 178.924 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 6.0 tmtt? -119.04 125.78 50.15 Favored 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 109.9 -0.408 . . . . 0.0 109.9 -179.366 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 82.5 t -80.25 136.65 22.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.591 179.741 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -157.59 167.66 34.14 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.884 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 76.0 m-85 -122.01 156.87 32.56 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-O 120.645 0.259 . . . . 0.0 110.444 -179.544 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -148.77 151.71 35.3 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-O 120.842 0.354 . . . . 0.0 110.472 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 30.0 t -63.23 141.26 58.83 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.478 -179.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 26.0 pttm -67.21 -15.1 63.5 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.193 -179.671 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 78.0 p -65.64 -33.19 75.33 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.68 -179.661 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -102.31 11.0 38.78 Favored 'General case' 0 N--CA 1.468 0.454 0 N-CA-C 111.867 0.321 . . . . 0.0 111.867 -179.04 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 47.8 mm -115.55 130.12 70.7 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.567 0 CA-C-O 120.997 0.427 . . . . 0.0 110.554 179.795 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 90.1 m -116.75 124.91 50.79 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.189 179.695 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 21.0 mm -81.79 134.64 26.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.44 -179.856 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.528 ' O ' ' N ' ' A' ' 64' ' ' GLU . 75.3 t -62.56 134.36 27.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.294 -179.901 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 10.1 m120 -40.83 90.04 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.951 -179.412 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . 0.528 ' N ' ' O ' ' A' ' 62' ' ' VAL . 80.9 tt0 -101.32 116.37 32.63 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.305 179.911 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 42.04 79.86 0.05 OUTLIER Glycine 0 CA--C 1.526 0.767 0 N-CA-C 111.242 -0.743 . . . . 0.0 111.242 179.762 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 85.9 p -64.74 152.21 43.15 Favored 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 120.864 -0.334 . . . . 0.0 110.332 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.45 ' O ' ' N ' ' A' ' 69' ' ' HIS . 54.0 tp -88.72 92.9 9.39 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.339 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.435 ' O ' ' CG ' ' A' ' 69' ' ' HIS . 83.8 tt0 38.15 -93.97 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.234 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.115 179.856 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.45 ' N ' ' O ' ' A' ' 67' ' ' LEU . 98.3 m-70 -155.36 168.75 26.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.446 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' HIS . . . . . . . . . . . . . 35.2 p-80 -61.13 122.06 14.06 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.603 -179.739 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 56.3 t-80 -65.93 -42.91 89.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.673 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.45 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 54.1 p-80 -86.75 121.54 29.4 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.709 -179.903 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 58.4 t-80 -61.41 -44.26 97.44 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.633 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 65.1 t-80 . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 118.016 -0.992 . . . . 0.0 110.601 179.946 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 51.0 ttp . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 88.6 mt-30 -124.33 129.54 50.92 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.684 -179.82 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -93.97 156.78 22.51 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.689 -0.964 . . . . 0.0 110.689 179.713 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 65.1 t -124.59 130.99 73.32 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 179.663 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 13.1 t -86.05 128.97 38.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.778 -179.584 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -130.81 106.23 8.31 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.939 0.4 . . . . 0.0 110.207 179.382 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.2 p -140.82 142.77 29.71 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.205 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.223 -179.563 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.526 ' OD1' ' N ' ' A' ' 9' ' ' SER . 13.9 p30 -63.28 -40.8 98.38 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.717 -179.732 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' SER . . . . . 0.526 ' N ' ' OD1' ' A' ' 8' ' ' ASN . 17.4 m -117.69 -139.76 0.36 Allowed 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.92 179.578 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -91.97 144.35 25.55 Favored 'General case' 0 C--O 1.233 0.21 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 179.498 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 60.6 tp -110.86 130.18 55.65 Favored 'General case' 0 N--CA 1.468 0.451 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 -179.835 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -85.23 133.63 34.17 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.403 179.827 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 38.4 ttp -100.71 142.16 32.57 Favored 'General case' 0 CA--C 1.51 -0.582 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 179.712 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . 0.511 HH12 ' CB ' ' A' ' 19' ' ' SER . 8.6 mtt180 -117.74 155.42 30.04 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.83 -178.83 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 87.5 p -77.73 -11.81 59.91 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 112.057 0.392 . . . . 0.0 112.057 -178.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -162.9 -173.04 31.14 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 179.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -83.29 77.02 3.67 Favored 'Trans proline' 0 C--N 1.307 -1.623 0 C-N-CA 122.704 2.269 . . . . 0.0 112.173 179.605 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 168.54 133.81 1.62 Allowed Glycine 0 CA--C 1.527 0.83 0 C-N-CA 120.753 -0.737 . . . . 0.0 111.699 179.717 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.511 ' CB ' HH12 ' A' ' 14' ' ' ARG . 6.0 t -65.86 -17.41 64.63 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-O 120.886 0.374 . . . . 0.0 110.985 179.807 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . 0.531 ' OD1' ' N ' ' A' ' 21' ' ' TYR . 41.1 p-10 -60.89 -36.09 78.32 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.508 -179.117 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 0.531 ' N ' ' OD1' ' A' ' 20' ' ' ASN . 76.6 m-85 -62.05 -37.02 83.39 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.04 179.342 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 89.48 173.71 45.91 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.451 ' CG2' ' O ' ' A' ' 25' ' ' GLY . 14.0 p -87.19 128.12 40.06 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.867 0.365 . . . . 0.0 110.487 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.402 HG21 HD13 ' A' ' 24' ' ' ILE . 25.4 pt -104.4 -4.32 9.61 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.502 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.451 ' O ' ' CG2' ' A' ' 23' ' ' VAL . . . -176.32 -177.12 45.06 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.414 -1.075 . . . . 0.0 110.414 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 69.7 p -132.2 150.22 52.2 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-O 120.947 0.403 . . . . 0.0 110.374 179.861 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 84.4 mt -129.06 148.54 51.02 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.757 -179.529 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 71.0 mtp180 -107.0 162.44 13.84 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.23 179.509 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 52.8 p30 -69.29 171.97 7.72 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.172 179.723 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 85.9 m-20 58.33 9.2 0.97 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.122 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 43.4 t0 -85.11 116.54 23.54 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.782 0.325 . . . . 0.0 110.676 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 65.5 mttp -77.0 135.13 38.66 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.056 179.674 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.0 m -137.75 159.85 34.03 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-O 120.89 0.376 . . . . 0.0 110.648 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -104.44 117.95 35.41 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.048 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 95.7 mt -90.72 125.76 43.51 Favored 'Isoleucine or valine' 0 C--O 1.232 0.172 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.518 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.556 ' CD1' ' N ' ' A' ' 36' ' ' ILE . 1.9 mp -92.96 -41.16 12.58 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.67 -179.819 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . 0.565 ' HZ3' ' HH ' ' A' ' 53' ' ' TYR . 22.6 pttp -171.83 158.86 5.01 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.604 -179.805 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . 0.476 ' OE1' ' CE1' ' A' ' 43' ' ' TYR . 81.4 tt0 -112.61 125.04 53.84 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.089 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 65.0 t -128.05 132.63 68.39 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 CA-C-O 120.906 0.384 . . . . 0.0 111.146 -179.694 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.435 ' OD1' ' O ' ' A' ' 40' ' ' ASP . 55.1 t0 56.85 25.37 10.33 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.924 179.394 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.01 -9.71 73.53 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 179.696 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 66.2 m95 -89.44 141.51 28.5 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 110.077 -0.342 . . . . 0.0 110.077 179.783 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . 0.476 ' CE1' ' OE1' ' A' ' 38' ' ' GLU . 38.3 m-85 -95.38 131.8 41.12 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-O 121.01 0.433 . . . . 0.0 110.403 179.915 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -92.03 119.64 31.93 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 178.9 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 41.1 pt -125.88 157.84 35.43 Favored 'Isoleucine or valine' 0 C--O 1.233 0.222 0 CA-C-O 121.123 0.487 . . . . 0.0 111.092 -179.311 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 79.0 ttt180 -115.83 124.93 51.93 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.593 179.035 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 28.2 t80 -141.83 132.77 25.94 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.454 -179.814 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 62.7 t30 61.08 27.67 17.47 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.398 -179.835 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 74.08 9.01 79.88 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 61.5 tttm -102.76 156.69 17.47 Favored 'General case' 0 C--O 1.231 0.129 0 N-CA-C 110.043 -0.355 . . . . 0.0 110.043 -179.825 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 56.6 t -115.9 131.17 69.16 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.009 -179.873 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -160.98 -170.43 25.59 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.565 ' HH ' ' HZ3' ' A' ' 37' ' ' LYS . 66.6 m-85 -130.31 162.62 28.62 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-O 120.779 0.323 . . . . 0.0 110.509 -179.632 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -146.68 154.3 41.28 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.369 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 20.2 m -66.25 143.19 57.37 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.619 -179.863 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 60.7 pttt -79.9 -19.44 48.17 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.167 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 11.7 t -61.59 -42.14 98.43 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.354 -179.558 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 99.3 m-85 -92.24 4.3 53.55 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.439 -0.346 . . . . 0.0 111.786 -178.833 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 97.6 mt -122.29 132.09 71.82 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.54 0 CA-C-O 121.001 0.429 . . . . 0.0 110.881 179.678 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 93.1 m -120.2 134.06 55.35 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.406 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.412 HG21 HD13 ' A' ' 61' ' ' ILE . 23.1 mm -77.15 132.73 32.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.649 -179.893 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 94.7 t -72.81 129.11 36.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.936 0.398 . . . . 0.0 110.764 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . 0.542 ' O ' ' N ' ' A' ' 65' ' ' GLY . 9.1 m120 49.29 28.43 2.27 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.497 179.552 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . 0.411 ' C ' ' O ' ' A' ' 63' ' ' ASN . 17.4 pt-20 34.23 29.41 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.272 -179.935 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.542 ' N ' ' O ' ' A' ' 63' ' ' ASN . . . 76.09 148.83 2.46 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 110.16 -1.176 . . . . 0.0 110.16 -179.214 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 61.9 p -89.38 105.89 18.09 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.892 0.377 . . . . 0.0 110.636 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 87.5 mt -93.57 -5.63 48.47 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.356 179.804 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -164.09 124.76 2.17 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.329 -179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.53 ' O ' ' CG ' ' A' ' 70' ' ' HIS . 75.1 m80 -65.1 -45.3 85.75 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.832 -179.9 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' HIS . . . . . 0.53 ' CG ' ' O ' ' A' ' 69' ' ' HIS . 99.5 m-70 -159.23 -115.75 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.221 -179.838 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.445 ' O ' ' O ' ' A' ' 72' ' ' HIS . 98.7 m-70 50.97 94.03 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.528 -0.306 . . . . 0.0 110.581 179.823 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.445 ' O ' ' O ' ' A' ' 71' ' ' HIS . 97.9 m-70 57.49 120.97 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.753 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 45.4 p-80 -153.9 159.69 41.85 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.643 179.872 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 86.3 t60 . . . . . 0 C--O 1.22 -0.45 0 CA-C-O 117.895 -1.05 . . . . 0.0 110.443 -179.993 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.577 ' SD ' ' N ' ' A' ' 1' ' ' MET . 0.0 OUTLIER . . . . . 0 N--CA 1.495 1.783 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 . . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.443 ' OE1' ' N ' ' A' ' 2' ' ' GLN . 1.1 mp0 -109.06 110.58 21.87 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-O 121.116 0.484 . . . . 0.0 111.371 179.812 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -92.96 158.18 23.84 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 110.685 -0.966 . . . . 0.0 110.685 179.351 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 73.3 t -126.1 134.47 66.43 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 O-C-N 122.615 -0.344 . . . . 0.0 110.309 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 18.2 t -85.1 126.29 40.34 Favored 'Isoleucine or valine' 0 C--O 1.234 0.248 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.751 -179.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 41.5 mmtm -112.24 106.63 15.25 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-O 120.763 0.316 . . . . 0.0 110.382 179.796 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 9.7 p -140.15 159.11 26.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 N-CA-C 110.307 -0.257 . . . . 0.0 110.307 179.671 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.478 ' OD1' ' N ' ' A' ' 9' ' ' SER . 21.5 p30 -64.37 -39.47 93.94 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.813 -0.355 . . . . 0.0 110.623 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' SER . . . . . 0.498 ' HG ' ' H ' ' A' ' 10' ' ' ALA . 59.5 p -141.09 -60.75 0.49 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.155 -179.656 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.498 ' H ' ' HG ' ' A' ' 9' ' ' SER . . . -149.63 145.84 26.97 Favored 'General case' 0 CA--C 1.519 -0.248 0 CA-C-O 121.196 0.522 . . . . 0.0 110.758 -179.699 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 39.9 tp -116.68 131.66 56.89 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.464 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 99.7 m-20 -74.94 138.38 42.28 Favored 'General case' 0 CA--C 1.518 -0.264 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.573 179.654 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 37.6 ttp -94.72 151.41 19.3 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.621 179.74 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . 0.631 ' NH1' ' H ' ' A' ' 16' ' ' GLY . 0.4 OUTLIER -129.89 154.18 47.56 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.94 0.4 . . . . 0.0 111.668 -179.151 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' SER . . . . . 0.59 ' H ' ' CZ ' ' A' ' 14' ' ' ARG . 85.9 p -87.5 -17.34 32.34 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 115.606 -0.725 . . . . 0.0 111.237 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.631 ' H ' ' NH1' ' A' ' 14' ' ' ARG . . . -149.2 -177.48 23.37 Favored Glycine 0 CA--C 1.528 0.875 0 C-N-CA 120.859 -0.686 . . . . 0.0 111.52 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -81.99 82.39 2.32 Favored 'Trans proline' 0 C--N 1.319 -0.983 0 C-N-CA 123.256 2.637 . . . . 0.0 112.107 -179.691 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 163.99 119.63 0.49 Allowed Glycine 0 CA--C 1.528 0.881 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 179.727 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 80.4 p -70.46 -12.39 61.54 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-O 120.605 0.241 . . . . 0.0 110.732 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -78.25 -14.98 59.21 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.322 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 13.6 m-85 -64.91 -41.89 95.21 Favored 'General case' 0 CA--C 1.519 -0.231 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.844 179.526 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.54 ' O ' ' NE ' ' A' ' 14' ' ' ARG . . . 117.07 133.76 5.12 Favored Glycine 0 C--N 1.333 0.394 0 N-CA-C 110.954 -0.859 . . . . 0.0 110.954 179.324 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 5.4 p -65.93 139.46 21.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 121.065 0.459 . . . . 0.0 110.399 179.756 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 34.8 pt -106.91 -10.08 10.58 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.215 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.975 -179.878 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.23 -172.93 43.16 Favored Glycine 0 CA--C 1.521 0.467 0 N-CA-C 110.626 -0.99 . . . . 0.0 110.626 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 97.5 m -125.94 147.57 49.47 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-O 120.923 0.392 . . . . 0.0 111.222 -179.301 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 60.5 mt -112.88 153.59 27.67 Favored 'General case' 0 C--O 1.233 0.207 0 CA-C-O 121.055 0.455 . . . . 0.0 110.006 179.458 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 24.1 mmt180 -100.83 159.87 14.83 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.436 -179.543 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.437 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 53.5 p-10 -65.32 143.98 57.41 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.828 -179.528 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 56.66 34.0 23.78 Favored 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.598 179.229 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 44.0 t0 -85.08 117.1 23.83 Favored 'General case' 0 N--CA 1.466 0.341 0 C-N-CA 120.884 -0.326 . . . . 0.0 110.891 179.749 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -72.38 130.48 40.82 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.998 0.428 . . . . 0.0 110.49 179.826 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 28.8 m -137.29 162.93 32.7 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.489 179.827 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -100.13 122.56 43.17 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.813 -0.631 . . . . 0.0 109.934 179.56 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.4 mt -97.4 128.66 48.47 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.169 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.211 -179.739 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.403 HG22 HD13 ' A' ' 36' ' ' ILE . 22.7 mm -94.04 -64.32 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.473 -179.693 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . 0.496 ' NZ ' ' OE1' ' A' ' 44' ' ' GLU . 25.3 pttm -154.47 163.52 40.06 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.789 -179.758 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 44.2 tt0 -103.85 126.72 51.18 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.583 179.757 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 61.4 t -127.86 131.64 69.54 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.2 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.335 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 51.1 t0 55.68 24.25 6.98 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.04 179.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.72 -16.01 57.62 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 111.54 -0.624 . . . . 0.0 111.54 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 17.0 m95 -88.2 141.97 28.13 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.806 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 -94.53 131.6 40.08 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-O 120.737 0.303 . . . . 0.0 111.083 -179.52 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.496 ' OE1' ' NZ ' ' A' ' 37' ' ' LYS . 81.0 tt0 -80.65 134.51 35.89 Favored 'General case' 0 N--CA 1.464 0.275 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 179.2 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 40.0 pt -134.54 155.39 38.73 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-O 121.006 0.431 . . . . 0.0 111.77 -179.441 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 56.4 ttp180 -118.58 124.44 47.48 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.501 179.568 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 36.1 t80 -148.19 134.83 19.84 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.683 179.734 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 65.5 t30 58.74 31.35 21.09 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.674 -179.798 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 70.18 19.54 75.82 Favored Glycine 0 CA--C 1.521 0.407 0 N-CA-C 110.668 -0.973 . . . . 0.0 110.668 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -122.0 145.57 48.0 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-O 120.709 0.29 . . . . 0.0 110.256 -179.587 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 16.8 t -96.78 113.3 30.79 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 CA-C-O 120.846 0.355 . . . . 0.0 110.36 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . 0.42 ' C ' ' CD1' ' A' ' 53' ' ' TYR . . . -119.84 -166.97 13.44 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 110.772 -0.931 . . . . 0.0 110.772 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.42 ' CD1' ' C ' ' A' ' 52' ' ' GLY . 85.3 m-85 -147.37 159.59 43.52 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 179.963 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -145.62 154.88 42.62 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.971 0.415 . . . . 0.0 110.809 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 15.1 m -69.51 146.08 52.16 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.666 -179.809 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 20.6 ptmt -68.23 -36.82 80.09 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.465 -179.836 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 78.3 p -66.92 -23.22 65.95 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.865 -179.007 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 80.9 m-85 -104.82 7.33 34.47 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.471 -179.888 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 4.9 mm -127.71 129.74 70.15 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.15 179.811 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 98.5 m -121.22 127.07 51.09 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.593 179.481 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 21.8 mm -86.23 128.94 38.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.107 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 21.2 t -81.79 133.13 29.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.822 -179.569 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 43.0 t-20 63.08 51.48 2.79 Favored 'General case' 0 C--O 1.232 0.146 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.553 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 77.0 mt-10 -44.5 133.01 5.93 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.525 -179.672 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -72.78 141.41 30.54 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.533 -1.027 . . . . 0.0 110.533 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 14.1 m 37.08 93.71 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.909 0.385 . . . . 0.0 111.334 -179.717 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.487 ' H ' ' CD2' ' A' ' 67' ' ' LEU . 0.1 OUTLIER -79.5 143.22 35.1 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.368 -179.891 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -157.46 113.16 2.83 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.314 179.724 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 51.5 p-80 -86.82 -0.77 57.02 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.289 179.792 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' HIS . . . . . . . . . . . . . 96.2 m-70 -73.09 130.09 39.52 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.056 -0.52 . . . . 0.0 109.856 179.855 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 24.9 p80 -101.71 20.05 16.97 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.714 -179.649 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 56.81 86.53 0.07 Allowed 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.582 -179.765 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 44.8 p-80 -83.01 146.54 28.7 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.463 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 58.2 m-70 . . . . . 0 C--O 1.22 -0.45 0 CA-C-O 118.177 -0.916 . . . . 0.0 110.595 -179.72 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 6.7 ttt . . . . . 0 N--CA 1.491 1.575 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 26.8 mt-30 -141.27 110.48 6.27 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.222 179.786 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -85.19 163.81 37.99 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.514 -1.034 . . . . 0.0 110.514 179.648 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 54.7 t -125.17 130.15 73.1 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-O 120.785 0.326 . . . . 0.0 110.143 179.858 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 15.7 t -95.4 125.92 48.01 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.08 179.681 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 33.1 ttpt -129.81 117.1 19.68 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.497 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 2.8 t -140.92 155.9 22.16 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 CA-C-O 120.872 0.368 . . . . 0.0 110.726 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 49.8 p30 -79.9 -11.49 59.8 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.504 179.548 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 73.6 m -162.07 -164.79 1.11 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.385 -179.76 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -65.25 142.95 58.11 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.735 -179.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 53.6 tp -126.16 132.12 51.88 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-N 116.169 -0.468 . . . . 0.0 109.879 179.701 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . 0.445 ' OD1' ' O ' ' A' ' 12' ' ' ASN . 47.8 p30 -77.62 142.44 38.9 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.001 0.429 . . . . 0.0 110.956 -179.873 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 43.3 ttp -111.43 138.44 47.93 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 179.691 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . 0.71 ' NH2' ' CE3' ' A' ' 42' ' ' TRP . 0.5 OUTLIER -109.18 141.2 41.75 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 120.867 0.365 . . . . 0.0 111.03 -178.81 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 38.4 t -63.44 -42.61 98.67 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.037 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -107.73 179.8 22.0 Favored Glycine 0 N--CA 1.466 0.665 0 N-CA-C 110.65 -0.98 . . . . 0.0 110.65 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -82.98 73.09 5.59 Favored 'Trans proline' 0 C--N 1.307 -1.652 0 C-N-CA 122.438 2.092 . . . . 0.0 111.959 179.665 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . 0.649 ' N ' HH21 ' A' ' 14' ' ' ARG . . . 174.52 158.07 17.64 Favored Glycine 0 CA--C 1.528 0.89 0 N-CA-C 111.344 -0.702 . . . . 0.0 111.344 179.918 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 69.5 m -82.4 -10.37 59.08 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.849 0.357 . . . . 0.0 110.643 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 14.4 m120 -89.64 5.03 47.56 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.188 -179.128 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 47.8 m-85 -92.11 -0.59 57.44 Favored 'General case' 0 N--CA 1.465 0.304 0 N-CA-C 109.993 -0.373 . . . . 0.0 109.993 179.775 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 78.53 -178.32 53.13 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 111.127 -0.789 . . . . 0.0 111.127 179.647 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 5.4 p -116.08 126.71 73.69 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 CA-C-O 120.932 0.396 . . . . 0.0 110.33 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 43.6 pt -103.66 -8.94 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.968 -179.866 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -177.87 -171.72 41.58 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 63.2 p -133.51 158.46 43.07 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-O 120.928 0.394 . . . . 0.0 110.642 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 75.9 mt -122.33 153.88 38.37 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 115.899 -0.592 . . . . 0.0 109.945 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.406 ' O ' ' CG ' ' A' ' 31' ' ' ASP . 70.3 mtm180 -124.54 147.14 48.6 Favored 'General case' 0 N--CA 1.465 0.309 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.914 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 53.0 p-10 -51.91 159.38 0.86 Allowed 'General case' 0 C--N 1.324 -0.536 0 C-N-CA 120.76 -0.376 . . . . 0.0 111.14 -179.168 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 58.0 t30 67.16 9.05 6.64 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.489 179.85 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . 0.406 ' CG ' ' O ' ' A' ' 28' ' ' ARG . 35.1 m-20 -84.88 113.7 21.57 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.746 0.308 . . . . 0.0 110.414 179.288 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 25.8 mtpp -78.57 136.77 37.61 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.084 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.4 m -137.24 163.05 32.65 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.252 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.784 -179.542 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 47.8 tp10 -103.01 123.8 47.3 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.401 179.497 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 90.4 mt -97.49 120.13 46.43 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.041 -179.424 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.401 HG22 HD12 ' A' ' 36' ' ' ILE . 82.2 mt -83.88 -44.96 18.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.733 179.533 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 62.1 pttt -173.93 174.89 2.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.452 -179.837 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -118.51 124.98 48.88 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.209 179.873 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 69.0 t -125.33 131.83 71.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.679 -179.577 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 54.83 27.53 9.1 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.12 179.574 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.11 -12.29 62.69 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 179.569 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . 0.71 ' CE3' ' NH2' ' A' ' 14' ' ' ARG . 82.9 m95 -88.73 145.02 25.88 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.731 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 65.6 m-85 -101.25 130.59 47.4 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-O 120.974 0.416 . . . . 0.0 110.521 -179.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -87.9 128.65 35.36 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.526 179.48 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.401 HD12 HG21 ' A' ' 45' ' ' ILE . 42.8 pt -128.94 150.51 34.64 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.253 0 CA-C-O 121.061 0.458 . . . . 0.0 111.312 -179.234 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 4.7 ttp180 -120.22 129.42 54.07 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.019 178.769 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 73.8 t80 -146.43 132.42 19.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.678 179.564 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 16.8 t-20 57.19 31.25 19.73 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.023 179.479 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 76.78 4.77 82.74 Favored Glycine 0 CA--C 1.528 0.863 0 N-CA-C 111.347 -0.701 . . . . 0.0 111.347 179.548 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 51.4 mtmt -102.21 150.27 23.46 Favored 'General case' 0 N--CA 1.466 0.358 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.567 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 58.0 t -116.65 132.79 65.3 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-O 120.881 0.372 . . . . 0.0 110.31 -179.641 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -153.93 -166.39 14.79 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.514 ' C ' ' NH1' ' A' ' 14' ' ' ARG . 52.8 m-85 -139.18 159.03 43.12 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-O 120.815 0.341 . . . . 0.0 110.694 -179.512 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . 0.497 ' N ' HH12 ' A' ' 14' ' ' ARG . . . -144.19 149.59 36.66 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.987 179.223 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 21.1 m -66.26 147.29 53.53 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.849 0.357 . . . . 0.0 110.574 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 62.3 pttt -64.63 -21.65 66.77 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.756 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 68.4 m -63.23 -40.29 97.02 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.55 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 72.7 m-85 -95.69 8.33 43.76 Favored 'General case' 0 N--CA 1.469 0.494 0 N-CA-C 111.93 0.345 . . . . 0.0 111.93 -178.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 46.0 mm -120.59 127.07 75.89 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 CA-C-O 120.905 0.383 . . . . 0.0 110.55 179.814 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 89.8 m -125.42 127.9 47.26 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 115.943 -0.572 . . . . 0.0 109.915 179.252 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.401 HD11 HG21 ' A' ' 61' ' ' ILE . 19.1 mm -85.21 127.93 39.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.543 -179.698 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 27.4 m -73.65 141.04 16.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.623 -179.785 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . 0.431 ' OD1' ' O ' ' A' ' 63' ' ' ASN . 45.8 p-10 -64.03 129.21 39.1 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.798 -179.579 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -66.42 142.46 57.58 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.426 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -66.88 140.59 38.47 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 110.826 -0.909 . . . . 0.0 110.826 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 69.9 m -95.69 119.66 34.58 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 120.905 0.383 . . . . 0.0 110.587 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -98.38 4.65 48.53 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.363 179.962 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 80.3 mm-40 -62.05 -39.05 91.04 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.622 -179.723 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . 0.441 ' CG ' ' O ' ' A' ' 69' ' ' HIS . 40.3 p-80 -140.7 98.65 3.45 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.156 179.655 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' HIS . . . . . 0.659 ' HD1' ' HD1' ' A' ' 71' ' ' HIS . 11.1 p80 -88.95 -45.55 9.59 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.756 -179.737 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.659 ' HD1' ' HD1' ' A' ' 70' ' ' HIS . 80.4 m80 -148.39 152.91 37.81 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.557 -179.874 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 85.9 t60 -160.98 119.85 2.54 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.018 179.76 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 59.5 t-80 -114.95 123.5 49.27 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.55 -179.664 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 79.5 m80 . . . . . 0 C--O 1.221 -0.443 0 CA-C-O 117.919 -1.039 . . . . 0.0 110.666 179.922 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 13.5 tpp . . . . . 0 N--CA 1.489 1.515 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 28.5 mp0 -125.06 114.65 19.35 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.27 179.788 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -97.29 168.02 24.04 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.73 -0.948 . . . . 0.0 110.73 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 55.4 t -125.55 132.07 71.36 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 N-CA-C 109.986 -0.375 . . . . 0.0 109.986 179.652 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 89.4 t -92.27 113.44 27.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.03 179.757 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 75.5 tttt -112.71 117.08 31.25 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.16 -179.765 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 9.1 p -144.11 154.0 15.48 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.995 -179.829 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 40.2 t30 -63.16 -41.03 99.18 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.891 -179.761 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' SER . . . . . 0.659 ' HG ' ' H ' ' A' ' 10' ' ' ALA . 20.3 p -133.3 -72.26 0.51 Allowed 'General case' 0 N--CA 1.468 0.439 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.733 -179.914 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.659 ' H ' ' HG ' ' A' ' 9' ' ' SER . . . -152.78 144.17 23.29 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.242 -179.884 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 42.5 tp -115.06 128.73 56.42 Favored 'General case' 0 N--CA 1.47 0.567 0 CA-C-O 120.979 0.418 . . . . 0.0 110.531 -179.664 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -74.77 144.56 43.53 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.481 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 33.3 ttp -107.26 150.31 26.8 Favored 'General case' 0 CA--C 1.519 -0.244 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 179.601 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . 0.508 ' HE ' ' HA ' ' A' ' 19' ' ' SER . 85.7 mtt85 -128.29 150.16 50.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.762 -178.303 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 23.0 t -69.15 -15.88 63.52 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 115.961 -0.563 . . . . 0.0 112.218 -179.417 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -161.01 -172.68 28.65 Favored Glycine 0 CA--C 1.524 0.646 0 C-N-CA 120.394 -0.908 . . . . 0.0 111.428 -179.673 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -82.76 78.43 3.34 Favored 'Trans proline' 0 C--N 1.304 -1.816 0 C-N-CA 122.729 2.286 . . . . 0.0 111.734 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 169.9 134.91 1.82 Allowed Glycine 0 CA--C 1.525 0.658 0 N-CA-C 111.29 -0.724 . . . . 0.0 111.29 179.878 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.508 ' HA ' ' HE ' ' A' ' 14' ' ' ARG . 34.5 t -66.69 -14.83 62.98 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.944 0.402 . . . . 0.0 110.642 179.705 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 91.6 m-20 -79.45 -1.13 35.92 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.941 -179.495 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 39.0 m-85 -89.21 -1.77 58.22 Favored 'General case' 0 C--O 1.232 0.163 0 N-CA-C 109.573 -0.529 . . . . 0.0 109.573 179.384 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 66.4 176.31 7.13 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 179.804 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 8.1 p -101.54 124.48 55.33 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 N-CA-C 110.105 -0.331 . . . . 0.0 110.105 179.603 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 42.9 pt -100.72 -3.27 9.45 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.714 -179.775 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 172.37 -177.84 44.8 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 53.0 p -132.73 158.51 42.19 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.76 0.314 . . . . 0.0 110.367 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 69.1 mt -112.65 135.47 53.34 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.286 -179.658 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -82.52 160.8 22.53 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 120.933 0.397 . . . . 0.0 110.407 -179.17 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 24.3 m120 -62.53 136.96 58.15 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.021 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . 0.406 ' OD1' ' O ' ' A' ' 30' ' ' ASN . 15.9 t-20 55.64 36.7 27.72 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.0 179.587 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -84.33 116.57 23.08 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.532 179.753 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -72.72 130.71 41.15 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 120.714 -0.394 . . . . 0.0 110.192 179.613 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.7 m -138.82 162.16 28.97 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.541 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -104.17 123.01 46.53 Favored 'General case' 0 N--CA 1.463 0.218 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 179.551 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.414 HG21 HD12 ' A' ' 35' ' ' ILE . 96.2 mt -90.35 106.25 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.214 -179.642 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.8 mt -66.24 -45.03 90.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.738 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 21.1 ptmt -175.82 170.8 2.77 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.366 -179.501 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -115.34 124.08 50.35 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.401 179.702 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 79.7 t -127.97 133.08 67.99 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.373 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.2 -179.833 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.428 ' OD1' ' O ' ' A' ' 40' ' ' ASP . 56.3 t0 56.52 23.02 7.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.901 0.382 . . . . 0.0 110.761 179.666 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 85.22 -6.69 78.69 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 111.249 -0.741 . . . . 0.0 111.249 179.68 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 49.0 m95 -85.85 145.78 27.04 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 109.697 -0.482 . . . . 0.0 109.697 179.31 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -95.75 115.25 27.16 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.977 0.418 . . . . 0.0 110.156 -179.672 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -83.65 122.55 28.76 Favored 'General case' 0 CA--C 1.517 -0.315 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 178.89 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 36.3 pt -128.74 162.42 35.79 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.494 0 CA-C-O 121.388 0.613 . . . . 0.0 111.65 -178.434 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 20.4 ttp180 -124.67 130.05 51.69 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.219 -0.9 . . . . 0.0 109.845 179.789 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 84.1 t80 -149.49 132.71 16.4 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.238 -179.507 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 66.0 t30 55.98 36.15 26.83 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.679 179.534 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 69.84 16.53 72.46 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.949 -0.86 . . . . 0.0 110.949 179.889 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 39.3 tptt -116.16 134.77 54.56 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-O 120.691 0.281 . . . . 0.0 110.285 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 58.5 t -108.89 131.22 60.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.155 -179.619 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -152.06 -156.82 7.65 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.736 -0.946 . . . . 0.0 110.736 -179.893 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 76.0 m-85 -137.75 155.85 48.62 Favored 'General case' 0 N--CA 1.464 0.225 0 CA-C-O 120.885 0.374 . . . . 0.0 110.78 -179.75 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -154.13 160.42 41.91 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.157 -179.709 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.7 p -64.47 151.63 43.82 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.044 -179.526 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 22.9 pttp -84.61 -27.21 27.36 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.665 179.828 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 38.9 t -62.27 -40.67 97.01 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.327 -179.614 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 58.8 m-85 -84.94 2.51 42.53 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.805 -179.027 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 97.6 mt -124.43 129.66 73.81 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.183 179.197 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 91.0 m -115.54 128.45 55.99 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.554 -179.707 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 95.3 mt -83.33 124.4 39.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.925 -0.58 . . . . 0.0 109.884 179.788 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 34.9 m -89.99 136.78 22.93 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 CA-C-O 120.938 0.399 . . . . 0.0 110.947 -179.511 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . 0.422 ' OD1' ' O ' ' A' ' 63' ' ' ASN . 15.8 p30 -53.55 125.78 19.3 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.418 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 79.5 mm-40 -67.27 -40.84 86.22 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.597 -179.767 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 59.56 -141.93 47.25 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 -179.847 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 2.7 t 42.05 89.17 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.986 0.422 . . . . 0.0 110.919 179.899 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.501 ' CD2' ' N ' ' A' ' 67' ' ' LEU . 3.5 mm? -87.91 -5.15 58.71 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.414 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 -67.09 139.65 57.57 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.804 -179.545 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 75.3 m80 -82.61 163.76 21.23 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.604 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' HIS . . . . . . . . . . . . . 55.0 t-80 -59.64 -42.93 93.87 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.902 -179.684 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 84.7 t60 -80.71 124.21 28.84 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.801 0.334 . . . . 0.0 110.643 -179.904 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 84.0 t60 -92.46 123.22 35.61 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.37 179.884 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 56.1 t-80 -166.37 129.54 1.98 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.446 179.717 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 51.3 t-80 . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 118.054 -0.974 . . . . 0.0 110.798 -179.771 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.487 ' CD ' ' N ' ' A' ' 2' ' ' GLN . 1.4 pm0 . . . . . 0 N--CA 1.462 0.16 0 CA-C-O 120.954 0.406 . . . . 0.0 110.538 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -88.42 149.8 21.47 Favored Glycine 0 CA--C 1.525 0.68 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 179.66 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 53.9 t -122.05 129.39 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 87.4 t -93.56 126.47 45.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.188 179.752 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 33.1 tptt -118.52 110.8 17.82 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.153 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.48 HG22 ' H ' ' A' ' 9' ' ' SER . 12.5 p -144.42 144.74 22.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.075 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -63.41 -41.23 98.71 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.7 -179.615 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' SER . . . . . 0.48 ' H ' HG22 ' A' ' 7' ' ' VAL . 38.6 m -119.06 -75.12 0.58 Allowed 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.985 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -157.87 145.67 18.61 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.386 -179.633 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 60.7 tp -108.98 131.12 55.37 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.138 -179.177 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 96.6 m-20 -80.89 145.63 31.22 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.666 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 42.5 ttp -106.81 149.84 26.96 Favored 'General case' 0 N--CA 1.471 0.597 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 179.857 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' ARG . . . . . 0.687 HH11 ' HA ' ' A' ' 19' ' ' SER . 58.1 mtt-85 -133.5 140.77 47.43 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-O 121.031 0.443 . . . . 0.0 111.768 -176.925 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 35.8 t -59.16 -41.93 89.55 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.358 -178.364 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -109.6 161.92 12.88 Favored Glycine 0 CA--C 1.53 0.987 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -77.99 73.3 5.78 Favored 'Trans proline' 0 N--CA 1.496 1.663 0 C-N-CA 122.922 2.414 . . . . 0.0 112.044 179.348 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 176.26 160.44 23.59 Favored Glycine 0 CA--C 1.516 0.146 0 N-CA-C 110.013 -1.235 . . . . 0.0 110.013 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' SER . . . . . 0.687 ' HA ' HH11 ' A' ' 14' ' ' ARG . 5.4 m -78.88 -16.9 56.44 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 120.457 -0.497 . . . . 0.0 110.54 -179.638 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -64.88 -36.05 83.1 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.971 -179.034 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -59.25 -42.52 91.32 Favored 'General case' 0 C--N 1.329 -0.284 0 C-N-CA 120.851 -0.339 . . . . 0.0 111.423 -178.922 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 101.86 162.21 26.8 Favored Glycine 0 N--CA 1.468 0.77 0 N-CA-C 111.29 -0.724 . . . . 0.0 111.29 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 7.2 p -77.16 132.79 32.11 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.123 0 CA-C-O 121.018 0.437 . . . . 0.0 111.594 -179.627 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 44.1 pt -113.45 -8.5 12.15 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.302 179.318 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -170.97 175.59 44.62 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.529 -1.029 . . . . 0.0 110.529 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 86.9 m -123.2 132.1 53.92 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-O 120.715 0.293 . . . . 0.0 110.451 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 73.0 mt -109.19 141.96 40.68 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.267 179.767 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.729 ' HG2' HH11 ' A' ' 28' ' ' ARG . 46.0 mtt-85 -95.32 168.06 10.96 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.274 179.383 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 50.7 p-10 -75.27 159.0 32.02 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 178.863 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 77.4 m-20 56.23 31.91 19.31 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.322 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 47.3 t0 -96.37 112.81 24.42 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 116.559 -0.291 . . . . 0.0 110.639 179.336 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 56.3 mtpt -74.06 134.34 42.96 Favored 'General case' 0 C--N 1.329 -0.288 0 C-N-CA 120.601 -0.44 . . . . 0.0 110.075 179.606 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 28.5 m -136.94 162.37 34.51 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.606 -179.81 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -101.82 121.1 41.45 Favored 'General case' 0 C--O 1.233 0.232 0 CA-C-N 116.083 -0.508 . . . . 0.0 109.869 179.618 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.3 mt -88.58 127.81 41.23 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.139 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.396 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 95.8 mt -91.77 -42.76 13.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.576 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 62.0 pttt -174.82 165.04 3.6 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.567 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -113.01 121.87 45.92 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.181 179.594 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 70.1 t -126.73 131.51 71.07 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.65 -179.64 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' ASP . . . . . 0.418 ' OD1' ' O ' ' A' ' 40' ' ' ASP . 56.6 t0 53.96 31.17 12.94 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.414 179.082 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 85.43 -16.49 39.48 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 111.043 -0.823 . . . . 0.0 111.043 179.694 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 79.9 m95 -83.35 146.14 28.65 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.401 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 58.7 m-85 -101.17 130.19 47.21 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.904 0.383 . . . . 0.0 110.402 179.669 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' GLU . . . . . 0.526 ' OE1' ' CE1' ' A' ' 53' ' ' TYR . 3.5 tp10 -88.12 118.52 27.75 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 179.207 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 44.7 pt -126.03 161.37 31.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-O 121.334 0.588 . . . . 0.0 110.678 -179.468 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.406 HH11 ' HD3' ' A' ' 46' ' ' ARG . 0.6 OUTLIER -126.88 127.23 44.61 Favored 'General case' 0 CA--C 1.537 0.467 0 CA-C-N 115.397 -0.82 . . . . 0.0 110.041 -178.262 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 32.9 t80 -145.79 133.47 21.03 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.461 -178.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 57.67 33.34 23.12 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.245 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 74.01 8.13 77.72 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 111.514 -0.634 . . . . 0.0 111.514 179.098 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 58.6 mttp -106.98 150.19 26.74 Favored 'General case' 0 N--CA 1.466 0.356 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 53.4 t -116.55 132.56 65.83 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.054 -179.808 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' GLY . . . . . 0.416 ' O ' ' OE1' ' A' ' 44' ' ' GLU . . . -159.78 -169.46 23.12 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 110.97 -0.852 . . . . 0.0 110.97 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' TYR . . . . . 0.526 ' CE1' ' OE1' ' A' ' 44' ' ' GLU . 97.8 m-85 -125.39 154.78 41.38 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.799 0.333 . . . . 0.0 110.482 -179.759 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -136.12 151.8 50.17 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.281 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 21.2 m -63.24 145.2 56.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.533 -179.71 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 58.8 pttt -77.53 -24.79 49.89 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.919 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 21.4 m -62.25 -41.27 98.29 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.394 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' TYR . . . . . 0.535 ' C ' HD12 ' A' ' 59' ' ' ILE . 90.2 m-85 -92.65 -2.07 56.38 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 116.552 -0.295 . . . . 0.0 111.635 -178.857 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.535 HD12 ' C ' ' A' ' 58' ' ' TYR . 1.3 mp -113.7 130.03 68.5 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 92.6 m -118.51 127.92 54.09 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.25 179.677 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 25.2 mm -77.36 133.83 29.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.439 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 78.7 t . . . . . 0 N--CA 1.463 0.224 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.608 -179.6 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 99.2 mm-40 . . . . . 0 N--CA 1.463 0.188 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -91.89 145.0 17.47 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 111.487 -0.645 . . . . 0.0 111.487 -179.471 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 58.8 t -123.62 131.83 72.4 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.451 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 70.6 t -93.28 127.39 45.39 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.249 0 CA-C-O 120.817 0.341 . . . . 0.0 110.607 -179.715 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 53.8 mtmt -126.43 107.1 9.96 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.37 179.703 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 9.8 p -137.96 159.46 33.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.002 -179.853 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 93.9 m-20 -61.26 -41.65 97.27 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.522 -0.308 . . . . 0.0 110.813 -179.291 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 5.2 t -143.68 -51.62 0.33 Allowed 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 120.803 0.335 . . . . 0.0 110.961 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -157.69 144.14 17.78 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.469 -179.659 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 52.3 tp -117.85 132.99 56.37 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 120.864 0.364 . . . . 0.0 110.118 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 99.7 m-20 -76.3 139.23 40.97 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.021 179.672 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 35.6 ttp -100.21 139.11 36.35 Favored 'General case' 0 N--CA 1.465 0.276 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' ARG . . . . . 0.46 ' HE ' ' HA ' ' A' ' 19' ' ' SER . 84.3 mtt85 -113.27 158.03 21.03 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.858 0.361 . . . . 0.0 110.818 -178.504 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 8.8 m -80.04 -11.53 59.77 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.94 -179.303 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -164.23 -173.01 32.41 Favored Glycine 0 CA--C 1.52 0.406 0 N-CA-C 110.815 -0.914 . . . . 0.0 110.815 179.47 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -82.74 75.82 4.37 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 122.612 2.208 . . . . 0.0 111.667 179.753 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.76 130.9 1.35 Allowed Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 179.722 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' SER . . . . . 0.46 ' HA ' ' HE ' ' A' ' 14' ' ' ARG . 80.6 p -70.1 -9.02 54.14 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.666 0.27 . . . . 0.0 110.963 -179.884 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 93.6 m-20 -83.55 -0.78 51.82 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.798 -179.876 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 43.0 m-85 -90.98 -2.71 57.66 Favored 'General case' 0 N--CA 1.462 0.167 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.654 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 71.87 -179.34 34.84 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.444 ' O ' HG13 ' A' ' 23' ' ' VAL . 14.2 p -108.61 127.04 65.39 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 CA-C-O 120.889 0.376 . . . . 0.0 110.176 179.594 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 26.1 pt -104.49 -3.3 9.67 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 CA-C-O 120.953 0.406 . . . . 0.0 110.717 -179.65 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.88 -178.52 48.53 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.865 -0.894 . . . . 0.0 110.865 -179.876 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 44.7 p -133.41 155.97 48.53 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.913 0.387 . . . . 0.0 110.549 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 78.6 mt -122.84 146.99 47.06 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.294 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 66.0 mtm180 -106.42 153.46 22.22 Favored 'General case' 0 CA--C 1.515 -0.368 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.517 179.877 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 50.8 p-10 -60.0 157.02 13.53 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.359 179.667 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 11.2 t-20 64.39 4.27 2.14 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.266 179.718 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 67.2 t0 -79.95 120.75 24.57 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.466 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 31.1 mtmm -101.15 138.18 38.51 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 120.864 0.364 . . . . 0.0 110.445 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 33.5 m -138.32 163.57 28.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.621 -179.723 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -85.34 134.95 34.08 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.479 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 86.6 mt -103.5 128.23 56.82 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.485 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.846 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.783 ' N ' HD12 ' A' ' 36' ' ' ILE . 2.0 mp -91.36 -44.49 14.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.834 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 62.6 pttt -172.52 160.09 4.67 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.648 -179.651 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' GLU . . . . . 0.473 ' CD ' ' CE1' ' A' ' 43' ' ' TYR . 82.6 tt0 -111.39 127.77 55.77 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.439 -179.866 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 57.5 t -127.91 129.94 69.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.707 179.794 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 53.19 30.83 10.47 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.361 -0.382 . . . . 0.0 111.592 179.137 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.9 -28.37 7.26 Favored Glycine 0 CA--C 1.521 0.427 0 N-CA-C 110.919 -0.873 . . . . 0.0 110.919 179.655 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 58.6 m95 -71.7 142.36 49.83 Favored 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 120.865 -0.334 . . . . 0.0 110.11 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' TYR . . . . . 0.473 ' CE1' ' CD ' ' A' ' 38' ' ' GLU . 59.9 m-85 -102.94 133.01 48.76 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.379 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 75.1 tt0 -91.79 121.36 33.34 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.308 179.414 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 46.2 pt -125.53 160.08 32.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.526 -0.306 . . . . 0.0 110.977 -179.124 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 22.0 ttt180 -120.54 126.95 51.63 Favored 'General case' 0 CA--C 1.54 0.566 0 CA-C-N 115.896 -0.593 . . . . 0.0 109.698 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.43 ' O ' ' CG ' ' A' ' 48' ' ' ASN . 32.7 t80 -145.09 145.39 31.4 Favored 'General case' 0 N--CA 1.473 0.676 0 O-C-N 123.04 0.212 . . . . 0.0 110.471 -178.353 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.43 ' CG ' ' O ' ' A' ' 47' ' ' PHE . 10.1 p30 51.52 25.74 2.88 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.109 -179.851 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 77.94 17.5 78.39 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 111.447 -0.661 . . . . 0.0 111.447 179.441 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -124.24 145.65 49.23 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-O 120.82 0.343 . . . . 0.0 110.283 179.675 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 53.2 t -112.14 131.65 62.99 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.317 -179.691 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -150.21 -164.17 11.67 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.478 -1.049 . . . . 0.0 110.478 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 55.3 m-85 -132.3 152.16 51.51 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 120.841 0.353 . . . . 0.0 110.695 -179.692 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -141.49 157.37 45.22 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.509 -179.581 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 38.1 t -61.19 139.8 58.05 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.226 -179.475 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -83.96 -12.94 54.58 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.691 179.807 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 37.3 m -70.6 -21.06 62.7 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.22 -179.28 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -115.74 4.43 14.01 Favored 'General case' 0 N--CA 1.47 0.562 0 CA-C-O 120.624 0.249 . . . . 0.0 111.131 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 97.1 mt -125.42 129.62 72.92 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 CA-C-O 120.879 0.371 . . . . 0.0 110.763 179.693 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 85.0 m -127.96 132.36 49.23 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.836 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.42 HD11 ' CE1' ' A' ' 43' ' ' TYR . 96.1 mt -80.79 128.32 38.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.359 179.583 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 22.1 m . . . . . 0 N--CA 1.465 0.319 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.693 -179.876 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 24.5 mp0 . . . . . 0 N--CA 1.465 0.29 0 CA-C-O 120.762 0.315 . . . . 0.0 110.567 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -90.68 171.0 35.7 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 179.49 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 53.3 t -124.71 130.12 73.48 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.541 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 59.7 t -91.0 127.24 43.54 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.259 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 59.9 mttp -121.79 110.57 16.07 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 120.841 0.353 . . . . 0.0 110.089 179.634 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.428 HG22 ' CD1' ' A' ' 58' ' ' TYR . 72.4 t -126.69 138.29 55.23 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.185 -179.317 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.422 ' O ' ' OD1' ' A' ' 8' ' ' ASN . 56.5 t-20 -62.73 -41.6 99.25 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.345 -179.192 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 21.6 m -130.87 -76.73 0.53 Allowed 'General case' 0 N--CA 1.468 0.433 0 CA-C-O 120.776 0.322 . . . . 0.0 110.806 -179.552 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -151.93 140.61 20.83 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.818 -179.696 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.429 HD22 ' CG ' ' A' ' 58' ' ' TYR . 53.8 tp -123.17 133.22 54.26 Favored 'General case' 0 N--CA 1.469 0.488 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.203 179.8 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ASN . . . . . 0.431 ' HB2' HH12 ' A' ' 14' ' ' ARG . 99.5 m-20 -81.7 140.08 34.54 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.977 179.755 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' MET . . . . . 0.474 ' SD ' HD11 ' A' ' 24' ' ' ILE . 7.3 tmm? -91.31 136.29 33.21 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-O 121.257 0.551 . . . . 0.0 110.37 -179.882 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' ARG . . . . . 0.431 HH12 ' HB2' ' A' ' 12' ' ' ASN . 4.0 mmt-85 -105.63 140.61 38.43 Favored 'General case' 0 CA--C 1.542 0.648 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.708 -178.127 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' SER . . . . . 0.505 ' OG ' HD13 ' A' ' 24' ' ' ILE . 68.5 m -78.6 -7.44 57.6 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.893 -177.941 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -153.77 -166.04 14.33 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -85.48 -0.68 8.92 Favored 'Trans proline' 0 C--N 1.302 -1.887 0 C-N-CA 122.479 2.119 . . . . 0.0 111.794 -179.768 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -99.12 128.2 9.49 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 110.808 -0.917 . . . . 0.0 110.808 179.503 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 78.5 p -69.64 -14.97 63.09 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.83 0.348 . . . . 0.0 110.622 179.672 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 96.7 m-20 -91.72 14.07 16.34 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.482 -179.368 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 7.9 m-85 -87.26 0.7 54.97 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.879 0.371 . . . . 0.0 110.041 179.853 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 79.47 171.33 41.32 Favored Glycine 0 CA--C 1.524 0.619 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 179.781 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.477 ' O ' HG13 ' A' ' 23' ' ' VAL . 11.3 p -106.99 126.72 63.01 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 CA-C-O 120.728 0.299 . . . . 0.0 110.471 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.505 HD13 ' OG ' ' A' ' 15' ' ' SER . 24.9 pt -106.07 -2.43 9.91 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.475 0 CA-C-O 121.005 0.431 . . . . 0.0 110.552 179.734 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -176.46 -177.15 45.22 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 110.47 -1.052 . . . . 0.0 110.47 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 61.3 p -131.92 153.6 50.1 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-O 121.03 0.443 . . . . 0.0 110.469 179.881 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 83.0 mt -123.6 147.62 47.16 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.402 179.238 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 1.7 mtm180 -124.32 153.84 41.17 Favored 'General case' 0 C--O 1.224 -0.287 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.666 -178.277 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 53.1 p-10 -56.19 165.52 1.01 Allowed 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.35 0.595 . . . . 0.0 112.059 -179.532 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 71.0 m-80 59.29 13.18 2.95 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 114.995 -1.002 . . . . 0.0 111.316 179.579 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 91.3 m-20 -87.86 113.78 23.85 Favored 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 120.844 -0.342 . . . . 0.0 110.451 179.493 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -92.23 129.57 38.15 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.016 0.436 . . . . 0.0 110.441 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.4 m -137.11 161.16 35.77 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.145 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.081 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -89.91 131.09 36.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.298 -179.887 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.2 mt -97.69 107.71 20.55 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.216 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.435 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 97.5 mt -66.64 -44.21 89.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.925 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 63.2 pttt -173.05 178.9 2.38 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.769 -179.533 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -119.94 123.92 44.71 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.12 179.554 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 62.3 t -126.07 131.68 71.42 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-O 120.974 0.416 . . . . 0.0 110.626 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 54.5 31.39 14.74 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.278 179.361 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.537 ' O ' ' NZ ' ' A' ' 56' ' ' LYS . . . 82.97 -15.91 30.13 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 179.755 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 11.4 m95 -86.08 148.29 25.78 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.708 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 51.5 m-85 -100.91 132.94 46.07 Favored 'General case' 0 C--O 1.233 0.187 0 CA-C-O 121.111 0.482 . . . . 0.0 110.523 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -94.46 127.04 40.11 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.376 -0.829 . . . . 0.0 109.271 179.163 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 43.7 pt -129.22 157.14 42.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 CA-C-O 121.135 0.493 . . . . 0.0 111.784 -178.862 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 31.1 ttp180 -115.6 124.37 50.79 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.719 178.748 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 34.4 t80 -145.14 132.95 21.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.709 -179.466 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 62.2 t30 56.62 32.92 21.86 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.608 179.77 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 71.83 11.87 74.13 Favored Glycine 0 CA--C 1.528 0.875 0 N-CA-C 111.369 -0.693 . . . . 0.0 111.369 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 65.6 mttp -111.62 147.31 35.75 Favored 'General case' 0 N--CA 1.467 0.409 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.755 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 52.9 t -117.44 132.06 68.35 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.067 -179.778 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' GLY . . . . . 0.418 ' C ' ' CD1' ' A' ' 53' ' ' TYR . . . -156.27 -167.02 16.99 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.491 -1.044 . . . . 0.0 110.491 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' TYR . . . . . 0.535 ' CD1' ' N ' ' A' ' 53' ' ' TYR . 10.1 m-85 -137.15 154.6 50.21 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-O 120.811 0.338 . . . . 0.0 110.451 -179.486 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -147.05 152.85 39.23 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.322 179.802 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 9.7 p -63.95 142.92 58.23 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.881 0.372 . . . . 0.0 110.753 -179.708 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.537 ' NZ ' ' O ' ' A' ' 41' ' ' GLY . 0.0 OUTLIER -66.24 -12.74 58.08 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.711 -179.358 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 6.1 m -65.06 -15.74 62.69 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.544 -0.298 . . . . 0.0 111.215 -179.515 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' TYR . . . . . 0.429 ' CG ' HD22 ' A' ' 11' ' ' LEU . 95.2 m-85 -117.8 5.67 12.26 Favored 'General case' 0 N--CA 1.472 0.651 0 N-CA-C 111.69 0.256 . . . . 0.0 111.69 -179.737 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 4.2 mp -121.49 130.15 74.9 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 CA-C-O 121.246 0.546 . . . . 0.0 110.154 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 85.5 m -123.91 132.63 53.77 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.197 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.0 mt -72.79 129.22 35.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.169 179.769 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 89.2 t . . . . . 0 C--N 1.327 -0.406 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.671 -179.882 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 98.4 mm-40 . . . . . 0 N--CA 1.466 0.327 0 CA-C-O 121.094 0.473 . . . . 0.0 110.148 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -100.03 154.27 19.52 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.748 -0.941 . . . . 0.0 110.748 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 64.1 t -124.4 130.85 73.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.586 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 88.1 t -88.47 128.41 40.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.62 -179.786 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -127.46 105.51 8.56 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.242 179.606 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 30.9 m -138.89 159.96 30.03 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.254 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.715 179.799 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 -91.41 -4.05 56.06 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.38 179.698 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 17.4 m -154.39 -166.95 2.48 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.34 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -67.18 143.82 56.35 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.466 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 51.3 tp -117.51 130.62 56.55 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 116.182 -0.463 . . . . 0.0 109.88 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 97.6 m-20 -89.22 134.2 34.13 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.439 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 52.1 ttp -105.38 145.96 30.08 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 116.174 -0.466 . . . . 0.0 109.834 179.765 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 93.8 mtt-85 -119.13 159.82 23.25 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-O 120.936 0.398 . . . . 0.0 111.162 -179.554 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 86.2 p -81.67 -5.94 58.56 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.617 -0.72 . . . . 0.0 110.133 179.638 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.433 ' C ' ' H ' ' A' ' 18' ' ' GLY . . . -159.55 167.31 35.13 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 110.625 -0.99 . . . . 0.0 110.625 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo -69.94 12.27 0.36 Allowed 'Trans proline' 0 C--N 1.308 -1.6 0 C-N-CA 121.883 1.722 . . . . 0.0 111.904 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' GLY . . . . . 0.433 ' H ' ' C ' ' A' ' 16' ' ' GLY . . . -99.4 124.12 8.13 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.861 -0.895 . . . . 0.0 110.861 179.225 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 79.5 p -66.94 -10.21 46.6 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.757 0.313 . . . . 0.0 110.535 179.779 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 55.0 p30 -90.95 6.18 45.7 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.64 -179.284 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 32.4 m-85 -88.5 -10.41 49.06 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.39 179.852 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 75.9 176.75 41.11 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 111.361 -0.696 . . . . 0.0 111.361 179.102 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.499 ' O ' HG13 ' A' ' 23' ' ' VAL . 12.1 p -92.48 127.17 44.82 Favored 'Isoleucine or valine' 0 C--O 1.232 0.151 0 CA-C-O 120.711 0.291 . . . . 0.0 110.528 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 24.5 pt -106.11 -5.02 9.97 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-O 120.872 0.368 . . . . 0.0 110.623 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.6 175.3 47.24 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.808 -0.917 . . . . 0.0 110.808 -179.824 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 73.9 m -125.88 130.36 51.18 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 120.878 0.371 . . . . 0.0 110.463 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 72.8 mt -112.44 142.43 44.99 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.711 179.633 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.774 HH11 ' HG3' ' A' ' 28' ' ' ARG . 71.4 mtm-85 -108.42 164.12 12.61 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-O 121.345 0.593 . . . . 0.0 111.117 -179.551 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.414 ' C ' ' H ' ' A' ' 31' ' ' ASP . 57.1 p30 -67.26 166.84 13.44 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.024 179.803 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 79.5 m-20 59.41 3.16 0.37 Allowed 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.098 -179.765 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.461 ' OD2' ' N ' ' A' ' 28' ' ' ARG . 98.3 m-20 -72.66 140.02 47.67 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.987 0.422 . . . . 0.0 110.59 179.37 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 53.4 mttp -107.19 125.78 51.55 Favored 'General case' 0 N--CA 1.476 0.859 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.38 179.017 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.3 m -136.65 162.4 35.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 178.912 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -100.56 123.89 45.37 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-O 120.835 0.35 . . . . 0.0 110.555 -179.738 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.7 mt -84.68 130.12 36.55 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.128 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.469 179.588 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.5 mt -98.88 -54.86 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.196 -179.603 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 8.7 ttmm -150.64 153.01 34.88 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-O 120.799 0.333 . . . . 0.0 110.974 -179.405 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' GLU . . . . . 0.448 ' CD ' ' CE1' ' A' ' 43' ' ' TYR . 83.5 tt0 -112.86 122.65 48.28 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.146 179.351 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 62.7 t -130.73 132.88 63.97 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.154 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 53.2 25.46 4.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.011 179.431 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.63 -24.62 25.03 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 179.625 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 33.2 m95 -74.38 144.74 44.24 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.762 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' TYR . . . . . 0.448 ' CE1' ' CD ' ' A' ' 38' ' ' GLU . 78.3 m-85 -105.98 131.67 53.0 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 120.852 0.358 . . . . 0.0 110.847 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 76.9 tt0 -88.21 123.23 32.63 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.328 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 46.2 pt -126.95 160.66 35.22 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.673 0 CA-C-O 121.594 0.711 . . . . 0.0 110.944 -179.017 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 12.5 ttm180 -122.6 129.46 51.92 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.123 -0.944 . . . . 0.0 110.853 -179.285 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 59.2 t80 -148.69 131.55 16.11 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.257 -179.82 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.574 ' ND2' ' O ' ' A' ' 48' ' ' ASN . 3.3 t30 57.48 36.74 27.32 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.907 179.518 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 69.64 15.36 70.89 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 179.774 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 35.9 ttmt -117.18 137.22 52.48 Favored 'General case' 0 N--CA 1.466 0.329 0 N-CA-C 110.321 -0.252 . . . . 0.0 110.321 -179.714 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 53.4 t -111.11 131.04 63.43 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.86 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -145.17 -161.94 9.33 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.759 -0.936 . . . . 0.0 110.759 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 81.3 m-85 -138.58 154.21 48.7 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 120.721 0.296 . . . . 0.0 110.396 -179.689 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -145.18 150.54 36.92 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.198 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' SER . . . . . 0.448 ' OG ' ' CD2' ' A' ' 58' ' ' TYR . 8.7 p -75.49 153.0 37.79 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.097 0.475 . . . . 0.0 111.434 -179.177 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -65.95 -30.17 70.7 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.63 -0.713 . . . . 0.0 111.609 179.278 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 95.8 p -55.67 -28.95 58.3 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.532 -178.719 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' TYR . . . . . 0.538 ' C ' HD12 ' A' ' 59' ' ' ILE . 19.9 m-85 -108.52 -6.22 16.19 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 111.446 0.165 . . . . 0.0 111.446 -179.709 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.538 HD12 ' C ' ' A' ' 58' ' ' TYR . 1.4 mp -112.68 130.05 67.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 N-CA-C 109.595 -0.521 . . . . 0.0 109.595 -179.764 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 92.8 m -123.63 132.03 53.76 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-N 115.716 -0.674 . . . . 0.0 109.979 179.591 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.3 mt -76.82 131.4 34.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.625 -179.63 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 95.3 t . . . . . 0 C--N 1.33 -0.24 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.26 179.641 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 23.0 mp0 . . . . . 0 N--CA 1.463 0.189 0 CA-C-O 120.813 0.339 . . . . 0.0 110.253 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -85.34 163.73 37.66 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.881 -0.888 . . . . 0.0 110.881 179.803 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 77.3 t -127.1 134.13 66.74 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-O 120.85 0.357 . . . . 0.0 110.131 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 19.8 t -83.15 128.39 38.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.55 179.76 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 68.0 mmtt -123.02 105.5 10.02 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.151 179.652 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.6 m -148.79 157.92 7.07 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.557 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 50.9 p30 -83.96 -9.78 58.43 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.81 179.789 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' SER . . . . . 0.473 ' OG ' ' N ' ' A' ' 10' ' ' ALA . 48.4 t -155.24 -165.26 1.97 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.856 0.36 . . . . 0.0 110.722 -179.759 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.473 ' N ' ' OG ' ' A' ' 9' ' ' SER . . . -64.38 143.55 57.82 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.659 -179.858 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 47.3 tp -121.55 133.08 55.01 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-O 120.953 0.406 . . . . 0.0 110.307 179.675 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 99.5 m-20 -82.74 142.47 31.59 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.991 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 49.6 ttp -113.48 148.57 35.72 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.939 179.544 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' ARG . . . . . 0.81 ' NH2' ' CH2' ' A' ' 42' ' ' TRP . 43.4 mtm180 -121.41 153.87 37.27 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-O 121.117 0.484 . . . . 0.0 111.599 -179.001 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 11.3 t -62.76 -41.83 99.4 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.439 179.748 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -140.99 -164.97 10.13 Favored Glycine 0 N--CA 1.466 0.676 0 N-CA-C 111.382 -0.687 . . . . 0.0 111.382 -179.401 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -85.03 71.41 5.08 Favored 'Trans proline' 0 C--N 1.31 -1.471 0 C-N-CA 122.893 2.395 . . . . 0.0 112.103 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' GLY . . . . . 0.706 ' H ' ' NH1' ' A' ' 14' ' ' ARG . . . -167.74 120.22 0.89 Allowed Glycine 0 CA--C 1.523 0.545 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 179.654 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 8.9 t -60.95 -9.01 3.6 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.944 0.402 . . . . 0.0 110.326 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 89.9 m-20 -89.79 5.55 45.57 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.993 -179.456 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 22.0 m-85 -88.22 -7.94 56.05 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 120.681 0.277 . . . . 0.0 110.377 179.887 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 67.68 179.07 14.02 Favored Glycine 0 CA--C 1.521 0.447 0 N-CA-C 110.84 -0.904 . . . . 0.0 110.84 179.641 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.455 ' O ' HG13 ' A' ' 23' ' ' VAL . 9.3 p -92.18 124.21 44.57 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.183 0 CA-C-O 120.787 0.327 . . . . 0.0 110.704 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 24.4 pt -104.35 -5.52 9.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.802 -179.856 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.65 177.05 47.52 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 111.038 -0.825 . . . . 0.0 111.038 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 91.0 m -126.56 130.47 50.61 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-O 120.853 0.359 . . . . 0.0 110.301 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 72.7 mt -112.38 146.31 38.55 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.22 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 87.0 mtm-85 -115.42 161.51 18.46 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.028 179.931 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.481 ' C ' ' H ' ' A' ' 31' ' ' ASP . 50.8 p30 -69.13 166.77 17.52 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.929 -179.501 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 56.5 t30 71.03 -27.85 0.18 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.509 179.735 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.481 ' H ' ' C ' ' A' ' 29' ' ' ASN . 33.9 m-20 -67.48 137.6 55.95 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.583 -0.447 . . . . 0.0 109.926 179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 18.1 ptpt -104.06 145.81 29.63 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.654 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.0 m -133.91 161.72 40.5 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.266 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.234 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -92.28 132.93 36.3 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.231 -0.44 . . . . 0.0 109.875 179.552 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 5.5 mm -98.89 125.77 52.26 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 CA-C-O 120.947 0.404 . . . . 0.0 110.721 -179.461 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.6 mt -93.14 -46.88 13.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.565 179.828 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 31.6 ttpt -173.03 162.57 4.62 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 120.941 0.4 . . . . 0.0 111.153 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' GLU . . . . . 0.501 ' OE1' ' CE1' ' A' ' 43' ' ' TYR . 82.2 tt0 -110.54 124.05 51.1 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.034 179.497 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 96.9 t -128.04 131.63 69.31 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.099 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 54.41 29.99 11.97 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.569 178.886 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.69 -11.25 64.68 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 111.254 -0.739 . . . . 0.0 111.254 179.388 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.81 ' CH2' ' NH2' ' A' ' 14' ' ' ARG . 82.8 m95 -89.45 143.25 26.97 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.604 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' TYR . . . . . 0.501 ' CE1' ' OE1' ' A' ' 38' ' ' GLU . 53.4 m-85 -100.94 130.52 46.95 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.732 0.301 . . . . 0.0 110.654 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -82.54 132.57 35.19 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 179.157 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 43.2 pt -132.67 153.02 37.28 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.241 0 CA-C-O 121.098 0.475 . . . . 0.0 111.236 -179.474 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 60.3 ttp180 -127.6 125.36 40.1 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.515 -0.766 . . . . 0.0 109.923 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.443 ' O ' ' OD1' ' A' ' 48' ' ' ASN . 19.0 t80 -151.4 146.13 25.74 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.886 -179.276 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.443 ' OD1' ' O ' ' A' ' 47' ' ' PHE . 8.2 p-10 47.19 38.2 6.54 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.526 179.723 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 67.62 23.1 73.76 Favored Glycine 0 CA--C 1.522 0.5 0 N-CA-C 111.33 -0.708 . . . . 0.0 111.33 179.085 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 69.4 mmtt -128.33 144.13 51.09 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.825 0.345 . . . . 0.0 110.143 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 75.4 t -113.82 133.29 60.27 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.205 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.158 -179.678 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -153.32 -166.26 14.38 Favored Glycine 0 CA--C 1.521 0.431 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 179.876 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 45.9 m-85 -136.24 155.88 49.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.837 0.351 . . . . 0.0 110.062 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -137.22 154.97 50.05 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.548 -179.647 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 41.3 t -61.78 142.39 57.32 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.505 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 61.9 pttt -68.24 -31.67 71.31 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.353 -179.601 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 19.8 m -60.92 -41.32 95.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.822 -179.245 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 70.7 m-85 -96.23 11.9 32.85 Favored 'General case' 0 N--CA 1.467 0.411 0 N-CA-C 111.837 0.31 . . . . 0.0 111.837 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 5.4 mm -121.33 129.32 75.72 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 CA-C-O 121.01 0.433 . . . . 0.0 110.503 179.748 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 99.4 m -122.71 127.52 49.36 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.348 179.754 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.7 mt -83.2 131.16 34.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.568 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 94.3 t . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.312 -0.403 . . . . 0.0 110.471 -179.852 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 22.4 mm100 . . . . . 0 N--CA 1.464 0.267 0 CA-C-O 120.911 0.386 . . . . 0.0 110.373 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -87.58 156.94 28.36 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 110.813 -0.915 . . . . 0.0 110.813 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 59.1 t -125.88 132.71 70.39 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.632 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 21.9 t -81.68 128.66 38.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.675 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 71.2 mmtt -115.48 105.84 13.28 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.188 -0.46 . . . . 0.0 109.764 179.512 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.406 HG22 ' N ' ' A' ' 8' ' ' ASN . 12.5 p -145.79 155.88 12.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.535 -179.711 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.406 ' N ' HG22 ' A' ' 7' ' ' VAL . 75.6 m-20 -62.56 -41.45 98.92 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.909 -179.426 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 21.5 m -136.59 -57.58 0.74 Allowed 'General case' 0 N--CA 1.466 0.326 0 CA-C-O 120.656 0.265 . . . . 0.0 110.92 -179.77 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -157.65 144.62 18.15 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.8 0.333 . . . . 0.0 110.558 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 44.9 tp -111.83 130.62 55.75 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.463 -179.627 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ASN . . . . . 0.4 ' OD1' ' O ' ' A' ' 12' ' ' ASN . 47.3 p-10 -71.95 137.99 47.73 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.701 179.762 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 37.7 ttp -100.45 136.69 39.94 Favored 'General case' 0 N--CA 1.464 0.275 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 179.734 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' ARG . . . . . 0.456 ' HE ' ' HA ' ' A' ' 19' ' ' SER . 84.0 mtt85 -107.67 157.52 18.02 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.669 -179.143 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 85.6 p -84.18 -10.34 57.82 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.681 179.795 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -161.99 -171.89 28.68 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 111.161 -0.776 . . . . 0.0 111.161 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_endo -84.02 68.84 6.61 Favored 'Trans proline' 0 C--N 1.309 -1.549 0 C-N-CA 122.815 2.344 . . . . 0.0 111.653 -179.833 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -179.97 134.77 2.3 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' SER . . . . . 0.456 ' HA ' ' HE ' ' A' ' 14' ' ' ARG . 15.9 m -76.89 -8.94 58.27 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.724 0.297 . . . . 0.0 111.003 -179.526 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 67.1 t30 -83.59 -1.48 53.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.878 -179.798 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 50.1 m-85 -86.71 -5.93 58.98 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 120.768 0.318 . . . . 0.0 110.294 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 77.18 166.35 25.74 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.92 -0.872 . . . . 0.0 110.92 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.466 ' O ' HG13 ' A' ' 23' ' ' VAL . 14.4 p -95.26 127.25 47.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.731 0.3 . . . . 0.0 110.481 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 25.4 pt -101.89 -5.06 9.23 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.288 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.804 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.76 -177.43 47.37 Favored Glycine 0 CA--C 1.529 0.948 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 62.8 p -134.74 157.99 45.28 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-O 120.885 0.374 . . . . 0.0 111.025 -179.705 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 67.6 mt -124.88 145.06 49.99 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.168 -0.469 . . . . 0.0 109.846 179.804 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 13.8 mtm180 -93.63 173.48 7.67 Favored 'General case' 0 C--O 1.233 0.235 0 CA-C-O 121.262 0.553 . . . . 0.0 110.847 179.863 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.433 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 51.7 p-10 -73.6 144.48 45.96 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.43 -0.804 . . . . 0.0 109.554 178.359 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 12.3 t-20 58.49 34.7 24.15 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.564 -0.289 . . . . 0.0 111.192 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -88.79 112.7 23.52 Favored 'General case' 0 N--CA 1.468 0.44 0 N-CA-C 110.018 -0.364 . . . . 0.0 110.018 179.447 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -75.88 130.37 38.43 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 120.665 -0.414 . . . . 0.0 110.091 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 33.2 m -137.87 163.24 30.46 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-O 120.902 0.382 . . . . 0.0 110.689 -179.696 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -102.28 123.64 46.44 Favored 'General case' 0 N--CA 1.463 0.203 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.265 179.805 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.2 mt -89.06 126.03 42.09 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.169 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.408 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.7 mt -92.91 -47.11 13.91 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.183 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.678 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 32.2 ttpt -168.94 158.0 8.42 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.876 -179.807 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -108.4 120.98 43.98 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.962 179.819 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 77.8 t -126.22 132.31 70.61 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.849 -179.442 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 47.5 t0 58.14 25.92 13.07 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.394 179.056 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.93 -10.69 67.18 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 179.774 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 65.9 m95 -89.56 144.63 25.87 Favored 'General case' 0 C--N 1.331 -0.198 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 179.407 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 79.9 m-85 -97.43 127.91 43.78 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.87 0.367 . . . . 0.0 110.45 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 79.4 tt0 -88.3 126.62 35.27 Favored 'General case' 0 CA--C 1.522 -0.119 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 179.499 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 42.0 pt -132.47 161.48 41.39 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.283 0 CA-C-O 121.011 0.434 . . . . 0.0 111.784 -178.752 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 78.7 ttt-85 -114.64 124.38 51.69 Favored 'General case' 0 N--CA 1.464 0.268 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 178.806 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 45.5 t80 -156.68 146.06 20.55 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.924 0.392 . . . . 0.0 111.191 -179.106 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 54.9 t30 58.76 31.63 21.39 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.356 179.59 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 69.74 18.56 74.2 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 111.704 -0.558 . . . . 0.0 111.704 178.783 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -144.37 152.4 40.65 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 120.825 0.345 . . . . 0.0 110.775 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.8 t -85.59 157.99 3.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.176 179.885 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -167.84 -178.2 39.68 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 111.422 -0.671 . . . . 0.0 111.422 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 85.1 m-85 -133.33 153.02 51.94 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 120.734 0.302 . . . . 0.0 110.4 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -139.65 152.32 46.65 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.008 -179.824 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 27.2 t -64.91 142.36 58.46 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.033 -179.796 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 61.3 pttt -66.79 -33.65 76.09 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.461 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 38.9 t -61.69 -42.99 99.67 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.602 -178.961 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 90.2 m-85 -90.43 4.02 52.19 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.66 -0.245 . . . . 0.0 111.48 -179.115 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 5.8 mm -119.7 127.99 75.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 CA-C-O 120.909 0.385 . . . . 0.0 110.246 179.797 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 94.4 m -123.69 129.75 51.58 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.422 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.0 mt -80.12 131.75 33.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.649 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 93.9 t . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.14 179.62 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 . . . . . 0 N--CA 1.466 0.338 0 CA-C-O 120.82 0.343 . . . . 0.0 110.606 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -89.44 166.53 33.24 Favored Glycine 0 CA--C 1.522 0.491 0 N-CA-C 110.542 -1.023 . . . . 0.0 110.542 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 56.1 t -124.11 129.33 74.19 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.756 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 13.7 t -97.01 110.28 24.69 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.145 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.092 179.795 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 32.0 ttmt -119.11 120.01 35.89 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.162 179.764 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.493 HG22 ' N ' ' A' ' 8' ' ' ASN . 9.3 p -140.59 159.72 24.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.32 -179.884 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.493 ' N ' HG22 ' A' ' 7' ' ' VAL . 28.9 t-20 -60.85 -41.58 96.14 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.352 -178.834 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 5.1 t -130.14 -68.47 0.7 Allowed 'General case' 0 N--CA 1.467 0.419 0 CA-C-O 120.901 0.381 . . . . 0.0 110.563 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -158.11 144.14 17.21 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.997 -0.547 . . . . 0.0 109.948 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 40.0 tp -111.45 129.06 56.15 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-O 120.895 0.378 . . . . 0.0 110.585 -179.525 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 77.2 m-20 -75.69 141.43 42.72 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.413 179.694 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 30.9 ttp -102.73 147.52 26.74 Favored 'General case' 0 N--CA 1.47 0.575 0 CA-C-N 116.701 -0.227 . . . . 0.0 111.14 -179.287 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 76.2 mtt85 -119.54 142.11 48.63 Favored 'General case' 0 CA--C 1.506 -0.74 0 CA-C-O 121.285 0.564 . . . . 0.0 111.934 -178.819 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 78.9 p -66.98 -39.51 87.19 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.079 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -115.4 170.34 13.24 Favored Glycine 0 CA--C 1.527 0.793 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 179.509 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.3 Cg_endo -79.51 58.25 6.87 Favored 'Trans proline' 0 N--CA 1.492 1.425 0 C-N-CA 122.644 2.229 . . . . 0.0 112.175 179.557 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -176.99 149.68 9.73 Favored Glycine 0 CA--C 1.532 1.11 0 C-N-CA 120.938 -0.648 . . . . 0.0 111.756 179.879 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 32.7 t -64.37 -16.14 61.74 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 120.869 0.366 . . . . 0.0 110.888 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -72.67 -7.39 50.17 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.984 -179.536 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 55.9 m-85 -92.52 -6.21 50.15 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-O 120.635 0.255 . . . . 0.0 110.801 -179.877 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 67.03 -175.78 23.28 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 110.978 -0.849 . . . . 0.0 110.978 179.681 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.442 ' O ' HG13 ' A' ' 23' ' ' VAL . 10.9 p -105.29 128.86 58.89 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 CA-C-O 120.81 0.338 . . . . 0.0 110.77 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 41.6 pt -105.94 -6.76 10.07 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.551 179.462 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.39 -177.25 44.31 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 -179.849 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 57.8 p -131.17 155.95 46.14 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-O 120.924 0.392 . . . . 0.0 110.358 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 71.4 mt -123.76 149.48 45.57 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.77 -179.583 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 34.5 ttp85 -113.7 143.17 45.05 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 -179.561 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.432 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 57.2 p30 -46.65 153.38 0.39 Allowed 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.316 0.579 . . . . 0.0 112.263 -179.022 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 63.3 m-20 58.93 31.25 21.14 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.106 -0.952 . . . . 0.0 111.856 179.299 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 29.3 t0 -93.55 118.16 31.0 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-O 120.68 0.276 . . . . 0.0 110.258 179.11 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 29.5 mmtp -72.97 132.37 43.34 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 109.986 -0.375 . . . . 0.0 109.986 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 26.8 m -138.41 160.97 31.54 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.518 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -108.39 120.25 41.87 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.031 179.566 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 95.8 mt -85.46 128.81 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.155 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.527 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 26.1 mt -93.63 -61.31 2.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.188 -179.742 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 22.0 mtmm -149.31 158.51 44.24 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.747 179.608 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' GLU . . . . . 0.408 ' CD ' ' CE1' ' A' ' 43' ' ' TYR . 83.9 tt0 -111.35 122.47 47.94 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.049 179.616 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 74.8 t -125.35 130.02 72.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.598 -179.794 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 44.8 t0 52.57 27.29 4.97 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.101 179.333 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.02 -21.92 37.21 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 179.56 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 43.8 m95 -77.32 140.18 39.95 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.76 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' TYR . . . . . 0.408 ' CE1' ' CD ' ' A' ' 38' ' ' GLU . 71.0 m-85 -99.06 129.97 45.36 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.831 0.348 . . . . 0.0 110.341 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -88.13 120.46 29.51 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 179.413 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 45.6 pt -127.17 158.6 38.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.455 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.075 -179.195 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 16.4 ttm180 -119.95 126.46 50.92 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 116.203 -0.453 . . . . 0.0 109.979 179.61 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 71.7 t80 -145.26 140.93 28.17 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.129 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 12.0 t-20 58.69 33.25 22.94 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.601 -179.873 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 71.34 3.98 55.09 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 179.614 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -107.65 150.32 27.04 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-O 120.685 0.278 . . . . 0.0 110.589 -179.818 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 55.1 t -116.4 131.94 67.46 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.226 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.36 -160.1 9.62 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.854 -0.898 . . . . 0.0 110.854 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 78.2 m-85 -132.85 157.5 44.89 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.835 0.35 . . . . 0.0 110.367 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -141.15 151.19 43.67 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.254 179.803 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 19.8 m -64.55 148.13 51.39 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.61 -179.678 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 26.6 pttm -79.36 -20.93 46.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.067 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 78.4 p -66.07 -37.88 86.91 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.465 -179.794 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' TYR . . . . . 0.538 ' C ' HD12 ' A' ' 59' ' ' ILE . 96.6 m-85 -97.03 -1.53 45.23 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 116.68 -0.237 . . . . 0.0 111.567 -179.119 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.538 HD12 ' C ' ' A' ' 58' ' ' TYR . 1.3 mp -113.51 130.86 66.77 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 96.2 m -121.02 127.84 52.12 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.002 179.508 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.3 mt -80.56 129.25 37.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.405 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 94.8 t . . . . . 0 C--N 1.327 -0.403 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.964 -179.67 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 . . . . . 0 N--CA 1.465 0.321 0 CA-C-O 120.959 0.409 . . . . 0.0 110.757 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -88.63 162.21 31.52 Favored Glycine 0 CA--C 1.521 0.466 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 179.319 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 95.4 t -125.62 129.2 72.74 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.575 0 CA-C-O 120.985 0.422 . . . . 0.0 110.086 179.759 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 16.3 t -87.05 127.96 40.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.418 -179.748 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 63.6 mttp -124.13 107.56 11.38 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.129 -0.487 . . . . 0.0 109.982 179.634 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.444 HG22 ' H ' ' A' ' 9' ' ' SER . 11.9 p -140.27 151.41 21.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.434 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.63 -179.748 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.532 ' OD1' ' N ' ' A' ' 9' ' ' SER . 30.4 p30 -61.67 -42.64 99.19 Favored 'General case' 0 C--N 1.333 -0.127 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.196 -179.526 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' SER . . . . . 0.532 ' N ' ' OD1' ' A' ' 8' ' ' ASN . 8.0 t -125.07 -67.19 0.92 Allowed 'General case' 0 N--CA 1.47 0.541 0 CA-C-O 120.617 0.246 . . . . 0.0 110.94 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -158.24 144.77 17.48 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.777 0.322 . . . . 0.0 110.649 -179.603 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 44.9 tp -106.77 125.98 51.7 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.076 179.681 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -79.53 143.57 34.72 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.438 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 48.4 ttp -109.4 151.46 26.64 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 116.057 -0.519 . . . . 0.0 109.731 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 94.4 mtt-85 -127.63 151.53 48.82 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-O 120.924 0.392 . . . . 0.0 110.313 -179.274 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 35.0 t -62.36 -41.79 98.89 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.818 -179.34 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -124.97 163.16 19.07 Favored Glycine 0 N--CA 1.471 0.985 0 N-CA-C 111.482 -0.647 . . . . 0.0 111.482 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -68.32 86.32 0.42 Allowed 'Trans proline' 0 N--CA 1.496 1.628 0 C-N-CA 122.485 2.123 . . . . 0.0 111.692 179.543 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 164.4 143.31 3.67 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 111.218 -0.753 . . . . 0.0 111.218 179.581 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 75.4 p -66.44 -16.18 63.91 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.851 0.358 . . . . 0.0 110.825 179.867 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 50.5 p30 -80.64 -2.38 46.3 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.565 -179.542 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 47.0 m-85 -89.7 -7.77 53.85 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-O 120.756 0.312 . . . . 0.0 110.554 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 71.55 168.38 9.37 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 179.553 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 7.5 p -94.77 128.16 46.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 CA-C-O 120.79 0.329 . . . . 0.0 110.537 179.795 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 43.6 pt -108.2 -6.62 10.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.702 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -173.02 169.33 42.49 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 111.325 -0.71 . . . . 0.0 111.325 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 92.1 m -123.3 135.01 54.01 Favored 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 67.9 mt -107.72 155.16 20.5 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-O 120.871 0.367 . . . . 0.0 110.499 -179.559 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 90.2 mtm-85 -105.25 165.75 10.89 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.595 -179.835 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.402 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 52.6 p-10 -69.53 149.0 48.7 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.181 -179.613 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 21.7 t-20 56.12 32.98 21.13 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 115.91 -0.586 . . . . 0.0 111.014 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -89.92 116.27 27.85 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-O 120.825 0.345 . . . . 0.0 110.645 179.587 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.565 ' HZ3' ' HB3' ' A' ' 32' ' ' LYS . 2.4 mmmp? -71.84 129.39 38.51 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.465 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.9 m -140.18 162.03 25.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.647 -179.496 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -104.89 121.06 42.91 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.353 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 89.3 mt -91.52 108.31 19.8 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.302 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 97.5 mt -67.41 -43.86 87.34 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.046 -0.524 . . . . 0.0 111.006 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 63.7 pttt -173.19 160.82 4.15 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.823 0.344 . . . . 0.0 111.001 -179.369 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -106.93 124.23 49.32 Favored 'General case' 0 N--CA 1.465 0.3 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 179.314 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 73.3 t -127.16 132.15 70.0 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 CA-C-O 120.952 0.406 . . . . 0.0 110.671 -179.436 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' ASP . . . . . 0.415 ' OD1' ' O ' ' A' ' 40' ' ' ASP . 36.1 t0 56.26 23.86 7.59 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.013 179.246 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.52 -10.02 74.95 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 111.016 -0.834 . . . . 0.0 111.016 179.705 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 34.3 m95 -91.21 149.26 21.85 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-O 120.751 0.31 . . . . 0.0 110.188 179.748 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 52.4 m-85 -99.94 130.84 46.16 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.136 -179.731 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 76.1 tt0 -98.29 120.24 38.36 Favored 'General case' 0 CA--C 1.518 -0.269 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 179.223 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 39.2 pt -126.05 160.21 33.44 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.321 0 CA-C-O 120.969 0.414 . . . . 0.0 110.983 -179.207 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 43.6 ttm180 -117.89 127.85 54.26 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-N 115.694 -0.685 . . . . 0.0 109.503 179.486 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 34.1 t80 -144.77 131.17 19.72 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-O 121.16 0.505 . . . . 0.0 111.11 -179.736 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 83.4 m-20 56.93 35.17 26.01 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 115.36 -0.837 . . . . 0.0 112.145 179.3 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 77.23 15.56 81.43 Favored Glycine 0 N--CA 1.465 0.592 0 C-N-CA 121.264 -0.493 . . . . 0.0 111.893 178.531 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -126.0 145.54 50.26 Favored 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 61.5 t -115.55 132.32 65.3 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.302 -179.732 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -149.67 -163.12 10.86 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 62.1 m-85 -132.86 160.27 37.46 Favored 'General case' 0 N--CA 1.466 0.347 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -149.72 159.17 44.57 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.04 0.448 . . . . 0.0 111.061 -179.617 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 18.4 p -69.54 148.89 48.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.696 -0.683 . . . . 0.0 110.304 179.885 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.415 ' O ' ' O ' ' A' ' 59' ' ' ILE . 59.0 pttt -82.59 -19.12 39.04 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.77 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 39.1 t -62.07 -42.39 99.15 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.954 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 90.5 m-85 -92.19 3.81 54.55 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.336 -179.171 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.415 ' O ' ' O ' ' A' ' 56' ' ' LYS . 98.1 mt -128.51 132.25 68.12 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 CA-C-O 120.699 0.285 . . . . 0.0 110.351 179.601 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 99.3 m -123.15 132.12 53.95 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.465 179.732 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 27.0 mm -80.45 129.46 37.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.063 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 35.7 m . . . . . 0 N--CA 1.469 0.476 0 CA-C-O 120.954 0.407 . . . . 0.0 110.427 -179.687 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 58.0 tt0 . . . . . 0 N--CA 1.467 0.388 0 CA-C-O 120.858 0.361 . . . . 0.0 110.231 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -93.16 155.2 22.22 Favored Glycine 0 CA--C 1.524 0.626 0 N-CA-C 111.054 -0.819 . . . . 0.0 111.054 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 59.9 t -128.01 132.14 68.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.698 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 18.0 t -88.74 127.74 41.38 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.087 179.694 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 64.7 mttp -124.57 105.81 9.65 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-O 120.912 0.386 . . . . 0.0 110.537 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 7.1 p -157.15 148.83 10.53 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-N 115.943 -0.572 . . . . 0.0 110.604 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.42 ' O ' ' ND2' ' A' ' 29' ' ' ASN . 92.9 m-20 -68.54 -50.84 48.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.937 0.399 . . . . 0.0 110.554 179.452 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 9.2 p -95.88 165.53 12.23 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.564 179.913 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -65.88 144.39 56.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.354 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 45.1 tp -111.22 132.78 54.07 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-O 120.972 0.415 . . . . 0.0 110.67 -179.794 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 84.7 m-20 -78.02 146.26 35.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.892 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 40.0 ttp -98.11 148.66 23.32 Favored 'General case' 0 C--O 1.233 0.201 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.616 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 84.9 mtt85 -123.32 157.75 32.55 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 120.715 0.293 . . . . 0.0 110.493 -179.23 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' SER . . . . . 0.508 ' N ' HD11 ' A' ' 24' ' ' ILE . 88.5 p -84.11 -13.11 53.84 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.972 -179.321 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -162.31 -172.58 29.92 Favored Glycine 0 CA--C 1.529 0.952 0 C-N-CA 120.846 -0.692 . . . . 0.0 111.388 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -80.0 78.95 3.49 Favored 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.771 2.314 . . . . 0.0 112.143 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 167.4 134.12 1.65 Allowed Glycine 0 CA--C 1.524 0.603 0 C-N-CA 120.68 -0.771 . . . . 0.0 111.448 179.713 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 95.7 p -71.2 -12.3 61.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.95 0.405 . . . . 0.0 110.215 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 52.1 p-10 -78.91 -4.63 50.72 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.692 -179.822 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -85.85 -1.62 57.44 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.291 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 71.6 178.5 29.75 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 110.724 -0.95 . . . . 0.0 110.724 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 9.2 p -107.4 134.52 48.89 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.37 0 CA-C-O 120.861 0.362 . . . . 0.0 110.474 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.508 HD11 ' N ' ' A' ' 15' ' ' SER . 3.5 mp -106.0 -12.01 9.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.52 -179.758 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -173.55 -170.66 37.3 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 110.8 -0.92 . . . . 0.0 110.8 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 82.0 p -131.84 152.21 51.16 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 120.737 0.303 . . . . 0.0 110.302 179.846 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 78.5 mt -122.7 146.29 47.63 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.07 -0.514 . . . . 0.0 109.841 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -106.84 164.52 12.04 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.877 -179.364 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.42 ' ND2' ' O ' ' A' ' 8' ' ' ASN . 2.9 m-20 -64.07 148.93 48.66 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.671 -179.836 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 58.96 32.71 22.51 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.324 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 16.5 m-20 -82.0 137.38 35.12 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.113 179.02 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 63.3 mttp -104.99 122.73 46.46 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.858 0.361 . . . . 0.0 110.317 179.55 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.6 m -138.69 161.61 29.95 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.185 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.12 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -99.03 132.74 44.11 Favored 'General case' 0 C--O 1.234 0.287 0 N-CA-C 109.727 -0.472 . . . . 0.0 109.727 179.689 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.2 mt -100.71 107.5 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.309 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.8 mt -66.55 -43.87 90.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.89 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 63.6 pttt -173.05 169.98 4.52 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.829 -179.41 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' GLU . . . . . 0.429 ' CD ' ' CE1' ' A' ' 43' ' ' TYR . 83.1 tt0 -111.91 126.29 54.96 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.646 179.591 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 76.3 t -126.79 131.91 70.61 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 CA-C-O 121.07 0.462 . . . . 0.0 111.133 -179.438 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 52.65 30.42 8.68 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.661 -0.7 . . . . 0.0 111.759 178.958 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.14 -18.02 47.66 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 111.651 -0.58 . . . . 0.0 111.651 179.204 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 40.3 m95 -85.95 145.23 27.23 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.845 0.355 . . . . 0.0 110.244 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' TYR . . . . . 0.429 ' CE1' ' CD ' ' A' ' 38' ' ' GLU . 72.7 m-85 -100.75 126.99 47.34 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.481 -179.642 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 79.2 tt0 -78.54 152.42 31.95 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 179.715 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.4 pt -144.04 153.36 15.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.679 0.276 . . . . 0.0 110.854 -179.702 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 76.3 ttt180 -121.16 123.32 42.0 Favored 'General case' 0 N--CA 1.468 0.454 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.265 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 74.5 t80 -142.08 125.8 16.96 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-O 120.884 0.373 . . . . 0.0 110.885 -179.444 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.535 ' ND2' ' O ' ' A' ' 48' ' ' ASN . 3.8 t30 54.8 35.97 25.37 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.999 179.766 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 73.01 15.19 78.52 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 111.145 -0.782 . . . . 0.0 111.145 179.521 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.9 ttmp? -112.43 147.93 35.42 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 110.228 -0.286 . . . . 0.0 110.228 179.771 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.0 t -110.2 132.85 57.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.933 0.397 . . . . 0.0 110.32 -179.785 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' GLY . . . . . 0.467 ' C ' ' CD1' ' A' ' 53' ' ' TYR . . . -148.63 -165.02 11.84 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 179.823 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' TYR . . . . . 0.467 ' CD1' ' C ' ' A' ' 52' ' ' GLY . 72.9 m-85 -146.46 157.81 43.81 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.729 0.299 . . . . 0.0 110.456 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -141.63 155.72 45.7 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.398 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' SER . . . . . 0.403 ' O ' ' CG1' ' A' ' 59' ' ' ILE . 18.1 m -69.41 147.87 50.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.031 -179.623 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 62.0 pttt -66.34 -34.69 78.53 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.233 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 37.1 m -61.56 -41.11 96.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.706 -179.205 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 89.1 m-85 -94.22 7.64 44.57 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 116.518 -0.31 . . . . 0.0 111.002 -179.285 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.403 ' CG1' ' O ' ' A' ' 55' ' ' SER . 5.3 mm -122.4 128.77 75.54 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-O 121.119 0.485 . . . . 0.0 110.293 179.637 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 86.8 m -122.56 126.89 48.67 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.512 -179.9 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.6 mt -91.22 127.9 43.32 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.497 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 33.2 m . . . . . 0 C--N 1.33 -0.256 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.437 179.873 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.8 mt-30 . . . . . 0 N--CA 1.464 0.265 0 CA-C-O 120.799 0.333 . . . . 0.0 110.131 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -84.69 164.88 39.81 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 -179.605 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 57.2 t -123.91 133.62 68.76 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.394 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 72.4 t -100.88 127.85 53.62 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-O 120.876 0.37 . . . . 0.0 110.314 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 68.8 mmtt -119.58 106.41 12.17 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.559 179.423 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.495 ' O ' ' ND2' ' A' ' 29' ' ' ASN . 28.0 m -131.41 160.05 42.62 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.302 -179.456 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 52.8 t-20 -63.59 -41.67 98.34 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.097 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 4.3 t -150.7 -53.33 0.14 Allowed 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.464 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -157.64 142.88 16.96 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.422 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.473 HD22 ' CG ' ' A' ' 58' ' ' TYR . 65.1 tp -125.46 135.68 52.59 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 116.1 -0.5 . . . . 0.0 109.92 -179.802 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 -77.93 138.83 39.09 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.197 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 50.5 ttp -98.11 138.59 35.18 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.074 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' ARG . . . . . 0.491 ' HE ' ' HA ' ' A' ' 19' ' ' SER . 22.0 mmt180 -103.9 156.96 17.42 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.517 -178.675 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' SER . . . . . 0.421 ' OG ' HG21 ' A' ' 24' ' ' ILE . 4.6 m -83.07 -7.68 59.62 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.76 -179.636 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -159.23 -169.63 22.8 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -83.24 72.21 5.82 Favored 'Trans proline' 0 C--N 1.304 -1.777 0 C-N-CA 122.659 2.239 . . . . 0.0 111.857 -179.755 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.78 147.81 6.34 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 111.104 -0.799 . . . . 0.0 111.104 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' SER . . . . . 0.491 ' HA ' ' HE ' ' A' ' 14' ' ' ARG . 15.7 m -81.47 -11.64 59.15 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.948 0.404 . . . . 0.0 110.728 -179.82 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 28.6 t-20 -84.14 7.06 20.09 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.979 -179.693 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 49.9 m-85 -92.71 -0.23 57.32 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 120.772 0.32 . . . . 0.0 110.414 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 75.62 179.22 44.61 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.451 ' O ' HG13 ' A' ' 23' ' ' VAL . 7.2 p -108.84 125.31 65.85 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-O 120.826 0.345 . . . . 0.0 110.621 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.421 HG21 ' OG ' ' A' ' 15' ' ' SER . 41.2 pt -108.66 -4.51 10.58 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.809 179.852 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -172.96 170.76 43.9 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 111.116 -0.793 . . . . 0.0 111.116 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 86.4 m -128.64 138.02 51.96 Favored 'General case' 0 N--CA 1.472 0.635 0 CA-C-O 120.494 0.187 . . . . 0.0 110.541 -179.673 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 77.4 mt -110.18 143.7 39.92 Favored 'General case' 0 N--CA 1.476 0.844 0 N-CA-C 112.12 0.415 . . . . 0.0 112.12 -178.793 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 49.2 mtt-85 -105.24 167.76 9.52 Favored 'General case' 0 N--CA 1.477 0.88 0 CA-C-O 121.773 0.797 . . . . 0.0 111.812 -179.079 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.495 ' ND2' ' O ' ' A' ' 7' ' ' VAL . 1.3 m-20 -64.32 146.17 54.83 Favored 'General case' 0 N--CA 1.437 -1.107 0 CA-C-N 114.993 -1.003 . . . . 0.0 108.976 -179.055 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 89.6 m-20 57.07 34.41 24.86 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.287 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 67.1 t0 -88.27 110.39 20.7 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 110.016 -0.364 . . . . 0.0 110.016 179.329 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -78.61 132.67 37.19 Favored 'General case' 0 C--N 1.331 -0.212 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 -179.811 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 28.9 m -139.88 162.05 25.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.657 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -99.89 131.55 45.79 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.19 -0.459 . . . . 0.0 109.811 179.393 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 86.7 mt -96.65 126.77 49.26 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-N 116.33 -0.396 . . . . 0.0 111.022 -179.245 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 18.5 mm -94.71 -62.97 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.427 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 22.2 mtmm -148.33 159.78 43.65 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 120.918 0.39 . . . . 0.0 111.018 179.756 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -111.81 123.34 50.03 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.339 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 72.0 t -127.47 132.47 69.29 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.604 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 55.23 30.7 15.1 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.143 179.25 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.5 -16.6 34.3 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 111.02 -0.832 . . . . 0.0 111.02 179.711 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.616 ' CZ2' ' OG ' ' A' ' 55' ' ' SER . 11.7 m95 -83.58 147.37 27.78 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 179.423 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 46.2 m-85 -100.83 130.34 46.84 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 121.047 0.451 . . . . 0.0 110.941 -179.609 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -87.1 122.74 31.33 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 178.805 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 39.1 pt -130.59 161.62 40.12 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.407 0 CA-C-O 121.176 0.512 . . . . 0.0 111.537 -178.601 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 13.6 ttt180 -118.7 123.66 45.44 Favored 'General case' 0 N--CA 1.464 0.275 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.332 179.432 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 87.4 t80 -144.39 135.97 25.74 Favored 'General case' 0 N--CA 1.473 0.713 0 CA-C-O 120.824 0.345 . . . . 0.0 111.322 -178.401 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.577 ' ND2' ' O ' ' A' ' 48' ' ' ASN . 2.7 t30 57.51 34.84 25.14 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.7 179.347 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 69.45 18.46 73.56 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 179.77 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -124.67 146.14 49.29 Favored 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 66.5 t -113.99 131.56 65.56 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.389 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' GLY . . . . . 0.405 ' C ' ' CD1' ' A' ' 53' ' ' TYR . . . -150.47 -164.6 12.02 Favored Glycine 0 CA--C 1.52 0.39 0 N-CA-C 110.664 -0.974 . . . . 0.0 110.664 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' TYR . . . . . 0.427 ' CD1' ' N ' ' A' ' 53' ' ' TYR . 28.4 m-85 -134.96 156.71 48.54 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.796 0.332 . . . . 0.0 110.54 -179.737 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -146.67 150.6 35.73 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.028 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' SER . . . . . 0.616 ' OG ' ' CZ2' ' A' ' 42' ' ' TRP . 37.8 m -70.39 142.0 52.13 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 177.81 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 64.4 pttt -68.2 -13.07 61.96 Favored 'General case' 0 CA--C 1.51 -0.578 0 CA-C-O 121.8 0.809 . . . . 0.0 108.847 178.84 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 87.8 p -56.29 -14.0 2.55 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 114.015 -1.448 . . . . 0.0 109.321 178.862 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' TYR . . . . . 0.473 ' CG ' HD22 ' A' ' 11' ' ' LEU . 91.7 m-85 -127.16 -28.26 2.88 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.202 179.816 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.593 ' N ' HD12 ' A' ' 59' ' ' ILE . 1.3 mp -90.1 129.29 41.21 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 179.162 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 87.5 m -123.81 129.34 50.89 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.388 -179.881 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.741 ' N ' HD12 ' A' ' 61' ' ' ILE . 1.7 mp -83.0 128.14 39.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.286 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 15.7 m . . . . . 0 C--N 1.328 -0.336 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.319 179.807 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 78.2 mt-30 . . . . . 0 N--CA 1.463 0.209 0 CA-C-O 120.841 0.353 . . . . 0.0 110.204 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -87.18 158.1 29.91 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 97.7 t -127.65 133.3 67.93 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 179.703 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 71.9 t -93.33 128.2 44.92 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-N 116.46 -0.337 . . . . 0.0 110.392 -179.884 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 65.5 mttp -132.02 107.01 8.38 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.453 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.512 HG22 ' H ' ' A' ' 9' ' ' SER . 4.0 p -138.79 154.03 26.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.162 -179.897 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 92.1 m-20 -62.06 -42.85 99.62 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-O 120.83 0.348 . . . . 0.0 111.235 -178.991 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' SER . . . . . 0.512 ' H ' HG22 ' A' ' 7' ' ' VAL . 85.2 p -136.76 -153.84 0.52 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.035 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -66.98 143.15 56.97 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.017 0.437 . . . . 0.0 110.545 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.401 HD22 ' CG ' ' A' ' 58' ' ' TYR . 47.2 tp -122.0 130.46 53.32 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.062 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' ASN . . . . . 0.425 ' O ' ' OD1' ' A' ' 12' ' ' ASN . 45.1 p30 -82.12 140.53 33.76 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.693 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 58.1 ttp -108.33 138.65 44.25 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.215 -0.448 . . . . 0.0 109.869 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 4.3 mpt_? -106.45 157.37 17.69 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 120.983 0.42 . . . . 0.0 111.233 -178.939 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 84.2 p -82.27 -6.22 59.08 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.243 179.732 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -162.36 -174.86 32.76 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.765 -0.934 . . . . 0.0 110.765 179.762 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -80.94 79.09 3.41 Favored 'Trans proline' 0 C--N 1.306 -1.692 0 C-N-CA 122.86 2.373 . . . . 0.0 111.926 179.766 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 171.03 137.17 2.24 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 94.9 p -74.64 -7.7 54.04 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.764 0.316 . . . . 0.0 110.857 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 89.5 m-20 -89.01 5.6 43.54 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.069 -179.414 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 42.7 m-85 -91.31 -0.56 57.68 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.869 0.366 . . . . 0.0 110.208 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 73.28 174.43 27.89 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.48 ' O ' HG13 ' A' ' 23' ' ' VAL . 11.7 p -105.64 125.34 60.99 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-O 120.894 0.378 . . . . 0.0 110.412 179.743 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 40.8 pt -101.81 -4.75 9.26 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.758 -179.855 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -174.3 174.08 46.29 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 89.7 m -125.17 132.21 53.09 Favored 'General case' 0 N--CA 1.464 0.226 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.627 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 72.1 mt -108.09 143.93 36.16 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 116.194 -0.457 . . . . 0.0 109.968 -179.759 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 37.8 ttt85 -119.51 142.62 48.15 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.171 0.51 . . . . 0.0 110.26 179.42 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 44.0 p-10 -48.26 165.09 0.04 OUTLIER 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.65 -0.704 . . . . 0.0 111.0 -179.766 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 65.8 t30 62.8 6.48 2.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.554 -0.748 . . . . 0.0 111.366 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 31.5 t0 -87.13 118.68 26.68 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.548 -0.297 . . . . 0.0 110.663 179.517 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -76.3 137.39 39.86 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.2 179.471 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.2 m -137.39 162.05 33.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.62 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 48.4 tp10 -105.84 123.65 48.3 Favored 'General case' 0 C--O 1.234 0.274 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 179.581 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.5 mt -91.38 127.8 43.52 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.123 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.94 -179.355 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 81.9 mt -91.4 -51.27 11.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.176 179.597 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 62.6 pttt -174.9 179.0 1.71 Allowed 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.558 179.705 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -112.84 125.06 53.95 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.219 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.408 HG21 ' OE2' ' A' ' 44' ' ' GLU . 79.5 t -124.93 129.74 73.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.28 -179.859 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 40' ' ' ASP . . . . . 0.44 ' OD1' ' O ' ' A' ' 40' ' ' ASP . 55.2 t0 54.74 24.28 5.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.071 179.362 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.86 -5.62 84.66 Favored Glycine 0 CA--C 1.526 0.753 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 179.739 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 56.4 m95 -90.52 149.38 22.2 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 179.364 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -96.88 130.35 44.18 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-O 121.098 0.475 . . . . 0.0 110.137 -179.669 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' GLU . . . . . 0.408 ' OE2' HG21 ' A' ' 39' ' ' VAL . 97.4 mt-10 -94.47 126.51 39.79 Favored 'General case' 0 CA--C 1.506 -0.714 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.018 179.369 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 44.3 pt -125.93 160.76 32.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 121.356 0.598 . . . . 0.0 110.249 179.626 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 3.2 ttp180 -126.89 113.89 17.14 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 114.777 -1.101 . . . . 0.0 109.624 -176.763 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 61.8 t80 -141.51 139.1 33.2 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 120.947 0.403 . . . . 0.0 111.605 -178.111 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 15.0 t-20 57.13 34.62 25.15 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.904 179.298 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 69.74 20.71 76.08 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 111.431 -0.668 . . . . 0.0 111.431 179.52 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 53.9 mtmt -131.23 143.58 50.68 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-O 120.688 0.28 . . . . 0.0 110.823 -179.81 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 19.8 t -102.26 111.8 33.29 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 CA-C-O 121.115 0.483 . . . . 0.0 110.656 179.535 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -107.55 -172.69 22.17 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 111.053 -0.819 . . . . 0.0 111.053 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 48.1 m-85 -132.3 142.36 49.33 Favored 'General case' 0 C--N 1.331 -0.233 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 179.624 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -154.29 153.0 30.93 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.404 -179.893 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 48.5 t -70.1 148.15 49.1 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.787 -179.887 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 63.9 pttt -64.2 -17.65 63.75 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.73 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 38.6 t -65.7 -18.22 65.17 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.395 -179.669 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' TYR . . . . . 0.6 ' C ' HD12 ' A' ' 59' ' ' ILE . 71.7 m-85 -105.73 -19.16 13.84 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 121.271 -0.172 . . . . 0.0 111.323 -179.554 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.64 ' N ' HD12 ' A' ' 59' ' ' ILE . 1.9 mp -109.87 130.99 62.04 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 CA-C-O 121.159 0.504 . . . . 0.0 110.631 -179.68 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 88.6 m -116.12 127.06 54.53 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-N 115.49 -0.777 . . . . 0.0 109.824 179.644 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.4 mt -78.91 133.21 30.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.774 -179.593 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 75.1 t . . . . . 0 C--N 1.332 -0.173 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.087 -179.907 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 . . . . . 0 N--CA 1.465 0.319 0 CA-C-O 120.884 0.373 . . . . 0.0 110.517 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -94.83 150.5 19.74 Favored Glycine 0 CA--C 1.521 0.452 0 N-CA-C 110.474 -1.05 . . . . 0.0 110.474 179.466 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 55.4 t -119.15 131.12 72.79 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 89.1 t -83.51 129.44 37.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.322 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 19.7 mmmt -115.35 106.27 13.82 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.128 179.903 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.507 HG22 ' H ' ' A' ' 9' ' ' SER . 3.2 p -141.7 144.5 25.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.062 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 19.3 m120 -63.04 -41.26 99.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.091 -179.607 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' SER . . . . . 0.507 ' H ' HG22 ' A' ' 7' ' ' VAL . 44.4 m -133.03 -96.15 0.31 Allowed 'General case' 0 N--CA 1.466 0.363 0 CA-C-O 120.891 0.377 . . . . 0.0 110.402 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -112.97 143.65 43.89 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.409 179.886 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.549 HD13 ' CD2' ' A' ' 58' ' ' TYR . 42.8 tp -116.97 128.69 55.44 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 120.985 0.421 . . . . 0.0 110.086 179.835 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -82.94 138.64 33.74 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.478 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 37.5 ttp -103.63 152.11 22.14 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.294 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' ARG . . . . . 0.432 ' NH1' ' HG3' ' A' ' 14' ' ' ARG . 1.9 mtt85 -129.82 155.33 46.15 Favored 'General case' 0 CA--C 1.543 0.697 0 N-CA-C 109.198 -0.667 . . . . 0.0 109.198 -178.871 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 86.2 p -84.39 -4.92 59.18 Favored 'General case' 0 N--CA 1.478 0.936 0 N-CA-C 113.291 0.849 . . . . 0.0 113.291 -179.536 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -162.64 158.05 30.15 Favored Glycine 0 CA--C 1.524 0.63 0 C-N-CA 120.367 -0.921 . . . . 0.0 110.842 -179.073 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -64.5 87.61 0.16 Allowed 'Trans proline' 0 C--N 1.307 -1.622 0 C-N-CA 122.273 1.982 . . . . 0.0 111.64 -179.803 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 157.75 136.96 2.18 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 111.012 -0.835 . . . . 0.0 111.012 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 32.6 t -65.41 -13.13 58.0 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.777 0.322 . . . . 0.0 110.702 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -75.71 -3.7 36.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.254 -179.284 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 40.6 m-85 -90.0 -5.66 56.43 Favored 'General case' 0 C--N 1.332 -0.169 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.479 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 66.88 178.92 10.36 Favored Glycine 0 CA--C 1.522 0.477 0 N-CA-C 110.634 -0.986 . . . . 0.0 110.634 179.87 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.447 ' O ' HG13 ' A' ' 23' ' ' VAL . 8.3 p -103.07 126.3 57.39 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.163 0 CA-C-O 120.783 0.325 . . . . 0.0 110.279 179.595 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 25.5 pt -101.97 -4.61 9.29 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.783 -179.677 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 175.35 -176.14 47.27 Favored Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 -179.866 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 59.6 p -134.87 158.67 43.64 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-O 120.848 0.356 . . . . 0.0 110.758 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 71.5 mt -122.63 150.39 42.72 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.015 -179.899 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.729 HH11 ' HG3' ' A' ' 28' ' ' ARG . 1.0 OUTLIER -94.56 160.96 14.4 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 -179.24 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.427 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 51.7 p30 -64.97 150.48 47.94 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.614 -178.791 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 56.2 t-20 59.61 32.08 21.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.69 -0.687 . . . . 0.0 111.514 179.555 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.518 ' OD2' ' N ' ' A' ' 28' ' ' ARG . 77.5 m-20 -82.78 136.85 34.55 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 179.22 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 53.0 mtmt -107.88 122.25 46.41 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.13 179.299 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.7 m -135.95 162.35 36.63 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.416 -179.876 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -85.82 129.82 34.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.269 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.6 mt -100.19 121.38 50.85 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.265 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.328 179.889 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 77.8 mt -83.99 -46.95 18.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.103 -179.832 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 62.1 pttt -174.79 163.28 3.37 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.749 -179.602 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -107.21 124.44 49.74 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.305 179.861 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 77.4 t -124.42 130.2 73.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.616 -179.578 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.5 m-20 53.97 27.06 6.92 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.022 179.508 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.33 -11.38 67.98 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 111.201 -0.76 . . . . 0.0 111.201 179.595 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 72.9 m95 -87.65 148.68 24.7 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 110.118 -0.327 . . . . 0.0 110.118 179.747 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 7.0 m-85 -103.56 132.25 49.98 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-O 121.099 0.476 . . . . 0.0 110.581 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -93.73 121.89 35.62 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 178.307 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 41.6 pt -127.53 157.9 39.14 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-O 120.922 0.391 . . . . 0.0 111.284 -178.803 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 38.6 ttm180 -112.05 119.65 39.18 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.699 179.51 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 39.9 t80 -138.92 132.28 30.11 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.52 -179.433 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 64.3 t30 58.38 34.58 24.13 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.821 179.813 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 72.85 5.93 66.05 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.985 -0.846 . . . . 0.0 110.985 179.614 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 62.2 tttp -114.18 146.31 40.53 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.721 0.296 . . . . 0.0 110.576 -179.498 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 53.9 t -113.12 130.9 66.2 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.015 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -145.19 -161.7 9.21 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 110.978 -0.849 . . . . 0.0 110.978 -179.664 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 65.2 m-85 -122.15 157.08 32.31 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-O 120.662 0.268 . . . . 0.0 110.346 -179.852 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.44 ' CB ' HD11 ' A' ' 59' ' ' ILE . . . -144.59 154.68 43.1 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.63 -179.694 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 47.6 t -68.27 133.9 49.53 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.231 -179.46 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -65.5 -44.7 86.23 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.537 179.79 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 35.8 t -57.11 -19.11 17.86 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.255 -178.584 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' TYR . . . . . 0.549 ' CD2' HD13 ' A' ' 11' ' ' LEU . 43.1 m-85 -103.57 6.31 37.2 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 116.504 -0.316 . . . . 0.0 111.218 -179.699 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.44 HD11 ' CB ' ' A' ' 54' ' ' ALA . 96.7 mt -131.82 132.23 61.81 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 CA-C-O 121.098 0.475 . . . . 0.0 111.455 179.756 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 92.5 m -123.41 130.55 52.87 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.085 179.33 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 22.1 mm -82.17 130.28 36.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.614 -179.781 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 99.5 t . . . . . 0 C--N 1.327 -0.371 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.449 -179.949 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 99.4 mt-30 . . . . . 0 N--CA 1.464 0.261 0 CA-C-O 120.764 0.316 . . . . 0.0 110.385 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -93.41 139.32 14.53 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.449 -1.06 . . . . 0.0 110.449 179.608 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 54.2 t -122.38 131.99 72.04 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.254 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 179.899 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 84.6 t -90.01 128.6 41.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.592 -179.431 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 55.4 mtpt -125.05 105.95 9.57 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.032 -0.531 . . . . 0.0 109.848 179.402 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 11.3 p -139.14 155.28 26.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.037 -179.61 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 23.4 t-20 -61.2 -41.24 96.49 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.144 -179.241 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 4.8 t -140.02 -62.78 0.51 Allowed 'General case' 0 N--CA 1.466 0.364 0 CA-C-O 120.747 0.308 . . . . 0.0 111.07 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -150.49 144.22 25.23 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.617 -179.63 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 50.8 tp -120.64 134.6 55.27 Favored 'General case' 0 N--CA 1.469 0.48 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.097 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' ASN . . . . . 0.426 ' O ' ' OD1' ' A' ' 12' ' ' ASN . 50.5 p-10 -81.47 140.11 34.79 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.669 -179.879 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 42.4 ttp -101.13 153.79 19.28 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.065 -179.706 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' ARG . . . . . 0.851 ' HG3' HH11 ' A' ' 14' ' ' ARG . 22.2 mtm-85 -125.83 156.83 38.95 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-O 121.381 0.61 . . . . 0.0 112.233 -178.196 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 94.0 p -80.52 -6.26 57.93 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.062 -0.972 . . . . 0.0 110.052 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -159.48 -171.0 24.75 Favored Glycine 0 CA--C 1.525 0.716 0 N-CA-C 110.942 -0.863 . . . . 0.0 110.942 179.678 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -87.05 6.99 5.04 Favored 'Trans proline' 0 C--N 1.305 -1.747 0 C-N-CA 122.744 2.296 . . . . 0.0 111.997 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -99.75 128.71 9.66 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 111.134 -0.787 . . . . 0.0 111.134 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 97.6 p -67.24 -10.33 49.55 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.786 0.327 . . . . 0.0 110.297 179.642 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 54.9 p30 -91.55 8.12 38.13 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.33 -179.574 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 19.6 m-85 -87.13 -5.59 58.96 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.904 0.383 . . . . 0.0 110.322 -179.896 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 72.53 177.14 30.45 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 111.587 -0.605 . . . . 0.0 111.587 179.039 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.41 ' O ' HG13 ' A' ' 23' ' ' VAL . 7.2 p -97.54 126.96 50.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-O 120.844 0.354 . . . . 0.0 110.539 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 42.7 pt -106.88 -6.44 10.35 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.542 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.26 175.39 47.15 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 88.5 m -125.45 134.74 51.98 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-O 120.891 0.377 . . . . 0.0 110.337 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 82.1 mt -105.63 148.31 27.49 Favored 'General case' 0 CA--C 1.516 -0.334 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.891 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 31.8 mmm-85 -103.06 161.64 13.6 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.366 -0.834 . . . . 0.0 110.888 -179.098 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.428 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 25.5 p30 -65.71 143.02 57.8 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-O 121.186 0.517 . . . . 0.0 111.271 -179.362 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 66.3 t30 57.26 34.55 24.94 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.761 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 67.3 t0 -84.73 115.01 22.46 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.775 179.379 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 29.9 mmtp -72.7 128.37 35.34 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.89 0.376 . . . . 0.0 110.387 -179.329 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.3 m -137.81 161.24 33.29 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.222 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.15 179.832 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.531 ' N ' ' OE1' ' A' ' 34' ' ' GLU . 55.9 mp0 -106.54 123.69 48.47 Favored 'General case' 0 C--O 1.234 0.248 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.091 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 95.2 mt -88.52 128.07 41.01 Favored 'Isoleucine or valine' 0 C--O 1.232 0.153 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.45 -179.719 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 95.9 mt -98.19 -56.62 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.22 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.026 -179.763 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 47.1 mtpt -143.13 153.16 42.61 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 121.2 0.524 . . . . 0.0 111.262 -179.497 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' GLU . . . . . 0.438 ' CD ' ' CE1' ' A' ' 43' ' ' TYR . 84.3 tt0 -115.47 120.72 40.45 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.747 179.159 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 60.1 t -128.89 131.95 67.86 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.51 0 CA-C-O 120.899 0.381 . . . . 0.0 111.558 -179.48 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 54.11 26.47 6.59 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.35 179.285 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.86 -14.05 64.33 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 179.589 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 46.1 m95 -83.59 144.01 29.75 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 179.499 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' TYR . . . . . 0.438 ' CE1' ' CD ' ' A' ' 38' ' ' GLU . 65.0 m-85 -103.31 130.35 50.56 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.931 0.396 . . . . 0.0 110.676 -179.809 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 79.4 tt0 -90.08 122.5 33.11 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 179.312 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 24.1 pt -128.72 159.04 40.95 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-O 120.732 0.301 . . . . 0.0 111.309 -178.819 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.439 ' HB2' ' HE ' ' A' ' 46' ' ' ARG . 9.4 ttm180 -118.01 128.65 54.98 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.271 -0.422 . . . . 0.0 109.957 179.553 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 42.1 t80 -146.54 135.28 22.25 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.557 -179.358 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 96.2 m-20 56.53 33.82 23.27 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.838 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 73.82 6.33 72.24 Favored Glycine 0 CA--C 1.525 0.716 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 179.576 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 56.4 mtpt -110.41 147.52 33.84 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 120.644 0.259 . . . . 0.0 110.419 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 55.7 t -117.9 131.43 70.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 CA-C-N 116.274 -0.421 . . . . 0.0 109.956 179.674 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -149.4 -160.98 9.48 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.382 -1.087 . . . . 0.0 110.382 -179.914 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 67.6 m-85 -135.22 158.18 45.02 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.933 0.397 . . . . 0.0 110.766 -179.586 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -146.84 155.83 42.64 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.309 -179.848 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 20.2 m -69.77 151.46 45.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.792 -179.559 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 22.6 pttp -75.13 -18.83 60.15 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.718 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 74.7 m -61.85 -42.94 99.66 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.699 -179.589 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' TYR . . . . . 0.581 ' C ' HD12 ' A' ' 59' ' ' ILE . 82.8 m-85 -96.73 -2.38 44.55 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.524 0.202 . . . . 0.0 111.395 -179.187 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.581 HD12 ' C ' ' A' ' 58' ' ' TYR . 1.6 mp -113.86 128.66 70.68 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 179.46 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 91.7 m -124.88 130.35 52.21 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.055 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 22.1 mm -78.46 129.61 37.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.353 -179.593 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 94.1 t . . . . . 0 C--N 1.332 -0.182 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.616 -179.908 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 85.8 mt-30 . . . . . 0 N--CA 1.464 0.238 0 N-CA-C 109.897 -0.409 . . . . 0.0 109.897 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -88.59 149.74 21.31 Favored Glycine 0 CA--C 1.523 0.576 0 N-CA-C 111.279 -0.728 . . . . 0.0 111.279 -179.529 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 53.8 t -126.65 132.55 70.06 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 179.818 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 83.0 t -91.11 128.76 42.71 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.196 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.359 179.757 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -125.63 106.46 9.76 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.318 179.904 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.547 HG22 ' H ' ' A' ' 9' ' ' SER . 3.0 p -138.02 145.4 28.79 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 116.263 -0.426 . . . . 0.0 109.862 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.526 ' OD1' ' N ' ' A' ' 9' ' ' SER . 38.7 p-10 -62.39 -41.18 98.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.776 -179.57 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' SER . . . . . 0.547 ' H ' HG22 ' A' ' 7' ' ' VAL . 6.9 t -123.28 -141.33 0.31 Allowed 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.424 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -92.73 144.15 25.59 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.491 179.788 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.408 ' CD1' ' CG ' ' A' ' 58' ' ' TYR . 6.4 tt -121.57 134.42 55.02 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.594 -179.828 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 92.2 m-20 -75.88 134.62 40.25 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.226 -179.412 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 27.4 ttt -89.05 152.68 21.53 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-N 115.847 -0.615 . . . . 0.0 109.485 179.104 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 84.2 mtt85 -124.71 144.35 50.27 Favored 'General case' 0 N--CA 1.478 0.971 0 CA-C-O 120.449 0.166 . . . . 0.0 111.026 -179.752 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' SER . . . . . 0.467 ' HA ' HD11 ' A' ' 24' ' ' ILE . 23.2 t -89.11 -2.18 58.42 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.909 0.385 . . . . 0.0 110.452 179.3 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -163.41 160.29 32.95 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.35 -1.1 . . . . 0.0 110.35 179.779 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_endo -62.69 99.02 0.2 Allowed 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.368 2.045 . . . . 0.0 111.891 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 135.35 141.82 4.44 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 110.573 -1.011 . . . . 0.0 110.573 179.932 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 35.3 t -67.53 -16.0 63.96 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.78 0.324 . . . . 0.0 110.725 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 52.6 t30 -84.87 8.38 17.63 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.687 -179.05 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 39.5 m-85 -96.85 8.24 44.82 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-O 120.766 0.317 . . . . 0.0 110.31 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 85.07 176.52 50.79 Favored Glycine 0 CA--C 1.522 0.502 0 N-CA-C 111.355 -0.698 . . . . 0.0 111.355 179.663 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.489 HG22 ' H ' ' A' ' 25' ' ' GLY . 14.8 p -121.27 133.84 66.57 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 CA-C-O 120.669 0.271 . . . . 0.0 110.397 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.467 HD11 ' HA ' ' A' ' 15' ' ' SER . 94.8 mt -92.93 -15.25 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-O 120.869 0.366 . . . . 0.0 110.589 -179.696 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.489 ' H ' HG22 ' A' ' 23' ' ' VAL . . . 157.35 -145.59 12.22 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 110.668 -0.973 . . . . 0.0 110.668 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 71.2 p -133.71 155.13 50.29 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-O 120.977 0.418 . . . . 0.0 110.309 179.75 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 85.0 mt -124.67 146.57 49.06 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.227 -179.79 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.408 ' N ' ' OD2' ' A' ' 31' ' ' ASP . 31.8 mtp85 -107.47 170.06 8.2 Favored 'General case' 0 CA--C 1.506 -0.714 0 CA-C-O 121.575 0.702 . . . . 0.0 111.206 -179.771 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 56.9 p30 -69.37 157.17 37.57 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 114.466 -1.243 . . . . 0.0 110.761 179.083 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 43.7 m-20 59.29 31.49 21.2 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 114.921 -1.036 . . . . 0.0 111.085 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.408 ' OD2' ' N ' ' A' ' 28' ' ' ARG . 98.5 m-20 -93.56 111.13 22.74 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-O 120.696 0.284 . . . . 0.0 110.419 179.343 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 56.2 mtpt -73.64 133.91 43.54 Favored 'General case' 0 C--N 1.328 -0.363 0 C-N-CA 120.639 -0.424 . . . . 0.0 109.986 179.599 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.7 m -136.59 160.9 37.33 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 120.84 0.353 . . . . 0.0 110.674 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -107.86 119.11 38.54 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 116.121 -0.491 . . . . 0.0 109.808 179.395 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.461 ' C ' HD12 ' A' ' 36' ' ' ILE . 97.0 mt -84.07 126.88 40.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.604 -179.533 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.707 ' N ' HD12 ' A' ' 36' ' ' ILE . 1.6 mp -94.33 -65.43 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.195 0 CA-C-N 116.197 -0.456 . . . . 0.0 109.983 179.9 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 50.4 mtmt -148.28 156.99 43.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.456 179.494 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' GLU . . . . . 0.45 ' CD ' ' CE1' ' A' ' 43' ' ' TYR . 83.6 tt0 -113.42 123.45 50.1 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.565 179.773 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 67.8 t -130.6 132.33 64.47 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.189 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 55.28 33.59 21.0 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.781 178.952 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 83.69 -11.39 56.59 Favored Glycine 0 CA--C 1.525 0.688 0 C-N-CA 120.965 -0.636 . . . . 0.0 111.715 179.0 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 84.2 m95 -89.72 140.69 29.32 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 179.725 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' TYR . . . . . 0.45 ' CE1' ' CD ' ' A' ' 38' ' ' GLU . 62.9 m-85 -101.56 126.43 48.37 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.822 0.344 . . . . 0.0 110.418 179.709 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -82.29 128.8 34.56 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.321 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 43.4 pt -129.48 156.99 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-O 121.28 0.562 . . . . 0.0 111.641 -179.015 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 28.8 ttt180 -124.83 131.42 53.44 Favored 'General case' 0 CA--C 1.51 -0.578 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.106 178.238 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 38.9 t80 -152.57 135.9 15.86 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.791 -0.641 . . . . 0.0 110.532 179.773 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 10.9 m120 56.56 34.3 24.15 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.307 179.736 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 73.81 5.75 70.4 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.429 -0.668 . . . . 0.0 111.429 179.4 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -107.04 144.87 33.08 Favored 'General case' 0 N--CA 1.467 0.394 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.684 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 53.0 t -118.88 133.57 65.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 CA-C-O 120.939 0.399 . . . . 0.0 110.545 -179.372 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -159.91 -168.63 22.15 Favored Glycine 0 CA--C 1.524 0.638 0 N-CA-C 110.576 -1.01 . . . . 0.0 110.576 179.91 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' TYR . . . . . 0.444 ' CD1' ' N ' ' A' ' 53' ' ' TYR . 38.9 m-85 -127.5 156.33 42.33 Favored 'General case' 0 N--CA 1.464 0.271 0 N-CA-C 110.119 -0.326 . . . . 0.0 110.119 -179.702 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -140.0 157.17 46.09 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-O 120.861 0.363 . . . . 0.0 110.62 -179.752 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 28.5 t -63.01 140.49 58.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.211 -179.63 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 25.4 pttm -69.21 -28.75 66.64 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.308 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 52.9 m -59.93 -38.84 83.57 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.463 -179.187 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' TYR . . . . . 0.408 ' CG ' ' CD1' ' A' ' 11' ' ' LEU . 84.2 m-85 -94.81 15.17 19.15 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 111.758 0.281 . . . . 0.0 111.758 -179.012 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 5.5 mm -119.21 128.14 75.83 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 CA-C-O 120.939 0.399 . . . . 0.0 110.163 179.534 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 92.7 m -125.18 127.52 46.92 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.063 179.79 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.6 mt -87.76 125.8 41.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.419 179.782 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 2.3 m . . . . . 0 N--CA 1.465 0.293 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.374 179.876 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 . . . . . 0 N--CA 1.465 0.3 0 CA-C-O 120.962 0.41 . . . . 0.0 110.524 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -86.74 148.08 21.57 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 179.756 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 74.3 t -124.96 130.27 73.28 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 CA-C-O 120.971 0.415 . . . . 0.0 110.271 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 19.1 t -92.57 128.56 44.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.499 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 21.9 mmtp -121.86 105.3 10.23 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.342 -0.39 . . . . 0.0 109.997 179.525 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 19.0 m -139.34 159.65 28.58 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.482 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 18.3 t-20 -81.2 -13.81 58.2 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.639 179.881 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 12.3 t -159.1 -166.19 1.78 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.5 -179.673 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -65.43 143.29 57.8 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.201 179.603 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 44.9 tp -124.13 132.2 53.62 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-O 120.792 0.33 . . . . 0.0 110.293 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 90.9 m-20 -75.24 142.77 43.32 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.297 179.688 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' MET . . . . . 0.43 ' SD ' HD11 ' A' ' 24' ' ' ILE . 12.0 tmm? -106.95 150.31 26.59 Favored 'General case' 0 N--CA 1.463 0.205 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 179.731 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' ARG . . . . . 0.746 ' NH2' ' H ' ' A' ' 22' ' ' GLY . 24.6 mtp85 -122.34 156.84 33.08 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-O 121.027 0.441 . . . . 0.0 110.572 -178.955 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 82.2 p -80.84 -6.42 58.56 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.584 -0.735 . . . . 0.0 111.046 -179.42 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.55 -168.95 20.72 Favored Glycine 0 CA--C 1.525 0.692 0 C-N-CA 120.831 -0.699 . . . . 0.0 111.422 -179.848 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -83.69 9.38 4.13 Favored 'Trans proline' 0 C--N 1.309 -1.511 0 C-N-CA 122.832 2.354 . . . . 0.0 112.631 -179.695 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -97.56 127.32 9.18 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' SER . . . . . 0.535 ' O ' ' NH2' ' A' ' 14' ' ' ARG . 96.1 p -70.97 -10.71 60.2 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.347 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 25.1 p30 -106.03 19.8 19.95 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.029 -179.712 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.433 ' N ' HH21 ' A' ' 14' ' ' ARG . 3.0 m-85 -86.3 -3.08 58.92 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.552 -0.294 . . . . 0.0 110.326 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.746 ' H ' ' NH2' ' A' ' 14' ' ' ARG . . . 81.1 168.61 40.24 Favored Glycine 0 CA--C 1.521 0.421 0 N-CA-C 111.01 -0.836 . . . . 0.0 111.01 179.913 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.465 ' O ' HG13 ' A' ' 23' ' ' VAL . 9.7 p -102.25 124.7 56.34 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 CA-C-O 120.827 0.346 . . . . 0.0 110.421 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.43 HD11 ' SD ' ' A' ' 13' ' ' MET . 23.1 pt -106.78 -0.22 9.98 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.804 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.83 167.8 39.77 Favored Glycine 0 CA--C 1.52 0.348 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 89.2 m -124.04 131.16 53.52 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 120.782 0.325 . . . . 0.0 110.626 -179.7 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 69.4 mt -101.67 161.48 13.62 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.744 -179.706 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 81.5 mtt180 -127.66 157.77 39.38 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 120.873 0.368 . . . . 0.0 110.247 179.54 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.436 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 52.7 p30 -57.25 150.64 17.41 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.285 -179.177 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 12.5 t-20 58.47 35.34 24.63 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.364 179.499 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 32.5 t0 -89.15 114.41 25.7 Favored 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 179.234 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -84.03 124.5 31.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.807 0.337 . . . . 0.0 110.357 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 28.2 m -138.22 162.39 30.59 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.94 -179.711 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' GLU . . . . . 0.634 ' OE1' ' NH1' ' A' ' 46' ' ' ARG . 78.1 tt0 -95.9 140.14 31.1 Favored 'General case' 0 C--O 1.233 0.222 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 179.054 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 91.3 mt -104.23 125.52 59.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.822 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 95.9 mt -93.03 -49.56 12.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.386 179.718 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 35.6 ttpt -172.79 157.66 3.76 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.659 -179.331 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' GLU . . . . . 0.57 ' H ' ' CD ' ' A' ' 38' ' ' GLU . 2.1 pm0 -110.0 143.56 39.82 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.35 -0.387 . . . . 0.0 110.371 179.833 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 34.4 t -129.95 126.35 62.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 CA-C-O 120.757 0.313 . . . . 0.0 110.644 -179.718 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 50.79 30.26 4.93 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.545 178.988 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 85.84 25.32 38.52 Favored Glycine 0 CA--C 1.525 0.687 0 C-N-CA 121.011 -0.614 . . . . 0.0 112.015 179.361 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 62.2 m95 -124.36 106.24 10.07 Favored 'General case' 0 N--CA 1.471 0.581 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.127 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 91.3 m-85 -70.97 135.3 47.8 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.968 0.413 . . . . 0.0 111.437 -179.243 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -88.4 141.89 28.17 Favored 'General case' 0 CA--C 1.518 -0.262 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 178.325 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 39.9 pt -135.38 154.45 35.42 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.684 0 CA-C-O 121.627 0.727 . . . . 0.0 111.034 -179.582 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.634 ' NH1' ' OE1' ' A' ' 34' ' ' GLU . 11.2 ttp180 -111.4 123.54 50.41 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 114.668 -1.151 . . . . 0.0 110.378 -179.917 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 66.9 t80 -151.72 134.91 15.91 Favored 'General case' 0 N--CA 1.463 0.224 0 C-N-CA 120.87 -0.332 . . . . 0.0 111.158 -179.497 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 55.3 t-20 57.96 35.11 25.01 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.423 179.603 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 66.87 22.5 72.12 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 111.091 -0.804 . . . . 0.0 111.091 179.738 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 54.9 mtpt -128.91 146.74 50.87 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 121.012 0.434 . . . . 0.0 111.019 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 53.8 t -113.51 131.77 64.33 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.922 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -143.97 -163.35 9.86 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -179.806 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 44.8 m-85 -127.64 153.1 46.84 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 110.242 -0.281 . . . . 0.0 110.242 -179.675 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -146.69 151.33 37.03 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-N 116.383 -0.372 . . . . 0.0 110.642 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 41.0 t -65.14 143.72 57.69 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.744 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 26.0 pttm -67.58 -17.6 64.69 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.849 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 16.0 m -64.28 -36.06 82.86 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.44 -179.52 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 41.6 m-85 -103.85 12.04 34.94 Favored 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 111.978 0.362 . . . . 0.0 111.978 -178.175 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 46.2 mm -121.43 129.67 75.36 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.573 0 CA-C-O 120.931 0.396 . . . . 0.0 110.623 179.846 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 62.2 p -116.98 131.9 56.84 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.422 -179.601 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.6 mt -84.4 129.65 37.3 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.174 179.597 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 87.9 t . . . . . 0 C--N 1.327 -0.397 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.354 -179.915 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.423 ' CD ' ' N ' ' A' ' 2' ' ' GLN . 21.3 mp0 . . . . . 0 N--CA 1.465 0.321 0 CA-C-O 120.778 0.323 . . . . 0.0 110.416 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -99.62 147.56 18.33 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.625 -0.99 . . . . 0.0 110.625 179.772 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 54.3 t -124.73 130.78 73.31 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-O 120.927 0.394 . . . . 0.0 110.127 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 13.6 t -87.55 127.17 41.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.306 179.865 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -123.09 105.59 10.06 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.858 0.361 . . . . 0.0 110.068 179.491 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 14.8 p -156.51 139.09 6.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.559 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 66.2 t30 -67.84 -48.98 64.65 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.824 0.345 . . . . 0.0 110.756 179.606 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 5.5 m -93.96 152.48 18.81 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.575 179.799 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -61.47 142.7 56.83 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.532 -0.467 . . . . 0.0 110.194 179.568 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 41.1 tp -117.58 128.23 54.74 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.894 179.851 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' ASN . . . . . 0.551 ' ND2' HH12 ' A' ' 14' ' ' ARG . 21.2 p-10 -72.08 145.47 48.2 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.687 179.549 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 62.6 ttp -96.69 140.05 31.85 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-O 121.207 0.527 . . . . 0.0 110.663 -179.627 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' ARG . . . . . 0.961 ' HE ' ' HA ' ' A' ' 19' ' ' SER . 1.0 OUTLIER -93.8 153.82 18.08 Favored 'General case' 0 CA--C 1.541 0.608 0 CA-C-N 115.345 -0.843 . . . . 0.0 111.472 -178.443 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 78.5 p -88.34 -9.66 52.01 Favored 'General case' 0 N--CA 1.462 0.127 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.845 179.13 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -162.82 -173.05 31.05 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.154 -1.178 . . . . 0.0 110.154 179.729 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -80.67 78.29 3.72 Favored 'Trans proline' 0 C--N 1.298 -2.115 0 C-N-CA 122.584 2.189 . . . . 0.0 112.391 179.547 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 167.13 134.5 1.71 Allowed Glycine 0 CA--C 1.525 0.676 0 N-CA-C 111.371 -0.691 . . . . 0.0 111.371 179.769 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' SER . . . . . 0.961 ' HA ' ' HE ' ' A' ' 14' ' ' ARG . 23.2 t -68.32 -13.46 62.29 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 112.102 0.408 . . . . 0.0 112.102 -179.113 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 93.5 m-20 -88.07 11.44 16.1 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.766 -179.762 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 17.8 m-85 -90.7 1.3 56.97 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.313 179.849 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 76.59 -173.47 54.4 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 179.848 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 4.8 p -118.87 127.69 75.74 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-O 120.841 0.353 . . . . 0.0 110.293 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 25.2 pt -110.21 -3.64 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.448 179.651 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.56 -176.55 43.89 Favored Glycine 0 CA--C 1.529 0.908 0 N-CA-C 111.246 -0.742 . . . . 0.0 111.246 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 69.4 p -131.55 155.29 47.73 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 120.647 0.26 . . . . 0.0 110.691 -179.82 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 84.1 mt -125.37 149.56 48.02 Favored 'General case' 0 N--CA 1.472 0.625 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.519 -179.35 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 92.1 mtt-85 -120.21 161.67 20.68 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 121.669 0.747 . . . . 0.0 111.103 -179.164 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 64.2 t30 -57.97 144.23 40.2 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.581 -178.608 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 59.2 34.23 23.06 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.47 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 65.7 t0 -85.25 114.89 22.68 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-O 120.778 0.323 . . . . 0.0 110.186 178.881 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -80.37 128.87 34.06 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.551 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.1 m -141.59 161.3 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.201 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.439 179.741 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 80.7 mm-40 -102.73 133.35 47.93 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.942 179.637 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 92.5 mt -102.75 109.43 26.63 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.625 -179.848 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 97.2 mt -66.46 -43.63 90.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.547 179.853 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 25.7 pttm -172.51 179.25 2.52 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.774 -179.401 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 2.5 tm-20 -112.89 124.62 53.03 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.179 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 54.1 t -125.66 133.01 70.16 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.784 -179.663 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 55.81 28.86 12.99 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.133 179.393 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.36 -8.6 57.96 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.854 -0.898 . . . . 0.0 110.854 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 11.1 m95 -94.05 148.38 22.23 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 110.035 -0.357 . . . . 0.0 110.035 179.633 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 64.2 m-85 -96.95 131.39 43.8 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.974 0.416 . . . . 0.0 110.689 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -83.18 152.99 25.0 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 108.496 -0.928 . . . . 0.0 108.496 178.499 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 34.5 pt -145.29 150.55 15.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 C-N-CA 120.707 -0.397 . . . . 0.0 111.143 -179.413 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.603 ' HE ' ' HA2' ' A' ' 49' ' ' GLY . 16.6 ttt180 -115.05 126.18 54.41 Favored 'General case' 0 CA--C 1.511 -0.534 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 177.398 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 79.5 t80 -138.1 129.05 27.09 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-N 115.16 -0.927 . . . . 0.0 110.304 179.574 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 67.0 t30 53.09 36.5 22.44 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.628 -0.714 . . . . 0.0 112.124 179.677 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.603 ' HA2' ' HE ' ' A' ' 46' ' ' ARG . . . 71.05 16.41 74.9 Favored Glycine 0 CA--C 1.525 0.665 0 C-N-CA 120.491 -0.861 . . . . 0.0 111.024 178.924 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.414 ' HD3' ' N ' ' A' ' 51' ' ' VAL . 6.0 tmtt? -119.04 125.78 50.15 Favored 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 109.9 -0.408 . . . . 0.0 109.9 -179.366 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.414 ' N ' ' HD3' ' A' ' 50' ' ' LYS . 82.5 t -80.25 136.65 22.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.591 179.741 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -157.59 167.66 34.14 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.884 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 76.0 m-85 -122.01 156.87 32.56 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-O 120.645 0.259 . . . . 0.0 110.444 -179.544 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -148.77 151.71 35.3 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-O 120.842 0.354 . . . . 0.0 110.472 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 30.0 t -63.23 141.26 58.83 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.478 -179.882 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 26.0 pttm -67.21 -15.1 63.5 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.193 -179.671 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 78.0 p -65.64 -33.19 75.33 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.68 -179.661 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -102.31 11.0 38.78 Favored 'General case' 0 N--CA 1.468 0.454 0 N-CA-C 111.867 0.321 . . . . 0.0 111.867 -179.04 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 47.8 mm -115.55 130.12 70.7 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.567 0 CA-C-O 120.997 0.427 . . . . 0.0 110.554 179.795 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 90.1 m -116.75 124.91 50.79 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.189 179.695 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 21.0 mm -81.79 134.64 26.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.44 -179.856 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 75.3 t . . . . . 0 C--N 1.328 -0.343 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.294 -179.901 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 88.6 mt-30 . . . . . 0 N--CA 1.466 0.373 0 CA-C-O 120.822 0.344 . . . . 0.0 110.684 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -93.97 156.78 22.51 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.689 -0.964 . . . . 0.0 110.689 179.713 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 65.1 t -124.59 130.99 73.32 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 179.663 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 13.1 t -86.05 128.97 38.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.778 -179.584 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -130.81 106.23 8.31 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.939 0.4 . . . . 0.0 110.207 179.382 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.492 HG22 ' H ' ' A' ' 9' ' ' SER . 3.2 p -140.82 142.77 29.71 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.205 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.223 -179.563 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.526 ' OD1' ' N ' ' A' ' 9' ' ' SER . 13.9 p30 -63.28 -40.8 98.38 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.717 -179.732 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' SER . . . . . 0.526 ' N ' ' OD1' ' A' ' 8' ' ' ASN . 17.4 m -117.69 -139.76 0.36 Allowed 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.92 179.578 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -91.97 144.35 25.55 Favored 'General case' 0 C--O 1.233 0.21 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 179.498 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 60.6 tp -110.86 130.18 55.65 Favored 'General case' 0 N--CA 1.468 0.451 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 -179.835 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -85.23 133.63 34.17 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.403 179.827 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 38.4 ttp -100.71 142.16 32.57 Favored 'General case' 0 CA--C 1.51 -0.582 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 179.712 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' ARG . . . . . 0.525 HH12 ' CB ' ' A' ' 19' ' ' SER . 8.6 mtt180 -117.74 155.42 30.04 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.83 -178.83 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 87.5 p -77.73 -11.81 59.91 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 112.057 0.392 . . . . 0.0 112.057 -178.885 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -162.9 -173.04 31.14 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 179.862 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -83.29 77.02 3.67 Favored 'Trans proline' 0 C--N 1.307 -1.623 0 C-N-CA 122.704 2.269 . . . . 0.0 112.173 179.605 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 168.54 133.81 1.62 Allowed Glycine 0 CA--C 1.527 0.83 0 C-N-CA 120.753 -0.737 . . . . 0.0 111.699 179.717 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' SER . . . . . 0.525 ' CB ' HH12 ' A' ' 14' ' ' ARG . 6.0 t -65.86 -17.41 64.63 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-O 120.886 0.374 . . . . 0.0 110.985 179.807 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' ASN . . . . . 0.531 ' OD1' ' N ' ' A' ' 21' ' ' TYR . 41.1 p-10 -60.89 -36.09 78.32 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.508 -179.117 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.531 ' N ' ' OD1' ' A' ' 20' ' ' ASN . 76.6 m-85 -62.05 -37.02 83.39 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.04 179.342 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 89.48 173.71 45.91 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.451 ' CG2' ' O ' ' A' ' 25' ' ' GLY . 14.0 p -87.19 128.12 40.06 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.867 0.365 . . . . 0.0 110.487 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 25.4 pt -104.4 -4.32 9.61 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.502 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.451 ' O ' ' CG2' ' A' ' 23' ' ' VAL . . . -176.32 -177.12 45.06 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.414 -1.075 . . . . 0.0 110.414 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 69.7 p -132.2 150.22 52.2 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-O 120.947 0.403 . . . . 0.0 110.374 179.861 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 84.4 mt -129.06 148.54 51.02 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.757 -179.529 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 71.0 mtp180 -107.0 162.44 13.84 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.23 179.509 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.426 ' HB3' ' H ' ' A' ' 7' ' ' VAL . 52.8 p30 -69.29 171.97 7.72 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.172 179.723 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 85.9 m-20 58.33 9.2 0.97 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.122 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 43.4 t0 -85.11 116.54 23.54 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.782 0.325 . . . . 0.0 110.676 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 65.5 mttp -77.0 135.13 38.66 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.056 179.674 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.0 m -137.75 159.85 34.03 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-O 120.89 0.376 . . . . 0.0 110.648 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -104.44 117.95 35.41 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.048 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.4 ' C ' HD12 ' A' ' 36' ' ' ILE . 95.7 mt -90.72 125.76 43.51 Favored 'Isoleucine or valine' 0 C--O 1.232 0.172 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.518 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.767 ' N ' HD12 ' A' ' 36' ' ' ILE . 1.9 mp -92.96 -41.16 12.58 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.67 -179.819 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 22.6 pttp -171.83 158.86 5.01 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.604 -179.805 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' GLU . . . . . 0.476 ' OE1' ' CE1' ' A' ' 43' ' ' TYR . 81.4 tt0 -112.61 125.04 53.84 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.089 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 65.0 t -128.05 132.63 68.39 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 CA-C-O 120.906 0.384 . . . . 0.0 111.146 -179.694 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' ASP . . . . . 0.435 ' OD1' ' O ' ' A' ' 40' ' ' ASP . 55.1 t0 56.85 25.37 10.33 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.924 179.394 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.01 -9.71 73.53 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 179.696 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 66.2 m95 -89.44 141.51 28.5 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 110.077 -0.342 . . . . 0.0 110.077 179.783 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' TYR . . . . . 0.476 ' CE1' ' OE1' ' A' ' 38' ' ' GLU . 38.3 m-85 -95.38 131.8 41.12 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-O 121.01 0.433 . . . . 0.0 110.403 179.915 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -92.03 119.64 31.93 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 178.9 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 41.1 pt -125.88 157.84 35.43 Favored 'Isoleucine or valine' 0 C--O 1.233 0.222 0 CA-C-O 121.123 0.487 . . . . 0.0 111.092 -179.311 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 79.0 ttt180 -115.83 124.93 51.93 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.593 179.035 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 28.2 t80 -141.83 132.77 25.94 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.454 -179.814 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 62.7 t30 61.08 27.67 17.47 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.398 -179.835 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 74.08 9.01 79.88 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 61.5 tttm -102.76 156.69 17.47 Favored 'General case' 0 C--O 1.231 0.129 0 N-CA-C 110.043 -0.355 . . . . 0.0 110.043 -179.825 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 56.6 t -115.9 131.17 69.16 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.009 -179.873 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -160.98 -170.43 25.59 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 66.6 m-85 -130.31 162.62 28.62 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-O 120.779 0.323 . . . . 0.0 110.509 -179.632 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -146.68 154.3 41.28 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.369 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 20.2 m -66.25 143.19 57.37 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.619 -179.863 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 60.7 pttt -79.9 -19.44 48.17 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.167 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 11.7 t -61.59 -42.14 98.43 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.354 -179.558 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 99.3 m-85 -92.24 4.3 53.55 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.439 -0.346 . . . . 0.0 111.786 -178.833 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 97.6 mt -122.29 132.09 71.82 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.54 0 CA-C-O 121.001 0.429 . . . . 0.0 110.881 179.678 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 93.1 m -120.2 134.06 55.35 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.406 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 23.1 mm -77.15 132.73 32.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.649 -179.893 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 94.7 t . . . . . 0 C--N 1.33 -0.262 0 CA-C-O 120.936 0.398 . . . . 0.0 110.764 -179.938 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.443 ' OE1' ' N ' ' A' ' 2' ' ' GLN . 1.1 mp0 . . . . . 0 N--CA 1.463 0.202 0 CA-C-O 121.116 0.484 . . . . 0.0 111.371 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -92.96 158.18 23.84 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 110.685 -0.966 . . . . 0.0 110.685 179.351 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 73.3 t -126.1 134.47 66.43 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 O-C-N 122.615 -0.344 . . . . 0.0 110.309 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 18.2 t -85.1 126.29 40.34 Favored 'Isoleucine or valine' 0 C--O 1.234 0.248 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.751 -179.905 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 41.5 mmtm -112.24 106.63 15.25 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-O 120.763 0.316 . . . . 0.0 110.382 179.796 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.402 HG22 ' N ' ' A' ' 8' ' ' ASN . 9.7 p -140.15 159.11 26.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 N-CA-C 110.307 -0.257 . . . . 0.0 110.307 179.671 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.478 ' OD1' ' N ' ' A' ' 9' ' ' SER . 21.5 p30 -64.37 -39.47 93.94 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.813 -0.355 . . . . 0.0 110.623 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' SER . . . . . 0.478 ' N ' ' OD1' ' A' ' 8' ' ' ASN . 59.5 p -141.09 -60.75 0.49 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.155 -179.656 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.417 ' N ' ' OG ' ' A' ' 9' ' ' SER . . . -149.63 145.84 26.97 Favored 'General case' 0 CA--C 1.519 -0.248 0 CA-C-O 121.196 0.522 . . . . 0.0 110.758 -179.699 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 39.9 tp -116.68 131.66 56.89 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.464 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 99.7 m-20 -74.94 138.38 42.28 Favored 'General case' 0 CA--C 1.518 -0.264 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.573 179.654 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 37.6 ttp -94.72 151.41 19.3 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.621 179.74 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' ARG . . . . . 0.65 ' NH1' ' H ' ' A' ' 16' ' ' GLY . 0.4 OUTLIER -129.89 154.18 47.56 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.94 0.4 . . . . 0.0 111.668 -179.151 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 15' ' ' SER . . . . . 0.618 ' H ' ' CZ ' ' A' ' 14' ' ' ARG . 85.9 p -87.5 -17.34 32.34 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 115.606 -0.725 . . . . 0.0 111.237 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.65 ' H ' ' NH1' ' A' ' 14' ' ' ARG . . . -149.2 -177.48 23.37 Favored Glycine 0 CA--C 1.528 0.875 0 C-N-CA 120.859 -0.686 . . . . 0.0 111.52 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -81.99 82.39 2.32 Favored 'Trans proline' 0 C--N 1.319 -0.983 0 C-N-CA 123.256 2.637 . . . . 0.0 112.107 -179.691 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 163.99 119.63 0.49 Allowed Glycine 0 CA--C 1.528 0.881 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 179.727 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 80.4 p -70.46 -12.39 61.54 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-O 120.605 0.241 . . . . 0.0 110.732 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -78.25 -14.98 59.21 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.322 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.412 ' HB3' ' NH2' ' A' ' 14' ' ' ARG . 13.6 m-85 -64.91 -41.89 95.21 Favored 'General case' 0 CA--C 1.519 -0.231 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.844 179.526 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.54 ' O ' ' NE ' ' A' ' 14' ' ' ARG . . . 117.07 133.76 5.12 Favored Glycine 0 C--N 1.333 0.394 0 N-CA-C 110.954 -0.859 . . . . 0.0 110.954 179.324 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 5.4 p -65.93 139.46 21.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 121.065 0.459 . . . . 0.0 110.399 179.756 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 34.8 pt -106.91 -10.08 10.58 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.215 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.975 -179.878 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.23 -172.93 43.16 Favored Glycine 0 CA--C 1.521 0.467 0 N-CA-C 110.626 -0.99 . . . . 0.0 110.626 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 97.5 m -125.94 147.57 49.47 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-O 120.923 0.392 . . . . 0.0 111.222 -179.301 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 60.5 mt -112.88 153.59 27.67 Favored 'General case' 0 C--O 1.233 0.207 0 CA-C-O 121.055 0.455 . . . . 0.0 110.006 179.458 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 24.1 mmt180 -100.83 159.87 14.83 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.436 -179.543 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.437 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 53.5 p-10 -65.32 143.98 57.41 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.828 -179.528 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 56.66 34.0 23.78 Favored 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.598 179.229 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 44.0 t0 -85.08 117.1 23.83 Favored 'General case' 0 N--CA 1.466 0.341 0 C-N-CA 120.884 -0.326 . . . . 0.0 110.891 179.749 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -72.38 130.48 40.82 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.998 0.428 . . . . 0.0 110.49 179.826 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 28.8 m -137.29 162.93 32.7 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.489 179.827 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -100.13 122.56 43.17 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.813 -0.631 . . . . 0.0 109.934 179.56 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.4 mt -97.4 128.66 48.47 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.169 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.211 -179.739 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 22.7 mm -94.04 -64.32 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.473 -179.693 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 25.3 pttm -154.47 163.52 40.06 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.789 -179.758 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 44.2 tt0 -103.85 126.72 51.18 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.583 179.757 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 61.4 t -127.86 131.64 69.54 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.2 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.335 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 51.1 t0 55.68 24.25 6.98 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.04 179.845 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.72 -16.01 57.62 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 111.54 -0.624 . . . . 0.0 111.54 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 17.0 m95 -88.2 141.97 28.13 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.806 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 -94.53 131.6 40.08 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-O 120.737 0.303 . . . . 0.0 111.083 -179.52 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -80.65 134.51 35.89 Favored 'General case' 0 N--CA 1.464 0.275 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 179.2 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 40.0 pt -134.54 155.39 38.73 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-O 121.006 0.431 . . . . 0.0 111.77 -179.441 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 56.4 ttp180 -118.58 124.44 47.48 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.501 179.568 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 36.1 t80 -148.19 134.83 19.84 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.683 179.734 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 65.5 t30 58.74 31.35 21.09 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.674 -179.798 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 70.18 19.54 75.82 Favored Glycine 0 CA--C 1.521 0.407 0 N-CA-C 110.668 -0.973 . . . . 0.0 110.668 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -122.0 145.57 48.0 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-O 120.709 0.29 . . . . 0.0 110.256 -179.587 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 16.8 t -96.78 113.3 30.79 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 CA-C-O 120.846 0.355 . . . . 0.0 110.36 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' GLY . . . . . 0.42 ' C ' ' CD1' ' A' ' 53' ' ' TYR . . . -119.84 -166.97 13.44 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 110.772 -0.931 . . . . 0.0 110.772 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 53' ' ' TYR . . . . . 0.42 ' CD1' ' C ' ' A' ' 52' ' ' GLY . 85.3 m-85 -147.37 159.59 43.52 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 179.963 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -145.62 154.88 42.62 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.971 0.415 . . . . 0.0 110.809 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 15.1 m -69.51 146.08 52.16 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.666 -179.809 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 20.6 ptmt -68.23 -36.82 80.09 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.465 -179.836 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 78.3 p -66.92 -23.22 65.95 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.865 -179.007 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 80.9 m-85 -104.82 7.33 34.47 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.471 -179.888 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 4.9 mm -127.71 129.74 70.15 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.15 179.811 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 98.5 m -121.22 127.07 51.09 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.593 179.481 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 21.8 mm -86.23 128.94 38.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.107 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 21.2 t . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.822 -179.569 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.9 mt-30 . . . . . 0 N--CA 1.465 0.277 0 CA-C-O 120.821 0.343 . . . . 0.0 110.222 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -85.19 163.81 37.99 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.514 -1.034 . . . . 0.0 110.514 179.648 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 54.7 t -125.17 130.15 73.1 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-O 120.785 0.326 . . . . 0.0 110.143 179.858 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 15.7 t -95.4 125.92 48.01 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.08 179.681 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 33.1 ttpt -129.81 117.1 19.68 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.497 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.4 HG12 ' H ' ' A' ' 9' ' ' SER . 2.8 t -140.92 155.9 22.16 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 CA-C-O 120.872 0.368 . . . . 0.0 110.726 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 49.8 p30 -79.9 -11.49 59.8 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.504 179.548 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' SER . . . . . 0.4 ' H ' HG12 ' A' ' 7' ' ' VAL . 73.6 m -162.07 -164.79 1.11 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.385 -179.76 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -65.25 142.95 58.11 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.735 -179.903 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 53.6 tp -126.16 132.12 51.88 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-N 116.169 -0.468 . . . . 0.0 109.879 179.701 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' ASN . . . . . 0.445 ' O ' ' OD1' ' A' ' 12' ' ' ASN . 47.8 p30 -77.62 142.44 38.9 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.001 0.429 . . . . 0.0 110.956 -179.873 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 43.3 ttp -111.43 138.44 47.93 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 179.691 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' ARG . . . . . 0.71 ' NH2' ' CE3' ' A' ' 42' ' ' TRP . 0.5 OUTLIER -109.18 141.2 41.75 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 120.867 0.365 . . . . 0.0 111.03 -178.81 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 38.4 t -63.44 -42.61 98.67 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.037 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -107.73 179.8 22.0 Favored Glycine 0 N--CA 1.466 0.665 0 N-CA-C 110.65 -0.98 . . . . 0.0 110.65 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -82.98 73.09 5.59 Favored 'Trans proline' 0 C--N 1.307 -1.652 0 C-N-CA 122.438 2.092 . . . . 0.0 111.959 179.665 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' GLY . . . . . 0.668 ' N ' HH21 ' A' ' 14' ' ' ARG . . . 174.52 158.07 17.64 Favored Glycine 0 CA--C 1.528 0.89 0 N-CA-C 111.344 -0.702 . . . . 0.0 111.344 179.918 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 69.5 m -82.4 -10.37 59.08 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.849 0.357 . . . . 0.0 110.643 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 92.1 m-20 -89.64 5.03 47.56 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.188 -179.128 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 47.8 m-85 -92.11 -0.59 57.44 Favored 'General case' 0 N--CA 1.465 0.304 0 N-CA-C 109.993 -0.373 . . . . 0.0 109.993 179.775 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 78.53 -178.32 53.13 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 111.127 -0.789 . . . . 0.0 111.127 179.647 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 5.4 p -116.08 126.71 73.69 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 CA-C-O 120.932 0.396 . . . . 0.0 110.33 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 43.6 pt -103.66 -8.94 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.968 -179.866 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -177.87 -171.72 41.58 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 63.2 p -133.51 158.46 43.07 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-O 120.928 0.394 . . . . 0.0 110.642 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 75.9 mt -122.33 153.88 38.37 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 115.899 -0.592 . . . . 0.0 109.945 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.406 ' O ' ' CG ' ' A' ' 31' ' ' ASP . 70.3 mtm180 -124.54 147.14 48.6 Favored 'General case' 0 N--CA 1.465 0.309 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.914 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 53.0 p-10 -51.91 159.38 0.86 Allowed 'General case' 0 C--N 1.324 -0.536 0 C-N-CA 120.76 -0.376 . . . . 0.0 111.14 -179.168 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 58.0 t30 67.16 9.05 6.64 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.489 179.85 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' ASP . . . . . 0.406 ' CG ' ' O ' ' A' ' 28' ' ' ARG . 35.1 m-20 -84.88 113.7 21.57 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.746 0.308 . . . . 0.0 110.414 179.288 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 25.8 mtpp -78.57 136.77 37.61 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.084 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.4 m -137.24 163.05 32.65 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.252 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.784 -179.542 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 47.8 tp10 -103.01 123.8 47.3 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.401 179.497 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 90.4 mt -97.49 120.13 46.43 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.041 -179.424 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 82.2 mt -83.88 -44.96 18.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.733 179.533 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 62.1 pttt -173.93 174.89 2.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.452 -179.837 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -118.51 124.98 48.88 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.209 179.873 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 69.0 t -125.33 131.83 71.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.679 -179.577 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 54.83 27.53 9.1 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.12 179.574 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.11 -12.29 62.69 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 179.569 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' TRP . . . . . 0.71 ' CE3' ' NH2' ' A' ' 14' ' ' ARG . 82.9 m95 -88.73 145.02 25.88 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.731 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 65.6 m-85 -101.25 130.59 47.4 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-O 120.974 0.416 . . . . 0.0 110.521 -179.878 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -87.9 128.65 35.36 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.526 179.48 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 42.8 pt -128.94 150.51 34.64 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.253 0 CA-C-O 121.061 0.458 . . . . 0.0 111.312 -179.234 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 4.7 ttp180 -120.22 129.42 54.07 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.019 178.769 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 73.8 t80 -146.43 132.42 19.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.678 179.564 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 16.8 t-20 57.19 31.25 19.73 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.023 179.479 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 76.78 4.77 82.74 Favored Glycine 0 CA--C 1.528 0.863 0 N-CA-C 111.347 -0.701 . . . . 0.0 111.347 179.548 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 51.4 mtmt -102.21 150.27 23.46 Favored 'General case' 0 N--CA 1.466 0.358 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.567 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 58.0 t -116.65 132.79 65.3 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-O 120.881 0.372 . . . . 0.0 110.31 -179.641 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -153.93 -166.39 14.79 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' TYR . . . . . 0.514 ' C ' ' NH1' ' A' ' 14' ' ' ARG . 52.8 m-85 -139.18 159.03 43.12 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-O 120.815 0.341 . . . . 0.0 110.694 -179.512 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.516 ' N ' HH12 ' A' ' 14' ' ' ARG . . . -144.19 149.59 36.66 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.987 179.223 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 21.1 m -66.26 147.29 53.53 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.849 0.357 . . . . 0.0 110.574 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 62.3 pttt -64.63 -21.65 66.77 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.756 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 68.4 m -63.23 -40.29 97.02 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.55 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 72.7 m-85 -95.69 8.33 43.76 Favored 'General case' 0 N--CA 1.469 0.494 0 N-CA-C 111.93 0.345 . . . . 0.0 111.93 -178.729 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 46.0 mm -120.59 127.07 75.89 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 CA-C-O 120.905 0.383 . . . . 0.0 110.55 179.814 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 89.8 m -125.42 127.9 47.26 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 115.943 -0.572 . . . . 0.0 109.915 179.252 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 19.1 mm -85.21 127.93 39.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.543 -179.698 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 27.4 m . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.623 -179.785 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 28.5 mp0 . . . . . 0 N--CA 1.465 0.319 0 CA-C-O 120.733 0.301 . . . . 0.0 110.27 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -97.29 168.02 24.04 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.73 -0.948 . . . . 0.0 110.73 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 55.4 t -125.55 132.07 71.36 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 N-CA-C 109.986 -0.375 . . . . 0.0 109.986 179.652 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 89.4 t -92.27 113.44 27.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.03 179.757 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 75.5 tttt -112.71 117.08 31.25 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.16 -179.765 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 9.1 p -144.11 154.0 15.48 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.995 -179.829 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 40.2 t30 -63.16 -41.03 99.18 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.891 -179.761 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' SER . . . . . 0.447 ' O ' ' ND2' ' A' ' 29' ' ' ASN . 20.3 p -133.3 -72.26 0.51 Allowed 'General case' 0 N--CA 1.468 0.439 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.733 -179.914 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -152.78 144.17 23.29 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.242 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 42.5 tp -115.06 128.73 56.42 Favored 'General case' 0 N--CA 1.47 0.567 0 CA-C-O 120.979 0.418 . . . . 0.0 110.531 -179.664 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -74.77 144.56 43.53 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.481 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 33.3 ttp -107.26 150.31 26.8 Favored 'General case' 0 CA--C 1.519 -0.244 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 179.601 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' ARG . . . . . 0.493 ' HE ' ' HA ' ' A' ' 19' ' ' SER . 85.7 mtt85 -128.29 150.16 50.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.762 -178.303 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 23.0 t -69.15 -15.88 63.52 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 115.961 -0.563 . . . . 0.0 112.218 -179.417 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -161.01 -172.68 28.65 Favored Glycine 0 CA--C 1.524 0.646 0 C-N-CA 120.394 -0.908 . . . . 0.0 111.428 -179.673 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -82.76 78.43 3.34 Favored 'Trans proline' 0 C--N 1.304 -1.816 0 C-N-CA 122.729 2.286 . . . . 0.0 111.734 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 169.9 134.91 1.82 Allowed Glycine 0 CA--C 1.525 0.658 0 N-CA-C 111.29 -0.724 . . . . 0.0 111.29 179.878 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' SER . . . . . 0.493 ' HA ' ' HE ' ' A' ' 14' ' ' ARG . 34.5 t -66.69 -14.83 62.98 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.944 0.402 . . . . 0.0 110.642 179.705 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 91.6 m-20 -79.45 -1.13 35.92 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.941 -179.495 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 39.0 m-85 -89.21 -1.77 58.22 Favored 'General case' 0 C--O 1.232 0.163 0 N-CA-C 109.573 -0.529 . . . . 0.0 109.573 179.384 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 66.4 176.31 7.13 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 179.804 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.463 ' O ' HG13 ' A' ' 23' ' ' VAL . 8.1 p -101.54 124.48 55.33 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 N-CA-C 110.105 -0.331 . . . . 0.0 110.105 179.603 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 42.9 pt -100.72 -3.27 9.45 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.714 -179.775 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 172.37 -177.84 44.8 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 53.0 p -132.73 158.51 42.19 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.76 0.314 . . . . 0.0 110.367 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 69.1 mt -112.65 135.47 53.34 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.286 -179.658 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -82.52 160.8 22.53 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 120.933 0.397 . . . . 0.0 110.407 -179.17 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.447 ' ND2' ' O ' ' A' ' 9' ' ' SER . 47.2 m-80 -62.53 136.96 58.15 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.021 179.855 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' ASN . . . . . 0.545 ' O ' ' ND2' ' A' ' 30' ' ' ASN . 2.5 t30 55.64 36.7 27.72 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.0 179.587 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -84.33 116.57 23.08 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.532 179.753 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -72.72 130.71 41.15 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 120.714 -0.394 . . . . 0.0 110.192 179.613 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.7 m -138.82 162.16 28.97 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.541 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -104.17 123.01 46.53 Favored 'General case' 0 N--CA 1.463 0.218 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 179.551 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.2 mt -90.35 106.25 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.214 -179.642 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.8 mt -66.24 -45.03 90.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.738 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 21.1 ptmt -175.82 170.8 2.77 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.366 -179.501 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -115.34 124.08 50.35 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.401 179.702 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 79.7 t -127.97 133.08 67.99 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.373 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.2 -179.833 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' ASP . . . . . 0.428 ' OD1' ' O ' ' A' ' 40' ' ' ASP . 56.3 t0 56.52 23.02 7.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.901 0.382 . . . . 0.0 110.761 179.666 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 85.22 -6.69 78.69 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 111.249 -0.741 . . . . 0.0 111.249 179.68 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 49.0 m95 -85.85 145.78 27.04 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 109.697 -0.482 . . . . 0.0 109.697 179.31 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -95.75 115.25 27.16 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.977 0.418 . . . . 0.0 110.156 -179.672 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -83.65 122.55 28.76 Favored 'General case' 0 CA--C 1.517 -0.315 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 178.89 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 36.3 pt -128.74 162.42 35.79 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.494 0 CA-C-O 121.388 0.613 . . . . 0.0 111.65 -178.434 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.413 ' HD3' HH11 ' A' ' 46' ' ' ARG . 20.4 ttp180 -124.67 130.05 51.69 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.219 -0.9 . . . . 0.0 109.845 179.789 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 84.1 t80 -149.49 132.71 16.4 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.238 -179.507 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 66.0 t30 55.98 36.15 26.83 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.679 179.534 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 69.84 16.53 72.46 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.949 -0.86 . . . . 0.0 110.949 179.889 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 39.3 tptt -116.16 134.77 54.56 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-O 120.691 0.281 . . . . 0.0 110.285 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 58.5 t -108.89 131.22 60.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.155 -179.619 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -152.06 -156.82 7.65 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.736 -0.946 . . . . 0.0 110.736 -179.893 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 76.0 m-85 -137.75 155.85 48.62 Favored 'General case' 0 N--CA 1.464 0.225 0 CA-C-O 120.885 0.374 . . . . 0.0 110.78 -179.75 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -154.13 160.42 41.91 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.157 -179.709 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.7 p -64.47 151.63 43.82 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.044 -179.526 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 22.9 pttp -84.61 -27.21 27.36 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.665 179.828 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 38.9 t -62.27 -40.67 97.01 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.327 -179.614 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 58.8 m-85 -84.94 2.51 42.53 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.805 -179.027 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 97.6 mt -124.43 129.66 73.81 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.183 179.197 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 91.0 m -115.54 128.45 55.99 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.554 -179.707 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 95.3 mt -83.33 124.4 39.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.925 -0.58 . . . . 0.0 109.884 179.788 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 34.9 m . . . . . 0 N--CA 1.463 0.202 0 CA-C-O 120.938 0.399 . . . . 0.0 110.947 -179.511 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 22.6 tpp . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.165 -0.679 . . . . 0.0 109.165 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.487 ' CD ' ' N ' ' A' ' 2' ' ' GLN . 1.4 pm0 -147.04 117.22 7.32 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-O 120.954 0.406 . . . . 0.0 110.538 -179.855 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -88.42 149.8 21.47 Favored Glycine 0 CA--C 1.525 0.68 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 179.66 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 53.9 t -122.05 129.39 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 87.4 t -93.56 126.47 45.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.188 179.752 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 33.1 tptt -118.52 110.8 17.82 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.153 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.48 HG22 ' H ' ' A' ' 9' ' ' SER . 12.5 p -144.42 144.74 22.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.075 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -63.41 -41.23 98.71 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.7 -179.615 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.48 ' H ' HG22 ' A' ' 7' ' ' VAL . 38.6 m -119.06 -75.12 0.58 Allowed 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.985 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -157.87 145.67 18.61 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.386 -179.633 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 60.7 tp -108.98 131.12 55.37 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.138 -179.177 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 96.6 m-20 -80.89 145.63 31.22 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.666 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 42.5 ttp -106.81 149.84 26.96 Favored 'General case' 0 N--CA 1.471 0.597 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 179.857 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ARG . . . . . 0.687 HH11 ' HA ' ' A' ' 19' ' ' SER . 58.1 mtt-85 -133.5 140.77 47.43 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-O 121.031 0.443 . . . . 0.0 111.768 -176.925 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 35.8 t -59.16 -41.93 89.55 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.358 -178.364 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -109.6 161.92 12.88 Favored Glycine 0 CA--C 1.53 0.987 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -77.99 73.3 5.78 Favored 'Trans proline' 0 N--CA 1.496 1.663 0 C-N-CA 122.922 2.414 . . . . 0.0 112.044 179.348 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 176.26 160.44 23.59 Favored Glycine 0 CA--C 1.516 0.146 0 N-CA-C 110.013 -1.235 . . . . 0.0 110.013 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.687 ' HA ' HH11 ' A' ' 14' ' ' ARG . 5.4 m -78.88 -16.9 56.44 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 120.457 -0.497 . . . . 0.0 110.54 -179.638 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -64.88 -36.05 83.1 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.971 -179.034 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -59.25 -42.52 91.32 Favored 'General case' 0 C--N 1.329 -0.284 0 C-N-CA 120.851 -0.339 . . . . 0.0 111.423 -178.922 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 101.86 162.21 26.8 Favored Glycine 0 N--CA 1.468 0.77 0 N-CA-C 111.29 -0.724 . . . . 0.0 111.29 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 7.2 p -77.16 132.79 32.11 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.123 0 CA-C-O 121.018 0.437 . . . . 0.0 111.594 -179.627 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 44.1 pt -113.45 -8.5 12.15 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.302 179.318 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -170.97 175.59 44.62 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.529 -1.029 . . . . 0.0 110.529 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 86.9 m -123.2 132.1 53.92 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-O 120.715 0.293 . . . . 0.0 110.451 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 73.0 mt -109.19 141.96 40.68 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.267 179.767 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.729 HH11 ' HG2' ' A' ' 28' ' ' ARG . 46.0 mtt-85 -95.32 168.06 10.96 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.274 179.383 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 50.7 p-10 -75.27 159.0 32.02 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 178.863 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 77.4 m-20 56.23 31.91 19.31 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.322 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 47.3 t0 -96.37 112.81 24.42 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 116.559 -0.291 . . . . 0.0 110.639 179.336 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 56.3 mtpt -74.06 134.34 42.96 Favored 'General case' 0 C--N 1.329 -0.288 0 C-N-CA 120.601 -0.44 . . . . 0.0 110.075 179.606 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 28.5 m -136.94 162.37 34.51 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.606 -179.81 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -101.82 121.1 41.45 Favored 'General case' 0 C--O 1.233 0.232 0 CA-C-N 116.083 -0.508 . . . . 0.0 109.869 179.618 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.3 mt -88.58 127.81 41.23 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.139 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.396 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 95.8 mt -91.77 -42.76 13.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.576 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 62.0 pttt -174.82 165.04 3.6 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.567 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -113.01 121.87 45.92 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.181 179.594 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 70.1 t -126.73 131.51 71.07 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.65 -179.64 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.418 ' O ' ' OD1' ' A' ' 40' ' ' ASP . 56.6 t0 53.96 31.17 12.94 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.414 179.082 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 85.43 -16.49 39.48 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 111.043 -0.823 . . . . 0.0 111.043 179.694 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 79.9 m95 -83.35 146.14 28.65 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.401 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 58.7 m-85 -101.17 130.19 47.21 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.904 0.383 . . . . 0.0 110.402 179.669 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.526 ' OE1' ' CE1' ' A' ' 53' ' ' TYR . 3.5 tp10 -88.12 118.52 27.75 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 179.207 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 44.7 pt -126.03 161.37 31.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-O 121.334 0.588 . . . . 0.0 110.678 -179.468 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.406 HH11 ' HD3' ' A' ' 46' ' ' ARG . 0.6 OUTLIER -126.88 127.23 44.61 Favored 'General case' 0 CA--C 1.537 0.467 0 CA-C-N 115.397 -0.82 . . . . 0.0 110.041 -178.262 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 32.9 t80 -145.79 133.47 21.03 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.461 -178.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 57.67 33.34 23.12 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.245 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 74.01 8.13 77.72 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 111.514 -0.634 . . . . 0.0 111.514 179.098 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 58.6 mttp -106.98 150.19 26.74 Favored 'General case' 0 N--CA 1.466 0.356 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 53.4 t -116.55 132.56 65.83 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.054 -179.808 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' GLY . . . . . 0.416 ' O ' ' OE1' ' A' ' 44' ' ' GLU . . . -159.78 -169.46 23.12 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 110.97 -0.852 . . . . 0.0 110.97 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.526 ' CE1' ' OE1' ' A' ' 44' ' ' GLU . 97.8 m-85 -125.39 154.78 41.38 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.799 0.333 . . . . 0.0 110.482 -179.759 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -136.12 151.8 50.17 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.281 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 21.2 m -63.24 145.2 56.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.533 -179.71 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 58.8 pttt -77.53 -24.79 49.89 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.919 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 21.4 m -62.25 -41.27 98.29 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.394 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' TYR . . . . . 0.535 ' C ' HD12 ' A' ' 59' ' ' ILE . 90.2 m-85 -92.65 -2.07 56.38 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 116.552 -0.295 . . . . 0.0 111.635 -178.857 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.535 HD12 ' C ' ' A' ' 58' ' ' TYR . 1.3 mp -113.7 130.03 68.5 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 92.6 m -118.51 127.92 54.09 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.25 179.677 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 25.2 mm -77.36 133.83 29.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.439 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 78.7 t -96.41 131.54 42.95 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.224 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.608 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' ASN . . . . . 0.416 ' O ' ' N ' ' A' ' 65' ' ' GLY . 51.8 t-20 59.0 51.86 6.84 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.157 179.695 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' GLU . . . . . 0.649 ' H ' ' CD ' ' A' ' 64' ' ' GLU . 2.0 pm0 -68.52 58.65 0.08 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.759 179.902 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' A' ' 63' ' ' ASN . . . 76.44 18.85 78.82 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.73 -0.948 . . . . 0.0 110.73 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 81.4 p -67.6 156.22 37.31 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.928 0.394 . . . . 0.0 110.573 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.408 ' O ' ' CE1' ' A' ' 69' ' ' HIS . 2.5 pp -148.98 -6.38 0.38 Allowed 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.23 -179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 57.7 mp0 -67.06 135.04 53.04 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.447 179.906 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' HIS . . . . . 0.475 ' C ' ' CG ' ' A' ' 70' ' ' HIS . 80.0 m80 -119.83 151.85 38.21 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.432 -179.895 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' HIS . . . . . 0.475 ' CG ' ' C ' ' A' ' 69' ' ' HIS . 12.5 p80 38.63 40.41 0.4 Allowed 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.997 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 33.8 p-80 -72.13 144.63 48.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.416 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 79.5 t60 -133.37 131.61 40.26 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.48 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 99.4 m-70 -85.07 135.43 34.0 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.429 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' HIS . . . . . 0.488 ' ND1' ' O ' ' A' ' 74' ' ' HIS . 60.7 t-80 . . . . . 0 C--O 1.22 -0.466 0 CA-C-O 117.972 -1.013 . . . . 0.0 110.552 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 93.6 mtp . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 120.838 0.351 . . . . 0.0 110.355 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 99.2 mm-40 -116.85 120.69 39.29 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.111 -0.495 . . . . 0.0 109.733 179.169 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -91.89 145.0 17.47 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 111.487 -0.645 . . . . 0.0 111.487 -179.471 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 58.8 t -123.62 131.83 72.4 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.451 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 70.6 t -93.28 127.39 45.39 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.249 0 CA-C-O 120.817 0.341 . . . . 0.0 110.607 -179.715 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 53.8 mtmt -126.43 107.1 9.96 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.37 179.703 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 9.8 p -137.96 159.46 33.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.002 -179.853 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 93.9 m-20 -61.26 -41.65 97.27 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.522 -0.308 . . . . 0.0 110.813 -179.291 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 5.2 t -143.68 -51.62 0.33 Allowed 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 120.803 0.335 . . . . 0.0 110.961 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -157.69 144.14 17.78 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.469 -179.659 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 52.3 tp -117.85 132.99 56.37 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 120.864 0.364 . . . . 0.0 110.118 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 99.7 m-20 -76.3 139.23 40.97 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.021 179.672 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 35.6 ttp -100.21 139.11 36.35 Favored 'General case' 0 N--CA 1.465 0.276 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' ARG . . . . . 0.46 ' HE ' ' HA ' ' A' ' 19' ' ' SER . 84.3 mtt85 -113.27 158.03 21.03 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.858 0.361 . . . . 0.0 110.818 -178.504 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 8.8 m -80.04 -11.53 59.77 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.94 -179.303 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -164.23 -173.01 32.41 Favored Glycine 0 CA--C 1.52 0.406 0 N-CA-C 110.815 -0.914 . . . . 0.0 110.815 179.47 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -82.74 75.82 4.37 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 122.612 2.208 . . . . 0.0 111.667 179.753 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.76 130.9 1.35 Allowed Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 179.722 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.46 ' HA ' ' HE ' ' A' ' 14' ' ' ARG . 80.6 p -70.1 -9.02 54.14 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.666 0.27 . . . . 0.0 110.963 -179.884 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 93.6 m-20 -83.55 -0.78 51.82 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.798 -179.876 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 43.0 m-85 -90.98 -2.71 57.66 Favored 'General case' 0 N--CA 1.462 0.167 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.654 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 71.87 -179.34 34.84 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.444 ' O ' HG13 ' A' ' 23' ' ' VAL . 14.2 p -108.61 127.04 65.39 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 CA-C-O 120.889 0.376 . . . . 0.0 110.176 179.594 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 26.1 pt -104.49 -3.3 9.67 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 CA-C-O 120.953 0.406 . . . . 0.0 110.717 -179.65 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.88 -178.52 48.53 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.865 -0.894 . . . . 0.0 110.865 -179.876 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 44.7 p -133.41 155.97 48.53 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.913 0.387 . . . . 0.0 110.549 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 78.6 mt -122.84 146.99 47.06 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.294 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 66.0 mtm180 -106.42 153.46 22.22 Favored 'General case' 0 CA--C 1.515 -0.368 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.517 179.877 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 50.8 p-10 -60.0 157.02 13.53 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.359 179.667 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 11.2 t-20 64.39 4.27 2.14 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.266 179.718 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 67.2 t0 -79.95 120.75 24.57 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.466 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 31.1 mtmm -101.15 138.18 38.51 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 120.864 0.364 . . . . 0.0 110.445 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 33.5 m -138.32 163.57 28.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.621 -179.723 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -85.34 134.95 34.08 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.479 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 86.6 mt -103.5 128.23 56.82 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.485 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.846 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.783 ' N ' HD12 ' A' ' 36' ' ' ILE . 2.0 mp -91.36 -44.49 14.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.834 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 62.6 pttt -172.52 160.09 4.67 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.648 -179.651 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' GLU . . . . . 0.473 ' CD ' ' CE1' ' A' ' 43' ' ' TYR . 82.6 tt0 -111.39 127.77 55.77 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.439 -179.866 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 57.5 t -127.91 129.94 69.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.707 179.794 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 53.19 30.83 10.47 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.361 -0.382 . . . . 0.0 111.592 179.137 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.9 -28.37 7.26 Favored Glycine 0 CA--C 1.521 0.427 0 N-CA-C 110.919 -0.873 . . . . 0.0 110.919 179.655 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 58.6 m95 -71.7 142.36 49.83 Favored 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 120.865 -0.334 . . . . 0.0 110.11 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' TYR . . . . . 0.473 ' CE1' ' CD ' ' A' ' 38' ' ' GLU . 59.9 m-85 -102.94 133.01 48.76 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.379 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 75.1 tt0 -91.79 121.36 33.34 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.308 179.414 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 46.2 pt -125.53 160.08 32.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.526 -0.306 . . . . 0.0 110.977 -179.124 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 22.0 ttt180 -120.54 126.95 51.63 Favored 'General case' 0 CA--C 1.54 0.566 0 CA-C-N 115.896 -0.593 . . . . 0.0 109.698 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.43 ' O ' ' CG ' ' A' ' 48' ' ' ASN . 32.7 t80 -145.09 145.39 31.4 Favored 'General case' 0 N--CA 1.473 0.676 0 O-C-N 123.04 0.212 . . . . 0.0 110.471 -178.353 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.43 ' CG ' ' O ' ' A' ' 47' ' ' PHE . 10.1 p30 51.52 25.74 2.88 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.109 -179.851 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 77.94 17.5 78.39 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 111.447 -0.661 . . . . 0.0 111.447 179.441 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -124.24 145.65 49.23 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-O 120.82 0.343 . . . . 0.0 110.283 179.675 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 53.2 t -112.14 131.65 62.99 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.317 -179.691 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -150.21 -164.17 11.67 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.478 -1.049 . . . . 0.0 110.478 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 55.3 m-85 -132.3 152.16 51.51 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 120.841 0.353 . . . . 0.0 110.695 -179.692 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -141.49 157.37 45.22 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.509 -179.581 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 38.1 t -61.19 139.8 58.05 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.226 -179.475 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -83.96 -12.94 54.58 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.691 179.807 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 37.3 m -70.6 -21.06 62.7 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.22 -179.28 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -115.74 4.43 14.01 Favored 'General case' 0 N--CA 1.47 0.562 0 CA-C-O 120.624 0.249 . . . . 0.0 111.131 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 97.1 mt -125.42 129.62 72.92 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 CA-C-O 120.879 0.371 . . . . 0.0 110.763 179.693 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 85.0 m -127.96 132.36 49.23 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.836 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.42 HD11 ' CE1' ' A' ' 43' ' ' TYR . 96.1 mt -80.79 128.32 38.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.359 179.583 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.425 ' O ' ' CB ' ' A' ' 63' ' ' ASN . 22.1 m -102.92 146.22 11.12 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.693 -179.876 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' ASN . . . . . 0.425 ' CB ' ' O ' ' A' ' 62' ' ' VAL . 3.1 t-20 79.83 -145.11 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.303 179.823 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 13.7 pt-20 -46.14 141.39 3.35 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.942 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 151.01 13.62 0.08 OUTLIER Glycine 0 CA--C 1.526 0.731 0 N-CA-C 111.224 -0.75 . . . . 0.0 111.224 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 73.7 m -157.79 169.55 24.37 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 110.027 -0.36 . . . . 0.0 110.027 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.506 HD13 ' N ' ' A' ' 68' ' ' GLU . 0.3 OUTLIER -89.05 114.08 25.26 Favored 'General case' 0 C--N 1.331 -0.2 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 -179.302 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.506 ' N ' HD13 ' A' ' 67' ' ' LEU . 45.7 tt0 -74.87 151.32 38.98 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.433 -179.541 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 31.2 p-80 -123.34 147.83 46.64 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.087 179.751 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' HIS . . . . . . . . . . . . . 51.7 p-80 -150.7 166.48 30.27 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-O 120.773 0.32 . . . . 0.0 110.628 -179.752 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 79.1 m80 -69.6 145.43 52.52 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.754 -179.479 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 52.7 p-80 -81.33 2.98 25.84 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.848 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 60.4 t-80 -65.25 -42.2 93.53 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.729 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 69.6 m80 . . . . . 0 C--O 1.22 -0.456 0 CA-C-O 117.98 -1.009 . . . . 0.0 110.5 -179.705 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 26.8 ttt . . . . . 0 N--CA 1.49 1.53 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 2.7 mp0 -136.37 117.27 14.19 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.567 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -90.68 171.0 35.7 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 179.49 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 53.3 t -124.71 130.12 73.48 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.541 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 59.7 t -91.0 127.24 43.54 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.259 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 59.9 mttp -121.79 110.57 16.07 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 120.841 0.353 . . . . 0.0 110.089 179.634 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.428 HG22 ' CD1' ' A' ' 58' ' ' TYR . 72.4 t -126.69 138.29 55.23 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.185 -179.317 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.422 ' O ' ' OD1' ' A' ' 8' ' ' ASN . 56.5 t-20 -62.73 -41.6 99.25 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.345 -179.192 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 21.6 m -130.87 -76.73 0.53 Allowed 'General case' 0 N--CA 1.468 0.433 0 CA-C-O 120.776 0.322 . . . . 0.0 110.806 -179.552 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -151.93 140.61 20.83 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.818 -179.696 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.429 HD22 ' CG ' ' A' ' 58' ' ' TYR . 53.8 tp -123.17 133.22 54.26 Favored 'General case' 0 N--CA 1.469 0.488 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.203 179.8 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ASN . . . . . 0.431 ' HB2' HH12 ' A' ' 14' ' ' ARG . 99.5 m-20 -81.7 140.08 34.54 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.977 179.755 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' MET . . . . . 0.474 ' SD ' HD11 ' A' ' 24' ' ' ILE . 7.3 tmm? -91.31 136.29 33.21 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-O 121.257 0.551 . . . . 0.0 110.37 -179.882 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' ARG . . . . . 0.431 HH12 ' HB2' ' A' ' 12' ' ' ASN . 4.0 mmt-85 -105.63 140.61 38.43 Favored 'General case' 0 CA--C 1.542 0.648 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.708 -178.127 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' SER . . . . . 0.505 ' OG ' HD13 ' A' ' 24' ' ' ILE . 68.5 m -78.6 -7.44 57.6 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.893 -177.941 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -153.77 -166.04 14.33 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -85.48 -0.68 8.92 Favored 'Trans proline' 0 C--N 1.302 -1.887 0 C-N-CA 122.479 2.119 . . . . 0.0 111.794 -179.768 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -99.12 128.2 9.49 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 110.808 -0.917 . . . . 0.0 110.808 179.503 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 78.5 p -69.64 -14.97 63.09 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.83 0.348 . . . . 0.0 110.622 179.672 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 96.7 m-20 -91.72 14.07 16.34 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.482 -179.368 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 7.9 m-85 -87.26 0.7 54.97 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.879 0.371 . . . . 0.0 110.041 179.853 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 79.47 171.33 41.32 Favored Glycine 0 CA--C 1.524 0.619 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 179.781 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.477 ' O ' HG13 ' A' ' 23' ' ' VAL . 11.3 p -106.99 126.72 63.01 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 CA-C-O 120.728 0.299 . . . . 0.0 110.471 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.505 HD13 ' OG ' ' A' ' 15' ' ' SER . 24.9 pt -106.07 -2.43 9.91 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.475 0 CA-C-O 121.005 0.431 . . . . 0.0 110.552 179.734 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -176.46 -177.15 45.22 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 110.47 -1.052 . . . . 0.0 110.47 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 61.3 p -131.92 153.6 50.1 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-O 121.03 0.443 . . . . 0.0 110.469 179.881 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 83.0 mt -123.6 147.62 47.16 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.402 179.238 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 1.7 mtm180 -124.32 153.84 41.17 Favored 'General case' 0 C--O 1.224 -0.287 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.666 -178.277 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 53.1 p-10 -56.19 165.52 1.01 Allowed 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.35 0.595 . . . . 0.0 112.059 -179.532 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 71.0 m-80 59.29 13.18 2.95 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 114.995 -1.002 . . . . 0.0 111.316 179.579 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 91.3 m-20 -87.86 113.78 23.85 Favored 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 120.844 -0.342 . . . . 0.0 110.451 179.493 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -92.23 129.57 38.15 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.016 0.436 . . . . 0.0 110.441 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.4 m -137.11 161.16 35.77 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.145 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.081 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -89.91 131.09 36.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.298 -179.887 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.2 mt -97.69 107.71 20.55 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.216 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.435 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 97.5 mt -66.64 -44.21 89.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.925 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 63.2 pttt -173.05 178.9 2.38 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.769 -179.533 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -119.94 123.92 44.71 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.12 179.554 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 62.3 t -126.07 131.68 71.42 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-O 120.974 0.416 . . . . 0.0 110.626 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 54.5 31.39 14.74 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.278 179.361 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.537 ' O ' ' NZ ' ' A' ' 56' ' ' LYS . . . 82.97 -15.91 30.13 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 179.755 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 11.4 m95 -86.08 148.29 25.78 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.708 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 51.5 m-85 -100.91 132.94 46.07 Favored 'General case' 0 C--O 1.233 0.187 0 CA-C-O 121.111 0.482 . . . . 0.0 110.523 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -94.46 127.04 40.11 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.376 -0.829 . . . . 0.0 109.271 179.163 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 43.7 pt -129.22 157.14 42.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 CA-C-O 121.135 0.493 . . . . 0.0 111.784 -178.862 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 31.1 ttp180 -115.6 124.37 50.79 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.719 178.748 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 34.4 t80 -145.14 132.95 21.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.709 -179.466 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 62.2 t30 56.62 32.92 21.86 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.608 179.77 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 71.83 11.87 74.13 Favored Glycine 0 CA--C 1.528 0.875 0 N-CA-C 111.369 -0.693 . . . . 0.0 111.369 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 65.6 mttp -111.62 147.31 35.75 Favored 'General case' 0 N--CA 1.467 0.409 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.755 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 52.9 t -117.44 132.06 68.35 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.067 -179.778 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' GLY . . . . . 0.418 ' C ' ' CD1' ' A' ' 53' ' ' TYR . . . -156.27 -167.02 16.99 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.491 -1.044 . . . . 0.0 110.491 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.535 ' CD1' ' N ' ' A' ' 53' ' ' TYR . 10.1 m-85 -137.15 154.6 50.21 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-O 120.811 0.338 . . . . 0.0 110.451 -179.486 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -147.05 152.85 39.23 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.322 179.802 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 9.7 p -63.95 142.92 58.23 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.881 0.372 . . . . 0.0 110.753 -179.708 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.537 ' NZ ' ' O ' ' A' ' 41' ' ' GLY . 0.0 OUTLIER -66.24 -12.74 58.08 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.711 -179.358 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 6.1 m -65.06 -15.74 62.69 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.544 -0.298 . . . . 0.0 111.215 -179.515 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' TYR . . . . . 0.429 ' CG ' HD22 ' A' ' 11' ' ' LEU . 95.2 m-85 -117.8 5.67 12.26 Favored 'General case' 0 N--CA 1.472 0.651 0 N-CA-C 111.69 0.256 . . . . 0.0 111.69 -179.737 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 4.2 mp -121.49 130.15 74.9 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 CA-C-O 121.246 0.546 . . . . 0.0 110.154 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 85.5 m -123.91 132.63 53.77 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.197 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.0 mt -72.79 129.22 35.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.169 179.769 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 89.2 t -74.5 134.05 30.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.671 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 57.49 42.11 24.97 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.744 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 11.5 tm-20 -56.67 -37.32 70.66 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.535 -179.75 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -77.11 -121.0 0.19 Allowed Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.635 -0.986 . . . . 0.0 110.635 179.695 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.9 m 56.65 96.65 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.989 0.424 . . . . 0.0 110.744 179.682 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.509 HD22 ' N ' ' A' ' 67' ' ' LEU . 3.9 mm? -62.72 -41.33 99.11 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.956 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.535 ' OE2' ' NE2' ' A' ' 70' ' ' HIS . 43.8 tp10 -159.38 -105.62 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.3 179.843 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 69.7 t60 40.42 85.88 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.264 0 CA-C-O 120.906 0.384 . . . . 0.0 111.088 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' HIS . . . . . 0.535 ' NE2' ' OE2' ' A' ' 68' ' ' GLU . 96.3 m-70 -64.76 -37.57 88.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.996 -179.775 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.427 ' O ' ' O ' ' A' ' 70' ' ' HIS . 53.2 t-80 57.11 120.56 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.138 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 31.0 p80 -153.43 159.64 42.4 Favored 'General case' 0 C--N 1.333 -0.142 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.64 179.712 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.519 ' O ' ' CG ' ' A' ' 73' ' ' HIS . 52.9 p-80 -168.76 94.23 0.33 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.635 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 8.5 p80 . . . . . 0 C--O 1.222 -0.378 0 CA-C-O 117.979 -1.01 . . . . 0.0 110.562 -179.75 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 24.3 ptp . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 98.4 mm-40 -124.07 108.59 12.51 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-O 121.094 0.473 . . . . 0.0 110.148 179.727 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -100.03 154.27 19.52 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.748 -0.941 . . . . 0.0 110.748 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 64.1 t -124.4 130.85 73.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.586 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 88.1 t -88.47 128.41 40.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.62 -179.786 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -127.46 105.51 8.56 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.242 179.606 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 30.9 m -138.89 159.96 30.03 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.254 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.715 179.799 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 -91.41 -4.05 56.06 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.38 179.698 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 17.4 m -154.39 -166.95 2.48 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.34 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -67.18 143.82 56.35 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.466 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 51.3 tp -117.51 130.62 56.55 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 116.182 -0.463 . . . . 0.0 109.88 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 97.6 m-20 -89.22 134.2 34.13 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.439 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 52.1 ttp -105.38 145.96 30.08 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 116.174 -0.466 . . . . 0.0 109.834 179.765 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 93.8 mtt-85 -119.13 159.82 23.25 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-O 120.936 0.398 . . . . 0.0 111.162 -179.554 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 86.2 p -81.67 -5.94 58.56 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.617 -0.72 . . . . 0.0 110.133 179.638 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.433 ' C ' ' H ' ' A' ' 18' ' ' GLY . . . -159.55 167.31 35.13 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 110.625 -0.99 . . . . 0.0 110.625 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo -69.94 12.27 0.36 Allowed 'Trans proline' 0 C--N 1.308 -1.6 0 C-N-CA 121.883 1.722 . . . . 0.0 111.904 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' GLY . . . . . 0.433 ' H ' ' C ' ' A' ' 16' ' ' GLY . . . -99.4 124.12 8.13 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.861 -0.895 . . . . 0.0 110.861 179.225 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 79.5 p -66.94 -10.21 46.6 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.757 0.313 . . . . 0.0 110.535 179.779 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 55.0 p30 -90.95 6.18 45.7 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.64 -179.284 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 32.4 m-85 -88.5 -10.41 49.06 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.39 179.852 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 75.9 176.75 41.11 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 111.361 -0.696 . . . . 0.0 111.361 179.102 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.499 ' O ' HG13 ' A' ' 23' ' ' VAL . 12.1 p -92.48 127.17 44.82 Favored 'Isoleucine or valine' 0 C--O 1.232 0.151 0 CA-C-O 120.711 0.291 . . . . 0.0 110.528 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 24.5 pt -106.11 -5.02 9.97 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-O 120.872 0.368 . . . . 0.0 110.623 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.6 175.3 47.24 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.808 -0.917 . . . . 0.0 110.808 -179.824 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 73.9 m -125.88 130.36 51.18 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 120.878 0.371 . . . . 0.0 110.463 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 72.8 mt -112.44 142.43 44.99 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.711 179.633 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.774 HH11 ' HG3' ' A' ' 28' ' ' ARG . 71.4 mtm-85 -108.42 164.12 12.61 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-O 121.345 0.593 . . . . 0.0 111.117 -179.551 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.414 ' C ' ' H ' ' A' ' 31' ' ' ASP . 57.1 p30 -67.26 166.84 13.44 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.024 179.803 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 79.5 m-20 59.41 3.16 0.37 Allowed 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.098 -179.765 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.461 ' OD2' ' N ' ' A' ' 28' ' ' ARG . 98.3 m-20 -72.66 140.02 47.67 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.987 0.422 . . . . 0.0 110.59 179.37 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 53.4 mttp -107.19 125.78 51.55 Favored 'General case' 0 N--CA 1.476 0.859 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.38 179.017 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.3 m -136.65 162.4 35.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 178.912 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -100.56 123.89 45.37 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-O 120.835 0.35 . . . . 0.0 110.555 -179.738 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.7 mt -84.68 130.12 36.55 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.128 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.469 179.588 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.5 mt -98.88 -54.86 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.196 -179.603 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 8.7 ttmm -150.64 153.01 34.88 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-O 120.799 0.333 . . . . 0.0 110.974 -179.405 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' GLU . . . . . 0.448 ' CD ' ' CE1' ' A' ' 43' ' ' TYR . 83.5 tt0 -112.86 122.65 48.28 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.146 179.351 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 62.7 t -130.73 132.88 63.97 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.154 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 53.2 25.46 4.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.011 179.431 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.63 -24.62 25.03 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 179.625 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 33.2 m95 -74.38 144.74 44.24 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.762 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' TYR . . . . . 0.448 ' CE1' ' CD ' ' A' ' 38' ' ' GLU . 78.3 m-85 -105.98 131.67 53.0 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 120.852 0.358 . . . . 0.0 110.847 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 76.9 tt0 -88.21 123.23 32.63 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.328 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 46.2 pt -126.95 160.66 35.22 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.673 0 CA-C-O 121.594 0.711 . . . . 0.0 110.944 -179.017 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 12.5 ttm180 -122.6 129.46 51.92 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.123 -0.944 . . . . 0.0 110.853 -179.285 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 59.2 t80 -148.69 131.55 16.11 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.257 -179.82 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.574 ' ND2' ' O ' ' A' ' 48' ' ' ASN . 3.3 t30 57.48 36.74 27.32 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.907 179.518 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 69.64 15.36 70.89 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 179.774 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 35.9 ttmt -117.18 137.22 52.48 Favored 'General case' 0 N--CA 1.466 0.329 0 N-CA-C 110.321 -0.252 . . . . 0.0 110.321 -179.714 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 53.4 t -111.11 131.04 63.43 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.86 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -145.17 -161.94 9.33 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.759 -0.936 . . . . 0.0 110.759 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 81.3 m-85 -138.58 154.21 48.7 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 120.721 0.296 . . . . 0.0 110.396 -179.689 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -145.18 150.54 36.92 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.198 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.448 ' OG ' ' CD2' ' A' ' 58' ' ' TYR . 8.7 p -75.49 153.0 37.79 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.097 0.475 . . . . 0.0 111.434 -179.177 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -65.95 -30.17 70.7 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.63 -0.713 . . . . 0.0 111.609 179.278 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 95.8 p -55.67 -28.95 58.3 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.532 -178.719 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' TYR . . . . . 0.538 ' C ' HD12 ' A' ' 59' ' ' ILE . 19.9 m-85 -108.52 -6.22 16.19 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 111.446 0.165 . . . . 0.0 111.446 -179.709 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.538 HD12 ' C ' ' A' ' 58' ' ' TYR . 1.4 mp -112.68 130.05 67.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 N-CA-C 109.595 -0.521 . . . . 0.0 109.595 -179.764 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 92.8 m -123.63 132.03 53.76 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-N 115.716 -0.674 . . . . 0.0 109.979 179.591 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.3 mt -76.82 131.4 34.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.625 -179.63 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 95.3 t -82.28 132.14 32.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.26 179.641 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' ASN . . . . . 0.438 ' O ' ' O ' ' A' ' 64' ' ' GLU . 98.3 m-20 57.34 67.91 0.92 Allowed 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.729 -179.646 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' GLU . . . . . 0.438 ' O ' ' O ' ' A' ' 63' ' ' ASN . 58.3 mp0 -52.57 -170.04 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.538 -179.789 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -67.42 102.03 0.76 Allowed Glycine 0 CA--C 1.526 0.743 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 36.2 t -71.39 146.82 48.49 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.081 0.467 . . . . 0.0 111.003 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 72.6 mt 58.39 177.32 0.06 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.863 179.663 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 52.95 21.17 1.91 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.728 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 55.9 p-80 -82.46 -14.96 54.19 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.888 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' HIS . . . . . 0.557 ' ND1' ' N ' ' A' ' 71' ' ' HIS . 56.3 t-80 48.67 -107.64 0.23 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.46 -0.337 . . . . 0.0 110.833 179.772 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.557 ' N ' ' ND1' ' A' ' 70' ' ' HIS . 56.4 t-80 -148.12 -47.39 0.16 Allowed 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.589 -179.827 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.537 ' CD2' ' H ' ' A' ' 73' ' ' HIS . 8.6 t-160 -154.0 163.72 39.62 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.592 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.537 ' H ' ' CD2' ' A' ' 72' ' ' HIS . 97.1 m-70 56.91 -178.31 0.05 Allowed 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.009 -179.913 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 76.2 m80 . . . . . 0 C--O 1.22 -0.488 0 CA-C-O 117.938 -1.029 . . . . 0.0 110.675 -179.866 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 39.7 tpp . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 2.6 mp0 -139.21 109.44 6.46 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.253 179.8 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -85.34 163.73 37.66 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.881 -0.888 . . . . 0.0 110.881 179.803 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 77.3 t -127.1 134.13 66.74 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-O 120.85 0.357 . . . . 0.0 110.131 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 19.8 t -83.15 128.39 38.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.55 179.76 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 68.0 mmtt -123.02 105.5 10.02 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.151 179.652 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.6 m -148.79 157.92 7.07 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.557 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 50.9 p30 -83.96 -9.78 58.43 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.81 179.789 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.473 ' OG ' ' N ' ' A' ' 10' ' ' ALA . 48.4 t -155.24 -165.26 1.97 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.856 0.36 . . . . 0.0 110.722 -179.759 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.473 ' N ' ' OG ' ' A' ' 9' ' ' SER . . . -64.38 143.55 57.82 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.659 -179.858 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 47.3 tp -121.55 133.08 55.01 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-O 120.953 0.406 . . . . 0.0 110.307 179.675 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 99.5 m-20 -82.74 142.47 31.59 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.991 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 49.6 ttp -113.48 148.57 35.72 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.939 179.544 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' ARG . . . . . 0.81 ' NH2' ' CH2' ' A' ' 42' ' ' TRP . 43.4 mtm180 -121.41 153.87 37.27 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-O 121.117 0.484 . . . . 0.0 111.599 -179.001 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 11.3 t -62.76 -41.83 99.4 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.439 179.748 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -140.99 -164.97 10.13 Favored Glycine 0 N--CA 1.466 0.676 0 N-CA-C 111.382 -0.687 . . . . 0.0 111.382 -179.401 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -85.03 71.41 5.08 Favored 'Trans proline' 0 C--N 1.31 -1.471 0 C-N-CA 122.893 2.395 . . . . 0.0 112.103 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' GLY . . . . . 0.706 ' H ' ' NH1' ' A' ' 14' ' ' ARG . . . -167.74 120.22 0.89 Allowed Glycine 0 CA--C 1.523 0.545 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 179.654 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 8.9 t -60.95 -9.01 3.6 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.944 0.402 . . . . 0.0 110.326 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 89.9 m-20 -89.79 5.55 45.57 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.993 -179.456 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 22.0 m-85 -88.22 -7.94 56.05 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 120.681 0.277 . . . . 0.0 110.377 179.887 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 67.68 179.07 14.02 Favored Glycine 0 CA--C 1.521 0.447 0 N-CA-C 110.84 -0.904 . . . . 0.0 110.84 179.641 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.455 ' O ' HG13 ' A' ' 23' ' ' VAL . 9.3 p -92.18 124.21 44.57 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.183 0 CA-C-O 120.787 0.327 . . . . 0.0 110.704 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 24.4 pt -104.35 -5.52 9.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.802 -179.856 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.65 177.05 47.52 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 111.038 -0.825 . . . . 0.0 111.038 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 91.0 m -126.56 130.47 50.61 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-O 120.853 0.359 . . . . 0.0 110.301 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 72.7 mt -112.38 146.31 38.55 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.22 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 87.0 mtm-85 -115.42 161.51 18.46 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.028 179.931 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.481 ' C ' ' H ' ' A' ' 31' ' ' ASP . 50.8 p30 -69.13 166.77 17.52 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.929 -179.501 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 56.5 t30 71.03 -27.85 0.18 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.509 179.735 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.481 ' H ' ' C ' ' A' ' 29' ' ' ASN . 33.9 m-20 -67.48 137.6 55.95 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.583 -0.447 . . . . 0.0 109.926 179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 18.1 ptpt -104.06 145.81 29.63 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.654 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.0 m -133.91 161.72 40.5 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.266 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.234 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -92.28 132.93 36.3 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.231 -0.44 . . . . 0.0 109.875 179.552 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 5.5 mm -98.89 125.77 52.26 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 CA-C-O 120.947 0.404 . . . . 0.0 110.721 -179.461 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.6 mt -93.14 -46.88 13.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.565 179.828 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 31.6 ttpt -173.03 162.57 4.62 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 120.941 0.4 . . . . 0.0 111.153 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' GLU . . . . . 0.501 ' OE1' ' CE1' ' A' ' 43' ' ' TYR . 82.2 tt0 -110.54 124.05 51.1 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.034 179.497 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 96.9 t -128.04 131.63 69.31 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.099 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 54.41 29.99 11.97 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.569 178.886 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.69 -11.25 64.68 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 111.254 -0.739 . . . . 0.0 111.254 179.388 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.81 ' CH2' ' NH2' ' A' ' 14' ' ' ARG . 82.8 m95 -89.45 143.25 26.97 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.604 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' TYR . . . . . 0.501 ' CE1' ' OE1' ' A' ' 38' ' ' GLU . 53.4 m-85 -100.94 130.52 46.95 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.732 0.301 . . . . 0.0 110.654 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -82.54 132.57 35.19 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 179.157 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 43.2 pt -132.67 153.02 37.28 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.241 0 CA-C-O 121.098 0.475 . . . . 0.0 111.236 -179.474 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 60.3 ttp180 -127.6 125.36 40.1 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.515 -0.766 . . . . 0.0 109.923 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.443 ' O ' ' OD1' ' A' ' 48' ' ' ASN . 19.0 t80 -151.4 146.13 25.74 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.886 -179.276 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.443 ' OD1' ' O ' ' A' ' 47' ' ' PHE . 8.2 p-10 47.19 38.2 6.54 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.526 179.723 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 67.62 23.1 73.76 Favored Glycine 0 CA--C 1.522 0.5 0 N-CA-C 111.33 -0.708 . . . . 0.0 111.33 179.085 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 69.4 mmtt -128.33 144.13 51.09 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.825 0.345 . . . . 0.0 110.143 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 75.4 t -113.82 133.29 60.27 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.205 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.158 -179.678 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -153.32 -166.26 14.38 Favored Glycine 0 CA--C 1.521 0.431 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 179.876 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 45.9 m-85 -136.24 155.88 49.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.837 0.351 . . . . 0.0 110.062 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -137.22 154.97 50.05 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.548 -179.647 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 41.3 t -61.78 142.39 57.32 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.505 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 61.9 pttt -68.24 -31.67 71.31 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.353 -179.601 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 19.8 m -60.92 -41.32 95.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.822 -179.245 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 70.7 m-85 -96.23 11.9 32.85 Favored 'General case' 0 N--CA 1.467 0.411 0 N-CA-C 111.837 0.31 . . . . 0.0 111.837 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 5.4 mm -121.33 129.32 75.72 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 CA-C-O 121.01 0.433 . . . . 0.0 110.503 179.748 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 99.4 m -122.71 127.52 49.36 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.348 179.754 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.7 mt -83.2 131.16 34.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.568 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 94.3 t -71.43 132.77 32.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.312 -0.403 . . . . 0.0 110.471 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' ASN . . . . . 0.515 ' CG ' ' H ' ' A' ' 64' ' ' GLU . 6.3 t-20 66.8 -164.75 0.22 Allowed 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.536 -179.803 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' GLU . . . . . 0.515 ' H ' ' CG ' ' A' ' 63' ' ' ASN . 80.6 mm-40 54.74 102.73 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.466 -179.764 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.47 ' O ' ' N ' ' A' ' 67' ' ' LEU . . . 65.8 -132.18 34.36 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 111.199 -0.76 . . . . 0.0 111.199 179.9 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 3.2 m 64.82 -62.71 0.19 Allowed 'General case' 0 N--CA 1.462 0.166 0 CA-C-O 120.559 0.218 . . . . 0.0 110.878 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.47 ' N ' ' O ' ' A' ' 65' ' ' GLY . 73.6 mt 56.2 -168.6 0.1 Allowed 'General case' 0 C--N 1.33 -0.249 0 N-CA-C 110.199 -0.297 . . . . 0.0 110.199 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 46.0 tp10 54.87 92.04 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.99 0.424 . . . . 0.0 110.31 -179.753 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' HIS . . . . . 0.533 ' ND1' ' N ' ' A' ' 69' ' ' HIS . 0.4 OUTLIER -150.56 169.85 20.55 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.105 -179.919 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 70' ' ' HIS . . . . . . . . . . . . . 38.6 m80 56.92 22.39 7.11 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.503 -179.648 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.415 ' CG ' ' N ' ' A' ' 72' ' ' HIS . 53.6 p-80 -66.16 -38.55 88.35 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.726 -179.921 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.415 ' N ' ' CG ' ' A' ' 71' ' ' HIS . 42.7 t-80 -60.98 -4.66 1.09 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.667 -179.847 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.465 ' O ' ' CG ' ' A' ' 74' ' ' HIS . 49.9 m80 55.16 -95.39 0.05 OUTLIER 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.642 -179.849 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' HIS . . . . . 0.465 ' CG ' ' O ' ' A' ' 73' ' ' HIS . 80.9 m80 . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 118.095 -0.955 . . . . 0.0 110.715 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 36.0 ttm . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 22.4 mm100 -129.31 116.42 19.07 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.373 179.682 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -87.58 156.94 28.36 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 110.813 -0.915 . . . . 0.0 110.813 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 59.1 t -125.88 132.71 70.39 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.632 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 21.9 t -81.68 128.66 38.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.675 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 71.2 mmtt -115.48 105.84 13.28 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.188 -0.46 . . . . 0.0 109.764 179.512 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.406 HG22 ' N ' ' A' ' 8' ' ' ASN . 12.5 p -145.79 155.88 12.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.535 -179.711 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.406 ' N ' HG22 ' A' ' 7' ' ' VAL . 75.6 m-20 -62.56 -41.45 98.92 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.909 -179.426 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 21.5 m -136.59 -57.58 0.74 Allowed 'General case' 0 N--CA 1.466 0.326 0 CA-C-O 120.656 0.265 . . . . 0.0 110.92 -179.77 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -157.65 144.62 18.15 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.8 0.333 . . . . 0.0 110.558 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 44.9 tp -111.83 130.62 55.75 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.463 -179.627 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ASN . . . . . 0.4 ' OD1' ' O ' ' A' ' 12' ' ' ASN . 47.3 p-10 -71.95 137.99 47.73 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.701 179.762 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 37.7 ttp -100.45 136.69 39.94 Favored 'General case' 0 N--CA 1.464 0.275 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 179.734 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' ARG . . . . . 0.456 ' HE ' ' HA ' ' A' ' 19' ' ' SER . 84.0 mtt85 -107.67 157.52 18.02 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.669 -179.143 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 85.6 p -84.18 -10.34 57.82 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.681 179.795 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -161.99 -171.89 28.68 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 111.161 -0.776 . . . . 0.0 111.161 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_endo -84.02 68.84 6.61 Favored 'Trans proline' 0 C--N 1.309 -1.549 0 C-N-CA 122.815 2.344 . . . . 0.0 111.653 -179.833 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -179.97 134.77 2.3 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.456 ' HA ' ' HE ' ' A' ' 14' ' ' ARG . 15.9 m -76.89 -8.94 58.27 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.724 0.297 . . . . 0.0 111.003 -179.526 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 67.1 t30 -83.59 -1.48 53.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.878 -179.798 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 50.1 m-85 -86.71 -5.93 58.98 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 120.768 0.318 . . . . 0.0 110.294 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 77.18 166.35 25.74 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.92 -0.872 . . . . 0.0 110.92 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.466 ' O ' HG13 ' A' ' 23' ' ' VAL . 14.4 p -95.26 127.25 47.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.731 0.3 . . . . 0.0 110.481 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 25.4 pt -101.89 -5.06 9.23 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.288 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.804 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.76 -177.43 47.37 Favored Glycine 0 CA--C 1.529 0.948 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 62.8 p -134.74 157.99 45.28 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-O 120.885 0.374 . . . . 0.0 111.025 -179.705 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 67.6 mt -124.88 145.06 49.99 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.168 -0.469 . . . . 0.0 109.846 179.804 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 13.8 mtm180 -93.63 173.48 7.67 Favored 'General case' 0 C--O 1.233 0.235 0 CA-C-O 121.262 0.553 . . . . 0.0 110.847 179.863 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.433 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 51.7 p-10 -73.6 144.48 45.96 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.43 -0.804 . . . . 0.0 109.554 178.359 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 12.3 t-20 58.49 34.7 24.15 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.564 -0.289 . . . . 0.0 111.192 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -88.79 112.7 23.52 Favored 'General case' 0 N--CA 1.468 0.44 0 N-CA-C 110.018 -0.364 . . . . 0.0 110.018 179.447 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -75.88 130.37 38.43 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 120.665 -0.414 . . . . 0.0 110.091 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 33.2 m -137.87 163.24 30.46 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-O 120.902 0.382 . . . . 0.0 110.689 -179.696 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -102.28 123.64 46.44 Favored 'General case' 0 N--CA 1.463 0.203 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.265 179.805 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.2 mt -89.06 126.03 42.09 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.169 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.408 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.7 mt -92.91 -47.11 13.91 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.183 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.678 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 32.2 ttpt -168.94 158.0 8.42 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.876 -179.807 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -108.4 120.98 43.98 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.962 179.819 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 77.8 t -126.22 132.31 70.61 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.849 -179.442 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 47.5 t0 58.14 25.92 13.07 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.394 179.056 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.93 -10.69 67.18 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 179.774 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 65.9 m95 -89.56 144.63 25.87 Favored 'General case' 0 C--N 1.331 -0.198 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 179.407 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 79.9 m-85 -97.43 127.91 43.78 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.87 0.367 . . . . 0.0 110.45 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 79.4 tt0 -88.3 126.62 35.27 Favored 'General case' 0 CA--C 1.522 -0.119 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 179.499 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 42.0 pt -132.47 161.48 41.39 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.283 0 CA-C-O 121.011 0.434 . . . . 0.0 111.784 -178.752 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 78.7 ttt-85 -114.64 124.38 51.69 Favored 'General case' 0 N--CA 1.464 0.268 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 178.806 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 45.5 t80 -156.68 146.06 20.55 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.924 0.392 . . . . 0.0 111.191 -179.106 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 54.9 t30 58.76 31.63 21.39 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.356 179.59 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 69.74 18.56 74.2 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 111.704 -0.558 . . . . 0.0 111.704 178.783 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -144.37 152.4 40.65 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 120.825 0.345 . . . . 0.0 110.775 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.8 t -85.59 157.99 3.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.176 179.885 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -167.84 -178.2 39.68 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 111.422 -0.671 . . . . 0.0 111.422 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 85.1 m-85 -133.33 153.02 51.94 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 120.734 0.302 . . . . 0.0 110.4 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -139.65 152.32 46.65 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.008 -179.824 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 27.2 t -64.91 142.36 58.46 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.033 -179.796 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 61.3 pttt -66.79 -33.65 76.09 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.461 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 38.9 t -61.69 -42.99 99.67 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.602 -178.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 90.2 m-85 -90.43 4.02 52.19 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.66 -0.245 . . . . 0.0 111.48 -179.115 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 5.8 mm -119.7 127.99 75.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 CA-C-O 120.909 0.385 . . . . 0.0 110.246 179.797 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 94.4 m -123.69 129.75 51.58 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.422 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.0 mt -80.12 131.75 33.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.649 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 93.9 t -69.23 134.43 30.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.14 179.62 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' ASN . . . . . 0.555 ' O ' ' ND2' ' A' ' 63' ' ' ASN . 0.4 OUTLIER -40.78 97.74 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.257 -0.428 . . . . 0.0 111.19 -179.533 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -68.59 -95.72 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.319 179.781 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -92.63 105.57 3.31 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.733 -0.947 . . . . 0.0 110.733 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 93.9 p -87.56 -7.18 57.86 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.775 0.321 . . . . 0.0 110.523 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.405 ' N ' HD23 ' A' ' 67' ' ' LEU . 0.1 OUTLIER -98.21 -4.95 34.32 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.108 -179.996 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -69.08 148.74 49.58 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.667 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' HIS . . . . . 0.616 ' CG ' ' H ' ' A' ' 70' ' ' HIS . 24.1 t-80 -152.47 -130.77 0.04 OUTLIER 'General case' 0 N--CA 1.463 0.176 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.662 -179.878 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' HIS . . . . . 0.616 ' H ' ' CG ' ' A' ' 69' ' ' HIS . 38.2 t-80 47.9 -115.52 0.69 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.674 -179.81 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.556 ' H ' ' CG ' ' A' ' 70' ' ' HIS . 90.4 m-70 39.04 83.83 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.07 -179.735 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 2.5 t-160 -93.21 123.16 36.29 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.365 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 84.5 t60 -117.41 119.83 36.28 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.43 179.895 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 52.1 p-80 . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 118.005 -0.998 . . . . 0.0 110.526 179.995 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 63.7 ttp . . . . . 0 N--CA 1.491 1.586 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 -129.66 128.05 41.79 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.606 -179.866 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -89.44 166.53 33.24 Favored Glycine 0 CA--C 1.522 0.491 0 N-CA-C 110.542 -1.023 . . . . 0.0 110.542 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 56.1 t -124.11 129.33 74.19 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.756 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 13.7 t -97.01 110.28 24.69 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.145 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.092 179.795 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 32.0 ttmt -119.11 120.01 35.89 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.162 179.764 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.493 HG22 ' N ' ' A' ' 8' ' ' ASN . 9.3 p -140.59 159.72 24.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.32 -179.884 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.493 ' N ' HG22 ' A' ' 7' ' ' VAL . 28.9 t-20 -60.85 -41.58 96.14 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.352 -178.834 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 5.1 t -130.14 -68.47 0.7 Allowed 'General case' 0 N--CA 1.467 0.419 0 CA-C-O 120.901 0.381 . . . . 0.0 110.563 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -158.11 144.14 17.21 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.997 -0.547 . . . . 0.0 109.948 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 40.0 tp -111.45 129.06 56.15 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-O 120.895 0.378 . . . . 0.0 110.585 -179.525 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 77.2 m-20 -75.69 141.43 42.72 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.413 179.694 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 30.9 ttp -102.73 147.52 26.74 Favored 'General case' 0 N--CA 1.47 0.575 0 CA-C-N 116.701 -0.227 . . . . 0.0 111.14 -179.287 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 76.2 mtt85 -119.54 142.11 48.63 Favored 'General case' 0 CA--C 1.506 -0.74 0 CA-C-O 121.285 0.564 . . . . 0.0 111.934 -178.819 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 78.9 p -66.98 -39.51 87.19 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.079 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -115.4 170.34 13.24 Favored Glycine 0 CA--C 1.527 0.793 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 179.509 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.3 Cg_endo -79.51 58.25 6.87 Favored 'Trans proline' 0 N--CA 1.492 1.425 0 C-N-CA 122.644 2.229 . . . . 0.0 112.175 179.557 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -176.99 149.68 9.73 Favored Glycine 0 CA--C 1.532 1.11 0 C-N-CA 120.938 -0.648 . . . . 0.0 111.756 179.879 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 32.7 t -64.37 -16.14 61.74 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 120.869 0.366 . . . . 0.0 110.888 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -72.67 -7.39 50.17 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.984 -179.536 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 55.9 m-85 -92.52 -6.21 50.15 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-O 120.635 0.255 . . . . 0.0 110.801 -179.877 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 67.03 -175.78 23.28 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 110.978 -0.849 . . . . 0.0 110.978 179.681 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.442 ' O ' HG13 ' A' ' 23' ' ' VAL . 10.9 p -105.29 128.86 58.89 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 CA-C-O 120.81 0.338 . . . . 0.0 110.77 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 41.6 pt -105.94 -6.76 10.07 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.551 179.462 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.39 -177.25 44.31 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 -179.849 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 57.8 p -131.17 155.95 46.14 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-O 120.924 0.392 . . . . 0.0 110.358 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 71.4 mt -123.76 149.48 45.57 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.77 -179.583 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 34.5 ttp85 -113.7 143.17 45.05 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 -179.561 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.432 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 57.2 p30 -46.65 153.38 0.39 Allowed 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.316 0.579 . . . . 0.0 112.263 -179.022 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 63.3 m-20 58.93 31.25 21.14 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.106 -0.952 . . . . 0.0 111.856 179.299 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 29.3 t0 -93.55 118.16 31.0 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-O 120.68 0.276 . . . . 0.0 110.258 179.11 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 29.5 mmtp -72.97 132.37 43.34 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 109.986 -0.375 . . . . 0.0 109.986 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 26.8 m -138.41 160.97 31.54 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.518 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -108.39 120.25 41.87 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.031 179.566 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 95.8 mt -85.46 128.81 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.155 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.527 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 26.1 mt -93.63 -61.31 2.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.188 -179.742 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 22.0 mtmm -149.31 158.51 44.24 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.747 179.608 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' GLU . . . . . 0.408 ' CD ' ' CE1' ' A' ' 43' ' ' TYR . 83.9 tt0 -111.35 122.47 47.94 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.049 179.616 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 74.8 t -125.35 130.02 72.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.598 -179.794 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 44.8 t0 52.57 27.29 4.97 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.101 179.333 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.02 -21.92 37.21 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 179.56 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 43.8 m95 -77.32 140.18 39.95 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.76 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' TYR . . . . . 0.408 ' CE1' ' CD ' ' A' ' 38' ' ' GLU . 71.0 m-85 -99.06 129.97 45.36 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.831 0.348 . . . . 0.0 110.341 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -88.13 120.46 29.51 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 179.413 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 45.6 pt -127.17 158.6 38.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.455 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.075 -179.195 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 16.4 ttm180 -119.95 126.46 50.92 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 116.203 -0.453 . . . . 0.0 109.979 179.61 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 71.7 t80 -145.26 140.93 28.17 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.129 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 12.0 t-20 58.69 33.25 22.94 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.601 -179.873 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 71.34 3.98 55.09 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 179.614 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -107.65 150.32 27.04 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-O 120.685 0.278 . . . . 0.0 110.589 -179.818 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 55.1 t -116.4 131.94 67.46 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.226 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.36 -160.1 9.62 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.854 -0.898 . . . . 0.0 110.854 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 78.2 m-85 -132.85 157.5 44.89 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.835 0.35 . . . . 0.0 110.367 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -141.15 151.19 43.67 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.254 179.803 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 19.8 m -64.55 148.13 51.39 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.61 -179.678 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 26.6 pttm -79.36 -20.93 46.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.067 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 78.4 p -66.07 -37.88 86.91 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.465 -179.794 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' TYR . . . . . 0.538 ' C ' HD12 ' A' ' 59' ' ' ILE . 96.6 m-85 -97.03 -1.53 45.23 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 116.68 -0.237 . . . . 0.0 111.567 -179.119 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.538 HD12 ' C ' ' A' ' 58' ' ' TYR . 1.3 mp -113.51 130.86 66.77 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 96.2 m -121.02 127.84 52.12 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.002 179.508 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.3 mt -80.56 129.25 37.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.405 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 94.8 t -63.64 147.8 11.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.964 -179.67 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 8.1 t-20 65.73 37.1 5.9 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.231 -179.877 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 89.3 mt-10 -146.95 -26.03 0.4 Allowed 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.372 179.176 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -71.45 145.1 38.41 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 111.274 -0.73 . . . . 0.0 111.274 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 13.3 m -141.25 18.18 2.25 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 120.841 0.353 . . . . 0.0 110.414 179.759 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.558 HD22 ' N ' ' A' ' 67' ' ' LEU . 3.5 mm? -87.26 -4.11 59.07 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.325 -179.895 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.52 ' N ' ' OE1' ' A' ' 68' ' ' GLU . 56.0 mp0 -82.04 126.74 32.35 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.417 -179.846 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' HIS . . . . . 0.435 ' O ' ' O ' ' A' ' 70' ' ' HIS . 99.6 m-70 -135.47 119.15 17.11 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.411 -0.358 . . . . 0.0 110.318 179.68 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' HIS . . . . . 0.435 ' O ' ' O ' ' A' ' 69' ' ' HIS . 75.6 m80 46.52 98.65 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.631 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 70.0 m80 -77.53 106.97 9.65 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 120.779 -0.368 . . . . 0.0 110.253 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 60.2 t-80 -66.5 -42.63 87.07 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.458 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 81.1 t60 -74.49 129.98 38.75 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.524 -179.732 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 86.1 t60 . . . . . 0 C--O 1.22 -0.461 0 CA-C-O 117.954 -1.022 . . . . 0.0 110.556 179.794 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 39.2 ttm . . . . . 0 N--CA 1.492 1.652 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 -140.67 115.19 9.44 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 120.959 0.409 . . . . 0.0 110.757 -179.782 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -88.63 162.21 31.52 Favored Glycine 0 CA--C 1.521 0.466 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 179.319 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 95.4 t -125.62 129.2 72.74 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.575 0 CA-C-O 120.985 0.422 . . . . 0.0 110.086 179.759 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 16.3 t -87.05 127.96 40.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.418 -179.748 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 63.6 mttp -124.13 107.56 11.38 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.129 -0.487 . . . . 0.0 109.982 179.634 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.444 HG22 ' H ' ' A' ' 9' ' ' SER . 11.9 p -140.27 151.41 21.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.434 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.63 -179.748 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.532 ' OD1' ' N ' ' A' ' 9' ' ' SER . 30.4 p30 -61.67 -42.64 99.19 Favored 'General case' 0 C--N 1.333 -0.127 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.196 -179.526 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.532 ' N ' ' OD1' ' A' ' 8' ' ' ASN . 8.0 t -125.07 -67.19 0.92 Allowed 'General case' 0 N--CA 1.47 0.541 0 CA-C-O 120.617 0.246 . . . . 0.0 110.94 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -158.24 144.77 17.48 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.777 0.322 . . . . 0.0 110.649 -179.603 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 44.9 tp -106.77 125.98 51.7 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.076 179.681 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -79.53 143.57 34.72 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.438 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 48.4 ttp -109.4 151.46 26.64 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 116.057 -0.519 . . . . 0.0 109.731 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 94.4 mtt-85 -127.63 151.53 48.82 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-O 120.924 0.392 . . . . 0.0 110.313 -179.274 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 35.0 t -62.36 -41.79 98.89 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.818 -179.34 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -124.97 163.16 19.07 Favored Glycine 0 N--CA 1.471 0.985 0 N-CA-C 111.482 -0.647 . . . . 0.0 111.482 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -68.32 86.32 0.42 Allowed 'Trans proline' 0 N--CA 1.496 1.628 0 C-N-CA 122.485 2.123 . . . . 0.0 111.692 179.543 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 164.4 143.31 3.67 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 111.218 -0.753 . . . . 0.0 111.218 179.581 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 75.4 p -66.44 -16.18 63.91 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.851 0.358 . . . . 0.0 110.825 179.867 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 50.5 p30 -80.64 -2.38 46.3 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.565 -179.542 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 47.0 m-85 -89.7 -7.77 53.85 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-O 120.756 0.312 . . . . 0.0 110.554 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 71.55 168.38 9.37 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 179.553 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 7.5 p -94.77 128.16 46.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 CA-C-O 120.79 0.329 . . . . 0.0 110.537 179.795 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 43.6 pt -108.2 -6.62 10.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.702 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -173.02 169.33 42.49 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 111.325 -0.71 . . . . 0.0 111.325 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 92.1 m -123.3 135.01 54.01 Favored 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 67.9 mt -107.72 155.16 20.5 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-O 120.871 0.367 . . . . 0.0 110.499 -179.559 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 90.2 mtm-85 -105.25 165.75 10.89 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.595 -179.835 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.402 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 52.6 p-10 -69.53 149.0 48.7 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.181 -179.613 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 21.7 t-20 56.12 32.98 21.13 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 115.91 -0.586 . . . . 0.0 111.014 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -89.92 116.27 27.85 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-O 120.825 0.345 . . . . 0.0 110.645 179.587 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.565 ' HZ3' ' HB3' ' A' ' 32' ' ' LYS . 2.4 mmmp? -71.84 129.39 38.51 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.465 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.9 m -140.18 162.03 25.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.647 -179.496 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -104.89 121.06 42.91 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.353 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 89.3 mt -91.52 108.31 19.8 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.302 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 97.5 mt -67.41 -43.86 87.34 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.046 -0.524 . . . . 0.0 111.006 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 63.7 pttt -173.19 160.82 4.15 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.823 0.344 . . . . 0.0 111.001 -179.369 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -106.93 124.23 49.32 Favored 'General case' 0 N--CA 1.465 0.3 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 179.314 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 73.3 t -127.16 132.15 70.0 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 CA-C-O 120.952 0.406 . . . . 0.0 110.671 -179.436 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.415 ' OD1' ' O ' ' A' ' 40' ' ' ASP . 36.1 t0 56.26 23.86 7.59 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.013 179.246 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.52 -10.02 74.95 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 111.016 -0.834 . . . . 0.0 111.016 179.705 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 34.3 m95 -91.21 149.26 21.85 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-O 120.751 0.31 . . . . 0.0 110.188 179.748 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 52.4 m-85 -99.94 130.84 46.16 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.136 -179.731 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 76.1 tt0 -98.29 120.24 38.36 Favored 'General case' 0 CA--C 1.518 -0.269 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 179.223 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 39.2 pt -126.05 160.21 33.44 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.321 0 CA-C-O 120.969 0.414 . . . . 0.0 110.983 -179.207 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 43.6 ttm180 -117.89 127.85 54.26 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-N 115.694 -0.685 . . . . 0.0 109.503 179.486 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 34.1 t80 -144.77 131.17 19.72 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-O 121.16 0.505 . . . . 0.0 111.11 -179.736 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 83.4 m-20 56.93 35.17 26.01 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 115.36 -0.837 . . . . 0.0 112.145 179.3 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 77.23 15.56 81.43 Favored Glycine 0 N--CA 1.465 0.592 0 C-N-CA 121.264 -0.493 . . . . 0.0 111.893 178.531 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -126.0 145.54 50.26 Favored 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 61.5 t -115.55 132.32 65.3 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.302 -179.732 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -149.67 -163.12 10.86 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 62.1 m-85 -132.86 160.27 37.46 Favored 'General case' 0 N--CA 1.466 0.347 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -149.72 159.17 44.57 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.04 0.448 . . . . 0.0 111.061 -179.617 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 18.4 p -69.54 148.89 48.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.696 -0.683 . . . . 0.0 110.304 179.885 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.415 ' O ' ' O ' ' A' ' 59' ' ' ILE . 59.0 pttt -82.59 -19.12 39.04 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.77 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 39.1 t -62.07 -42.39 99.15 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.954 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 90.5 m-85 -92.19 3.81 54.55 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.336 -179.171 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.415 ' O ' ' O ' ' A' ' 56' ' ' LYS . 98.1 mt -128.51 132.25 68.12 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 CA-C-O 120.699 0.285 . . . . 0.0 110.351 179.601 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 99.3 m -123.15 132.12 53.95 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.465 179.732 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 27.0 mm -80.45 129.46 37.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.063 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 35.7 m -112.59 131.6 63.67 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 CA-C-O 120.954 0.407 . . . . 0.0 110.427 -179.687 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 53.5 t-20 61.69 91.42 0.06 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.592 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -56.64 142.15 40.88 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.127 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -73.29 119.72 6.79 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 111.352 -0.699 . . . . 0.0 111.352 -179.429 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 43.6 t -75.55 150.37 38.13 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.787 0.327 . . . . 0.0 110.312 179.602 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.536 ' N ' HD12 ' A' ' 67' ' ' LEU . 10.3 mp -83.79 -5.88 59.3 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.702 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 54.31 92.19 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.561 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 79.5 m80 -93.76 17.83 11.29 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.42 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' HIS . . . . . . . . . . . . . 82.2 t60 -52.96 -13.12 0.39 Allowed 'General case' 0 C--N 1.332 -0.196 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.472 -179.669 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 58.9 t-80 -74.18 136.49 42.84 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.966 0.412 . . . . 0.0 111.233 -179.823 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 41.1 p-80 -141.85 124.98 16.32 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.336 179.632 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 49.8 p-80 -85.68 -17.08 37.02 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.288 179.794 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 86.4 t60 . . . . . 0 C--O 1.222 -0.384 0 CA-C-O 117.952 -1.023 . . . . 0.0 110.807 -179.759 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 36.5 ttm . . . . . 0 N--CA 1.49 1.535 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 58.0 tt0 -134.64 121.93 21.55 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-O 120.858 0.361 . . . . 0.0 110.231 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -93.16 155.2 22.22 Favored Glycine 0 CA--C 1.524 0.626 0 N-CA-C 111.054 -0.819 . . . . 0.0 111.054 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 59.9 t -128.01 132.14 68.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.698 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 18.0 t -88.74 127.74 41.38 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.087 179.694 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 64.7 mttp -124.57 105.81 9.65 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-O 120.912 0.386 . . . . 0.0 110.537 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 7.1 p -157.15 148.83 10.53 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-N 115.943 -0.572 . . . . 0.0 110.604 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.42 ' O ' ' ND2' ' A' ' 29' ' ' ASN . 92.9 m-20 -68.54 -50.84 48.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.937 0.399 . . . . 0.0 110.554 179.452 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 9.2 p -95.88 165.53 12.23 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.564 179.913 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -65.88 144.39 56.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.354 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 45.1 tp -111.22 132.78 54.07 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-O 120.972 0.415 . . . . 0.0 110.67 -179.794 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 84.7 m-20 -78.02 146.26 35.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.892 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 40.0 ttp -98.11 148.66 23.32 Favored 'General case' 0 C--O 1.233 0.201 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.616 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 84.9 mtt85 -123.32 157.75 32.55 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 120.715 0.293 . . . . 0.0 110.493 -179.23 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' SER . . . . . 0.508 ' N ' HD11 ' A' ' 24' ' ' ILE . 88.5 p -84.11 -13.11 53.84 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.972 -179.321 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -162.31 -172.58 29.92 Favored Glycine 0 CA--C 1.529 0.952 0 C-N-CA 120.846 -0.692 . . . . 0.0 111.388 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -80.0 78.95 3.49 Favored 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.771 2.314 . . . . 0.0 112.143 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 167.4 134.12 1.65 Allowed Glycine 0 CA--C 1.524 0.603 0 C-N-CA 120.68 -0.771 . . . . 0.0 111.448 179.713 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 95.7 p -71.2 -12.3 61.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.95 0.405 . . . . 0.0 110.215 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 52.1 p-10 -78.91 -4.63 50.72 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.692 -179.822 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -85.85 -1.62 57.44 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.291 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 71.6 178.5 29.75 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 110.724 -0.95 . . . . 0.0 110.724 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 9.2 p -107.4 134.52 48.89 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.37 0 CA-C-O 120.861 0.362 . . . . 0.0 110.474 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.508 HD11 ' N ' ' A' ' 15' ' ' SER . 3.5 mp -106.0 -12.01 9.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.52 -179.758 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -173.55 -170.66 37.3 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 110.8 -0.92 . . . . 0.0 110.8 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 82.0 p -131.84 152.21 51.16 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 120.737 0.303 . . . . 0.0 110.302 179.846 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 78.5 mt -122.7 146.29 47.63 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.07 -0.514 . . . . 0.0 109.841 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -106.84 164.52 12.04 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.877 -179.364 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.42 ' ND2' ' O ' ' A' ' 8' ' ' ASN . 2.9 m-20 -64.07 148.93 48.66 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.671 -179.836 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 58.96 32.71 22.51 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.324 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 16.5 m-20 -82.0 137.38 35.12 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.113 179.02 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 63.3 mttp -104.99 122.73 46.46 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.858 0.361 . . . . 0.0 110.317 179.55 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.6 m -138.69 161.61 29.95 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.185 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.12 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -99.03 132.74 44.11 Favored 'General case' 0 C--O 1.234 0.287 0 N-CA-C 109.727 -0.472 . . . . 0.0 109.727 179.689 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.2 mt -100.71 107.5 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.309 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.8 mt -66.55 -43.87 90.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.89 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 63.6 pttt -173.05 169.98 4.52 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.829 -179.41 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' GLU . . . . . 0.429 ' CD ' ' CE1' ' A' ' 43' ' ' TYR . 83.1 tt0 -111.91 126.29 54.96 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.646 179.591 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 76.3 t -126.79 131.91 70.61 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 CA-C-O 121.07 0.462 . . . . 0.0 111.133 -179.438 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 52.65 30.42 8.68 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.661 -0.7 . . . . 0.0 111.759 178.958 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.14 -18.02 47.66 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 111.651 -0.58 . . . . 0.0 111.651 179.204 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 40.3 m95 -85.95 145.23 27.23 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.845 0.355 . . . . 0.0 110.244 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' TYR . . . . . 0.429 ' CE1' ' CD ' ' A' ' 38' ' ' GLU . 72.7 m-85 -100.75 126.99 47.34 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.481 -179.642 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 79.2 tt0 -78.54 152.42 31.95 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 179.715 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.4 pt -144.04 153.36 15.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.679 0.276 . . . . 0.0 110.854 -179.702 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 76.3 ttt180 -121.16 123.32 42.0 Favored 'General case' 0 N--CA 1.468 0.454 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.265 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 74.5 t80 -142.08 125.8 16.96 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-O 120.884 0.373 . . . . 0.0 110.885 -179.444 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.535 ' ND2' ' O ' ' A' ' 48' ' ' ASN . 3.8 t30 54.8 35.97 25.37 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.999 179.766 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 73.01 15.19 78.52 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 111.145 -0.782 . . . . 0.0 111.145 179.521 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.9 ttmp? -112.43 147.93 35.42 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 110.228 -0.286 . . . . 0.0 110.228 179.771 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.0 t -110.2 132.85 57.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.933 0.397 . . . . 0.0 110.32 -179.785 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' GLY . . . . . 0.467 ' C ' ' CD1' ' A' ' 53' ' ' TYR . . . -148.63 -165.02 11.84 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 179.823 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.467 ' CD1' ' C ' ' A' ' 52' ' ' GLY . 72.9 m-85 -146.46 157.81 43.81 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.729 0.299 . . . . 0.0 110.456 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -141.63 155.72 45.7 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.398 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.403 ' O ' ' CG1' ' A' ' 59' ' ' ILE . 18.1 m -69.41 147.87 50.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.031 -179.623 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 62.0 pttt -66.34 -34.69 78.53 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.233 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 37.1 m -61.56 -41.11 96.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.706 -179.205 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 89.1 m-85 -94.22 7.64 44.57 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 116.518 -0.31 . . . . 0.0 111.002 -179.285 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.403 ' CG1' ' O ' ' A' ' 55' ' ' SER . 5.3 mm -122.4 128.77 75.54 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-O 121.119 0.485 . . . . 0.0 110.293 179.637 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 86.8 m -122.56 126.89 48.67 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.512 -179.9 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.439 HG21 ' OE1' ' A' ' 64' ' ' GLU . 96.6 mt -91.22 127.9 43.32 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.497 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 33.2 m -80.36 148.29 5.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.437 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 13.6 m120 60.45 35.9 20.3 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.67 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' GLU . . . . . 0.439 ' OE1' HG21 ' A' ' 61' ' ' ILE . 39.8 tp10 -85.33 -17.76 35.86 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-O 120.968 0.413 . . . . 0.0 110.459 -179.716 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 165.77 23.26 0.02 OUTLIER Glycine 0 CA--C 1.526 0.739 0 N-CA-C 111.12 -0.792 . . . . 0.0 111.12 179.641 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.3 t 51.43 83.36 0.05 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.797 0.332 . . . . 0.0 110.578 179.915 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 77.0 mt -73.49 148.41 43.16 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.354 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 51.0 tp10 -52.14 142.32 16.66 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.926 -179.437 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' HIS . . . . . 0.446 ' O ' ' O ' ' A' ' 70' ' ' HIS . 95.3 m-70 -76.95 136.05 38.76 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.609 179.704 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' HIS . . . . . 0.446 ' O ' ' O ' ' A' ' 69' ' ' HIS . 80.0 m80 45.02 -173.66 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.677 -179.648 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 98.7 m-70 -141.86 140.75 32.99 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.53 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -141.62 145.26 34.8 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.023 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 79.4 m80 -110.49 139.46 45.7 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.689 -179.796 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 77.9 m80 . . . . . 0 C--O 1.221 -0.443 0 CA-C-O 118.002 -0.999 . . . . 0.0 110.433 179.998 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 7.9 ttt . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.8 mt-30 -136.11 116.55 13.71 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.131 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -84.69 164.88 39.81 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 -179.605 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 57.2 t -123.91 133.62 68.76 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.394 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 72.4 t -100.88 127.85 53.62 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-O 120.876 0.37 . . . . 0.0 110.314 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 68.8 mmtt -119.58 106.41 12.17 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.559 179.423 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.495 ' O ' ' ND2' ' A' ' 29' ' ' ASN . 28.0 m -131.41 160.05 42.62 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.302 -179.456 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 52.8 t-20 -63.59 -41.67 98.34 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.097 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 4.3 t -150.7 -53.33 0.14 Allowed 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.464 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -157.64 142.88 16.96 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.422 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.473 HD22 ' CG ' ' A' ' 58' ' ' TYR . 65.1 tp -125.46 135.68 52.59 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 116.1 -0.5 . . . . 0.0 109.92 -179.802 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 -77.93 138.83 39.09 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.197 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 50.5 ttp -98.11 138.59 35.18 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.074 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' ARG . . . . . 0.491 ' HE ' ' HA ' ' A' ' 19' ' ' SER . 22.0 mmt180 -103.9 156.96 17.42 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.517 -178.675 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' SER . . . . . 0.421 ' OG ' HG21 ' A' ' 24' ' ' ILE . 4.6 m -83.07 -7.68 59.62 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.76 -179.636 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -159.23 -169.63 22.8 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -83.24 72.21 5.82 Favored 'Trans proline' 0 C--N 1.304 -1.777 0 C-N-CA 122.659 2.239 . . . . 0.0 111.857 -179.755 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.78 147.81 6.34 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 111.104 -0.799 . . . . 0.0 111.104 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.491 ' HA ' ' HE ' ' A' ' 14' ' ' ARG . 15.7 m -81.47 -11.64 59.15 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.948 0.404 . . . . 0.0 110.728 -179.82 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 28.6 t-20 -84.14 7.06 20.09 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.979 -179.693 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 49.9 m-85 -92.71 -0.23 57.32 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 120.772 0.32 . . . . 0.0 110.414 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 75.62 179.22 44.61 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.451 ' O ' HG13 ' A' ' 23' ' ' VAL . 7.2 p -108.84 125.31 65.85 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-O 120.826 0.345 . . . . 0.0 110.621 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.421 HG21 ' OG ' ' A' ' 15' ' ' SER . 41.2 pt -108.66 -4.51 10.58 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.809 179.852 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -172.96 170.76 43.9 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 111.116 -0.793 . . . . 0.0 111.116 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 86.4 m -128.64 138.02 51.96 Favored 'General case' 0 N--CA 1.472 0.635 0 CA-C-O 120.494 0.187 . . . . 0.0 110.541 -179.673 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 77.4 mt -110.18 143.7 39.92 Favored 'General case' 0 N--CA 1.476 0.844 0 N-CA-C 112.12 0.415 . . . . 0.0 112.12 -178.793 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 49.2 mtt-85 -105.24 167.76 9.52 Favored 'General case' 0 N--CA 1.477 0.88 0 CA-C-O 121.773 0.797 . . . . 0.0 111.812 -179.079 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.495 ' ND2' ' O ' ' A' ' 7' ' ' VAL . 1.3 m-20 -64.32 146.17 54.83 Favored 'General case' 0 N--CA 1.437 -1.107 0 CA-C-N 114.993 -1.003 . . . . 0.0 108.976 -179.055 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 89.6 m-20 57.07 34.41 24.86 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.287 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 67.1 t0 -88.27 110.39 20.7 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 110.016 -0.364 . . . . 0.0 110.016 179.329 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -78.61 132.67 37.19 Favored 'General case' 0 C--N 1.331 -0.212 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 -179.811 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 28.9 m -139.88 162.05 25.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.657 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -99.89 131.55 45.79 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.19 -0.459 . . . . 0.0 109.811 179.393 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 86.7 mt -96.65 126.77 49.26 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-N 116.33 -0.396 . . . . 0.0 111.022 -179.245 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 18.5 mm -94.71 -62.97 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.427 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 22.2 mtmm -148.33 159.78 43.65 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 120.918 0.39 . . . . 0.0 111.018 179.756 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -111.81 123.34 50.03 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.339 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 72.0 t -127.47 132.47 69.29 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.604 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 55.23 30.7 15.1 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.143 179.25 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.5 -16.6 34.3 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 111.02 -0.832 . . . . 0.0 111.02 179.711 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.616 ' CZ2' ' OG ' ' A' ' 55' ' ' SER . 11.7 m95 -83.58 147.37 27.78 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 179.423 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 46.2 m-85 -100.83 130.34 46.84 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 121.047 0.451 . . . . 0.0 110.941 -179.609 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -87.1 122.74 31.33 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 178.805 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 39.1 pt -130.59 161.62 40.12 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.407 0 CA-C-O 121.176 0.512 . . . . 0.0 111.537 -178.601 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 13.6 ttt180 -118.7 123.66 45.44 Favored 'General case' 0 N--CA 1.464 0.275 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.332 179.432 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 87.4 t80 -144.39 135.97 25.74 Favored 'General case' 0 N--CA 1.473 0.713 0 CA-C-O 120.824 0.345 . . . . 0.0 111.322 -178.401 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.577 ' ND2' ' O ' ' A' ' 48' ' ' ASN . 2.7 t30 57.51 34.84 25.14 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.7 179.347 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 69.45 18.46 73.56 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 179.77 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -124.67 146.14 49.29 Favored 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 66.5 t -113.99 131.56 65.56 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.389 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' GLY . . . . . 0.405 ' C ' ' CD1' ' A' ' 53' ' ' TYR . . . -150.47 -164.6 12.02 Favored Glycine 0 CA--C 1.52 0.39 0 N-CA-C 110.664 -0.974 . . . . 0.0 110.664 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.427 ' CD1' ' N ' ' A' ' 53' ' ' TYR . 28.4 m-85 -134.96 156.71 48.54 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.796 0.332 . . . . 0.0 110.54 -179.737 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -146.67 150.6 35.73 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.028 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' SER . . . . . 0.616 ' OG ' ' CZ2' ' A' ' 42' ' ' TRP . 37.8 m -70.39 142.0 52.13 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 177.81 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 64.4 pttt -68.2 -13.07 61.96 Favored 'General case' 0 CA--C 1.51 -0.578 0 CA-C-O 121.8 0.809 . . . . 0.0 108.847 178.84 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 87.8 p -56.29 -14.0 2.55 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 114.015 -1.448 . . . . 0.0 109.321 178.862 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' TYR . . . . . 0.473 ' CG ' HD22 ' A' ' 11' ' ' LEU . 91.7 m-85 -127.16 -28.26 2.88 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.202 179.816 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.593 ' N ' HD12 ' A' ' 59' ' ' ILE . 1.3 mp -90.1 129.29 41.21 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 179.162 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 87.5 m -123.81 129.34 50.89 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.388 -179.881 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.741 ' N ' HD12 ' A' ' 61' ' ' ILE . 1.7 mp -83.0 128.14 39.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.286 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.421 ' O ' ' O ' ' A' ' 63' ' ' ASN . 15.7 m -83.45 138.36 19.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.319 179.807 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' ASN . . . . . 0.477 ' CG ' ' H ' ' A' ' 64' ' ' GLU . 6.9 t-20 45.33 -172.17 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.743 -179.769 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' GLU . . . . . 0.477 ' H ' ' CG ' ' A' ' 63' ' ' ASN . 4.3 tm-20 66.25 69.32 0.43 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.424 -179.77 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -90.18 -72.8 1.26 Allowed Glycine 0 CA--C 1.525 0.69 0 N-CA-C 110.67 -0.972 . . . . 0.0 110.67 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 82.3 p -75.52 161.8 28.86 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 179.815 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 41.1 tp -77.41 126.75 31.4 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.975 0.417 . . . . 0.0 110.798 -179.713 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -83.91 150.72 25.51 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.171 179.584 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 98.7 m-70 -105.44 128.31 53.46 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.328 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' HIS . . . . . . . . . . . . . 59.0 t-80 -85.94 122.62 30.25 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.728 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 98.7 m-70 -91.32 144.32 25.72 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.486 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 56.6 p-80 -67.82 139.7 56.59 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.661 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 85.2 t60 -83.56 126.2 32.58 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.512 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 79.7 m80 . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 118.008 -0.996 . . . . 0.0 110.786 -179.996 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 39.0 tpp . . . . . 0 N--CA 1.49 1.575 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 78.2 mt-30 -142.81 108.34 5.07 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.204 179.747 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -87.18 158.1 29.91 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 97.7 t -127.65 133.3 67.93 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 179.703 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 71.9 t -93.33 128.2 44.92 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-N 116.46 -0.337 . . . . 0.0 110.392 -179.884 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 65.5 mttp -132.02 107.01 8.38 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.453 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.512 HG22 ' H ' ' A' ' 9' ' ' SER . 4.0 p -138.79 154.03 26.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.162 -179.897 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 92.1 m-20 -62.06 -42.85 99.62 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-O 120.83 0.348 . . . . 0.0 111.235 -178.991 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.512 ' H ' HG22 ' A' ' 7' ' ' VAL . 85.2 p -136.76 -153.84 0.52 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.035 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -66.98 143.15 56.97 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.017 0.437 . . . . 0.0 110.545 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.401 HD22 ' CG ' ' A' ' 58' ' ' TYR . 47.2 tp -122.0 130.46 53.32 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.062 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ASN . . . . . 0.425 ' O ' ' OD1' ' A' ' 12' ' ' ASN . 45.1 p30 -82.12 140.53 33.76 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.693 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 58.1 ttp -108.33 138.65 44.25 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.215 -0.448 . . . . 0.0 109.869 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 4.3 mpt_? -106.45 157.37 17.69 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 120.983 0.42 . . . . 0.0 111.233 -178.939 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 84.2 p -82.27 -6.22 59.08 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.243 179.732 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -162.36 -174.86 32.76 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.765 -0.934 . . . . 0.0 110.765 179.762 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -80.94 79.09 3.41 Favored 'Trans proline' 0 C--N 1.306 -1.692 0 C-N-CA 122.86 2.373 . . . . 0.0 111.926 179.766 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 171.03 137.17 2.24 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 94.9 p -74.64 -7.7 54.04 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.764 0.316 . . . . 0.0 110.857 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 89.5 m-20 -89.01 5.6 43.54 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.069 -179.414 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 42.7 m-85 -91.31 -0.56 57.68 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.869 0.366 . . . . 0.0 110.208 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 73.28 174.43 27.89 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.48 ' O ' HG13 ' A' ' 23' ' ' VAL . 11.7 p -105.64 125.34 60.99 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-O 120.894 0.378 . . . . 0.0 110.412 179.743 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 40.8 pt -101.81 -4.75 9.26 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.758 -179.855 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -174.3 174.08 46.29 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 89.7 m -125.17 132.21 53.09 Favored 'General case' 0 N--CA 1.464 0.226 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.627 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 72.1 mt -108.09 143.93 36.16 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 116.194 -0.457 . . . . 0.0 109.968 -179.759 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 37.8 ttt85 -119.51 142.62 48.15 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.171 0.51 . . . . 0.0 110.26 179.42 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 44.0 p-10 -48.26 165.09 0.04 OUTLIER 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.65 -0.704 . . . . 0.0 111.0 -179.766 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 65.8 t30 62.8 6.48 2.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.554 -0.748 . . . . 0.0 111.366 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 31.5 t0 -87.13 118.68 26.68 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.548 -0.297 . . . . 0.0 110.663 179.517 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -76.3 137.39 39.86 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.2 179.471 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.2 m -137.39 162.05 33.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.62 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 48.4 tp10 -105.84 123.65 48.3 Favored 'General case' 0 C--O 1.234 0.274 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 179.581 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.5 mt -91.38 127.8 43.52 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.123 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.94 -179.355 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 81.9 mt -91.4 -51.27 11.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.176 179.597 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 62.6 pttt -174.9 179.0 1.71 Allowed 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.558 179.705 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -112.84 125.06 53.95 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.219 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.408 HG21 ' OE2' ' A' ' 44' ' ' GLU . 79.5 t -124.93 129.74 73.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.28 -179.859 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.44 ' OD1' ' O ' ' A' ' 40' ' ' ASP . 55.2 t0 54.74 24.28 5.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.071 179.362 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.86 -5.62 84.66 Favored Glycine 0 CA--C 1.526 0.753 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 179.739 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 56.4 m95 -90.52 149.38 22.2 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 179.364 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -96.88 130.35 44.18 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-O 121.098 0.475 . . . . 0.0 110.137 -179.669 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.408 ' OE2' HG21 ' A' ' 39' ' ' VAL . 97.4 mt-10 -94.47 126.51 39.79 Favored 'General case' 0 CA--C 1.506 -0.714 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.018 179.369 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 44.3 pt -125.93 160.76 32.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 121.356 0.598 . . . . 0.0 110.249 179.626 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 3.2 ttp180 -126.89 113.89 17.14 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 114.777 -1.101 . . . . 0.0 109.624 -176.763 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 61.8 t80 -141.51 139.1 33.2 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 120.947 0.403 . . . . 0.0 111.605 -178.111 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 15.0 t-20 57.13 34.62 25.15 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.904 179.298 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 69.74 20.71 76.08 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 111.431 -0.668 . . . . 0.0 111.431 179.52 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 53.9 mtmt -131.23 143.58 50.68 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-O 120.688 0.28 . . . . 0.0 110.823 -179.81 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 19.8 t -102.26 111.8 33.29 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 CA-C-O 121.115 0.483 . . . . 0.0 110.656 179.535 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -107.55 -172.69 22.17 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 111.053 -0.819 . . . . 0.0 111.053 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 48.1 m-85 -132.3 142.36 49.33 Favored 'General case' 0 C--N 1.331 -0.233 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 179.624 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -154.29 153.0 30.93 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.404 -179.893 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 48.5 t -70.1 148.15 49.1 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.787 -179.887 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 63.9 pttt -64.2 -17.65 63.75 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.73 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 38.6 t -65.7 -18.22 65.17 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.395 -179.669 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' TYR . . . . . 0.6 ' C ' HD12 ' A' ' 59' ' ' ILE . 71.7 m-85 -105.73 -19.16 13.84 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 121.271 -0.172 . . . . 0.0 111.323 -179.554 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.64 ' N ' HD12 ' A' ' 59' ' ' ILE . 1.9 mp -109.87 130.99 62.04 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 CA-C-O 121.159 0.504 . . . . 0.0 110.631 -179.68 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 88.6 m -116.12 127.06 54.53 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-N 115.49 -0.777 . . . . 0.0 109.824 179.644 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.4 mt -78.91 133.21 30.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.774 -179.593 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.423 ' O ' ' O ' ' A' ' 63' ' ' ASN . 75.1 t -93.67 131.82 39.56 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.087 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' ASN . . . . . 0.423 ' O ' ' O ' ' A' ' 62' ' ' VAL . 70.2 m-20 59.05 122.62 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.458 -179.641 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -75.33 -4.75 41.07 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.625 -179.746 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.525 ' O ' ' N ' ' A' ' 67' ' ' LEU . . . 144.29 -18.15 2.09 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 111.051 -0.82 . . . . 0.0 111.051 179.884 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 32.0 t 56.19 -80.2 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.598 0.237 . . . . 0.0 110.526 -179.892 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.565 HD22 ' N ' ' A' ' 67' ' ' LEU . 3.6 mm? -73.61 146.29 44.76 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 179.58 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -48.8 135.88 14.57 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.68 -179.744 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 50.4 m170 -66.68 -40.05 88.39 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.789 -179.759 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -94.92 123.5 38.43 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.573 -179.763 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -144.28 103.34 3.97 Favored 'General case' 0 N--CA 1.462 0.169 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.46 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 98.4 m-70 -82.3 150.62 27.15 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.56 179.891 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 13.0 p80 -140.41 124.04 17.12 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.487 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 99.5 m-70 . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 118.012 -0.994 . . . . 0.0 110.472 179.953 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 36.9 ttm . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 -132.4 114.21 14.07 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.517 179.683 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -94.83 150.5 19.74 Favored Glycine 0 CA--C 1.521 0.452 0 N-CA-C 110.474 -1.05 . . . . 0.0 110.474 179.466 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 55.4 t -119.15 131.12 72.79 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 89.1 t -83.51 129.44 37.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.322 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 19.7 mmmt -115.35 106.27 13.82 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.128 179.903 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.507 HG22 ' H ' ' A' ' 9' ' ' SER . 3.2 p -141.7 144.5 25.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.062 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 19.3 m120 -63.04 -41.26 99.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.091 -179.607 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.507 ' H ' HG22 ' A' ' 7' ' ' VAL . 44.4 m -133.03 -96.15 0.31 Allowed 'General case' 0 N--CA 1.466 0.363 0 CA-C-O 120.891 0.377 . . . . 0.0 110.402 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -112.97 143.65 43.89 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.409 179.886 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.549 HD13 ' CD2' ' A' ' 58' ' ' TYR . 42.8 tp -116.97 128.69 55.44 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 120.985 0.421 . . . . 0.0 110.086 179.835 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -82.94 138.64 33.74 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.478 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 37.5 ttp -103.63 152.11 22.14 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.294 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' ARG . . . . . 0.432 ' NH1' ' HG3' ' A' ' 14' ' ' ARG . 1.9 mtt85 -129.82 155.33 46.15 Favored 'General case' 0 CA--C 1.543 0.697 0 N-CA-C 109.198 -0.667 . . . . 0.0 109.198 -178.871 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 86.2 p -84.39 -4.92 59.18 Favored 'General case' 0 N--CA 1.478 0.936 0 N-CA-C 113.291 0.849 . . . . 0.0 113.291 -179.536 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -162.64 158.05 30.15 Favored Glycine 0 CA--C 1.524 0.63 0 C-N-CA 120.367 -0.921 . . . . 0.0 110.842 -179.073 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -64.5 87.61 0.16 Allowed 'Trans proline' 0 C--N 1.307 -1.622 0 C-N-CA 122.273 1.982 . . . . 0.0 111.64 -179.803 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 157.75 136.96 2.18 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 111.012 -0.835 . . . . 0.0 111.012 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 32.6 t -65.41 -13.13 58.0 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.777 0.322 . . . . 0.0 110.702 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -75.71 -3.7 36.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.254 -179.284 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 40.6 m-85 -90.0 -5.66 56.43 Favored 'General case' 0 C--N 1.332 -0.169 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.479 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 66.88 178.92 10.36 Favored Glycine 0 CA--C 1.522 0.477 0 N-CA-C 110.634 -0.986 . . . . 0.0 110.634 179.87 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.447 ' O ' HG13 ' A' ' 23' ' ' VAL . 8.3 p -103.07 126.3 57.39 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.163 0 CA-C-O 120.783 0.325 . . . . 0.0 110.279 179.595 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 25.5 pt -101.97 -4.61 9.29 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.783 -179.677 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 175.35 -176.14 47.27 Favored Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 -179.866 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 59.6 p -134.87 158.67 43.64 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-O 120.848 0.356 . . . . 0.0 110.758 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 71.5 mt -122.63 150.39 42.72 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.015 -179.899 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.729 HH11 ' HG3' ' A' ' 28' ' ' ARG . 1.0 OUTLIER -94.56 160.96 14.4 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 -179.24 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.427 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 51.7 p30 -64.97 150.48 47.94 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.614 -178.791 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 56.2 t-20 59.61 32.08 21.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.69 -0.687 . . . . 0.0 111.514 179.555 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.518 ' OD2' ' N ' ' A' ' 28' ' ' ARG . 77.5 m-20 -82.78 136.85 34.55 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 179.22 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 53.0 mtmt -107.88 122.25 46.41 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.13 179.299 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.7 m -135.95 162.35 36.63 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.416 -179.876 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -85.82 129.82 34.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.269 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.6 mt -100.19 121.38 50.85 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.265 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.328 179.889 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 77.8 mt -83.99 -46.95 18.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.103 -179.832 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 62.1 pttt -174.79 163.28 3.37 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.749 -179.602 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -107.21 124.44 49.74 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.305 179.861 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 77.4 t -124.42 130.2 73.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.616 -179.578 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.5 m-20 53.97 27.06 6.92 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.022 179.508 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.33 -11.38 67.98 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 111.201 -0.76 . . . . 0.0 111.201 179.595 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 72.9 m95 -87.65 148.68 24.7 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 110.118 -0.327 . . . . 0.0 110.118 179.747 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 7.0 m-85 -103.56 132.25 49.98 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-O 121.099 0.476 . . . . 0.0 110.581 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -93.73 121.89 35.62 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 178.307 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 41.6 pt -127.53 157.9 39.14 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-O 120.922 0.391 . . . . 0.0 111.284 -178.803 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 38.6 ttm180 -112.05 119.65 39.18 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.699 179.51 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 39.9 t80 -138.92 132.28 30.11 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.52 -179.433 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 64.3 t30 58.38 34.58 24.13 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.821 179.813 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 72.85 5.93 66.05 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.985 -0.846 . . . . 0.0 110.985 179.614 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 62.2 tttp -114.18 146.31 40.53 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.721 0.296 . . . . 0.0 110.576 -179.498 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 53.9 t -113.12 130.9 66.2 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.015 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -145.19 -161.7 9.21 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 110.978 -0.849 . . . . 0.0 110.978 -179.664 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 65.2 m-85 -122.15 157.08 32.31 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-O 120.662 0.268 . . . . 0.0 110.346 -179.852 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.44 ' CB ' HD11 ' A' ' 59' ' ' ILE . . . -144.59 154.68 43.1 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.63 -179.694 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 47.6 t -68.27 133.9 49.53 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.231 -179.46 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -65.5 -44.7 86.23 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.537 179.79 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 35.8 t -57.11 -19.11 17.86 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.255 -178.584 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' TYR . . . . . 0.549 ' CD2' HD13 ' A' ' 11' ' ' LEU . 43.1 m-85 -103.57 6.31 37.2 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 116.504 -0.316 . . . . 0.0 111.218 -179.699 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.44 HD11 ' CB ' ' A' ' 54' ' ' ALA . 96.7 mt -131.82 132.23 61.81 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 CA-C-O 121.098 0.475 . . . . 0.0 111.455 179.756 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 92.5 m -123.41 130.55 52.87 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.085 179.33 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 22.1 mm -82.17 130.28 36.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.614 -179.781 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 99.5 t -70.66 134.42 30.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.449 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -59.3 122.14 13.15 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.443 -179.821 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -83.49 121.58 27.39 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.7 -179.886 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.466 ' O ' ' N ' ' A' ' 67' ' ' LEU . . . 72.99 -171.7 50.46 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 179.678 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 3.5 m 42.16 22.46 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.925 0.393 . . . . 0.0 110.873 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.466 ' N ' ' O ' ' A' ' 65' ' ' GLY . 47.9 tp -73.5 -82.99 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.605 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.493 ' N ' ' OE1' ' A' ' 68' ' ' GLU . 58.2 mp0 43.76 -169.26 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.385 -179.759 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' HIS . . . . . 0.52 ' O ' ' N ' ' A' ' 71' ' ' HIS . 98.5 m-70 -87.15 131.21 34.24 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.784 179.743 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' HIS . . . . . . . . . . . . . 75.7 m80 40.7 -90.05 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.949 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.52 ' N ' ' O ' ' A' ' 69' ' ' HIS . 74.1 t60 41.16 82.23 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.997 179.849 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.51 ' O ' ' N ' ' A' ' 74' ' ' HIS . 85.9 t60 -144.02 103.2 3.99 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.144 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 41.32 -91.02 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.805 -179.636 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' HIS . . . . . 0.51 ' N ' ' O ' ' A' ' 72' ' ' HIS . 80.2 m80 . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 117.983 -1.008 . . . . 0.0 110.505 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 86.8 mmm . . . . . 0 N--CA 1.491 1.622 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 99.4 mt-30 -133.53 120.7 21.13 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.385 179.735 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -93.41 139.32 14.53 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.449 -1.06 . . . . 0.0 110.449 179.608 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 54.2 t -122.38 131.99 72.04 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.254 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 179.899 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 84.6 t -90.01 128.6 41.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.592 -179.431 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 55.4 mtpt -125.05 105.95 9.57 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.032 -0.531 . . . . 0.0 109.848 179.402 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 11.3 p -139.14 155.28 26.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.037 -179.61 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 23.4 t-20 -61.2 -41.24 96.49 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.144 -179.241 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 4.8 t -140.02 -62.78 0.51 Allowed 'General case' 0 N--CA 1.466 0.364 0 CA-C-O 120.747 0.308 . . . . 0.0 111.07 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -150.49 144.22 25.23 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.617 -179.63 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 50.8 tp -120.64 134.6 55.27 Favored 'General case' 0 N--CA 1.469 0.48 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.097 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ASN . . . . . 0.426 ' O ' ' OD1' ' A' ' 12' ' ' ASN . 50.5 p-10 -81.47 140.11 34.79 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.669 -179.879 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 42.4 ttp -101.13 153.79 19.28 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.065 -179.706 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' ARG . . . . . 0.851 ' HG3' HH11 ' A' ' 14' ' ' ARG . 22.2 mtm-85 -125.83 156.83 38.95 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-O 121.381 0.61 . . . . 0.0 112.233 -178.196 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 94.0 p -80.52 -6.26 57.93 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.062 -0.972 . . . . 0.0 110.052 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -159.48 -171.0 24.75 Favored Glycine 0 CA--C 1.525 0.716 0 N-CA-C 110.942 -0.863 . . . . 0.0 110.942 179.678 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -87.05 6.99 5.04 Favored 'Trans proline' 0 C--N 1.305 -1.747 0 C-N-CA 122.744 2.296 . . . . 0.0 111.997 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -99.75 128.71 9.66 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 111.134 -0.787 . . . . 0.0 111.134 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 97.6 p -67.24 -10.33 49.55 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.786 0.327 . . . . 0.0 110.297 179.642 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 54.9 p30 -91.55 8.12 38.13 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.33 -179.574 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 19.6 m-85 -87.13 -5.59 58.96 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.904 0.383 . . . . 0.0 110.322 -179.896 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 72.53 177.14 30.45 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 111.587 -0.605 . . . . 0.0 111.587 179.039 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.41 ' O ' HG13 ' A' ' 23' ' ' VAL . 7.2 p -97.54 126.96 50.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-O 120.844 0.354 . . . . 0.0 110.539 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 42.7 pt -106.88 -6.44 10.35 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.542 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.26 175.39 47.15 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 88.5 m -125.45 134.74 51.98 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-O 120.891 0.377 . . . . 0.0 110.337 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 82.1 mt -105.63 148.31 27.49 Favored 'General case' 0 CA--C 1.516 -0.334 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.891 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 31.8 mmm-85 -103.06 161.64 13.6 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.366 -0.834 . . . . 0.0 110.888 -179.098 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.428 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 25.5 p30 -65.71 143.02 57.8 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-O 121.186 0.517 . . . . 0.0 111.271 -179.362 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 66.3 t30 57.26 34.55 24.94 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.761 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 67.3 t0 -84.73 115.01 22.46 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.775 179.379 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 29.9 mmtp -72.7 128.37 35.34 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.89 0.376 . . . . 0.0 110.387 -179.329 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.3 m -137.81 161.24 33.29 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.222 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.15 179.832 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.531 ' N ' ' OE1' ' A' ' 34' ' ' GLU . 55.9 mp0 -106.54 123.69 48.47 Favored 'General case' 0 C--O 1.234 0.248 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.091 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 95.2 mt -88.52 128.07 41.01 Favored 'Isoleucine or valine' 0 C--O 1.232 0.153 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.45 -179.719 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 95.9 mt -98.19 -56.62 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.22 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.026 -179.763 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 47.1 mtpt -143.13 153.16 42.61 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 121.2 0.524 . . . . 0.0 111.262 -179.497 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' GLU . . . . . 0.438 ' CD ' ' CE1' ' A' ' 43' ' ' TYR . 84.3 tt0 -115.47 120.72 40.45 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.747 179.159 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 60.1 t -128.89 131.95 67.86 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.51 0 CA-C-O 120.899 0.381 . . . . 0.0 111.558 -179.48 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 54.11 26.47 6.59 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.35 179.285 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.86 -14.05 64.33 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 179.589 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 46.1 m95 -83.59 144.01 29.75 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 179.499 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' TYR . . . . . 0.438 ' CE1' ' CD ' ' A' ' 38' ' ' GLU . 65.0 m-85 -103.31 130.35 50.56 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.931 0.396 . . . . 0.0 110.676 -179.809 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 79.4 tt0 -90.08 122.5 33.11 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 179.312 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 24.1 pt -128.72 159.04 40.95 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-O 120.732 0.301 . . . . 0.0 111.309 -178.819 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.439 ' HB2' ' HE ' ' A' ' 46' ' ' ARG . 9.4 ttm180 -118.01 128.65 54.98 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.271 -0.422 . . . . 0.0 109.957 179.553 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 42.1 t80 -146.54 135.28 22.25 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.557 -179.358 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 96.2 m-20 56.53 33.82 23.27 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.838 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 73.82 6.33 72.24 Favored Glycine 0 CA--C 1.525 0.716 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 179.576 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 56.4 mtpt -110.41 147.52 33.84 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 120.644 0.259 . . . . 0.0 110.419 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 55.7 t -117.9 131.43 70.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 CA-C-N 116.274 -0.421 . . . . 0.0 109.956 179.674 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -149.4 -160.98 9.48 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.382 -1.087 . . . . 0.0 110.382 -179.914 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 67.6 m-85 -135.22 158.18 45.02 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.933 0.397 . . . . 0.0 110.766 -179.586 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -146.84 155.83 42.64 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.309 -179.848 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 20.2 m -69.77 151.46 45.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.792 -179.559 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 22.6 pttp -75.13 -18.83 60.15 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.718 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 74.7 m -61.85 -42.94 99.66 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.699 -179.589 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' TYR . . . . . 0.581 ' C ' HD12 ' A' ' 59' ' ' ILE . 82.8 m-85 -96.73 -2.38 44.55 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.524 0.202 . . . . 0.0 111.395 -179.187 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.581 HD12 ' C ' ' A' ' 58' ' ' TYR . 1.6 mp -113.86 128.66 70.68 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 179.46 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 91.7 m -124.88 130.35 52.21 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.055 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 22.1 mm -78.46 129.61 37.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.353 -179.593 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 94.1 t -95.66 129.24 46.03 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.182 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.616 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 56.5 t-20 57.51 85.08 0.09 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.621 179.759 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 75.9 mt-10 -78.41 -4.11 46.64 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.587 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 91.09 152.83 28.67 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 111.156 -0.778 . . . . 0.0 111.156 179.916 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 21.6 m -74.26 142.59 45.29 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.763 0.316 . . . . 0.0 110.41 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.575 ' N ' HD12 ' A' ' 67' ' ' LEU . 10.0 mp -91.43 -3.84 56.24 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.294 179.875 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 43.8 tp10 -67.35 132.52 47.86 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.267 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 99.5 m-70 -82.79 153.05 25.43 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.77 -179.92 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' HIS . . . . . 0.439 ' O ' ' O ' ' A' ' 71' ' ' HIS . 81.0 m80 -74.15 123.69 24.93 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.646 179.87 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.588 ' CG ' ' H ' ' A' ' 72' ' ' HIS . 28.4 t-80 49.91 174.33 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.898 179.55 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.588 ' H ' ' CG ' ' A' ' 71' ' ' HIS . 84.3 t60 -83.29 -3.86 57.87 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.698 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 86.4 t60 47.83 92.5 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.564 -179.672 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 42.6 m80 . . . . . 0 C--O 1.22 -0.477 0 CA-C-O 118.005 -0.998 . . . . 0.0 110.828 -179.876 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 22.5 tpp . . . . . 0 N--CA 1.491 1.621 0 N-CA-C 109.47 -0.566 . . . . 0.0 109.47 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 85.8 mt-30 -141.61 114.09 8.28 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 116.085 -0.507 . . . . 0.0 109.897 179.727 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -88.59 149.74 21.31 Favored Glycine 0 CA--C 1.523 0.576 0 N-CA-C 111.279 -0.728 . . . . 0.0 111.279 -179.529 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 53.8 t -126.65 132.55 70.06 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 179.818 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 83.0 t -91.11 128.76 42.71 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.196 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.359 179.757 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -125.63 106.46 9.76 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.318 179.904 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.547 HG22 ' H ' ' A' ' 9' ' ' SER . 3.0 p -138.02 145.4 28.79 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 116.263 -0.426 . . . . 0.0 109.862 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.526 ' OD1' ' N ' ' A' ' 9' ' ' SER . 38.7 p-10 -62.39 -41.18 98.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.776 -179.57 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.547 ' H ' HG22 ' A' ' 7' ' ' VAL . 6.9 t -123.28 -141.33 0.31 Allowed 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.424 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -92.73 144.15 25.59 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.491 179.788 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.408 ' CD1' ' CG ' ' A' ' 58' ' ' TYR . 6.4 tt -121.57 134.42 55.02 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.594 -179.828 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 92.2 m-20 -75.88 134.62 40.25 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.226 -179.412 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 27.4 ttt -89.05 152.68 21.53 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-N 115.847 -0.615 . . . . 0.0 109.485 179.104 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 84.2 mtt85 -124.71 144.35 50.27 Favored 'General case' 0 N--CA 1.478 0.971 0 CA-C-O 120.449 0.166 . . . . 0.0 111.026 -179.752 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' SER . . . . . 0.467 ' HA ' HD11 ' A' ' 24' ' ' ILE . 23.2 t -89.11 -2.18 58.42 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.909 0.385 . . . . 0.0 110.452 179.3 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -163.41 160.29 32.95 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.35 -1.1 . . . . 0.0 110.35 179.779 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_endo -62.69 99.02 0.2 Allowed 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.368 2.045 . . . . 0.0 111.891 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 135.35 141.82 4.44 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 110.573 -1.011 . . . . 0.0 110.573 179.932 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 35.3 t -67.53 -16.0 63.96 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.78 0.324 . . . . 0.0 110.725 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 52.6 t30 -84.87 8.38 17.63 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.687 -179.05 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 39.5 m-85 -96.85 8.24 44.82 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-O 120.766 0.317 . . . . 0.0 110.31 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 85.07 176.52 50.79 Favored Glycine 0 CA--C 1.522 0.502 0 N-CA-C 111.355 -0.698 . . . . 0.0 111.355 179.663 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.489 HG22 ' H ' ' A' ' 25' ' ' GLY . 14.8 p -121.27 133.84 66.57 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 CA-C-O 120.669 0.271 . . . . 0.0 110.397 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.467 HD11 ' HA ' ' A' ' 15' ' ' SER . 94.8 mt -92.93 -15.25 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-O 120.869 0.366 . . . . 0.0 110.589 -179.696 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.489 ' H ' HG22 ' A' ' 23' ' ' VAL . . . 157.35 -145.59 12.22 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 110.668 -0.973 . . . . 0.0 110.668 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 71.2 p -133.71 155.13 50.29 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-O 120.977 0.418 . . . . 0.0 110.309 179.75 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 85.0 mt -124.67 146.57 49.06 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.227 -179.79 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.408 ' N ' ' OD2' ' A' ' 31' ' ' ASP . 31.8 mtp85 -107.47 170.06 8.2 Favored 'General case' 0 CA--C 1.506 -0.714 0 CA-C-O 121.575 0.702 . . . . 0.0 111.206 -179.771 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 56.9 p30 -69.37 157.17 37.57 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 114.466 -1.243 . . . . 0.0 110.761 179.083 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 43.7 m-20 59.29 31.49 21.2 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 114.921 -1.036 . . . . 0.0 111.085 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.408 ' OD2' ' N ' ' A' ' 28' ' ' ARG . 98.5 m-20 -93.56 111.13 22.74 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-O 120.696 0.284 . . . . 0.0 110.419 179.343 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 56.2 mtpt -73.64 133.91 43.54 Favored 'General case' 0 C--N 1.328 -0.363 0 C-N-CA 120.639 -0.424 . . . . 0.0 109.986 179.599 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.7 m -136.59 160.9 37.33 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 120.84 0.353 . . . . 0.0 110.674 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -107.86 119.11 38.54 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 116.121 -0.491 . . . . 0.0 109.808 179.395 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.461 ' C ' HD12 ' A' ' 36' ' ' ILE . 97.0 mt -84.07 126.88 40.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.604 -179.533 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.707 ' N ' HD12 ' A' ' 36' ' ' ILE . 1.6 mp -94.33 -65.43 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.195 0 CA-C-N 116.197 -0.456 . . . . 0.0 109.983 179.9 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 50.4 mtmt -148.28 156.99 43.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.456 179.494 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' GLU . . . . . 0.45 ' CD ' ' CE1' ' A' ' 43' ' ' TYR . 83.6 tt0 -113.42 123.45 50.1 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.565 179.773 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 67.8 t -130.6 132.33 64.47 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.189 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 55.28 33.59 21.0 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.781 178.952 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 83.69 -11.39 56.59 Favored Glycine 0 CA--C 1.525 0.688 0 C-N-CA 120.965 -0.636 . . . . 0.0 111.715 179.0 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 84.2 m95 -89.72 140.69 29.32 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 179.725 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' TYR . . . . . 0.45 ' CE1' ' CD ' ' A' ' 38' ' ' GLU . 62.9 m-85 -101.56 126.43 48.37 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.822 0.344 . . . . 0.0 110.418 179.709 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -82.29 128.8 34.56 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.321 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 43.4 pt -129.48 156.99 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-O 121.28 0.562 . . . . 0.0 111.641 -179.015 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 28.8 ttt180 -124.83 131.42 53.44 Favored 'General case' 0 CA--C 1.51 -0.578 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.106 178.238 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 38.9 t80 -152.57 135.9 15.86 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.791 -0.641 . . . . 0.0 110.532 179.773 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 10.9 m120 56.56 34.3 24.15 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.307 179.736 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 73.81 5.75 70.4 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.429 -0.668 . . . . 0.0 111.429 179.4 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -107.04 144.87 33.08 Favored 'General case' 0 N--CA 1.467 0.394 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.684 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 53.0 t -118.88 133.57 65.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 CA-C-O 120.939 0.399 . . . . 0.0 110.545 -179.372 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -159.91 -168.63 22.15 Favored Glycine 0 CA--C 1.524 0.638 0 N-CA-C 110.576 -1.01 . . . . 0.0 110.576 179.91 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.444 ' CD1' ' N ' ' A' ' 53' ' ' TYR . 38.9 m-85 -127.5 156.33 42.33 Favored 'General case' 0 N--CA 1.464 0.271 0 N-CA-C 110.119 -0.326 . . . . 0.0 110.119 -179.702 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -140.0 157.17 46.09 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-O 120.861 0.363 . . . . 0.0 110.62 -179.752 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 28.5 t -63.01 140.49 58.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.211 -179.63 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 25.4 pttm -69.21 -28.75 66.64 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.308 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 52.9 m -59.93 -38.84 83.57 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.463 -179.187 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' TYR . . . . . 0.408 ' CG ' ' CD1' ' A' ' 11' ' ' LEU . 84.2 m-85 -94.81 15.17 19.15 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 111.758 0.281 . . . . 0.0 111.758 -179.012 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 5.5 mm -119.21 128.14 75.83 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 CA-C-O 120.939 0.399 . . . . 0.0 110.163 179.534 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 92.7 m -125.18 127.52 46.92 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.063 179.79 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.6 mt -87.76 125.8 41.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.419 179.782 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 2.3 m -107.08 106.82 21.36 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.374 179.876 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 63.5 t30 -173.45 22.71 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.655 179.831 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 79.8 mm-40 -66.17 140.74 58.21 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.732 -179.555 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.4 ' O ' ' O ' ' A' ' 66' ' ' SER . . . -177.92 73.89 0.07 OUTLIER Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.681 -0.968 . . . . 0.0 110.681 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.4 ' O ' ' O ' ' A' ' 65' ' ' GLY . 2.5 m 59.79 119.65 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.863 0.363 . . . . 0.0 110.475 -179.878 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 83.4 mt -74.53 145.63 43.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.675 -179.716 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -83.02 -84.9 0.12 Allowed 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.577 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 80.5 m80 -85.24 140.07 31.14 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.49 179.939 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' HIS . . . . . . . . . . . . . 86.0 t60 -153.34 143.63 22.37 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.724 -179.839 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -81.92 147.71 29.13 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.946 -179.885 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 85.1 t60 53.14 85.51 0.05 OUTLIER 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.655 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 59.6 t-80 -144.16 137.16 27.24 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.54 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 75.9 m80 . . . . . 0 C--O 1.221 -0.436 0 CA-C-O 118.256 -0.878 . . . . 0.0 110.512 179.762 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 25.8 ttt . . . . . 0 N--CA 1.489 1.518 0 N-CA-C 109.379 -0.601 . . . . 0.0 109.379 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -125.57 123.47 39.13 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 120.962 0.41 . . . . 0.0 110.524 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -86.74 148.08 21.57 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 179.756 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 74.3 t -124.96 130.27 73.28 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 CA-C-O 120.971 0.415 . . . . 0.0 110.271 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 19.1 t -92.57 128.56 44.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.499 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 21.9 mmtp -121.86 105.3 10.23 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.342 -0.39 . . . . 0.0 109.997 179.525 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 19.0 m -139.34 159.65 28.58 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.482 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 18.3 t-20 -81.2 -13.81 58.2 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.639 179.881 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 12.3 t -159.1 -166.19 1.78 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.5 -179.673 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -65.43 143.29 57.8 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.201 179.603 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 44.9 tp -124.13 132.2 53.62 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-O 120.792 0.33 . . . . 0.0 110.293 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 90.9 m-20 -75.24 142.77 43.32 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.297 179.688 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' MET . . . . . 0.43 ' SD ' HD11 ' A' ' 24' ' ' ILE . 12.0 tmm? -106.95 150.31 26.59 Favored 'General case' 0 N--CA 1.463 0.205 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 179.731 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' ARG . . . . . 0.746 ' NH2' ' H ' ' A' ' 22' ' ' GLY . 24.6 mtp85 -122.34 156.84 33.08 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-O 121.027 0.441 . . . . 0.0 110.572 -178.955 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 82.2 p -80.84 -6.42 58.56 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.584 -0.735 . . . . 0.0 111.046 -179.42 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.55 -168.95 20.72 Favored Glycine 0 CA--C 1.525 0.692 0 C-N-CA 120.831 -0.699 . . . . 0.0 111.422 -179.848 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -83.69 9.38 4.13 Favored 'Trans proline' 0 C--N 1.309 -1.511 0 C-N-CA 122.832 2.354 . . . . 0.0 112.631 -179.695 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -97.56 127.32 9.18 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.535 ' O ' ' NH2' ' A' ' 14' ' ' ARG . 96.1 p -70.97 -10.71 60.2 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.347 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 25.1 p30 -106.03 19.8 19.95 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.029 -179.712 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.433 ' N ' HH21 ' A' ' 14' ' ' ARG . 3.0 m-85 -86.3 -3.08 58.92 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.552 -0.294 . . . . 0.0 110.326 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.746 ' H ' ' NH2' ' A' ' 14' ' ' ARG . . . 81.1 168.61 40.24 Favored Glycine 0 CA--C 1.521 0.421 0 N-CA-C 111.01 -0.836 . . . . 0.0 111.01 179.913 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.465 ' O ' HG13 ' A' ' 23' ' ' VAL . 9.7 p -102.25 124.7 56.34 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 CA-C-O 120.827 0.346 . . . . 0.0 110.421 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.43 HD11 ' SD ' ' A' ' 13' ' ' MET . 23.1 pt -106.78 -0.22 9.98 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.804 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.83 167.8 39.77 Favored Glycine 0 CA--C 1.52 0.348 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 89.2 m -124.04 131.16 53.52 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 120.782 0.325 . . . . 0.0 110.626 -179.7 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 69.4 mt -101.67 161.48 13.62 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.744 -179.706 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 81.5 mtt180 -127.66 157.77 39.38 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 120.873 0.368 . . . . 0.0 110.247 179.54 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.436 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 52.7 p30 -57.25 150.64 17.41 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.285 -179.177 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 12.5 t-20 58.47 35.34 24.63 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.364 179.499 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 32.5 t0 -89.15 114.41 25.7 Favored 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 179.234 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -84.03 124.5 31.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.807 0.337 . . . . 0.0 110.357 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 28.2 m -138.22 162.39 30.59 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.94 -179.711 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' GLU . . . . . 0.634 ' OE1' ' NH1' ' A' ' 46' ' ' ARG . 78.1 tt0 -95.9 140.14 31.1 Favored 'General case' 0 C--O 1.233 0.222 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 179.054 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 91.3 mt -104.23 125.52 59.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.822 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 95.9 mt -93.03 -49.56 12.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.386 179.718 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 35.6 ttpt -172.79 157.66 3.76 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.659 -179.331 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' GLU . . . . . 0.57 ' H ' ' CD ' ' A' ' 38' ' ' GLU . 2.1 pm0 -110.0 143.56 39.82 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.35 -0.387 . . . . 0.0 110.371 179.833 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 34.4 t -129.95 126.35 62.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 CA-C-O 120.757 0.313 . . . . 0.0 110.644 -179.718 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 50.79 30.26 4.93 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.545 178.988 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 85.84 25.32 38.52 Favored Glycine 0 CA--C 1.525 0.687 0 C-N-CA 121.011 -0.614 . . . . 0.0 112.015 179.361 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 62.2 m95 -124.36 106.24 10.07 Favored 'General case' 0 N--CA 1.471 0.581 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.127 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 91.3 m-85 -70.97 135.3 47.8 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.968 0.413 . . . . 0.0 111.437 -179.243 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -88.4 141.89 28.17 Favored 'General case' 0 CA--C 1.518 -0.262 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 178.325 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 39.9 pt -135.38 154.45 35.42 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.684 0 CA-C-O 121.627 0.727 . . . . 0.0 111.034 -179.582 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.634 ' NH1' ' OE1' ' A' ' 34' ' ' GLU . 11.2 ttp180 -111.4 123.54 50.41 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 114.668 -1.151 . . . . 0.0 110.378 -179.917 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 66.9 t80 -151.72 134.91 15.91 Favored 'General case' 0 N--CA 1.463 0.224 0 C-N-CA 120.87 -0.332 . . . . 0.0 111.158 -179.497 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 55.3 t-20 57.96 35.11 25.01 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.423 179.603 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 66.87 22.5 72.12 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 111.091 -0.804 . . . . 0.0 111.091 179.738 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 54.9 mtpt -128.91 146.74 50.87 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 121.012 0.434 . . . . 0.0 111.019 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 53.8 t -113.51 131.77 64.33 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.922 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -143.97 -163.35 9.86 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -179.806 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 44.8 m-85 -127.64 153.1 46.84 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 110.242 -0.281 . . . . 0.0 110.242 -179.675 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -146.69 151.33 37.03 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-N 116.383 -0.372 . . . . 0.0 110.642 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 41.0 t -65.14 143.72 57.69 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.744 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 26.0 pttm -67.58 -17.6 64.69 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.849 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 16.0 m -64.28 -36.06 82.86 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.44 -179.52 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 41.6 m-85 -103.85 12.04 34.94 Favored 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 111.978 0.362 . . . . 0.0 111.978 -178.175 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 46.2 mm -121.43 129.67 75.36 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.573 0 CA-C-O 120.931 0.396 . . . . 0.0 110.623 179.846 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 62.2 p -116.98 131.9 56.84 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.422 -179.601 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.6 mt -84.4 129.65 37.3 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.174 179.597 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 87.9 t -84.09 132.52 31.33 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.354 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 95.5 m-20 55.3 -170.67 0.07 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.622 -179.788 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 55.62 25.69 8.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.418 -179.805 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 165.13 48.51 0.02 OUTLIER Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.832 -0.907 . . . . 0.0 110.832 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 22.6 t -84.39 -5.8 59.31 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.732 0.301 . . . . 0.0 111.158 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.57 ' N ' HD12 ' A' ' 67' ' ' LEU . 9.4 mp -78.46 132.94 37.48 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.069 0.461 . . . . 0.0 110.45 179.906 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -140.1 48.13 1.79 Allowed 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.48 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' HIS . . . . . 0.498 ' O ' ' CG ' ' A' ' 69' ' ' HIS . 38.2 t-80 42.55 33.92 0.5 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.038 0.446 . . . . 0.0 110.745 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' HIS . . . . . . . . . . . . . 59.6 t-80 -59.59 -42.48 92.63 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.317 179.864 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.428 ' O ' ' CG ' ' A' ' 71' ' ' HIS . 52.6 p-80 -72.48 124.0 24.29 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.205 179.851 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.602 ' CE1' ' CE1' ' A' ' 74' ' ' HIS . 74.6 t60 -148.51 136.68 21.08 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.58 -179.815 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.518 ' O ' ' CG ' ' A' ' 74' ' ' HIS . 98.7 m-70 -149.46 124.23 9.87 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.376 179.706 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' HIS . . . . . 0.602 ' CE1' ' CE1' ' A' ' 72' ' ' HIS . 74.9 m80 . . . . . 0 C--O 1.221 -0.444 0 CA-C-O 118.136 -0.935 . . . . 0.0 110.483 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 6.8 ttt . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.423 ' CD ' ' N ' ' A' ' 2' ' ' GLN . 2.2 mp0 -136.69 120.53 17.44 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.416 179.93 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -99.62 147.56 18.33 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.625 -0.99 . . . . 0.0 110.625 179.772 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 54.3 t -124.73 130.78 73.31 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-O 120.927 0.394 . . . . 0.0 110.127 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 13.6 t -87.55 127.17 41.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.306 179.865 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -123.09 105.59 10.06 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.858 0.361 . . . . 0.0 110.068 179.491 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 14.8 p -156.51 139.09 6.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.559 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 66.2 t30 -67.84 -48.98 64.65 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.824 0.345 . . . . 0.0 110.756 179.606 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 5.5 m -93.96 152.48 18.81 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.575 179.799 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -61.47 142.7 56.83 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.532 -0.467 . . . . 0.0 110.194 179.568 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 41.1 tp -117.58 128.23 54.74 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.894 179.851 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' ASN . . . . . 0.551 ' ND2' HH12 ' A' ' 14' ' ' ARG . 21.2 p-10 -72.08 145.47 48.2 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.687 179.549 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 62.6 ttp -96.69 140.05 31.85 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-O 121.207 0.527 . . . . 0.0 110.663 -179.627 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' ARG . . . . . 0.961 ' HE ' ' HA ' ' A' ' 19' ' ' SER . 1.0 OUTLIER -93.8 153.82 18.08 Favored 'General case' 0 CA--C 1.541 0.608 0 CA-C-N 115.345 -0.843 . . . . 0.0 111.472 -178.443 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 78.5 p -88.34 -9.66 52.01 Favored 'General case' 0 N--CA 1.462 0.127 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.845 179.13 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -162.82 -173.05 31.05 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.154 -1.178 . . . . 0.0 110.154 179.729 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -80.67 78.29 3.72 Favored 'Trans proline' 0 C--N 1.298 -2.115 0 C-N-CA 122.584 2.189 . . . . 0.0 112.391 179.547 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 167.13 134.5 1.71 Allowed Glycine 0 CA--C 1.525 0.676 0 N-CA-C 111.371 -0.691 . . . . 0.0 111.371 179.769 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.961 ' HA ' ' HE ' ' A' ' 14' ' ' ARG . 23.2 t -68.32 -13.46 62.29 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 112.102 0.408 . . . . 0.0 112.102 -179.113 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 93.5 m-20 -88.07 11.44 16.1 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.766 -179.762 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 17.8 m-85 -90.7 1.3 56.97 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.313 179.849 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 76.59 -173.47 54.4 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 179.848 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 4.8 p -118.87 127.69 75.74 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-O 120.841 0.353 . . . . 0.0 110.293 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 25.2 pt -110.21 -3.64 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.448 179.651 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.56 -176.55 43.89 Favored Glycine 0 CA--C 1.529 0.908 0 N-CA-C 111.246 -0.742 . . . . 0.0 111.246 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 69.4 p -131.55 155.29 47.73 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 120.647 0.26 . . . . 0.0 110.691 -179.82 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 84.1 mt -125.37 149.56 48.02 Favored 'General case' 0 N--CA 1.472 0.625 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.519 -179.35 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 92.1 mtt-85 -120.21 161.67 20.68 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 121.669 0.747 . . . . 0.0 111.103 -179.164 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 64.2 t30 -57.97 144.23 40.2 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.581 -178.608 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 59.2 34.23 23.06 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.47 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 65.7 t0 -85.25 114.89 22.68 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-O 120.778 0.323 . . . . 0.0 110.186 178.881 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -80.37 128.87 34.06 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.551 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.1 m -141.59 161.3 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.201 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.439 179.741 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 80.7 mm-40 -102.73 133.35 47.93 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.942 179.637 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 92.5 mt -102.75 109.43 26.63 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.625 -179.848 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 97.2 mt -66.46 -43.63 90.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.547 179.853 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 25.7 pttm -172.51 179.25 2.52 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.774 -179.401 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 2.5 tm-20 -112.89 124.62 53.03 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.179 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 54.1 t -125.66 133.01 70.16 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.784 -179.663 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 55.81 28.86 12.99 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.133 179.393 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.36 -8.6 57.96 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.854 -0.898 . . . . 0.0 110.854 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 11.1 m95 -94.05 148.38 22.23 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 110.035 -0.357 . . . . 0.0 110.035 179.633 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 64.2 m-85 -96.95 131.39 43.8 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.974 0.416 . . . . 0.0 110.689 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -83.18 152.99 25.0 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 108.496 -0.928 . . . . 0.0 108.496 178.499 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 34.5 pt -145.29 150.55 15.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 C-N-CA 120.707 -0.397 . . . . 0.0 111.143 -179.413 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.603 ' HE ' ' HA2' ' A' ' 49' ' ' GLY . 16.6 ttt180 -115.05 126.18 54.41 Favored 'General case' 0 CA--C 1.511 -0.534 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 177.398 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 79.5 t80 -138.1 129.05 27.09 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-N 115.16 -0.927 . . . . 0.0 110.304 179.574 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 67.0 t30 53.09 36.5 22.44 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.628 -0.714 . . . . 0.0 112.124 179.677 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.603 ' HA2' ' HE ' ' A' ' 46' ' ' ARG . . . 71.05 16.41 74.9 Favored Glycine 0 CA--C 1.525 0.665 0 C-N-CA 120.491 -0.861 . . . . 0.0 111.024 178.924 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.414 ' HD3' ' N ' ' A' ' 51' ' ' VAL . 6.0 tmtt? -119.04 125.78 50.15 Favored 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 109.9 -0.408 . . . . 0.0 109.9 -179.366 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.414 ' N ' ' HD3' ' A' ' 50' ' ' LYS . 82.5 t -80.25 136.65 22.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.591 179.741 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -157.59 167.66 34.14 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.884 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 76.0 m-85 -122.01 156.87 32.56 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-O 120.645 0.259 . . . . 0.0 110.444 -179.544 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -148.77 151.71 35.3 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-O 120.842 0.354 . . . . 0.0 110.472 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 30.0 t -63.23 141.26 58.83 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.478 -179.882 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 26.0 pttm -67.21 -15.1 63.5 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.193 -179.671 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 78.0 p -65.64 -33.19 75.33 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.68 -179.661 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -102.31 11.0 38.78 Favored 'General case' 0 N--CA 1.468 0.454 0 N-CA-C 111.867 0.321 . . . . 0.0 111.867 -179.04 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 47.8 mm -115.55 130.12 70.7 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.567 0 CA-C-O 120.997 0.427 . . . . 0.0 110.554 179.795 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 90.1 m -116.75 124.91 50.79 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.189 179.695 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 21.0 mm -81.79 134.64 26.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.44 -179.856 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.528 ' O ' ' N ' ' A' ' 64' ' ' GLU . 75.3 t -62.56 134.36 27.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.294 -179.901 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 86.0 m-20 -40.83 90.04 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.951 -179.412 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' GLU . . . . . 0.528 ' N ' ' O ' ' A' ' 62' ' ' VAL . 80.9 tt0 -101.32 116.37 32.63 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.305 179.911 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 42.04 79.86 0.05 OUTLIER Glycine 0 CA--C 1.526 0.767 0 N-CA-C 111.242 -0.743 . . . . 0.0 111.242 179.762 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 85.9 p -64.74 152.21 43.15 Favored 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 120.864 -0.334 . . . . 0.0 110.332 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.45 ' O ' ' N ' ' A' ' 69' ' ' HIS . 54.0 tp -88.72 92.9 9.39 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.339 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.435 ' O ' ' CG ' ' A' ' 69' ' ' HIS . 83.8 tt0 38.15 -93.97 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.234 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.115 179.856 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 69' ' ' HIS . . . . . 0.45 ' N ' ' O ' ' A' ' 67' ' ' LEU . 98.3 m-70 -155.36 168.75 26.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.446 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' HIS . . . . . . . . . . . . . 35.2 p-80 -61.13 122.06 14.06 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.603 -179.739 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 56.3 t-80 -65.93 -42.91 89.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.673 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.45 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 54.1 p-80 -86.75 121.54 29.4 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.709 -179.903 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 58.4 t-80 -61.41 -44.26 97.44 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.633 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 65.1 t-80 . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 118.016 -0.992 . . . . 0.0 110.601 179.946 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 51.0 ttp . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 88.6 mt-30 -124.33 129.54 50.92 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.684 -179.82 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -93.97 156.78 22.51 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.689 -0.964 . . . . 0.0 110.689 179.713 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 65.1 t -124.59 130.99 73.32 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 179.663 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 13.1 t -86.05 128.97 38.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.778 -179.584 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -130.81 106.23 8.31 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.939 0.4 . . . . 0.0 110.207 179.382 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.492 HG22 ' H ' ' A' ' 9' ' ' SER . 3.2 p -140.82 142.77 29.71 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.205 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.223 -179.563 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.526 ' OD1' ' N ' ' A' ' 9' ' ' SER . 13.9 p30 -63.28 -40.8 98.38 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.717 -179.732 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.526 ' N ' ' OD1' ' A' ' 8' ' ' ASN . 17.4 m -117.69 -139.76 0.36 Allowed 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.92 179.578 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -91.97 144.35 25.55 Favored 'General case' 0 C--O 1.233 0.21 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 179.498 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 60.6 tp -110.86 130.18 55.65 Favored 'General case' 0 N--CA 1.468 0.451 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 -179.835 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -85.23 133.63 34.17 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.403 179.827 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 38.4 ttp -100.71 142.16 32.57 Favored 'General case' 0 CA--C 1.51 -0.582 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 179.712 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' ARG . . . . . 0.525 HH12 ' CB ' ' A' ' 19' ' ' SER . 8.6 mtt180 -117.74 155.42 30.04 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.83 -178.83 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 87.5 p -77.73 -11.81 59.91 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 112.057 0.392 . . . . 0.0 112.057 -178.885 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -162.9 -173.04 31.14 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 179.862 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -83.29 77.02 3.67 Favored 'Trans proline' 0 C--N 1.307 -1.623 0 C-N-CA 122.704 2.269 . . . . 0.0 112.173 179.605 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 168.54 133.81 1.62 Allowed Glycine 0 CA--C 1.527 0.83 0 C-N-CA 120.753 -0.737 . . . . 0.0 111.699 179.717 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.525 ' CB ' HH12 ' A' ' 14' ' ' ARG . 6.0 t -65.86 -17.41 64.63 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-O 120.886 0.374 . . . . 0.0 110.985 179.807 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' ASN . . . . . 0.531 ' OD1' ' N ' ' A' ' 21' ' ' TYR . 41.1 p-10 -60.89 -36.09 78.32 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.508 -179.117 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.531 ' N ' ' OD1' ' A' ' 20' ' ' ASN . 76.6 m-85 -62.05 -37.02 83.39 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.04 179.342 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 89.48 173.71 45.91 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.451 ' CG2' ' O ' ' A' ' 25' ' ' GLY . 14.0 p -87.19 128.12 40.06 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.867 0.365 . . . . 0.0 110.487 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 25.4 pt -104.4 -4.32 9.61 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.502 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.451 ' O ' ' CG2' ' A' ' 23' ' ' VAL . . . -176.32 -177.12 45.06 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.414 -1.075 . . . . 0.0 110.414 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 69.7 p -132.2 150.22 52.2 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-O 120.947 0.403 . . . . 0.0 110.374 179.861 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 84.4 mt -129.06 148.54 51.02 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.757 -179.529 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 71.0 mtp180 -107.0 162.44 13.84 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.23 179.509 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.426 ' HB3' ' H ' ' A' ' 7' ' ' VAL . 52.8 p30 -69.29 171.97 7.72 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.172 179.723 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 85.9 m-20 58.33 9.2 0.97 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.122 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 43.4 t0 -85.11 116.54 23.54 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.782 0.325 . . . . 0.0 110.676 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 65.5 mttp -77.0 135.13 38.66 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.056 179.674 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.0 m -137.75 159.85 34.03 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-O 120.89 0.376 . . . . 0.0 110.648 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -104.44 117.95 35.41 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.048 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.4 ' C ' HD12 ' A' ' 36' ' ' ILE . 95.7 mt -90.72 125.76 43.51 Favored 'Isoleucine or valine' 0 C--O 1.232 0.172 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.518 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.767 ' N ' HD12 ' A' ' 36' ' ' ILE . 1.9 mp -92.96 -41.16 12.58 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.67 -179.819 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 22.6 pttp -171.83 158.86 5.01 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.604 -179.805 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' GLU . . . . . 0.476 ' OE1' ' CE1' ' A' ' 43' ' ' TYR . 81.4 tt0 -112.61 125.04 53.84 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.089 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 65.0 t -128.05 132.63 68.39 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 CA-C-O 120.906 0.384 . . . . 0.0 111.146 -179.694 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.435 ' OD1' ' O ' ' A' ' 40' ' ' ASP . 55.1 t0 56.85 25.37 10.33 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.924 179.394 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.01 -9.71 73.53 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 179.696 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 66.2 m95 -89.44 141.51 28.5 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 110.077 -0.342 . . . . 0.0 110.077 179.783 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' TYR . . . . . 0.476 ' CE1' ' OE1' ' A' ' 38' ' ' GLU . 38.3 m-85 -95.38 131.8 41.12 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-O 121.01 0.433 . . . . 0.0 110.403 179.915 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -92.03 119.64 31.93 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 178.9 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 41.1 pt -125.88 157.84 35.43 Favored 'Isoleucine or valine' 0 C--O 1.233 0.222 0 CA-C-O 121.123 0.487 . . . . 0.0 111.092 -179.311 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 79.0 ttt180 -115.83 124.93 51.93 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.593 179.035 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 28.2 t80 -141.83 132.77 25.94 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.454 -179.814 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 62.7 t30 61.08 27.67 17.47 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.398 -179.835 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 74.08 9.01 79.88 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 61.5 tttm -102.76 156.69 17.47 Favored 'General case' 0 C--O 1.231 0.129 0 N-CA-C 110.043 -0.355 . . . . 0.0 110.043 -179.825 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 56.6 t -115.9 131.17 69.16 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.009 -179.873 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -160.98 -170.43 25.59 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 66.6 m-85 -130.31 162.62 28.62 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-O 120.779 0.323 . . . . 0.0 110.509 -179.632 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -146.68 154.3 41.28 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.369 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 20.2 m -66.25 143.19 57.37 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.619 -179.863 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 60.7 pttt -79.9 -19.44 48.17 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.167 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 11.7 t -61.59 -42.14 98.43 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.354 -179.558 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 99.3 m-85 -92.24 4.3 53.55 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.439 -0.346 . . . . 0.0 111.786 -178.833 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 97.6 mt -122.29 132.09 71.82 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.54 0 CA-C-O 121.001 0.429 . . . . 0.0 110.881 179.678 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 93.1 m -120.2 134.06 55.35 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.406 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 23.1 mm -77.15 132.73 32.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.649 -179.893 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 94.7 t -72.81 129.11 36.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.936 0.398 . . . . 0.0 110.764 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' ASN . . . . . 0.542 ' O ' ' N ' ' A' ' 65' ' ' GLY . 99.1 m-20 49.29 28.43 2.27 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.497 179.552 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' GLU . . . . . 0.411 ' C ' ' O ' ' A' ' 63' ' ' ASN . 17.4 pt-20 34.23 29.41 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.272 -179.935 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.542 ' N ' ' O ' ' A' ' 63' ' ' ASN . . . 76.09 148.83 2.46 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 110.16 -1.176 . . . . 0.0 110.16 -179.214 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 61.9 p -89.38 105.89 18.09 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.892 0.377 . . . . 0.0 110.636 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 87.5 mt -93.57 -5.63 48.47 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.356 179.804 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -164.09 124.76 2.17 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.329 -179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' HIS . . . . . 0.53 ' O ' ' CG ' ' A' ' 70' ' ' HIS . 75.1 m80 -65.1 -45.3 85.75 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.832 -179.9 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 70' ' ' HIS . . . . . 0.53 ' CG ' ' O ' ' A' ' 69' ' ' HIS . 99.5 m-70 -159.23 -115.75 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.221 -179.838 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.445 ' O ' ' O ' ' A' ' 72' ' ' HIS . 98.7 m-70 50.97 94.03 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.528 -0.306 . . . . 0.0 110.581 179.823 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.445 ' O ' ' O ' ' A' ' 71' ' ' HIS . 97.9 m-70 57.49 120.97 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.753 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 45.4 p-80 -153.9 159.69 41.85 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.643 179.872 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 86.3 t60 . . . . . 0 C--O 1.22 -0.45 0 CA-C-O 117.895 -1.05 . . . . 0.0 110.443 -179.993 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.517 ' SD ' ' N ' ' A' ' 1' ' ' MET . 0.0 OUTLIER . . . . . 0 N--CA 1.495 1.783 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 . . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.443 ' OE1' ' N ' ' A' ' 2' ' ' GLN . 1.1 mp0 -109.06 110.58 21.87 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-O 121.116 0.484 . . . . 0.0 111.371 179.812 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -92.96 158.18 23.84 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 110.685 -0.966 . . . . 0.0 110.685 179.351 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 73.3 t -126.1 134.47 66.43 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 O-C-N 122.615 -0.344 . . . . 0.0 110.309 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 18.2 t -85.1 126.29 40.34 Favored 'Isoleucine or valine' 0 C--O 1.234 0.248 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.751 -179.905 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 41.5 mmtm -112.24 106.63 15.25 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-O 120.763 0.316 . . . . 0.0 110.382 179.796 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.402 HG22 ' N ' ' A' ' 8' ' ' ASN . 9.7 p -140.15 159.11 26.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 N-CA-C 110.307 -0.257 . . . . 0.0 110.307 179.671 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.478 ' OD1' ' N ' ' A' ' 9' ' ' SER . 21.5 p30 -64.37 -39.47 93.94 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.813 -0.355 . . . . 0.0 110.623 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.478 ' N ' ' OD1' ' A' ' 8' ' ' ASN . 59.5 p -141.09 -60.75 0.49 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.155 -179.656 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.417 ' N ' ' OG ' ' A' ' 9' ' ' SER . . . -149.63 145.84 26.97 Favored 'General case' 0 CA--C 1.519 -0.248 0 CA-C-O 121.196 0.522 . . . . 0.0 110.758 -179.699 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 39.9 tp -116.68 131.66 56.89 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.464 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 99.7 m-20 -74.94 138.38 42.28 Favored 'General case' 0 CA--C 1.518 -0.264 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.573 179.654 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 37.6 ttp -94.72 151.41 19.3 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.621 179.74 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' ARG . . . . . 0.65 ' NH1' ' H ' ' A' ' 16' ' ' GLY . 0.4 OUTLIER -129.89 154.18 47.56 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.94 0.4 . . . . 0.0 111.668 -179.151 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 15' ' ' SER . . . . . 0.618 ' H ' ' CZ ' ' A' ' 14' ' ' ARG . 85.9 p -87.5 -17.34 32.34 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 115.606 -0.725 . . . . 0.0 111.237 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.65 ' H ' ' NH1' ' A' ' 14' ' ' ARG . . . -149.2 -177.48 23.37 Favored Glycine 0 CA--C 1.528 0.875 0 C-N-CA 120.859 -0.686 . . . . 0.0 111.52 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -81.99 82.39 2.32 Favored 'Trans proline' 0 C--N 1.319 -0.983 0 C-N-CA 123.256 2.637 . . . . 0.0 112.107 -179.691 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 163.99 119.63 0.49 Allowed Glycine 0 CA--C 1.528 0.881 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 179.727 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 80.4 p -70.46 -12.39 61.54 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-O 120.605 0.241 . . . . 0.0 110.732 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -78.25 -14.98 59.21 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.322 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.412 ' HB3' ' NH2' ' A' ' 14' ' ' ARG . 13.6 m-85 -64.91 -41.89 95.21 Favored 'General case' 0 CA--C 1.519 -0.231 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.844 179.526 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.54 ' O ' ' NE ' ' A' ' 14' ' ' ARG . . . 117.07 133.76 5.12 Favored Glycine 0 C--N 1.333 0.394 0 N-CA-C 110.954 -0.859 . . . . 0.0 110.954 179.324 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 5.4 p -65.93 139.46 21.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 121.065 0.459 . . . . 0.0 110.399 179.756 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 34.8 pt -106.91 -10.08 10.58 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.215 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.975 -179.878 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.23 -172.93 43.16 Favored Glycine 0 CA--C 1.521 0.467 0 N-CA-C 110.626 -0.99 . . . . 0.0 110.626 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 97.5 m -125.94 147.57 49.47 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-O 120.923 0.392 . . . . 0.0 111.222 -179.301 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 60.5 mt -112.88 153.59 27.67 Favored 'General case' 0 C--O 1.233 0.207 0 CA-C-O 121.055 0.455 . . . . 0.0 110.006 179.458 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 24.1 mmt180 -100.83 159.87 14.83 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.436 -179.543 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.437 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 53.5 p-10 -65.32 143.98 57.41 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.828 -179.528 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 56.66 34.0 23.78 Favored 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.598 179.229 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 44.0 t0 -85.08 117.1 23.83 Favored 'General case' 0 N--CA 1.466 0.341 0 C-N-CA 120.884 -0.326 . . . . 0.0 110.891 179.749 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -72.38 130.48 40.82 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.998 0.428 . . . . 0.0 110.49 179.826 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 28.8 m -137.29 162.93 32.7 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.489 179.827 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -100.13 122.56 43.17 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.813 -0.631 . . . . 0.0 109.934 179.56 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.4 mt -97.4 128.66 48.47 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.169 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.211 -179.739 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 22.7 mm -94.04 -64.32 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.473 -179.693 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 25.3 pttm -154.47 163.52 40.06 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.789 -179.758 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 44.2 tt0 -103.85 126.72 51.18 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.583 179.757 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 61.4 t -127.86 131.64 69.54 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.2 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.335 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 51.1 t0 55.68 24.25 6.98 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.04 179.845 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.72 -16.01 57.62 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 111.54 -0.624 . . . . 0.0 111.54 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 17.0 m95 -88.2 141.97 28.13 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.806 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 -94.53 131.6 40.08 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-O 120.737 0.303 . . . . 0.0 111.083 -179.52 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -80.65 134.51 35.89 Favored 'General case' 0 N--CA 1.464 0.275 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 179.2 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 40.0 pt -134.54 155.39 38.73 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-O 121.006 0.431 . . . . 0.0 111.77 -179.441 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 56.4 ttp180 -118.58 124.44 47.48 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.501 179.568 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 36.1 t80 -148.19 134.83 19.84 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.683 179.734 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 65.5 t30 58.74 31.35 21.09 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.674 -179.798 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 70.18 19.54 75.82 Favored Glycine 0 CA--C 1.521 0.407 0 N-CA-C 110.668 -0.973 . . . . 0.0 110.668 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -122.0 145.57 48.0 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-O 120.709 0.29 . . . . 0.0 110.256 -179.587 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 16.8 t -96.78 113.3 30.79 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 CA-C-O 120.846 0.355 . . . . 0.0 110.36 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' GLY . . . . . 0.42 ' C ' ' CD1' ' A' ' 53' ' ' TYR . . . -119.84 -166.97 13.44 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 110.772 -0.931 . . . . 0.0 110.772 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.42 ' CD1' ' C ' ' A' ' 52' ' ' GLY . 85.3 m-85 -147.37 159.59 43.52 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 179.963 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -145.62 154.88 42.62 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.971 0.415 . . . . 0.0 110.809 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 15.1 m -69.51 146.08 52.16 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.666 -179.809 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 20.6 ptmt -68.23 -36.82 80.09 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.465 -179.836 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 78.3 p -66.92 -23.22 65.95 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.865 -179.007 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 80.9 m-85 -104.82 7.33 34.47 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.471 -179.888 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 4.9 mm -127.71 129.74 70.15 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.15 179.811 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 98.5 m -121.22 127.07 51.09 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.593 179.481 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 21.8 mm -86.23 128.94 38.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.107 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 21.2 t -81.79 133.13 29.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.822 -179.569 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 43.0 t-20 63.08 51.48 2.79 Favored 'General case' 0 C--O 1.232 0.146 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.553 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 77.0 mt-10 -44.5 133.01 5.93 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.525 -179.672 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -72.78 141.41 30.54 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.533 -1.027 . . . . 0.0 110.533 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 14.1 m 37.08 93.71 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.909 0.385 . . . . 0.0 111.334 -179.717 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.57 ' H ' HD23 ' A' ' 67' ' ' LEU . 0.1 OUTLIER -79.5 143.22 35.1 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.368 -179.891 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -157.46 113.16 2.83 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.314 179.724 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 51.5 p-80 -86.82 -0.77 57.02 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.289 179.792 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' HIS . . . . . . . . . . . . . 96.2 m-70 -73.09 130.09 39.52 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.056 -0.52 . . . . 0.0 109.856 179.855 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 24.9 p80 -101.71 20.05 16.97 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.714 -179.649 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 56.81 86.53 0.07 Allowed 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.582 -179.765 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 44.8 p-80 -83.01 146.54 28.7 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.463 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 58.2 m-70 . . . . . 0 C--O 1.22 -0.45 0 CA-C-O 118.177 -0.916 . . . . 0.0 110.595 -179.72 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 6.7 ttt . . . . . 0 N--CA 1.491 1.575 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.9 mt-30 -141.27 110.48 6.27 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.222 179.786 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -85.19 163.81 37.99 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.514 -1.034 . . . . 0.0 110.514 179.648 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 54.7 t -125.17 130.15 73.1 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-O 120.785 0.326 . . . . 0.0 110.143 179.858 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 15.7 t -95.4 125.92 48.01 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.08 179.681 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 33.1 ttpt -129.81 117.1 19.68 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.497 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.4 HG12 ' H ' ' A' ' 9' ' ' SER . 2.8 t -140.92 155.9 22.16 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 CA-C-O 120.872 0.368 . . . . 0.0 110.726 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 49.8 p30 -79.9 -11.49 59.8 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.504 179.548 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.4 ' H ' HG12 ' A' ' 7' ' ' VAL . 73.6 m -162.07 -164.79 1.11 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.385 -179.76 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -65.25 142.95 58.11 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.735 -179.903 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 53.6 tp -126.16 132.12 51.88 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-N 116.169 -0.468 . . . . 0.0 109.879 179.701 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' ASN . . . . . 0.445 ' O ' ' OD1' ' A' ' 12' ' ' ASN . 47.8 p30 -77.62 142.44 38.9 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.001 0.429 . . . . 0.0 110.956 -179.873 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 43.3 ttp -111.43 138.44 47.93 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 179.691 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' ARG . . . . . 0.71 ' NH2' ' CE3' ' A' ' 42' ' ' TRP . 0.5 OUTLIER -109.18 141.2 41.75 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 120.867 0.365 . . . . 0.0 111.03 -178.81 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 38.4 t -63.44 -42.61 98.67 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.037 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -107.73 179.8 22.0 Favored Glycine 0 N--CA 1.466 0.665 0 N-CA-C 110.65 -0.98 . . . . 0.0 110.65 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -82.98 73.09 5.59 Favored 'Trans proline' 0 C--N 1.307 -1.652 0 C-N-CA 122.438 2.092 . . . . 0.0 111.959 179.665 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' GLY . . . . . 0.668 ' N ' HH21 ' A' ' 14' ' ' ARG . . . 174.52 158.07 17.64 Favored Glycine 0 CA--C 1.528 0.89 0 N-CA-C 111.344 -0.702 . . . . 0.0 111.344 179.918 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 69.5 m -82.4 -10.37 59.08 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.849 0.357 . . . . 0.0 110.643 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 92.1 m-20 -89.64 5.03 47.56 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.188 -179.128 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 47.8 m-85 -92.11 -0.59 57.44 Favored 'General case' 0 N--CA 1.465 0.304 0 N-CA-C 109.993 -0.373 . . . . 0.0 109.993 179.775 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 78.53 -178.32 53.13 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 111.127 -0.789 . . . . 0.0 111.127 179.647 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 5.4 p -116.08 126.71 73.69 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 CA-C-O 120.932 0.396 . . . . 0.0 110.33 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 43.6 pt -103.66 -8.94 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.968 -179.866 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -177.87 -171.72 41.58 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 63.2 p -133.51 158.46 43.07 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-O 120.928 0.394 . . . . 0.0 110.642 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 75.9 mt -122.33 153.88 38.37 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 115.899 -0.592 . . . . 0.0 109.945 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.406 ' O ' ' CG ' ' A' ' 31' ' ' ASP . 70.3 mtm180 -124.54 147.14 48.6 Favored 'General case' 0 N--CA 1.465 0.309 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.914 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 53.0 p-10 -51.91 159.38 0.86 Allowed 'General case' 0 C--N 1.324 -0.536 0 C-N-CA 120.76 -0.376 . . . . 0.0 111.14 -179.168 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 58.0 t30 67.16 9.05 6.64 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.489 179.85 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' ASP . . . . . 0.406 ' CG ' ' O ' ' A' ' 28' ' ' ARG . 35.1 m-20 -84.88 113.7 21.57 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.746 0.308 . . . . 0.0 110.414 179.288 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 25.8 mtpp -78.57 136.77 37.61 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.084 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.4 m -137.24 163.05 32.65 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.252 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.784 -179.542 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 47.8 tp10 -103.01 123.8 47.3 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.401 179.497 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 90.4 mt -97.49 120.13 46.43 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.041 -179.424 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 82.2 mt -83.88 -44.96 18.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.733 179.533 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 62.1 pttt -173.93 174.89 2.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.452 -179.837 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -118.51 124.98 48.88 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.209 179.873 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 69.0 t -125.33 131.83 71.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.679 -179.577 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 54.83 27.53 9.1 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.12 179.574 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.11 -12.29 62.69 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 179.569 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' TRP . . . . . 0.71 ' CE3' ' NH2' ' A' ' 14' ' ' ARG . 82.9 m95 -88.73 145.02 25.88 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.731 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 65.6 m-85 -101.25 130.59 47.4 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-O 120.974 0.416 . . . . 0.0 110.521 -179.878 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -87.9 128.65 35.36 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.526 179.48 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 42.8 pt -128.94 150.51 34.64 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.253 0 CA-C-O 121.061 0.458 . . . . 0.0 111.312 -179.234 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 4.7 ttp180 -120.22 129.42 54.07 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.019 178.769 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 73.8 t80 -146.43 132.42 19.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.678 179.564 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 16.8 t-20 57.19 31.25 19.73 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.023 179.479 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 76.78 4.77 82.74 Favored Glycine 0 CA--C 1.528 0.863 0 N-CA-C 111.347 -0.701 . . . . 0.0 111.347 179.548 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 51.4 mtmt -102.21 150.27 23.46 Favored 'General case' 0 N--CA 1.466 0.358 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.567 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 58.0 t -116.65 132.79 65.3 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-O 120.881 0.372 . . . . 0.0 110.31 -179.641 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -153.93 -166.39 14.79 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.514 ' C ' ' NH1' ' A' ' 14' ' ' ARG . 52.8 m-85 -139.18 159.03 43.12 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-O 120.815 0.341 . . . . 0.0 110.694 -179.512 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.516 ' N ' HH12 ' A' ' 14' ' ' ARG . . . -144.19 149.59 36.66 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.987 179.223 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 21.1 m -66.26 147.29 53.53 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.849 0.357 . . . . 0.0 110.574 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 62.3 pttt -64.63 -21.65 66.77 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.756 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 68.4 m -63.23 -40.29 97.02 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.55 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 72.7 m-85 -95.69 8.33 43.76 Favored 'General case' 0 N--CA 1.469 0.494 0 N-CA-C 111.93 0.345 . . . . 0.0 111.93 -178.729 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 46.0 mm -120.59 127.07 75.89 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 CA-C-O 120.905 0.383 . . . . 0.0 110.55 179.814 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 89.8 m -125.42 127.9 47.26 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 115.943 -0.572 . . . . 0.0 109.915 179.252 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 19.1 mm -85.21 127.93 39.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.543 -179.698 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 27.4 m -73.65 141.04 16.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.623 -179.785 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' ASN . . . . . 0.431 ' OD1' ' O ' ' A' ' 63' ' ' ASN . 45.8 p-10 -64.03 129.21 39.1 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.798 -179.579 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -66.42 142.46 57.58 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.426 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -66.88 140.59 38.47 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 110.826 -0.909 . . . . 0.0 110.826 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 69.9 m -95.69 119.66 34.58 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 120.905 0.383 . . . . 0.0 110.587 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.48 HD12 ' N ' ' A' ' 68' ' ' GLU . 0.3 OUTLIER -98.38 4.65 48.53 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.363 179.962 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.48 ' N ' HD12 ' A' ' 67' ' ' LEU . 80.3 mm-40 -62.05 -39.05 91.04 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.622 -179.723 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 69' ' ' HIS . . . . . 0.441 ' O ' ' CG ' ' A' ' 69' ' ' HIS . 40.3 p-80 -140.7 98.65 3.45 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.156 179.655 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' HIS . . . . . 0.507 ' H ' ' CD2' ' A' ' 70' ' ' HIS . 11.1 p80 -88.95 -45.55 9.59 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.756 -179.737 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 80.4 m80 -148.39 152.91 37.81 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.557 -179.874 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 85.9 t60 -160.98 119.85 2.54 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.018 179.76 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 59.5 t-80 -114.95 123.5 49.27 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.55 -179.664 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 79.5 m80 . . . . . 0 C--O 1.221 -0.443 0 CA-C-O 117.919 -1.039 . . . . 0.0 110.666 179.922 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 13.5 tpp . . . . . 0 N--CA 1.489 1.515 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 28.5 mp0 -125.06 114.65 19.35 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.27 179.788 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -97.29 168.02 24.04 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.73 -0.948 . . . . 0.0 110.73 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 55.4 t -125.55 132.07 71.36 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 N-CA-C 109.986 -0.375 . . . . 0.0 109.986 179.652 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 89.4 t -92.27 113.44 27.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.03 179.757 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 75.5 tttt -112.71 117.08 31.25 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.16 -179.765 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 9.1 p -144.11 154.0 15.48 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.995 -179.829 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 40.2 t30 -63.16 -41.03 99.18 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.891 -179.761 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.447 ' O ' ' ND2' ' A' ' 29' ' ' ASN . 20.3 p -133.3 -72.26 0.51 Allowed 'General case' 0 N--CA 1.468 0.439 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.733 -179.914 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -152.78 144.17 23.29 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.242 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 42.5 tp -115.06 128.73 56.42 Favored 'General case' 0 N--CA 1.47 0.567 0 CA-C-O 120.979 0.418 . . . . 0.0 110.531 -179.664 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -74.77 144.56 43.53 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.481 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 33.3 ttp -107.26 150.31 26.8 Favored 'General case' 0 CA--C 1.519 -0.244 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 179.601 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' ARG . . . . . 0.493 ' HE ' ' HA ' ' A' ' 19' ' ' SER . 85.7 mtt85 -128.29 150.16 50.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.762 -178.303 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 23.0 t -69.15 -15.88 63.52 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 115.961 -0.563 . . . . 0.0 112.218 -179.417 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -161.01 -172.68 28.65 Favored Glycine 0 CA--C 1.524 0.646 0 C-N-CA 120.394 -0.908 . . . . 0.0 111.428 -179.673 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -82.76 78.43 3.34 Favored 'Trans proline' 0 C--N 1.304 -1.816 0 C-N-CA 122.729 2.286 . . . . 0.0 111.734 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 169.9 134.91 1.82 Allowed Glycine 0 CA--C 1.525 0.658 0 N-CA-C 111.29 -0.724 . . . . 0.0 111.29 179.878 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.493 ' HA ' ' HE ' ' A' ' 14' ' ' ARG . 34.5 t -66.69 -14.83 62.98 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.944 0.402 . . . . 0.0 110.642 179.705 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 91.6 m-20 -79.45 -1.13 35.92 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.941 -179.495 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 39.0 m-85 -89.21 -1.77 58.22 Favored 'General case' 0 C--O 1.232 0.163 0 N-CA-C 109.573 -0.529 . . . . 0.0 109.573 179.384 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 66.4 176.31 7.13 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 179.804 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.463 ' O ' HG13 ' A' ' 23' ' ' VAL . 8.1 p -101.54 124.48 55.33 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 N-CA-C 110.105 -0.331 . . . . 0.0 110.105 179.603 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 42.9 pt -100.72 -3.27 9.45 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.714 -179.775 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 172.37 -177.84 44.8 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 53.0 p -132.73 158.51 42.19 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.76 0.314 . . . . 0.0 110.367 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 69.1 mt -112.65 135.47 53.34 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.286 -179.658 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -82.52 160.8 22.53 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 120.933 0.397 . . . . 0.0 110.407 -179.17 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.447 ' ND2' ' O ' ' A' ' 9' ' ' SER . 47.2 m-80 -62.53 136.96 58.15 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.021 179.855 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' ASN . . . . . 0.545 ' O ' ' ND2' ' A' ' 30' ' ' ASN . 2.5 t30 55.64 36.7 27.72 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.0 179.587 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -84.33 116.57 23.08 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.532 179.753 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -72.72 130.71 41.15 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 120.714 -0.394 . . . . 0.0 110.192 179.613 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.7 m -138.82 162.16 28.97 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.541 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -104.17 123.01 46.53 Favored 'General case' 0 N--CA 1.463 0.218 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 179.551 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.2 mt -90.35 106.25 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.214 -179.642 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.8 mt -66.24 -45.03 90.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.738 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 21.1 ptmt -175.82 170.8 2.77 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.366 -179.501 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -115.34 124.08 50.35 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.401 179.702 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 79.7 t -127.97 133.08 67.99 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.373 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.2 -179.833 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.428 ' OD1' ' O ' ' A' ' 40' ' ' ASP . 56.3 t0 56.52 23.02 7.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.901 0.382 . . . . 0.0 110.761 179.666 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 85.22 -6.69 78.69 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 111.249 -0.741 . . . . 0.0 111.249 179.68 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 49.0 m95 -85.85 145.78 27.04 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 109.697 -0.482 . . . . 0.0 109.697 179.31 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -95.75 115.25 27.16 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.977 0.418 . . . . 0.0 110.156 -179.672 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -83.65 122.55 28.76 Favored 'General case' 0 CA--C 1.517 -0.315 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 178.89 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 36.3 pt -128.74 162.42 35.79 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.494 0 CA-C-O 121.388 0.613 . . . . 0.0 111.65 -178.434 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.413 ' HD3' HH11 ' A' ' 46' ' ' ARG . 20.4 ttp180 -124.67 130.05 51.69 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.219 -0.9 . . . . 0.0 109.845 179.789 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 84.1 t80 -149.49 132.71 16.4 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.238 -179.507 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 66.0 t30 55.98 36.15 26.83 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.679 179.534 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 69.84 16.53 72.46 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.949 -0.86 . . . . 0.0 110.949 179.889 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 39.3 tptt -116.16 134.77 54.56 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-O 120.691 0.281 . . . . 0.0 110.285 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 58.5 t -108.89 131.22 60.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.155 -179.619 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -152.06 -156.82 7.65 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.736 -0.946 . . . . 0.0 110.736 -179.893 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 76.0 m-85 -137.75 155.85 48.62 Favored 'General case' 0 N--CA 1.464 0.225 0 CA-C-O 120.885 0.374 . . . . 0.0 110.78 -179.75 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -154.13 160.42 41.91 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.157 -179.709 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.7 p -64.47 151.63 43.82 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.044 -179.526 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 22.9 pttp -84.61 -27.21 27.36 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.665 179.828 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 38.9 t -62.27 -40.67 97.01 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.327 -179.614 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 58.8 m-85 -84.94 2.51 42.53 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.805 -179.027 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 97.6 mt -124.43 129.66 73.81 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.183 179.197 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 91.0 m -115.54 128.45 55.99 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.554 -179.707 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 95.3 mt -83.33 124.4 39.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.925 -0.58 . . . . 0.0 109.884 179.788 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 34.9 m -89.99 136.78 22.93 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 CA-C-O 120.938 0.399 . . . . 0.0 110.947 -179.511 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' ASN . . . . . 0.422 ' OD1' ' O ' ' A' ' 63' ' ' ASN . 15.8 p30 -53.55 125.78 19.3 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.418 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 79.5 mm-40 -67.27 -40.84 86.22 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.597 -179.767 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 59.56 -141.93 47.25 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 -179.847 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 2.7 t 42.05 89.17 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.986 0.422 . . . . 0.0 110.919 179.899 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.53 HD22 ' N ' ' A' ' 67' ' ' LEU . 3.5 mm? -87.91 -5.15 58.71 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.414 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 -67.09 139.65 57.57 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.804 -179.545 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 75.3 m80 -82.61 163.76 21.23 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.604 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' HIS . . . . . . . . . . . . . 55.0 t-80 -59.64 -42.93 93.87 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.902 -179.684 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 84.7 t60 -80.71 124.21 28.84 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.801 0.334 . . . . 0.0 110.643 -179.904 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 84.0 t60 -92.46 123.22 35.61 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.37 179.884 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 56.1 t-80 -166.37 129.54 1.98 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.446 179.717 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 51.3 t-80 . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 118.054 -0.974 . . . . 0.0 110.798 -179.771 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.487 ' CD ' ' N ' ' A' ' 2' ' ' GLN . 1.4 pm0 . . . . . 0 N--CA 1.462 0.16 0 CA-C-O 120.954 0.406 . . . . 0.0 110.538 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -88.42 149.8 21.47 Favored Glycine 0 CA--C 1.525 0.68 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 179.66 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 53.9 t -122.05 129.39 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 87.4 t -93.56 126.47 45.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.188 179.752 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 33.1 tptt -118.52 110.8 17.82 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.153 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.48 HG22 ' H ' ' A' ' 9' ' ' SER . 12.5 p -144.42 144.74 22.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.075 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -63.41 -41.23 98.71 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.7 -179.615 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . 0.48 ' H ' HG22 ' A' ' 7' ' ' VAL . 38.6 m -119.06 -75.12 0.58 Allowed 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.985 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -157.87 145.67 18.61 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.386 -179.633 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 60.7 tp -108.98 131.12 55.37 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.138 -179.177 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 10.9 m120 -80.89 145.63 31.22 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.666 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 42.5 ttp -106.81 149.84 26.96 Favored 'General case' 0 N--CA 1.471 0.597 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 179.857 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . 0.687 HH11 ' HA ' ' A' ' 19' ' ' SER . 58.1 mtt-85 -133.5 140.77 47.43 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-O 121.031 0.443 . . . . 0.0 111.768 -176.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 35.8 t -59.16 -41.93 89.55 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.358 -178.364 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -109.6 161.92 12.88 Favored Glycine 0 CA--C 1.53 0.987 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -77.99 73.3 5.78 Favored 'Trans proline' 0 N--CA 1.496 1.663 0 C-N-CA 122.922 2.414 . . . . 0.0 112.044 179.348 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 176.26 160.44 23.59 Favored Glycine 0 CA--C 1.516 0.146 0 N-CA-C 110.013 -1.235 . . . . 0.0 110.013 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . 0.687 ' HA ' HH11 ' A' ' 14' ' ' ARG . 5.4 m -78.88 -16.9 56.44 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 120.457 -0.497 . . . . 0.0 110.54 -179.638 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -64.88 -36.05 83.1 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.971 -179.034 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -59.25 -42.52 91.32 Favored 'General case' 0 C--N 1.329 -0.284 0 C-N-CA 120.851 -0.339 . . . . 0.0 111.423 -178.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 101.86 162.21 26.8 Favored Glycine 0 N--CA 1.468 0.77 0 N-CA-C 111.29 -0.724 . . . . 0.0 111.29 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 7.2 p -77.16 132.79 32.11 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.123 0 CA-C-O 121.018 0.437 . . . . 0.0 111.594 -179.627 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 44.1 pt -113.45 -8.5 12.15 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.302 179.318 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -170.97 175.59 44.62 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.529 -1.029 . . . . 0.0 110.529 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 86.9 m -123.2 132.1 53.92 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-O 120.715 0.293 . . . . 0.0 110.451 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 73.0 mt -109.19 141.96 40.68 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.267 179.767 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.729 HH11 ' HG2' ' A' ' 28' ' ' ARG . 46.0 mtt-85 -95.32 168.06 10.96 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.274 179.383 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 50.7 p-10 -75.27 159.0 32.02 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 178.863 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 77.4 m-20 56.23 31.91 19.31 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.322 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 47.3 t0 -96.37 112.81 24.42 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 116.559 -0.291 . . . . 0.0 110.639 179.336 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 56.3 mtpt -74.06 134.34 42.96 Favored 'General case' 0 C--N 1.329 -0.288 0 C-N-CA 120.601 -0.44 . . . . 0.0 110.075 179.606 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 28.5 m -136.94 162.37 34.51 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.606 -179.81 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -101.82 121.1 41.45 Favored 'General case' 0 C--O 1.233 0.232 0 CA-C-N 116.083 -0.508 . . . . 0.0 109.869 179.618 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.3 mt -88.58 127.81 41.23 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.139 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.396 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 95.8 mt -91.77 -42.76 13.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.576 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 62.0 pttt -174.82 165.04 3.6 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.567 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -113.01 121.87 45.92 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.181 179.594 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 70.1 t -126.73 131.51 71.07 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.65 -179.64 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . 0.418 ' OD1' ' O ' ' A' ' 40' ' ' ASP . 56.6 t0 53.96 31.17 12.94 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.414 179.082 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 85.43 -16.49 39.48 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 111.043 -0.823 . . . . 0.0 111.043 179.694 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 79.9 m95 -83.35 146.14 28.65 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.401 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 58.7 m-85 -101.17 130.19 47.21 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.904 0.383 . . . . 0.0 110.402 179.669 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . 0.526 ' OE1' ' CE1' ' A' ' 53' ' ' TYR . 3.5 tp10 -88.12 118.52 27.75 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 179.207 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 44.7 pt -126.03 161.37 31.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-O 121.334 0.588 . . . . 0.0 110.678 -179.468 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.406 HH11 ' HD3' ' A' ' 46' ' ' ARG . 0.6 OUTLIER -126.88 127.23 44.61 Favored 'General case' 0 CA--C 1.537 0.467 0 CA-C-N 115.397 -0.82 . . . . 0.0 110.041 -178.262 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 32.9 t80 -145.79 133.47 21.03 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.461 -178.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 57.67 33.34 23.12 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.245 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 74.01 8.13 77.72 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 111.514 -0.634 . . . . 0.0 111.514 179.098 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 58.6 mttp -106.98 150.19 26.74 Favored 'General case' 0 N--CA 1.466 0.356 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 53.4 t -116.55 132.56 65.83 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.054 -179.808 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . 0.416 ' O ' ' OE1' ' A' ' 44' ' ' GLU . . . -159.78 -169.46 23.12 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 110.97 -0.852 . . . . 0.0 110.97 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.526 ' CE1' ' OE1' ' A' ' 44' ' ' GLU . 97.8 m-85 -125.39 154.78 41.38 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.799 0.333 . . . . 0.0 110.482 -179.759 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -136.12 151.8 50.17 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.281 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 21.2 m -63.24 145.2 56.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.533 -179.71 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 58.8 pttt -77.53 -24.79 49.89 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.919 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 21.4 m -62.25 -41.27 98.29 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.394 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' TYR . . . . . 0.535 ' C ' HD12 ' A' ' 59' ' ' ILE . 90.2 m-85 -92.65 -2.07 56.38 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 116.552 -0.295 . . . . 0.0 111.635 -178.857 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.535 HD12 ' C ' ' A' ' 58' ' ' TYR . 1.3 mp -113.7 130.03 68.5 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 92.6 m -118.51 127.92 54.09 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.25 179.677 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 25.2 mm -77.36 133.83 29.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.439 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 78.7 t . . . . . 0 N--CA 1.463 0.224 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.608 -179.6 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 99.2 mm-40 . . . . . 0 N--CA 1.463 0.188 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -91.89 145.0 17.47 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 111.487 -0.645 . . . . 0.0 111.487 -179.471 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 58.8 t -123.62 131.83 72.4 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.451 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 70.6 t -93.28 127.39 45.39 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.249 0 CA-C-O 120.817 0.341 . . . . 0.0 110.607 -179.715 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 53.8 mtmt -126.43 107.1 9.96 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.37 179.703 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 9.8 p -137.96 159.46 33.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.002 -179.853 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 93.9 m-20 -61.26 -41.65 97.27 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.522 -0.308 . . . . 0.0 110.813 -179.291 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 5.2 t -143.68 -51.62 0.33 Allowed 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 120.803 0.335 . . . . 0.0 110.961 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -157.69 144.14 17.78 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.469 -179.659 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 52.3 tp -117.85 132.99 56.37 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 120.864 0.364 . . . . 0.0 110.118 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 99.7 m-20 -76.3 139.23 40.97 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.021 179.672 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 35.6 ttp -100.21 139.11 36.35 Favored 'General case' 0 N--CA 1.465 0.276 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . 0.46 ' HE ' ' HA ' ' A' ' 19' ' ' SER . 84.3 mtt85 -113.27 158.03 21.03 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.858 0.361 . . . . 0.0 110.818 -178.504 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 8.8 m -80.04 -11.53 59.77 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.94 -179.303 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -164.23 -173.01 32.41 Favored Glycine 0 CA--C 1.52 0.406 0 N-CA-C 110.815 -0.914 . . . . 0.0 110.815 179.47 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -82.74 75.82 4.37 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 122.612 2.208 . . . . 0.0 111.667 179.753 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.76 130.9 1.35 Allowed Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 179.722 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . 0.46 ' HA ' ' HE ' ' A' ' 14' ' ' ARG . 80.6 p -70.1 -9.02 54.14 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.666 0.27 . . . . 0.0 110.963 -179.884 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 12.9 m120 -83.55 -0.78 51.82 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.798 -179.876 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 43.0 m-85 -90.98 -2.71 57.66 Favored 'General case' 0 N--CA 1.462 0.167 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.654 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 71.87 -179.34 34.84 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.444 HG13 ' O ' ' A' ' 23' ' ' VAL . 14.2 p -108.61 127.04 65.39 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 CA-C-O 120.889 0.376 . . . . 0.0 110.176 179.594 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 26.1 pt -104.49 -3.3 9.67 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 CA-C-O 120.953 0.406 . . . . 0.0 110.717 -179.65 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.88 -178.52 48.53 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.865 -0.894 . . . . 0.0 110.865 -179.876 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 44.7 p -133.41 155.97 48.53 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.913 0.387 . . . . 0.0 110.549 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 78.6 mt -122.84 146.99 47.06 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.294 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 66.0 mtm180 -106.42 153.46 22.22 Favored 'General case' 0 CA--C 1.515 -0.368 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.517 179.877 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 50.8 p-10 -60.0 157.02 13.53 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.359 179.667 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 11.2 t-20 64.39 4.27 2.14 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.266 179.718 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 67.2 t0 -79.95 120.75 24.57 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.466 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 31.1 mtmm -101.15 138.18 38.51 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 120.864 0.364 . . . . 0.0 110.445 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 33.5 m -138.32 163.57 28.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.621 -179.723 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -85.34 134.95 34.08 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.479 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 86.6 mt -103.5 128.23 56.82 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.485 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.846 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.783 HD12 ' N ' ' A' ' 36' ' ' ILE . 2.0 mp -91.36 -44.49 14.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.834 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 62.6 pttt -172.52 160.09 4.67 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.648 -179.651 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . 0.473 ' CD ' ' CE1' ' A' ' 43' ' ' TYR . 82.6 tt0 -111.39 127.77 55.77 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.439 -179.866 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 57.5 t -127.91 129.94 69.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.707 179.794 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 53.19 30.83 10.47 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.361 -0.382 . . . . 0.0 111.592 179.137 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.9 -28.37 7.26 Favored Glycine 0 CA--C 1.521 0.427 0 N-CA-C 110.919 -0.873 . . . . 0.0 110.919 179.655 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 58.6 m95 -71.7 142.36 49.83 Favored 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 120.865 -0.334 . . . . 0.0 110.11 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . 0.473 ' CE1' ' CD ' ' A' ' 38' ' ' GLU . 59.9 m-85 -102.94 133.01 48.76 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.379 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 75.1 tt0 -91.79 121.36 33.34 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.308 179.414 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 46.2 pt -125.53 160.08 32.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.526 -0.306 . . . . 0.0 110.977 -179.124 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 22.0 ttt180 -120.54 126.95 51.63 Favored 'General case' 0 CA--C 1.54 0.566 0 CA-C-N 115.896 -0.593 . . . . 0.0 109.698 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.43 ' O ' ' CG ' ' A' ' 48' ' ' ASN . 32.7 t80 -145.09 145.39 31.4 Favored 'General case' 0 N--CA 1.473 0.676 0 O-C-N 123.04 0.212 . . . . 0.0 110.471 -178.353 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.43 ' CG ' ' O ' ' A' ' 47' ' ' PHE . 10.1 p30 51.52 25.74 2.88 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.109 -179.851 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 77.94 17.5 78.39 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 111.447 -0.661 . . . . 0.0 111.447 179.441 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -124.24 145.65 49.23 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-O 120.82 0.343 . . . . 0.0 110.283 179.675 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 53.2 t -112.14 131.65 62.99 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.317 -179.691 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -150.21 -164.17 11.67 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.478 -1.049 . . . . 0.0 110.478 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 55.3 m-85 -132.3 152.16 51.51 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 120.841 0.353 . . . . 0.0 110.695 -179.692 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -141.49 157.37 45.22 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.509 -179.581 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 38.1 t -61.19 139.8 58.05 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.226 -179.475 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -83.96 -12.94 54.58 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.691 179.807 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 37.3 m -70.6 -21.06 62.7 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.22 -179.28 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -115.74 4.43 14.01 Favored 'General case' 0 N--CA 1.47 0.562 0 CA-C-O 120.624 0.249 . . . . 0.0 111.131 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 97.1 mt -125.42 129.62 72.92 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 CA-C-O 120.879 0.371 . . . . 0.0 110.763 179.693 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 85.0 m -127.96 132.36 49.23 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.836 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.42 HD11 ' CE1' ' A' ' 43' ' ' TYR . 96.1 mt -80.79 128.32 38.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.359 179.583 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 22.1 m . . . . . 0 N--CA 1.465 0.319 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.693 -179.876 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 24.5 mp0 . . . . . 0 N--CA 1.465 0.29 0 CA-C-O 120.762 0.315 . . . . 0.0 110.567 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -90.68 171.0 35.7 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 179.49 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 53.3 t -124.71 130.12 73.48 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.541 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 59.7 t -91.0 127.24 43.54 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.259 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 59.9 mttp -121.79 110.57 16.07 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 120.841 0.353 . . . . 0.0 110.089 179.634 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.428 HG22 ' CD1' ' A' ' 58' ' ' TYR . 72.4 t -126.69 138.29 55.23 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.185 -179.317 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.422 ' OD1' ' O ' ' A' ' 8' ' ' ASN . 56.5 t-20 -62.73 -41.6 99.25 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.345 -179.192 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 21.6 m -130.87 -76.73 0.53 Allowed 'General case' 0 N--CA 1.468 0.433 0 CA-C-O 120.776 0.322 . . . . 0.0 110.806 -179.552 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -151.93 140.61 20.83 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.818 -179.696 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.429 HD22 ' CG ' ' A' ' 58' ' ' TYR . 53.8 tp -123.17 133.22 54.26 Favored 'General case' 0 N--CA 1.469 0.488 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.203 179.8 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . 0.431 ' HB2' HH12 ' A' ' 14' ' ' ARG . 99.5 m-20 -81.7 140.08 34.54 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.977 179.755 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' MET . . . . . 0.474 ' SD ' HD11 ' A' ' 24' ' ' ILE . 7.3 tmm? -91.31 136.29 33.21 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-O 121.257 0.551 . . . . 0.0 110.37 -179.882 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . 0.431 HH12 ' HB2' ' A' ' 12' ' ' ASN . 4.0 mmt-85 -105.63 140.61 38.43 Favored 'General case' 0 CA--C 1.542 0.648 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.708 -178.127 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . 0.505 ' OG ' HD13 ' A' ' 24' ' ' ILE . 68.5 m -78.6 -7.44 57.6 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.893 -177.941 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -153.77 -166.04 14.33 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -85.48 -0.68 8.92 Favored 'Trans proline' 0 C--N 1.302 -1.887 0 C-N-CA 122.479 2.119 . . . . 0.0 111.794 -179.768 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -99.12 128.2 9.49 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 110.808 -0.917 . . . . 0.0 110.808 179.503 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 78.5 p -69.64 -14.97 63.09 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.83 0.348 . . . . 0.0 110.622 179.672 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 96.7 m-20 -91.72 14.07 16.34 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.482 -179.368 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 7.9 m-85 -87.26 0.7 54.97 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.879 0.371 . . . . 0.0 110.041 179.853 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 79.47 171.33 41.32 Favored Glycine 0 CA--C 1.524 0.619 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 179.781 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.477 HG13 ' O ' ' A' ' 23' ' ' VAL . 11.3 p -106.99 126.72 63.01 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 CA-C-O 120.728 0.299 . . . . 0.0 110.471 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.505 HD13 ' OG ' ' A' ' 15' ' ' SER . 24.9 pt -106.07 -2.43 9.91 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.475 0 CA-C-O 121.005 0.431 . . . . 0.0 110.552 179.734 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -176.46 -177.15 45.22 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 110.47 -1.052 . . . . 0.0 110.47 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 61.3 p -131.92 153.6 50.1 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-O 121.03 0.443 . . . . 0.0 110.469 179.881 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 83.0 mt -123.6 147.62 47.16 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.402 179.238 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 1.7 mtm180 -124.32 153.84 41.17 Favored 'General case' 0 C--O 1.224 -0.287 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.666 -178.277 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 53.1 p-10 -56.19 165.52 1.01 Allowed 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.35 0.595 . . . . 0.0 112.059 -179.532 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 71.0 m-80 59.29 13.18 2.95 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 114.995 -1.002 . . . . 0.0 111.316 179.579 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 91.3 m-20 -87.86 113.78 23.85 Favored 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 120.844 -0.342 . . . . 0.0 110.451 179.493 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -92.23 129.57 38.15 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.016 0.436 . . . . 0.0 110.441 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.4 m -137.11 161.16 35.77 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.145 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.081 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -89.91 131.09 36.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.298 -179.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.2 mt -97.69 107.71 20.55 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.216 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.435 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 97.5 mt -66.64 -44.21 89.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.925 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 63.2 pttt -173.05 178.9 2.38 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.769 -179.533 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -119.94 123.92 44.71 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.12 179.554 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 62.3 t -126.07 131.68 71.42 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-O 120.974 0.416 . . . . 0.0 110.626 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 54.5 31.39 14.74 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.278 179.361 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.537 ' O ' ' NZ ' ' A' ' 56' ' ' LYS . . . 82.97 -15.91 30.13 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 179.755 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 11.4 m95 -86.08 148.29 25.78 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.708 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 51.5 m-85 -100.91 132.94 46.07 Favored 'General case' 0 C--O 1.233 0.187 0 CA-C-O 121.111 0.482 . . . . 0.0 110.523 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -94.46 127.04 40.11 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.376 -0.829 . . . . 0.0 109.271 179.163 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 43.7 pt -129.22 157.14 42.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 CA-C-O 121.135 0.493 . . . . 0.0 111.784 -178.862 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 31.1 ttp180 -115.6 124.37 50.79 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.719 178.748 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 34.4 t80 -145.14 132.95 21.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.709 -179.466 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 62.2 t30 56.62 32.92 21.86 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.608 179.77 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 71.83 11.87 74.13 Favored Glycine 0 CA--C 1.528 0.875 0 N-CA-C 111.369 -0.693 . . . . 0.0 111.369 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 65.6 mttp -111.62 147.31 35.75 Favored 'General case' 0 N--CA 1.467 0.409 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.755 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 52.9 t -117.44 132.06 68.35 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.067 -179.778 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . 0.418 ' C ' ' CD1' ' A' ' 53' ' ' TYR . . . -156.27 -167.02 16.99 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.491 -1.044 . . . . 0.0 110.491 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.535 ' N ' ' CD1' ' A' ' 53' ' ' TYR . 10.1 m-85 -137.15 154.6 50.21 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-O 120.811 0.338 . . . . 0.0 110.451 -179.486 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -147.05 152.85 39.23 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.322 179.802 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 9.7 p -63.95 142.92 58.23 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.881 0.372 . . . . 0.0 110.753 -179.708 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.537 ' NZ ' ' O ' ' A' ' 41' ' ' GLY . 0.0 OUTLIER -66.24 -12.74 58.08 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.711 -179.358 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 6.1 m -65.06 -15.74 62.69 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.544 -0.298 . . . . 0.0 111.215 -179.515 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' TYR . . . . . 0.429 ' CG ' HD22 ' A' ' 11' ' ' LEU . 95.2 m-85 -117.8 5.67 12.26 Favored 'General case' 0 N--CA 1.472 0.651 0 N-CA-C 111.69 0.256 . . . . 0.0 111.69 -179.737 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 4.2 mp -121.49 130.15 74.9 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 CA-C-O 121.246 0.546 . . . . 0.0 110.154 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 85.5 m -123.91 132.63 53.77 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.197 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.0 mt -72.79 129.22 35.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.169 179.769 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 89.2 t . . . . . 0 C--N 1.327 -0.406 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.671 -179.882 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 98.4 mm-40 . . . . . 0 N--CA 1.466 0.327 0 CA-C-O 121.094 0.473 . . . . 0.0 110.148 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -100.03 154.27 19.52 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.748 -0.941 . . . . 0.0 110.748 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 64.1 t -124.4 130.85 73.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.586 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 88.1 t -88.47 128.41 40.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.62 -179.786 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -127.46 105.51 8.56 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.242 179.606 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 30.9 m -138.89 159.96 30.03 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.254 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.715 179.799 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 11.7 m120 -91.41 -4.05 56.06 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.38 179.698 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 17.4 m -154.39 -166.95 2.48 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.34 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -67.18 143.82 56.35 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.466 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 51.3 tp -117.51 130.62 56.55 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 116.182 -0.463 . . . . 0.0 109.88 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 10.7 m120 -89.22 134.2 34.13 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.439 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 52.1 ttp -105.38 145.96 30.08 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 116.174 -0.466 . . . . 0.0 109.834 179.765 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 93.8 mtt-85 -119.13 159.82 23.25 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-O 120.936 0.398 . . . . 0.0 111.162 -179.554 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 86.2 p -81.67 -5.94 58.56 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.617 -0.72 . . . . 0.0 110.133 179.638 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.433 ' C ' ' H ' ' A' ' 18' ' ' GLY . . . -159.55 167.31 35.13 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 110.625 -0.99 . . . . 0.0 110.625 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo -69.94 12.27 0.36 Allowed 'Trans proline' 0 C--N 1.308 -1.6 0 C-N-CA 121.883 1.722 . . . . 0.0 111.904 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . 0.433 ' H ' ' C ' ' A' ' 16' ' ' GLY . . . -99.4 124.12 8.13 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.861 -0.895 . . . . 0.0 110.861 179.225 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 79.5 p -66.94 -10.21 46.6 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.757 0.313 . . . . 0.0 110.535 179.779 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 55.0 p30 -90.95 6.18 45.7 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.64 -179.284 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 32.4 m-85 -88.5 -10.41 49.06 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.39 179.852 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 75.9 176.75 41.11 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 111.361 -0.696 . . . . 0.0 111.361 179.102 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.499 HG13 ' O ' ' A' ' 23' ' ' VAL . 12.1 p -92.48 127.17 44.82 Favored 'Isoleucine or valine' 0 C--O 1.232 0.151 0 CA-C-O 120.711 0.291 . . . . 0.0 110.528 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 24.5 pt -106.11 -5.02 9.97 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-O 120.872 0.368 . . . . 0.0 110.623 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.6 175.3 47.24 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.808 -0.917 . . . . 0.0 110.808 -179.824 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 73.9 m -125.88 130.36 51.18 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 120.878 0.371 . . . . 0.0 110.463 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 72.8 mt -112.44 142.43 44.99 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.711 179.633 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.774 HH11 ' HG3' ' A' ' 28' ' ' ARG . 71.4 mtm-85 -108.42 164.12 12.61 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-O 121.345 0.593 . . . . 0.0 111.117 -179.551 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.414 ' C ' ' H ' ' A' ' 31' ' ' ASP . 57.1 p30 -67.26 166.84 13.44 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.024 179.803 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 10.0 m120 59.41 3.16 0.37 Allowed 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.098 -179.765 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.461 ' OD2' ' N ' ' A' ' 28' ' ' ARG . 98.3 m-20 -72.66 140.02 47.67 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.987 0.422 . . . . 0.0 110.59 179.37 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 53.4 mttp -107.19 125.78 51.55 Favored 'General case' 0 N--CA 1.476 0.859 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.38 179.017 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.3 m -136.65 162.4 35.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 178.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -100.56 123.89 45.37 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-O 120.835 0.35 . . . . 0.0 110.555 -179.738 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.7 mt -84.68 130.12 36.55 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.128 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.469 179.588 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.5 mt -98.88 -54.86 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.196 -179.603 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 8.7 ttmm -150.64 153.01 34.88 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-O 120.799 0.333 . . . . 0.0 110.974 -179.405 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . 0.448 ' CD ' ' CE1' ' A' ' 43' ' ' TYR . 83.5 tt0 -112.86 122.65 48.28 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.146 179.351 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 62.7 t -130.73 132.88 63.97 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.154 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 53.2 25.46 4.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.011 179.431 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.63 -24.62 25.03 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 179.625 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 33.2 m95 -74.38 144.74 44.24 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.762 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . 0.448 ' CE1' ' CD ' ' A' ' 38' ' ' GLU . 78.3 m-85 -105.98 131.67 53.0 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 120.852 0.358 . . . . 0.0 110.847 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 76.9 tt0 -88.21 123.23 32.63 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.328 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 46.2 pt -126.95 160.66 35.22 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.673 0 CA-C-O 121.594 0.711 . . . . 0.0 110.944 -179.017 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 12.5 ttm180 -122.6 129.46 51.92 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.123 -0.944 . . . . 0.0 110.853 -179.285 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 59.2 t80 -148.69 131.55 16.11 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.257 -179.82 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.411 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 17.1 t-20 57.48 36.74 27.32 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.907 179.518 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 69.64 15.36 70.89 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 179.774 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 35.9 ttmt -117.18 137.22 52.48 Favored 'General case' 0 N--CA 1.466 0.329 0 N-CA-C 110.321 -0.252 . . . . 0.0 110.321 -179.714 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 53.4 t -111.11 131.04 63.43 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.86 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -145.17 -161.94 9.33 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.759 -0.936 . . . . 0.0 110.759 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 81.3 m-85 -138.58 154.21 48.7 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 120.721 0.296 . . . . 0.0 110.396 -179.689 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -145.18 150.54 36.92 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.198 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . 0.448 ' OG ' ' CD2' ' A' ' 58' ' ' TYR . 8.7 p -75.49 153.0 37.79 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.097 0.475 . . . . 0.0 111.434 -179.177 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -65.95 -30.17 70.7 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.63 -0.713 . . . . 0.0 111.609 179.278 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 95.8 p -55.67 -28.95 58.3 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.532 -178.719 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' TYR . . . . . 0.538 ' C ' HD12 ' A' ' 59' ' ' ILE . 19.9 m-85 -108.52 -6.22 16.19 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 111.446 0.165 . . . . 0.0 111.446 -179.709 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.538 HD12 ' C ' ' A' ' 58' ' ' TYR . 1.4 mp -112.68 130.05 67.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 N-CA-C 109.595 -0.521 . . . . 0.0 109.595 -179.764 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 92.8 m -123.63 132.03 53.76 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-N 115.716 -0.674 . . . . 0.0 109.979 179.591 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.3 mt -76.82 131.4 34.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.625 -179.63 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 95.3 t . . . . . 0 C--N 1.33 -0.24 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.26 179.641 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 23.0 mp0 . . . . . 0 N--CA 1.463 0.189 0 CA-C-O 120.813 0.339 . . . . 0.0 110.253 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -85.34 163.73 37.66 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.881 -0.888 . . . . 0.0 110.881 179.803 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 77.3 t -127.1 134.13 66.74 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-O 120.85 0.357 . . . . 0.0 110.131 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 19.8 t -83.15 128.39 38.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.55 179.76 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 68.0 mmtt -123.02 105.5 10.02 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.151 179.652 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.6 m -148.79 157.92 7.07 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.557 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 50.9 p30 -83.96 -9.78 58.43 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.81 179.789 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . 0.473 ' OG ' ' N ' ' A' ' 10' ' ' ALA . 48.4 t -155.24 -165.26 1.97 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.856 0.36 . . . . 0.0 110.722 -179.759 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.473 ' N ' ' OG ' ' A' ' 9' ' ' SER . . . -64.38 143.55 57.82 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.659 -179.858 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 47.3 tp -121.55 133.08 55.01 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-O 120.953 0.406 . . . . 0.0 110.307 179.675 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 99.5 m-20 -82.74 142.47 31.59 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.991 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 49.6 ttp -113.48 148.57 35.72 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.939 179.544 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . 0.81 ' NH2' ' CH2' ' A' ' 42' ' ' TRP . 43.4 mtm180 -121.41 153.87 37.27 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-O 121.117 0.484 . . . . 0.0 111.599 -179.001 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 11.3 t -62.76 -41.83 99.4 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.439 179.748 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -140.99 -164.97 10.13 Favored Glycine 0 N--CA 1.466 0.676 0 N-CA-C 111.382 -0.687 . . . . 0.0 111.382 -179.401 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -85.03 71.41 5.08 Favored 'Trans proline' 0 C--N 1.31 -1.471 0 C-N-CA 122.893 2.395 . . . . 0.0 112.103 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . 0.706 ' H ' ' NH1' ' A' ' 14' ' ' ARG . . . -167.74 120.22 0.89 Allowed Glycine 0 CA--C 1.523 0.545 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 179.654 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 8.9 t -60.95 -9.01 3.6 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.944 0.402 . . . . 0.0 110.326 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 11.8 m120 -89.79 5.55 45.57 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.993 -179.456 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 22.0 m-85 -88.22 -7.94 56.05 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 120.681 0.277 . . . . 0.0 110.377 179.887 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 67.68 179.07 14.02 Favored Glycine 0 CA--C 1.521 0.447 0 N-CA-C 110.84 -0.904 . . . . 0.0 110.84 179.641 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.455 HG13 ' O ' ' A' ' 23' ' ' VAL . 9.3 p -92.18 124.21 44.57 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.183 0 CA-C-O 120.787 0.327 . . . . 0.0 110.704 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 24.4 pt -104.35 -5.52 9.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.802 -179.856 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.65 177.05 47.52 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 111.038 -0.825 . . . . 0.0 111.038 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 91.0 m -126.56 130.47 50.61 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-O 120.853 0.359 . . . . 0.0 110.301 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 72.7 mt -112.38 146.31 38.55 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.22 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 87.0 mtm-85 -115.42 161.51 18.46 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.028 179.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.481 ' C ' ' H ' ' A' ' 31' ' ' ASP . 50.8 p30 -69.13 166.77 17.52 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.929 -179.501 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 56.5 t30 71.03 -27.85 0.18 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.509 179.735 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.481 ' H ' ' C ' ' A' ' 29' ' ' ASN . 33.9 m-20 -67.48 137.6 55.95 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.583 -0.447 . . . . 0.0 109.926 179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 18.1 ptpt -104.06 145.81 29.63 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.654 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.0 m -133.91 161.72 40.5 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.266 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.234 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -92.28 132.93 36.3 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.231 -0.44 . . . . 0.0 109.875 179.552 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 5.5 mm -98.89 125.77 52.26 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 CA-C-O 120.947 0.404 . . . . 0.0 110.721 -179.461 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.6 mt -93.14 -46.88 13.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.565 179.828 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 31.6 ttpt -173.03 162.57 4.62 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 120.941 0.4 . . . . 0.0 111.153 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . 0.501 ' OE1' ' CE1' ' A' ' 43' ' ' TYR . 82.2 tt0 -110.54 124.05 51.1 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.034 179.497 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 96.9 t -128.04 131.63 69.31 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.099 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 54.41 29.99 11.97 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.569 178.886 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.69 -11.25 64.68 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 111.254 -0.739 . . . . 0.0 111.254 179.388 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.81 ' CH2' ' NH2' ' A' ' 14' ' ' ARG . 82.8 m95 -89.45 143.25 26.97 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.604 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . 0.501 ' CE1' ' OE1' ' A' ' 38' ' ' GLU . 53.4 m-85 -100.94 130.52 46.95 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.732 0.301 . . . . 0.0 110.654 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -82.54 132.57 35.19 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 179.157 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 43.2 pt -132.67 153.02 37.28 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.241 0 CA-C-O 121.098 0.475 . . . . 0.0 111.236 -179.474 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 60.3 ttp180 -127.6 125.36 40.1 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.515 -0.766 . . . . 0.0 109.923 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.443 ' O ' ' OD1' ' A' ' 48' ' ' ASN . 19.0 t80 -151.4 146.13 25.74 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.886 -179.276 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.443 ' OD1' ' O ' ' A' ' 47' ' ' PHE . 8.2 p-10 47.19 38.2 6.54 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.526 179.723 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 67.62 23.1 73.76 Favored Glycine 0 CA--C 1.522 0.5 0 N-CA-C 111.33 -0.708 . . . . 0.0 111.33 179.085 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 69.4 mmtt -128.33 144.13 51.09 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.825 0.345 . . . . 0.0 110.143 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 75.4 t -113.82 133.29 60.27 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.205 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.158 -179.678 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -153.32 -166.26 14.38 Favored Glycine 0 CA--C 1.521 0.431 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 179.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 45.9 m-85 -136.24 155.88 49.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.837 0.351 . . . . 0.0 110.062 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -137.22 154.97 50.05 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.548 -179.647 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 41.3 t -61.78 142.39 57.32 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.505 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 61.9 pttt -68.24 -31.67 71.31 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.353 -179.601 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 19.8 m -60.92 -41.32 95.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.822 -179.245 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 70.7 m-85 -96.23 11.9 32.85 Favored 'General case' 0 N--CA 1.467 0.411 0 N-CA-C 111.837 0.31 . . . . 0.0 111.837 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 5.4 mm -121.33 129.32 75.72 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 CA-C-O 121.01 0.433 . . . . 0.0 110.503 179.748 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 99.4 m -122.71 127.52 49.36 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.348 179.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.7 mt -83.2 131.16 34.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.568 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 94.3 t . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.312 -0.403 . . . . 0.0 110.471 -179.852 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 22.4 mm100 . . . . . 0 N--CA 1.464 0.267 0 CA-C-O 120.911 0.386 . . . . 0.0 110.373 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -87.58 156.94 28.36 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 110.813 -0.915 . . . . 0.0 110.813 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 59.1 t -125.88 132.71 70.39 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.632 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 21.9 t -81.68 128.66 38.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.675 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 71.2 mmtt -115.48 105.84 13.28 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.188 -0.46 . . . . 0.0 109.764 179.512 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.406 HG22 ' N ' ' A' ' 8' ' ' ASN . 12.5 p -145.79 155.88 12.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.535 -179.711 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.406 ' N ' HG22 ' A' ' 7' ' ' VAL . 9.6 m120 -62.56 -41.45 98.92 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.909 -179.426 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 21.5 m -136.59 -57.58 0.74 Allowed 'General case' 0 N--CA 1.466 0.326 0 CA-C-O 120.656 0.265 . . . . 0.0 110.92 -179.77 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -157.65 144.62 18.15 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.8 0.333 . . . . 0.0 110.558 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 44.9 tp -111.83 130.62 55.75 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.463 -179.627 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . 0.4 ' OD1' ' O ' ' A' ' 12' ' ' ASN . 47.3 p-10 -71.95 137.99 47.73 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.701 179.762 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 37.7 ttp -100.45 136.69 39.94 Favored 'General case' 0 N--CA 1.464 0.275 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 179.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . 0.456 ' HE ' ' HA ' ' A' ' 19' ' ' SER . 84.0 mtt85 -107.67 157.52 18.02 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.669 -179.143 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 85.6 p -84.18 -10.34 57.82 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.681 179.795 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -161.99 -171.89 28.68 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 111.161 -0.776 . . . . 0.0 111.161 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_endo -84.02 68.84 6.61 Favored 'Trans proline' 0 C--N 1.309 -1.549 0 C-N-CA 122.815 2.344 . . . . 0.0 111.653 -179.833 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -179.97 134.77 2.3 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . 0.456 ' HA ' ' HE ' ' A' ' 14' ' ' ARG . 15.9 m -76.89 -8.94 58.27 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.724 0.297 . . . . 0.0 111.003 -179.526 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 67.1 t30 -83.59 -1.48 53.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.878 -179.798 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 50.1 m-85 -86.71 -5.93 58.98 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 120.768 0.318 . . . . 0.0 110.294 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 77.18 166.35 25.74 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.92 -0.872 . . . . 0.0 110.92 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.466 HG13 ' O ' ' A' ' 23' ' ' VAL . 14.4 p -95.26 127.25 47.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.731 0.3 . . . . 0.0 110.481 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 25.4 pt -101.89 -5.06 9.23 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.288 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.804 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.76 -177.43 47.37 Favored Glycine 0 CA--C 1.529 0.948 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 62.8 p -134.74 157.99 45.28 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-O 120.885 0.374 . . . . 0.0 111.025 -179.705 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 67.6 mt -124.88 145.06 49.99 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.168 -0.469 . . . . 0.0 109.846 179.804 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 13.8 mtm180 -93.63 173.48 7.67 Favored 'General case' 0 C--O 1.233 0.235 0 CA-C-O 121.262 0.553 . . . . 0.0 110.847 179.863 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.433 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 51.7 p-10 -73.6 144.48 45.96 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.43 -0.804 . . . . 0.0 109.554 178.359 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 12.3 t-20 58.49 34.7 24.15 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.564 -0.289 . . . . 0.0 111.192 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -88.79 112.7 23.52 Favored 'General case' 0 N--CA 1.468 0.44 0 N-CA-C 110.018 -0.364 . . . . 0.0 110.018 179.447 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -75.88 130.37 38.43 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 120.665 -0.414 . . . . 0.0 110.091 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 33.2 m -137.87 163.24 30.46 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-O 120.902 0.382 . . . . 0.0 110.689 -179.696 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -102.28 123.64 46.44 Favored 'General case' 0 N--CA 1.463 0.203 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.265 179.805 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.2 mt -89.06 126.03 42.09 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.169 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.408 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.7 mt -92.91 -47.11 13.91 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.183 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.678 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 32.2 ttpt -168.94 158.0 8.42 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.876 -179.807 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -108.4 120.98 43.98 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.962 179.819 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 77.8 t -126.22 132.31 70.61 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.849 -179.442 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 47.5 t0 58.14 25.92 13.07 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.394 179.056 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.93 -10.69 67.18 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 179.774 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 65.9 m95 -89.56 144.63 25.87 Favored 'General case' 0 C--N 1.331 -0.198 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 179.407 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 79.9 m-85 -97.43 127.91 43.78 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.87 0.367 . . . . 0.0 110.45 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 79.4 tt0 -88.3 126.62 35.27 Favored 'General case' 0 CA--C 1.522 -0.119 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 179.499 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 42.0 pt -132.47 161.48 41.39 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.283 0 CA-C-O 121.011 0.434 . . . . 0.0 111.784 -178.752 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 78.7 ttt-85 -114.64 124.38 51.69 Favored 'General case' 0 N--CA 1.464 0.268 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 178.806 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 45.5 t80 -156.68 146.06 20.55 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.924 0.392 . . . . 0.0 111.191 -179.106 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 54.9 t30 58.76 31.63 21.39 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.356 179.59 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 69.74 18.56 74.2 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 111.704 -0.558 . . . . 0.0 111.704 178.783 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -144.37 152.4 40.65 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 120.825 0.345 . . . . 0.0 110.775 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.8 t -85.59 157.99 3.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.176 179.885 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -167.84 -178.2 39.68 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 111.422 -0.671 . . . . 0.0 111.422 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 85.1 m-85 -133.33 153.02 51.94 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 120.734 0.302 . . . . 0.0 110.4 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -139.65 152.32 46.65 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.008 -179.824 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 27.2 t -64.91 142.36 58.46 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.033 -179.796 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 61.3 pttt -66.79 -33.65 76.09 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.461 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 38.9 t -61.69 -42.99 99.67 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.602 -178.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 90.2 m-85 -90.43 4.02 52.19 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.66 -0.245 . . . . 0.0 111.48 -179.115 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 5.8 mm -119.7 127.99 75.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 CA-C-O 120.909 0.385 . . . . 0.0 110.246 179.797 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 94.4 m -123.69 129.75 51.58 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.422 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.0 mt -80.12 131.75 33.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.649 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 93.9 t . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.14 179.62 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 . . . . . 0 N--CA 1.466 0.338 0 CA-C-O 120.82 0.343 . . . . 0.0 110.606 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -89.44 166.53 33.24 Favored Glycine 0 CA--C 1.522 0.491 0 N-CA-C 110.542 -1.023 . . . . 0.0 110.542 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 56.1 t -124.11 129.33 74.19 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.756 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 13.7 t -97.01 110.28 24.69 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.145 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.092 179.795 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 32.0 ttmt -119.11 120.01 35.89 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.162 179.764 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.493 HG22 ' N ' ' A' ' 8' ' ' ASN . 9.3 p -140.59 159.72 24.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.32 -179.884 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.493 ' N ' HG22 ' A' ' 7' ' ' VAL . 28.9 t-20 -60.85 -41.58 96.14 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.352 -178.834 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 5.1 t -130.14 -68.47 0.7 Allowed 'General case' 0 N--CA 1.467 0.419 0 CA-C-O 120.901 0.381 . . . . 0.0 110.563 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -158.11 144.14 17.21 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.997 -0.547 . . . . 0.0 109.948 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 40.0 tp -111.45 129.06 56.15 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-O 120.895 0.378 . . . . 0.0 110.585 -179.525 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 77.2 m-20 -75.69 141.43 42.72 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.413 179.694 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 30.9 ttp -102.73 147.52 26.74 Favored 'General case' 0 N--CA 1.47 0.575 0 CA-C-N 116.701 -0.227 . . . . 0.0 111.14 -179.287 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 76.2 mtt85 -119.54 142.11 48.63 Favored 'General case' 0 CA--C 1.506 -0.74 0 CA-C-O 121.285 0.564 . . . . 0.0 111.934 -178.819 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 78.9 p -66.98 -39.51 87.19 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.079 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -115.4 170.34 13.24 Favored Glycine 0 CA--C 1.527 0.793 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 179.509 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.3 Cg_endo -79.51 58.25 6.87 Favored 'Trans proline' 0 N--CA 1.492 1.425 0 C-N-CA 122.644 2.229 . . . . 0.0 112.175 179.557 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -176.99 149.68 9.73 Favored Glycine 0 CA--C 1.532 1.11 0 C-N-CA 120.938 -0.648 . . . . 0.0 111.756 179.879 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 32.7 t -64.37 -16.14 61.74 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 120.869 0.366 . . . . 0.0 110.888 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -72.67 -7.39 50.17 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.984 -179.536 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 55.9 m-85 -92.52 -6.21 50.15 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-O 120.635 0.255 . . . . 0.0 110.801 -179.877 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 67.03 -175.78 23.28 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 110.978 -0.849 . . . . 0.0 110.978 179.681 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.442 HG13 ' O ' ' A' ' 23' ' ' VAL . 10.9 p -105.29 128.86 58.89 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 CA-C-O 120.81 0.338 . . . . 0.0 110.77 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 41.6 pt -105.94 -6.76 10.07 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.551 179.462 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.39 -177.25 44.31 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 -179.849 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 57.8 p -131.17 155.95 46.14 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-O 120.924 0.392 . . . . 0.0 110.358 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 71.4 mt -123.76 149.48 45.57 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.77 -179.583 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 34.5 ttp85 -113.7 143.17 45.05 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 -179.561 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.432 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 57.2 p30 -46.65 153.38 0.39 Allowed 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.316 0.579 . . . . 0.0 112.263 -179.022 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 63.3 m-20 58.93 31.25 21.14 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.106 -0.952 . . . . 0.0 111.856 179.299 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 29.3 t0 -93.55 118.16 31.0 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-O 120.68 0.276 . . . . 0.0 110.258 179.11 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 29.5 mmtp -72.97 132.37 43.34 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 109.986 -0.375 . . . . 0.0 109.986 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 26.8 m -138.41 160.97 31.54 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.518 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -108.39 120.25 41.87 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.031 179.566 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 95.8 mt -85.46 128.81 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.155 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.527 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 26.1 mt -93.63 -61.31 2.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.188 -179.742 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 22.0 mtmm -149.31 158.51 44.24 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.747 179.608 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . 0.408 ' CD ' ' CE1' ' A' ' 43' ' ' TYR . 83.9 tt0 -111.35 122.47 47.94 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.049 179.616 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 74.8 t -125.35 130.02 72.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.598 -179.794 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 44.8 t0 52.57 27.29 4.97 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.101 179.333 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.02 -21.92 37.21 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 179.56 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 43.8 m95 -77.32 140.18 39.95 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.76 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . 0.408 ' CE1' ' CD ' ' A' ' 38' ' ' GLU . 71.0 m-85 -99.06 129.97 45.36 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.831 0.348 . . . . 0.0 110.341 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -88.13 120.46 29.51 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 179.413 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 45.6 pt -127.17 158.6 38.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.455 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.075 -179.195 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 16.4 ttm180 -119.95 126.46 50.92 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 116.203 -0.453 . . . . 0.0 109.979 179.61 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 71.7 t80 -145.26 140.93 28.17 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.129 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 12.0 t-20 58.69 33.25 22.94 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.601 -179.873 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 71.34 3.98 55.09 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 179.614 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -107.65 150.32 27.04 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-O 120.685 0.278 . . . . 0.0 110.589 -179.818 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 55.1 t -116.4 131.94 67.46 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.226 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.36 -160.1 9.62 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.854 -0.898 . . . . 0.0 110.854 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 78.2 m-85 -132.85 157.5 44.89 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.835 0.35 . . . . 0.0 110.367 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -141.15 151.19 43.67 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.254 179.803 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 19.8 m -64.55 148.13 51.39 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.61 -179.678 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 26.6 pttm -79.36 -20.93 46.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.067 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 78.4 p -66.07 -37.88 86.91 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.465 -179.794 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' TYR . . . . . 0.538 ' C ' HD12 ' A' ' 59' ' ' ILE . 96.6 m-85 -97.03 -1.53 45.23 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 116.68 -0.237 . . . . 0.0 111.567 -179.119 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.538 HD12 ' C ' ' A' ' 58' ' ' TYR . 1.3 mp -113.51 130.86 66.77 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 96.2 m -121.02 127.84 52.12 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.002 179.508 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.3 mt -80.56 129.25 37.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.405 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 94.8 t . . . . . 0 C--N 1.327 -0.403 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.964 -179.67 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 . . . . . 0 N--CA 1.465 0.321 0 CA-C-O 120.959 0.409 . . . . 0.0 110.757 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -88.63 162.21 31.52 Favored Glycine 0 CA--C 1.521 0.466 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 179.319 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 95.4 t -125.62 129.2 72.74 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.575 0 CA-C-O 120.985 0.422 . . . . 0.0 110.086 179.759 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 16.3 t -87.05 127.96 40.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.418 -179.748 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 63.6 mttp -124.13 107.56 11.38 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.129 -0.487 . . . . 0.0 109.982 179.634 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.444 HG22 ' H ' ' A' ' 9' ' ' SER . 11.9 p -140.27 151.41 21.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.434 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.63 -179.748 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.532 ' OD1' ' N ' ' A' ' 9' ' ' SER . 30.4 p30 -61.67 -42.64 99.19 Favored 'General case' 0 C--N 1.333 -0.127 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.196 -179.526 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . 0.532 ' N ' ' OD1' ' A' ' 8' ' ' ASN . 8.0 t -125.07 -67.19 0.92 Allowed 'General case' 0 N--CA 1.47 0.541 0 CA-C-O 120.617 0.246 . . . . 0.0 110.94 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -158.24 144.77 17.48 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.777 0.322 . . . . 0.0 110.649 -179.603 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 44.9 tp -106.77 125.98 51.7 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.076 179.681 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -79.53 143.57 34.72 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.438 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 48.4 ttp -109.4 151.46 26.64 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 116.057 -0.519 . . . . 0.0 109.731 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 94.4 mtt-85 -127.63 151.53 48.82 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-O 120.924 0.392 . . . . 0.0 110.313 -179.274 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 35.0 t -62.36 -41.79 98.89 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.818 -179.34 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -124.97 163.16 19.07 Favored Glycine 0 N--CA 1.471 0.985 0 N-CA-C 111.482 -0.647 . . . . 0.0 111.482 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -68.32 86.32 0.42 Allowed 'Trans proline' 0 N--CA 1.496 1.628 0 C-N-CA 122.485 2.123 . . . . 0.0 111.692 179.543 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 164.4 143.31 3.67 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 111.218 -0.753 . . . . 0.0 111.218 179.581 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 75.4 p -66.44 -16.18 63.91 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.851 0.358 . . . . 0.0 110.825 179.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 50.5 p30 -80.64 -2.38 46.3 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.565 -179.542 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 47.0 m-85 -89.7 -7.77 53.85 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-O 120.756 0.312 . . . . 0.0 110.554 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 71.55 168.38 9.37 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 179.553 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 7.5 p -94.77 128.16 46.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 CA-C-O 120.79 0.329 . . . . 0.0 110.537 179.795 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 43.6 pt -108.2 -6.62 10.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.702 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -173.02 169.33 42.49 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 111.325 -0.71 . . . . 0.0 111.325 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 92.1 m -123.3 135.01 54.01 Favored 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 67.9 mt -107.72 155.16 20.5 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-O 120.871 0.367 . . . . 0.0 110.499 -179.559 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 90.2 mtm-85 -105.25 165.75 10.89 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.595 -179.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.402 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 52.6 p-10 -69.53 149.0 48.7 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.181 -179.613 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 21.7 t-20 56.12 32.98 21.13 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 115.91 -0.586 . . . . 0.0 111.014 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -89.92 116.27 27.85 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-O 120.825 0.345 . . . . 0.0 110.645 179.587 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.565 ' HZ3' ' HB3' ' A' ' 32' ' ' LYS . 2.4 mmmp? -71.84 129.39 38.51 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.465 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.9 m -140.18 162.03 25.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.647 -179.496 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -104.89 121.06 42.91 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.353 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 89.3 mt -91.52 108.31 19.8 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.302 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 97.5 mt -67.41 -43.86 87.34 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.046 -0.524 . . . . 0.0 111.006 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 63.7 pttt -173.19 160.82 4.15 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.823 0.344 . . . . 0.0 111.001 -179.369 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -106.93 124.23 49.32 Favored 'General case' 0 N--CA 1.465 0.3 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 179.314 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 73.3 t -127.16 132.15 70.0 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 CA-C-O 120.952 0.406 . . . . 0.0 110.671 -179.436 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . 0.415 ' OD1' ' O ' ' A' ' 40' ' ' ASP . 36.1 t0 56.26 23.86 7.59 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.013 179.246 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.52 -10.02 74.95 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 111.016 -0.834 . . . . 0.0 111.016 179.705 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 34.3 m95 -91.21 149.26 21.85 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-O 120.751 0.31 . . . . 0.0 110.188 179.748 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 52.4 m-85 -99.94 130.84 46.16 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.136 -179.731 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 76.1 tt0 -98.29 120.24 38.36 Favored 'General case' 0 CA--C 1.518 -0.269 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 179.223 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 39.2 pt -126.05 160.21 33.44 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.321 0 CA-C-O 120.969 0.414 . . . . 0.0 110.983 -179.207 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 43.6 ttm180 -117.89 127.85 54.26 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-N 115.694 -0.685 . . . . 0.0 109.503 179.486 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 34.1 t80 -144.77 131.17 19.72 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-O 121.16 0.505 . . . . 0.0 111.11 -179.736 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 6.1 m120 56.93 35.17 26.01 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 115.36 -0.837 . . . . 0.0 112.145 179.3 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 77.23 15.56 81.43 Favored Glycine 0 N--CA 1.465 0.592 0 C-N-CA 121.264 -0.493 . . . . 0.0 111.893 178.531 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -126.0 145.54 50.26 Favored 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 61.5 t -115.55 132.32 65.3 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.302 -179.732 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -149.67 -163.12 10.86 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 62.1 m-85 -132.86 160.27 37.46 Favored 'General case' 0 N--CA 1.466 0.347 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -149.72 159.17 44.57 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.04 0.448 . . . . 0.0 111.061 -179.617 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 18.4 p -69.54 148.89 48.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.696 -0.683 . . . . 0.0 110.304 179.885 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.415 ' O ' ' O ' ' A' ' 59' ' ' ILE . 59.0 pttt -82.59 -19.12 39.04 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.77 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 39.1 t -62.07 -42.39 99.15 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.954 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 90.5 m-85 -92.19 3.81 54.55 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.336 -179.171 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.415 ' O ' ' O ' ' A' ' 56' ' ' LYS . 98.1 mt -128.51 132.25 68.12 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 CA-C-O 120.699 0.285 . . . . 0.0 110.351 179.601 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 99.3 m -123.15 132.12 53.95 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.465 179.732 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 27.0 mm -80.45 129.46 37.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.063 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 35.7 m . . . . . 0 N--CA 1.469 0.476 0 CA-C-O 120.954 0.407 . . . . 0.0 110.427 -179.687 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 58.0 tt0 . . . . . 0 N--CA 1.467 0.388 0 CA-C-O 120.858 0.361 . . . . 0.0 110.231 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -93.16 155.2 22.22 Favored Glycine 0 CA--C 1.524 0.626 0 N-CA-C 111.054 -0.819 . . . . 0.0 111.054 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 59.9 t -128.01 132.14 68.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.698 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 18.0 t -88.74 127.74 41.38 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.087 179.694 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 64.7 mttp -124.57 105.81 9.65 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-O 120.912 0.386 . . . . 0.0 110.537 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 7.1 p -157.15 148.83 10.53 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-N 115.943 -0.572 . . . . 0.0 110.604 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.42 ' O ' ' ND2' ' A' ' 29' ' ' ASN . 7.7 m120 -68.54 -50.84 48.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.937 0.399 . . . . 0.0 110.554 179.452 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 9.2 p -95.88 165.53 12.23 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.564 179.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -65.88 144.39 56.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.354 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 45.1 tp -111.22 132.78 54.07 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-O 120.972 0.415 . . . . 0.0 110.67 -179.794 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 6.2 m120 -78.02 146.26 35.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.892 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 40.0 ttp -98.11 148.66 23.32 Favored 'General case' 0 C--O 1.233 0.201 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.616 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 84.9 mtt85 -123.32 157.75 32.55 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 120.715 0.293 . . . . 0.0 110.493 -179.23 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . 0.508 ' N ' HD11 ' A' ' 24' ' ' ILE . 88.5 p -84.11 -13.11 53.84 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.972 -179.321 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -162.31 -172.58 29.92 Favored Glycine 0 CA--C 1.529 0.952 0 C-N-CA 120.846 -0.692 . . . . 0.0 111.388 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -80.0 78.95 3.49 Favored 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.771 2.314 . . . . 0.0 112.143 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 167.4 134.12 1.65 Allowed Glycine 0 CA--C 1.524 0.603 0 C-N-CA 120.68 -0.771 . . . . 0.0 111.448 179.713 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 95.7 p -71.2 -12.3 61.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.95 0.405 . . . . 0.0 110.215 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 52.1 p-10 -78.91 -4.63 50.72 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.692 -179.822 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -85.85 -1.62 57.44 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.291 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 71.6 178.5 29.75 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 110.724 -0.95 . . . . 0.0 110.724 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 9.2 p -107.4 134.52 48.89 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.37 0 CA-C-O 120.861 0.362 . . . . 0.0 110.474 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.508 HD11 ' N ' ' A' ' 15' ' ' SER . 3.5 mp -106.0 -12.01 9.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.52 -179.758 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -173.55 -170.66 37.3 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 110.8 -0.92 . . . . 0.0 110.8 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 82.0 p -131.84 152.21 51.16 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 120.737 0.303 . . . . 0.0 110.302 179.846 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 78.5 mt -122.7 146.29 47.63 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.07 -0.514 . . . . 0.0 109.841 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -106.84 164.52 12.04 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.877 -179.364 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.42 ' ND2' ' O ' ' A' ' 8' ' ' ASN . 2.9 m-20 -64.07 148.93 48.66 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.671 -179.836 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 58.96 32.71 22.51 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.324 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 16.5 m-20 -82.0 137.38 35.12 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.113 179.02 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 63.3 mttp -104.99 122.73 46.46 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.858 0.361 . . . . 0.0 110.317 179.55 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.6 m -138.69 161.61 29.95 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.185 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.12 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -99.03 132.74 44.11 Favored 'General case' 0 C--O 1.234 0.287 0 N-CA-C 109.727 -0.472 . . . . 0.0 109.727 179.689 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.2 mt -100.71 107.5 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.309 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.8 mt -66.55 -43.87 90.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.89 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 63.6 pttt -173.05 169.98 4.52 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.829 -179.41 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . 0.429 ' CD ' ' CE1' ' A' ' 43' ' ' TYR . 83.1 tt0 -111.91 126.29 54.96 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.646 179.591 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 76.3 t -126.79 131.91 70.61 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 CA-C-O 121.07 0.462 . . . . 0.0 111.133 -179.438 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 52.65 30.42 8.68 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.661 -0.7 . . . . 0.0 111.759 178.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.14 -18.02 47.66 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 111.651 -0.58 . . . . 0.0 111.651 179.204 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 40.3 m95 -85.95 145.23 27.23 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.845 0.355 . . . . 0.0 110.244 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . 0.429 ' CE1' ' CD ' ' A' ' 38' ' ' GLU . 72.7 m-85 -100.75 126.99 47.34 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.481 -179.642 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 79.2 tt0 -78.54 152.42 31.95 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 179.715 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.4 pt -144.04 153.36 15.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.679 0.276 . . . . 0.0 110.854 -179.702 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 76.3 ttt180 -121.16 123.32 42.0 Favored 'General case' 0 N--CA 1.468 0.454 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.265 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 74.5 t80 -142.08 125.8 16.96 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-O 120.884 0.373 . . . . 0.0 110.885 -179.444 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 17.0 t-20 54.8 35.97 25.37 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.999 179.766 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 73.01 15.19 78.52 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 111.145 -0.782 . . . . 0.0 111.145 179.521 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.9 ttmp? -112.43 147.93 35.42 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 110.228 -0.286 . . . . 0.0 110.228 179.771 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.0 t -110.2 132.85 57.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.933 0.397 . . . . 0.0 110.32 -179.785 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . 0.467 ' C ' ' CD1' ' A' ' 53' ' ' TYR . . . -148.63 -165.02 11.84 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 179.823 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.467 ' CD1' ' C ' ' A' ' 52' ' ' GLY . 72.9 m-85 -146.46 157.81 43.81 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.729 0.299 . . . . 0.0 110.456 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -141.63 155.72 45.7 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.398 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . 0.403 ' O ' ' CG1' ' A' ' 59' ' ' ILE . 18.1 m -69.41 147.87 50.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.031 -179.623 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 62.0 pttt -66.34 -34.69 78.53 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.233 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 37.1 m -61.56 -41.11 96.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.706 -179.205 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 89.1 m-85 -94.22 7.64 44.57 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 116.518 -0.31 . . . . 0.0 111.002 -179.285 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.403 ' CG1' ' O ' ' A' ' 55' ' ' SER . 5.3 mm -122.4 128.77 75.54 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-O 121.119 0.485 . . . . 0.0 110.293 179.637 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 86.8 m -122.56 126.89 48.67 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.512 -179.9 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.6 mt -91.22 127.9 43.32 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.497 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 33.2 m . . . . . 0 C--N 1.33 -0.256 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.437 179.873 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 27.0 mt-30 . . . . . 0 N--CA 1.464 0.265 0 CA-C-O 120.799 0.333 . . . . 0.0 110.131 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -84.69 164.88 39.81 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 -179.605 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 57.2 t -123.91 133.62 68.76 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.394 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 72.4 t -100.88 127.85 53.62 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-O 120.876 0.37 . . . . 0.0 110.314 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 68.8 mmtt -119.58 106.41 12.17 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.559 179.423 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.495 ' O ' ' ND2' ' A' ' 29' ' ' ASN . 28.0 m -131.41 160.05 42.62 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.302 -179.456 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 52.8 t-20 -63.59 -41.67 98.34 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.097 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 4.3 t -150.7 -53.33 0.14 Allowed 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.464 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -157.64 142.88 16.96 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.422 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.473 HD22 ' CG ' ' A' ' 58' ' ' TYR . 65.1 tp -125.46 135.68 52.59 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 116.1 -0.5 . . . . 0.0 109.92 -179.802 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 13.7 m120 -77.93 138.83 39.09 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.197 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 50.5 ttp -98.11 138.59 35.18 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.074 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . 0.491 ' HE ' ' HA ' ' A' ' 19' ' ' SER . 22.0 mmt180 -103.9 156.96 17.42 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.517 -178.675 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . 0.421 ' OG ' HG21 ' A' ' 24' ' ' ILE . 4.6 m -83.07 -7.68 59.62 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.76 -179.636 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -159.23 -169.63 22.8 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -83.24 72.21 5.82 Favored 'Trans proline' 0 C--N 1.304 -1.777 0 C-N-CA 122.659 2.239 . . . . 0.0 111.857 -179.755 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.78 147.81 6.34 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 111.104 -0.799 . . . . 0.0 111.104 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . 0.491 ' HA ' ' HE ' ' A' ' 14' ' ' ARG . 15.7 m -81.47 -11.64 59.15 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.948 0.404 . . . . 0.0 110.728 -179.82 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 28.6 t-20 -84.14 7.06 20.09 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.979 -179.693 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 49.9 m-85 -92.71 -0.23 57.32 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 120.772 0.32 . . . . 0.0 110.414 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 75.62 179.22 44.61 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.451 HG13 ' O ' ' A' ' 23' ' ' VAL . 7.2 p -108.84 125.31 65.85 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-O 120.826 0.345 . . . . 0.0 110.621 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.421 HG21 ' OG ' ' A' ' 15' ' ' SER . 41.2 pt -108.66 -4.51 10.58 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.809 179.852 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -172.96 170.76 43.9 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 111.116 -0.793 . . . . 0.0 111.116 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 86.4 m -128.64 138.02 51.96 Favored 'General case' 0 N--CA 1.472 0.635 0 CA-C-O 120.494 0.187 . . . . 0.0 110.541 -179.673 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 77.4 mt -110.18 143.7 39.92 Favored 'General case' 0 N--CA 1.476 0.844 0 N-CA-C 112.12 0.415 . . . . 0.0 112.12 -178.793 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 49.2 mtt-85 -105.24 167.76 9.52 Favored 'General case' 0 N--CA 1.477 0.88 0 CA-C-O 121.773 0.797 . . . . 0.0 111.812 -179.079 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.495 ' ND2' ' O ' ' A' ' 7' ' ' VAL . 1.3 m-20 -64.32 146.17 54.83 Favored 'General case' 0 N--CA 1.437 -1.107 0 CA-C-N 114.993 -1.003 . . . . 0.0 108.976 -179.055 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 15.5 m120 57.07 34.41 24.86 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.287 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 67.1 t0 -88.27 110.39 20.7 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 110.016 -0.364 . . . . 0.0 110.016 179.329 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -78.61 132.67 37.19 Favored 'General case' 0 C--N 1.331 -0.212 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 -179.811 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 28.9 m -139.88 162.05 25.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.657 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -99.89 131.55 45.79 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.19 -0.459 . . . . 0.0 109.811 179.393 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 86.7 mt -96.65 126.77 49.26 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-N 116.33 -0.396 . . . . 0.0 111.022 -179.245 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 18.5 mm -94.71 -62.97 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.427 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 22.2 mtmm -148.33 159.78 43.65 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 120.918 0.39 . . . . 0.0 111.018 179.756 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -111.81 123.34 50.03 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.339 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 72.0 t -127.47 132.47 69.29 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.604 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 55.23 30.7 15.1 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.143 179.25 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.5 -16.6 34.3 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 111.02 -0.832 . . . . 0.0 111.02 179.711 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.616 ' CZ2' ' OG ' ' A' ' 55' ' ' SER . 11.7 m95 -83.58 147.37 27.78 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 179.423 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 46.2 m-85 -100.83 130.34 46.84 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 121.047 0.451 . . . . 0.0 110.941 -179.609 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -87.1 122.74 31.33 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 178.805 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 39.1 pt -130.59 161.62 40.12 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.407 0 CA-C-O 121.176 0.512 . . . . 0.0 111.537 -178.601 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 13.6 ttt180 -118.7 123.66 45.44 Favored 'General case' 0 N--CA 1.464 0.275 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.332 179.432 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 87.4 t80 -144.39 135.97 25.74 Favored 'General case' 0 N--CA 1.473 0.713 0 CA-C-O 120.824 0.345 . . . . 0.0 111.322 -178.401 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.438 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 17.6 t-20 57.51 34.84 25.14 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.7 179.347 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 69.45 18.46 73.56 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 179.77 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -124.67 146.14 49.29 Favored 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 66.5 t -113.99 131.56 65.56 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.389 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . 0.405 ' C ' ' CD1' ' A' ' 53' ' ' TYR . . . -150.47 -164.6 12.02 Favored Glycine 0 CA--C 1.52 0.39 0 N-CA-C 110.664 -0.974 . . . . 0.0 110.664 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.427 ' N ' ' CD1' ' A' ' 53' ' ' TYR . 28.4 m-85 -134.96 156.71 48.54 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.796 0.332 . . . . 0.0 110.54 -179.737 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -146.67 150.6 35.73 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.028 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . 0.616 ' OG ' ' CZ2' ' A' ' 42' ' ' TRP . 37.8 m -70.39 142.0 52.13 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 177.81 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 64.4 pttt -68.2 -13.07 61.96 Favored 'General case' 0 CA--C 1.51 -0.578 0 CA-C-O 121.8 0.809 . . . . 0.0 108.847 178.84 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 87.8 p -56.29 -14.0 2.55 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 114.015 -1.448 . . . . 0.0 109.321 178.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' TYR . . . . . 0.473 ' CG ' HD22 ' A' ' 11' ' ' LEU . 91.7 m-85 -127.16 -28.26 2.88 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.202 179.816 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.593 ' N ' HD12 ' A' ' 59' ' ' ILE . 1.3 mp -90.1 129.29 41.21 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 179.162 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 87.5 m -123.81 129.34 50.89 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.388 -179.881 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.741 HD12 ' N ' ' A' ' 61' ' ' ILE . 1.7 mp -83.0 128.14 39.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.286 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 15.7 m . . . . . 0 C--N 1.328 -0.336 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.319 179.807 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 78.2 mt-30 . . . . . 0 N--CA 1.463 0.209 0 CA-C-O 120.841 0.353 . . . . 0.0 110.204 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -87.18 158.1 29.91 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 97.7 t -127.65 133.3 67.93 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 179.703 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 71.9 t -93.33 128.2 44.92 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-N 116.46 -0.337 . . . . 0.0 110.392 -179.884 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 65.5 mttp -132.02 107.01 8.38 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.453 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.512 HG22 ' H ' ' A' ' 9' ' ' SER . 4.0 p -138.79 154.03 26.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.162 -179.897 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 92.1 m-20 -62.06 -42.85 99.62 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-O 120.83 0.348 . . . . 0.0 111.235 -178.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . 0.512 ' H ' HG22 ' A' ' 7' ' ' VAL . 85.2 p -136.76 -153.84 0.52 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.035 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -66.98 143.15 56.97 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.017 0.437 . . . . 0.0 110.545 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.401 HD22 ' CG ' ' A' ' 58' ' ' TYR . 47.2 tp -122.0 130.46 53.32 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.062 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . 0.425 ' OD1' ' O ' ' A' ' 12' ' ' ASN . 45.1 p30 -82.12 140.53 33.76 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.693 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 58.1 ttp -108.33 138.65 44.25 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.215 -0.448 . . . . 0.0 109.869 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 4.3 mpt_? -106.45 157.37 17.69 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 120.983 0.42 . . . . 0.0 111.233 -178.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 84.2 p -82.27 -6.22 59.08 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.243 179.732 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -162.36 -174.86 32.76 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.765 -0.934 . . . . 0.0 110.765 179.762 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -80.94 79.09 3.41 Favored 'Trans proline' 0 C--N 1.306 -1.692 0 C-N-CA 122.86 2.373 . . . . 0.0 111.926 179.766 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 171.03 137.17 2.24 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 94.9 p -74.64 -7.7 54.04 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.764 0.316 . . . . 0.0 110.857 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 12.0 m120 -89.01 5.6 43.54 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.069 -179.414 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 42.7 m-85 -91.31 -0.56 57.68 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.869 0.366 . . . . 0.0 110.208 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 73.28 174.43 27.89 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.48 HG13 ' O ' ' A' ' 23' ' ' VAL . 11.7 p -105.64 125.34 60.99 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-O 120.894 0.378 . . . . 0.0 110.412 179.743 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 40.8 pt -101.81 -4.75 9.26 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.758 -179.855 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -174.3 174.08 46.29 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 89.7 m -125.17 132.21 53.09 Favored 'General case' 0 N--CA 1.464 0.226 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.627 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 72.1 mt -108.09 143.93 36.16 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 116.194 -0.457 . . . . 0.0 109.968 -179.759 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 37.8 ttt85 -119.51 142.62 48.15 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.171 0.51 . . . . 0.0 110.26 179.42 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 44.0 p-10 -48.26 165.09 0.04 OUTLIER 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.65 -0.704 . . . . 0.0 111.0 -179.766 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 65.8 t30 62.8 6.48 2.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.554 -0.748 . . . . 0.0 111.366 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 31.5 t0 -87.13 118.68 26.68 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.548 -0.297 . . . . 0.0 110.663 179.517 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -76.3 137.39 39.86 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.2 179.471 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.2 m -137.39 162.05 33.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.62 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 48.4 tp10 -105.84 123.65 48.3 Favored 'General case' 0 C--O 1.234 0.274 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 179.581 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.5 mt -91.38 127.8 43.52 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.123 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.94 -179.355 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 81.9 mt -91.4 -51.27 11.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.176 179.597 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 62.6 pttt -174.9 179.0 1.71 Allowed 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.558 179.705 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -112.84 125.06 53.95 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.219 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.408 HG21 ' OE2' ' A' ' 44' ' ' GLU . 79.5 t -124.93 129.74 73.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.28 -179.859 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . 0.44 ' OD1' ' O ' ' A' ' 40' ' ' ASP . 55.2 t0 54.74 24.28 5.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.071 179.362 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.86 -5.62 84.66 Favored Glycine 0 CA--C 1.526 0.753 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 179.739 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 56.4 m95 -90.52 149.38 22.2 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 179.364 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -96.88 130.35 44.18 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-O 121.098 0.475 . . . . 0.0 110.137 -179.669 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . 0.408 ' OE2' HG21 ' A' ' 39' ' ' VAL . 97.4 mt-10 -94.47 126.51 39.79 Favored 'General case' 0 CA--C 1.506 -0.714 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.018 179.369 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 44.3 pt -125.93 160.76 32.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 121.356 0.598 . . . . 0.0 110.249 179.626 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 3.2 ttp180 -126.89 113.89 17.14 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 114.777 -1.101 . . . . 0.0 109.624 -176.763 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 61.8 t80 -141.51 139.1 33.2 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 120.947 0.403 . . . . 0.0 111.605 -178.111 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 15.0 t-20 57.13 34.62 25.15 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.904 179.298 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 69.74 20.71 76.08 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 111.431 -0.668 . . . . 0.0 111.431 179.52 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 53.9 mtmt -131.23 143.58 50.68 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-O 120.688 0.28 . . . . 0.0 110.823 -179.81 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 19.8 t -102.26 111.8 33.29 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 CA-C-O 121.115 0.483 . . . . 0.0 110.656 179.535 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -107.55 -172.69 22.17 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 111.053 -0.819 . . . . 0.0 111.053 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 48.1 m-85 -132.3 142.36 49.33 Favored 'General case' 0 C--N 1.331 -0.233 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 179.624 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -154.29 153.0 30.93 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.404 -179.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 48.5 t -70.1 148.15 49.1 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.787 -179.887 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 63.9 pttt -64.2 -17.65 63.75 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.73 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 38.6 t -65.7 -18.22 65.17 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.395 -179.669 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' TYR . . . . . 0.6 ' C ' HD12 ' A' ' 59' ' ' ILE . 71.7 m-85 -105.73 -19.16 13.84 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 121.271 -0.172 . . . . 0.0 111.323 -179.554 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.64 ' N ' HD12 ' A' ' 59' ' ' ILE . 1.9 mp -109.87 130.99 62.04 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 CA-C-O 121.159 0.504 . . . . 0.0 110.631 -179.68 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 88.6 m -116.12 127.06 54.53 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-N 115.49 -0.777 . . . . 0.0 109.824 179.644 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.4 mt -78.91 133.21 30.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.774 -179.593 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 75.1 t . . . . . 0 C--N 1.332 -0.173 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.087 -179.907 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 . . . . . 0 N--CA 1.465 0.319 0 CA-C-O 120.884 0.373 . . . . 0.0 110.517 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -94.83 150.5 19.74 Favored Glycine 0 CA--C 1.521 0.452 0 N-CA-C 110.474 -1.05 . . . . 0.0 110.474 179.466 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 55.4 t -119.15 131.12 72.79 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 89.1 t -83.51 129.44 37.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.322 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 19.7 mmmt -115.35 106.27 13.82 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.128 179.903 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.507 HG22 ' H ' ' A' ' 9' ' ' SER . 3.2 p -141.7 144.5 25.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.062 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 19.3 m120 -63.04 -41.26 99.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.091 -179.607 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . 0.507 ' H ' HG22 ' A' ' 7' ' ' VAL . 44.4 m -133.03 -96.15 0.31 Allowed 'General case' 0 N--CA 1.466 0.363 0 CA-C-O 120.891 0.377 . . . . 0.0 110.402 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -112.97 143.65 43.89 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.409 179.886 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.549 HD13 ' CD2' ' A' ' 58' ' ' TYR . 42.8 tp -116.97 128.69 55.44 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 120.985 0.421 . . . . 0.0 110.086 179.835 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -82.94 138.64 33.74 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.478 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 37.5 ttp -103.63 152.11 22.14 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.294 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . 0.432 ' NH1' ' HG3' ' A' ' 14' ' ' ARG . 1.9 mtt85 -129.82 155.33 46.15 Favored 'General case' 0 CA--C 1.543 0.697 0 N-CA-C 109.198 -0.667 . . . . 0.0 109.198 -178.871 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 86.2 p -84.39 -4.92 59.18 Favored 'General case' 0 N--CA 1.478 0.936 0 N-CA-C 113.291 0.849 . . . . 0.0 113.291 -179.536 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -162.64 158.05 30.15 Favored Glycine 0 CA--C 1.524 0.63 0 C-N-CA 120.367 -0.921 . . . . 0.0 110.842 -179.073 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -64.5 87.61 0.16 Allowed 'Trans proline' 0 C--N 1.307 -1.622 0 C-N-CA 122.273 1.982 . . . . 0.0 111.64 -179.803 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 157.75 136.96 2.18 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 111.012 -0.835 . . . . 0.0 111.012 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 32.6 t -65.41 -13.13 58.0 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.777 0.322 . . . . 0.0 110.702 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -75.71 -3.7 36.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.254 -179.284 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 40.6 m-85 -90.0 -5.66 56.43 Favored 'General case' 0 C--N 1.332 -0.169 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.479 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 66.88 178.92 10.36 Favored Glycine 0 CA--C 1.522 0.477 0 N-CA-C 110.634 -0.986 . . . . 0.0 110.634 179.87 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.447 HG13 ' O ' ' A' ' 23' ' ' VAL . 8.3 p -103.07 126.3 57.39 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.163 0 CA-C-O 120.783 0.325 . . . . 0.0 110.279 179.595 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 25.5 pt -101.97 -4.61 9.29 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.783 -179.677 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 175.35 -176.14 47.27 Favored Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 -179.866 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 59.6 p -134.87 158.67 43.64 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-O 120.848 0.356 . . . . 0.0 110.758 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 71.5 mt -122.63 150.39 42.72 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.015 -179.899 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.729 HH11 ' HG3' ' A' ' 28' ' ' ARG . 1.0 OUTLIER -94.56 160.96 14.4 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 -179.24 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.427 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 51.7 p30 -64.97 150.48 47.94 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.614 -178.791 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 56.2 t-20 59.61 32.08 21.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.69 -0.687 . . . . 0.0 111.514 179.555 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.518 ' OD2' ' N ' ' A' ' 28' ' ' ARG . 77.5 m-20 -82.78 136.85 34.55 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 179.22 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 53.0 mtmt -107.88 122.25 46.41 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.13 179.299 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.7 m -135.95 162.35 36.63 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.416 -179.876 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -85.82 129.82 34.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.269 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.6 mt -100.19 121.38 50.85 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.265 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.328 179.889 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 77.8 mt -83.99 -46.95 18.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.103 -179.832 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 62.1 pttt -174.79 163.28 3.37 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.749 -179.602 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -107.21 124.44 49.74 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.305 179.861 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 77.4 t -124.42 130.2 73.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.616 -179.578 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.5 m-20 53.97 27.06 6.92 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.022 179.508 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.33 -11.38 67.98 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 111.201 -0.76 . . . . 0.0 111.201 179.595 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 72.9 m95 -87.65 148.68 24.7 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 110.118 -0.327 . . . . 0.0 110.118 179.747 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 7.0 m-85 -103.56 132.25 49.98 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-O 121.099 0.476 . . . . 0.0 110.581 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -93.73 121.89 35.62 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 178.307 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 41.6 pt -127.53 157.9 39.14 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-O 120.922 0.391 . . . . 0.0 111.284 -178.803 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 38.6 ttm180 -112.05 119.65 39.18 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.699 179.51 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 39.9 t80 -138.92 132.28 30.11 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.52 -179.433 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 64.3 t30 58.38 34.58 24.13 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.821 179.813 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 72.85 5.93 66.05 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.985 -0.846 . . . . 0.0 110.985 179.614 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 62.2 tttp -114.18 146.31 40.53 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.721 0.296 . . . . 0.0 110.576 -179.498 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 53.9 t -113.12 130.9 66.2 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.015 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -145.19 -161.7 9.21 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 110.978 -0.849 . . . . 0.0 110.978 -179.664 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 65.2 m-85 -122.15 157.08 32.31 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-O 120.662 0.268 . . . . 0.0 110.346 -179.852 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.44 ' CB ' HD11 ' A' ' 59' ' ' ILE . . . -144.59 154.68 43.1 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.63 -179.694 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 47.6 t -68.27 133.9 49.53 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.231 -179.46 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -65.5 -44.7 86.23 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.537 179.79 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 35.8 t -57.11 -19.11 17.86 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.255 -178.584 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' TYR . . . . . 0.549 ' CD2' HD13 ' A' ' 11' ' ' LEU . 43.1 m-85 -103.57 6.31 37.2 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 116.504 -0.316 . . . . 0.0 111.218 -179.699 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.44 HD11 ' CB ' ' A' ' 54' ' ' ALA . 96.7 mt -131.82 132.23 61.81 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 CA-C-O 121.098 0.475 . . . . 0.0 111.455 179.756 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 92.5 m -123.41 130.55 52.87 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.085 179.33 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 22.1 mm -82.17 130.28 36.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.614 -179.781 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 99.5 t . . . . . 0 C--N 1.327 -0.371 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.449 -179.949 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 99.4 mt-30 . . . . . 0 N--CA 1.464 0.261 0 CA-C-O 120.764 0.316 . . . . 0.0 110.385 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -93.41 139.32 14.53 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.449 -1.06 . . . . 0.0 110.449 179.608 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 54.2 t -122.38 131.99 72.04 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.254 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 179.899 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 84.6 t -90.01 128.6 41.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.592 -179.431 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 55.4 mtpt -125.05 105.95 9.57 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.032 -0.531 . . . . 0.0 109.848 179.402 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 11.3 p -139.14 155.28 26.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.037 -179.61 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 23.4 t-20 -61.2 -41.24 96.49 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.144 -179.241 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 4.8 t -140.02 -62.78 0.51 Allowed 'General case' 0 N--CA 1.466 0.364 0 CA-C-O 120.747 0.308 . . . . 0.0 111.07 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -150.49 144.22 25.23 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.617 -179.63 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 50.8 tp -120.64 134.6 55.27 Favored 'General case' 0 N--CA 1.469 0.48 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.097 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . 0.426 ' OD1' ' O ' ' A' ' 12' ' ' ASN . 50.5 p-10 -81.47 140.11 34.79 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.669 -179.879 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 42.4 ttp -101.13 153.79 19.28 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.065 -179.706 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . 0.851 ' HG3' HH11 ' A' ' 14' ' ' ARG . 22.2 mtm-85 -125.83 156.83 38.95 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-O 121.381 0.61 . . . . 0.0 112.233 -178.196 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 94.0 p -80.52 -6.26 57.93 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.062 -0.972 . . . . 0.0 110.052 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -159.48 -171.0 24.75 Favored Glycine 0 CA--C 1.525 0.716 0 N-CA-C 110.942 -0.863 . . . . 0.0 110.942 179.678 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -87.05 6.99 5.04 Favored 'Trans proline' 0 C--N 1.305 -1.747 0 C-N-CA 122.744 2.296 . . . . 0.0 111.997 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -99.75 128.71 9.66 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 111.134 -0.787 . . . . 0.0 111.134 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 97.6 p -67.24 -10.33 49.55 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.786 0.327 . . . . 0.0 110.297 179.642 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 54.9 p30 -91.55 8.12 38.13 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.33 -179.574 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 19.6 m-85 -87.13 -5.59 58.96 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.904 0.383 . . . . 0.0 110.322 -179.896 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 72.53 177.14 30.45 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 111.587 -0.605 . . . . 0.0 111.587 179.039 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.41 HG13 ' O ' ' A' ' 23' ' ' VAL . 7.2 p -97.54 126.96 50.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-O 120.844 0.354 . . . . 0.0 110.539 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 42.7 pt -106.88 -6.44 10.35 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.542 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.26 175.39 47.15 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 88.5 m -125.45 134.74 51.98 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-O 120.891 0.377 . . . . 0.0 110.337 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 82.1 mt -105.63 148.31 27.49 Favored 'General case' 0 CA--C 1.516 -0.334 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.891 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 31.8 mmm-85 -103.06 161.64 13.6 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.366 -0.834 . . . . 0.0 110.888 -179.098 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.428 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 25.5 p30 -65.71 143.02 57.8 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-O 121.186 0.517 . . . . 0.0 111.271 -179.362 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 66.3 t30 57.26 34.55 24.94 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.761 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 67.3 t0 -84.73 115.01 22.46 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.775 179.379 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 29.9 mmtp -72.7 128.37 35.34 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.89 0.376 . . . . 0.0 110.387 -179.329 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.3 m -137.81 161.24 33.29 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.222 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.15 179.832 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.531 ' N ' ' OE1' ' A' ' 34' ' ' GLU . 55.9 mp0 -106.54 123.69 48.47 Favored 'General case' 0 C--O 1.234 0.248 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.091 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 95.2 mt -88.52 128.07 41.01 Favored 'Isoleucine or valine' 0 C--O 1.232 0.153 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.45 -179.719 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 95.9 mt -98.19 -56.62 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.22 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.026 -179.763 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 47.1 mtpt -143.13 153.16 42.61 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 121.2 0.524 . . . . 0.0 111.262 -179.497 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . 0.438 ' CD ' ' CE1' ' A' ' 43' ' ' TYR . 84.3 tt0 -115.47 120.72 40.45 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.747 179.159 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 60.1 t -128.89 131.95 67.86 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.51 0 CA-C-O 120.899 0.381 . . . . 0.0 111.558 -179.48 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 54.11 26.47 6.59 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.35 179.285 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.86 -14.05 64.33 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 179.589 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 46.1 m95 -83.59 144.01 29.75 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 179.499 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . 0.438 ' CE1' ' CD ' ' A' ' 38' ' ' GLU . 65.0 m-85 -103.31 130.35 50.56 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.931 0.396 . . . . 0.0 110.676 -179.809 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 79.4 tt0 -90.08 122.5 33.11 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 179.312 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 24.1 pt -128.72 159.04 40.95 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-O 120.732 0.301 . . . . 0.0 111.309 -178.819 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.439 ' HE ' ' HB2' ' A' ' 46' ' ' ARG . 9.4 ttm180 -118.01 128.65 54.98 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.271 -0.422 . . . . 0.0 109.957 179.553 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 42.1 t80 -146.54 135.28 22.25 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.557 -179.358 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 8.5 m120 56.53 33.82 23.27 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.838 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 73.82 6.33 72.24 Favored Glycine 0 CA--C 1.525 0.716 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 179.576 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 56.4 mtpt -110.41 147.52 33.84 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 120.644 0.259 . . . . 0.0 110.419 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 55.7 t -117.9 131.43 70.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 CA-C-N 116.274 -0.421 . . . . 0.0 109.956 179.674 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -149.4 -160.98 9.48 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.382 -1.087 . . . . 0.0 110.382 -179.914 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 67.6 m-85 -135.22 158.18 45.02 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.933 0.397 . . . . 0.0 110.766 -179.586 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -146.84 155.83 42.64 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.309 -179.848 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 20.2 m -69.77 151.46 45.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.792 -179.559 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 22.6 pttp -75.13 -18.83 60.15 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.718 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 74.7 m -61.85 -42.94 99.66 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.699 -179.589 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' TYR . . . . . 0.581 ' C ' HD12 ' A' ' 59' ' ' ILE . 82.8 m-85 -96.73 -2.38 44.55 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.524 0.202 . . . . 0.0 111.395 -179.187 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.581 HD12 ' C ' ' A' ' 58' ' ' TYR . 1.6 mp -113.86 128.66 70.68 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 179.46 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 91.7 m -124.88 130.35 52.21 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.055 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 22.1 mm -78.46 129.61 37.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.353 -179.593 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 94.1 t . . . . . 0 C--N 1.332 -0.182 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.616 -179.908 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 85.8 mt-30 . . . . . 0 N--CA 1.464 0.238 0 N-CA-C 109.897 -0.409 . . . . 0.0 109.897 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -88.59 149.74 21.31 Favored Glycine 0 CA--C 1.523 0.576 0 N-CA-C 111.279 -0.728 . . . . 0.0 111.279 -179.529 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 53.8 t -126.65 132.55 70.06 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 179.818 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 83.0 t -91.11 128.76 42.71 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.196 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.359 179.757 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -125.63 106.46 9.76 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.318 179.904 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.547 HG22 ' H ' ' A' ' 9' ' ' SER . 3.0 p -138.02 145.4 28.79 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 116.263 -0.426 . . . . 0.0 109.862 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.526 ' OD1' ' N ' ' A' ' 9' ' ' SER . 38.7 p-10 -62.39 -41.18 98.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.776 -179.57 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . 0.547 ' H ' HG22 ' A' ' 7' ' ' VAL . 6.9 t -123.28 -141.33 0.31 Allowed 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.424 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -92.73 144.15 25.59 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.491 179.788 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.408 ' CD1' ' CG ' ' A' ' 58' ' ' TYR . 6.4 tt -121.57 134.42 55.02 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.594 -179.828 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 11.1 m120 -75.88 134.62 40.25 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.226 -179.412 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 27.4 ttt -89.05 152.68 21.53 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-N 115.847 -0.615 . . . . 0.0 109.485 179.104 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 84.2 mtt85 -124.71 144.35 50.27 Favored 'General case' 0 N--CA 1.478 0.971 0 CA-C-O 120.449 0.166 . . . . 0.0 111.026 -179.752 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . 0.467 ' HA ' HD11 ' A' ' 24' ' ' ILE . 23.2 t -89.11 -2.18 58.42 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.909 0.385 . . . . 0.0 110.452 179.3 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -163.41 160.29 32.95 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.35 -1.1 . . . . 0.0 110.35 179.779 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_endo -62.69 99.02 0.2 Allowed 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.368 2.045 . . . . 0.0 111.891 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 135.35 141.82 4.44 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 110.573 -1.011 . . . . 0.0 110.573 179.932 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 35.3 t -67.53 -16.0 63.96 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.78 0.324 . . . . 0.0 110.725 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 52.6 t30 -84.87 8.38 17.63 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.687 -179.05 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 39.5 m-85 -96.85 8.24 44.82 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-O 120.766 0.317 . . . . 0.0 110.31 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 85.07 176.52 50.79 Favored Glycine 0 CA--C 1.522 0.502 0 N-CA-C 111.355 -0.698 . . . . 0.0 111.355 179.663 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.489 HG22 ' H ' ' A' ' 25' ' ' GLY . 14.8 p -121.27 133.84 66.57 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 CA-C-O 120.669 0.271 . . . . 0.0 110.397 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.467 HD11 ' HA ' ' A' ' 15' ' ' SER . 94.8 mt -92.93 -15.25 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-O 120.869 0.366 . . . . 0.0 110.589 -179.696 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.489 ' H ' HG22 ' A' ' 23' ' ' VAL . . . 157.35 -145.59 12.22 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 110.668 -0.973 . . . . 0.0 110.668 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 71.2 p -133.71 155.13 50.29 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-O 120.977 0.418 . . . . 0.0 110.309 179.75 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 85.0 mt -124.67 146.57 49.06 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.227 -179.79 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.408 ' N ' ' OD2' ' A' ' 31' ' ' ASP . 31.8 mtp85 -107.47 170.06 8.2 Favored 'General case' 0 CA--C 1.506 -0.714 0 CA-C-O 121.575 0.702 . . . . 0.0 111.206 -179.771 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 56.9 p30 -69.37 157.17 37.57 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 114.466 -1.243 . . . . 0.0 110.761 179.083 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 8.9 m120 59.29 31.49 21.2 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 114.921 -1.036 . . . . 0.0 111.085 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.408 ' OD2' ' N ' ' A' ' 28' ' ' ARG . 98.5 m-20 -93.56 111.13 22.74 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-O 120.696 0.284 . . . . 0.0 110.419 179.343 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 56.2 mtpt -73.64 133.91 43.54 Favored 'General case' 0 C--N 1.328 -0.363 0 C-N-CA 120.639 -0.424 . . . . 0.0 109.986 179.599 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.7 m -136.59 160.9 37.33 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 120.84 0.353 . . . . 0.0 110.674 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -107.86 119.11 38.54 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 116.121 -0.491 . . . . 0.0 109.808 179.395 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.461 ' C ' HD12 ' A' ' 36' ' ' ILE . 97.0 mt -84.07 126.88 40.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.604 -179.533 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.707 HD12 ' N ' ' A' ' 36' ' ' ILE . 1.6 mp -94.33 -65.43 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.195 0 CA-C-N 116.197 -0.456 . . . . 0.0 109.983 179.9 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 50.4 mtmt -148.28 156.99 43.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.456 179.494 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . 0.45 ' CD ' ' CE1' ' A' ' 43' ' ' TYR . 83.6 tt0 -113.42 123.45 50.1 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.565 179.773 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 67.8 t -130.6 132.33 64.47 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.189 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 55.28 33.59 21.0 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.781 178.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 83.69 -11.39 56.59 Favored Glycine 0 CA--C 1.525 0.688 0 C-N-CA 120.965 -0.636 . . . . 0.0 111.715 179.0 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 84.2 m95 -89.72 140.69 29.32 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 179.725 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . 0.45 ' CE1' ' CD ' ' A' ' 38' ' ' GLU . 62.9 m-85 -101.56 126.43 48.37 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.822 0.344 . . . . 0.0 110.418 179.709 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -82.29 128.8 34.56 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.321 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 43.4 pt -129.48 156.99 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-O 121.28 0.562 . . . . 0.0 111.641 -179.015 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 28.8 ttt180 -124.83 131.42 53.44 Favored 'General case' 0 CA--C 1.51 -0.578 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.106 178.238 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 38.9 t80 -152.57 135.9 15.86 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.791 -0.641 . . . . 0.0 110.532 179.773 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 10.9 m120 56.56 34.3 24.15 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.307 179.736 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 73.81 5.75 70.4 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.429 -0.668 . . . . 0.0 111.429 179.4 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -107.04 144.87 33.08 Favored 'General case' 0 N--CA 1.467 0.394 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.684 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 53.0 t -118.88 133.57 65.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 CA-C-O 120.939 0.399 . . . . 0.0 110.545 -179.372 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -159.91 -168.63 22.15 Favored Glycine 0 CA--C 1.524 0.638 0 N-CA-C 110.576 -1.01 . . . . 0.0 110.576 179.91 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.444 ' N ' ' CD1' ' A' ' 53' ' ' TYR . 38.9 m-85 -127.5 156.33 42.33 Favored 'General case' 0 N--CA 1.464 0.271 0 N-CA-C 110.119 -0.326 . . . . 0.0 110.119 -179.702 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -140.0 157.17 46.09 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-O 120.861 0.363 . . . . 0.0 110.62 -179.752 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 28.5 t -63.01 140.49 58.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.211 -179.63 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 25.4 pttm -69.21 -28.75 66.64 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.308 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 52.9 m -59.93 -38.84 83.57 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.463 -179.187 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' TYR . . . . . 0.408 ' CG ' ' CD1' ' A' ' 11' ' ' LEU . 84.2 m-85 -94.81 15.17 19.15 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 111.758 0.281 . . . . 0.0 111.758 -179.012 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 5.5 mm -119.21 128.14 75.83 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 CA-C-O 120.939 0.399 . . . . 0.0 110.163 179.534 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 92.7 m -125.18 127.52 46.92 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.063 179.79 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.6 mt -87.76 125.8 41.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.419 179.782 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 2.3 m . . . . . 0 N--CA 1.465 0.293 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.374 179.876 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 . . . . . 0 N--CA 1.465 0.3 0 CA-C-O 120.962 0.41 . . . . 0.0 110.524 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -86.74 148.08 21.57 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 179.756 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 74.3 t -124.96 130.27 73.28 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 CA-C-O 120.971 0.415 . . . . 0.0 110.271 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 19.1 t -92.57 128.56 44.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.499 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 21.9 mmtp -121.86 105.3 10.23 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.342 -0.39 . . . . 0.0 109.997 179.525 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 19.0 m -139.34 159.65 28.58 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.482 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 18.3 t-20 -81.2 -13.81 58.2 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.639 179.881 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 12.3 t -159.1 -166.19 1.78 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.5 -179.673 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -65.43 143.29 57.8 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.201 179.603 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 44.9 tp -124.13 132.2 53.62 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-O 120.792 0.33 . . . . 0.0 110.293 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 14.3 m120 -75.24 142.77 43.32 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.297 179.688 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' MET . . . . . 0.43 ' SD ' HD11 ' A' ' 24' ' ' ILE . 12.0 tmm? -106.95 150.31 26.59 Favored 'General case' 0 N--CA 1.463 0.205 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 179.731 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . 0.746 ' NH2' ' H ' ' A' ' 22' ' ' GLY . 24.6 mtp85 -122.34 156.84 33.08 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-O 121.027 0.441 . . . . 0.0 110.572 -178.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 82.2 p -80.84 -6.42 58.56 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.584 -0.735 . . . . 0.0 111.046 -179.42 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.55 -168.95 20.72 Favored Glycine 0 CA--C 1.525 0.692 0 C-N-CA 120.831 -0.699 . . . . 0.0 111.422 -179.848 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -83.69 9.38 4.13 Favored 'Trans proline' 0 C--N 1.309 -1.511 0 C-N-CA 122.832 2.354 . . . . 0.0 112.631 -179.695 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -97.56 127.32 9.18 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . 0.535 ' O ' ' NH2' ' A' ' 14' ' ' ARG . 96.1 p -70.97 -10.71 60.2 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.347 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 25.1 p30 -106.03 19.8 19.95 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.029 -179.712 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . 0.433 ' N ' HH21 ' A' ' 14' ' ' ARG . 3.0 m-85 -86.3 -3.08 58.92 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.552 -0.294 . . . . 0.0 110.326 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.746 ' H ' ' NH2' ' A' ' 14' ' ' ARG . . . 81.1 168.61 40.24 Favored Glycine 0 CA--C 1.521 0.421 0 N-CA-C 111.01 -0.836 . . . . 0.0 111.01 179.913 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.465 HG13 ' O ' ' A' ' 23' ' ' VAL . 9.7 p -102.25 124.7 56.34 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 CA-C-O 120.827 0.346 . . . . 0.0 110.421 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.43 HD11 ' SD ' ' A' ' 13' ' ' MET . 23.1 pt -106.78 -0.22 9.98 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.804 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.83 167.8 39.77 Favored Glycine 0 CA--C 1.52 0.348 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 89.2 m -124.04 131.16 53.52 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 120.782 0.325 . . . . 0.0 110.626 -179.7 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 69.4 mt -101.67 161.48 13.62 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.744 -179.706 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 81.5 mtt180 -127.66 157.77 39.38 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 120.873 0.368 . . . . 0.0 110.247 179.54 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.436 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 52.7 p30 -57.25 150.64 17.41 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.285 -179.177 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 12.5 t-20 58.47 35.34 24.63 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.364 179.499 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 32.5 t0 -89.15 114.41 25.7 Favored 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 179.234 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -84.03 124.5 31.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.807 0.337 . . . . 0.0 110.357 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 28.2 m -138.22 162.39 30.59 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.94 -179.711 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . 0.634 ' OE1' ' NH1' ' A' ' 46' ' ' ARG . 78.1 tt0 -95.9 140.14 31.1 Favored 'General case' 0 C--O 1.233 0.222 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 179.054 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 91.3 mt -104.23 125.52 59.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.822 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 95.9 mt -93.03 -49.56 12.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.386 179.718 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 35.6 ttpt -172.79 157.66 3.76 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.659 -179.331 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . 0.57 ' H ' ' CD ' ' A' ' 38' ' ' GLU . 2.1 pm0 -110.0 143.56 39.82 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.35 -0.387 . . . . 0.0 110.371 179.833 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 34.4 t -129.95 126.35 62.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 CA-C-O 120.757 0.313 . . . . 0.0 110.644 -179.718 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 50.79 30.26 4.93 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.545 178.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 85.84 25.32 38.52 Favored Glycine 0 CA--C 1.525 0.687 0 C-N-CA 121.011 -0.614 . . . . 0.0 112.015 179.361 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 62.2 m95 -124.36 106.24 10.07 Favored 'General case' 0 N--CA 1.471 0.581 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.127 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 91.3 m-85 -70.97 135.3 47.8 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.968 0.413 . . . . 0.0 111.437 -179.243 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -88.4 141.89 28.17 Favored 'General case' 0 CA--C 1.518 -0.262 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 178.325 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 39.9 pt -135.38 154.45 35.42 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.684 0 CA-C-O 121.627 0.727 . . . . 0.0 111.034 -179.582 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.634 ' NH1' ' OE1' ' A' ' 34' ' ' GLU . 11.2 ttp180 -111.4 123.54 50.41 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 114.668 -1.151 . . . . 0.0 110.378 -179.917 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 66.9 t80 -151.72 134.91 15.91 Favored 'General case' 0 N--CA 1.463 0.224 0 C-N-CA 120.87 -0.332 . . . . 0.0 111.158 -179.497 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 55.3 t-20 57.96 35.11 25.01 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.423 179.603 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 66.87 22.5 72.12 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 111.091 -0.804 . . . . 0.0 111.091 179.738 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 54.9 mtpt -128.91 146.74 50.87 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 121.012 0.434 . . . . 0.0 111.019 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 53.8 t -113.51 131.77 64.33 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.922 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -143.97 -163.35 9.86 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -179.806 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 44.8 m-85 -127.64 153.1 46.84 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 110.242 -0.281 . . . . 0.0 110.242 -179.675 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -146.69 151.33 37.03 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-N 116.383 -0.372 . . . . 0.0 110.642 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 41.0 t -65.14 143.72 57.69 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.744 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 26.0 pttm -67.58 -17.6 64.69 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.849 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 16.0 m -64.28 -36.06 82.86 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.44 -179.52 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 41.6 m-85 -103.85 12.04 34.94 Favored 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 111.978 0.362 . . . . 0.0 111.978 -178.175 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 46.2 mm -121.43 129.67 75.36 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.573 0 CA-C-O 120.931 0.396 . . . . 0.0 110.623 179.846 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 62.2 p -116.98 131.9 56.84 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.422 -179.601 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.6 mt -84.4 129.65 37.3 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.174 179.597 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 87.9 t . . . . . 0 C--N 1.327 -0.397 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.354 -179.915 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.423 ' CD ' ' N ' ' A' ' 2' ' ' GLN . 21.3 mp0 . . . . . 0 N--CA 1.465 0.321 0 CA-C-O 120.778 0.323 . . . . 0.0 110.416 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -99.62 147.56 18.33 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.625 -0.99 . . . . 0.0 110.625 179.772 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 54.3 t -124.73 130.78 73.31 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-O 120.927 0.394 . . . . 0.0 110.127 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 13.6 t -87.55 127.17 41.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.306 179.865 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -123.09 105.59 10.06 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.858 0.361 . . . . 0.0 110.068 179.491 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 14.8 p -156.51 139.09 6.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.559 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 66.2 t30 -67.84 -48.98 64.65 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.824 0.345 . . . . 0.0 110.756 179.606 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 5.5 m -93.96 152.48 18.81 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.575 179.799 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -61.47 142.7 56.83 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.532 -0.467 . . . . 0.0 110.194 179.568 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 41.1 tp -117.58 128.23 54.74 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.894 179.851 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . 0.551 ' ND2' HH12 ' A' ' 14' ' ' ARG . 21.2 p-10 -72.08 145.47 48.2 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.687 179.549 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 62.6 ttp -96.69 140.05 31.85 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-O 121.207 0.527 . . . . 0.0 110.663 -179.627 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . 0.961 ' HE ' ' HA ' ' A' ' 19' ' ' SER . 1.0 OUTLIER -93.8 153.82 18.08 Favored 'General case' 0 CA--C 1.541 0.608 0 CA-C-N 115.345 -0.843 . . . . 0.0 111.472 -178.443 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 78.5 p -88.34 -9.66 52.01 Favored 'General case' 0 N--CA 1.462 0.127 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.845 179.13 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -162.82 -173.05 31.05 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.154 -1.178 . . . . 0.0 110.154 179.729 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -80.67 78.29 3.72 Favored 'Trans proline' 0 C--N 1.298 -2.115 0 C-N-CA 122.584 2.189 . . . . 0.0 112.391 179.547 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 167.13 134.5 1.71 Allowed Glycine 0 CA--C 1.525 0.676 0 N-CA-C 111.371 -0.691 . . . . 0.0 111.371 179.769 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . 0.961 ' HA ' ' HE ' ' A' ' 14' ' ' ARG . 23.2 t -68.32 -13.46 62.29 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 112.102 0.408 . . . . 0.0 112.102 -179.113 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 14.1 m120 -88.07 11.44 16.1 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.766 -179.762 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 17.8 m-85 -90.7 1.3 56.97 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.313 179.849 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 76.59 -173.47 54.4 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 179.848 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 4.8 p -118.87 127.69 75.74 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-O 120.841 0.353 . . . . 0.0 110.293 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 25.2 pt -110.21 -3.64 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.448 179.651 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.56 -176.55 43.89 Favored Glycine 0 CA--C 1.529 0.908 0 N-CA-C 111.246 -0.742 . . . . 0.0 111.246 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 69.4 p -131.55 155.29 47.73 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 120.647 0.26 . . . . 0.0 110.691 -179.82 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 84.1 mt -125.37 149.56 48.02 Favored 'General case' 0 N--CA 1.472 0.625 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.519 -179.35 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 92.1 mtt-85 -120.21 161.67 20.68 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 121.669 0.747 . . . . 0.0 111.103 -179.164 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 64.2 t30 -57.97 144.23 40.2 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.581 -178.608 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 59.2 34.23 23.06 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.47 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 65.7 t0 -85.25 114.89 22.68 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-O 120.778 0.323 . . . . 0.0 110.186 178.881 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -80.37 128.87 34.06 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.551 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.1 m -141.59 161.3 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.201 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.439 179.741 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 80.7 mm-40 -102.73 133.35 47.93 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.942 179.637 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 92.5 mt -102.75 109.43 26.63 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.625 -179.848 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 97.2 mt -66.46 -43.63 90.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.547 179.853 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 25.7 pttm -172.51 179.25 2.52 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.774 -179.401 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 2.5 tm-20 -112.89 124.62 53.03 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.179 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 54.1 t -125.66 133.01 70.16 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.784 -179.663 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 55.81 28.86 12.99 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.133 179.393 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.36 -8.6 57.96 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.854 -0.898 . . . . 0.0 110.854 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 11.1 m95 -94.05 148.38 22.23 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 110.035 -0.357 . . . . 0.0 110.035 179.633 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 64.2 m-85 -96.95 131.39 43.8 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.974 0.416 . . . . 0.0 110.689 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -83.18 152.99 25.0 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 108.496 -0.928 . . . . 0.0 108.496 178.499 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 34.5 pt -145.29 150.55 15.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 C-N-CA 120.707 -0.397 . . . . 0.0 111.143 -179.413 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.603 ' HE ' ' HA2' ' A' ' 49' ' ' GLY . 16.6 ttt180 -115.05 126.18 54.41 Favored 'General case' 0 CA--C 1.511 -0.534 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 177.398 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 79.5 t80 -138.1 129.05 27.09 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-N 115.16 -0.927 . . . . 0.0 110.304 179.574 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 67.0 t30 53.09 36.5 22.44 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.628 -0.714 . . . . 0.0 112.124 179.677 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.603 ' HA2' ' HE ' ' A' ' 46' ' ' ARG . . . 71.05 16.41 74.9 Favored Glycine 0 CA--C 1.525 0.665 0 C-N-CA 120.491 -0.861 . . . . 0.0 111.024 178.924 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.414 ' HD3' ' N ' ' A' ' 51' ' ' VAL . 6.0 tmtt? -119.04 125.78 50.15 Favored 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 109.9 -0.408 . . . . 0.0 109.9 -179.366 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.414 ' N ' ' HD3' ' A' ' 50' ' ' LYS . 82.5 t -80.25 136.65 22.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.591 179.741 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -157.59 167.66 34.14 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.884 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 76.0 m-85 -122.01 156.87 32.56 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-O 120.645 0.259 . . . . 0.0 110.444 -179.544 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -148.77 151.71 35.3 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-O 120.842 0.354 . . . . 0.0 110.472 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 30.0 t -63.23 141.26 58.83 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.478 -179.882 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 26.0 pttm -67.21 -15.1 63.5 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.193 -179.671 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 78.0 p -65.64 -33.19 75.33 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.68 -179.661 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -102.31 11.0 38.78 Favored 'General case' 0 N--CA 1.468 0.454 0 N-CA-C 111.867 0.321 . . . . 0.0 111.867 -179.04 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 47.8 mm -115.55 130.12 70.7 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.567 0 CA-C-O 120.997 0.427 . . . . 0.0 110.554 179.795 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 90.1 m -116.75 124.91 50.79 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.189 179.695 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 21.0 mm -81.79 134.64 26.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.44 -179.856 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 75.3 t . . . . . 0 C--N 1.328 -0.343 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.294 -179.901 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 88.6 mt-30 . . . . . 0 N--CA 1.466 0.373 0 CA-C-O 120.822 0.344 . . . . 0.0 110.684 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -93.97 156.78 22.51 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.689 -0.964 . . . . 0.0 110.689 179.713 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 65.1 t -124.59 130.99 73.32 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 179.663 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 13.1 t -86.05 128.97 38.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.778 -179.584 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -130.81 106.23 8.31 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.939 0.4 . . . . 0.0 110.207 179.382 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.492 HG22 ' H ' ' A' ' 9' ' ' SER . 3.2 p -140.82 142.77 29.71 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.205 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.223 -179.563 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.526 ' OD1' ' N ' ' A' ' 9' ' ' SER . 13.9 p30 -63.28 -40.8 98.38 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.717 -179.732 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . 0.526 ' N ' ' OD1' ' A' ' 8' ' ' ASN . 17.4 m -117.69 -139.76 0.36 Allowed 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.92 179.578 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -91.97 144.35 25.55 Favored 'General case' 0 C--O 1.233 0.21 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 179.498 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 60.6 tp -110.86 130.18 55.65 Favored 'General case' 0 N--CA 1.468 0.451 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 -179.835 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -85.23 133.63 34.17 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.403 179.827 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 38.4 ttp -100.71 142.16 32.57 Favored 'General case' 0 CA--C 1.51 -0.582 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 179.712 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . 0.525 HH12 ' CB ' ' A' ' 19' ' ' SER . 8.6 mtt180 -117.74 155.42 30.04 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.83 -178.83 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 87.5 p -77.73 -11.81 59.91 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 112.057 0.392 . . . . 0.0 112.057 -178.885 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -162.9 -173.04 31.14 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 179.862 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -83.29 77.02 3.67 Favored 'Trans proline' 0 C--N 1.307 -1.623 0 C-N-CA 122.704 2.269 . . . . 0.0 112.173 179.605 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 168.54 133.81 1.62 Allowed Glycine 0 CA--C 1.527 0.83 0 C-N-CA 120.753 -0.737 . . . . 0.0 111.699 179.717 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . 0.525 ' CB ' HH12 ' A' ' 14' ' ' ARG . 6.0 t -65.86 -17.41 64.63 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-O 120.886 0.374 . . . . 0.0 110.985 179.807 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . 0.531 ' OD1' ' N ' ' A' ' 21' ' ' TYR . 41.1 p-10 -60.89 -36.09 78.32 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.508 -179.117 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . 0.531 ' N ' ' OD1' ' A' ' 20' ' ' ASN . 76.6 m-85 -62.05 -37.02 83.39 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.04 179.342 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 89.48 173.71 45.91 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.451 ' CG2' ' O ' ' A' ' 25' ' ' GLY . 14.0 p -87.19 128.12 40.06 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.867 0.365 . . . . 0.0 110.487 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 25.4 pt -104.4 -4.32 9.61 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.502 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.451 ' O ' ' CG2' ' A' ' 23' ' ' VAL . . . -176.32 -177.12 45.06 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.414 -1.075 . . . . 0.0 110.414 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 69.7 p -132.2 150.22 52.2 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-O 120.947 0.403 . . . . 0.0 110.374 179.861 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 84.4 mt -129.06 148.54 51.02 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.757 -179.529 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 71.0 mtp180 -107.0 162.44 13.84 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.23 179.509 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.426 ' HB3' ' H ' ' A' ' 7' ' ' VAL . 52.8 p30 -69.29 171.97 7.72 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.172 179.723 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 85.9 m-20 58.33 9.2 0.97 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.122 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 43.4 t0 -85.11 116.54 23.54 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.782 0.325 . . . . 0.0 110.676 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 65.5 mttp -77.0 135.13 38.66 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.056 179.674 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.0 m -137.75 159.85 34.03 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-O 120.89 0.376 . . . . 0.0 110.648 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -104.44 117.95 35.41 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.048 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.4 ' C ' HD12 ' A' ' 36' ' ' ILE . 95.7 mt -90.72 125.76 43.51 Favored 'Isoleucine or valine' 0 C--O 1.232 0.172 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.518 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.767 HD12 ' N ' ' A' ' 36' ' ' ILE . 1.9 mp -92.96 -41.16 12.58 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.67 -179.819 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 22.6 pttp -171.83 158.86 5.01 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.604 -179.805 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . 0.476 ' OE1' ' CE1' ' A' ' 43' ' ' TYR . 81.4 tt0 -112.61 125.04 53.84 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.089 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 65.0 t -128.05 132.63 68.39 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 CA-C-O 120.906 0.384 . . . . 0.0 111.146 -179.694 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . 0.435 ' OD1' ' O ' ' A' ' 40' ' ' ASP . 55.1 t0 56.85 25.37 10.33 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.924 179.394 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.01 -9.71 73.53 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 179.696 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 66.2 m95 -89.44 141.51 28.5 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 110.077 -0.342 . . . . 0.0 110.077 179.783 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . 0.476 ' CE1' ' OE1' ' A' ' 38' ' ' GLU . 38.3 m-85 -95.38 131.8 41.12 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-O 121.01 0.433 . . . . 0.0 110.403 179.915 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -92.03 119.64 31.93 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 178.9 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 41.1 pt -125.88 157.84 35.43 Favored 'Isoleucine or valine' 0 C--O 1.233 0.222 0 CA-C-O 121.123 0.487 . . . . 0.0 111.092 -179.311 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 79.0 ttt180 -115.83 124.93 51.93 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.593 179.035 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 28.2 t80 -141.83 132.77 25.94 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.454 -179.814 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 62.7 t30 61.08 27.67 17.47 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.398 -179.835 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 74.08 9.01 79.88 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 61.5 tttm -102.76 156.69 17.47 Favored 'General case' 0 C--O 1.231 0.129 0 N-CA-C 110.043 -0.355 . . . . 0.0 110.043 -179.825 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 56.6 t -115.9 131.17 69.16 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.009 -179.873 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -160.98 -170.43 25.59 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 66.6 m-85 -130.31 162.62 28.62 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-O 120.779 0.323 . . . . 0.0 110.509 -179.632 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -146.68 154.3 41.28 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.369 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 20.2 m -66.25 143.19 57.37 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.619 -179.863 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 60.7 pttt -79.9 -19.44 48.17 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.167 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 11.7 t -61.59 -42.14 98.43 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.354 -179.558 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 99.3 m-85 -92.24 4.3 53.55 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.439 -0.346 . . . . 0.0 111.786 -178.833 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 97.6 mt -122.29 132.09 71.82 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.54 0 CA-C-O 121.001 0.429 . . . . 0.0 110.881 179.678 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 93.1 m -120.2 134.06 55.35 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.406 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 23.1 mm -77.15 132.73 32.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.649 -179.893 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 94.7 t . . . . . 0 C--N 1.33 -0.262 0 CA-C-O 120.936 0.398 . . . . 0.0 110.764 -179.938 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.443 ' OE1' ' N ' ' A' ' 2' ' ' GLN . 1.1 mp0 . . . . . 0 N--CA 1.463 0.202 0 CA-C-O 121.116 0.484 . . . . 0.0 111.371 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -92.96 158.18 23.84 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 110.685 -0.966 . . . . 0.0 110.685 179.351 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 73.3 t -126.1 134.47 66.43 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 O-C-N 122.615 -0.344 . . . . 0.0 110.309 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 18.2 t -85.1 126.29 40.34 Favored 'Isoleucine or valine' 0 C--O 1.234 0.248 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.751 -179.905 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 41.5 mmtm -112.24 106.63 15.25 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-O 120.763 0.316 . . . . 0.0 110.382 179.796 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.402 HG22 ' N ' ' A' ' 8' ' ' ASN . 9.7 p -140.15 159.11 26.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 N-CA-C 110.307 -0.257 . . . . 0.0 110.307 179.671 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.478 ' OD1' ' N ' ' A' ' 9' ' ' SER . 21.5 p30 -64.37 -39.47 93.94 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.813 -0.355 . . . . 0.0 110.623 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . 0.478 ' N ' ' OD1' ' A' ' 8' ' ' ASN . 59.5 p -141.09 -60.75 0.49 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.155 -179.656 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.417 ' N ' ' OG ' ' A' ' 9' ' ' SER . . . -149.63 145.84 26.97 Favored 'General case' 0 CA--C 1.519 -0.248 0 CA-C-O 121.196 0.522 . . . . 0.0 110.758 -179.699 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 39.9 tp -116.68 131.66 56.89 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.464 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 99.7 m-20 -74.94 138.38 42.28 Favored 'General case' 0 CA--C 1.518 -0.264 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.573 179.654 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 37.6 ttp -94.72 151.41 19.3 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.621 179.74 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . 0.65 ' NH1' ' H ' ' A' ' 16' ' ' GLY . 0.4 OUTLIER -129.89 154.18 47.56 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.94 0.4 . . . . 0.0 111.668 -179.151 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . 0.618 ' H ' ' CZ ' ' A' ' 14' ' ' ARG . 85.9 p -87.5 -17.34 32.34 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 115.606 -0.725 . . . . 0.0 111.237 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.65 ' H ' ' NH1' ' A' ' 14' ' ' ARG . . . -149.2 -177.48 23.37 Favored Glycine 0 CA--C 1.528 0.875 0 C-N-CA 120.859 -0.686 . . . . 0.0 111.52 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -81.99 82.39 2.32 Favored 'Trans proline' 0 C--N 1.319 -0.983 0 C-N-CA 123.256 2.637 . . . . 0.0 112.107 -179.691 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 163.99 119.63 0.49 Allowed Glycine 0 CA--C 1.528 0.881 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 179.727 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 80.4 p -70.46 -12.39 61.54 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-O 120.605 0.241 . . . . 0.0 110.732 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -78.25 -14.98 59.21 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.322 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . 0.412 ' HB3' ' NH2' ' A' ' 14' ' ' ARG . 13.6 m-85 -64.91 -41.89 95.21 Favored 'General case' 0 CA--C 1.519 -0.231 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.844 179.526 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.54 ' O ' ' NE ' ' A' ' 14' ' ' ARG . . . 117.07 133.76 5.12 Favored Glycine 0 C--N 1.333 0.394 0 N-CA-C 110.954 -0.859 . . . . 0.0 110.954 179.324 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 5.4 p -65.93 139.46 21.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 121.065 0.459 . . . . 0.0 110.399 179.756 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 34.8 pt -106.91 -10.08 10.58 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.215 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.975 -179.878 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.23 -172.93 43.16 Favored Glycine 0 CA--C 1.521 0.467 0 N-CA-C 110.626 -0.99 . . . . 0.0 110.626 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 97.5 m -125.94 147.57 49.47 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-O 120.923 0.392 . . . . 0.0 111.222 -179.301 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 60.5 mt -112.88 153.59 27.67 Favored 'General case' 0 C--O 1.233 0.207 0 CA-C-O 121.055 0.455 . . . . 0.0 110.006 179.458 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 24.1 mmt180 -100.83 159.87 14.83 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.436 -179.543 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.437 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 53.5 p-10 -65.32 143.98 57.41 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.828 -179.528 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 56.66 34.0 23.78 Favored 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.598 179.229 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 44.0 t0 -85.08 117.1 23.83 Favored 'General case' 0 N--CA 1.466 0.341 0 C-N-CA 120.884 -0.326 . . . . 0.0 110.891 179.749 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -72.38 130.48 40.82 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.998 0.428 . . . . 0.0 110.49 179.826 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 28.8 m -137.29 162.93 32.7 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.489 179.827 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -100.13 122.56 43.17 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.813 -0.631 . . . . 0.0 109.934 179.56 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.4 mt -97.4 128.66 48.47 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.169 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.211 -179.739 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 22.7 mm -94.04 -64.32 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.473 -179.693 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 25.3 pttm -154.47 163.52 40.06 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.789 -179.758 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 44.2 tt0 -103.85 126.72 51.18 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.583 179.757 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 61.4 t -127.86 131.64 69.54 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.2 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.335 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 51.1 t0 55.68 24.25 6.98 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.04 179.845 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.72 -16.01 57.62 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 111.54 -0.624 . . . . 0.0 111.54 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 17.0 m95 -88.2 141.97 28.13 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.806 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 -94.53 131.6 40.08 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-O 120.737 0.303 . . . . 0.0 111.083 -179.52 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -80.65 134.51 35.89 Favored 'General case' 0 N--CA 1.464 0.275 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 179.2 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 40.0 pt -134.54 155.39 38.73 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-O 121.006 0.431 . . . . 0.0 111.77 -179.441 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 56.4 ttp180 -118.58 124.44 47.48 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.501 179.568 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 36.1 t80 -148.19 134.83 19.84 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.683 179.734 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 65.5 t30 58.74 31.35 21.09 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.674 -179.798 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 70.18 19.54 75.82 Favored Glycine 0 CA--C 1.521 0.407 0 N-CA-C 110.668 -0.973 . . . . 0.0 110.668 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -122.0 145.57 48.0 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-O 120.709 0.29 . . . . 0.0 110.256 -179.587 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 16.8 t -96.78 113.3 30.79 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 CA-C-O 120.846 0.355 . . . . 0.0 110.36 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . 0.42 ' C ' ' CD1' ' A' ' 53' ' ' TYR . . . -119.84 -166.97 13.44 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 110.772 -0.931 . . . . 0.0 110.772 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.42 ' CD1' ' C ' ' A' ' 52' ' ' GLY . 85.3 m-85 -147.37 159.59 43.52 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 179.963 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -145.62 154.88 42.62 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.971 0.415 . . . . 0.0 110.809 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 15.1 m -69.51 146.08 52.16 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.666 -179.809 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 20.6 ptmt -68.23 -36.82 80.09 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.465 -179.836 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 78.3 p -66.92 -23.22 65.95 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.865 -179.007 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 80.9 m-85 -104.82 7.33 34.47 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.471 -179.888 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 4.9 mm -127.71 129.74 70.15 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.15 179.811 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 98.5 m -121.22 127.07 51.09 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.593 179.481 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 21.8 mm -86.23 128.94 38.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.107 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 21.2 t . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.822 -179.569 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 26.8 mt-30 . . . . . 0 N--CA 1.465 0.277 0 CA-C-O 120.821 0.343 . . . . 0.0 110.222 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -85.19 163.81 37.99 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.514 -1.034 . . . . 0.0 110.514 179.648 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 54.7 t -125.17 130.15 73.1 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-O 120.785 0.326 . . . . 0.0 110.143 179.858 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 15.7 t -95.4 125.92 48.01 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.08 179.681 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 33.1 ttpt -129.81 117.1 19.68 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.497 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.4 HG12 ' H ' ' A' ' 9' ' ' SER . 2.8 t -140.92 155.9 22.16 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 CA-C-O 120.872 0.368 . . . . 0.0 110.726 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 49.8 p30 -79.9 -11.49 59.8 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.504 179.548 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . 0.4 ' H ' HG12 ' A' ' 7' ' ' VAL . 73.6 m -162.07 -164.79 1.11 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.385 -179.76 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -65.25 142.95 58.11 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.735 -179.903 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 53.6 tp -126.16 132.12 51.88 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-N 116.169 -0.468 . . . . 0.0 109.879 179.701 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . 0.445 ' OD1' ' O ' ' A' ' 12' ' ' ASN . 47.8 p30 -77.62 142.44 38.9 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.001 0.429 . . . . 0.0 110.956 -179.873 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 43.3 ttp -111.43 138.44 47.93 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 179.691 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . 0.71 ' NH2' ' CE3' ' A' ' 42' ' ' TRP . 0.5 OUTLIER -109.18 141.2 41.75 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 120.867 0.365 . . . . 0.0 111.03 -178.81 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 38.4 t -63.44 -42.61 98.67 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.037 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -107.73 179.8 22.0 Favored Glycine 0 N--CA 1.466 0.665 0 N-CA-C 110.65 -0.98 . . . . 0.0 110.65 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -82.98 73.09 5.59 Favored 'Trans proline' 0 C--N 1.307 -1.652 0 C-N-CA 122.438 2.092 . . . . 0.0 111.959 179.665 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . 0.668 ' N ' HH21 ' A' ' 14' ' ' ARG . . . 174.52 158.07 17.64 Favored Glycine 0 CA--C 1.528 0.89 0 N-CA-C 111.344 -0.702 . . . . 0.0 111.344 179.918 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 69.5 m -82.4 -10.37 59.08 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.849 0.357 . . . . 0.0 110.643 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 14.4 m120 -89.64 5.03 47.56 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.188 -179.128 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 47.8 m-85 -92.11 -0.59 57.44 Favored 'General case' 0 N--CA 1.465 0.304 0 N-CA-C 109.993 -0.373 . . . . 0.0 109.993 179.775 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 78.53 -178.32 53.13 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 111.127 -0.789 . . . . 0.0 111.127 179.647 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 5.4 p -116.08 126.71 73.69 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 CA-C-O 120.932 0.396 . . . . 0.0 110.33 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 43.6 pt -103.66 -8.94 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.968 -179.866 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -177.87 -171.72 41.58 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 63.2 p -133.51 158.46 43.07 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-O 120.928 0.394 . . . . 0.0 110.642 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 75.9 mt -122.33 153.88 38.37 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 115.899 -0.592 . . . . 0.0 109.945 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.406 ' O ' ' CG ' ' A' ' 31' ' ' ASP . 70.3 mtm180 -124.54 147.14 48.6 Favored 'General case' 0 N--CA 1.465 0.309 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.914 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 53.0 p-10 -51.91 159.38 0.86 Allowed 'General case' 0 C--N 1.324 -0.536 0 C-N-CA 120.76 -0.376 . . . . 0.0 111.14 -179.168 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 58.0 t30 67.16 9.05 6.64 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.489 179.85 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . 0.406 ' CG ' ' O ' ' A' ' 28' ' ' ARG . 35.1 m-20 -84.88 113.7 21.57 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.746 0.308 . . . . 0.0 110.414 179.288 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 25.8 mtpp -78.57 136.77 37.61 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.084 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.4 m -137.24 163.05 32.65 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.252 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.784 -179.542 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 47.8 tp10 -103.01 123.8 47.3 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.401 179.497 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 90.4 mt -97.49 120.13 46.43 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.041 -179.424 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 82.2 mt -83.88 -44.96 18.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.733 179.533 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 62.1 pttt -173.93 174.89 2.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.452 -179.837 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -118.51 124.98 48.88 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.209 179.873 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 69.0 t -125.33 131.83 71.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.679 -179.577 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 54.83 27.53 9.1 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.12 179.574 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.11 -12.29 62.69 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 179.569 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . 0.71 ' CE3' ' NH2' ' A' ' 14' ' ' ARG . 82.9 m95 -88.73 145.02 25.88 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.731 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 65.6 m-85 -101.25 130.59 47.4 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-O 120.974 0.416 . . . . 0.0 110.521 -179.878 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -87.9 128.65 35.36 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.526 179.48 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 42.8 pt -128.94 150.51 34.64 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.253 0 CA-C-O 121.061 0.458 . . . . 0.0 111.312 -179.234 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 4.7 ttp180 -120.22 129.42 54.07 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.019 178.769 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 73.8 t80 -146.43 132.42 19.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.678 179.564 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 16.8 t-20 57.19 31.25 19.73 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.023 179.479 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 76.78 4.77 82.74 Favored Glycine 0 CA--C 1.528 0.863 0 N-CA-C 111.347 -0.701 . . . . 0.0 111.347 179.548 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 51.4 mtmt -102.21 150.27 23.46 Favored 'General case' 0 N--CA 1.466 0.358 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.567 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 58.0 t -116.65 132.79 65.3 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-O 120.881 0.372 . . . . 0.0 110.31 -179.641 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -153.93 -166.39 14.79 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.514 ' C ' ' NH1' ' A' ' 14' ' ' ARG . 52.8 m-85 -139.18 159.03 43.12 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-O 120.815 0.341 . . . . 0.0 110.694 -179.512 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.516 ' N ' HH12 ' A' ' 14' ' ' ARG . . . -144.19 149.59 36.66 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.987 179.223 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 21.1 m -66.26 147.29 53.53 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.849 0.357 . . . . 0.0 110.574 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 62.3 pttt -64.63 -21.65 66.77 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.756 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 68.4 m -63.23 -40.29 97.02 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.55 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 72.7 m-85 -95.69 8.33 43.76 Favored 'General case' 0 N--CA 1.469 0.494 0 N-CA-C 111.93 0.345 . . . . 0.0 111.93 -178.729 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 46.0 mm -120.59 127.07 75.89 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 CA-C-O 120.905 0.383 . . . . 0.0 110.55 179.814 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 89.8 m -125.42 127.9 47.26 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 115.943 -0.572 . . . . 0.0 109.915 179.252 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 19.1 mm -85.21 127.93 39.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.543 -179.698 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 27.4 m . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.623 -179.785 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 28.5 mp0 . . . . . 0 N--CA 1.465 0.319 0 CA-C-O 120.733 0.301 . . . . 0.0 110.27 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -97.29 168.02 24.04 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.73 -0.948 . . . . 0.0 110.73 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 55.4 t -125.55 132.07 71.36 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 N-CA-C 109.986 -0.375 . . . . 0.0 109.986 179.652 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 89.4 t -92.27 113.44 27.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.03 179.757 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 75.5 tttt -112.71 117.08 31.25 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.16 -179.765 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.488 HG13 ' ND2' ' A' ' 29' ' ' ASN . 9.1 p -144.11 154.0 15.48 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.995 -179.829 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 40.2 t30 -63.16 -41.03 99.18 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.891 -179.761 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 20.3 p -133.3 -72.26 0.51 Allowed 'General case' 0 N--CA 1.468 0.439 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.733 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -152.78 144.17 23.29 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.242 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 42.5 tp -115.06 128.73 56.42 Favored 'General case' 0 N--CA 1.47 0.567 0 CA-C-O 120.979 0.418 . . . . 0.0 110.531 -179.664 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -74.77 144.56 43.53 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.481 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 33.3 ttp -107.26 150.31 26.8 Favored 'General case' 0 CA--C 1.519 -0.244 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 179.601 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . 0.493 ' HE ' ' HA ' ' A' ' 19' ' ' SER . 85.7 mtt85 -128.29 150.16 50.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.762 -178.303 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 23.0 t -69.15 -15.88 63.52 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 115.961 -0.563 . . . . 0.0 112.218 -179.417 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -161.01 -172.68 28.65 Favored Glycine 0 CA--C 1.524 0.646 0 C-N-CA 120.394 -0.908 . . . . 0.0 111.428 -179.673 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -82.76 78.43 3.34 Favored 'Trans proline' 0 C--N 1.304 -1.816 0 C-N-CA 122.729 2.286 . . . . 0.0 111.734 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 169.9 134.91 1.82 Allowed Glycine 0 CA--C 1.525 0.658 0 N-CA-C 111.29 -0.724 . . . . 0.0 111.29 179.878 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . 0.493 ' HA ' ' HE ' ' A' ' 14' ' ' ARG . 34.5 t -66.69 -14.83 62.98 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.944 0.402 . . . . 0.0 110.642 179.705 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 91.6 m-20 -79.45 -1.13 35.92 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.941 -179.495 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 39.0 m-85 -89.21 -1.77 58.22 Favored 'General case' 0 C--O 1.232 0.163 0 N-CA-C 109.573 -0.529 . . . . 0.0 109.573 179.384 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 66.4 176.31 7.13 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 179.804 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.463 HG13 ' O ' ' A' ' 23' ' ' VAL . 8.1 p -101.54 124.48 55.33 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 N-CA-C 110.105 -0.331 . . . . 0.0 110.105 179.603 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 42.9 pt -100.72 -3.27 9.45 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.714 -179.775 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 172.37 -177.84 44.8 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 53.0 p -132.73 158.51 42.19 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.76 0.314 . . . . 0.0 110.367 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 69.1 mt -112.65 135.47 53.34 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.286 -179.658 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -82.52 160.8 22.53 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 120.933 0.397 . . . . 0.0 110.407 -179.17 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.488 ' ND2' HG13 ' A' ' 7' ' ' VAL . 24.3 m120 -62.53 136.96 58.15 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.021 179.855 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . 0.406 ' OD1' ' O ' ' A' ' 30' ' ' ASN . 15.9 t-20 55.64 36.7 27.72 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.0 179.587 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -84.33 116.57 23.08 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.532 179.753 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -72.72 130.71 41.15 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 120.714 -0.394 . . . . 0.0 110.192 179.613 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.7 m -138.82 162.16 28.97 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.541 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -104.17 123.01 46.53 Favored 'General case' 0 N--CA 1.463 0.218 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 179.551 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.2 mt -90.35 106.25 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.214 -179.642 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.8 mt -66.24 -45.03 90.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.738 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 21.1 ptmt -175.82 170.8 2.77 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.366 -179.501 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -115.34 124.08 50.35 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.401 179.702 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 79.7 t -127.97 133.08 67.99 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.373 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.2 -179.833 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' ASP . . . . . 0.428 ' OD1' ' O ' ' A' ' 40' ' ' ASP . 56.3 t0 56.52 23.02 7.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.901 0.382 . . . . 0.0 110.761 179.666 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 85.22 -6.69 78.69 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 111.249 -0.741 . . . . 0.0 111.249 179.68 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 49.0 m95 -85.85 145.78 27.04 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 109.697 -0.482 . . . . 0.0 109.697 179.31 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -95.75 115.25 27.16 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.977 0.418 . . . . 0.0 110.156 -179.672 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -83.65 122.55 28.76 Favored 'General case' 0 CA--C 1.517 -0.315 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 178.89 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 36.3 pt -128.74 162.42 35.79 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.494 0 CA-C-O 121.388 0.613 . . . . 0.0 111.65 -178.434 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.413 ' HD3' HH11 ' A' ' 46' ' ' ARG . 20.4 ttp180 -124.67 130.05 51.69 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.219 -0.9 . . . . 0.0 109.845 179.789 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 84.1 t80 -149.49 132.71 16.4 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.238 -179.507 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 66.0 t30 55.98 36.15 26.83 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.679 179.534 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 69.84 16.53 72.46 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.949 -0.86 . . . . 0.0 110.949 179.889 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 39.3 tptt -116.16 134.77 54.56 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-O 120.691 0.281 . . . . 0.0 110.285 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 58.5 t -108.89 131.22 60.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.155 -179.619 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -152.06 -156.82 7.65 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.736 -0.946 . . . . 0.0 110.736 -179.893 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 76.0 m-85 -137.75 155.85 48.62 Favored 'General case' 0 N--CA 1.464 0.225 0 CA-C-O 120.885 0.374 . . . . 0.0 110.78 -179.75 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -154.13 160.42 41.91 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.157 -179.709 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.7 p -64.47 151.63 43.82 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.044 -179.526 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 22.9 pttp -84.61 -27.21 27.36 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.665 179.828 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 38.9 t -62.27 -40.67 97.01 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.327 -179.614 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 58.8 m-85 -84.94 2.51 42.53 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.805 -179.027 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 97.6 mt -124.43 129.66 73.81 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.183 179.197 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 91.0 m -115.54 128.45 55.99 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.554 -179.707 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 95.3 mt -83.33 124.4 39.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.925 -0.58 . . . . 0.0 109.884 179.788 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 34.9 m . . . . . 0 N--CA 1.463 0.202 0 CA-C-O 120.938 0.399 . . . . 0.0 110.947 -179.511 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 22.6 tpp . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.165 -0.679 . . . . 0.0 109.165 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.487 ' N ' ' CD ' ' A' ' 2' ' ' GLN . 1.4 pm0 -147.04 117.22 7.32 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-O 120.954 0.406 . . . . 0.0 110.538 -179.855 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -88.42 149.8 21.47 Favored Glycine 0 CA--C 1.525 0.68 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 179.66 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 53.9 t -122.05 129.39 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 87.4 t -93.56 126.47 45.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.188 179.752 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 33.1 tptt -118.52 110.8 17.82 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.153 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.48 HG22 ' H ' ' A' ' 9' ' ' SER . 12.5 p -144.42 144.74 22.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.075 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -63.41 -41.23 98.71 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.7 -179.615 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.48 ' H ' HG22 ' A' ' 7' ' ' VAL . 38.6 m -119.06 -75.12 0.58 Allowed 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.985 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -157.87 145.67 18.61 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.386 -179.633 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 60.7 tp -108.98 131.12 55.37 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.138 -179.177 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 10.9 m120 -80.89 145.63 31.22 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.666 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 42.5 ttp -106.81 149.84 26.96 Favored 'General case' 0 N--CA 1.471 0.597 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 179.857 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . 0.687 HH11 ' HA ' ' A' ' 19' ' ' SER . 58.1 mtt-85 -133.5 140.77 47.43 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-O 121.031 0.443 . . . . 0.0 111.768 -176.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 35.8 t -59.16 -41.93 89.55 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.358 -178.364 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -109.6 161.92 12.88 Favored Glycine 0 CA--C 1.53 0.987 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -77.99 73.3 5.78 Favored 'Trans proline' 0 N--CA 1.496 1.663 0 C-N-CA 122.922 2.414 . . . . 0.0 112.044 179.348 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 176.26 160.44 23.59 Favored Glycine 0 CA--C 1.516 0.146 0 N-CA-C 110.013 -1.235 . . . . 0.0 110.013 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.687 ' HA ' HH11 ' A' ' 14' ' ' ARG . 5.4 m -78.88 -16.9 56.44 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 120.457 -0.497 . . . . 0.0 110.54 -179.638 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -64.88 -36.05 83.1 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.971 -179.034 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -59.25 -42.52 91.32 Favored 'General case' 0 C--N 1.329 -0.284 0 C-N-CA 120.851 -0.339 . . . . 0.0 111.423 -178.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 101.86 162.21 26.8 Favored Glycine 0 N--CA 1.468 0.77 0 N-CA-C 111.29 -0.724 . . . . 0.0 111.29 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 7.2 p -77.16 132.79 32.11 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.123 0 CA-C-O 121.018 0.437 . . . . 0.0 111.594 -179.627 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 44.1 pt -113.45 -8.5 12.15 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.302 179.318 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -170.97 175.59 44.62 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.529 -1.029 . . . . 0.0 110.529 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 86.9 m -123.2 132.1 53.92 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-O 120.715 0.293 . . . . 0.0 110.451 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 73.0 mt -109.19 141.96 40.68 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.267 179.767 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.729 ' HG2' HH11 ' A' ' 28' ' ' ARG . 46.0 mtt-85 -95.32 168.06 10.96 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.274 179.383 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 50.7 p-10 -75.27 159.0 32.02 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 178.863 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 77.4 m-20 56.23 31.91 19.31 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.322 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 47.3 t0 -96.37 112.81 24.42 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 116.559 -0.291 . . . . 0.0 110.639 179.336 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 56.3 mtpt -74.06 134.34 42.96 Favored 'General case' 0 C--N 1.329 -0.288 0 C-N-CA 120.601 -0.44 . . . . 0.0 110.075 179.606 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 28.5 m -136.94 162.37 34.51 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.606 -179.81 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -101.82 121.1 41.45 Favored 'General case' 0 C--O 1.233 0.232 0 CA-C-N 116.083 -0.508 . . . . 0.0 109.869 179.618 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.3 mt -88.58 127.81 41.23 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.139 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.396 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 95.8 mt -91.77 -42.76 13.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.576 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 62.0 pttt -174.82 165.04 3.6 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.567 -179.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -113.01 121.87 45.92 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.181 179.594 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 70.1 t -126.73 131.51 71.07 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.65 -179.64 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.418 ' O ' ' OD1' ' A' ' 40' ' ' ASP . 56.6 t0 53.96 31.17 12.94 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.414 179.082 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 85.43 -16.49 39.48 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 111.043 -0.823 . . . . 0.0 111.043 179.694 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 79.9 m95 -83.35 146.14 28.65 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.401 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 58.7 m-85 -101.17 130.19 47.21 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.904 0.383 . . . . 0.0 110.402 179.669 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.526 ' OE1' ' CE1' ' A' ' 53' ' ' TYR . 3.5 tp10 -88.12 118.52 27.75 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 179.207 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 44.7 pt -126.03 161.37 31.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-O 121.334 0.588 . . . . 0.0 110.678 -179.468 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.406 HH11 ' HD3' ' A' ' 46' ' ' ARG . 0.6 OUTLIER -126.88 127.23 44.61 Favored 'General case' 0 CA--C 1.537 0.467 0 CA-C-N 115.397 -0.82 . . . . 0.0 110.041 -178.262 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 32.9 t80 -145.79 133.47 21.03 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.461 -178.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 57.67 33.34 23.12 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.245 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 74.01 8.13 77.72 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 111.514 -0.634 . . . . 0.0 111.514 179.098 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 58.6 mttp -106.98 150.19 26.74 Favored 'General case' 0 N--CA 1.466 0.356 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 53.4 t -116.55 132.56 65.83 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.054 -179.808 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . 0.416 ' O ' ' OE1' ' A' ' 44' ' ' GLU . . . -159.78 -169.46 23.12 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 110.97 -0.852 . . . . 0.0 110.97 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.526 ' CE1' ' OE1' ' A' ' 44' ' ' GLU . 97.8 m-85 -125.39 154.78 41.38 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.799 0.333 . . . . 0.0 110.482 -179.759 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -136.12 151.8 50.17 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.281 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 21.2 m -63.24 145.2 56.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.533 -179.71 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 58.8 pttt -77.53 -24.79 49.89 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.919 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 21.4 m -62.25 -41.27 98.29 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.394 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' TYR . . . . . 0.535 ' C ' HD12 ' A' ' 59' ' ' ILE . 90.2 m-85 -92.65 -2.07 56.38 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 116.552 -0.295 . . . . 0.0 111.635 -178.857 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.535 HD12 ' C ' ' A' ' 58' ' ' TYR . 1.3 mp -113.7 130.03 68.5 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 92.6 m -118.51 127.92 54.09 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.25 179.677 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 25.2 mm -77.36 133.83 29.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.439 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 78.7 t -96.41 131.54 42.95 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.224 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.608 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . 0.416 ' O ' ' N ' ' A' ' 65' ' ' GLY . 51.8 t-20 59.0 51.86 6.84 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.157 179.695 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . 0.649 ' H ' ' CD ' ' A' ' 64' ' ' GLU . 2.0 pm0 -68.52 58.65 0.08 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.759 179.902 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' A' ' 63' ' ' ASN . . . 76.44 18.85 78.82 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.73 -0.948 . . . . 0.0 110.73 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 81.4 p -67.6 156.22 37.31 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.928 0.394 . . . . 0.0 110.573 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.408 ' O ' ' CE1' ' A' ' 69' ' ' HIS . 2.5 pp -148.98 -6.38 0.38 Allowed 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.23 -179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 57.7 mp0 -67.06 135.04 53.04 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.447 179.906 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.475 ' C ' ' CG ' ' A' ' 70' ' ' HIS . 80.0 m80 -119.83 151.85 38.21 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.432 -179.895 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' HIS . . . . . 0.475 ' CG ' ' C ' ' A' ' 69' ' ' HIS . 12.5 p80 38.63 40.41 0.4 Allowed 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.997 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.553 ' CD2' ' H ' ' A' ' 71' ' ' HIS . 9.5 p80 -72.13 144.63 48.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.416 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 79.5 t60 -133.37 131.61 40.26 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.48 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 99.4 m-70 -85.07 135.43 34.0 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.429 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' HIS . . . . . 0.488 ' ND1' ' O ' ' A' ' 74' ' ' HIS . 60.7 t-80 . . . . . 0 C--O 1.22 -0.466 0 CA-C-O 117.972 -1.013 . . . . 0.0 110.552 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 93.6 mtp . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 120.838 0.351 . . . . 0.0 110.355 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 99.2 mm-40 -116.85 120.69 39.29 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.111 -0.495 . . . . 0.0 109.733 179.169 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -91.89 145.0 17.47 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 111.487 -0.645 . . . . 0.0 111.487 -179.471 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 58.8 t -123.62 131.83 72.4 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.451 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 70.6 t -93.28 127.39 45.39 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.249 0 CA-C-O 120.817 0.341 . . . . 0.0 110.607 -179.715 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 53.8 mtmt -126.43 107.1 9.96 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.37 179.703 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 9.8 p -137.96 159.46 33.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.002 -179.853 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 93.9 m-20 -61.26 -41.65 97.27 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.522 -0.308 . . . . 0.0 110.813 -179.291 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 5.2 t -143.68 -51.62 0.33 Allowed 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 120.803 0.335 . . . . 0.0 110.961 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -157.69 144.14 17.78 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.469 -179.659 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 52.3 tp -117.85 132.99 56.37 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 120.864 0.364 . . . . 0.0 110.118 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 99.7 m-20 -76.3 139.23 40.97 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.021 179.672 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 35.6 ttp -100.21 139.11 36.35 Favored 'General case' 0 N--CA 1.465 0.276 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . 0.46 ' HE ' ' HA ' ' A' ' 19' ' ' SER . 84.3 mtt85 -113.27 158.03 21.03 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.858 0.361 . . . . 0.0 110.818 -178.504 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 8.8 m -80.04 -11.53 59.77 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.94 -179.303 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -164.23 -173.01 32.41 Favored Glycine 0 CA--C 1.52 0.406 0 N-CA-C 110.815 -0.914 . . . . 0.0 110.815 179.47 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -82.74 75.82 4.37 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 122.612 2.208 . . . . 0.0 111.667 179.753 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.76 130.9 1.35 Allowed Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 179.722 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.46 ' HA ' ' HE ' ' A' ' 14' ' ' ARG . 80.6 p -70.1 -9.02 54.14 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.666 0.27 . . . . 0.0 110.963 -179.884 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 12.9 m120 -83.55 -0.78 51.82 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.798 -179.876 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 43.0 m-85 -90.98 -2.71 57.66 Favored 'General case' 0 N--CA 1.462 0.167 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.654 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 71.87 -179.34 34.84 Favored Glycine 0 CA--C 1.522 0.52 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.444 HG13 ' O ' ' A' ' 23' ' ' VAL . 14.2 p -108.61 127.04 65.39 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 CA-C-O 120.889 0.376 . . . . 0.0 110.176 179.594 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 26.1 pt -104.49 -3.3 9.67 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 CA-C-O 120.953 0.406 . . . . 0.0 110.717 -179.65 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -179.88 -178.52 48.53 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.865 -0.894 . . . . 0.0 110.865 -179.876 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 44.7 p -133.41 155.97 48.53 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.913 0.387 . . . . 0.0 110.549 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 78.6 mt -122.84 146.99 47.06 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.294 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 66.0 mtm180 -106.42 153.46 22.22 Favored 'General case' 0 CA--C 1.515 -0.368 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.517 179.877 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 50.8 p-10 -60.0 157.02 13.53 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.359 179.667 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 11.2 t-20 64.39 4.27 2.14 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.266 179.718 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 67.2 t0 -79.95 120.75 24.57 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.466 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 31.1 mtmm -101.15 138.18 38.51 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 120.864 0.364 . . . . 0.0 110.445 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 33.5 m -138.32 163.57 28.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.621 -179.723 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -85.34 134.95 34.08 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.479 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 86.6 mt -103.5 128.23 56.82 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.485 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.846 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.783 HD12 ' N ' ' A' ' 36' ' ' ILE . 2.0 mp -91.36 -44.49 14.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.834 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 62.6 pttt -172.52 160.09 4.67 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.648 -179.651 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . 0.473 ' CD ' ' CE1' ' A' ' 43' ' ' TYR . 82.6 tt0 -111.39 127.77 55.77 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.439 -179.866 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 57.5 t -127.91 129.94 69.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.707 179.794 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 53.19 30.83 10.47 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.361 -0.382 . . . . 0.0 111.592 179.137 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.9 -28.37 7.26 Favored Glycine 0 CA--C 1.521 0.427 0 N-CA-C 110.919 -0.873 . . . . 0.0 110.919 179.655 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 58.6 m95 -71.7 142.36 49.83 Favored 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 120.865 -0.334 . . . . 0.0 110.11 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . 0.473 ' CE1' ' CD ' ' A' ' 38' ' ' GLU . 59.9 m-85 -102.94 133.01 48.76 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.379 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 75.1 tt0 -91.79 121.36 33.34 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.308 179.414 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 46.2 pt -125.53 160.08 32.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.526 -0.306 . . . . 0.0 110.977 -179.124 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 22.0 ttt180 -120.54 126.95 51.63 Favored 'General case' 0 CA--C 1.54 0.566 0 CA-C-N 115.896 -0.593 . . . . 0.0 109.698 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.43 ' O ' ' CG ' ' A' ' 48' ' ' ASN . 32.7 t80 -145.09 145.39 31.4 Favored 'General case' 0 N--CA 1.473 0.676 0 O-C-N 123.04 0.212 . . . . 0.0 110.471 -178.353 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.43 ' CG ' ' O ' ' A' ' 47' ' ' PHE . 10.1 p30 51.52 25.74 2.88 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.109 -179.851 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 77.94 17.5 78.39 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 111.447 -0.661 . . . . 0.0 111.447 179.441 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -124.24 145.65 49.23 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-O 120.82 0.343 . . . . 0.0 110.283 179.675 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 53.2 t -112.14 131.65 62.99 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.317 -179.691 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -150.21 -164.17 11.67 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.478 -1.049 . . . . 0.0 110.478 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 55.3 m-85 -132.3 152.16 51.51 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 120.841 0.353 . . . . 0.0 110.695 -179.692 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -141.49 157.37 45.22 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.509 -179.581 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 38.1 t -61.19 139.8 58.05 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.226 -179.475 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -83.96 -12.94 54.58 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.691 179.807 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 37.3 m -70.6 -21.06 62.7 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.22 -179.28 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -115.74 4.43 14.01 Favored 'General case' 0 N--CA 1.47 0.562 0 CA-C-O 120.624 0.249 . . . . 0.0 111.131 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 97.1 mt -125.42 129.62 72.92 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 CA-C-O 120.879 0.371 . . . . 0.0 110.763 179.693 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 85.0 m -127.96 132.36 49.23 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.836 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.42 HD11 ' CE1' ' A' ' 43' ' ' TYR . 96.1 mt -80.79 128.32 38.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.359 179.583 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.425 ' O ' ' CB ' ' A' ' 63' ' ' ASN . 22.1 m -102.92 146.22 11.12 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.693 -179.876 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . 0.425 ' CB ' ' O ' ' A' ' 62' ' ' VAL . 3.1 t-20 79.83 -145.11 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.303 179.823 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 13.7 pt-20 -46.14 141.39 3.35 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.942 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 151.01 13.62 0.08 OUTLIER Glycine 0 CA--C 1.526 0.731 0 N-CA-C 111.224 -0.75 . . . . 0.0 111.224 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 73.7 m -157.79 169.55 24.37 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 110.027 -0.36 . . . . 0.0 110.027 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.506 HD13 ' N ' ' A' ' 68' ' ' GLU . 0.3 OUTLIER -89.05 114.08 25.26 Favored 'General case' 0 C--N 1.331 -0.2 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 -179.302 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.506 ' N ' HD13 ' A' ' 67' ' ' LEU . 45.7 tt0 -74.87 151.32 38.98 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.433 -179.541 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 7.8 p80 -123.34 147.83 46.64 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.087 179.751 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' HIS . . . . . . . . . . . . . 51.7 p-80 -150.7 166.48 30.27 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-O 120.773 0.32 . . . . 0.0 110.628 -179.752 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 79.1 m80 -69.6 145.43 52.52 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.754 -179.479 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 52.7 p-80 -81.33 2.98 25.84 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.848 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 60.4 t-80 -65.25 -42.2 93.53 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.729 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 69.6 m80 . . . . . 0 C--O 1.22 -0.456 0 CA-C-O 117.98 -1.009 . . . . 0.0 110.5 -179.705 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.442 ' N ' ' NE2' ' A' ' 2' ' ' GLN . 26.8 ttt . . . . . 0 N--CA 1.49 1.53 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.442 ' NE2' ' N ' ' A' ' 1' ' ' MET . 24.5 mp0 -136.37 117.27 14.19 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.567 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -90.68 171.0 35.7 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 179.49 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 53.3 t -124.71 130.12 73.48 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.541 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 59.7 t -91.0 127.24 43.54 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.259 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 59.9 mttp -121.79 110.57 16.07 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 120.841 0.353 . . . . 0.0 110.089 179.634 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.428 HG22 ' CD1' ' A' ' 58' ' ' TYR . 72.4 t -126.69 138.29 55.23 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.185 -179.317 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.422 ' OD1' ' O ' ' A' ' 8' ' ' ASN . 56.5 t-20 -62.73 -41.6 99.25 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.345 -179.192 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 21.6 m -130.87 -76.73 0.53 Allowed 'General case' 0 N--CA 1.468 0.433 0 CA-C-O 120.776 0.322 . . . . 0.0 110.806 -179.552 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -151.93 140.61 20.83 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.818 -179.696 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.429 HD22 ' CG ' ' A' ' 58' ' ' TYR . 53.8 tp -123.17 133.22 54.26 Favored 'General case' 0 N--CA 1.469 0.488 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.203 179.8 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . 0.431 ' HB2' HH12 ' A' ' 14' ' ' ARG . 99.5 m-20 -81.7 140.08 34.54 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.977 179.755 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' MET . . . . . 0.474 ' SD ' HD11 ' A' ' 24' ' ' ILE . 7.3 tmm? -91.31 136.29 33.21 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-O 121.257 0.551 . . . . 0.0 110.37 -179.882 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . 0.431 HH12 ' HB2' ' A' ' 12' ' ' ASN . 4.0 mmt-85 -105.63 140.61 38.43 Favored 'General case' 0 CA--C 1.542 0.648 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.708 -178.127 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . 0.505 ' OG ' HD13 ' A' ' 24' ' ' ILE . 68.5 m -78.6 -7.44 57.6 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.893 -177.941 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -153.77 -166.04 14.33 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -85.48 -0.68 8.92 Favored 'Trans proline' 0 C--N 1.302 -1.887 0 C-N-CA 122.479 2.119 . . . . 0.0 111.794 -179.768 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -99.12 128.2 9.49 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 110.808 -0.917 . . . . 0.0 110.808 179.503 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 78.5 p -69.64 -14.97 63.09 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.83 0.348 . . . . 0.0 110.622 179.672 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 96.7 m-20 -91.72 14.07 16.34 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.482 -179.368 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 7.9 m-85 -87.26 0.7 54.97 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.879 0.371 . . . . 0.0 110.041 179.853 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 79.47 171.33 41.32 Favored Glycine 0 CA--C 1.524 0.619 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 179.781 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.477 HG13 ' O ' ' A' ' 23' ' ' VAL . 11.3 p -106.99 126.72 63.01 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 CA-C-O 120.728 0.299 . . . . 0.0 110.471 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.505 HD13 ' OG ' ' A' ' 15' ' ' SER . 24.9 pt -106.07 -2.43 9.91 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.475 0 CA-C-O 121.005 0.431 . . . . 0.0 110.552 179.734 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -176.46 -177.15 45.22 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 110.47 -1.052 . . . . 0.0 110.47 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 61.3 p -131.92 153.6 50.1 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-O 121.03 0.443 . . . . 0.0 110.469 179.881 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 83.0 mt -123.6 147.62 47.16 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.402 179.238 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 1.7 mtm180 -124.32 153.84 41.17 Favored 'General case' 0 C--O 1.224 -0.287 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.666 -178.277 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 53.1 p-10 -56.19 165.52 1.01 Allowed 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.35 0.595 . . . . 0.0 112.059 -179.532 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 71.0 m-80 59.29 13.18 2.95 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 114.995 -1.002 . . . . 0.0 111.316 179.579 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 91.3 m-20 -87.86 113.78 23.85 Favored 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 120.844 -0.342 . . . . 0.0 110.451 179.493 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -92.23 129.57 38.15 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.016 0.436 . . . . 0.0 110.441 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.4 m -137.11 161.16 35.77 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.145 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.081 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -89.91 131.09 36.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.298 -179.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.2 mt -97.69 107.71 20.55 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.216 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.435 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 97.5 mt -66.64 -44.21 89.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.925 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 63.2 pttt -173.05 178.9 2.38 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.769 -179.533 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -119.94 123.92 44.71 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.12 179.554 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 62.3 t -126.07 131.68 71.42 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-O 120.974 0.416 . . . . 0.0 110.626 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 54.5 31.39 14.74 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.278 179.361 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.537 ' O ' ' NZ ' ' A' ' 56' ' ' LYS . . . 82.97 -15.91 30.13 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 179.755 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 11.4 m95 -86.08 148.29 25.78 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.708 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 51.5 m-85 -100.91 132.94 46.07 Favored 'General case' 0 C--O 1.233 0.187 0 CA-C-O 121.111 0.482 . . . . 0.0 110.523 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -94.46 127.04 40.11 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.376 -0.829 . . . . 0.0 109.271 179.163 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 43.7 pt -129.22 157.14 42.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 CA-C-O 121.135 0.493 . . . . 0.0 111.784 -178.862 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 31.1 ttp180 -115.6 124.37 50.79 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.719 178.748 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 34.4 t80 -145.14 132.95 21.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.709 -179.466 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 62.2 t30 56.62 32.92 21.86 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.608 179.77 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 71.83 11.87 74.13 Favored Glycine 0 CA--C 1.528 0.875 0 N-CA-C 111.369 -0.693 . . . . 0.0 111.369 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 65.6 mttp -111.62 147.31 35.75 Favored 'General case' 0 N--CA 1.467 0.409 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.755 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 52.9 t -117.44 132.06 68.35 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.067 -179.778 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . 0.418 ' C ' ' CD1' ' A' ' 53' ' ' TYR . . . -156.27 -167.02 16.99 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.491 -1.044 . . . . 0.0 110.491 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.535 ' N ' ' CD1' ' A' ' 53' ' ' TYR . 10.1 m-85 -137.15 154.6 50.21 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-O 120.811 0.338 . . . . 0.0 110.451 -179.486 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -147.05 152.85 39.23 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.322 179.802 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 9.7 p -63.95 142.92 58.23 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.881 0.372 . . . . 0.0 110.753 -179.708 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.537 ' NZ ' ' O ' ' A' ' 41' ' ' GLY . 0.0 OUTLIER -66.24 -12.74 58.08 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.711 -179.358 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 6.1 m -65.06 -15.74 62.69 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.544 -0.298 . . . . 0.0 111.215 -179.515 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' TYR . . . . . 0.429 ' CG ' HD22 ' A' ' 11' ' ' LEU . 95.2 m-85 -117.8 5.67 12.26 Favored 'General case' 0 N--CA 1.472 0.651 0 N-CA-C 111.69 0.256 . . . . 0.0 111.69 -179.737 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 4.2 mp -121.49 130.15 74.9 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 CA-C-O 121.246 0.546 . . . . 0.0 110.154 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 85.5 m -123.91 132.63 53.77 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.197 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.0 mt -72.79 129.22 35.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.169 179.769 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 89.2 t -74.5 134.05 30.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.671 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 57.49 42.11 24.97 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.744 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 11.5 tm-20 -56.67 -37.32 70.66 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.535 -179.75 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -77.11 -121.0 0.19 Allowed Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.635 -0.986 . . . . 0.0 110.635 179.695 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.9 m 56.65 96.65 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.989 0.424 . . . . 0.0 110.744 179.682 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.509 HD22 ' N ' ' A' ' 67' ' ' LEU . 3.9 mm? -62.72 -41.33 99.11 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.956 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.535 ' OE2' ' NE2' ' A' ' 70' ' ' HIS . 43.8 tp10 -159.38 -105.62 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.3 179.843 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 69.7 t60 40.42 85.88 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.264 0 CA-C-O 120.906 0.384 . . . . 0.0 111.088 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' HIS . . . . . 0.535 ' NE2' ' OE2' ' A' ' 68' ' ' GLU . 96.3 m-70 -64.76 -37.57 88.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.996 -179.775 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.427 ' O ' ' O ' ' A' ' 70' ' ' HIS . 53.2 t-80 57.11 120.56 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.138 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 31.0 p80 -153.43 159.64 42.4 Favored 'General case' 0 C--N 1.333 -0.142 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.64 179.712 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.519 ' CG ' ' O ' ' A' ' 73' ' ' HIS . 52.9 p-80 -168.76 94.23 0.33 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.635 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 8.5 p80 . . . . . 0 C--O 1.222 -0.378 0 CA-C-O 117.979 -1.01 . . . . 0.0 110.562 -179.75 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 24.3 ptp . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 98.4 mm-40 -124.07 108.59 12.51 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-O 121.094 0.473 . . . . 0.0 110.148 179.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -100.03 154.27 19.52 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.748 -0.941 . . . . 0.0 110.748 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 64.1 t -124.4 130.85 73.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 179.586 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 88.1 t -88.47 128.41 40.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.62 -179.786 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -127.46 105.51 8.56 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.242 179.606 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 30.9 m -138.89 159.96 30.03 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.254 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.715 179.799 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 11.7 m120 -91.41 -4.05 56.06 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.38 179.698 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 17.4 m -154.39 -166.95 2.48 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.34 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -67.18 143.82 56.35 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.466 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 51.3 tp -117.51 130.62 56.55 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 116.182 -0.463 . . . . 0.0 109.88 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 10.7 m120 -89.22 134.2 34.13 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.439 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 52.1 ttp -105.38 145.96 30.08 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 116.174 -0.466 . . . . 0.0 109.834 179.765 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 93.8 mtt-85 -119.13 159.82 23.25 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-O 120.936 0.398 . . . . 0.0 111.162 -179.554 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 86.2 p -81.67 -5.94 58.56 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.617 -0.72 . . . . 0.0 110.133 179.638 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.433 ' C ' ' H ' ' A' ' 18' ' ' GLY . . . -159.55 167.31 35.13 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 110.625 -0.99 . . . . 0.0 110.625 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo -69.94 12.27 0.36 Allowed 'Trans proline' 0 C--N 1.308 -1.6 0 C-N-CA 121.883 1.722 . . . . 0.0 111.904 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . 0.433 ' H ' ' C ' ' A' ' 16' ' ' GLY . . . -99.4 124.12 8.13 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.861 -0.895 . . . . 0.0 110.861 179.225 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 79.5 p -66.94 -10.21 46.6 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.757 0.313 . . . . 0.0 110.535 179.779 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 55.0 p30 -90.95 6.18 45.7 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.64 -179.284 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 32.4 m-85 -88.5 -10.41 49.06 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.39 179.852 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 75.9 176.75 41.11 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 111.361 -0.696 . . . . 0.0 111.361 179.102 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.499 HG13 ' O ' ' A' ' 23' ' ' VAL . 12.1 p -92.48 127.17 44.82 Favored 'Isoleucine or valine' 0 C--O 1.232 0.151 0 CA-C-O 120.711 0.291 . . . . 0.0 110.528 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 24.5 pt -106.11 -5.02 9.97 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-O 120.872 0.368 . . . . 0.0 110.623 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.6 175.3 47.24 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.808 -0.917 . . . . 0.0 110.808 -179.824 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 73.9 m -125.88 130.36 51.18 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 120.878 0.371 . . . . 0.0 110.463 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 72.8 mt -112.44 142.43 44.99 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.711 179.633 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.774 HH11 ' HG3' ' A' ' 28' ' ' ARG . 71.4 mtm-85 -108.42 164.12 12.61 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-O 121.345 0.593 . . . . 0.0 111.117 -179.551 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.414 ' C ' ' H ' ' A' ' 31' ' ' ASP . 57.1 p30 -67.26 166.84 13.44 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.024 179.803 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 10.0 m120 59.41 3.16 0.37 Allowed 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.098 -179.765 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.461 ' OD2' ' N ' ' A' ' 28' ' ' ARG . 98.3 m-20 -72.66 140.02 47.67 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.987 0.422 . . . . 0.0 110.59 179.37 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 53.4 mttp -107.19 125.78 51.55 Favored 'General case' 0 N--CA 1.476 0.859 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.38 179.017 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.3 m -136.65 162.4 35.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 178.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -100.56 123.89 45.37 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-O 120.835 0.35 . . . . 0.0 110.555 -179.738 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.7 mt -84.68 130.12 36.55 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.128 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.469 179.588 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.5 mt -98.88 -54.86 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.196 -179.603 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 8.7 ttmm -150.64 153.01 34.88 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-O 120.799 0.333 . . . . 0.0 110.974 -179.405 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . 0.448 ' CD ' ' CE1' ' A' ' 43' ' ' TYR . 83.5 tt0 -112.86 122.65 48.28 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.146 179.351 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 62.7 t -130.73 132.88 63.97 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.154 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 53.2 25.46 4.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.011 179.431 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.63 -24.62 25.03 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 179.625 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 33.2 m95 -74.38 144.74 44.24 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.762 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . 0.448 ' CE1' ' CD ' ' A' ' 38' ' ' GLU . 78.3 m-85 -105.98 131.67 53.0 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 120.852 0.358 . . . . 0.0 110.847 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 76.9 tt0 -88.21 123.23 32.63 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.328 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 46.2 pt -126.95 160.66 35.22 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.673 0 CA-C-O 121.594 0.711 . . . . 0.0 110.944 -179.017 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 12.5 ttm180 -122.6 129.46 51.92 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.123 -0.944 . . . . 0.0 110.853 -179.285 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 59.2 t80 -148.69 131.55 16.11 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.257 -179.82 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.411 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 17.1 t-20 57.48 36.74 27.32 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.907 179.518 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 69.64 15.36 70.89 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 179.774 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 35.9 ttmt -117.18 137.22 52.48 Favored 'General case' 0 N--CA 1.466 0.329 0 N-CA-C 110.321 -0.252 . . . . 0.0 110.321 -179.714 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 53.4 t -111.11 131.04 63.43 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.86 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -145.17 -161.94 9.33 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.759 -0.936 . . . . 0.0 110.759 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 81.3 m-85 -138.58 154.21 48.7 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 120.721 0.296 . . . . 0.0 110.396 -179.689 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -145.18 150.54 36.92 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.198 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.448 ' OG ' ' CD2' ' A' ' 58' ' ' TYR . 8.7 p -75.49 153.0 37.79 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.097 0.475 . . . . 0.0 111.434 -179.177 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -65.95 -30.17 70.7 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.63 -0.713 . . . . 0.0 111.609 179.278 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 95.8 p -55.67 -28.95 58.3 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.532 -178.719 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' TYR . . . . . 0.538 ' C ' HD12 ' A' ' 59' ' ' ILE . 19.9 m-85 -108.52 -6.22 16.19 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 111.446 0.165 . . . . 0.0 111.446 -179.709 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.538 HD12 ' C ' ' A' ' 58' ' ' TYR . 1.4 mp -112.68 130.05 67.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 N-CA-C 109.595 -0.521 . . . . 0.0 109.595 -179.764 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 92.8 m -123.63 132.03 53.76 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-N 115.716 -0.674 . . . . 0.0 109.979 179.591 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.3 mt -76.82 131.4 34.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.625 -179.63 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 95.3 t -82.28 132.14 32.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.26 179.641 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . 0.438 ' O ' ' O ' ' A' ' 64' ' ' GLU . 98.3 m-20 57.34 67.91 0.92 Allowed 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.729 -179.646 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . 0.438 ' O ' ' O ' ' A' ' 63' ' ' ASN . 58.3 mp0 -52.57 -170.04 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.538 -179.789 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -67.42 102.03 0.76 Allowed Glycine 0 CA--C 1.526 0.743 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 36.2 t -71.39 146.82 48.49 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.081 0.467 . . . . 0.0 111.003 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 72.6 mt 58.39 177.32 0.06 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.863 179.663 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 52.95 21.17 1.91 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.728 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 55.9 p-80 -82.46 -14.96 54.19 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.888 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' HIS . . . . . 0.557 ' ND1' ' N ' ' A' ' 71' ' ' HIS . 56.3 t-80 48.67 -107.64 0.23 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.46 -0.337 . . . . 0.0 110.833 179.772 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.557 ' N ' ' ND1' ' A' ' 70' ' ' HIS . 56.4 t-80 -148.12 -47.39 0.16 Allowed 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.589 -179.827 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.466 ' CD2' ' CD2' ' A' ' 73' ' ' HIS . 12.8 t60 -154.0 163.72 39.62 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.592 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.466 ' CD2' ' CD2' ' A' ' 72' ' ' HIS . 97.1 m-70 56.91 -178.31 0.05 Allowed 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.009 -179.913 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 76.2 m80 . . . . . 0 C--O 1.22 -0.488 0 CA-C-O 117.938 -1.029 . . . . 0.0 110.675 -179.866 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.45 ' N ' ' NE2' ' A' ' 2' ' ' GLN . 39.7 tpp . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.45 ' NE2' ' N ' ' A' ' 1' ' ' MET . 23.0 mp0 -139.21 109.44 6.46 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.253 179.8 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -85.34 163.73 37.66 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.881 -0.888 . . . . 0.0 110.881 179.803 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 77.3 t -127.1 134.13 66.74 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-O 120.85 0.357 . . . . 0.0 110.131 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 19.8 t -83.15 128.39 38.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.55 179.76 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 68.0 mmtt -123.02 105.5 10.02 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.151 179.652 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.6 m -148.79 157.92 7.07 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.557 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 50.9 p30 -83.96 -9.78 58.43 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.81 179.789 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.473 ' OG ' ' N ' ' A' ' 10' ' ' ALA . 48.4 t -155.24 -165.26 1.97 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.856 0.36 . . . . 0.0 110.722 -179.759 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.473 ' N ' ' OG ' ' A' ' 9' ' ' SER . . . -64.38 143.55 57.82 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.659 -179.858 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 47.3 tp -121.55 133.08 55.01 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-O 120.953 0.406 . . . . 0.0 110.307 179.675 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 99.5 m-20 -82.74 142.47 31.59 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.991 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 49.6 ttp -113.48 148.57 35.72 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.939 179.544 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . 0.81 ' NH2' ' CH2' ' A' ' 42' ' ' TRP . 43.4 mtm180 -121.41 153.87 37.27 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-O 121.117 0.484 . . . . 0.0 111.599 -179.001 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 11.3 t -62.76 -41.83 99.4 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.439 179.748 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -140.99 -164.97 10.13 Favored Glycine 0 N--CA 1.466 0.676 0 N-CA-C 111.382 -0.687 . . . . 0.0 111.382 -179.401 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -85.03 71.41 5.08 Favored 'Trans proline' 0 C--N 1.31 -1.471 0 C-N-CA 122.893 2.395 . . . . 0.0 112.103 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . 0.706 ' H ' ' NH1' ' A' ' 14' ' ' ARG . . . -167.74 120.22 0.89 Allowed Glycine 0 CA--C 1.523 0.545 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 179.654 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 8.9 t -60.95 -9.01 3.6 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.944 0.402 . . . . 0.0 110.326 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 11.8 m120 -89.79 5.55 45.57 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.993 -179.456 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 22.0 m-85 -88.22 -7.94 56.05 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 120.681 0.277 . . . . 0.0 110.377 179.887 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 67.68 179.07 14.02 Favored Glycine 0 CA--C 1.521 0.447 0 N-CA-C 110.84 -0.904 . . . . 0.0 110.84 179.641 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.455 HG13 ' O ' ' A' ' 23' ' ' VAL . 9.3 p -92.18 124.21 44.57 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.183 0 CA-C-O 120.787 0.327 . . . . 0.0 110.704 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 24.4 pt -104.35 -5.52 9.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.802 -179.856 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.65 177.05 47.52 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 111.038 -0.825 . . . . 0.0 111.038 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 91.0 m -126.56 130.47 50.61 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-O 120.853 0.359 . . . . 0.0 110.301 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 72.7 mt -112.38 146.31 38.55 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.22 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 87.0 mtm-85 -115.42 161.51 18.46 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.028 179.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.481 ' C ' ' H ' ' A' ' 31' ' ' ASP . 50.8 p30 -69.13 166.77 17.52 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.929 -179.501 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 56.5 t30 71.03 -27.85 0.18 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.509 179.735 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.481 ' H ' ' C ' ' A' ' 29' ' ' ASN . 33.9 m-20 -67.48 137.6 55.95 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 120.583 -0.447 . . . . 0.0 109.926 179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 18.1 ptpt -104.06 145.81 29.63 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.654 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.0 m -133.91 161.72 40.5 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.266 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.234 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -92.28 132.93 36.3 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.231 -0.44 . . . . 0.0 109.875 179.552 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 5.5 mm -98.89 125.77 52.26 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 CA-C-O 120.947 0.404 . . . . 0.0 110.721 -179.461 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.6 mt -93.14 -46.88 13.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.565 179.828 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 31.6 ttpt -173.03 162.57 4.62 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 120.941 0.4 . . . . 0.0 111.153 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . 0.501 ' OE1' ' CE1' ' A' ' 43' ' ' TYR . 82.2 tt0 -110.54 124.05 51.1 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.034 179.497 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 96.9 t -128.04 131.63 69.31 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.099 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 54.41 29.99 11.97 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.569 178.886 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.69 -11.25 64.68 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 111.254 -0.739 . . . . 0.0 111.254 179.388 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.81 ' CH2' ' NH2' ' A' ' 14' ' ' ARG . 82.8 m95 -89.45 143.25 26.97 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.604 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . 0.501 ' CE1' ' OE1' ' A' ' 38' ' ' GLU . 53.4 m-85 -100.94 130.52 46.95 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.732 0.301 . . . . 0.0 110.654 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -82.54 132.57 35.19 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 179.157 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 43.2 pt -132.67 153.02 37.28 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.241 0 CA-C-O 121.098 0.475 . . . . 0.0 111.236 -179.474 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 60.3 ttp180 -127.6 125.36 40.1 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.515 -0.766 . . . . 0.0 109.923 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.443 ' O ' ' OD1' ' A' ' 48' ' ' ASN . 19.0 t80 -151.4 146.13 25.74 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.886 -179.276 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.443 ' OD1' ' O ' ' A' ' 47' ' ' PHE . 8.2 p-10 47.19 38.2 6.54 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.526 179.723 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 67.62 23.1 73.76 Favored Glycine 0 CA--C 1.522 0.5 0 N-CA-C 111.33 -0.708 . . . . 0.0 111.33 179.085 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 69.4 mmtt -128.33 144.13 51.09 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.825 0.345 . . . . 0.0 110.143 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 75.4 t -113.82 133.29 60.27 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.205 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.158 -179.678 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -153.32 -166.26 14.38 Favored Glycine 0 CA--C 1.521 0.431 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 179.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 45.9 m-85 -136.24 155.88 49.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.837 0.351 . . . . 0.0 110.062 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -137.22 154.97 50.05 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.548 -179.647 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 41.3 t -61.78 142.39 57.32 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.505 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 61.9 pttt -68.24 -31.67 71.31 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.353 -179.601 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 19.8 m -60.92 -41.32 95.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.822 -179.245 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 70.7 m-85 -96.23 11.9 32.85 Favored 'General case' 0 N--CA 1.467 0.411 0 N-CA-C 111.837 0.31 . . . . 0.0 111.837 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 5.4 mm -121.33 129.32 75.72 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 CA-C-O 121.01 0.433 . . . . 0.0 110.503 179.748 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 99.4 m -122.71 127.52 49.36 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.348 179.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.7 mt -83.2 131.16 34.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.568 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 94.3 t -71.43 132.77 32.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.312 -0.403 . . . . 0.0 110.471 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . 0.515 ' CG ' ' H ' ' A' ' 64' ' ' GLU . 6.3 t-20 66.8 -164.75 0.22 Allowed 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.536 -179.803 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . 0.515 ' H ' ' CG ' ' A' ' 63' ' ' ASN . 80.6 mm-40 54.74 102.73 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.466 -179.764 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.47 ' O ' ' N ' ' A' ' 67' ' ' LEU . . . 65.8 -132.18 34.36 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 111.199 -0.76 . . . . 0.0 111.199 179.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 3.2 m 64.82 -62.71 0.19 Allowed 'General case' 0 N--CA 1.462 0.166 0 CA-C-O 120.559 0.218 . . . . 0.0 110.878 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.47 ' N ' ' O ' ' A' ' 65' ' ' GLY . 73.6 mt 56.2 -168.6 0.1 Allowed 'General case' 0 C--N 1.33 -0.249 0 N-CA-C 110.199 -0.297 . . . . 0.0 110.199 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 46.0 tp10 54.87 92.04 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.99 0.424 . . . . 0.0 110.31 -179.753 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.533 ' N ' ' ND1' ' A' ' 69' ' ' HIS . 0.4 OUTLIER -150.56 169.85 20.55 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.105 -179.919 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' HIS . . . . . . . . . . . . . 85.3 m-70 56.92 22.39 7.11 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.503 -179.648 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.415 ' CG ' ' N ' ' A' ' 72' ' ' HIS . 53.6 p-80 -66.16 -38.55 88.35 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.726 -179.921 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.415 ' N ' ' CG ' ' A' ' 71' ' ' HIS . 42.7 t-80 -60.98 -4.66 1.09 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.667 -179.847 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.465 ' O ' ' CG ' ' A' ' 74' ' ' HIS . 96.7 m-70 55.16 -95.39 0.05 OUTLIER 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.642 -179.849 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' HIS . . . . . 0.465 ' CG ' ' O ' ' A' ' 73' ' ' HIS . 80.9 m80 . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 118.095 -0.955 . . . . 0.0 110.715 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 36.0 ttm . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 22.4 mm100 -129.31 116.42 19.07 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.373 179.682 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -87.58 156.94 28.36 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 110.813 -0.915 . . . . 0.0 110.813 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 59.1 t -125.88 132.71 70.39 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.632 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 21.9 t -81.68 128.66 38.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.675 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 71.2 mmtt -115.48 105.84 13.28 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.188 -0.46 . . . . 0.0 109.764 179.512 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.406 HG22 ' N ' ' A' ' 8' ' ' ASN . 12.5 p -145.79 155.88 12.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.535 -179.711 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.406 ' N ' HG22 ' A' ' 7' ' ' VAL . 9.6 m120 -62.56 -41.45 98.92 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.909 -179.426 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 21.5 m -136.59 -57.58 0.74 Allowed 'General case' 0 N--CA 1.466 0.326 0 CA-C-O 120.656 0.265 . . . . 0.0 110.92 -179.77 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -157.65 144.62 18.15 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.8 0.333 . . . . 0.0 110.558 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 44.9 tp -111.83 130.62 55.75 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.463 -179.627 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . 0.4 ' OD1' ' O ' ' A' ' 12' ' ' ASN . 47.3 p-10 -71.95 137.99 47.73 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.701 179.762 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 37.7 ttp -100.45 136.69 39.94 Favored 'General case' 0 N--CA 1.464 0.275 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 179.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . 0.456 ' HE ' ' HA ' ' A' ' 19' ' ' SER . 84.0 mtt85 -107.67 157.52 18.02 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.669 -179.143 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 85.6 p -84.18 -10.34 57.82 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.681 179.795 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -161.99 -171.89 28.68 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 111.161 -0.776 . . . . 0.0 111.161 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_endo -84.02 68.84 6.61 Favored 'Trans proline' 0 C--N 1.309 -1.549 0 C-N-CA 122.815 2.344 . . . . 0.0 111.653 -179.833 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -179.97 134.77 2.3 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.456 ' HA ' ' HE ' ' A' ' 14' ' ' ARG . 15.9 m -76.89 -8.94 58.27 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.724 0.297 . . . . 0.0 111.003 -179.526 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 67.1 t30 -83.59 -1.48 53.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.878 -179.798 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 50.1 m-85 -86.71 -5.93 58.98 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 120.768 0.318 . . . . 0.0 110.294 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 77.18 166.35 25.74 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.92 -0.872 . . . . 0.0 110.92 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.466 HG13 ' O ' ' A' ' 23' ' ' VAL . 14.4 p -95.26 127.25 47.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.731 0.3 . . . . 0.0 110.481 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 25.4 pt -101.89 -5.06 9.23 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.288 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.804 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.76 -177.43 47.37 Favored Glycine 0 CA--C 1.529 0.948 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 62.8 p -134.74 157.99 45.28 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-O 120.885 0.374 . . . . 0.0 111.025 -179.705 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 67.6 mt -124.88 145.06 49.99 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.168 -0.469 . . . . 0.0 109.846 179.804 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 13.8 mtm180 -93.63 173.48 7.67 Favored 'General case' 0 C--O 1.233 0.235 0 CA-C-O 121.262 0.553 . . . . 0.0 110.847 179.863 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.433 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 51.7 p-10 -73.6 144.48 45.96 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.43 -0.804 . . . . 0.0 109.554 178.359 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 12.3 t-20 58.49 34.7 24.15 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.564 -0.289 . . . . 0.0 111.192 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -88.79 112.7 23.52 Favored 'General case' 0 N--CA 1.468 0.44 0 N-CA-C 110.018 -0.364 . . . . 0.0 110.018 179.447 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -75.88 130.37 38.43 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 120.665 -0.414 . . . . 0.0 110.091 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 33.2 m -137.87 163.24 30.46 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-O 120.902 0.382 . . . . 0.0 110.689 -179.696 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -102.28 123.64 46.44 Favored 'General case' 0 N--CA 1.463 0.203 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.265 179.805 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.2 mt -89.06 126.03 42.09 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.169 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.408 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.7 mt -92.91 -47.11 13.91 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.183 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.678 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 32.2 ttpt -168.94 158.0 8.42 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.876 -179.807 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -108.4 120.98 43.98 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.962 179.819 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 77.8 t -126.22 132.31 70.61 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.849 -179.442 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 47.5 t0 58.14 25.92 13.07 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.394 179.056 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.93 -10.69 67.18 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 179.774 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 65.9 m95 -89.56 144.63 25.87 Favored 'General case' 0 C--N 1.331 -0.198 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 179.407 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 79.9 m-85 -97.43 127.91 43.78 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.87 0.367 . . . . 0.0 110.45 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 79.4 tt0 -88.3 126.62 35.27 Favored 'General case' 0 CA--C 1.522 -0.119 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 179.499 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 42.0 pt -132.47 161.48 41.39 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.283 0 CA-C-O 121.011 0.434 . . . . 0.0 111.784 -178.752 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 78.7 ttt-85 -114.64 124.38 51.69 Favored 'General case' 0 N--CA 1.464 0.268 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 178.806 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 45.5 t80 -156.68 146.06 20.55 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.924 0.392 . . . . 0.0 111.191 -179.106 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 54.9 t30 58.76 31.63 21.39 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.356 179.59 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 69.74 18.56 74.2 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 111.704 -0.558 . . . . 0.0 111.704 178.783 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -144.37 152.4 40.65 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 120.825 0.345 . . . . 0.0 110.775 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 3.8 t -85.59 157.99 3.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.176 179.885 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -167.84 -178.2 39.68 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 111.422 -0.671 . . . . 0.0 111.422 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 85.1 m-85 -133.33 153.02 51.94 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 120.734 0.302 . . . . 0.0 110.4 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -139.65 152.32 46.65 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.008 -179.824 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 27.2 t -64.91 142.36 58.46 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.033 -179.796 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 61.3 pttt -66.79 -33.65 76.09 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.461 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 38.9 t -61.69 -42.99 99.67 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.602 -178.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 90.2 m-85 -90.43 4.02 52.19 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.66 -0.245 . . . . 0.0 111.48 -179.115 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 5.8 mm -119.7 127.99 75.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 CA-C-O 120.909 0.385 . . . . 0.0 110.246 179.797 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 94.4 m -123.69 129.75 51.58 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.422 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.0 mt -80.12 131.75 33.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.649 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 93.9 t -69.23 134.43 30.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.14 179.62 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . 0.438 ' OD1' ' O ' ' A' ' 63' ' ' ASN . 9.3 p30 -40.78 97.74 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.257 -0.428 . . . . 0.0 111.19 -179.533 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -68.59 -95.72 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.319 179.781 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -92.63 105.57 3.31 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.733 -0.947 . . . . 0.0 110.733 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 93.9 p -87.56 -7.18 57.86 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.775 0.321 . . . . 0.0 110.523 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.405 ' N ' HD23 ' A' ' 67' ' ' LEU . 0.1 OUTLIER -98.21 -4.95 34.32 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.108 -179.996 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -69.08 148.74 49.58 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.667 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.699 ' CD2' ' H ' ' A' ' 70' ' ' HIS . 69.2 t60 -152.47 -130.77 0.04 OUTLIER 'General case' 0 N--CA 1.463 0.176 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.662 -179.878 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' HIS . . . . . 0.699 ' H ' ' CD2' ' A' ' 69' ' ' HIS . 85.6 t60 47.9 -115.52 0.69 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.674 -179.81 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.641 ' H ' ' CD2' ' A' ' 70' ' ' HIS . 90.4 m-70 39.04 83.83 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.07 -179.735 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 2.5 t-160 -93.21 123.16 36.29 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.365 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 84.5 t60 -117.41 119.83 36.28 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.43 179.895 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 52.1 p-80 . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 118.005 -0.998 . . . . 0.0 110.526 179.995 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 63.7 ttp . . . . . 0 N--CA 1.491 1.586 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 -129.66 128.05 41.79 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.606 -179.866 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -89.44 166.53 33.24 Favored Glycine 0 CA--C 1.522 0.491 0 N-CA-C 110.542 -1.023 . . . . 0.0 110.542 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 56.1 t -124.11 129.33 74.19 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 179.756 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 13.7 t -97.01 110.28 24.69 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.145 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.092 179.795 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 32.0 ttmt -119.11 120.01 35.89 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.162 179.764 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.493 HG22 ' N ' ' A' ' 8' ' ' ASN . 9.3 p -140.59 159.72 24.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.32 -179.884 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.493 ' N ' HG22 ' A' ' 7' ' ' VAL . 28.9 t-20 -60.85 -41.58 96.14 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.352 -178.834 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 5.1 t -130.14 -68.47 0.7 Allowed 'General case' 0 N--CA 1.467 0.419 0 CA-C-O 120.901 0.381 . . . . 0.0 110.563 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -158.11 144.14 17.21 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.997 -0.547 . . . . 0.0 109.948 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 40.0 tp -111.45 129.06 56.15 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-O 120.895 0.378 . . . . 0.0 110.585 -179.525 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 77.2 m-20 -75.69 141.43 42.72 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.413 179.694 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 30.9 ttp -102.73 147.52 26.74 Favored 'General case' 0 N--CA 1.47 0.575 0 CA-C-N 116.701 -0.227 . . . . 0.0 111.14 -179.287 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 76.2 mtt85 -119.54 142.11 48.63 Favored 'General case' 0 CA--C 1.506 -0.74 0 CA-C-O 121.285 0.564 . . . . 0.0 111.934 -178.819 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 78.9 p -66.98 -39.51 87.19 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.079 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -115.4 170.34 13.24 Favored Glycine 0 CA--C 1.527 0.793 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 179.509 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.3 Cg_endo -79.51 58.25 6.87 Favored 'Trans proline' 0 N--CA 1.492 1.425 0 C-N-CA 122.644 2.229 . . . . 0.0 112.175 179.557 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -176.99 149.68 9.73 Favored Glycine 0 CA--C 1.532 1.11 0 C-N-CA 120.938 -0.648 . . . . 0.0 111.756 179.879 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 32.7 t -64.37 -16.14 61.74 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 120.869 0.366 . . . . 0.0 110.888 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -72.67 -7.39 50.17 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.984 -179.536 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 55.9 m-85 -92.52 -6.21 50.15 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-O 120.635 0.255 . . . . 0.0 110.801 -179.877 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 67.03 -175.78 23.28 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 110.978 -0.849 . . . . 0.0 110.978 179.681 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.442 HG13 ' O ' ' A' ' 23' ' ' VAL . 10.9 p -105.29 128.86 58.89 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 CA-C-O 120.81 0.338 . . . . 0.0 110.77 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 41.6 pt -105.94 -6.76 10.07 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.551 179.462 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.39 -177.25 44.31 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 -179.849 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 57.8 p -131.17 155.95 46.14 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-O 120.924 0.392 . . . . 0.0 110.358 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 71.4 mt -123.76 149.48 45.57 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.77 -179.583 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 34.5 ttp85 -113.7 143.17 45.05 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 -179.561 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.432 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 57.2 p30 -46.65 153.38 0.39 Allowed 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.316 0.579 . . . . 0.0 112.263 -179.022 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 63.3 m-20 58.93 31.25 21.14 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.106 -0.952 . . . . 0.0 111.856 179.299 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 29.3 t0 -93.55 118.16 31.0 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-O 120.68 0.276 . . . . 0.0 110.258 179.11 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 29.5 mmtp -72.97 132.37 43.34 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 109.986 -0.375 . . . . 0.0 109.986 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 26.8 m -138.41 160.97 31.54 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.518 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -108.39 120.25 41.87 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.031 179.566 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 95.8 mt -85.46 128.81 38.81 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.155 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.527 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 26.1 mt -93.63 -61.31 2.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.188 -179.742 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 22.0 mtmm -149.31 158.51 44.24 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.747 179.608 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . 0.408 ' CD ' ' CE1' ' A' ' 43' ' ' TYR . 83.9 tt0 -111.35 122.47 47.94 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.049 179.616 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 74.8 t -125.35 130.02 72.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.598 -179.794 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 44.8 t0 52.57 27.29 4.97 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.101 179.333 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.02 -21.92 37.21 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 179.56 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 43.8 m95 -77.32 140.18 39.95 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.76 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . 0.408 ' CE1' ' CD ' ' A' ' 38' ' ' GLU . 71.0 m-85 -99.06 129.97 45.36 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.831 0.348 . . . . 0.0 110.341 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -88.13 120.46 29.51 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 179.413 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 45.6 pt -127.17 158.6 38.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.455 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.075 -179.195 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 16.4 ttm180 -119.95 126.46 50.92 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 116.203 -0.453 . . . . 0.0 109.979 179.61 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 71.7 t80 -145.26 140.93 28.17 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.129 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 12.0 t-20 58.69 33.25 22.94 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.601 -179.873 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 71.34 3.98 55.09 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 179.614 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -107.65 150.32 27.04 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-O 120.685 0.278 . . . . 0.0 110.589 -179.818 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 55.1 t -116.4 131.94 67.46 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.226 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -154.36 -160.1 9.62 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.854 -0.898 . . . . 0.0 110.854 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 78.2 m-85 -132.85 157.5 44.89 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.835 0.35 . . . . 0.0 110.367 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -141.15 151.19 43.67 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.254 179.803 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 19.8 m -64.55 148.13 51.39 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.61 -179.678 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 26.6 pttm -79.36 -20.93 46.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.067 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 78.4 p -66.07 -37.88 86.91 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.465 -179.794 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' TYR . . . . . 0.538 ' C ' HD12 ' A' ' 59' ' ' ILE . 96.6 m-85 -97.03 -1.53 45.23 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 116.68 -0.237 . . . . 0.0 111.567 -179.119 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.538 HD12 ' C ' ' A' ' 58' ' ' TYR . 1.3 mp -113.51 130.86 66.77 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 96.2 m -121.02 127.84 52.12 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.002 179.508 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.3 mt -80.56 129.25 37.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.405 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 94.8 t -63.64 147.8 11.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.964 -179.67 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 8.1 t-20 65.73 37.1 5.9 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.231 -179.877 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 89.3 mt-10 -146.95 -26.03 0.4 Allowed 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.372 179.176 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -71.45 145.1 38.41 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 111.274 -0.73 . . . . 0.0 111.274 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 13.3 m -141.25 18.18 2.25 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 120.841 0.353 . . . . 0.0 110.414 179.759 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.558 HD22 ' N ' ' A' ' 67' ' ' LEU . 3.5 mm? -87.26 -4.11 59.07 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.325 -179.895 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.52 ' N ' ' OE1' ' A' ' 68' ' ' GLU . 56.0 mp0 -82.04 126.74 32.35 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.417 -179.846 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.435 ' O ' ' O ' ' A' ' 70' ' ' HIS . 99.6 m-70 -135.47 119.15 17.11 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.411 -0.358 . . . . 0.0 110.318 179.68 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' HIS . . . . . 0.435 ' O ' ' O ' ' A' ' 69' ' ' HIS . 75.6 m80 46.52 98.65 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.631 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 70.0 m80 -77.53 106.97 9.65 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 120.779 -0.368 . . . . 0.0 110.253 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 60.2 t-80 -66.5 -42.63 87.07 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.458 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 81.1 t60 -74.49 129.98 38.75 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.524 -179.732 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 86.1 t60 . . . . . 0 C--O 1.22 -0.461 0 CA-C-O 117.954 -1.022 . . . . 0.0 110.556 179.794 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 39.2 ttm . . . . . 0 N--CA 1.492 1.652 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 -140.67 115.19 9.44 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 120.959 0.409 . . . . 0.0 110.757 -179.782 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -88.63 162.21 31.52 Favored Glycine 0 CA--C 1.521 0.466 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 179.319 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 95.4 t -125.62 129.2 72.74 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.575 0 CA-C-O 120.985 0.422 . . . . 0.0 110.086 179.759 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 16.3 t -87.05 127.96 40.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.418 -179.748 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 63.6 mttp -124.13 107.56 11.38 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.129 -0.487 . . . . 0.0 109.982 179.634 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.444 HG22 ' H ' ' A' ' 9' ' ' SER . 11.9 p -140.27 151.41 21.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.434 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.63 -179.748 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.532 ' OD1' ' N ' ' A' ' 9' ' ' SER . 30.4 p30 -61.67 -42.64 99.19 Favored 'General case' 0 C--N 1.333 -0.127 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.196 -179.526 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.532 ' N ' ' OD1' ' A' ' 8' ' ' ASN . 8.0 t -125.07 -67.19 0.92 Allowed 'General case' 0 N--CA 1.47 0.541 0 CA-C-O 120.617 0.246 . . . . 0.0 110.94 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -158.24 144.77 17.48 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.777 0.322 . . . . 0.0 110.649 -179.603 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 44.9 tp -106.77 125.98 51.7 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.076 179.681 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -79.53 143.57 34.72 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.438 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 48.4 ttp -109.4 151.46 26.64 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 116.057 -0.519 . . . . 0.0 109.731 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 94.4 mtt-85 -127.63 151.53 48.82 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-O 120.924 0.392 . . . . 0.0 110.313 -179.274 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 35.0 t -62.36 -41.79 98.89 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.818 -179.34 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -124.97 163.16 19.07 Favored Glycine 0 N--CA 1.471 0.985 0 N-CA-C 111.482 -0.647 . . . . 0.0 111.482 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -68.32 86.32 0.42 Allowed 'Trans proline' 0 N--CA 1.496 1.628 0 C-N-CA 122.485 2.123 . . . . 0.0 111.692 179.543 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 164.4 143.31 3.67 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 111.218 -0.753 . . . . 0.0 111.218 179.581 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 75.4 p -66.44 -16.18 63.91 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.851 0.358 . . . . 0.0 110.825 179.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 50.5 p30 -80.64 -2.38 46.3 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.565 -179.542 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 47.0 m-85 -89.7 -7.77 53.85 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-O 120.756 0.312 . . . . 0.0 110.554 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 71.55 168.38 9.37 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 179.553 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 7.5 p -94.77 128.16 46.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 CA-C-O 120.79 0.329 . . . . 0.0 110.537 179.795 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 43.6 pt -108.2 -6.62 10.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.702 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -173.02 169.33 42.49 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 111.325 -0.71 . . . . 0.0 111.325 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 92.1 m -123.3 135.01 54.01 Favored 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 67.9 mt -107.72 155.16 20.5 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-O 120.871 0.367 . . . . 0.0 110.499 -179.559 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 90.2 mtm-85 -105.25 165.75 10.89 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.595 -179.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.402 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 52.6 p-10 -69.53 149.0 48.7 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.181 -179.613 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 21.7 t-20 56.12 32.98 21.13 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 115.91 -0.586 . . . . 0.0 111.014 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -89.92 116.27 27.85 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-O 120.825 0.345 . . . . 0.0 110.645 179.587 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.565 ' HZ3' ' HB3' ' A' ' 32' ' ' LYS . 2.4 mmmp? -71.84 129.39 38.51 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.465 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.9 m -140.18 162.03 25.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.647 -179.496 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -104.89 121.06 42.91 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.353 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 89.3 mt -91.52 108.31 19.8 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.302 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 97.5 mt -67.41 -43.86 87.34 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.046 -0.524 . . . . 0.0 111.006 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 63.7 pttt -173.19 160.82 4.15 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.823 0.344 . . . . 0.0 111.001 -179.369 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -106.93 124.23 49.32 Favored 'General case' 0 N--CA 1.465 0.3 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 179.314 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 73.3 t -127.16 132.15 70.0 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 CA-C-O 120.952 0.406 . . . . 0.0 110.671 -179.436 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.415 ' OD1' ' O ' ' A' ' 40' ' ' ASP . 36.1 t0 56.26 23.86 7.59 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.013 179.246 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.52 -10.02 74.95 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 111.016 -0.834 . . . . 0.0 111.016 179.705 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 34.3 m95 -91.21 149.26 21.85 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-O 120.751 0.31 . . . . 0.0 110.188 179.748 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 52.4 m-85 -99.94 130.84 46.16 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.136 -179.731 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 76.1 tt0 -98.29 120.24 38.36 Favored 'General case' 0 CA--C 1.518 -0.269 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 179.223 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 39.2 pt -126.05 160.21 33.44 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.321 0 CA-C-O 120.969 0.414 . . . . 0.0 110.983 -179.207 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 43.6 ttm180 -117.89 127.85 54.26 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-N 115.694 -0.685 . . . . 0.0 109.503 179.486 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 34.1 t80 -144.77 131.17 19.72 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-O 121.16 0.505 . . . . 0.0 111.11 -179.736 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 6.1 m120 56.93 35.17 26.01 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 115.36 -0.837 . . . . 0.0 112.145 179.3 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 77.23 15.56 81.43 Favored Glycine 0 N--CA 1.465 0.592 0 C-N-CA 121.264 -0.493 . . . . 0.0 111.893 178.531 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -126.0 145.54 50.26 Favored 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 61.5 t -115.55 132.32 65.3 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.302 -179.732 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -149.67 -163.12 10.86 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 62.1 m-85 -132.86 160.27 37.46 Favored 'General case' 0 N--CA 1.466 0.347 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -149.72 159.17 44.57 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.04 0.448 . . . . 0.0 111.061 -179.617 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 18.4 p -69.54 148.89 48.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.696 -0.683 . . . . 0.0 110.304 179.885 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.415 ' O ' ' O ' ' A' ' 59' ' ' ILE . 59.0 pttt -82.59 -19.12 39.04 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.77 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 39.1 t -62.07 -42.39 99.15 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.954 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 90.5 m-85 -92.19 3.81 54.55 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.336 -179.171 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.415 ' O ' ' O ' ' A' ' 56' ' ' LYS . 98.1 mt -128.51 132.25 68.12 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 CA-C-O 120.699 0.285 . . . . 0.0 110.351 179.601 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 99.3 m -123.15 132.12 53.95 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.465 179.732 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 27.0 mm -80.45 129.46 37.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.063 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 35.7 m -112.59 131.6 63.67 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 CA-C-O 120.954 0.407 . . . . 0.0 110.427 -179.687 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 53.5 t-20 61.69 91.42 0.06 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.592 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -56.64 142.15 40.88 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.127 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -73.29 119.72 6.79 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 111.352 -0.699 . . . . 0.0 111.352 -179.429 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 43.6 t -75.55 150.37 38.13 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.787 0.327 . . . . 0.0 110.312 179.602 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.536 ' N ' HD12 ' A' ' 67' ' ' LEU . 10.3 mp -83.79 -5.88 59.3 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.702 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 54.31 92.19 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 -179.561 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 79.5 m80 -93.76 17.83 11.29 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.42 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' HIS . . . . . . . . . . . . . 82.2 t60 -52.96 -13.12 0.39 Allowed 'General case' 0 C--N 1.332 -0.196 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.472 -179.669 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 58.9 t-80 -74.18 136.49 42.84 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.966 0.412 . . . . 0.0 111.233 -179.823 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 41.1 p-80 -141.85 124.98 16.32 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.336 179.632 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 49.8 p-80 -85.68 -17.08 37.02 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.288 179.794 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 86.4 t60 . . . . . 0 C--O 1.222 -0.384 0 CA-C-O 117.952 -1.023 . . . . 0.0 110.807 -179.759 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 36.5 ttm . . . . . 0 N--CA 1.49 1.535 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 58.0 tt0 -134.64 121.93 21.55 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-O 120.858 0.361 . . . . 0.0 110.231 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -93.16 155.2 22.22 Favored Glycine 0 CA--C 1.524 0.626 0 N-CA-C 111.054 -0.819 . . . . 0.0 111.054 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 59.9 t -128.01 132.14 68.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.698 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 18.0 t -88.74 127.74 41.38 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.087 179.694 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 64.7 mttp -124.57 105.81 9.65 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-O 120.912 0.386 . . . . 0.0 110.537 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 7.1 p -157.15 148.83 10.53 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-N 115.943 -0.572 . . . . 0.0 110.604 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.42 ' O ' ' ND2' ' A' ' 29' ' ' ASN . 7.7 m120 -68.54 -50.84 48.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.937 0.399 . . . . 0.0 110.554 179.452 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 9.2 p -95.88 165.53 12.23 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.564 179.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -65.88 144.39 56.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.354 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 45.1 tp -111.22 132.78 54.07 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-O 120.972 0.415 . . . . 0.0 110.67 -179.794 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 6.2 m120 -78.02 146.26 35.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.892 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 40.0 ttp -98.11 148.66 23.32 Favored 'General case' 0 C--O 1.233 0.201 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.616 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 84.9 mtt85 -123.32 157.75 32.55 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 120.715 0.293 . . . . 0.0 110.493 -179.23 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . 0.508 ' N ' HD11 ' A' ' 24' ' ' ILE . 88.5 p -84.11 -13.11 53.84 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.972 -179.321 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -162.31 -172.58 29.92 Favored Glycine 0 CA--C 1.529 0.952 0 C-N-CA 120.846 -0.692 . . . . 0.0 111.388 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -80.0 78.95 3.49 Favored 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.771 2.314 . . . . 0.0 112.143 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 167.4 134.12 1.65 Allowed Glycine 0 CA--C 1.524 0.603 0 C-N-CA 120.68 -0.771 . . . . 0.0 111.448 179.713 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 95.7 p -71.2 -12.3 61.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.95 0.405 . . . . 0.0 110.215 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 52.1 p-10 -78.91 -4.63 50.72 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.692 -179.822 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -85.85 -1.62 57.44 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.291 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 71.6 178.5 29.75 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 110.724 -0.95 . . . . 0.0 110.724 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 9.2 p -107.4 134.52 48.89 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.37 0 CA-C-O 120.861 0.362 . . . . 0.0 110.474 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.508 HD11 ' N ' ' A' ' 15' ' ' SER . 3.5 mp -106.0 -12.01 9.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.52 -179.758 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -173.55 -170.66 37.3 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 110.8 -0.92 . . . . 0.0 110.8 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 82.0 p -131.84 152.21 51.16 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 120.737 0.303 . . . . 0.0 110.302 179.846 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 78.5 mt -122.7 146.29 47.63 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.07 -0.514 . . . . 0.0 109.841 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -106.84 164.52 12.04 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.877 -179.364 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.42 ' ND2' ' O ' ' A' ' 8' ' ' ASN . 2.9 m-20 -64.07 148.93 48.66 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.671 -179.836 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 58.96 32.71 22.51 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.324 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 16.5 m-20 -82.0 137.38 35.12 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.113 179.02 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 63.3 mttp -104.99 122.73 46.46 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.858 0.361 . . . . 0.0 110.317 179.55 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.6 m -138.69 161.61 29.95 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.185 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.12 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -99.03 132.74 44.11 Favored 'General case' 0 C--O 1.234 0.287 0 N-CA-C 109.727 -0.472 . . . . 0.0 109.727 179.689 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.2 mt -100.71 107.5 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.309 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.8 mt -66.55 -43.87 90.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.89 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 63.6 pttt -173.05 169.98 4.52 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.829 -179.41 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . 0.429 ' CD ' ' CE1' ' A' ' 43' ' ' TYR . 83.1 tt0 -111.91 126.29 54.96 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.646 179.591 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 76.3 t -126.79 131.91 70.61 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 CA-C-O 121.07 0.462 . . . . 0.0 111.133 -179.438 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 52.65 30.42 8.68 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.661 -0.7 . . . . 0.0 111.759 178.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.14 -18.02 47.66 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 111.651 -0.58 . . . . 0.0 111.651 179.204 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 40.3 m95 -85.95 145.23 27.23 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.845 0.355 . . . . 0.0 110.244 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . 0.429 ' CE1' ' CD ' ' A' ' 38' ' ' GLU . 72.7 m-85 -100.75 126.99 47.34 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.481 -179.642 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 79.2 tt0 -78.54 152.42 31.95 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 179.715 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.4 pt -144.04 153.36 15.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.679 0.276 . . . . 0.0 110.854 -179.702 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 76.3 ttt180 -121.16 123.32 42.0 Favored 'General case' 0 N--CA 1.468 0.454 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 179.265 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 74.5 t80 -142.08 125.8 16.96 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-O 120.884 0.373 . . . . 0.0 110.885 -179.444 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 17.0 t-20 54.8 35.97 25.37 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.999 179.766 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 73.01 15.19 78.52 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 111.145 -0.782 . . . . 0.0 111.145 179.521 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.9 ttmp? -112.43 147.93 35.42 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 110.228 -0.286 . . . . 0.0 110.228 179.771 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.0 t -110.2 132.85 57.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.933 0.397 . . . . 0.0 110.32 -179.785 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . 0.467 ' C ' ' CD1' ' A' ' 53' ' ' TYR . . . -148.63 -165.02 11.84 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 179.823 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.467 ' CD1' ' C ' ' A' ' 52' ' ' GLY . 72.9 m-85 -146.46 157.81 43.81 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.729 0.299 . . . . 0.0 110.456 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -141.63 155.72 45.7 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.398 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.403 ' O ' ' CG1' ' A' ' 59' ' ' ILE . 18.1 m -69.41 147.87 50.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.031 -179.623 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 62.0 pttt -66.34 -34.69 78.53 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.233 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 37.1 m -61.56 -41.11 96.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.706 -179.205 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 89.1 m-85 -94.22 7.64 44.57 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 116.518 -0.31 . . . . 0.0 111.002 -179.285 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.403 ' CG1' ' O ' ' A' ' 55' ' ' SER . 5.3 mm -122.4 128.77 75.54 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-O 121.119 0.485 . . . . 0.0 110.293 179.637 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 86.8 m -122.56 126.89 48.67 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.512 -179.9 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.439 HG21 ' OE1' ' A' ' 64' ' ' GLU . 96.6 mt -91.22 127.9 43.32 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.497 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 33.2 m -80.36 148.29 5.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.437 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 13.6 m120 60.45 35.9 20.3 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.67 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . 0.439 ' OE1' HG21 ' A' ' 61' ' ' ILE . 39.8 tp10 -85.33 -17.76 35.86 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-O 120.968 0.413 . . . . 0.0 110.459 -179.716 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 165.77 23.26 0.02 OUTLIER Glycine 0 CA--C 1.526 0.739 0 N-CA-C 111.12 -0.792 . . . . 0.0 111.12 179.641 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 1.3 t 51.43 83.36 0.05 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.797 0.332 . . . . 0.0 110.578 179.915 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 77.0 mt -73.49 148.41 43.16 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.354 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 51.0 tp10 -52.14 142.32 16.66 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.926 -179.437 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.446 ' O ' ' O ' ' A' ' 70' ' ' HIS . 95.3 m-70 -76.95 136.05 38.76 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.609 179.704 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' HIS . . . . . 0.446 ' O ' ' O ' ' A' ' 69' ' ' HIS . 80.0 m80 45.02 -173.66 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.677 -179.648 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 98.7 m-70 -141.86 140.75 32.99 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.53 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -141.62 145.26 34.8 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.023 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 79.4 m80 -110.49 139.46 45.7 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.689 -179.796 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 77.9 m80 . . . . . 0 C--O 1.221 -0.443 0 CA-C-O 118.002 -0.999 . . . . 0.0 110.433 179.998 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 7.9 ttt . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 27.0 mt-30 -136.11 116.55 13.71 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.131 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -84.69 164.88 39.81 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 -179.605 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 57.2 t -123.91 133.62 68.76 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.394 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 72.4 t -100.88 127.85 53.62 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-O 120.876 0.37 . . . . 0.0 110.314 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 68.8 mmtt -119.58 106.41 12.17 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.559 179.423 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.495 ' O ' ' ND2' ' A' ' 29' ' ' ASN . 28.0 m -131.41 160.05 42.62 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.302 -179.456 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 52.8 t-20 -63.59 -41.67 98.34 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.097 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 4.3 t -150.7 -53.33 0.14 Allowed 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.464 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -157.64 142.88 16.96 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.422 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.473 HD22 ' CG ' ' A' ' 58' ' ' TYR . 65.1 tp -125.46 135.68 52.59 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 116.1 -0.5 . . . . 0.0 109.92 -179.802 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 13.7 m120 -77.93 138.83 39.09 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.197 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 50.5 ttp -98.11 138.59 35.18 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.074 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . 0.491 ' HE ' ' HA ' ' A' ' 19' ' ' SER . 22.0 mmt180 -103.9 156.96 17.42 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.517 -178.675 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . 0.421 ' OG ' HG21 ' A' ' 24' ' ' ILE . 4.6 m -83.07 -7.68 59.62 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.76 -179.636 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -159.23 -169.63 22.8 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -83.24 72.21 5.82 Favored 'Trans proline' 0 C--N 1.304 -1.777 0 C-N-CA 122.659 2.239 . . . . 0.0 111.857 -179.755 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 174.78 147.81 6.34 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 111.104 -0.799 . . . . 0.0 111.104 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.491 ' HA ' ' HE ' ' A' ' 14' ' ' ARG . 15.7 m -81.47 -11.64 59.15 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.948 0.404 . . . . 0.0 110.728 -179.82 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 28.6 t-20 -84.14 7.06 20.09 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.979 -179.693 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 49.9 m-85 -92.71 -0.23 57.32 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 120.772 0.32 . . . . 0.0 110.414 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 75.62 179.22 44.61 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.451 HG13 ' O ' ' A' ' 23' ' ' VAL . 7.2 p -108.84 125.31 65.85 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-O 120.826 0.345 . . . . 0.0 110.621 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.421 HG21 ' OG ' ' A' ' 15' ' ' SER . 41.2 pt -108.66 -4.51 10.58 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.809 179.852 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -172.96 170.76 43.9 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 111.116 -0.793 . . . . 0.0 111.116 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 86.4 m -128.64 138.02 51.96 Favored 'General case' 0 N--CA 1.472 0.635 0 CA-C-O 120.494 0.187 . . . . 0.0 110.541 -179.673 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 77.4 mt -110.18 143.7 39.92 Favored 'General case' 0 N--CA 1.476 0.844 0 N-CA-C 112.12 0.415 . . . . 0.0 112.12 -178.793 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 49.2 mtt-85 -105.24 167.76 9.52 Favored 'General case' 0 N--CA 1.477 0.88 0 CA-C-O 121.773 0.797 . . . . 0.0 111.812 -179.079 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.495 ' ND2' ' O ' ' A' ' 7' ' ' VAL . 1.3 m-20 -64.32 146.17 54.83 Favored 'General case' 0 N--CA 1.437 -1.107 0 CA-C-N 114.993 -1.003 . . . . 0.0 108.976 -179.055 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 15.5 m120 57.07 34.41 24.86 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.287 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 67.1 t0 -88.27 110.39 20.7 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 110.016 -0.364 . . . . 0.0 110.016 179.329 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -78.61 132.67 37.19 Favored 'General case' 0 C--N 1.331 -0.212 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 -179.811 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 28.9 m -139.88 162.05 25.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.657 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -99.89 131.55 45.79 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.19 -0.459 . . . . 0.0 109.811 179.393 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 86.7 mt -96.65 126.77 49.26 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-N 116.33 -0.396 . . . . 0.0 111.022 -179.245 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 18.5 mm -94.71 -62.97 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.427 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 22.2 mtmm -148.33 159.78 43.65 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 120.918 0.39 . . . . 0.0 111.018 179.756 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -111.81 123.34 50.03 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.339 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 72.0 t -127.47 132.47 69.29 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.604 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 55.23 30.7 15.1 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.143 179.25 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 84.5 -16.6 34.3 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 111.02 -0.832 . . . . 0.0 111.02 179.711 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.616 ' CZ2' ' OG ' ' A' ' 55' ' ' SER . 11.7 m95 -83.58 147.37 27.78 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 179.423 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 46.2 m-85 -100.83 130.34 46.84 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 121.047 0.451 . . . . 0.0 110.941 -179.609 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -87.1 122.74 31.33 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 178.805 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 39.1 pt -130.59 161.62 40.12 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.407 0 CA-C-O 121.176 0.512 . . . . 0.0 111.537 -178.601 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 13.6 ttt180 -118.7 123.66 45.44 Favored 'General case' 0 N--CA 1.464 0.275 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.332 179.432 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 87.4 t80 -144.39 135.97 25.74 Favored 'General case' 0 N--CA 1.473 0.713 0 CA-C-O 120.824 0.345 . . . . 0.0 111.322 -178.401 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.438 ' OD1' ' O ' ' A' ' 48' ' ' ASN . 17.6 t-20 57.51 34.84 25.14 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.7 179.347 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 69.45 18.46 73.56 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 179.77 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -124.67 146.14 49.29 Favored 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 66.5 t -113.99 131.56 65.56 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.389 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . 0.405 ' C ' ' CD1' ' A' ' 53' ' ' TYR . . . -150.47 -164.6 12.02 Favored Glycine 0 CA--C 1.52 0.39 0 N-CA-C 110.664 -0.974 . . . . 0.0 110.664 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.427 ' N ' ' CD1' ' A' ' 53' ' ' TYR . 28.4 m-85 -134.96 156.71 48.54 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.796 0.332 . . . . 0.0 110.54 -179.737 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -146.67 150.6 35.73 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.028 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . 0.616 ' OG ' ' CZ2' ' A' ' 42' ' ' TRP . 37.8 m -70.39 142.0 52.13 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 177.81 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 64.4 pttt -68.2 -13.07 61.96 Favored 'General case' 0 CA--C 1.51 -0.578 0 CA-C-O 121.8 0.809 . . . . 0.0 108.847 178.84 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 87.8 p -56.29 -14.0 2.55 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 114.015 -1.448 . . . . 0.0 109.321 178.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' TYR . . . . . 0.473 ' CG ' HD22 ' A' ' 11' ' ' LEU . 91.7 m-85 -127.16 -28.26 2.88 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.202 179.816 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.593 ' N ' HD12 ' A' ' 59' ' ' ILE . 1.3 mp -90.1 129.29 41.21 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 179.162 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 87.5 m -123.81 129.34 50.89 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.388 -179.881 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.741 HD12 ' N ' ' A' ' 61' ' ' ILE . 1.7 mp -83.0 128.14 39.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.286 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.421 ' O ' ' O ' ' A' ' 63' ' ' ASN . 15.7 m -83.45 138.36 19.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.319 179.807 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . 0.477 ' CG ' ' H ' ' A' ' 64' ' ' GLU . 6.9 t-20 45.33 -172.17 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.743 -179.769 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . 0.477 ' H ' ' CG ' ' A' ' 63' ' ' ASN . 4.3 tm-20 66.25 69.32 0.43 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.424 -179.77 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -90.18 -72.8 1.26 Allowed Glycine 0 CA--C 1.525 0.69 0 N-CA-C 110.67 -0.972 . . . . 0.0 110.67 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 82.3 p -75.52 161.8 28.86 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 179.815 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 41.1 tp -77.41 126.75 31.4 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.975 0.417 . . . . 0.0 110.798 -179.713 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -83.91 150.72 25.51 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.171 179.584 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 98.7 m-70 -105.44 128.31 53.46 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.328 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' HIS . . . . . . . . . . . . . 59.0 t-80 -85.94 122.62 30.25 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.728 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 98.7 m-70 -91.32 144.32 25.72 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.486 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 56.6 p-80 -67.82 139.7 56.59 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.661 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 85.2 t60 -83.56 126.2 32.58 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.512 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 79.7 m80 . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 118.008 -0.996 . . . . 0.0 110.786 -179.996 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 39.0 tpp . . . . . 0 N--CA 1.49 1.575 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 78.2 mt-30 -142.81 108.34 5.07 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.204 179.747 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -87.18 158.1 29.91 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 97.7 t -127.65 133.3 67.93 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 179.703 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 71.9 t -93.33 128.2 44.92 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-N 116.46 -0.337 . . . . 0.0 110.392 -179.884 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 65.5 mttp -132.02 107.01 8.38 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.453 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.512 HG22 ' H ' ' A' ' 9' ' ' SER . 4.0 p -138.79 154.03 26.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.162 -179.897 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 92.1 m-20 -62.06 -42.85 99.62 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-O 120.83 0.348 . . . . 0.0 111.235 -178.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.512 ' H ' HG22 ' A' ' 7' ' ' VAL . 85.2 p -136.76 -153.84 0.52 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.035 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -66.98 143.15 56.97 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.017 0.437 . . . . 0.0 110.545 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.401 HD22 ' CG ' ' A' ' 58' ' ' TYR . 47.2 tp -122.0 130.46 53.32 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.062 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . 0.425 ' OD1' ' O ' ' A' ' 12' ' ' ASN . 45.1 p30 -82.12 140.53 33.76 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.693 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 58.1 ttp -108.33 138.65 44.25 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.215 -0.448 . . . . 0.0 109.869 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 4.3 mpt_? -106.45 157.37 17.69 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 120.983 0.42 . . . . 0.0 111.233 -178.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 84.2 p -82.27 -6.22 59.08 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.243 179.732 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -162.36 -174.86 32.76 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.765 -0.934 . . . . 0.0 110.765 179.762 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -80.94 79.09 3.41 Favored 'Trans proline' 0 C--N 1.306 -1.692 0 C-N-CA 122.86 2.373 . . . . 0.0 111.926 179.766 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 171.03 137.17 2.24 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 94.9 p -74.64 -7.7 54.04 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.764 0.316 . . . . 0.0 110.857 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 12.0 m120 -89.01 5.6 43.54 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.069 -179.414 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 42.7 m-85 -91.31 -0.56 57.68 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.869 0.366 . . . . 0.0 110.208 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 73.28 174.43 27.89 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.48 HG13 ' O ' ' A' ' 23' ' ' VAL . 11.7 p -105.64 125.34 60.99 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-O 120.894 0.378 . . . . 0.0 110.412 179.743 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 40.8 pt -101.81 -4.75 9.26 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.758 -179.855 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -174.3 174.08 46.29 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 89.7 m -125.17 132.21 53.09 Favored 'General case' 0 N--CA 1.464 0.226 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.627 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 72.1 mt -108.09 143.93 36.16 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 116.194 -0.457 . . . . 0.0 109.968 -179.759 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 37.8 ttt85 -119.51 142.62 48.15 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.171 0.51 . . . . 0.0 110.26 179.42 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 44.0 p-10 -48.26 165.09 0.04 OUTLIER 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.65 -0.704 . . . . 0.0 111.0 -179.766 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 65.8 t30 62.8 6.48 2.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.554 -0.748 . . . . 0.0 111.366 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 31.5 t0 -87.13 118.68 26.68 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.548 -0.297 . . . . 0.0 110.663 179.517 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -76.3 137.39 39.86 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.2 179.471 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.2 m -137.39 162.05 33.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.62 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 48.4 tp10 -105.84 123.65 48.3 Favored 'General case' 0 C--O 1.234 0.274 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 179.581 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.5 mt -91.38 127.8 43.52 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.123 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.94 -179.355 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 81.9 mt -91.4 -51.27 11.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.176 179.597 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 62.6 pttt -174.9 179.0 1.71 Allowed 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.558 179.705 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -112.84 125.06 53.95 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.219 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.408 HG21 ' OE2' ' A' ' 44' ' ' GLU . 79.5 t -124.93 129.74 73.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.28 -179.859 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.44 ' OD1' ' O ' ' A' ' 40' ' ' ASP . 55.2 t0 54.74 24.28 5.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.071 179.362 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 86.86 -5.62 84.66 Favored Glycine 0 CA--C 1.526 0.753 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 179.739 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 56.4 m95 -90.52 149.38 22.2 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 179.364 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -96.88 130.35 44.18 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-O 121.098 0.475 . . . . 0.0 110.137 -179.669 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.408 ' OE2' HG21 ' A' ' 39' ' ' VAL . 97.4 mt-10 -94.47 126.51 39.79 Favored 'General case' 0 CA--C 1.506 -0.714 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.018 179.369 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 44.3 pt -125.93 160.76 32.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 121.356 0.598 . . . . 0.0 110.249 179.626 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 3.2 ttp180 -126.89 113.89 17.14 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 114.777 -1.101 . . . . 0.0 109.624 -176.763 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 61.8 t80 -141.51 139.1 33.2 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 120.947 0.403 . . . . 0.0 111.605 -178.111 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 15.0 t-20 57.13 34.62 25.15 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.904 179.298 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 69.74 20.71 76.08 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 111.431 -0.668 . . . . 0.0 111.431 179.52 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 53.9 mtmt -131.23 143.58 50.68 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-O 120.688 0.28 . . . . 0.0 110.823 -179.81 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 19.8 t -102.26 111.8 33.29 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 CA-C-O 121.115 0.483 . . . . 0.0 110.656 179.535 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -107.55 -172.69 22.17 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 111.053 -0.819 . . . . 0.0 111.053 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 48.1 m-85 -132.3 142.36 49.33 Favored 'General case' 0 C--N 1.331 -0.233 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 179.624 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -154.29 153.0 30.93 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.404 -179.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 48.5 t -70.1 148.15 49.1 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.787 -179.887 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 63.9 pttt -64.2 -17.65 63.75 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.73 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 38.6 t -65.7 -18.22 65.17 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.395 -179.669 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' TYR . . . . . 0.6 ' C ' HD12 ' A' ' 59' ' ' ILE . 71.7 m-85 -105.73 -19.16 13.84 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 121.271 -0.172 . . . . 0.0 111.323 -179.554 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.64 ' N ' HD12 ' A' ' 59' ' ' ILE . 1.9 mp -109.87 130.99 62.04 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 CA-C-O 121.159 0.504 . . . . 0.0 110.631 -179.68 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 88.6 m -116.12 127.06 54.53 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-N 115.49 -0.777 . . . . 0.0 109.824 179.644 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.4 mt -78.91 133.21 30.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.774 -179.593 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.423 ' O ' ' O ' ' A' ' 63' ' ' ASN . 75.1 t -93.67 131.82 39.56 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.087 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . 0.423 ' O ' ' O ' ' A' ' 62' ' ' VAL . 11.7 m120 59.05 122.62 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.458 -179.641 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -75.33 -4.75 41.07 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.625 -179.746 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.525 ' O ' ' N ' ' A' ' 67' ' ' LEU . . . 144.29 -18.15 2.09 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 111.051 -0.82 . . . . 0.0 111.051 179.884 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 32.0 t 56.19 -80.2 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.598 0.237 . . . . 0.0 110.526 -179.892 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.565 HD22 ' N ' ' A' ' 67' ' ' LEU . 3.6 mm? -73.61 146.29 44.76 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 179.58 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -48.8 135.88 14.57 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.68 -179.744 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 50.4 m170 -66.68 -40.05 88.39 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.789 -179.759 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -94.92 123.5 38.43 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.573 -179.763 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -144.28 103.34 3.97 Favored 'General case' 0 N--CA 1.462 0.169 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.46 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 98.4 m-70 -82.3 150.62 27.15 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.56 179.891 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 13.0 p80 -140.41 124.04 17.12 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.487 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 99.5 m-70 . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 118.012 -0.994 . . . . 0.0 110.472 179.953 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 36.9 ttm . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 -132.4 114.21 14.07 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.517 179.683 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -94.83 150.5 19.74 Favored Glycine 0 CA--C 1.521 0.452 0 N-CA-C 110.474 -1.05 . . . . 0.0 110.474 179.466 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 55.4 t -119.15 131.12 72.79 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 89.1 t -83.51 129.44 37.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.322 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 19.7 mmmt -115.35 106.27 13.82 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.128 179.903 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.507 HG22 ' H ' ' A' ' 9' ' ' SER . 3.2 p -141.7 144.5 25.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.062 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 19.3 m120 -63.04 -41.26 99.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.091 -179.607 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.507 ' H ' HG22 ' A' ' 7' ' ' VAL . 44.4 m -133.03 -96.15 0.31 Allowed 'General case' 0 N--CA 1.466 0.363 0 CA-C-O 120.891 0.377 . . . . 0.0 110.402 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -112.97 143.65 43.89 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.409 179.886 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.549 HD13 ' CD2' ' A' ' 58' ' ' TYR . 42.8 tp -116.97 128.69 55.44 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 120.985 0.421 . . . . 0.0 110.086 179.835 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -82.94 138.64 33.74 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.478 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 37.5 ttp -103.63 152.11 22.14 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.294 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . 0.432 ' NH1' ' HG3' ' A' ' 14' ' ' ARG . 1.9 mtt85 -129.82 155.33 46.15 Favored 'General case' 0 CA--C 1.543 0.697 0 N-CA-C 109.198 -0.667 . . . . 0.0 109.198 -178.871 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 86.2 p -84.39 -4.92 59.18 Favored 'General case' 0 N--CA 1.478 0.936 0 N-CA-C 113.291 0.849 . . . . 0.0 113.291 -179.536 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -162.64 158.05 30.15 Favored Glycine 0 CA--C 1.524 0.63 0 C-N-CA 120.367 -0.921 . . . . 0.0 110.842 -179.073 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -64.5 87.61 0.16 Allowed 'Trans proline' 0 C--N 1.307 -1.622 0 C-N-CA 122.273 1.982 . . . . 0.0 111.64 -179.803 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 157.75 136.96 2.18 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 111.012 -0.835 . . . . 0.0 111.012 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 32.6 t -65.41 -13.13 58.0 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.777 0.322 . . . . 0.0 110.702 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -75.71 -3.7 36.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.254 -179.284 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 40.6 m-85 -90.0 -5.66 56.43 Favored 'General case' 0 C--N 1.332 -0.169 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.479 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 66.88 178.92 10.36 Favored Glycine 0 CA--C 1.522 0.477 0 N-CA-C 110.634 -0.986 . . . . 0.0 110.634 179.87 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.447 HG13 ' O ' ' A' ' 23' ' ' VAL . 8.3 p -103.07 126.3 57.39 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.163 0 CA-C-O 120.783 0.325 . . . . 0.0 110.279 179.595 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 25.5 pt -101.97 -4.61 9.29 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.783 -179.677 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 175.35 -176.14 47.27 Favored Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 -179.866 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 59.6 p -134.87 158.67 43.64 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-O 120.848 0.356 . . . . 0.0 110.758 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 71.5 mt -122.63 150.39 42.72 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.015 -179.899 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.729 HH11 ' HG3' ' A' ' 28' ' ' ARG . 1.0 OUTLIER -94.56 160.96 14.4 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 -179.24 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.427 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 51.7 p30 -64.97 150.48 47.94 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.614 -178.791 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 56.2 t-20 59.61 32.08 21.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.69 -0.687 . . . . 0.0 111.514 179.555 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.518 ' OD2' ' N ' ' A' ' 28' ' ' ARG . 77.5 m-20 -82.78 136.85 34.55 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 179.22 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 53.0 mtmt -107.88 122.25 46.41 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.13 179.299 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.7 m -135.95 162.35 36.63 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.416 -179.876 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -85.82 129.82 34.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.269 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.6 mt -100.19 121.38 50.85 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.265 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.328 179.889 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 77.8 mt -83.99 -46.95 18.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.103 -179.832 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 62.1 pttt -174.79 163.28 3.37 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.749 -179.602 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -107.21 124.44 49.74 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.305 179.861 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 77.4 t -124.42 130.2 73.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.616 -179.578 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.5 m-20 53.97 27.06 6.92 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.022 179.508 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.33 -11.38 67.98 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 111.201 -0.76 . . . . 0.0 111.201 179.595 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 72.9 m95 -87.65 148.68 24.7 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 110.118 -0.327 . . . . 0.0 110.118 179.747 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 7.0 m-85 -103.56 132.25 49.98 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-O 121.099 0.476 . . . . 0.0 110.581 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -93.73 121.89 35.62 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 178.307 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 41.6 pt -127.53 157.9 39.14 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-O 120.922 0.391 . . . . 0.0 111.284 -178.803 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 38.6 ttm180 -112.05 119.65 39.18 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.699 179.51 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 39.9 t80 -138.92 132.28 30.11 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.52 -179.433 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 64.3 t30 58.38 34.58 24.13 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.821 179.813 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 72.85 5.93 66.05 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.985 -0.846 . . . . 0.0 110.985 179.614 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 62.2 tttp -114.18 146.31 40.53 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.721 0.296 . . . . 0.0 110.576 -179.498 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 53.9 t -113.12 130.9 66.2 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.015 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -145.19 -161.7 9.21 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 110.978 -0.849 . . . . 0.0 110.978 -179.664 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 65.2 m-85 -122.15 157.08 32.31 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-O 120.662 0.268 . . . . 0.0 110.346 -179.852 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.44 ' CB ' HD11 ' A' ' 59' ' ' ILE . . . -144.59 154.68 43.1 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.63 -179.694 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 47.6 t -68.27 133.9 49.53 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.231 -179.46 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -65.5 -44.7 86.23 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.537 179.79 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 35.8 t -57.11 -19.11 17.86 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.255 -178.584 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' TYR . . . . . 0.549 ' CD2' HD13 ' A' ' 11' ' ' LEU . 43.1 m-85 -103.57 6.31 37.2 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 116.504 -0.316 . . . . 0.0 111.218 -179.699 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.44 HD11 ' CB ' ' A' ' 54' ' ' ALA . 96.7 mt -131.82 132.23 61.81 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 CA-C-O 121.098 0.475 . . . . 0.0 111.455 179.756 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 92.5 m -123.41 130.55 52.87 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.085 179.33 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 22.1 mm -82.17 130.28 36.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.614 -179.781 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 99.5 t -70.66 134.42 30.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.449 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -59.3 122.14 13.15 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.443 -179.821 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -83.49 121.58 27.39 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.7 -179.886 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.466 ' O ' ' N ' ' A' ' 67' ' ' LEU . . . 72.99 -171.7 50.46 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 179.678 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 3.5 m 42.16 22.46 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.925 0.393 . . . . 0.0 110.873 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.466 ' N ' ' O ' ' A' ' 65' ' ' GLY . 47.9 tp -73.5 -82.99 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.605 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.493 ' N ' ' OE1' ' A' ' 68' ' ' GLU . 58.2 mp0 43.76 -169.26 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.385 -179.759 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.52 ' O ' ' N ' ' A' ' 71' ' ' HIS . 98.5 m-70 -87.15 131.21 34.24 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.784 179.743 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' HIS . . . . . . . . . . . . . 75.7 m80 40.7 -90.05 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.949 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.52 ' N ' ' O ' ' A' ' 69' ' ' HIS . 74.1 t60 41.16 82.23 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.997 179.849 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.51 ' O ' ' N ' ' A' ' 74' ' ' HIS . 85.9 t60 -144.02 103.2 3.99 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.144 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 41.32 -91.02 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.805 -179.636 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' HIS . . . . . 0.51 ' N ' ' O ' ' A' ' 72' ' ' HIS . 80.2 m80 . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 117.983 -1.008 . . . . 0.0 110.505 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 86.8 mmm . . . . . 0 N--CA 1.491 1.622 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 99.4 mt-30 -133.53 120.7 21.13 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.385 179.735 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -93.41 139.32 14.53 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.449 -1.06 . . . . 0.0 110.449 179.608 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 54.2 t -122.38 131.99 72.04 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.254 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 179.899 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 84.6 t -90.01 128.6 41.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.592 -179.431 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 55.4 mtpt -125.05 105.95 9.57 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.032 -0.531 . . . . 0.0 109.848 179.402 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 11.3 p -139.14 155.28 26.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.037 -179.61 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 23.4 t-20 -61.2 -41.24 96.49 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.426 -0.352 . . . . 0.0 111.144 -179.241 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 4.8 t -140.02 -62.78 0.51 Allowed 'General case' 0 N--CA 1.466 0.364 0 CA-C-O 120.747 0.308 . . . . 0.0 111.07 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -150.49 144.22 25.23 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.617 -179.63 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 50.8 tp -120.64 134.6 55.27 Favored 'General case' 0 N--CA 1.469 0.48 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.097 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . 0.426 ' OD1' ' O ' ' A' ' 12' ' ' ASN . 50.5 p-10 -81.47 140.11 34.79 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.669 -179.879 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 42.4 ttp -101.13 153.79 19.28 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.065 -179.706 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . 0.851 ' HG3' HH11 ' A' ' 14' ' ' ARG . 22.2 mtm-85 -125.83 156.83 38.95 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-O 121.381 0.61 . . . . 0.0 112.233 -178.196 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 94.0 p -80.52 -6.26 57.93 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.062 -0.972 . . . . 0.0 110.052 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -159.48 -171.0 24.75 Favored Glycine 0 CA--C 1.525 0.716 0 N-CA-C 110.942 -0.863 . . . . 0.0 110.942 179.678 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -87.05 6.99 5.04 Favored 'Trans proline' 0 C--N 1.305 -1.747 0 C-N-CA 122.744 2.296 . . . . 0.0 111.997 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -99.75 128.71 9.66 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 111.134 -0.787 . . . . 0.0 111.134 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 97.6 p -67.24 -10.33 49.55 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.786 0.327 . . . . 0.0 110.297 179.642 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 54.9 p30 -91.55 8.12 38.13 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.33 -179.574 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 19.6 m-85 -87.13 -5.59 58.96 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.904 0.383 . . . . 0.0 110.322 -179.896 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 72.53 177.14 30.45 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 111.587 -0.605 . . . . 0.0 111.587 179.039 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.41 HG13 ' O ' ' A' ' 23' ' ' VAL . 7.2 p -97.54 126.96 50.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-O 120.844 0.354 . . . . 0.0 110.539 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 42.7 pt -106.88 -6.44 10.35 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.542 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.26 175.39 47.15 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 88.5 m -125.45 134.74 51.98 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-O 120.891 0.377 . . . . 0.0 110.337 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 82.1 mt -105.63 148.31 27.49 Favored 'General case' 0 CA--C 1.516 -0.334 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.891 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 31.8 mmm-85 -103.06 161.64 13.6 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.366 -0.834 . . . . 0.0 110.888 -179.098 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.428 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 25.5 p30 -65.71 143.02 57.8 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-O 121.186 0.517 . . . . 0.0 111.271 -179.362 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 66.3 t30 57.26 34.55 24.94 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.761 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 67.3 t0 -84.73 115.01 22.46 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.775 179.379 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 29.9 mmtp -72.7 128.37 35.34 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.89 0.376 . . . . 0.0 110.387 -179.329 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.3 m -137.81 161.24 33.29 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.222 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.15 179.832 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.531 ' N ' ' OE1' ' A' ' 34' ' ' GLU . 55.9 mp0 -106.54 123.69 48.47 Favored 'General case' 0 C--O 1.234 0.248 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.091 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 95.2 mt -88.52 128.07 41.01 Favored 'Isoleucine or valine' 0 C--O 1.232 0.153 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.45 -179.719 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 95.9 mt -98.19 -56.62 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.22 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.026 -179.763 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 47.1 mtpt -143.13 153.16 42.61 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 121.2 0.524 . . . . 0.0 111.262 -179.497 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . 0.438 ' CD ' ' CE1' ' A' ' 43' ' ' TYR . 84.3 tt0 -115.47 120.72 40.45 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.747 179.159 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 60.1 t -128.89 131.95 67.86 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.51 0 CA-C-O 120.899 0.381 . . . . 0.0 111.558 -179.48 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 54.11 26.47 6.59 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.35 179.285 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.86 -14.05 64.33 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 179.589 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 46.1 m95 -83.59 144.01 29.75 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 179.499 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . 0.438 ' CE1' ' CD ' ' A' ' 38' ' ' GLU . 65.0 m-85 -103.31 130.35 50.56 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.931 0.396 . . . . 0.0 110.676 -179.809 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 79.4 tt0 -90.08 122.5 33.11 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 179.312 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 24.1 pt -128.72 159.04 40.95 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-O 120.732 0.301 . . . . 0.0 111.309 -178.819 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.439 ' HE ' ' HB2' ' A' ' 46' ' ' ARG . 9.4 ttm180 -118.01 128.65 54.98 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.271 -0.422 . . . . 0.0 109.957 179.553 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 42.1 t80 -146.54 135.28 22.25 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.557 -179.358 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 8.5 m120 56.53 33.82 23.27 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.838 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 73.82 6.33 72.24 Favored Glycine 0 CA--C 1.525 0.716 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 179.576 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 56.4 mtpt -110.41 147.52 33.84 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 120.644 0.259 . . . . 0.0 110.419 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 55.7 t -117.9 131.43 70.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 CA-C-N 116.274 -0.421 . . . . 0.0 109.956 179.674 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -149.4 -160.98 9.48 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.382 -1.087 . . . . 0.0 110.382 -179.914 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 67.6 m-85 -135.22 158.18 45.02 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.933 0.397 . . . . 0.0 110.766 -179.586 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -146.84 155.83 42.64 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.309 -179.848 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 20.2 m -69.77 151.46 45.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.792 -179.559 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 22.6 pttp -75.13 -18.83 60.15 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.718 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 74.7 m -61.85 -42.94 99.66 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.699 -179.589 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' TYR . . . . . 0.581 ' C ' HD12 ' A' ' 59' ' ' ILE . 82.8 m-85 -96.73 -2.38 44.55 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.524 0.202 . . . . 0.0 111.395 -179.187 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.581 HD12 ' C ' ' A' ' 58' ' ' TYR . 1.6 mp -113.86 128.66 70.68 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 179.46 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 91.7 m -124.88 130.35 52.21 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.055 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 22.1 mm -78.46 129.61 37.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.353 -179.593 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 94.1 t -95.66 129.24 46.03 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.182 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.616 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 56.5 t-20 57.51 85.08 0.09 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.621 179.759 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 75.9 mt-10 -78.41 -4.11 46.64 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.587 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 91.09 152.83 28.67 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 111.156 -0.778 . . . . 0.0 111.156 179.916 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 21.6 m -74.26 142.59 45.29 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.763 0.316 . . . . 0.0 110.41 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.575 ' N ' HD12 ' A' ' 67' ' ' LEU . 10.0 mp -91.43 -3.84 56.24 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.294 179.875 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 43.8 tp10 -67.35 132.52 47.86 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.267 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 99.5 m-70 -82.79 153.05 25.43 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.77 -179.92 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' HIS . . . . . 0.439 ' O ' ' O ' ' A' ' 71' ' ' HIS . 81.0 m80 -74.15 123.69 24.93 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.646 179.87 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.588 ' CG ' ' H ' ' A' ' 72' ' ' HIS . 82.3 t60 49.91 174.33 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.898 179.55 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.588 ' H ' ' CG ' ' A' ' 71' ' ' HIS . 84.3 t60 -83.29 -3.86 57.87 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.698 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.541 ' H ' ' CD2' ' A' ' 71' ' ' HIS . 86.4 t60 47.83 92.5 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.564 -179.672 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 95.6 m-70 . . . . . 0 C--O 1.22 -0.477 0 CA-C-O 118.005 -0.998 . . . . 0.0 110.828 -179.876 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 22.5 tpp . . . . . 0 N--CA 1.491 1.621 0 N-CA-C 109.47 -0.566 . . . . 0.0 109.47 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 85.8 mt-30 -141.61 114.09 8.28 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 116.085 -0.507 . . . . 0.0 109.897 179.727 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -88.59 149.74 21.31 Favored Glycine 0 CA--C 1.523 0.576 0 N-CA-C 111.279 -0.728 . . . . 0.0 111.279 -179.529 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 53.8 t -126.65 132.55 70.06 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 179.818 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 83.0 t -91.11 128.76 42.71 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.196 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.359 179.757 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -125.63 106.46 9.76 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.318 179.904 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.547 HG22 ' H ' ' A' ' 9' ' ' SER . 3.0 p -138.02 145.4 28.79 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 116.263 -0.426 . . . . 0.0 109.862 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.526 ' OD1' ' N ' ' A' ' 9' ' ' SER . 38.7 p-10 -62.39 -41.18 98.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.776 -179.57 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.547 ' H ' HG22 ' A' ' 7' ' ' VAL . 6.9 t -123.28 -141.33 0.31 Allowed 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.424 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -92.73 144.15 25.59 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.491 179.788 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.408 ' CD1' ' CG ' ' A' ' 58' ' ' TYR . 6.4 tt -121.57 134.42 55.02 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.594 -179.828 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 11.1 m120 -75.88 134.62 40.25 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.226 -179.412 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 27.4 ttt -89.05 152.68 21.53 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-N 115.847 -0.615 . . . . 0.0 109.485 179.104 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 84.2 mtt85 -124.71 144.35 50.27 Favored 'General case' 0 N--CA 1.478 0.971 0 CA-C-O 120.449 0.166 . . . . 0.0 111.026 -179.752 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . 0.467 ' HA ' HD11 ' A' ' 24' ' ' ILE . 23.2 t -89.11 -2.18 58.42 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.909 0.385 . . . . 0.0 110.452 179.3 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -163.41 160.29 32.95 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.35 -1.1 . . . . 0.0 110.35 179.779 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_endo -62.69 99.02 0.2 Allowed 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.368 2.045 . . . . 0.0 111.891 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 135.35 141.82 4.44 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 110.573 -1.011 . . . . 0.0 110.573 179.932 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 35.3 t -67.53 -16.0 63.96 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.78 0.324 . . . . 0.0 110.725 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 52.6 t30 -84.87 8.38 17.63 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.687 -179.05 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 39.5 m-85 -96.85 8.24 44.82 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-O 120.766 0.317 . . . . 0.0 110.31 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 85.07 176.52 50.79 Favored Glycine 0 CA--C 1.522 0.502 0 N-CA-C 111.355 -0.698 . . . . 0.0 111.355 179.663 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.489 HG22 ' H ' ' A' ' 25' ' ' GLY . 14.8 p -121.27 133.84 66.57 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 CA-C-O 120.669 0.271 . . . . 0.0 110.397 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.467 HD11 ' HA ' ' A' ' 15' ' ' SER . 94.8 mt -92.93 -15.25 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-O 120.869 0.366 . . . . 0.0 110.589 -179.696 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.489 ' H ' HG22 ' A' ' 23' ' ' VAL . . . 157.35 -145.59 12.22 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 110.668 -0.973 . . . . 0.0 110.668 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 71.2 p -133.71 155.13 50.29 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-O 120.977 0.418 . . . . 0.0 110.309 179.75 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 85.0 mt -124.67 146.57 49.06 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.227 -179.79 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.408 ' N ' ' OD2' ' A' ' 31' ' ' ASP . 31.8 mtp85 -107.47 170.06 8.2 Favored 'General case' 0 CA--C 1.506 -0.714 0 CA-C-O 121.575 0.702 . . . . 0.0 111.206 -179.771 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 56.9 p30 -69.37 157.17 37.57 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 114.466 -1.243 . . . . 0.0 110.761 179.083 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 8.9 m120 59.29 31.49 21.2 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 114.921 -1.036 . . . . 0.0 111.085 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.408 ' OD2' ' N ' ' A' ' 28' ' ' ARG . 98.5 m-20 -93.56 111.13 22.74 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-O 120.696 0.284 . . . . 0.0 110.419 179.343 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 56.2 mtpt -73.64 133.91 43.54 Favored 'General case' 0 C--N 1.328 -0.363 0 C-N-CA 120.639 -0.424 . . . . 0.0 109.986 179.599 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.7 m -136.59 160.9 37.33 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 120.84 0.353 . . . . 0.0 110.674 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -107.86 119.11 38.54 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 116.121 -0.491 . . . . 0.0 109.808 179.395 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.461 ' C ' HD12 ' A' ' 36' ' ' ILE . 97.0 mt -84.07 126.88 40.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.604 -179.533 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.707 HD12 ' N ' ' A' ' 36' ' ' ILE . 1.6 mp -94.33 -65.43 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.195 0 CA-C-N 116.197 -0.456 . . . . 0.0 109.983 179.9 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 50.4 mtmt -148.28 156.99 43.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.456 179.494 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . 0.45 ' CD ' ' CE1' ' A' ' 43' ' ' TYR . 83.6 tt0 -113.42 123.45 50.1 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.565 179.773 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 67.8 t -130.6 132.33 64.47 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.189 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 55.28 33.59 21.0 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.781 178.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 83.69 -11.39 56.59 Favored Glycine 0 CA--C 1.525 0.688 0 C-N-CA 120.965 -0.636 . . . . 0.0 111.715 179.0 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 84.2 m95 -89.72 140.69 29.32 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 179.725 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . 0.45 ' CE1' ' CD ' ' A' ' 38' ' ' GLU . 62.9 m-85 -101.56 126.43 48.37 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.822 0.344 . . . . 0.0 110.418 179.709 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -82.29 128.8 34.56 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.321 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 43.4 pt -129.48 156.99 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-O 121.28 0.562 . . . . 0.0 111.641 -179.015 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 28.8 ttt180 -124.83 131.42 53.44 Favored 'General case' 0 CA--C 1.51 -0.578 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.106 178.238 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 38.9 t80 -152.57 135.9 15.86 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.791 -0.641 . . . . 0.0 110.532 179.773 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 10.9 m120 56.56 34.3 24.15 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.307 179.736 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 73.81 5.75 70.4 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.429 -0.668 . . . . 0.0 111.429 179.4 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -107.04 144.87 33.08 Favored 'General case' 0 N--CA 1.467 0.394 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.684 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 53.0 t -118.88 133.57 65.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 CA-C-O 120.939 0.399 . . . . 0.0 110.545 -179.372 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -159.91 -168.63 22.15 Favored Glycine 0 CA--C 1.524 0.638 0 N-CA-C 110.576 -1.01 . . . . 0.0 110.576 179.91 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.444 ' N ' ' CD1' ' A' ' 53' ' ' TYR . 38.9 m-85 -127.5 156.33 42.33 Favored 'General case' 0 N--CA 1.464 0.271 0 N-CA-C 110.119 -0.326 . . . . 0.0 110.119 -179.702 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -140.0 157.17 46.09 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-O 120.861 0.363 . . . . 0.0 110.62 -179.752 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 28.5 t -63.01 140.49 58.88 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.211 -179.63 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 25.4 pttm -69.21 -28.75 66.64 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.308 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 52.9 m -59.93 -38.84 83.57 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.463 -179.187 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' TYR . . . . . 0.408 ' CG ' ' CD1' ' A' ' 11' ' ' LEU . 84.2 m-85 -94.81 15.17 19.15 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 111.758 0.281 . . . . 0.0 111.758 -179.012 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 5.5 mm -119.21 128.14 75.83 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 CA-C-O 120.939 0.399 . . . . 0.0 110.163 179.534 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 92.7 m -125.18 127.52 46.92 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.063 179.79 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.6 mt -87.76 125.8 41.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.419 179.782 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 2.3 m -107.08 106.82 21.36 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.374 179.876 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 63.5 t30 -173.45 22.71 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.655 179.831 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 79.8 mm-40 -66.17 140.74 58.21 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.732 -179.555 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.4 ' O ' ' O ' ' A' ' 66' ' ' SER . . . -177.92 73.89 0.07 OUTLIER Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.681 -0.968 . . . . 0.0 110.681 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.4 ' O ' ' O ' ' A' ' 65' ' ' GLY . 2.5 m 59.79 119.65 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.863 0.363 . . . . 0.0 110.475 -179.878 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 83.4 mt -74.53 145.63 43.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.675 -179.716 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -83.02 -84.9 0.12 Allowed 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.577 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 80.5 m80 -85.24 140.07 31.14 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.49 179.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' HIS . . . . . . . . . . . . . 86.0 t60 -153.34 143.63 22.37 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.724 -179.839 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -81.92 147.71 29.13 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.946 -179.885 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 85.1 t60 53.14 85.51 0.05 OUTLIER 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.655 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 59.6 t-80 -144.16 137.16 27.24 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.54 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 75.9 m80 . . . . . 0 C--O 1.221 -0.436 0 CA-C-O 118.256 -0.878 . . . . 0.0 110.512 179.762 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 25.8 ttt . . . . . 0 N--CA 1.489 1.518 0 N-CA-C 109.379 -0.601 . . . . 0.0 109.379 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -125.57 123.47 39.13 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 120.962 0.41 . . . . 0.0 110.524 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -86.74 148.08 21.57 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 179.756 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 74.3 t -124.96 130.27 73.28 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 CA-C-O 120.971 0.415 . . . . 0.0 110.271 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 19.1 t -92.57 128.56 44.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.499 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 21.9 mmtp -121.86 105.3 10.23 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.342 -0.39 . . . . 0.0 109.997 179.525 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 19.0 m -139.34 159.65 28.58 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.482 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 18.3 t-20 -81.2 -13.81 58.2 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.639 179.881 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 12.3 t -159.1 -166.19 1.78 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.5 -179.673 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -65.43 143.29 57.8 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.201 179.603 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 44.9 tp -124.13 132.2 53.62 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-O 120.792 0.33 . . . . 0.0 110.293 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 14.3 m120 -75.24 142.77 43.32 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.297 179.688 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' MET . . . . . 0.43 ' SD ' HD11 ' A' ' 24' ' ' ILE . 12.0 tmm? -106.95 150.31 26.59 Favored 'General case' 0 N--CA 1.463 0.205 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 179.731 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . 0.746 ' NH2' ' H ' ' A' ' 22' ' ' GLY . 24.6 mtp85 -122.34 156.84 33.08 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-O 121.027 0.441 . . . . 0.0 110.572 -178.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 82.2 p -80.84 -6.42 58.56 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.584 -0.735 . . . . 0.0 111.046 -179.42 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -157.55 -168.95 20.72 Favored Glycine 0 CA--C 1.525 0.692 0 C-N-CA 120.831 -0.699 . . . . 0.0 111.422 -179.848 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -83.69 9.38 4.13 Favored 'Trans proline' 0 C--N 1.309 -1.511 0 C-N-CA 122.832 2.354 . . . . 0.0 112.631 -179.695 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -97.56 127.32 9.18 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 179.877 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.535 ' O ' ' NH2' ' A' ' 14' ' ' ARG . 96.1 p -70.97 -10.71 60.2 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.347 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 25.1 p30 -106.03 19.8 19.95 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.029 -179.712 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.433 ' N ' HH21 ' A' ' 14' ' ' ARG . 3.0 m-85 -86.3 -3.08 58.92 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.552 -0.294 . . . . 0.0 110.326 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.746 ' H ' ' NH2' ' A' ' 14' ' ' ARG . . . 81.1 168.61 40.24 Favored Glycine 0 CA--C 1.521 0.421 0 N-CA-C 111.01 -0.836 . . . . 0.0 111.01 179.913 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.465 HG13 ' O ' ' A' ' 23' ' ' VAL . 9.7 p -102.25 124.7 56.34 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 CA-C-O 120.827 0.346 . . . . 0.0 110.421 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.43 HD11 ' SD ' ' A' ' 13' ' ' MET . 23.1 pt -106.78 -0.22 9.98 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.804 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.83 167.8 39.77 Favored Glycine 0 CA--C 1.52 0.348 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 89.2 m -124.04 131.16 53.52 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 120.782 0.325 . . . . 0.0 110.626 -179.7 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 69.4 mt -101.67 161.48 13.62 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.744 -179.706 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 81.5 mtt180 -127.66 157.77 39.38 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 120.873 0.368 . . . . 0.0 110.247 179.54 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.436 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 52.7 p30 -57.25 150.64 17.41 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.285 -179.177 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 12.5 t-20 58.47 35.34 24.63 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.364 179.499 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 32.5 t0 -89.15 114.41 25.7 Favored 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 179.234 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -84.03 124.5 31.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.807 0.337 . . . . 0.0 110.357 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 28.2 m -138.22 162.39 30.59 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.94 -179.711 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . 0.634 ' OE1' ' NH1' ' A' ' 46' ' ' ARG . 78.1 tt0 -95.9 140.14 31.1 Favored 'General case' 0 C--O 1.233 0.222 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 179.054 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 91.3 mt -104.23 125.52 59.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.822 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 95.9 mt -93.03 -49.56 12.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.386 179.718 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 35.6 ttpt -172.79 157.66 3.76 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.659 -179.331 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . 0.57 ' H ' ' CD ' ' A' ' 38' ' ' GLU . 2.1 pm0 -110.0 143.56 39.82 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.35 -0.387 . . . . 0.0 110.371 179.833 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 34.4 t -129.95 126.35 62.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 CA-C-O 120.757 0.313 . . . . 0.0 110.644 -179.718 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 50.79 30.26 4.93 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.545 178.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 85.84 25.32 38.52 Favored Glycine 0 CA--C 1.525 0.687 0 C-N-CA 121.011 -0.614 . . . . 0.0 112.015 179.361 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 62.2 m95 -124.36 106.24 10.07 Favored 'General case' 0 N--CA 1.471 0.581 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.127 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 91.3 m-85 -70.97 135.3 47.8 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.968 0.413 . . . . 0.0 111.437 -179.243 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -88.4 141.89 28.17 Favored 'General case' 0 CA--C 1.518 -0.262 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 178.325 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 39.9 pt -135.38 154.45 35.42 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.684 0 CA-C-O 121.627 0.727 . . . . 0.0 111.034 -179.582 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.634 ' NH1' ' OE1' ' A' ' 34' ' ' GLU . 11.2 ttp180 -111.4 123.54 50.41 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 114.668 -1.151 . . . . 0.0 110.378 -179.917 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 66.9 t80 -151.72 134.91 15.91 Favored 'General case' 0 N--CA 1.463 0.224 0 C-N-CA 120.87 -0.332 . . . . 0.0 111.158 -179.497 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 55.3 t-20 57.96 35.11 25.01 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.423 179.603 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 66.87 22.5 72.12 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 111.091 -0.804 . . . . 0.0 111.091 179.738 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 54.9 mtpt -128.91 146.74 50.87 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 121.012 0.434 . . . . 0.0 111.019 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 53.8 t -113.51 131.77 64.33 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.922 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -143.97 -163.35 9.86 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -179.806 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 44.8 m-85 -127.64 153.1 46.84 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 110.242 -0.281 . . . . 0.0 110.242 -179.675 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -146.69 151.33 37.03 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-N 116.383 -0.372 . . . . 0.0 110.642 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 41.0 t -65.14 143.72 57.69 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.744 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 26.0 pttm -67.58 -17.6 64.69 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.849 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 16.0 m -64.28 -36.06 82.86 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.44 -179.52 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 41.6 m-85 -103.85 12.04 34.94 Favored 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 111.978 0.362 . . . . 0.0 111.978 -178.175 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 46.2 mm -121.43 129.67 75.36 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.573 0 CA-C-O 120.931 0.396 . . . . 0.0 110.623 179.846 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 62.2 p -116.98 131.9 56.84 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.422 -179.601 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.6 mt -84.4 129.65 37.3 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.174 179.597 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 87.9 t -84.09 132.52 31.33 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.354 -179.915 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 95.5 m-20 55.3 -170.67 0.07 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.622 -179.788 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 55.62 25.69 8.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.418 -179.805 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 165.13 48.51 0.02 OUTLIER Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.832 -0.907 . . . . 0.0 110.832 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 22.6 t -84.39 -5.8 59.31 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.732 0.301 . . . . 0.0 111.158 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.57 ' N ' HD12 ' A' ' 67' ' ' LEU . 9.4 mp -78.46 132.94 37.48 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.069 0.461 . . . . 0.0 110.45 179.906 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -140.1 48.13 1.79 Allowed 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.48 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.498 ' CG ' ' O ' ' A' ' 69' ' ' HIS . 38.2 t-80 42.55 33.92 0.5 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.038 0.446 . . . . 0.0 110.745 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' HIS . . . . . . . . . . . . . 59.6 t-80 -59.59 -42.48 92.63 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.317 179.864 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.428 ' O ' ' CG ' ' A' ' 71' ' ' HIS . 52.6 p-80 -72.48 124.0 24.29 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.205 179.851 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.602 ' CE1' ' CE1' ' A' ' 74' ' ' HIS . 74.6 t60 -148.51 136.68 21.08 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.58 -179.815 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.518 ' O ' ' CG ' ' A' ' 74' ' ' HIS . 98.7 m-70 -149.46 124.23 9.87 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.376 179.706 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' HIS . . . . . 0.602 ' CE1' ' CE1' ' A' ' 72' ' ' HIS . 74.9 m80 . . . . . 0 C--O 1.221 -0.444 0 CA-C-O 118.136 -0.935 . . . . 0.0 110.483 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.501 ' N ' ' NE2' ' A' ' 2' ' ' GLN . 6.8 ttt . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.501 ' NE2' ' N ' ' A' ' 1' ' ' MET . 21.3 mp0 -136.69 120.53 17.44 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.416 179.93 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -99.62 147.56 18.33 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.625 -0.99 . . . . 0.0 110.625 179.772 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 54.3 t -124.73 130.78 73.31 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-O 120.927 0.394 . . . . 0.0 110.127 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 13.6 t -87.55 127.17 41.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.306 179.865 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -123.09 105.59 10.06 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.858 0.361 . . . . 0.0 110.068 179.491 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 14.8 p -156.51 139.09 6.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.559 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 66.2 t30 -67.84 -48.98 64.65 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.824 0.345 . . . . 0.0 110.756 179.606 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 5.5 m -93.96 152.48 18.81 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.575 179.799 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -61.47 142.7 56.83 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.532 -0.467 . . . . 0.0 110.194 179.568 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 41.1 tp -117.58 128.23 54.74 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.894 179.851 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . 0.551 ' ND2' HH12 ' A' ' 14' ' ' ARG . 21.2 p-10 -72.08 145.47 48.2 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.687 179.549 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 62.6 ttp -96.69 140.05 31.85 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-O 121.207 0.527 . . . . 0.0 110.663 -179.627 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . 0.961 ' HE ' ' HA ' ' A' ' 19' ' ' SER . 1.0 OUTLIER -93.8 153.82 18.08 Favored 'General case' 0 CA--C 1.541 0.608 0 CA-C-N 115.345 -0.843 . . . . 0.0 111.472 -178.443 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 78.5 p -88.34 -9.66 52.01 Favored 'General case' 0 N--CA 1.462 0.127 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.845 179.13 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -162.82 -173.05 31.05 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.154 -1.178 . . . . 0.0 110.154 179.729 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -80.67 78.29 3.72 Favored 'Trans proline' 0 C--N 1.298 -2.115 0 C-N-CA 122.584 2.189 . . . . 0.0 112.391 179.547 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 167.13 134.5 1.71 Allowed Glycine 0 CA--C 1.525 0.676 0 N-CA-C 111.371 -0.691 . . . . 0.0 111.371 179.769 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.961 ' HA ' ' HE ' ' A' ' 14' ' ' ARG . 23.2 t -68.32 -13.46 62.29 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 112.102 0.408 . . . . 0.0 112.102 -179.113 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 14.1 m120 -88.07 11.44 16.1 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.766 -179.762 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 17.8 m-85 -90.7 1.3 56.97 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.313 179.849 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 76.59 -173.47 54.4 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 179.848 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 4.8 p -118.87 127.69 75.74 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-O 120.841 0.353 . . . . 0.0 110.293 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 25.2 pt -110.21 -3.64 10.6 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.448 179.651 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.56 -176.55 43.89 Favored Glycine 0 CA--C 1.529 0.908 0 N-CA-C 111.246 -0.742 . . . . 0.0 111.246 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 69.4 p -131.55 155.29 47.73 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 120.647 0.26 . . . . 0.0 110.691 -179.82 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 84.1 mt -125.37 149.56 48.02 Favored 'General case' 0 N--CA 1.472 0.625 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.519 -179.35 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 92.1 mtt-85 -120.21 161.67 20.68 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 121.669 0.747 . . . . 0.0 111.103 -179.164 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 64.2 t30 -57.97 144.23 40.2 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.581 -178.608 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 59.2 34.23 23.06 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.47 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 65.7 t0 -85.25 114.89 22.68 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-O 120.778 0.323 . . . . 0.0 110.186 178.881 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -80.37 128.87 34.06 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.551 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.1 m -141.59 161.3 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.201 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.439 179.741 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 80.7 mm-40 -102.73 133.35 47.93 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.942 179.637 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 92.5 mt -102.75 109.43 26.63 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.625 -179.848 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 97.2 mt -66.46 -43.63 90.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.547 179.853 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 25.7 pttm -172.51 179.25 2.52 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.774 -179.401 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 2.5 tm-20 -112.89 124.62 53.03 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.179 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 54.1 t -125.66 133.01 70.16 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.784 -179.663 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 55.81 28.86 12.99 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.133 179.393 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.36 -8.6 57.96 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.854 -0.898 . . . . 0.0 110.854 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 11.1 m95 -94.05 148.38 22.23 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 110.035 -0.357 . . . . 0.0 110.035 179.633 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 64.2 m-85 -96.95 131.39 43.8 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.974 0.416 . . . . 0.0 110.689 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -83.18 152.99 25.0 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 108.496 -0.928 . . . . 0.0 108.496 178.499 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 34.5 pt -145.29 150.55 15.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 C-N-CA 120.707 -0.397 . . . . 0.0 111.143 -179.413 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.603 ' HE ' ' HA2' ' A' ' 49' ' ' GLY . 16.6 ttt180 -115.05 126.18 54.41 Favored 'General case' 0 CA--C 1.511 -0.534 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 177.398 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 79.5 t80 -138.1 129.05 27.09 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-N 115.16 -0.927 . . . . 0.0 110.304 179.574 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 67.0 t30 53.09 36.5 22.44 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.628 -0.714 . . . . 0.0 112.124 179.677 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.603 ' HA2' ' HE ' ' A' ' 46' ' ' ARG . . . 71.05 16.41 74.9 Favored Glycine 0 CA--C 1.525 0.665 0 C-N-CA 120.491 -0.861 . . . . 0.0 111.024 178.924 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.414 ' HD3' ' N ' ' A' ' 51' ' ' VAL . 6.0 tmtt? -119.04 125.78 50.15 Favored 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 109.9 -0.408 . . . . 0.0 109.9 -179.366 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.414 ' N ' ' HD3' ' A' ' 50' ' ' LYS . 82.5 t -80.25 136.65 22.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.591 179.741 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -157.59 167.66 34.14 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.884 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 76.0 m-85 -122.01 156.87 32.56 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-O 120.645 0.259 . . . . 0.0 110.444 -179.544 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -148.77 151.71 35.3 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-O 120.842 0.354 . . . . 0.0 110.472 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 30.0 t -63.23 141.26 58.83 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.478 -179.882 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 26.0 pttm -67.21 -15.1 63.5 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.193 -179.671 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 78.0 p -65.64 -33.19 75.33 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.68 -179.661 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -102.31 11.0 38.78 Favored 'General case' 0 N--CA 1.468 0.454 0 N-CA-C 111.867 0.321 . . . . 0.0 111.867 -179.04 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 47.8 mm -115.55 130.12 70.7 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.567 0 CA-C-O 120.997 0.427 . . . . 0.0 110.554 179.795 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 90.1 m -116.75 124.91 50.79 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.189 179.695 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 21.0 mm -81.79 134.64 26.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.44 -179.856 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.528 ' O ' ' N ' ' A' ' 64' ' ' GLU . 75.3 t -62.56 134.36 27.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.294 -179.901 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 10.1 m120 -40.83 90.04 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.951 -179.412 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . 0.528 ' N ' ' O ' ' A' ' 62' ' ' VAL . 80.9 tt0 -101.32 116.37 32.63 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.305 179.911 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 42.04 79.86 0.05 OUTLIER Glycine 0 CA--C 1.526 0.767 0 N-CA-C 111.242 -0.743 . . . . 0.0 111.242 179.762 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 85.9 p -64.74 152.21 43.15 Favored 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 120.864 -0.334 . . . . 0.0 110.332 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.45 ' O ' ' N ' ' A' ' 69' ' ' HIS . 54.0 tp -88.72 92.9 9.39 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.339 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.435 ' O ' ' CG ' ' A' ' 69' ' ' HIS . 83.8 tt0 38.15 -93.97 0.01 OUTLIER 'General case' 0 CA--C 1.531 0.234 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.115 179.856 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.45 ' N ' ' O ' ' A' ' 67' ' ' LEU . 98.3 m-70 -155.36 168.75 26.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.446 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' HIS . . . . . . . . . . . . . 35.2 p-80 -61.13 122.06 14.06 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.603 -179.739 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 56.3 t-80 -65.93 -42.91 89.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.673 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.45 ' O ' ' CG ' ' A' ' 72' ' ' HIS . 54.1 p-80 -86.75 121.54 29.4 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.709 -179.903 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 58.4 t-80 -61.41 -44.26 97.44 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.633 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 65.1 t-80 . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 118.016 -0.992 . . . . 0.0 110.601 179.946 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 51.0 ttp . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 88.6 mt-30 -124.33 129.54 50.92 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.684 -179.82 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -93.97 156.78 22.51 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.689 -0.964 . . . . 0.0 110.689 179.713 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 65.1 t -124.59 130.99 73.32 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 179.663 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 13.1 t -86.05 128.97 38.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.778 -179.584 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -130.81 106.23 8.31 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.939 0.4 . . . . 0.0 110.207 179.382 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.492 HG22 ' H ' ' A' ' 9' ' ' SER . 3.2 p -140.82 142.77 29.71 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.205 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.223 -179.563 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.526 ' OD1' ' N ' ' A' ' 9' ' ' SER . 13.9 p30 -63.28 -40.8 98.38 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.717 -179.732 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.526 ' N ' ' OD1' ' A' ' 8' ' ' ASN . 17.4 m -117.69 -139.76 0.36 Allowed 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.92 179.578 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -91.97 144.35 25.55 Favored 'General case' 0 C--O 1.233 0.21 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 179.498 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 60.6 tp -110.86 130.18 55.65 Favored 'General case' 0 N--CA 1.468 0.451 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 -179.835 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -85.23 133.63 34.17 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.403 179.827 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 38.4 ttp -100.71 142.16 32.57 Favored 'General case' 0 CA--C 1.51 -0.582 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 179.712 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . 0.525 HH12 ' CB ' ' A' ' 19' ' ' SER . 8.6 mtt180 -117.74 155.42 30.04 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.83 -178.83 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 87.5 p -77.73 -11.81 59.91 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 112.057 0.392 . . . . 0.0 112.057 -178.885 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -162.9 -173.04 31.14 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 179.862 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -83.29 77.02 3.67 Favored 'Trans proline' 0 C--N 1.307 -1.623 0 C-N-CA 122.704 2.269 . . . . 0.0 112.173 179.605 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 168.54 133.81 1.62 Allowed Glycine 0 CA--C 1.527 0.83 0 C-N-CA 120.753 -0.737 . . . . 0.0 111.699 179.717 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.525 ' CB ' HH12 ' A' ' 14' ' ' ARG . 6.0 t -65.86 -17.41 64.63 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-O 120.886 0.374 . . . . 0.0 110.985 179.807 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . 0.531 ' OD1' ' N ' ' A' ' 21' ' ' TYR . 41.1 p-10 -60.89 -36.09 78.32 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.508 -179.117 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.531 ' N ' ' OD1' ' A' ' 20' ' ' ASN . 76.6 m-85 -62.05 -37.02 83.39 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.04 179.342 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 89.48 173.71 45.91 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.451 ' CG2' ' O ' ' A' ' 25' ' ' GLY . 14.0 p -87.19 128.12 40.06 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.867 0.365 . . . . 0.0 110.487 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 25.4 pt -104.4 -4.32 9.61 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.502 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.451 ' O ' ' CG2' ' A' ' 23' ' ' VAL . . . -176.32 -177.12 45.06 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.414 -1.075 . . . . 0.0 110.414 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 69.7 p -132.2 150.22 52.2 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-O 120.947 0.403 . . . . 0.0 110.374 179.861 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 84.4 mt -129.06 148.54 51.02 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.757 -179.529 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 71.0 mtp180 -107.0 162.44 13.84 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.23 179.509 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.426 ' HB3' ' H ' ' A' ' 7' ' ' VAL . 52.8 p30 -69.29 171.97 7.72 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.172 179.723 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 85.9 m-20 58.33 9.2 0.97 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.122 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 43.4 t0 -85.11 116.54 23.54 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.782 0.325 . . . . 0.0 110.676 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 65.5 mttp -77.0 135.13 38.66 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.056 179.674 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.0 m -137.75 159.85 34.03 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-O 120.89 0.376 . . . . 0.0 110.648 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -104.44 117.95 35.41 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.048 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.4 ' C ' HD12 ' A' ' 36' ' ' ILE . 95.7 mt -90.72 125.76 43.51 Favored 'Isoleucine or valine' 0 C--O 1.232 0.172 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.518 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.767 HD12 ' N ' ' A' ' 36' ' ' ILE . 1.9 mp -92.96 -41.16 12.58 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.67 -179.819 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 22.6 pttp -171.83 158.86 5.01 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.604 -179.805 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . 0.476 ' OE1' ' CE1' ' A' ' 43' ' ' TYR . 81.4 tt0 -112.61 125.04 53.84 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.089 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 65.0 t -128.05 132.63 68.39 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 CA-C-O 120.906 0.384 . . . . 0.0 111.146 -179.694 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.435 ' OD1' ' O ' ' A' ' 40' ' ' ASP . 55.1 t0 56.85 25.37 10.33 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.924 179.394 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.01 -9.71 73.53 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 179.696 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 66.2 m95 -89.44 141.51 28.5 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 110.077 -0.342 . . . . 0.0 110.077 179.783 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . 0.476 ' CE1' ' OE1' ' A' ' 38' ' ' GLU . 38.3 m-85 -95.38 131.8 41.12 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-O 121.01 0.433 . . . . 0.0 110.403 179.915 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -92.03 119.64 31.93 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 178.9 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 41.1 pt -125.88 157.84 35.43 Favored 'Isoleucine or valine' 0 C--O 1.233 0.222 0 CA-C-O 121.123 0.487 . . . . 0.0 111.092 -179.311 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 79.0 ttt180 -115.83 124.93 51.93 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.593 179.035 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 28.2 t80 -141.83 132.77 25.94 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.454 -179.814 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 62.7 t30 61.08 27.67 17.47 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.398 -179.835 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 74.08 9.01 79.88 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 61.5 tttm -102.76 156.69 17.47 Favored 'General case' 0 C--O 1.231 0.129 0 N-CA-C 110.043 -0.355 . . . . 0.0 110.043 -179.825 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 56.6 t -115.9 131.17 69.16 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.009 -179.873 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -160.98 -170.43 25.59 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 66.6 m-85 -130.31 162.62 28.62 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-O 120.779 0.323 . . . . 0.0 110.509 -179.632 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -146.68 154.3 41.28 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.369 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 20.2 m -66.25 143.19 57.37 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.619 -179.863 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 60.7 pttt -79.9 -19.44 48.17 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.167 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 11.7 t -61.59 -42.14 98.43 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.354 -179.558 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 99.3 m-85 -92.24 4.3 53.55 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.439 -0.346 . . . . 0.0 111.786 -178.833 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 97.6 mt -122.29 132.09 71.82 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.54 0 CA-C-O 121.001 0.429 . . . . 0.0 110.881 179.678 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 93.1 m -120.2 134.06 55.35 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.406 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 23.1 mm -77.15 132.73 32.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.649 -179.893 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 94.7 t -72.81 129.11 36.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.936 0.398 . . . . 0.0 110.764 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . 0.542 ' O ' ' N ' ' A' ' 65' ' ' GLY . 9.1 m120 49.29 28.43 2.27 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.497 179.552 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . 0.411 ' C ' ' O ' ' A' ' 63' ' ' ASN . 17.4 pt-20 34.23 29.41 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.272 -179.935 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.542 ' N ' ' O ' ' A' ' 63' ' ' ASN . . . 76.09 148.83 2.46 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 110.16 -1.176 . . . . 0.0 110.16 -179.214 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 61.9 p -89.38 105.89 18.09 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.892 0.377 . . . . 0.0 110.636 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 87.5 mt -93.57 -5.63 48.47 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.356 179.804 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -164.09 124.76 2.17 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.329 -179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.53 ' O ' ' CG ' ' A' ' 70' ' ' HIS . 75.1 m80 -65.1 -45.3 85.75 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.832 -179.9 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' HIS . . . . . 0.53 ' CG ' ' O ' ' A' ' 69' ' ' HIS . 99.5 m-70 -159.23 -115.75 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.221 -179.838 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.445 ' O ' ' O ' ' A' ' 72' ' ' HIS . 98.7 m-70 50.97 94.03 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.528 -0.306 . . . . 0.0 110.581 179.823 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.445 ' O ' ' O ' ' A' ' 71' ' ' HIS . 97.9 m-70 57.49 120.97 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.753 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 45.4 p-80 -153.9 159.69 41.85 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.643 179.872 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 86.3 t60 . . . . . 0 C--O 1.22 -0.45 0 CA-C-O 117.895 -1.05 . . . . 0.0 110.443 -179.993 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.517 ' SD ' ' N ' ' A' ' 1' ' ' MET . 0.0 OUTLIER . . . . . 0 N--CA 1.495 1.783 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 . . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.443 ' OE1' ' N ' ' A' ' 2' ' ' GLN . 1.1 mp0 -109.06 110.58 21.87 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-O 121.116 0.484 . . . . 0.0 111.371 179.812 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -92.96 158.18 23.84 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 110.685 -0.966 . . . . 0.0 110.685 179.351 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 73.3 t -126.1 134.47 66.43 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 O-C-N 122.615 -0.344 . . . . 0.0 110.309 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 18.2 t -85.1 126.29 40.34 Favored 'Isoleucine or valine' 0 C--O 1.234 0.248 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.751 -179.905 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 41.5 mmtm -112.24 106.63 15.25 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-O 120.763 0.316 . . . . 0.0 110.382 179.796 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.402 HG22 ' N ' ' A' ' 8' ' ' ASN . 9.7 p -140.15 159.11 26.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 N-CA-C 110.307 -0.257 . . . . 0.0 110.307 179.671 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.478 ' OD1' ' N ' ' A' ' 9' ' ' SER . 21.5 p30 -64.37 -39.47 93.94 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.813 -0.355 . . . . 0.0 110.623 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.478 ' N ' ' OD1' ' A' ' 8' ' ' ASN . 59.5 p -141.09 -60.75 0.49 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.155 -179.656 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.417 ' N ' ' OG ' ' A' ' 9' ' ' SER . . . -149.63 145.84 26.97 Favored 'General case' 0 CA--C 1.519 -0.248 0 CA-C-O 121.196 0.522 . . . . 0.0 110.758 -179.699 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 39.9 tp -116.68 131.66 56.89 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.464 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 99.7 m-20 -74.94 138.38 42.28 Favored 'General case' 0 CA--C 1.518 -0.264 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.573 179.654 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 37.6 ttp -94.72 151.41 19.3 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.621 179.74 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . 0.65 ' NH1' ' H ' ' A' ' 16' ' ' GLY . 0.4 OUTLIER -129.89 154.18 47.56 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.94 0.4 . . . . 0.0 111.668 -179.151 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . 0.618 ' H ' ' CZ ' ' A' ' 14' ' ' ARG . 85.9 p -87.5 -17.34 32.34 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 115.606 -0.725 . . . . 0.0 111.237 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.65 ' H ' ' NH1' ' A' ' 14' ' ' ARG . . . -149.2 -177.48 23.37 Favored Glycine 0 CA--C 1.528 0.875 0 C-N-CA 120.859 -0.686 . . . . 0.0 111.52 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -81.99 82.39 2.32 Favored 'Trans proline' 0 C--N 1.319 -0.983 0 C-N-CA 123.256 2.637 . . . . 0.0 112.107 -179.691 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 163.99 119.63 0.49 Allowed Glycine 0 CA--C 1.528 0.881 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 179.727 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 80.4 p -70.46 -12.39 61.54 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-O 120.605 0.241 . . . . 0.0 110.732 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -78.25 -14.98 59.21 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.322 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.412 ' HB3' ' NH2' ' A' ' 14' ' ' ARG . 13.6 m-85 -64.91 -41.89 95.21 Favored 'General case' 0 CA--C 1.519 -0.231 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.844 179.526 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.54 ' O ' ' NE ' ' A' ' 14' ' ' ARG . . . 117.07 133.76 5.12 Favored Glycine 0 C--N 1.333 0.394 0 N-CA-C 110.954 -0.859 . . . . 0.0 110.954 179.324 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 5.4 p -65.93 139.46 21.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 121.065 0.459 . . . . 0.0 110.399 179.756 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 34.8 pt -106.91 -10.08 10.58 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.215 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.975 -179.878 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.23 -172.93 43.16 Favored Glycine 0 CA--C 1.521 0.467 0 N-CA-C 110.626 -0.99 . . . . 0.0 110.626 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 97.5 m -125.94 147.57 49.47 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-O 120.923 0.392 . . . . 0.0 111.222 -179.301 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 60.5 mt -112.88 153.59 27.67 Favored 'General case' 0 C--O 1.233 0.207 0 CA-C-O 121.055 0.455 . . . . 0.0 110.006 179.458 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 24.1 mmt180 -100.83 159.87 14.83 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.436 -179.543 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.437 ' OD1' ' O ' ' A' ' 29' ' ' ASN . 53.5 p-10 -65.32 143.98 57.41 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.828 -179.528 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 56.66 34.0 23.78 Favored 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.598 179.229 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 44.0 t0 -85.08 117.1 23.83 Favored 'General case' 0 N--CA 1.466 0.341 0 C-N-CA 120.884 -0.326 . . . . 0.0 110.891 179.749 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -72.38 130.48 40.82 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.998 0.428 . . . . 0.0 110.49 179.826 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 28.8 m -137.29 162.93 32.7 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.489 179.827 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -100.13 122.56 43.17 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.813 -0.631 . . . . 0.0 109.934 179.56 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.4 mt -97.4 128.66 48.47 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.169 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.211 -179.739 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 22.7 mm -94.04 -64.32 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.473 -179.693 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 25.3 pttm -154.47 163.52 40.06 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.789 -179.758 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 44.2 tt0 -103.85 126.72 51.18 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.583 179.757 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 61.4 t -127.86 131.64 69.54 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.2 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.335 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 51.1 t0 55.68 24.25 6.98 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.04 179.845 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 89.72 -16.01 57.62 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 111.54 -0.624 . . . . 0.0 111.54 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 17.0 m95 -88.2 141.97 28.13 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.806 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 -94.53 131.6 40.08 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-O 120.737 0.303 . . . . 0.0 111.083 -179.52 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -80.65 134.51 35.89 Favored 'General case' 0 N--CA 1.464 0.275 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 179.2 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 40.0 pt -134.54 155.39 38.73 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-O 121.006 0.431 . . . . 0.0 111.77 -179.441 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 56.4 ttp180 -118.58 124.44 47.48 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.501 179.568 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 36.1 t80 -148.19 134.83 19.84 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.683 179.734 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 65.5 t30 58.74 31.35 21.09 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.674 -179.798 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 70.18 19.54 75.82 Favored Glycine 0 CA--C 1.521 0.407 0 N-CA-C 110.668 -0.973 . . . . 0.0 110.668 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -122.0 145.57 48.0 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-O 120.709 0.29 . . . . 0.0 110.256 -179.587 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 16.8 t -96.78 113.3 30.79 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 CA-C-O 120.846 0.355 . . . . 0.0 110.36 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . 0.42 ' C ' ' CD1' ' A' ' 53' ' ' TYR . . . -119.84 -166.97 13.44 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 110.772 -0.931 . . . . 0.0 110.772 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.42 ' CD1' ' C ' ' A' ' 52' ' ' GLY . 85.3 m-85 -147.37 159.59 43.52 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 179.963 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -145.62 154.88 42.62 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.971 0.415 . . . . 0.0 110.809 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 15.1 m -69.51 146.08 52.16 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.666 -179.809 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 20.6 ptmt -68.23 -36.82 80.09 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.465 -179.836 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 78.3 p -66.92 -23.22 65.95 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.865 -179.007 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 80.9 m-85 -104.82 7.33 34.47 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.471 -179.888 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 4.9 mm -127.71 129.74 70.15 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.15 179.811 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 98.5 m -121.22 127.07 51.09 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.593 179.481 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 21.8 mm -86.23 128.94 38.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.107 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 21.2 t -81.79 133.13 29.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.822 -179.569 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 43.0 t-20 63.08 51.48 2.79 Favored 'General case' 0 C--O 1.232 0.146 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.553 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 77.0 mt-10 -44.5 133.01 5.93 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.525 -179.672 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -72.78 141.41 30.54 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.533 -1.027 . . . . 0.0 110.533 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 14.1 m 37.08 93.71 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.909 0.385 . . . . 0.0 111.334 -179.717 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.57 HD23 ' H ' ' A' ' 67' ' ' LEU . 0.1 OUTLIER -79.5 143.22 35.1 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.368 -179.891 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -157.46 113.16 2.83 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.314 179.724 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 51.5 p-80 -86.82 -0.77 57.02 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.289 179.792 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' HIS . . . . . . . . . . . . . 96.2 m-70 -73.09 130.09 39.52 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.056 -0.52 . . . . 0.0 109.856 179.855 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 24.9 p80 -101.71 20.05 16.97 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.714 -179.649 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 56.81 86.53 0.07 Allowed 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.582 -179.765 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 44.8 p-80 -83.01 146.54 28.7 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.463 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 58.2 m-70 . . . . . 0 C--O 1.22 -0.45 0 CA-C-O 118.177 -0.916 . . . . 0.0 110.595 -179.72 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 6.7 ttt . . . . . 0 N--CA 1.491 1.575 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 26.8 mt-30 -141.27 110.48 6.27 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.222 179.786 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -85.19 163.81 37.99 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.514 -1.034 . . . . 0.0 110.514 179.648 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 54.7 t -125.17 130.15 73.1 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-O 120.785 0.326 . . . . 0.0 110.143 179.858 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 15.7 t -95.4 125.92 48.01 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.08 179.681 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 33.1 ttpt -129.81 117.1 19.68 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.497 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.4 HG12 ' H ' ' A' ' 9' ' ' SER . 2.8 t -140.92 155.9 22.16 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 CA-C-O 120.872 0.368 . . . . 0.0 110.726 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 49.8 p30 -79.9 -11.49 59.8 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.504 179.548 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.4 ' H ' HG12 ' A' ' 7' ' ' VAL . 73.6 m -162.07 -164.79 1.11 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.385 -179.76 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -65.25 142.95 58.11 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.735 -179.903 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 53.6 tp -126.16 132.12 51.88 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-N 116.169 -0.468 . . . . 0.0 109.879 179.701 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . 0.445 ' OD1' ' O ' ' A' ' 12' ' ' ASN . 47.8 p30 -77.62 142.44 38.9 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.001 0.429 . . . . 0.0 110.956 -179.873 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 43.3 ttp -111.43 138.44 47.93 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 179.691 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . 0.71 ' NH2' ' CE3' ' A' ' 42' ' ' TRP . 0.5 OUTLIER -109.18 141.2 41.75 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 120.867 0.365 . . . . 0.0 111.03 -178.81 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 38.4 t -63.44 -42.61 98.67 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.037 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -107.73 179.8 22.0 Favored Glycine 0 N--CA 1.466 0.665 0 N-CA-C 110.65 -0.98 . . . . 0.0 110.65 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -82.98 73.09 5.59 Favored 'Trans proline' 0 C--N 1.307 -1.652 0 C-N-CA 122.438 2.092 . . . . 0.0 111.959 179.665 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . 0.668 ' N ' HH21 ' A' ' 14' ' ' ARG . . . 174.52 158.07 17.64 Favored Glycine 0 CA--C 1.528 0.89 0 N-CA-C 111.344 -0.702 . . . . 0.0 111.344 179.918 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 69.5 m -82.4 -10.37 59.08 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.849 0.357 . . . . 0.0 110.643 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 14.4 m120 -89.64 5.03 47.56 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.188 -179.128 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 47.8 m-85 -92.11 -0.59 57.44 Favored 'General case' 0 N--CA 1.465 0.304 0 N-CA-C 109.993 -0.373 . . . . 0.0 109.993 179.775 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 78.53 -178.32 53.13 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 111.127 -0.789 . . . . 0.0 111.127 179.647 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 5.4 p -116.08 126.71 73.69 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 CA-C-O 120.932 0.396 . . . . 0.0 110.33 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 43.6 pt -103.66 -8.94 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.968 -179.866 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -177.87 -171.72 41.58 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 63.2 p -133.51 158.46 43.07 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-O 120.928 0.394 . . . . 0.0 110.642 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 75.9 mt -122.33 153.88 38.37 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 115.899 -0.592 . . . . 0.0 109.945 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.406 ' O ' ' CG ' ' A' ' 31' ' ' ASP . 70.3 mtm180 -124.54 147.14 48.6 Favored 'General case' 0 N--CA 1.465 0.309 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.914 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 53.0 p-10 -51.91 159.38 0.86 Allowed 'General case' 0 C--N 1.324 -0.536 0 C-N-CA 120.76 -0.376 . . . . 0.0 111.14 -179.168 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 58.0 t30 67.16 9.05 6.64 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.489 179.85 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . 0.406 ' CG ' ' O ' ' A' ' 28' ' ' ARG . 35.1 m-20 -84.88 113.7 21.57 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.746 0.308 . . . . 0.0 110.414 179.288 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 25.8 mtpp -78.57 136.77 37.61 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.084 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.4 m -137.24 163.05 32.65 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.252 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.784 -179.542 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 47.8 tp10 -103.01 123.8 47.3 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.401 179.497 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 90.4 mt -97.49 120.13 46.43 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.041 -179.424 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 82.2 mt -83.88 -44.96 18.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.733 179.533 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 62.1 pttt -173.93 174.89 2.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.452 -179.837 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -118.51 124.98 48.88 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.209 179.873 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 69.0 t -125.33 131.83 71.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.679 -179.577 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 54.83 27.53 9.1 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.12 179.574 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.11 -12.29 62.69 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 179.569 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . 0.71 ' CE3' ' NH2' ' A' ' 14' ' ' ARG . 82.9 m95 -88.73 145.02 25.88 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.731 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 65.6 m-85 -101.25 130.59 47.4 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-O 120.974 0.416 . . . . 0.0 110.521 -179.878 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -87.9 128.65 35.36 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.526 179.48 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 42.8 pt -128.94 150.51 34.64 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.253 0 CA-C-O 121.061 0.458 . . . . 0.0 111.312 -179.234 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 4.7 ttp180 -120.22 129.42 54.07 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.019 178.769 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 73.8 t80 -146.43 132.42 19.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.678 179.564 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 16.8 t-20 57.19 31.25 19.73 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.023 179.479 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 76.78 4.77 82.74 Favored Glycine 0 CA--C 1.528 0.863 0 N-CA-C 111.347 -0.701 . . . . 0.0 111.347 179.548 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 51.4 mtmt -102.21 150.27 23.46 Favored 'General case' 0 N--CA 1.466 0.358 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.567 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 58.0 t -116.65 132.79 65.3 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-O 120.881 0.372 . . . . 0.0 110.31 -179.641 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -153.93 -166.39 14.79 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.514 ' C ' ' NH1' ' A' ' 14' ' ' ARG . 52.8 m-85 -139.18 159.03 43.12 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-O 120.815 0.341 . . . . 0.0 110.694 -179.512 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.516 ' N ' HH12 ' A' ' 14' ' ' ARG . . . -144.19 149.59 36.66 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.987 179.223 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 21.1 m -66.26 147.29 53.53 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.849 0.357 . . . . 0.0 110.574 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 62.3 pttt -64.63 -21.65 66.77 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.756 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 68.4 m -63.23 -40.29 97.02 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.55 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 72.7 m-85 -95.69 8.33 43.76 Favored 'General case' 0 N--CA 1.469 0.494 0 N-CA-C 111.93 0.345 . . . . 0.0 111.93 -178.729 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 46.0 mm -120.59 127.07 75.89 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 CA-C-O 120.905 0.383 . . . . 0.0 110.55 179.814 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 89.8 m -125.42 127.9 47.26 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 115.943 -0.572 . . . . 0.0 109.915 179.252 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 19.1 mm -85.21 127.93 39.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.543 -179.698 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 27.4 m -73.65 141.04 16.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.623 -179.785 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . 0.431 ' OD1' ' O ' ' A' ' 63' ' ' ASN . 45.8 p-10 -64.03 129.21 39.1 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.798 -179.579 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -66.42 142.46 57.58 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.426 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -66.88 140.59 38.47 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 110.826 -0.909 . . . . 0.0 110.826 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 69.9 m -95.69 119.66 34.58 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 120.905 0.383 . . . . 0.0 110.587 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.48 HD12 ' N ' ' A' ' 68' ' ' GLU . 0.3 OUTLIER -98.38 4.65 48.53 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.363 179.962 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.48 ' N ' HD12 ' A' ' 67' ' ' LEU . 80.3 mm-40 -62.05 -39.05 91.04 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.622 -179.723 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . 0.441 ' CG ' ' O ' ' A' ' 69' ' ' HIS . 40.3 p-80 -140.7 98.65 3.45 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.156 179.655 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' HIS . . . . . 0.507 ' CD2' ' H ' ' A' ' 70' ' ' HIS . 11.1 p80 -88.95 -45.55 9.59 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.756 -179.737 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 80.4 m80 -148.39 152.91 37.81 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.557 -179.874 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 85.9 t60 -160.98 119.85 2.54 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.018 179.76 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 59.5 t-80 -114.95 123.5 49.27 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.55 -179.664 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 79.5 m80 . . . . . 0 C--O 1.221 -0.443 0 CA-C-O 117.919 -1.039 . . . . 0.0 110.666 179.922 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 13.5 tpp . . . . . 0 N--CA 1.489 1.515 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 28.5 mp0 -125.06 114.65 19.35 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.27 179.788 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -97.29 168.02 24.04 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.73 -0.948 . . . . 0.0 110.73 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 55.4 t -125.55 132.07 71.36 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 N-CA-C 109.986 -0.375 . . . . 0.0 109.986 179.652 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 89.4 t -92.27 113.44 27.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.03 179.757 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 75.5 tttt -112.71 117.08 31.25 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.16 -179.765 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.488 HG13 ' ND2' ' A' ' 29' ' ' ASN . 9.1 p -144.11 154.0 15.48 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.995 -179.829 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 40.2 t30 -63.16 -41.03 99.18 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.891 -179.761 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 20.3 p -133.3 -72.26 0.51 Allowed 'General case' 0 N--CA 1.468 0.439 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.733 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -152.78 144.17 23.29 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.242 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 42.5 tp -115.06 128.73 56.42 Favored 'General case' 0 N--CA 1.47 0.567 0 CA-C-O 120.979 0.418 . . . . 0.0 110.531 -179.664 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -74.77 144.56 43.53 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.481 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 33.3 ttp -107.26 150.31 26.8 Favored 'General case' 0 CA--C 1.519 -0.244 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 179.601 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . 0.493 ' HE ' ' HA ' ' A' ' 19' ' ' SER . 85.7 mtt85 -128.29 150.16 50.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.762 -178.303 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 23.0 t -69.15 -15.88 63.52 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 115.961 -0.563 . . . . 0.0 112.218 -179.417 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -161.01 -172.68 28.65 Favored Glycine 0 CA--C 1.524 0.646 0 C-N-CA 120.394 -0.908 . . . . 0.0 111.428 -179.673 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -82.76 78.43 3.34 Favored 'Trans proline' 0 C--N 1.304 -1.816 0 C-N-CA 122.729 2.286 . . . . 0.0 111.734 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 169.9 134.91 1.82 Allowed Glycine 0 CA--C 1.525 0.658 0 N-CA-C 111.29 -0.724 . . . . 0.0 111.29 179.878 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.493 ' HA ' ' HE ' ' A' ' 14' ' ' ARG . 34.5 t -66.69 -14.83 62.98 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.944 0.402 . . . . 0.0 110.642 179.705 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 91.6 m-20 -79.45 -1.13 35.92 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.941 -179.495 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 39.0 m-85 -89.21 -1.77 58.22 Favored 'General case' 0 C--O 1.232 0.163 0 N-CA-C 109.573 -0.529 . . . . 0.0 109.573 179.384 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 66.4 176.31 7.13 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 179.804 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.463 HG13 ' O ' ' A' ' 23' ' ' VAL . 8.1 p -101.54 124.48 55.33 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 N-CA-C 110.105 -0.331 . . . . 0.0 110.105 179.603 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 42.9 pt -100.72 -3.27 9.45 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.714 -179.775 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 172.37 -177.84 44.8 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 53.0 p -132.73 158.51 42.19 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.76 0.314 . . . . 0.0 110.367 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 69.1 mt -112.65 135.47 53.34 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.286 -179.658 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -82.52 160.8 22.53 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 120.933 0.397 . . . . 0.0 110.407 -179.17 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.488 ' ND2' HG13 ' A' ' 7' ' ' VAL . 24.3 m120 -62.53 136.96 58.15 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.021 179.855 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . 0.406 ' OD1' ' O ' ' A' ' 30' ' ' ASN . 15.9 t-20 55.64 36.7 27.72 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.0 179.587 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -84.33 116.57 23.08 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.532 179.753 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -72.72 130.71 41.15 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 120.714 -0.394 . . . . 0.0 110.192 179.613 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.7 m -138.82 162.16 28.97 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.541 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -104.17 123.01 46.53 Favored 'General case' 0 N--CA 1.463 0.218 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 179.551 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 96.2 mt -90.35 106.25 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.214 -179.642 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.8 mt -66.24 -45.03 90.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.738 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 21.1 ptmt -175.82 170.8 2.77 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.366 -179.501 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 2.0 tm-20 -115.34 124.08 50.35 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.401 179.702 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 79.7 t -127.97 133.08 67.99 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.373 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.2 -179.833 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.428 ' OD1' ' O ' ' A' ' 40' ' ' ASP . 56.3 t0 56.52 23.02 7.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.901 0.382 . . . . 0.0 110.761 179.666 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 85.22 -6.69 78.69 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 111.249 -0.741 . . . . 0.0 111.249 179.68 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' TRP . . . . . . . . . . . . . 49.0 m95 -85.85 145.78 27.04 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 109.697 -0.482 . . . . 0.0 109.697 179.31 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -95.75 115.25 27.16 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.977 0.418 . . . . 0.0 110.156 -179.672 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -83.65 122.55 28.76 Favored 'General case' 0 CA--C 1.517 -0.315 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 178.89 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 36.3 pt -128.74 162.42 35.79 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.494 0 CA-C-O 121.388 0.613 . . . . 0.0 111.65 -178.434 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.413 ' HD3' HH11 ' A' ' 46' ' ' ARG . 20.4 ttp180 -124.67 130.05 51.69 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.219 -0.9 . . . . 0.0 109.845 179.789 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 84.1 t80 -149.49 132.71 16.4 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.238 -179.507 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 66.0 t30 55.98 36.15 26.83 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.679 179.534 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 69.84 16.53 72.46 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.949 -0.86 . . . . 0.0 110.949 179.889 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 39.3 tptt -116.16 134.77 54.56 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-O 120.691 0.281 . . . . 0.0 110.285 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 58.5 t -108.89 131.22 60.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.155 -179.619 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -152.06 -156.82 7.65 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.736 -0.946 . . . . 0.0 110.736 -179.893 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 76.0 m-85 -137.75 155.85 48.62 Favored 'General case' 0 N--CA 1.464 0.225 0 CA-C-O 120.885 0.374 . . . . 0.0 110.78 -179.75 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -154.13 160.42 41.91 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.157 -179.709 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' SER . . . . . . . . . . . . . 24.7 p -64.47 151.63 43.82 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.044 -179.526 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 22.9 pttp -84.61 -27.21 27.36 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.665 179.828 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 38.9 t -62.27 -40.67 97.01 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.327 -179.614 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' TYR . . . . . . . . . . . . . 58.8 m-85 -84.94 2.51 42.53 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.805 -179.027 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 97.6 mt -124.43 129.66 73.81 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.183 179.197 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 91.0 m -115.54 128.45 55.99 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.554 -179.707 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 95.3 mt -83.33 124.4 39.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.925 -0.58 . . . . 0.0 109.884 179.788 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 34.9 m -89.99 136.78 22.93 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 CA-C-O 120.938 0.399 . . . . 0.0 110.947 -179.511 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . 0.422 ' OD1' ' O ' ' A' ' 63' ' ' ASN . 15.8 p30 -53.55 125.78 19.3 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.418 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 79.5 mm-40 -67.27 -40.84 86.22 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.597 -179.767 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 59.56 -141.93 47.25 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 -179.847 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 2.7 t 42.05 89.17 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.986 0.422 . . . . 0.0 110.919 179.899 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.53 HD22 ' N ' ' A' ' 67' ' ' LEU . 3.5 mm? -87.91 -5.15 58.71 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.414 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 -67.09 139.65 57.57 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.804 -179.545 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 75.3 m80 -82.61 163.76 21.23 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.604 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' HIS . . . . . . . . . . . . . 55.0 t-80 -59.64 -42.93 93.87 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.902 -179.684 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 84.7 t60 -80.71 124.21 28.84 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.801 0.334 . . . . 0.0 110.643 -179.904 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 84.0 t60 -92.46 123.22 35.61 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.37 179.884 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 56.1 t-80 -166.37 129.54 1.98 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.446 179.717 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' HIS . . . . . . . . . . . . . 51.3 t-80 . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 118.054 -0.974 . . . . 0.0 110.798 -179.771 . . . . . . . . 0 0 . 1 stop_ save_